<SEC-DOCUMENT>0001564590-18-011543.txt : 20180508
<SEC-HEADER>0001564590-18-011543.hdr.sgml : 20180508
<ACCEPTANCE-DATETIME>20180508104017
ACCESSION NUMBER:		0001564590-18-011543
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		67
CONFORMED PERIOD OF REPORT:	20180331
FILED AS OF DATE:		20180508
DATE AS OF CHANGE:		20180508

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MERRIMACK PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001274792
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35409
		FILM NUMBER:		18813356

	BUSINESS ADDRESS:	
		STREET 1:		ONE KENDALL SQUARE
		STREET 2:		SUITE B7201
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		617-441-1000

	MAIL ADDRESS:	
		STREET 1:		ONE KENDALL SQUARE
		STREET 2:		SUITE B7201
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>mack-10q_20180331.htm
<DESCRIPTION>10-Q
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
mack-10q_20180331.htm
</title>
</head>
<!-- NG Converter v4.0.8.21 -->
<body>

<p style="border-bottom:none 0pt;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="border-top:Double 2.25pt;padding-top:1pt;border-bottom:none 0pt;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549</p>
<p style="margin-bottom:6pt;text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 10-Q</p>
<p style="margin-bottom:6pt;text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Mark One)</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-weight:bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#9746;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p></td></tr></table></div>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">For the quarterly period ended March&#160;31, 2018</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">OR</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-weight:bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p></td></tr></table></div>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">For the transition period from <font style="text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> to <font style="text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Commission file number: 001-35409</p>
<p style="margin-bottom:6pt;text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Merrimack Pharmaceuticals, Inc.</p>
<p style="margin-bottom:6pt;text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of registrant as specified in its charter)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p></td>
<td valign="top"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">04-3210530</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">incorporation or organization)</p></td>
<td valign="top"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification Number)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">One Kendall Square, Suite B7201</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cambridge, MA</p></td>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">02139</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices)</p></td>
<td valign="top"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(617) 441-1000</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Registrant&#8217;s telephone number, including area code)</p>
<p style="margin-bottom:6pt;text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;Yes&#160;&#160;<font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9746;</font></font>&#160;&#160;&#160;&#160;No&#160;&#160;<font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&#160;&#160;&#160;&#160;Yes&#160;&#160;<font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9746;</font></font>&#160;&#160;&#160;&#160;No&#160;&#160;<font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Large accelerated filer</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated filer</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9746;</font></p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-accelerated filer</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Do not check if a smaller reporting company)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller reporting company</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;<font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;<font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></font>&#160;&#160;&#160;&#160;No&#160;&#160;<font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9746;</font></font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of May 3, 2018, there were 13,342,784 shares of Common Stock, $0.01 par value per share, outstanding.</p>
<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">TABLE OF CONTENTS</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART I</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">FINANCIAL INFORMATION</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0.1pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;">P<font style="text-transform:none;">age</font></p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 1.</p></td>
<td valign="top"  style="width:47.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_FINANCIAL_STATEMENTS"><font style="text-decoration:underline;">Financial Statements.</font></a></p></td>
<td valign="top"  style="width:4.12%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;font-variant: normal;">2</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#MERRIMACK_PHARMACEUTICALS_INC_CONDENSED"><font style="text-decoration:underline;">Condensed Consolidated Balance Sheets &#8211; March&#160;31, 2018 and December&#160;31, 2017 (unaudited)</font></a></p></td>
<td valign="top"  style="width:4.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;font-variant: normal;">2</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:17pt;;text-indent:-17pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:-24.5pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#MERRIMACK_PHARMACEUTICALS_INC_CONDENSED_"><font style="text-decoration:underline;">Condensed Consolidated Statements of Operations and Comprehensive Loss &#8211;Three Months Ended March&#160;31, 2018 and 2017 (unaudited)</font></a></p></td>
<td valign="top"  style="width:4.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:-24.5pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONDENSED_CONSOLIDATED_STATEMENTS_CASH_F"><font style="text-decoration:underline;">Condensed Consolidated Statements of Cash Flows &#8211; Three Months Ended March&#160;31, 2018 and 2017 (unaudited)</font></a></p></td>
<td valign="top"  style="width:4.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_TO_CONDENSED_CONSOLIDATED_FINANCIA"><font style="text-decoration:underline;">Notes to Condensed Consolidated Financial Statements (unaudited)</font></a></p></td>
<td valign="top"  style="width:4.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;font-variant: normal;">5</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 2.</p></td>
<td valign="top"  style="width:47.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_MANAGEMENTS_DISCUSSION_ANALYSIS_F"><font style="text-decoration:underline;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</font></a></p></td>
<td valign="top"  style="width:4.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;font-variant: normal;">13</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 3.</p></td>
<td valign="top"  style="width:47.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_QUANTITATIVE_QUALITATIVE_DISCLOSU"><font style="text-decoration:underline;">Quantitative and Qualitative Disclosures About Market Risk.</font></a></p></td>
<td valign="top"  style="width:4.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;font-variant: normal;">20</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 4.</p></td>
<td valign="top"  style="width:47.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_CONTROLS_PROCEDURES"><font style="text-decoration:underline;">Controls and Procedures.</font></a></p></td>
<td valign="top"  style="width:4.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;font-variant: normal;">20</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART II</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">OTHER INFORMATION</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:8.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 1A.</p></td>
<td valign="top"  style="width:84.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1A_RISK_FACTORS"><font style="text-decoration:underline;">Risk Factors.</font></a></p></td>
<td valign="top"  style="width:7.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;font-variant: normal;">21</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:84.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 6.</p></td>
<td valign="top"  style="width:84.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_6_EXHIBITS"><font style="text-decoration:underline;">Exhibits.</font></a></p></td>
<td valign="top"  style="width:7.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;font-variant: normal;">47</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:92.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:92.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#SIGNATURES"><font style="text-decoration:underline;">Signatures</font></a></p></td>
<td valign="top"  style="width:7.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;font-variant: normal;">48</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">FORWARD-LOOKING STATEMENTS</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Quarterly Report on Form 10-Q, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;target,&#8221; &#8220;potential,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;continue&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The forward-looking statements in this Quarterly Report on Form 10-Q include, among other things, statements about:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our plans to develop and commercialize our clinical stage product candidates and diagnostics;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ongoing and planned discovery programs, preclinical studies and clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the timing of the completion of our clinical trials and the availability of results from such trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to establish and maintain collaborations for our product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our receipt of payments related to the milestone events under the asset purchase and sale agreement with Ipsen S.A. or under the license and collaboration agreement between Baxalta Incorporated, Baxalta US Inc., Baxalta GmbH and Ipsen S.A., when expected or at all;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the timing of and our ability to obtain and maintain regulatory approvals for our product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the rate and degree of market acceptance and clinical utility of our product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our intellectual property position;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our commercialization, marketing and manufacturing capabilities and strategy;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the potential advantages of our approach to drug research and development; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our estimates regarding expenses, future revenues, capital requirements and needs for additional financing.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in this Quarterly Report on Form 10-Q, particularly in Part II, Item 1A. Risk Factors, that could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, collaborations or investments that we may make.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You should read this Quarterly Report on Form 10-Q and the documents that we have filed as exhibits to this Quarterly Report on Form 10-Q completely and with the understanding that our actual future results may be materially different from what we expect. We do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.</p>
<p style="text-align:center;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE REGARDING TRADEMARKS</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ONIVYDE<sup style="font-size:85%; vertical-align:top">&#174;</sup> is a trademark of Ipsen S.A. Any other trademarks, trade names and service marks referred to in this Quarterly Report on Form&#160;10-Q are the property of their respective owners.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a><a name="PART_I"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_I"></a>PAR</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">T I</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">FINANCIAL INFORMATION</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1_FINANCIAL_STATEMENTS"></a>Item 1.<font style="margin-left:36pt;"><a name="ITEM_1_FINANCIAL_STATEMENTS"></a>Financi</font>al Statements.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="MERRIMACK_PHARMACEUTICALS_INC_CONDENSED"></a>Merrimack Pharmaceuticals, Inc.<br /><a name="MERRIMACK_PHARMACEUTICALS_INC_CONDENSED"></a>Condensed Consolidated Balance Sheets</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(unaudited)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> (in thousands, except per share amounts)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,268</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93,441</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,998</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">844</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,605</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77,110</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95,046</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">674</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">674</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,358</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,467</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity method investment</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,805</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,551</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,548</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,588</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97,495</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117,326</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities and stockholders&#8217; equity</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.46%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable, accrued expenses and other</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,323</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,606</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,211</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,171</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,534</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,777</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent, net of current portion</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">651</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,209</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other long-term liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,241</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,042</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commitments and contingencies</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217; equity:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock, $0.01 par value: 10,000 shares authorized at March 31, 2018 and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; December 31, 2017; no shares issued or outstanding at March 31, 2018 or</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; December 31, 2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock, $0.01 par value: 20,000 shares authorized at March 31, 2018 and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; December 31, 2017; 13,343 shares issued and outstanding at</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; March 31, 2018 and December 31, 2017</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,334</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,334</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">578,485</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">577,721</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(500,553</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(482,771</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated other comprehensive loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders&#8217; equity</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79,254</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96,284</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities and stockholders&#8217; equity</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97,495</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117,326</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these condensed consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a><a name="MERRIMACK_PHARMACEUTICALS_INC_CONDENSED_"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Merrimack </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Pharmaceuticals, Inc.</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><br /><a name="MERRIMACK_PHARMACEUTICALS_INC_CONDENSED_"></a>Condensed Consolida</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ted Statements of Opera</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">tions and Comprehensive Loss</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(unaudited)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except per share amounts)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,106</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,605</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,270</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,634</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,376</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,239</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from continuing operations</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,376</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27,239</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income and expenses:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">275</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,979</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense), net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(681</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other income and expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(406</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,967</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss from continuing operations</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,782</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(29,206</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Discontinued operations:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from discontinued operations, net of tax</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(947</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,782</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(30,153</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to non-controlling interest</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(467</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to Merrimack Pharmaceuticals, Inc.</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,782</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(29,686</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive loss:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized loss on marketable securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,794</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(29,686</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts attributable to Merrimack Pharmaceuticals, Inc.:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss from continuing operations</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,782</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(28,739</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from discontinued operations, net of tax</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(947</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss attributable to Merrimack Pharmaceuticals, Inc.</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,782</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(29,686</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and dilutive net loss per common share</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss from continuing operations</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.33</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.20</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss from discontinued operations, net of tax</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.07</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.33</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.27</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average common shares used per share calculations&#8212;basic and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; diluted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,343</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,059</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these condensed consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU6"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Merrimack Pharmaceuticals, Inc.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONDENSED_CONSOLIDATED_STATEMENTS_CASH_F"></a><a name="CONDENSED_CONSOLIDATED_STATEMENTS_CASH_F"></a>Condensed Consolidated Statements of Cash Flows</p>
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(unaudited)</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from operating activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,782</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(30,153</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from discontinued operations</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(947</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from continuing operations</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,782</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(29,206</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile net loss to net cash used in operating activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-cash interest expense</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,508</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,239</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,182</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Premiums paid on marketable securities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(51</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization and accretion on marketable securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(141</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">764</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">796</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss on equity method investment</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">746</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in operating assets and liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">801</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(372</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable, accrued expenses and other</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,397</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,054</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(518</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(86</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in continuing operations for operating activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,339</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,124</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by discontinuing operations for operating activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,968</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,339</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,156</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from investing activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchase of property and equipment</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(290</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of marketable securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41,818</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41,834</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(290</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from financing activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from exercise of options to purchase common stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,053</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of Series C preferred stock by Silver Creek Pharmaceuticals, Inc., net of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; issuance costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,024</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,077</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net decrease in cash, cash equivalents and restricted cash</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(59,173</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,369</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents and restricted cash, beginning of period</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94,217</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,300</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents and restricted cash, end of period</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,044</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,931</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Non-cash investing and financing activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of property and equipment in accounts payable, accrued expenses and other</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Receivables related to property and equipment sale in other current assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Supplemental disclosure of cash flows</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for interest</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,368</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these condensed consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU7"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Merrimack Pharmaceuticals, Inc.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="NOTES_TO_CONDENSED_CONSOLIDATED_FINANCIA"></a><a name="NOTES_TO_CONDENSED_CONSOLIDATED_FINANCIA"></a>Notes to Condensed Consolidated Financial Statements</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(unaudited)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1. Nature of the Business</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Merrimack Pharmaceuticals, Inc. (the &#8220;Company&#8221;) is a clinical stage biopharmaceutical company based in Cambridge, Massachusetts that is outthinking cancer by targeting biomarker-defined cancers. The Company&#8217;s vision is to ensure that cancer patients and their families live fulfilling lives. The Company&#8217;s mission is to transform cancer care through the smart design and development of targeted solutions based on a deep understanding of cancer pathways and biological markers. All of the Company&#8217;s development programs, including four clinical trials and six candidates in preclinical development, fit into the Company&#8217;s strategy of (1) understanding the biological problems it is trying to solve, (2) designing specific solutions against the problems it is trying to solve and (3) developing those solutions for biomarker-selected patients. This three-pronged strategy seeks to ensure optimal patient outcomes.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company owns worldwide development and commercial rights to all of its clinical and preclinical programs. The Company&#8217;s most advanced assets and a description of the status of each asset are as follows:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-family:Times New Roman;">MM-121 (seribantumab)</font><font style="font-family:Times New Roman;">: MM-121 is a fully human monoclonal antibody that binds to the ErbB3 (HER3) receptor and targets heregulin positive cancers. There are two active development programs for MM-121, each in a Phase 2 clinical trial. The Company is conducting the global, open-label, biomarker-selected, Phase 2 randomized SHERLOC clinical trial evaluating MM-121 in combination with docetaxel in patients with heregulin positive non-small cell lung cancer. The Company is also conducting the global, double-blinded, placebo-controlled, biomarker-selected, Phase 2 randomized SHERBOC clinical trial evaluating MM-121 in combination with fulvestrant in patients with heregulin positive, hormone receptor positive, ErbB2 (HER2) negative, metastatic breast cancer;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.63%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-family:Times New Roman;">MM-141 (istiratumab)</font><font style="font-family:Times New Roman;">: MM-141 is a fully human tetravalent bispecific antibody designed to block tumor survival signals by targeting receptor complexes containing the insulin-like growth factor 1 (&#8220;IGF-1&#8221;), receptor and ErbB3 (HER3) cell surface receptor. The Company is conducting and has completed enrollment of the global, double-blinded, placebo-controlled, Phase 2 randomized CARRIE clinical trial evaluating MM-141 in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer with high serum levels of free IGF-1; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.63%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-family:Times New Roman;">MM-310</font><font style="font-family:Times New Roman;">: MM-310 is an antibody-directed nanotherapeutic that targets the ephrin receptor A2 (&#8220;EphA2&#8221;) receptor and contains a novel prodrug of the highly potent chemotherapy docetaxel. The EphA2 receptor is highly expressed in most solid tumor types, such as prostate, ovarian, bladder, gastric, pancreatic and lung cancers. The Company is conducting a Phase 1 clinical trial to evaluate safety and preliminary activity of MM-310 in patients with solid tumors and to identify the maximum tolerated dose.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks and uncertainties common to companies in the biopharmaceutical industry, including, among other things, its ability to secure additional capital to fund operations, success of clinical trials, development by competitors of new technological innovations, dependence on collaborative arrangements, protection of proprietary technology, compliance with government regulations and dependence on key personnel. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of capital, adequate personnel, infrastructure and extensive compliance reporting capabilities.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s product candidates are in development, and none are approved for any indication by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) or any other regulatory agency. There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s intellectual property will be obtained or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies, among others. In addition, the Company is dependent upon the services of its employees and consultants.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 205-40, <font style="font-style:italic;">Going Concern</font>, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued. As of March 31, 2018, the Company had an accumulated deficit of $500.6 million.&#160;During the three months ended March 31, 2018, the Company incurred a net loss from continuing operations of $17.8 million and used $17.3 million of cash in continuing operations for operating activities.&#160;The Company expects to continue to generate operating losses in the foreseeable future. The Company expects that its cash and cash equivalents and marketable securities of $76.3 million at March 31, 2018 will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next 12 months from the date that the condensed consolidated financial statements are issued.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU8"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will ultimately need to seek additional funding through </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">equity offerings, debt financings, collaborations, licensing arrangements and other marketing and distribution arrangements, partnerships, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">joint ventures, combinations or di</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">vestitures of one or more of its</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> businesses</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborative arrangements or divest its assets. Th</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e terms of any financing may adversely affect the holdings or the rights of the Company&#8217;s stockholders. Arrangements with collaborators or others may require the Company to relinquish rights to certain of its technologies or product candidates. If the Comp</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any is unable to obtain funding, the Company could be forced to delay, reduce or eliminate its research and development programs or commercialization efforts, which could adversely</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> affect its business prospects.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2. Summary of Significant Accounting Policies </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Basis of Presentation </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying condensed consolidated financial statements reflect the operations of Merrimack Pharmaceuticals, Inc. and its wholly owned subsidiary. All intercompany accounts and transactions have been eliminated.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The condensed consolidated financial statements are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;).</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accounting policies followed in the preparation of the interim condensed consolidated financial statements are consistent in all material respects with those presented in Note 1 to the financial statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2017.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain reclassifications have been made to the prior year&#8217;s condensed consolidated balance sheet and condensed consolidated statement of cash flows to enhance comparability with the current year&#8217;s condensed consolidated financial statements presentation. These reclassifications had no effect on previously reported net income within the condensed consolidated statement of operations and comprehensive loss.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Consolidation</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying condensed consolidated financial statements reflect Merrimack Pharmaceuticals, Inc. and its wholly owned subsidiary. For the three months ended March 31, 2017, the condensed consolidated financial statements also include the accounts of Silver Creek Pharmaceuticals, Inc. (&#8220;Silver Creek&#8221;). For the three months ended March 31, 2017, Silver Creek represented a variable interest entity that the Company consolidated as the primary beneficiary. In the third quarter of 2017, the Company deconsolidated Silver Creek from its financial statements since the Company was no longer the primary beneficiary of Silver Creek. The Company&#8217;s ownership percentage decreased to less than 50% and the Company no longer controlled Silver Creek&#8217;s board of directors or directed the activities that had the most significant impact on Silver Creek&#8217;s economic performance. The Company accounts for its investment in Silver Creek under the equity method of accounting.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April&#160;3, 2017, the Company completed the sale of its right, title and interest in the non-cash assets, equipment, inventory, contracts and intellectual property primarily related to developing, manufacturing and commercializing ONIVYDE and MM-436 (the &#8220;Commercial Business&#8221;). As of March 31, 2017, the Commercial Business met all the conditions to be classified as a discontinued operation since the disposal of the Commercial Business represented a strategic shift that had a major effect on the Company&#8217;s operations and financial results. Therefore, the operating results of the Commercial Business are reported as a loss from discontinued operations, net of tax in the condensed consolidated statements of operations and comprehensive loss for the three months ended March 31, 2017. During the three months ended March 31, 2018, there were no discontinued operations. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unaudited Interim Financial Information</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The condensed consolidated balance sheet as of December&#160;31, 2017 was derived from audited financial statements, but does not include all disclosures required by GAAP. The condensed consolidated balance sheet as of March 31, 2018, the condensed consolidated statements of operations and comprehensive loss for the three months ended March 31, 2018 and 2017 and the condensed consolidated statements of cash flows for the three months ended March 31, 2018 and 2017 are unaudited. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the Company&#8217;s financial position as of March 31, 2018, the results of its operations for the three months ended March 31, 2018 and 2017, and its statements of cash flows for the three months ended March 31, 2018 and 2017. The financial data and other information disclosed in the notes related to the three months ended March 31, 2018 and 2017 are unaudited. The results for the three months ended March 31, 2018 and 2017 are not necessarily indicative of results to be expected for the year ending December&#160;31, 2018, any other interim periods, or any future year or period.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU9"></a><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The unaudited interim financial statements of the Company included herein have been prepared pursuant to the rules and regulations of the </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities and Exchange Commission (the &#8220;SEC&#8221;)</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this report, as is permitted by such rules and regul</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ations. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and the notes thereto </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">contained</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2017</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> filed w</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ith the SEC on March 12, 2018</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Condensed Consolidated Statements of Cash Flows</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the statement of financial position that sum to the total of the same such amounts shown in the statement of cash flows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.13%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,268</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,155</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash in prepaid expenses and other current assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash (short term)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash (long term)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">674</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">674</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash, cash equivalents and restricted cash shown in the condensed consolidated</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; statement of cash flows</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,044</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,931</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash included in prepaid expenses and other current assets and restricted cash long term on the statement of financial position represent amounts pledged as collateral for operating lease obligations as contractually required. This restriction will lapse when the arrangements expire.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates, assumptions and judgments reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuation of stock-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from the Company&#8217;s estimates.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Marketable Securities</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities consist of investments with original maturities greater than ninety days. The Company has classified its investments with maturities beyond one year as short term based on their highly liquid nature and because such marketable securities represent the investment of cash that is available for current operations. The Company considers its investment portfolio of marketable debt securities as available-for-sale. Accordingly, these marketable debt securities are recorded at fair value and unrealized gains and losses are reported as a component of accumulated other comprehensive loss in stockholders&#8217; equity. Realized gains and losses and declines in value judged to be other than temporary are included as a component of other income (expense), net based on the specific identification method. When determining whether a decline in value is other than temporary, the Company considers various factors, including whether the Company has the intent to sell the security, and whether it is more likely than not that the Company will be required to sell the security prior to recovery of its amortized cost basis.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3. Fair Value of Financial Instruments</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. Fair value is determined based on observable and unobservable inputs. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect certain market assumptions. As a basis for considering such assumptions, GAAP establishes a three-tier value hierarchy, which prioritizes the inputs used to develop the assumptions and for measuring fair value as follows: Level 1 observable inputs such as quoted prices in active markets for identical assets; Level 2 inputs other than the quoted prices in active markets that are observable either directly or indirectly; and Level 3 unobservable inputs in which there is little or no market data, which requires the Company to develop its own assumptions. This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU10"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables show assets measured at fair value on a recurring basis as of </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2017</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">:</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,785</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,009</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,781</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Totals</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,785</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,790</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,217</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,841</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,940</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Totals</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,998</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89,310</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Totals</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89,310</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the three months ended March 31, 2018 and the year ended December&#160;31, 2017, there were no transfers between Level 1 and Level 2. The fair value of Level 2 instruments classified as cash equivalents and marketable debt securities were determined through third-party pricing services.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amounts reflected in the condensed consolidated balance sheets for accounts payable, accrued expenses and other liabilities approximate fair value due to their short-term maturities.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4. Marketable Securities and Cash Equivalents</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company&#8217;s marketable securities and cash equivalents as of March 31, 2018. The Company did not hold any marketable securities as of December 31, 2017.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,785</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,785</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,010</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,009</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,781</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,781</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash equivalents</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,576</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,575</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,227</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,217</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,841</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,841</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,941</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,940</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total marketable securities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,009</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,998</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash equivalents and marketable securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,585</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,573</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU11"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> Accounts Payable, Accrued Expenses and Other</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable, accrued expenses and other as of March&#160;31, 2018 and December&#160;31, 2017 consisted of the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,560</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,887</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued goods and services</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,027</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,682</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued clinical trial costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,925</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,901</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued drug purchase costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">918</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">222</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued payroll and related benefits</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,240</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,884</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued restructuring expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">251</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">628</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax incentives</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,402</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,402</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accounts payable, accrued expenses and other</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,323</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,606</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6. Stock-Based Compensation</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s 2011 Stock Incentive Plan (the &#8220;2011 Plan&#8221;) is administered by the Company&#8217;s Board of Directors and permits the Company to grant incentive and non-qualified stock options, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At March&#160;31, 2018, there were 0.5 million shares remaining available for grant under the 2011 Plan.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the three months ended March 31, 2018 and 2017, the Company issued options to purchase 0.6 million and 0.0 million shares of common stock, respectively. These options generally vest over a three-year period for employees. Options granted to directors generally vest immediately.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of stock options granted to employees during the three months ended March&#160;31, 2018 and 2017 was estimated at the date of grant using the following assumptions:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="4" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.16%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.3 &#8211; 2.7%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.8 years</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.8 years</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62 &#8211; 63%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67 &#8211; 68%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company uses the simplified method to calculate the expected term, as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term. The computation of expected volatility is based on the historical volatility of comparable companies from a representative peer group selected based on industry and market capitalization. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected life of the stock options. Management estimates expected forfeitures based on historical experience and recognizes compensation costs only for those equity awards expected to vest.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognized stock-based compensation expense during the three months ended March&#160;31, 2018 and 2017 as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee awards:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">334</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">468</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expense</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">430</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">328</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">764</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">796</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes stock option activity during the three months ended March&#160;31, 2018:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except per share amounts)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise&#160;Price</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual&#160;Term</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December&#160;31, 2017</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,616</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22.07</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.65</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,031</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">566</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.74</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(145</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.12%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.04</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.48%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.74%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at March&#160;31, 2018</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,037</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.12%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.00</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.22</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.74%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and expected to vest at March&#160;31, 2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,036</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.00</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.22</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at March&#160;31, 2018</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,032</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25.17</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.97</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average grant date fair value per share of stock options granted during the three months ended March&#160;31, 2018 and 2017 was $6.26 and $24.30, respectively. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate intrinsic value is calculated as the difference between the exercise price of the stock options and the fair value of the underlying common stock. The aggregate intrinsic value of stock options exercised during the three months ended March&#160;31, 2017 was $1.4 million. There were no options exercised during the three months ended March 31, 2018.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March&#160;31, 2018, there was $7.2 million of total unrecognized stock-based compensation expense related to unvested employee stock awards. The Company expects to recognize this expense over a weighted-average period of approximately 2.58 years.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;">&nbsp;</p>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7. Net Loss Per Common Share</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is calculated by dividing the net loss attributable to Merrimack Pharmaceuticals, Inc. by the weighted-average number of common shares outstanding during the period. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Diluted net loss per share is computed by dividing the net loss attributable to Merrimack Pharmaceuticals, Inc. by the weighted-average number of dilutive common shares outstanding during the period. Dilutive shares outstanding is calculated by adding to the weighted shares outstanding any potential (unissued) shares of common stock from outstanding stock options based on the treasury stock method. In a period when a net loss is reported, all common stock equivalents are excluded from the calculation because they would have an anti-dilutive effect, meaning the loss per share would be reduced. Therefore, in periods where a loss is reported, there is no difference in basic and dilutive loss per share.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company follows the two-class method when computing net loss per share when it has issued shares that meet the definition of participating securities. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participating rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based on their respective rights to receive dividends, as if all income for the period has been distributed or losses to be allocated if they are contractually required to fund losses. There were no amounts allocated to participating securities for the three months ended March 31, 2018 and 2017, as the Company was in a loss position and had no shares that met the definition of participating securities outstanding as of March 31, 2018 and 2017. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The stock options and conversion premium on the 4.50% convertible notes due 2020 (the &#8220;Convertible Notes&#8221;) are excluded from the calculation of diluted loss per share because the net loss for the three months ended March&#160;31, 2017 causes such securities to be anti-dilutive. Outstanding securities excluded from the calculation of diluted loss per share for the three months ended March&#160;31, 2018 and 2017 are shown in the chart below:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding options to purchase common stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,037</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,652</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of the Convertible Notes</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,216</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU12"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8. Discontinued Operations</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April&#160;3, 2017, the Company completed the sale of the Commercial Business. As of March 31, 2017, the Commercial Business met all the conditions to be classified as a discontinued operation since the disposal of the Commercial Business represented a strategic shift that had a major effect on the Company&#8217;s operations and financial results.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The condensed consolidated financial statements for the three months ended March 31, 2017 reflect the operations of the Commercial Business as a discontinued operation.&#160;Discontinued operations for the three months ended March 31, 2017 includes the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.2%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues:</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenues, net</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,135</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License and collaboration revenues</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,797</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other revenues</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,973</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenues</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,905</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs and expenses:</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of revenues</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,890</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,730</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expenses</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,733</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restructuring expenses</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,265</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total costs and expenses</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,618</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income and expenses:</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,234</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from discontinued operations</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(947</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:5pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 8, 2017, the Company announced a reduction in headcount by approximately 30% in connection with the sale of the Commercial Business and the completion of its strategic pipeline review. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under this corporate restructuring, for the three months ended March 31, 2017, the Company recognized total restructuring expenses of $5.3 million related to contractual termination benefits for employees with pre-existing severance arrangements. These one-time employee termination benefits are comprised of severance, benefits and related costs, all of which resulted in cash expenditures. The expense of $5.3 million was included in discontinued operations, as the costs are directly associated with the sale of the Commercial Business. For the three months ended March 31, 2018, there were no discontinued operations.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9. Investment in Silver Creek</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 20, 2010, the Company acquired a controlling financial interest in Silver Creek. At such time, the Company had the ability to direct the activities of Silver Creek that most significantly impacted Silver Creek&#8217;s economic performance through its ownership percentage and through the board of director seats controlled by the Company. As such, Silver Creek was consolidated by the Company.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since the Company acquired its financial interest, Silver Creek has raised funding through the issuance of preferred stock. The Company has not participated in any Silver Creek financings nor has it provided any funding. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the third quarter of 2017, Silver Creek completed its Series C preferred stock financing, reducing the Company&#8217;s ownership percentage in Silver Creek below 50% and resulting in the Company no longer controlling the Silver Creek board of directors. Accordingly, the Company determined that it was no longer the primary beneficiary of Silver Creek and deconsolidated Silver Creek from its financial statements on July 13, 2017. Starting on July 14, 2017, the Company accounted for its investment in Silver Creek under the equity method of accounting since the Company has the ability to exercise significant influence over Silver Creek. Under the equity method of accounting, the Company has recorded its proportionate share of the investee&#8217;s earnings (losses) in its results of operations with a corresponding increase (decrease) in the carrying value of the investment. Silver Creek continues to be a related party to the Company after deconsolidation.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU13"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">0</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">. Recent Accounting Pronouncements</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Financial Accounting Standards Board (&#8220;FASB&#8221;) issued the following new Accounting Standards Updates (&#8220;ASU&#8221;), which the Company adopted on January 1, 2018:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">ASU 2014-09, &#8220;Revenue from Contracts with Customers (Topic 606)&#8221; and related amendments;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">ASU 2016-01, &#8220;Financial Instruments &#8211; Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Liabilities&#8221;;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">ASU 2016-15, &#8220;Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments&#8221;;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">ASU 2016-18, &#8220;Statement of Cash Flows - Restricted Cash (a consensus of the FASB Emerging Issues Task Force)&#8221;; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">ASU 2017-09, &#8220;Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting.&#8221;</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The adoption of these standards did not have a material impact on the Company&#8217;s financial position, results of operations or statement of cash flows; however, the adoption of ASU 2016-18 resulted in the reclassification of certain prior year amounts in the Company&#8217;s condensed consolidated statements of cash flows to conform to the current year presentation. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued ASU 2016-02, &#8220;Leases (Topic 842),&#8221; which supersedes all existing lease accounting guidance within ASC 840, <font style="font-style:italic;">Leases</font>. The new standard requires that lease assets and lease liabilities be recognized by lessees for those leases previously classified as operating leases under ASC 840, with limited exceptions. This update also creates a new definition of a lease and provides guidance as to whether a contract is or contains a lease. This guidance will be effective for annual reporting periods beginning after December 15, 2018, including interim periods within those annual reporting periods, and early adoption is permitted. The Company is currently evaluating the potential impact that the adoption of this guidance may have on the condensed consolidated financial statements.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU 2016-13, &#8220;Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,&#8221; which represents a new credit loss standard that will change the impairment model for most financial assets and certain other financial instruments. Specifically, this guidance will require entities to utilize a new &#8220;expected loss&#8221; model as it relates to trade and other receivables. In addition, entities will be required to recognize an allowance for estimated credit losses on available-for-sale debt securities, regardless of the length of time that a security has been in an unrealized loss position. This guidance will be effective for annual reporting periods beginning after December 15, 2019, including interim periods within those annual reporting periods, and early adoption is permitted. The Company is currently evaluating the potential impact that the adoption of this guidance may have on the condensed consolidated financial statements.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2018, the FASB issued ASU 2018-02, &#8220;Income Statement - Reporting Comprehensive Income (Topic 220)&#8221;. ASU 2018-02 addresses the effect of the change in the U.S. federal corporate tax rate due to the enactment of the December 22, 2017 Tax Cuts and Jobs Act (the &#8220;Tax Act&#8221;) on items within accumulated other comprehensive loss. The guidance will be effective for the Company in the first quarter of fiscal 2020 with early adoption permitted. The Company is currently assessing the impact that adopting this new accounting standard will have on the condensed consolidated financial statements.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed above, the Company does not believe that the adoption of recently issued standards has or may have a material impact on the Company&#8217;s condensed consolidated financial statements or disclosures.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU14"></a><a name="ITEM_2_MANAGEMENTS_DISCUSSION_ANALYSIS_F"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item 2.</font><font style="margin-left:36pt;"><a name="ITEM_2_MANAGEMENTS_DISCUSSION_ANALYSIS_F"></a> Management&#8217;s Discussion and Analysis of </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial Condition and Results of Operations.</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The following discussion of our financial condition and results of operations should be read in conjunction with our financial statements and the notes to those financial statements appearing elsewhere in this Quarterly Report on Form 10-Q and the audited consolidated financial statements and notes thereto and management&#8217;s discussion and analysis of financial condition and results of operations for the year ended December&#160;31, 2017 included in our Annual Report on Form 10-K. This discussion contains forward-looking statements that involve significant risks and uncertainties. As a result of many factors, such as those set forth in Part II, Item 1A. Risk Factors of this Quarterly Report on Form 10-Q, which are incorporated herein by reference, our actual results may differ materially from those anticipated in these forward-looking statements.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Overview</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical stage biopharmaceutical company based in Cambridge, Massachusetts that is outthinking cancer by targeting biomarker-defined cancers. Our vision is to ensure that cancer patients and their families live fulfilling lives. Our mission is to transform cancer care through the smart design and development of targeted solutions based on a deep understanding of cancer pathways and biological markers. All of our development programs, including four clinical trials and six candidates in preclinical development, fit into our strategy of (1) understanding the biological problems we are trying to solve, (2) designing specific solutions against the problems we are trying to solve and (3) developing those solutions for biomarker-selected patients. This three-pronged strategy seeks to ensure optimal patient outcomes.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We own worldwide development and commercial rights to all of our clinical and preclinical programs. Our most advanced assets and a description of the status of each asset are as follows: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-family:Times New Roman;">MM-121 (seribantumab)</font><font style="font-family:Times New Roman;">: MM-121 is a fully human monoclonal antibody that binds to the ErbB3 (HER3) receptor and targets heregulin positive cancers. There are two active development programs for MM-121, each in a Phase 2 clinical trial. We are conducting the global, open-label, biomarker-selected, Phase 2 randomized SHERLOC clinical trial evaluating MM-121 in combination with docetaxel in patients with heregulin positive non-small cell lung cancer, or NSCLC. We are also conducting the global, double-blinded, placebo-controlled, biomarker-selected, Phase 2 randomized SHERBOC clinical trial evaluating MM-121 in combination with fulvestrant in patients with heregulin positive, hormone receptor positive, ErbB2 (HER2) negative, metastatic breast cancer;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-family:Times New Roman;">MM-141 (istiratumab)</font><font style="font-family:Times New Roman;">: MM-141 is a fully human tetravalent bispecific antibody designed to block tumor survival signals by targeting receptor complexes containing the insulin-like growth factor 1, or IGF-1, receptor and ErbB3 (HER3) cell surface receptor. We are conducting and have completed enrollment of the global, double-blinded, placebo-controlled, Phase 2 randomized CARRIE clinical trial evaluating MM-141 in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer with high serum levels of free IGF-1; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-family:Times New Roman;">MM-310</font><font style="font-family:Times New Roman;">: MM-310 is an antibody-directed nanotherapeutic that targets the ephrin receptor A2, or EphA2, receptor and contains a novel prodrug of the highly potent chemotherapy docetaxel. The EphA2 receptor is highly expressed in most solid tumor types, such as prostate, ovarian, bladder, gastric, pancreatic and lung cancers. We are conducting a Phase 1 clinical trial to evaluate safety and preliminary activity of MM-310 in patients with solid tumors and to identify the maximum tolerated dose.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 3, 2017,<font style="font-weight:bold;"> </font>we completed the sale, or the asset sale, to Ipsen S.A., or Ipsen, of our right, title and interest in the non-cash assets, equipment, inventory, contracts and intellectual property primarily related to or used in our business operations and activities involving or relating to developing, manufacturing and commercializing ONIVYDE, our first commercial product, and MM-436, or the commercial business, for $580.7 million. Pursuant to the Asset Purchase and Sale Agreement, dated as of January&#160;7, 2017, or the asset sale agreement, between us and Ipsen, we are eligible to receive up to $450.0 million in additional regulatory approval-based milestone payments. We also retained the right to receive net milestone payments that may become payable for the ex-U.S. development and commercialization of ONIVYDE for up to $33.0 million pursuant to a license and collaboration agreement, which we refer to as the Baxalta agreement, with Baxalta Incorporated, Baxalta US Inc. and Baxalta GmbH, collectively Baxalta. The Baxalta agreement was assigned to Ipsen in connection with the completion of the asset sale. As of March 31, 2017, the commercial business met all the conditions to be classified as a discontinued operation since the disposal of the commercial business represented a strategic shift that had a major effect on our operations and financial results. Therefore, the operating results of the commercial business are reported as a loss from discontinued operations, net of tax in the condensed consolidated statements of operations and comprehensive loss for the three months ended March 31, 2017. During the three months ended March 31, 2018, there were no discontinued operations.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have devoted substantially all of our resources to our drug discovery and development efforts, including conducting clinical trials for our product candidates, protecting our intellectual property and providing general and administrative support for these operations. <font style="Background-color:#FFFFFF;color:#000000;">We currently have no products approved for sale</font>. We have financed our operations primarily through private placements of convertible preferred stock, collaborations, public offerings of our securities, secured debt financings, sales of ONIVYDE and the asset sale.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU15"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, we had unrestricted cash </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and cash equivalents and marketable securities of $</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76.3</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million. </font><font style="letter-spacing:-0.1pt;">W</font><font style="Background-color:#FFFFFF;color:#000000;letter-spacing:-0.1pt;">e believe that at our currently forecasted spending rates, our existing financial resources, together with the net milestone payments we expect to receive under the Baxalta agreement, assumi</font><font style="Background-color:#FFFFFF;color:#000000;letter-spacing:-0.1pt;">ng certain milestones under such agreement are met, will be sufficient to fund our planned operations into the second half of 2019.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never been profitable and, as of March&#160;31, 2018, we had an accumulated deficit of $500.6 million. Our net loss from continuing operations was $17.8 million and $29.2 million for the three months ended March 31, 2018 and 2017, respectively. We expect to continue to incur significant expenses and operating losses for at least the next several years as we continue the research and development of our product candidates, including multiple clinical trials for certain product candidates. Until such time, if ever, as we can generate sufficient product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, licensing arrangements and other marketing and distribution arrangements. We also could engage in discussions with third parties regarding partnerships, joint ventures, combinations or divestitures of one or more of our product candidates as we seek to further the development of our research programs, improve our cash position and maximize stockholder value. There can be no assurance as to the timing, terms or consummation of any financing, collaboration, licensing arrangement or other marketing and distribution arrangement, partnership, joint venture, combination or divestiture. We may be unable to raise capital when needed or on attractive terms, which would force us to delay, limit, reduce or terminate our research and development programs. We will need to generate significant revenues to achieve profitability, and we may never do so.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial Operations Overview</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenues</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the future, we may generate revenue from a combination of research and development payments, license fees and other upfront payments, milestone payments, product sales and royalties in connection with any future collaborations and licenses. We expect that any revenue we generate will fluctuate in future periods as a result of the timing of our or a collaborator&#8217;s achievement of preclinical, clinical, regulatory and commercialization milestones, if at all, the timing and amount of any payments to us relating to such milestones and the extent to which any of our product candidates are approved and successfully commercialized by us or a collaborator. If we fail, or any future collaborator fails, to develop product candidates in a timely manner or to obtain regulatory approval for them, our ability to generate future revenue, and our results of operations and financial position, would be materially adversely affected.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and development expenses</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses consist of the costs associated with our preclinical research activities, conduct of clinical trials, manufacturing development efforts and activities related to regulatory filings. Our research and development expenses consist of:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">employee salaries and related expenses, which include stock-based compensation and benefits for the personnel involved in our drug discovery and development activities;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">external research and development expenses incurred under agreements with third-party contract research organizations and investigative sites;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">manufacturing material expense for third-party manufacturing organizations and consultants, including costs associated with manufacturing product prior to product approval;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">license fees for and milestone payments related to in-licensed products and technologies; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">facilities, depreciation and other allocated expenses, which include direct and allocated expenses for rent and maintenance of facilities, depreciation of leasehold improvements and equipment, and laboratory and other supplies.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expense research and development costs as incurred. Conducting a significant amount of research and development is central to our business model. Product candidates in late stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of late stage clinical trials. We expect to maintain or increase our research and development expenses for the foreseeable future as we continue to develop our clinical stage product candidates and further advance our preclinical products and earlier stage research and development projects. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We use our employee and infrastructure resources across multiple research and development programs. We track expenses related to our most advanced product candidates on a per project basis. Accordingly, we allocate internal employee-related and infrastructure costs, as well as third-party costs, to each of these programs. We do not allocate to specific development programs either stock-based compensation expense or expenses related to preclinical programs. Costs that are not directly attributable to specific clinical programs, such as wages related to shared laboratory services, travel and employee training and development, are not allocated and are considered general research and discovery expenses.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU16"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our principal product development programs, including the research and development expenses allocated to each clinical product candidate, for the </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">three </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">months ended March&#160;31, 2018 and 2017</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">:</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MM-121</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,308</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,595</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MM-141</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,363</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,787</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MM-310</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,292</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,300</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preclinical, general research and discovery</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,681</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,986</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Legacy programs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,469</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">334</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">468</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total research and development expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,106</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,605</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The successful development of our product candidates is highly uncertain. At this time, other than as discussed below, we cannot reasonably estimate the nature, timing or costs of the efforts that will be necessary to complete the remainder of the development of any of our product candidates or the period, if any, in which material net cash flows from these product candidates may commence. This is due to the numerous risks and uncertainties associated with developing drugs, including the uncertainty of:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the scope, rate of progress and expense of our ongoing, as well as any additional, clinical trials and other research and development activities;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the potential benefits of our product candidates over other therapies;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to market, commercialize and achieve market acceptance for any of our product candidates that we are developing or may develop in the future;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">future clinical trial results;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the terms and timing of regulatory approvals; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the expense of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate. For example, if the U.S. Food and Drug Administration, or FDA, or another regulatory authority were to require us to conduct clinical trials beyond those which we currently anticipate will be required for the completion of clinical development of a product candidate or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">MM-121 (seribantumab)</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2015, we initiated the global, open-label, biomarker-selected, Phase 2 randomized SHERLOC clinical trial evaluating MM-121 in combination with docetaxel, versus docetaxel alone, in patients with heregulin positive NSCLC. We expect to report top-line results from the SHERLOC clinical trial in the second half of 2018.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2018, we dosed the first patient in our global, double-blinded, placebo-controlled, biomarker-selected Phase 2 randomized SHERBOC clinical trial evaluating MM-121 in combination with fulvestrant, versus fulvestrant alone, in patients with heregulin positive, hormone receptor positive, ErbB2 (HER2) negative, metastatic breast cancer.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">MM-141 (istiratumab)</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2015, we initiated the global, double-blinded, placebo-controlled, Phase 2 randomized CARRIE clinical trial evaluating MM-141 in combination with nab-paclitaxel and gemcitabine, versus nab-paclitaxel and gemcitabine alone, in patients with previously untreated metastatic pancreatic cancer with high serum levels of free IGF-1. We expect to report top-line results from the CARRIE clinical trial in the first half of 2018.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU17"></a><font style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">MM-310</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2017, we initiated a Phase 1 clinical trial of MM-310 to evaluate its safety and preliminary activity in patients with solid tumors and to identify the maximum tolerated dose. We expect to report safety data and the maximum tolerated dose from this trial in the second half of 2018.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Legacy Programs</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2017, we announced the completion of our strategic pipeline review resulting in the identification of what we believe to be our three most promising clinical programs, MM-121, MM-141 and MM-310. As a result, certain other product candidates in our pipeline were put on hold or discontinued, and we do not plan to invest in their additional development at this time.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">General and administrative expenses</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses consist primarily of salaries and other related costs for personnel, including stock-based compensation expenses and benefits, in our legal, intellectual property, business development, finance, information technology, corporate communications, investor relations and human resources departments. Other general and administrative expenses include costs for employee training and development, board of directors costs, depreciation, insurance expenses, facility-related costs not otherwise included in research and development expenses and professional fees for legal, accounting and information technology services. We expect to maintain general and administrative expenses at similar levels in future periods as we continue to support the further research and development and commercialization of our product candidates.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Interest income</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income for the three months ended March 31, 2018 consisted primarily of interest income associated with our marketable securities. Interest income for the three months ended March 31, 2017 consisted primarily of interest income associated with our interest bearing cash and cash equivalent accounts.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Interest expense</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense for the three months ended March 31, 2017 consisted primarily of cash and non-cash interest related to our 4.50% convertible notes due 2020, or convertible notes, and our 11.50% senior secured notes due 2022, or 2022 notes, both of which were extinguished in 2017. We had no debt at March 31, 2018.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Other income (expense), net</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense), net consists primarily of our proportionate share of losses from our equity method investment in Silver Creek Pharmaceuticals, Inc., or Silver Creek.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Critical Accounting Policies and Significant Judgments and Estimates</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which we have prepared in accordance with the rules and regulations of the Securities and Exchange Commission, or the SEC, and generally accepted accounting principles in the United States, or GAAP. The preparation of these condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported expenses during the reporting periods. We evaluate our estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Our actual results may differ from these estimates under different assumptions or conditions.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our critical accounting policies and the methodologies and assumptions we apply under them have not materially changed since March 12, 2018, the date we filed our Annual Report on Form 10-K for the year ended December&#160;31, 2017<font style="Background-color:#FFFFFF;color:#000000;">.</font> For more information on our critical accounting policies, refer to our Annual Report on Form 10-K for the year ended December&#160;31, 2017. </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU18"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Results of Operations</font></p>
<p style="margin-bottom:10pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Comparison of the three months ended March&#160;31, 2018 and 2017</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,106</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21,605</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,270</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,634</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from continuing operations</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,376</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27,239</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">275</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,979</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense), net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(681</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss from continuing operations</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,782</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(29,206</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Research and development expenses</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:6pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses were $13.1&#160;million for the three months ended March&#160;31, 2018 compared to $21.6 million for the three months ended March&#160;31, 2017, a decrease of $8.5 million, or 39%. This decrease was primarily attributable to:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">$4.3 million of decreased expenses related to our legacy programs </font><font style="color:#000000;font-family:Times New Roman;">as a result of our </font><font style="font-family:Times New Roman;">prioritization of MM-121, MM-141 and MM-310 and close-out activities associated with the legacy programs</font><font style="color:#000000;font-family:Times New Roman;">; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">$5.3 million of decreased expenses related to our preclinical, general research and discovery efforts related to the refocus of our early stage development spend and lower overhead costs to support general research and development expense related to the reduction in headcount.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This decrease was partially offset by $1.3 million of increased expenses related to the progression of the MM-121 and MM-141 programs.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">General and administrative expenses</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses were $4.3 million for the three months ended March&#160;31, 2018 compared to $5.6 million for the three months ended March&#160;31, 2017, a decrease of $1.3 million, or 23%. This decrease was primarily attributable to a decrease in corporate expenses related to headcount and stock-based compensation.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Interest income</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income was $0.3 million for the three months ended March 31, 2018 compared to $0.0 million for the three months ended March 31, 2017, primarily attributable to the interest income associated with our marketable securities. </p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Interest expense</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense was $2.0 million for the three months ended March 31, 2017. There was no interest expense during the three months ended March 31, 2018 due to the extinguishment of our debt in 2017.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Other income (expense), net</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense), net was $0.7 million of expense for the three months ended March 31, 2018 compared to $0.0 million for the three months ended March 31, 2017, primarily attributable to our proportionate share of losses from our equity method investment in Silver Creek. </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU19"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liquidity and</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> Capital Resources</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Sources of liquidity</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have financed our operations through March 31, 2018 primarily through private placements of convertible preferred stock, collaborations, public offerings of our securities, secured debt financings, sales of ONIVYDE and the asset sale. Through March&#160;31, 2018, we have received $580.7 million from the asset sale, $268.2 million from the sale of convertible preferred stock and warrants, $126.7 million of net proceeds from the sale of common stock in our initial public offering and a July 2013 follow-on public offering, $38.6 million of net proceeds from our 2015 &#8220;at the market offering&#8221; program, $39.6 million of net proceeds from a secured debt financing, $120.6 million of net proceeds from the issuance of the convertible notes in our July 2013 public offering, $168.5 million of net proceeds from the issuance of the 2022 notes, $492.5 million of upfront license fees, milestone payments, reimbursement of research and development costs and manufacturing services and other payments from our collaborations and $68.9 million of cash receipts related to ONIVYDE sales. As of March&#160;31, 2018, we had unrestricted cash and cash equivalents and marketable securities of $76.3 million.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash flows</p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides information regarding our cash flows for the three months ended March&#160;31, 2018 and 2017:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,339</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,156</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41,834</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(290</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,077</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net decrease in cash, cash equivalents and restricted cash</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(59,173</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,369</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Operating activities</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash used in operating activities was $17.3 million during the three months ended March&#160;31, 2018. The cash used in operating activities was primarily a result of our $17.8 million net loss from operations and changes in assets and liabilities of $2.1 million. The net decrease in operating assets and liabilities during the three months ended March&#160;31, 2018 was primarily driven by decreases in accounts payable, accrued expenses and other, prepaid expenses and other current assets and deferred rent. This decrease was offset by non-cash items, including $1.2 million in depreciation and amortization, $0.8 million of stock-based compensation expense, $0.7 million in loss on equity method investment. <font style="color:#000000;">Cash used in operating activities of $10.2 million during the three months ended March&#160;31, 2017, of which $18.1 million was used by continuing operations and $8.0 million was provided by discontinued operations, was primarily a result of our $29.2 million net loss from continuing operations and a net increase in operating assets and liabilities of $7.6 million. The net increase in operating assets and liabilities during the three months ended March&#160;31, 2017 was primarily driven by cash management strategies. This increase was offset by $3.5 million of non-cash items, including $0.8 million of stock-based compensation expense and $1.5 million in non-cash interest expense.</font></p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Investing activities</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash used in investing activities of $41.8 million during the three months ended March&#160;31, 2018 was primarily due to purchases of marketable securities totaling $41.8 million. <font style="color:#000000;">Cash used in investing activities of $0.3 million during the three months ended March&#160;31, 2017 was primarily due to purchases of property and equipment.</font></p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Financing activities</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There was no cash provided by or used in financing activities during the three months ended March&#160;31, 2018. <font style="color:#000000;">Cash provided by financing activities of $6.1 million during the three months ended March&#160;31, 2017 was primarily due to $4.0 million of proceeds received from the exercise of stock options and $2.0 million of proceeds received from the issuance of Series C preferred stock by Silver Creek.</font></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU20"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Funding requirements</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have incurred significant expenses and operating losses to date, and we expect to continue to incur significant expenses and operating losses for at least the next several years. We anticipate that we will continue to incur significant expenses as we:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">initiate or continue clinical trials of our most advanced product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">continue the research and development of our other product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">seek to discover additional product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">seek regulatory approvals for our product candidates that successfully complete clinical trials; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">continue to provide the operational, financial and management information systems and personnel to support our product development.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that at our currently forecasted spending rates, our existing financial resources, together with the net milestone payments we expect to receive under the Baxalta agreement, assuming certain milestones under such agreement are met, will be sufficient to fund our planned operations into the second half of 2019. We have based this estimate on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Because of the numerous risks and uncertainties associated with the development and commercialization of our product candidates, and the extent to which we utilize collaborations with third parties to participate in their development and commercialization, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and anticipated clinical trials. Our future capital requirements will depend on many factors, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the progress and results of the clinical trials of our most advanced product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to establish and maintain additional collaborations on favorable terms, and the success of any such future collaborations;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the timing and amount of potential milestone payments related to ONIVYDE that we may receive from Ipsen and Baxalta;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the scope, progress, results and costs of preclinical development, laboratory testing and clinical trials for our other product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the costs, timing and outcome of regulatory review of our current and future product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the costs of preparing, filing and prosecuting patent applications and maintaining, enforcing and defending intellectual property-related claims; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the extent to which we acquire or invest in businesses, products and technologies.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Until such time, if ever, as we can generate sufficient product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, licensing arrangements and other marketing and distribution arrangements. We also could engage in discussions with third parties regarding partnerships, joint ventures, combinations or divestitures of one or more of our product candidates as we seek to further the development of our research programs, improve our cash position and maximize stockholder value. There can be no assurance as to the timing, terms or consummation of any financing, collaboration, licensing arrangement or other marketing and distribution arrangement, partnership, joint venture, combination or divestiture. We do not have any committed external sources of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our stockholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. For example, if we raise additional funds through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Contractual Obligations and Commitments</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our contractual obligations and commitments were reported in our Annual Report on Form 10-K for the year ended December&#160;31, 2017, which was filed with the SEC on March 12, 2018. </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU21"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been no material changes from the contractual ob</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ligations and commitments previously disclosed in our Annual Report on Form 10-K.</font></p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Off-Balance Sheet Arrangements</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under SEC rules.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See Note 10, &#8220;<font style="Background-color:#FFFFFF;color:#000000;">Recent Accounting Pronouncements,</font>&#8221; in the accompanying notes to the condensed consolidated financial statements for a full description of recent accounting pronouncements.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_3_QUANTITATIVE_QUALITATIVE_DISCLOSU"></a>Item 3.<font style="margin-left:36pt;"><a name="ITEM_3_QUANTITATIVE_QUALITATIVE_DISCLOSU"></a>Quantitative and Qualitati</font>ve Disclosures About Market Risk.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We invest in a variety of financial instruments, principally cash deposits, money market funds, securities issued by the U.S. government and its agencies and corporate debt securities. The goals of our investment policy are preservation of capital, fulfillment of liquidity needs and fiduciary control of cash and investments. We also seek to maximize income from our investments without assuming significant risk.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of interest rates, particularly because our investments are in short-term marketable securities. Due to the short-term duration of our investment portfolio and the low risk profile of our investments, an immediate 10% change in interest rates would not have a material effect on the fair market value of our portfolio. We have the ability and intention to hold our investments until maturity, and therefore, we would not expect our operating results or cash flows to be affected to any significant degree by the effect of a sudden change in market interest rates on our investment portfolio.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not currently have any auction rate or mortgage-backed securities. We do not believe our cash, cash equivalents and marketable securities have significant risk of default or illiquidity, however we cannot provide absolute assurance that in the future our investments will not be subject to adverse changes in market value.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_4_CONTROLS_PROCEDURES"></a>Item 4.<font style="margin-left:36pt;"><a name="ITEM_4_CONTROLS_PROCEDURES"></a>Controls </font>and Procedures.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Evaluation of Disclosure Controls and Procedures</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer (our principal executive officer and principal financial officer, respectively), evaluated the effectiveness of our disclosure controls and procedures as of March&#160;31, 2018. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of March&#160;31, 2018, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Changes in Internal Control Over Financial Reporting</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the three months ended March&#160;31, 2018 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU22"></a><a name="PART_II"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_II"></a>PART</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> II</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">OTHER INFORMATION</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1A_RISK_FACTORS"></a>Item 1A.<font style="margin-left:36pt;"><a name="ITEM_1A_RISK_FACTORS"></a>Ris</font>k Factors.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The following risk factors and other information included in this Quarterly Report on Form 10-Q should be carefully considered. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we presently deem less significant may also impair our business operations. Please see page 1 of this Quarterly Report on Form 10-Q for a discussion of some of the forward-looking statements that are qualified by these risk factors. If any of the following risks occur, our business, financial condition, results of operations and future growth prospects could be materially and adversely affected.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to the Sale of the Commercial Business to Ipsen</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Because the commercial business represented all of our revenues for fiscal year 2016 and the three months ended March 31, 2017, our business following the sale of the commercial business is substantially different than it was prior to such sale. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of the completion of the asset sale with Ipsen, Ipsen acquired our right, title and interest in the commercial business. The commercial business represented all of our revenues for the fiscal year 2016 and the three months ended March 31, 2017. Following the asset sale, we retained only non-commercial assets, including our clinical and preclinical development programs, or the pipeline business. Our results of operations and financial condition may be materially affected if we fail to grow the pipeline business, if we are unable to raise additional capital when needed to run the pipeline business, if we must incur significant costs in order to raise additional capital to run the pipeline business or if we are unable to successfully develop and commercialize our remaining product candidates. </p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have been, and in the future may be, subject to securities litigation, which is expensive and could divert our attention. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have been, and may in the future be, subject to securities class action litigation in connection with the asset sale. Securities litigation against us could result in substantial costs and divert our management&#8217;s attention, which could seriously harm our business. For instance, a putative stockholder class action suit was filed by a purported stockholder of ours in the Superior Court of Massachusetts for the County of Middlesex against us and our directors. The case was captioned <font style="font-style:italic;">Robert Garfield v. Merrimack Pharmaceuticals Inc., et al.</font>, or the Garfield Action. The Garfield Action complaint alleged that our directors breached their fiduciary duties by entering into the asset sale agreement and that the definitive proxy statement relating to the asset sale contained inadequate disclosures and omissions. Although we believed that the Garfield Action was without merit, to avoid the risk of the litigation delaying or adversely affecting the asset sale and to minimize the expense of defending the litigation related to the asset sale, we agreed to make supplemental disclosures related to the asset sale and to pay the plaintiff&#8217;s counsel $375,000 in attorney&#8217;s fees in connection with the resolution of the Garfield Action. As a result, the plaintiff concluded that the claims in the Garfield Action were mooted, and the Garfield Action was dismissed with prejudice. Nonetheless, there can be no guarantee that there will not be additional securities class action litigation in connection with the asset sale. </p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">There can be no guarantee that Ipsen will comply with its obligation to use commercially reasonable efforts in connection with the development of ONIVYDE or that the milestones set forth in the Baxalta agreement will be achieved. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ipsen has agreed to use commercially reasonable efforts to develop ONIVYDE in connection with obtaining the regulatory approval by the FDA of ONIVYDE for certain indications. Although the results of this approval process may enable Ipsen to achieve the milestones necessary for us to receive the contingent payments under the asset sale agreement, there is no guarantee that Ipsen will take the steps set forth in the asset sale agreement and that such development will lead to the successful approval of ONIVYDE for such additional indications. Therefore, there can be no guarantees that any of the milestones set forth in the asset sale agreement will be achieved and that we will receive any future contingent payments. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, although the asset sale agreement entitles us to receive certain net milestone payments of up to $33.0&#160;million that may become payable under the Baxalta agreement, achievement of such milestones and payment of any or all of the $33.0&#160;million is not guaranteed.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU23"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Ipsen did not assume</font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> any of the excluded liabilities under the asset sale agreement. </font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the asset sale agreement, Ipsen assumed only certain specified liabilities set forth in the asset sale agreement and did not assume all of the liabilities associated with the commercial business. Certain liabilities remain with us post-closing. While we believe that we have adequately accrued for these liabilities or are adequately insured against certain of the risks associated with such excluded liabilities, there can be no assurances that additional expenditures will not be incurred in resolving any such liabilities. </p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The asset sale agreement may expose us to contingent liabilities. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have agreed to indemnify Ipsen for certain breaches of representations, warranties or covenants made by us in the asset sale agreement and for certain specified existing litigation. We have agreed that if we cannot pay our indemnification obligations, Ipsen will have set-off rights against any future contingent payments. Significant indemnification claims by Ipsen could further materially and adversely affect our financial condition and/or significantly reduce any future contingent payments.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Financial Position and Need for Additional Capital</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have incurred significant losses since our inception. We expect to incur operating losses for the foreseeable future and may never achieve or maintain profitability.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since inception, we have incurred significant operating losses. Our net loss from continuing operations was $17.8&#160;million for the three months ended March&#160;31, 2018. Our net loss from continuing operations before income tax benefit was $118.4 million for the year ended December&#160;31, 2017, $169.5 million for the year ended December 31, 2016 and $162.8 million for the year ended December 31, 2015. As of March&#160;31, 2018, we had an accumulated deficit of $500.6 million. To date, we have financed our operations primarily through private placements of convertible preferred stock, collaborations, public offerings of our securities, secured debt financings, sales of ONIVYDE and the asset sale. We have devoted substantially all of our efforts to research and development, including clinical trials and recently to commercialization of our first product, ONIVYDE, which was sold to Ipsen. We have not completed development of or commercialized any other product candidates or diagnostics other than ONIVYDE. We expect to continue to incur significant expenses and increasing operating losses for at least the next several years. We anticipate that our expenses will increase substantially as we:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">initiate or continue clinical trials of our most advanced product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">continue the research and development of our other product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">seek to discover additional product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">seek regulatory approvals for our product candidates that successfully complete clinical trials; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">continue to provide the operational, financial and management information systems and personnel to support our product development.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To become and remain profitable, we must succeed in developing and commercializing products with significant market potential. This will require us to be successful in a range of challenging activities, including discovering product candidates, completing preclinical testing and clinical trials of our product candidates, obtaining regulatory approval for these product candidates and manufacturing, marketing and selling or partnering those products for which we may seek and receive regulatory approval. We may never succeed in these activities and may never generate revenues that are significant or large enough to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would depress the value of our company and could impair our ability to raise capital, expand our business, diversify our product offerings or continue our operations. A decline in the value of our company could also cause our stockholders to lose all or part of their investment.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We will need substantial additional funding. If we are unable to raise capital when needed, we would be forced to delay, reduce or eliminate our product development programs or commercialization efforts.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will need substantial additional funding in connection with our continuing operations. We expect to continue to incur significant research and development expenses in connection with our ongoing activities, particularly as we continue the research, development and clinical trials of, and seek regulatory approval for, our product candidates. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs or commercialization efforts.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU24"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon the closing of </font><font style="Background-color:#FFFFFF;color:#000000;">the asset sale with Ipsen, which occurred on April 3, 2017, we received a $575.0 million upfront cash payment from Ipsen,</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> subject to the working capital adjustment</font><font style="Background-color:#FFFFFF;color:#000000;">. We used these proceeds to redeem the 2022 notes, including pay</font><font style="Background-color:#FFFFFF;color:#000000;">ment of the $175.0 million outstanding aggregate principal amount, interest through the redemption date and an additional make-whole premium payment of approximately $20.1 million, and our board of directors declared a special cash dividend of $140.0 milli</font><font style="Background-color:#FFFFFF;color:#000000;">on, which was payable on May 26, 2017 to stockholders of record as of the close of business on May 17, 2017. Additionally, if certain milestones under the Baxalta agreement are met, we currently expect to receive up to an aggregate of $33.0 million in net </font><font style="Background-color:#FFFFFF;color:#000000;">mi</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lestone payments in future periods. As a result of the cash received from the consummation of the asset sale, we believe that at our currently forecasted spending rates, our existing financial resources, together with the net milestone payments we expect</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to receive under the Baxalta agreement, assuming certain milestones under such agreement are met, will be sufficient to fund our planned operations into the second half of 2019. We have based this estimate on assumptions that may prove to be wrong, and we</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> could use our available capital resources sooner than we currently expect. Because of the numerous risks and uncertainties associated with the development and commercialization of our product candidates, and the extent to which we may utilize collaboratio</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ns with third parties to participate in their development and commercialization, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and anticipated clinical trials. Our future capital r</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">equirements will depend on many factors, including:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the progress and results of the clinical trials of our most advanced product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to establish and maintain additional collaborations on favorable terms, and the success of any such future collaborations;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_cp_blt_1_42"></a><font style="font-family:Times New Roman;">the timing and amount of potential milestone payments related to ONIVYDE that we may receive from Ipsen and Baxalta;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the scope, progress, results and costs of preclinical development, laboratory testing and clinical trials for our product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the costs, timing and outcome of regulatory review of our current and future product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the costs of preparing, filing and prosecuting patent applications and maintaining, enforcing and defending intellectual property-related claims; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the extent to which we acquire or invest in businesses, products and technologies.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data required to obtain regulatory approval and, even if regulatory approval is obtained, achieve product sales of any of our product candidates. In addition, any of our product candidates, even if approved, may not achieve commercial success. If we fail to generate sufficient revenues from collaborations or the commercialization of any of our product candidates, we will need to continue to rely on additional financing to achieve our business objectives.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not have any committed external source of funds. Sources of funds may not be available or, if available, may not be available on terms satisfactory to us and could result in significant stockholder dilution.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Until such time, if ever, as we can generate sufficient product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, licensing arrangements and other marketing and distribution arrangements. We also could engage in discussions with third parties regarding partnerships, joint ventures, combinations or divestitures of one or more of our product candidates as we seek to further the development of our research programs, improve our cash position and maximize stockholder value. There can be no assurance as to the timing, terms or consummation of any financing, collaboration, licensing arrangement or other marketing and distribution arrangement, partnership, joint venture, combination or divestiture.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU25"></a>On December 15, 2017, we filed a registration statement on Form S-3 with the SEC to allow the issuance of our securities from time to time in one or more offerings of up to $150,000,000 in aggregate dollar amount. This registration statement was declared effective by the SEC on January 5, 2018. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our existing common stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our stockholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, and these covenants may also require us to attain certain levels of financial performance and we may not be able to do so; any such failure may result in the acceleration of such debt and the foreclosure by our creditors on the collateral we used to secure the debt. The debt issued in a debt financing would also be senior to our outstanding shares of capital </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">stock upon our liquidation. Significant indebtedness and the pledge of our assets as collateral in the future could limit our ability to obtain additional debt financing. If we raise additional funds through marketing and distribution arra</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ngements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or commercialization efforts or grant rights to deve</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lop and market product candidates that we would otherwise prefer to develop and market ourselves.</font></p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Future indebtedness may limit cash flow available to invest in the ongoing needs of our business.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have had in the past, and may in the future have, a significant amount of indebtedness. In July 2013, we issued $125.0 million aggregate principal amount of convertible notes. In December 2015, we issued $175.0 million aggregate principal amount of 2022 notes. Although we used a portion of the proceeds from the asset sale to fully extinguish the 2022 notes, and we have extinguished all but $56,000 of the aggregate remaining principal amount of the convertible notes, we could in the future incur additional indebtedness.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Substantial debt combined with our other financial obligations and contractual commitments could have significant adverse consequences, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">requiring us to dedicate a substantial portion of cash flow from operations to the payment of interest on, and principal of, our debt, which will reduce the amounts available to fund working capital, capital expenditures, product development efforts and other general corporate purposes;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">increasing our vulnerability to adverse changes in general economic, industry and market conditions;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">obligating us to restrictive covenants that may reduce our ability to take certain corporate actions or obtain further debt or equity financing;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">limiting our flexibility in planning for, or reacting to, changes in our business and the industry in which we compete; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">placing us at a competitive disadvantage compared to our competitors that have less debt or better debt servicing options.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent we seek funds from external sources in the future, such funds may not be available on acceptable terms, if at all. In addition, a failure to comply with the covenants under any future debt instruments could result in an event of default under those instruments, and such debt instruments could require covenants and pledges of our assets as collateral which could limit our ability to obtain other debt financing.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The recently passed comprehensive tax reform bill could adversely affect our business and financial condition.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 22, 2017, President Trump signed into law new legislation that significantly revises the Internal Revenue Code of 1986, as amended. The newly enacted federal income tax law, among other things, contains significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%, limitation of the tax deduction for net interest expense to 30% of adjusted earnings (except for certain small businesses), limitation of the deduction for net operating losses to 80% of current year taxable income and elimination of net operating loss carrybacks, in each case, for losses arising in taxable years beginning after December 31, 2017 (though any such net operating losses may be carried forward indefinitely), one time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, elimination of U.S. tax on foreign earnings (subject to certain important exceptions), immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits. Notwithstanding the reduction in the corporate income tax rate, the overall impact of the new federal tax law is uncertain and our business and financial condition could be adversely affected. In addition, it is uncertain how various states will respond to the newly enacted federal tax law. The impact of this tax reform on holders of our common stock is also uncertain and could be adverse. We urge our stockholders to consult with their legal and tax advisors with respect to this legislation and the potential tax consequences of investing in or holding our common stock.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU26"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We might not be able to utilize a significant portion of our net operating loss carryforwards and research and development tax credit carryforwards.</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2017, we had federal net operating loss carryforwards of $138.1 million, which begin to expire in 2034, and state net operating loss carryforwards of $223.4 million, which begin to expire in 2028. As of December 31, 2017, we also had federal research and development tax credit carryforwards of $28.8 million and state research and development tax credit carryforwards $18.7 million, which begin to expire in 2022 and 2026, respectively. These net operating loss and tax credit carryforwards could expire unused and be unavailable to offset our future income tax liabilities. Under the newly enacted federal income tax law, federal net operating losses incurred in 2018 and in future years may be carried forward indefinitely, but the deductibility of such federal net operating losses is limited. It is uncertain how various states will respond to the newly enacted federal tax law. If our ability to use our historical net operating loss and tax credit carryforwards is materially limited, it would harm our future operating results by effectively increasing our future tax obligations.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our investments are subject to risks that could result in losses.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have invested and plan to continue to invest our cash in a variety of financial instruments, principally securities issued by the U.S. government and its agencies, investment grade corporate bonds, including commercial paper, and money market instruments. All of these investments are subject to credit, liquidity, market and interest rate risk. Such risks, including the failure or severe financial distress of the financial institutions that hold our cash, cash equivalents and investments, may result in a loss of liquidity, impairment to our investments, realization of substantial future losses, or a complete loss of the investments in the long-term, which may have a material adverse effect on our business, results of operations, liquidity and financial condition. In order to manage the risk to our investments, we maintain an investment policy that, among other things, limits the amount that we may invest in any one issue or any single issuer and requires us to only invest in high credit quality securities, but there can be no guarantee that our investments will not result in losses.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">A decrease in the carrying value of our equity holdings in Silver Creek could adversely affect our balance sheet.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2010, we acquired 12,000,000 shares of Series A preferred stock of Silver Creek in exchange for our grant to Silver Creek of technology licenses. As these shares represented a controlling financial interest, we consolidated Silver Creek in our consolidated financial statements. In the third quarter of 2017, Silver Creek completed its Series C preferred stock financing, which reduced our ownership percentage of Silver Creek below 50% and resulted in us deconsolidating Silver Creek from our consolidated financial statements. As a result of the deconsolidation, we now account for our investment in Silver Creek under the equity method of accounting. The carrying value of our shares of Series A preferred stock of Silver Creek was $9.8 million at March 31, 2018. There can be no guarantee that the value of our investment in Silver Creek will not realize a substantial future loss or complete loss of value, which would in turn adversely affect our balance sheet.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to the Development and Commercialization of Our Product Candidates</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We depend heavily on the success of our clinical stage product candidates. All of our product candidates are in preclinical and clinical development. Clinical trials of our product candidates may not be successful. If we are unable to successfully commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We invest a significant portion of our efforts and financial resources in the development of our clinical stage product candidates for the treatment of various types of cancer. All of our product candidates are still in preclinical and clinical development. Our ability to generate meaningful product revenues will depend heavily on the successful development of our product candidates. The success of our product candidates, which include both our product candidates and companion diagnostic candidates, will depend on several factors, including the following:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">successful enrollment in, and completion of, preclinical studies and clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">receipt of marketing approvals from the FDA and similar regulatory authorities outside the United States for our product candidates, including our diagnostics;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">establishing commercial manufacturing capabilities, which we anticipate doing primarily through arrangements with third-party manufacturers;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">launching commercial sales of any approved products, whether alone or in collaboration with others;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">acceptance of any approved products by patients, the medical community and third-party payors;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">effectively competing with other therapies;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a continued acceptable safety profile of any products following approval; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">qualifying for, maintaining, enforcing and defending intellectual property rights and claims.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU27"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully develop our product candidates, which would materially harm our business.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, in connection with our strategic review of our pipeline which was completed in January 2017, we amended several of our clinical trials, such as our SHERLOC and CARRIE clinical trials, resulting in changes to their power, design and timing, and also discontinued several trials, including our Phase 2 clinical trial of MM-302. </p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If clinical trials of our product candidates fail to demonstrate safety and efficacy to the satisfaction of the FDA or similar regulatory authorities outside the United States or do not otherwise produce positive results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may never receive approval to commercialize our product candidates in the United States or other jurisdictions. Before obtaining regulatory approval for the sale of our product candidates, we must conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome. A failure of one or more of our clinical trials can occur at any stage of testing. The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and successful interim results of a clinical trial do not necessarily predict successful final results.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may experience numerous unexpected events during, or as a result of, clinical trials that could delay or prevent our ability to receive regulatory approval or commercialize our product candidates, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">regulators or institutional review boards may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be insufficient or slower than we anticipate or patients may drop out of these clinical trials at a higher rate than we anticipate;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">we might have to suspend or terminate clinical trials of our product candidates for various reasons, including a finding of a lack of clinical response or a finding that the patients are being exposed to unacceptable health risks;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">regulators or institutional review boards may require that we or our investigators suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the cost of clinical trials of our product candidates may be greater than we anticipate;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the supply or quality of our product candidates, companion diagnostics or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate or prohibitively expensive; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our product candidates may have undesirable side effects or other unexpected characteristics, causing us or our investigators to suspend or terminate the trials.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, in December 2016, we decided to discontinue our Phase 2 clinical trial of MM-302 in combination with trastuzumab in patients with ErbB2 (HER2) positive, locally advanced or metastatic breast cancer based on an opinion from the Data Safety Monitoring Board that continuing the clinical trial would be unlikely to demonstrate benefit over the comparator treatments. Additionally, the previous Phase 2 clinical trials of MM-121 in unselected patient populations with NSCLC, ovarian cancer and breast cancer did not meet their primary endpoints.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preclinical and clinical data may not be predictive of the success of later clinical trials, and are often susceptible to varying interpretations and analyses. Many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU28"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are required to condu</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tes</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ts are not positive or are only modestly positive or if there are safety concerns, we may:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">be delayed in obtaining marketing approval for our product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">not obtain marketing approval at all;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">obtain approval for indications that are not as broad as intended;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">have the product removed from the market after obtaining marketing approval;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">be subject to additional post-marketing testing requirements;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">be subject to restrictions on how the product is distributed or used; or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">be unable to obtain reimbursement for use of the product.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Delays in testing or approvals may result in increases to our product development costs. We do not know whether any clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do and impair our ability to commercialize our product candidates and may harm our business and results of operations.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If serious adverse or undesirable side effects are identified during the development of our product candidates or following their approval and commercialization, we may need to modify or abandon our development or marketing of such product or product candidate.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All of our product candidates are still in preclinical or clinical development and their risk of failure is high. It is impossible to predict when or if any of our product candidates will prove effective or safe in humans or will receive regulatory approval, and it is impossible to ensure that safety or efficacy issues will not arise following regulatory approval. Currently marketed therapies for solid tumors are generally limited to some extent by their toxicity. Use of our product candidates as monotherapies in clinical trials also has resulted in adverse events consistent in nature with other marketed therapies. When used in combination with other marketed or investigational therapies, our product candidates may exacerbate adverse events associated with the other therapy. If our products or product candidates, either alone or in combination with other therapies, result in undesirable side effects or have characteristics that are unexpected, we may need to modify or abandon their development or marketing. </p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we experience delays in the enrollment of patients in our clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials to obtain a statistically significant result as required by the FDA or other regulatory authorities. In addition, many of our competitors have ongoing clinical trials for product candidates that could be competitive with our product candidates. Patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors&#8217; product candidates or rely upon treatment with existing therapies that may preclude them from eligibility for our clinical trials.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Enrollment delays in our clinical trials may result in increased development costs for our product candidates, which would cause the value of the company to decline and limit our ability to obtain additional financing. Our inability to enroll a sufficient number of patients for any of our current or future clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In general, we forecast enrollment for our clinical trials based on experience from previous clinical trials and monitor enrollment to be able to make adjustments to clinical trials when appropriate, including as a result of slower than expected enrollment that we experience from time to time in our clinical trials. It is possible that slow enrollment could require us to make adjustments to our clinical trials. If these adjustments do not overcome problems with slow enrollment, we could experience significant delays or abandon the applicable clinical trial altogether.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU29"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we are unable to successfully develop companion diagnostics for our product candidates, or experience significan</font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">t delays in doing so, we may not realize the full commercial potential of our product candidates.</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An important component of our business strategy is to develop, either alone or together with third parties, companion diagnostics for each of our product candidates. There has been limited success to date industry-wide in developing companion diagnostics. To be successful, we will need to address a number of scientific, technical, regulatory and logistical challenges. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All of our companion diagnostic candidates are in preclinical or clinical development. We have limited experience in the development of companion diagnostics and may not be successful in developing appropriate diagnostics to pair with any of our product candidates that receive marketing approval. The FDA and similar regulatory authorities outside the United States are generally expected to regulate <font style="font-style:italic;">in vitro</font> companion diagnostics as medical devices and to require separate regulatory approval prior to commercialization. Given our limited experience in developing diagnostics, we expect to rely in part on third parties for their design, development and manufacture. If we, or any third parties that we engage to assist us, are unable to successfully develop companion diagnostics for our product candidates, or experience delays in doing so, the development of our product candidates may be adversely affected, our product candidates may not receive marketing approval and we may not realize the full commercial potential of any product candidates that receive marketing approval. As a result, our business would be harmed, possibly materially.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Any of our product candidates that receive regulatory approval may fail to achieve the degree of market acceptance by physicians, patients, healthcare payors and others in the medical community necessary for commercial success.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if any of our product candidates receive marketing approval, they may nonetheless not gain sufficient market acceptance by physicians, patients, healthcare payors and others in the medical community. If these products do not achieve an adequate level of acceptance, we may not generate significant product revenues and we may not become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors that may be uncertain or subjective, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the prevalence and severity of any side effects;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">efficacy and potential advantages or disadvantages compared to alternative treatments;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the price we charge for our product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">convenience and ease of administration compared to alternative treatments;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to successfully develop companion diagnostics that effectively identify patient populations likely to benefit from treatment with our product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the strength of marketing and distribution support; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">sufficient third-party coverage or reimbursement.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The development and commercialization of new therapeutic and diagnostic products is highly competitive. We face competition with respect to our current product candidates, and will face competition with respect to any products that we may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. Several large pharmaceutical and biotechnology companies currently market and sell products for the treatment of the solid tumor indications for which we are developing our product candidates. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization. Many of these competitors are attempting to develop therapeutics for our target indications.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing our product candidates for the treatment of solid tumors. There are a variety of available therapies marketed for solid tumors. In many cases, these drugs are administered in combination to enhance efficacy. Some of these drugs are branded and subject to patent protection, and others are available on a generic basis. Many of these approved drugs are well established therapies and are widely accepted by physicians, patients and third-party payors. This may make it difficult for us to achieve our business strategy of replacing existing therapies with our product candidates.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU30"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are also a number of products in late stage clinical development to treat solid tumors. Our competitors may develop pro</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ducts that are more effective, safer, more convenient or less costly than any that we are developing or that would render our product candidates obsolete or non-competitive. Our competitors may also obtain FDA or other regulatory approval for their product</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s more rapidly than we may obtain approval for ours. In addition, our ability to compete may be affected because in many cases insurers or other third-party payors seek to encourage the use of generic products. There are many generic products currently on </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the market for the indications that we are pursuing, and additional products are expected to become available on a generic basis over the coming years.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of our competitors have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Even if we are able to commercialize any of our product candidates, those product candidates may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, which could harm our business.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The regulations that govern marketing approvals, pricing and reimbursement for new therapeutic and diagnostic products vary widely from country to country. Some countries require approval of the sale price of a product before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain regulatory approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product and negatively impact the revenues we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtain regulatory approval.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to commercialize any approved products successfully also will depend in part on the extent to which coverage and reimbursement for these products and related treatments will be available from third-party payors, including government payors such as Medicare and Medicaid, private health insurers and managed care organizations. There have been, and we expect there will continue to be, legislative and regulatory proposals to change the healthcare system in ways that could impact our ability to sell our products profitably. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. The federal government, state legislatures and foreign governments have shown significant interest in implementing cost containment programs to limit the growth of government-paid healthcare costs, including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs. Adoption of such controls and measures, and tightening of restrictive policies in jurisdictions with existing controls and measures, could limit payments for pharmaceuticals and the other product candidates that we are developing and could have a material adverse effect our net revenue and results.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third-party payors decide which drugs they will pay for and establish reimbursement and co-pay levels. The growing emphasis on managed care in the United States has increased and we expect will continue to increase the pressure on drug pricing. Third-party payors are increasingly challenging the prices charged for medical products and services and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. If these third-party payors do not consider our products to be cost-effective compared to other available therapies, they may not cover our products after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow us to sell our products at a profit. In order to secure coverage and reimbursement for any product that might be approved for sale, we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA or other comparable regulatory approvals. Even with clinical trials, our product candidates may be considered less safe, less effective or less cost-effective than other products, and third-party payors may not provide coverage and reimbursement for our products or any of our product candidates that we commercialize, in whole or in part.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The process for determining whether a payor will provide coverage for a drug product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the drug product once coverage is approved. Third-party payors may limit coverage to specific drug products on a formulary, which might not include all of the approved drugs for a particular indication, and a payor&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU31"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot be sure that reimbursement will be available for any product that we commercialize and, if reimbursement is available, what the level of reimbursement will be. Reimbursement may impact the d</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">emand for, or the price of, any product for which we obtain marketing approval. Third-party reimbursement may not be sufficient to enable us to maintain price levels high enough to realize an appropriate return on our investment in product development. Obt</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">aining reimbursement for our products may be particularly difficult because of the higher prices often associated with products administered under the supervision of a physician. In addition, coverage policies, third-party reimbursement rates and drug pric</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ing regulation may change at any time. Thus, even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in t</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">he future. The marketability of any products for which we receive regulatory approval for commercial sale may also suffer if the government and third-party payors fail to provide adequate coverage and reimbursement. If reimbursement is not available or is </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">available only to limited levels, we may not be able to successfully commercialize any product candidate that we successfully develop.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, there may be significant delays in obtaining reimbursement for any approved products, and coverage may be more limited than the purposes for which the product is approved by the FDA or regulatory authorities in other countries. Eligibility for reimbursement does not imply that any product will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim payments for new products, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Payment rates may vary according to the use of the product and the clinical setting in which it is used, may be based on payments allowed for lower cost products that are already reimbursed, and may be incorporated into existing payments for other services. Net prices for products may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future weakening of laws that presently restrict imports of products from countries where they may be sold at lower prices than in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. Our inability to promptly obtain coverage and appropriate payment rates from both government-funded and private payors for new products that we develop could therefore have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products, and our overall financial condition.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and an even greater risk related to the commercial sale of any products that we may develop. If we cannot successfully defend ourselves against claims that any of our product candidates caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">decreased demand for the products or product candidates that we may develop;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">injury to our reputation and significant negative media attention;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">withdrawal of patients from clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">significant costs to defend the related litigation;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">substantial monetary awards to patients;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">loss of revenue; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the inability to commercialize any products that we may develop.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently hold $10.0 million in product liability insurance coverage, which may not be adequate to cover all liabilities that we may incur. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any or every liability that may arise.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because we have limited financial and managerial resources, we focus on research programs and product candidates for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU32"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also may not be successful in our efforts to identify or discover new or additional product candidates beyond our current preclinical and clinical product candidates. Research programs to identify new product candidates require substantial techni</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cal, financial and human resources. These research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have otherwise been more advantageous for us to retain sole development and commercialization rights.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and radioactive and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We also store certain low level radioactive waste at our facilities until the materials can be properly disposed of. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage, use or disposal of biological, hazardous or radioactive materials.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we may be required to incur substantial costs to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Fluctuations in foreign currency exchange rates could substantially increase the costs of our clinical trial programs.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A significant portion of our clinical trial activities are conducted outside of the United States, and associated costs may be incurred in the local currency of the country in which the trial is being conducted, which costs could be subject to fluctuations in foreign exchange rates. At present, we do not engage in hedging transactions to protect against uncertainty in future exchange rates between particular foreign currencies and the U.S. dollar. A decline in the value of the U.S. dollar against currencies in geographies in which we conduct clinical trials could have a negative impact on our research and development costs. We cannot predict the impact of foreign currency fluctuations, and foreign currency fluctuations in the future may adversely affect our development costs.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Dependence on Third Parties</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may depend on collaborations with third parties for the development and commercialization of our product candidates. If those collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depending on our capital requirements, development and commercialization costs, need for additional therapeutic expertise and other factors, it is possible that we will enter into additional development and commercialization arrangements with respect to either oncology product candidates or product candidates in other therapeutic areas.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our potential collaborators for any distribution, marketing, licensing or broader collaboration arrangements include large and mid-size pharmaceutical companies, regional and national pharmaceutical companies and biotechnology companies. We will have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of our product candidates. Our ability to generate revenues from these arrangements will depend on our collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_226"></a><a name="_cp_text_1_226"></a>Collaborations involving our product candidates pose the following risks to us:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU33"></a><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs based on clinical trial result</font><font style="font-family:Times New Roman;">s, changes in their strategic focus or available funding, or external factors such as an acquisition that diverts resources or creates competing priorities;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a collaborator with marketing and distribution rights to one or more products may not commit sufficient resources to their marketing and distribution;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our proprietary information or expose us to potential litigation;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">disputes may arise between us and the collaborators that result in the delay or termination of the research, development or commercialization of our product candidates or that result in costly litigation or arbitration that diverts management attention and resources; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">collaborations may be terminated, such as the termination of our license and collaboration agreement with Sanofi effective December 17, 2014, and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. If a present or future collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program could be delayed, diminished or terminated.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For instance, although it is not a collaboration agreement, Ipsen has agreed pursuant to the asset sale agreement to use commercially reasonable efforts to develop ONIVYDE in connection with obtaining the regulatory approval by the FDA of ONIVYDE for certain indications. Although the results of this approval process may enable Ipsen to achieve the milestones necessary for us to receive the contingent payments under the asset sale agreement, there is no guarantee that Ipsen will take the steps set forth in the asset sale agreement and that such development will lead to the successful approval of ONIVYDE for such additional indications. Therefore, there can be no guarantees that any of the milestones set forth in the asset sale agreement will be achieved and that we will receive any future contingent payments. Similarly, although the asset sale agreement entitles us to receive certain net milestone payments of up to $33.0&#160;million under the Baxalta agreement, achievement of such milestones and payment of any or all of the $33.0&#160;million is not guaranteed.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we are not able to establish additional collaborations, we may have to alter our development plans.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product development programs and the potential commercialization of any approved product candidates will require substantial additional cash to fund expenses. For some of our product candidates, we may decide to collaborate with pharmaceutical and biotechnology companies for the development and potential commercialization of those product candidates.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We face significant competition in seeking appropriate collaborators. Collaborations are complex and time-consuming to negotiate and document. We may also be restricted under existing collaboration agreements from entering into agreements on certain terms with other potential collaborators. We may not be able to negotiate collaborations on acceptable terms, or at all. If that were to occur, we may have to curtail the development of a particular product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of our sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we will not be able to bring our product candidates to market and generate product revenue.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU34"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We rely on third parties to conduct our clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials.</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not independently conduct clinical trials of our product candidates. We rely on third parties, such as contract research organizations, clinical data management organizations, medical institutions and clinical investigators, to perform this function. Our reliance on these third parties for clinical development activities reduces our control over these activities but does not relieve us of our responsibilities. We remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA and other international regulatory agencies require us to comply with standards, commonly referred to as good clinical practices, for conducting, recording and reporting the results of clinical trials to assure that adverse event data are reported within required timeframes, that data and reported results are credible and accurate and that the rights, integrity and confidentiality of patients in clinical trials are protected. Furthermore, these third parties may also have relationships with other entities, some of which may be our competitors. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, regulatory approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also rely on other third parties to store and distribute supplies for our clinical trials. Any performance failure on the part of our existing or future distributors could delay clinical development or regulatory approval of our product candidates or commercialization of our products or cause us to incur additional costs, producing additional losses and depriving us of potential product revenue.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also intend to utilize companion diagnostics in several of our current and planned clinical trials, including our current clinical trials of MM-121, MM-141 and MM-310, to preselect patients who will receive specified treatment regimens. We will rely on third-party laboratories to test patient samples in connection with such companion diagnostics. Any failure on the part of these laboratories to properly perform such testing could jeopardize those clinical trials and delay or prevent the approval of the associated product candidate.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to the Manufacturing of Our Product Candidates</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We rely on third parties for the production of our product candidates. This increases the risk that we will not have sufficient quantities of our product candidates at an acceptable cost or on an acceptable schedule, which could delay, prevent or impair our development or commercialization efforts.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely on third-party manufacturers for most of the aspects of the production of our product candidates, including the production of bulk drug substance and fill finish and labeling activities. Reliance on third-party manufacturers entails risks, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">reliance on the third party for regulatory compliance and quality assurance;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the possible breach of the manufacturing agreement by the third party; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third-party manufacturers may not be able to comply with current good manufacturing practices, or cGMP, or Quality System Regulation, or QSR, or similar regulatory requirements outside the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For instance, in 2010, a former fill finish third-party contractor that we used to fill and package MM-121 experienced FDA inspection issues with its quality control processes that resulted in a formal warning letter from the FDA. As a result, we pulled some MM-121 from clinical trial sites and replaced it with MM-121 that was filled by a different contractor. This restocking resulted in a few patients missing one or two doses of MM-121. It is possible that we could experience similar issues with other contractors.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, our products may compete with the products of other companies for access to manufacturing facilities. Because there are a limited number of manufacturers that operate under cGMP or QSR regulations and that might be capable of manufacturing for us at an appropriate scale, we may not have access to such manufacturers.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the asset sale, we entered into a transition services agreement with Ipsen, pursuant to which we and Ipsen are providing certain services to each other for a period of 24 months, including Ipsen&#8217;s agreement to manufacture MM-310 pursuant to a manufacturing services agreement. We are also party to a manufacturing agreement with Samsung Biologics Co., Ltd. for the manufacture of MM-121 and performance of associated quality related services. Although we are discussing arrangements with other third parties for our other product candidates, we do not currently have agreements for such arrangements in place and may be unable to conclude such agreements or to do so on acceptable terms.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU35"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also rely on certain single </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">suppliers for certain materials that we use for the manufacture of our product candidates. We purchase these materials from our suppliers on a purchase order basis and do not have long-term supply agreements in place. Any performance failure or refusal to </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">supply on the part of our existing or future suppliers could delay clinical development, marketing approval or commercialization of our products. If our current suppliers cannot perform as agreed, we may be required to replace one or more of these supplier</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s. Although we believe that there may be a number of potential long-term replacements to each supplier, we may incur added costs and delays in identifying and qualifying any such replacements.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also rely upon third-party manufacturers to provide us with necessary reagents and instruments to develop, test and manufacture our <font style="font-style:italic;">in vitro</font> diagnostics.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our dependence upon others for the manufacture of our product candidates and companion diagnostics may adversely affect our future profit margins and our ability to commercialize any products that receive regulatory approval on a timely and competitive basis.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Intellectual Property</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we fail to fulfill our obligations under our intellectual property licenses with third parties, we could lose license rights that are important to our business.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a party to a number of intellectual property license agreements with third parties, including with respect to MM-121, MM-141 and MM-310, and expect to enter into additional license agreements in the future. Our existing license agreements impose, and we expect that our future license agreements will impose, various diligence, milestone payment, royalty, insurance and other obligations on us. If we fail to comply with these obligations, our licensors may have the right to terminate these agreements, in which event we might not be able to develop and market any product that is covered by these agreements. Termination of these licenses or reduction or elimination of our licensed rights may result in our having to negotiate new or reinstated licenses with less favorable terms. The occurrence of such events could materially harm our business.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we are unable to obtain and maintain patent protection for our technology and products, or if our licensors are unable to obtain and maintain patent protection for the technology or products that we license from them, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully commercialize our technology and products may be adversely affected.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our success depends in large part on our and our licensors&#8217; ability to obtain and maintain patent protection in the United States and other countries with respect to our proprietary technology and products. In some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology or products that we license from third parties. Therefore, we cannot be certain that these patents and applications will be prosecuted and enforced in a manner consistent with the best interests of our business. In addition, if third parties who license patents to us fail to maintain such patents, or lose rights to those patents, the rights we have licensed may be reduced or eliminated.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have sought to protect our proprietary position by filing patent applications in the United States and abroad related to our novel technologies and products that are important to our business. This process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our and our licensors&#8217; patent rights are highly uncertain. Our and our licensors&#8217; pending and future patent applications may not result in patents being issued that protect our technology or products or that effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. The laws of foreign countries may not protect our rights to the same extent as the laws of the United States. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we or our licensors were the first to make the inventions claimed in our owned and licensed patents or pending patent applications, or that we or our licensors were the first to file for patent protection of such inventions. Assuming the other requirements for patentability are met, the first to file a patent application is entitled to the patent. Under the America Invents Act enacted in 2011, the United States moved to this first to file system in 2013 from the previous system under which the first to make the claimed invention was entitled to the patent. We may become involved in opposition, interference or derivation proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such proceeding could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU36"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">if our owned and licensed patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competi</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tors may be able to circumvent our owned or licensed patents by developing similar or alternative technologies or products in a non-infringing manner. The issuance of a patent is not conclusive as to its scope, validity or enforceability, and our owned and</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in patent claims being narrowed, invalidated or held unenforceable, which could limit our ability to stop or prevent us from sto</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pping others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. Given the amount of time required for the development, testing and regulatory review of </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commer</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cializing products similar or identical to ours.</font></p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may become involved in lawsuits to protect or enforce our patents, which could be expensive, time-consuming and unsuccessful.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competitors may infringe our patents. To counter infringement or unauthorized use, we may be required to initiate infringement lawsuits, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours is invalid or unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success depends upon our ability and the ability of our collaborators to develop, manufacture, market and sell our products and product candidates and use our proprietary technologies without infringing the enforceable proprietary rights of third parties. We may become party to, or threatened with, future adversarial proceedings or litigation regarding intellectual property rights with respect to our products and technology, including interference or derivation proceedings before the U.S. Patent and Trademark Office. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future. If we are found to infringe a third party&#8217;s intellectual property rights, we could be required to obtain a license from such third party to continue developing and marketing our products and technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. We could be forced, including by court order, to cease commercializing the infringing technology or product. In addition, we could be found liable for monetary damages. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties can have a similar negative impact on our business.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of our employees were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these employees have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such employee&#8217;s former employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU37"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Intellectual </font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities.</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce our resources available for development activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to our patented technology and products, we rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect these trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties that have access to them, such as our employees, corporate collaborators, outside scientific collaborators, sponsored researchers, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. Any of these parties may breach these agreements and disclose our proprietary information, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may not be able to obtain, maintain or protect proprietary rights necessary for the continued development and commercialization of our products, product candidates and research technologies, including as a result of challenges from companies who seek to sell generic or biosimilar versions of our products after expiration of any regulatory exclusivity but prior to the applicable patent expiration.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success depends in large part on obtaining and maintaining U.S. and foreign patent protection for our products, our product candidates and our research technologies and successfully enforcing and defending these patents against third-party challenges, including with respect to generic or biosimilar challenges. The validity of our patents in one or more jurisdictions may be challenged by third parties, resulting in our patents being deemed invalid, unenforceable or narrowed in scope, which could compromise the scope or duration of our exclusive rights in the relevant product, product candidate or technology. For example, the validity of a U.S. patent can be challenged in the U.S. Patent and Trademark Office (e.g., through an Inter Partes Review and/or Post Grant Review proceeding) and/or in U.S. federal district court.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, our patents may also be challenged in a federal court in connection with a third party&#8217;s abbreviated new drug application, or ANDA, a Section 505(b)(2) new drug application, or NDA, or a Biologic License Application under Section 351(k), or BLA, seeking FDA approval to market a generic version or a biosimilar version of our products, resulting in a patent challenge to one or more patents listed in the Orange Book for our product or that protect our biologic product. This patent challenge can result in one or more of those patents for our products being deemed uninfringed, invalid, unenforceable and/or narrowed in scope, which could compromise the scope or duration of our exclusive rights in the relevant product. An ANDA, Section 505(b)(2) NDA or BLA can be filed after FDA approval of a product and the expiration of any relevant regulatory exclusivity. Other challenges to a patent may be mounted without regard to the date of an FDA approval.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU38"></a>Our patents as issued or as subsequently limited by any litigation might not contain claims that are sufficiently broad to prevent others from circumventing our patent protection and utilizing our technologies. For instance, the issued patents relating to our product candidates may be limited to a particular indication and/or composition and may not cover similar compositions that have similar clinical properties. Consequently, our competitors may independently develop competing products that do not infringe our patents or other intellectual property. Also, our pending patent applications may not issue, and we may not receive any additional patents. We cannot be sure that our patents and patent applications, including our own and those that we have rights to under licenses from third parties, will adequately protect our intellectual property for a number of reasons, including, among other things, the following: (i) the patent positions of pharmaceutical and biotechnology companies can be highly uncertain and involve complex legal and factual questions; (ii) the actual protection afforded by a patent can vary from country to country and may depend upon the type of patent, the scope of its coverage and the availability of legal remedies in the country; (iii) the laws of foreign countries in which we market our </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">products may afford little</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or no effective protection to our intellectual property, thereby easing our competitors' ability to compete with us in such countries; (iv) intellectual property laws and regulations and legal standards relating to the validity, scope and enforcement of p</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">atents covering pharmaceutical and biotechnological inventions are continually developing and changing, both in the United States and in other important markets outside the United States; (v) third parties may challenge, infringe, circumvent or seek to inv</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">alidate existing or future patents owned by or licensed to us; and (vi) the coverage claimed in a patent application can be significantly reduced before the patent is issued, and, as a consequence, our and our partners' patent applications may result in pa</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tents with narrower coverage than we desire or have planned for.</font></p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Regulatory Approval of Our Product Candidates</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we are not able to obtain required regulatory approvals, we will not be able to commercialize our product candidates, and our ability to generate revenue will be materially impaired.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidates, including our clinical stage product candidates, and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, import, export, sampling and marketing are subject to comprehensive regulation by the FDA and other regulatory agencies in the United States and by comparable authorities in other countries. Failure to obtain regulatory approval for a product candidate will prevent us from commercializing the product candidate. ONIVYDE was our first and only product candidate to receive regulatory approval, and so we have only limited experience in filing and supporting the applications necessary to gain regulatory approvals. Securing regulatory approval requires the submission of extensive preclinical and clinical data and supporting information to the FDA and other regulatory agencies for each therapeutic indication to establish the product candidate&#8217;s safety and efficacy. Securing regulatory approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the FDA or other regulatory agencies. Our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining regulatory approval or prevent or limit commercial use.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The process of obtaining regulatory approvals is expensive, may take many years if additional clinical trials are required, if approval is obtained at all, and can vary substantially based on a variety of factors, including the type, complexity and novelty of the product candidates involved. Changes in regulatory approval policies during the development period, changes in or the enactment of additional statutes or regulations, changes in regulatory review for each submitted product application or approval of other products for the same indication may cause delays in the approval or rejection of an application. Regulatory agencies have substantial discretion in the approval process and may refuse to accept any application or may decide that our data is insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent regulatory approval of a product candidate. Any regulatory approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we continue to pursue development of companion diagnostics to identify patients who are likely to benefit from our product candidates, failure to obtain approval for the companion diagnostic may prevent or delay approval of the product candidate.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are attempting to develop companion diagnostics to identify patients who are likely to benefit from our product candidates. We currently rely on and expect to continue to rely on third parties for much of the development, testing and manufacturing of our companion diagnostics. We will likely rely on such third parties to also obtain any required regulatory approval for and then commercially supply such companion diagnostics. All of our companion diagnostic candidates are in preclinical development or clinical feasibility testing. We have very limited experience in the development of diagnostics and, even with the help of third parties with greater experience, may fail to obtain the required diagnostic product marketing approval, which could prevent or delay approval of the product candidate.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2014, the FDA issued final guidance that stated that if safe and effective use of a therapeutic depends on an <font style="font-style:italic;">in vitro</font> diagnostic, then the FDA generally will not approve the therapeutic unless the FDA approves or clears this &#8220;<font style="font-style:italic;">in vitro</font> companion diagnostic device&#8221; at the same time that the FDA approves the therapeutic. The approval or clearance of the <font style="font-style:italic;">in vitro</font> diagnostic most likely will occur through the FDA&#8217;s Center for Devices and Radiological Health Office of In Vitro Diagnostics and Radiological Health. Even with the issuance of the final guidance, the FDA&#8217;s expectations for <font style="font-style:italic;">in vitro</font> companion diagnostics remain unclear in some respects. The FDA&#8217;s developing expectations will affect our <font style="font-style:italic;">in vitro</font> companion diagnostics. In particular, the FDA may limit our ability to use retrospective data, otherwise disagree with our approaches to trial design, biomarker qualification, clinical and analytical validity and clinical utility, or make us repeat aspects of the trial or initiate new trials.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU39"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Becau</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">se our companion diagnostic candidates are at an early stage of development, we cannot yet know what the FDA will require for any of these tests. For our clinical stage product candidates, we are attempting to develop an </font><font style="font-style:italic;">in vitro</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> companion diagnostic that </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will help identify patients likely to benefit from the therapy. Whether the FDA will consider these </font><font style="font-style:italic;">in vitro</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> diagnostics to be &#8220;</font><font style="font-style:italic;">in vitro</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> companion diagnostic devices&#8221; that require simultaneous approval or clearance with the therapeutics will depend on whether the FDA views the diagnostics to be essential to the safety and efficacy of these therapeutics.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on the FDA&#8217;s past practice with companion diagnostics, if we are successful in developing a diagnostic for any of our clinical stage product candidates, we would expect that FDA approval of an <font style="font-style:italic;">in vitro</font> companion diagnostic would be required for approval and subsequent commercialization of each such product candidate. We are not aware of any currently available diagnostics that, if necessary, would otherwise allow us to proceed with the approval and subsequent commercialization of our product candidates despite a delay in or failure of our attempts to develop diagnostics.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because we expect to rely on third parties for various aspects of the development, testing and manufacture, as well as for regulatory approval for and commercial supply, of our companion diagnostics, the commercial success of any of our product candidates that require a diagnostic will be tied to and dependent on the continued ability of such third parties to make the diagnostic commercially available on reasonable terms in the relevant geographies. </p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we fail to maintain orphan drug designation for MM-121 or MM-141, we will have to rely on other rights and protections.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We obtained orphan drug designation in the United States for MM-121 for the treatment of heregulin positive NSCLC and for MM-141 for the treatment of pancreatic cancer. In the United States, under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the United States.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, the company that first obtains FDA approval for a designated orphan drug for the specified rare disease or condition receives orphan drug marketing exclusivity for that drug for that indication for a period of seven years. This orphan drug exclusivity prevents the FDA from approving another application, including a full NDA, to market the same drug for the same orphan indication, except in limited circumstances. For purposes of small molecule drugs, the FDA defines the term &#8220;same drug&#8221; to mean a drug that contains the same active molecule and that is intended for the same use as the approved orphan drug. Orphan drug exclusivity may be lost if the FDA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition. Additionally, maintenance of the orphan drug designation requires the company holding such designation to continue to actively pursue development in that indication.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs can be approved for the same condition. Even after an orphan drug is approved, the FDA can subsequently approve the same drug for the same condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 3, 2017, Congress passed the FDA Reauthorization Act of 2017, or FDARA. FDARA, among other things, codified the FDA&#8217;s pre-existing regulatory interpretation to require that a drug sponsor demonstrate the clinical superiority of an orphan drug that is otherwise the same as a previously approved drug for the same rare disease in order to receive orphan drug exclusivity. The new legislation reverses prior precedent holding that the Orphan Drug Act unambiguously requires that the FDA recognize the orphan exclusivity period regardless of a showing of clinical superiority. The FDA may further reevaluate the Orphan Drug Act and its regulations and policies. We do not know if, when or how the FDA may change the orphan drug regulations and policies in the future, and it is uncertain how any such changes might affect our business. Depending on what changes the FDA may make to its orphan drug regulations and policies, our business could be adversely impacted.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our product candidates for which we intend to seek approval as biological or drug products may face competition sooner than expected.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With the enactment of the Biologics Price Competition and Innovation Act of 2009, or BPCIA, as part of the Health Care and Education Reconciliation Act of 2010, or the Health Care Reform Laws, an abbreviated pathway for the approval of biosimilar and interchangeable biological products was created. The abbreviated regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &#8220;interchangeable&#8221; based on their similarity to existing brand product. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until twelve years after the original branded product was approved under a biologics license application, or BLA. The BPCIA is complex and has yet to be fully interpreted and implemented by the FDA. As a result, its ultimate impact, implementation and meaning is subject to uncertainty. While it is uncertain when any such processes may be fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial prospects for our biological products.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU40"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that any of our produ</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cts approved as a biological product under a BLA should qualify for the twelve year period of exclusivity. However:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a potential competitor could seek and obtain approval of its own BLA during our exclusivity period instead of seeking approval of a biosimilar version; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the FDA could consider a particular product candidate which contains both drug and biological product components to be a drug subject to review pursuant to an NDA, and therefore eligible for a significantly shorter marketing exclusivity period as provided under the Drug Price Competition and Patent Term Restoration Act of 1984.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear and will depend on a number of marketplace and regulatory factors that are still developing.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, a drug product approved under an NDA could face generic competition earlier than expected. The enactment of the Generic Drug User Fee Amendments of 2012 as part of the Food and Drug Administration Safety and Innovation Act of 2012 established a user fee program that will generate hundreds of millions of dollars in funding for the FDA&#8217;s generic drug review program. Funding from the user fee program, along with performance goals that the FDA negotiated with the generic drug industry, is significantly decreasing the timeframe for FDA review and approval of generic drug applications.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Failure to obtain regulatory approval in international jurisdictions would prevent us from marketing our products abroad.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We intend to market any product for which we obtain marketing approval, either ourselves or with commercialization partners, both within and outside the United States. This may increase the risks described below with respect to our compliance with foreign regulations.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to market and sell any approved products in the European Union and many other jurisdictions, we or our commercialization partners must obtain separate regulatory approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing, including sometimes additional testing in children. The time required to obtain approval in foreign countries may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, it is required that the product be approved for reimbursement before the product can be sold in that country. We or our future commercialization partners may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. We or our future commercialization partners may not be able to file for regulatory approvals and may not receive necessary approvals to commercialize our products in any market.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, on June 23, 2016, the electorate in the United Kingdom voted in favor of leaving the European Union, commonly referred to as Brexit. On March 29, 2017, the country formally notified the European Union of its intention to withdraw pursuant to Article 50 of the Lisbon Treaty. Since a significant proportion of the regulatory framework in the United Kingdom is derived from European Union directives and regulations, the referendum could materially impact the regulatory regime with respect to the approval of our product candidates in the United Kingdom or the European Union. Any delay in obtaining, or an inability to obtain, any marketing approvals as a result of Brexit or otherwise would prevent us from commercializing our product candidates in the United Kingdom and/or the European Union and restrict our ability to generate revenue and achieve and sustain profitability. If any of these outcomes occur, we may be forced to restrict or delay efforts to seek regulatory approval in the United Kingdom and/or European Union for our product candidates, which could significantly and materially harm our business.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU41"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Any product for which we obtain marketing approval could be subject to restrictions or withdrawal from the market and we may be subject to penalties if we </font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">fail to comply with regulatory requirements or if we experience unanticipated problems with our products, when and if any of them are approved.</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any product for which we may obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, advertising and promotional activities for such product, will be subject to continual requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, cGMP or QSR requirements relating to quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping. Even if regulatory approval of a product is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the product. Later discovery of previously unknown problems with our products, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in actions such as:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">restrictions on such products, manufacturers or manufacturing processes;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">restrictions on the marketing of a product;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">restrictions on product distribution;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">requirements to conduct post-marketing clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">warning or untitled letters;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">withdrawal of the products from the market;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">refusal to approve pending applications or supplements to approved applications that we submit;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">recall of products;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">fines, restitution or disgorgement of profits or revenue;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">suspension or withdrawal of regulatory approvals;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">refusal to permit the import or export of our products;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">product seizure; or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">injunctions or the imposition of civil or criminal penalties.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA has sweeping inspection authorities to enforce the Federal Food, Drug, and Cosmetic Act. Under the statute, a drug or biologic will be considered adulterated, with possible resulting civil and criminal penalties, if the owner or operator of the establishment where it is made, processed, packed or held delays, denies, limits or refuses inspection. The FDA employs a risk-based inspection schedule to ensure compliance. The law grants the FDA authority to require a drug or biologics manufacturer to provide, in advance or instead of an inspection, and at the manufacturer&#8217;s expense, any records or other information that the agency may otherwise inspect at the facility. The FDA may also share inspection information with foreign governments under certain circumstances.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA also has broad authority to take action against manufacturers of drugs or biologics that are not adhering to pediatric study requirements, which apply even if the manufacturer is not seeking to market the drug or biologic to pediatric patients. As of April 2013, the FDA must issue non-compliance letters to companies who do not meet the pediatric study requirements. Any company receiving a non-compliance letter would have an opportunity to respond, and the non-compliance letter and company response would become publicly available.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Current and future legislation may increase the difficulty and cost for us and any future collaborators to obtain marketing approval of and commercialize our product candidates and affect the prices we, or they, may obtain.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States and some foreign jurisdictions, there have been and continue to be a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could, among other things, prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability, or the ability of any future collaborators, to profitably sell any products for which we, or they, obtain marketing approval. We expect that current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we, or any future collaborators, may receive for any approved products.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU42"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2010, the </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Health Care Reform Laws</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">w</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ere</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> enacted, which include measures that have significantly </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">changed healthcare financing by both governmental and private </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">insurers</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Since enactment of the </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Health Care Reform Laws</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, there have been numerous legal challenges and legislative actions to repeal and replace provisions of the law, and we expect these to co</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ntinue. For example, with enactment of the Tax Cuts and Jobs Act of 2017, which was signed by President Trump on December 22, 2017, the U.S. Congress repealed the &#8220;individual mandate.&#8221; The repeal of this provision, which requires most Americans to carry a </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">minimal level of health insurance, will become effective in 2019. According to the U.S. Congressional Budget Office, the repeal of the individual mandate will cause 13 million fewer Americans to be insured in 2027 and premiums in insurance markets may rise</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Additionally, on January 22, 2018, President Trump signed a continuing resolution on appropriations for fiscal year 2018 that delayed the implementation of certain </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Health Care Reform Law</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-mandated fees, including the so-called &#8220;Cadillac&#8221; tax on certain hi</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">gh cost employer-sponsored insurance plans, the annual fee imposed on certain health insurance providers based on market share and the medical device excise tax on non-exempt medical devices.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The U.S. Congress may consider other legislation to replace elements of the Health Care Reform Laws during the next Congressional session. These healthcare reforms, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price for any approved product and/or the level of reimbursement physicians receive for administering any approved product. Reductions in reimbursement levels may negatively impact the prices or the frequency with which products are prescribed or administered. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, there have been several recent U.S. congressional inquiries and proposed federal and proposed and enacted state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, reduce the costs of products under Medicare and reform government program reimbursement methodologies for products. At the federal level, the U.S. Congress and the Trump administration have each indicated that it will continue to seek new legislative and/or administrative measures to control costs. At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription product and other healthcare programs. These measures could reduce the ultimate demand for our product candidates, once approved, or put pressure on our product pricing.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Legislative and regulatory proposals have also been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us and any future collaborators to more stringent product labeling and post-marketing testing and other requirements.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Commercialization of Our Product Candidates</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription products. If we are found to have improperly promoted off-label uses for any product for which we receive marking approval, we may become subject to significant fines and other liability.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription products. In particular, a product may not be promoted for uses that are not approved by the FDA or such other regulatory agencies as reflected in the product&#8217;s approved labeling. If we are found to have promoted for off-label uses, we may become subject to significant government fines and other related liability. For example, the U.S. government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. The government has also required companies to enter into complex multi-year corporate integrity agreements and/or non-prosecution agreements that can impose significant restrictions and other burdens on the affected companies.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, incentives under applicable U.S. laws encourage employees and physicians to report violations of rules governing promotional activities for pharmaceutical products. These incentives could lead to so called whistleblower lawsuits as part of which such persons seek to collect a portion of moneys allegedly overbilled to government agencies due to, for example, promotion of pharmaceutical products beyond labeled claims. Such lawsuits, whether with or without merit, are typically time consuming and costly to defend. Such suits may also result in related stockholder lawsuits, which are also costly to defend.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU43"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our relationships with customers and payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could exp</font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Healthcare providers, physicians and others play a primary role in the recommendation and prescription of products for which we obtain marketing approval. Arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute any products for which we obtain marketing approval. Restrictions under applicable federal, state and foreign healthcare laws and regulations include the following:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the federal healthcare anti-kickback statute prohibits, among other things, knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward the purchasing, leasing, ordering or arranging for the purchase, order or recommendation of any item or service reimbursable under Medicare, Medicaid, or other federal healthcare programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other, and violations are punishable by imprisonment, criminal fines, civil monetary penalties and exclusion from participation in federal healthcare programs. Although there are a number of statutory exemptions and regulatory safe harbors protecting certain common activities from prosecution or other regulatory sanctions, the exemptions and safe harbors are drawn narrowly, and practices that involve remuneration intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exemption or safe harbor;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the federal False Claims Act prohibits any person from knowingly presenting, or causing to be presented, a false claim for payment to the federal government, or knowingly making, or causing to be made, a false statement to have a false claim paid. Government enforcement agencies and private whistleblowers have initiated investigations or brought private lawsuits against pharmaceutical companies for a variety of allegedly improper promotional or marketing activities, such as allegedly inflating drug prices they report to pricing services, which in turn were used by the government to set Medicare and Medicaid reimbursement rates; allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product; or engaging in promotion for &#8220;off-label&#8221; uses. Additionally, the Health Care Reform Laws amended the federal False Claims Act such that a violation of the federal anti-kickback statute can serve as a basis for liability under the False Claims Act;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the federal Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act, or HIPAA, makes it a crime to knowingly and willfully execute or attempt to execute a scheme to defraud any healthcare benefit program and also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the federal false statements statute prohibits, among other things, knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the federal transparency requirements under the Health Care Reform Laws require manufacturers of drugs, devices, biologics and medical supplies reimbursable under Medicare and Medicaid to report to the Department of Health and Human Services information related to payments and other transfers of value to physicians and teaching hospitals, as well as physician ownership and investment interests, and provide for public reporting of the data reported by manufacturers;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the U.S. Foreign Corrupt Practices Act prohibits U.S. companies and their representatives from paying, offering to pay, promising or authorizing the payment of anything of value to any foreign government official, government staff member, political party or political candidate for the purpose of obtaining or retaining business or to otherwise obtain favorable treatment or influence a person working in an official capacity, and encompasses many healthcare professionals in many countries under the definition of a foreign government official;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the Bribery Act, which applies to U.S. companies such as ourselves that conduct business in the United Kingdom, proscribes giving and receiving bribes in the public and private sectors, bribing a foreign public official and failing to have adequate procedures to prevent employees and other agents from giving bribes; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">analogous state laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers. In addition, some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government. Other states require pharmaceutical manufacturers to report information related to payments to physicians and other healthcare providers or marketing expenditures, or prohibit certain marketing-related activities including the provision of gifts, meals or other items to certain healthcare providers.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU44"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Efforts to ensure that our business arrangements with third parties comply with applicable healthcare laws and regulations involve substanti</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">al costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our o</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">perations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, exclusion from government funded healthca</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">re programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we do business are found to be not in compliance with applicable laws, they may be subject</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of si</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">gnificant resources and generate negative publicity, which could also harm our financial condition. Responding to government investigations or whistleblower lawsuits, defending any claims raised, and any resulting fines, damages, penalties, settlement paym</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ents or administrative actions, as well as any related actions brought by stockholders or other third parties, could have a material impact on our reputation, business and financial condition and divert the attention of our management from operating our bu</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">siness.</font></p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our corporate compliance efforts cannot guarantee that we are in compliance with all potentially applicable regulations.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The development, manufacturing, pricing, sales, coverage and reimbursement of our products, together with our general operations, are and will be subject to extensive regulation by federal, state and other authorities within the United States and numerous entities outside of the United States. While we have implemented a corporate compliance program based on what we believe are the current best practices, we cannot provide any assurance that governmental authorities will find that our business practices comply with current or future administrative or judicial interpretations of potentially applicable laws and regulations. If we fail to comply with any of these laws and regulations, we could be subject to a range of regulatory actions, including suspension or termination of clinical trials, the failure to approve a product candidate, restrictions on our products or manufacturing processes, withdrawal of products from the market, significant fines, disqualification or debarment from participation in federally-funded healthcare programs or other sanctions or litigation, any of which events may have a significant adverse impact on our business.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Data Protection and Cybersecurity</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our failure to comply with data protection laws and regulations could lead to government enforcement actions, private litigation and/or adverse publicity and could negatively affect our operating results and business.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to data protection laws and regulations that address privacy and data security. The legislative and regulatory landscape for data protection continues to evolve, and in recent years there has been an increasing focus on privacy and data security issues. In the United States, numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws and federal and state consumer protection laws govern the collection, use, disclosure and protection of health-related and other personal information. Failure to comply with data protection laws and regulations could result in government enforcement actions, which could include civil or criminal penalties, private litigation and/or adverse publicity and could negatively affect our operating results and business. In addition, we may obtain health information from third parties (e.g., healthcare providers who prescribe our products) that are subject to privacy and security requirements under HIPAA. We could be subject to criminal penalties if we knowingly obtain or disclose individually identifiable health information in a manner that is not authorized or permitted.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The collection and use of personal health data in the European Union will be governed by the provisions of the General Data Protection Regulation, or GDPR, which comes into effect in May 2018. This regulation imposes several requirements relating to the consent of the individuals to whom the personal data relates, the information provided to the individuals, notification of data processing obligations to the competent national data protection authorities and the security and confidentiality of the personal data. The GDPR also imposes strict rules on the transfer of personal data out of the European Union to the United States. Failure to comply with the requirements of the GDPR and the related national data protection laws of the European Union Member States may result in fines and other administrative penalties.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Significant disruptions of information technology systems or security breaches could adversely affect our business.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU45"></a>We are increasingly dependent upon information technology systems, infrastructure and data to operate our business. In the ordinary course of business, we collect, store and transmit large amounts of confidential information (including, among other things, trade secrets or other intellectual property, proprietary business information and personal information). It is critical that we do so in a secure manner to maintain the confidentiality and integrity of such confidential information. We also have outsourced elements of our operations to third parties, and as a result we manage a number of third-party vendors who may or could have access to our confidential information. The size and complexity of our information technology systems, and those of third-party vendors with whom we contract, and the large amounts of confidential information stored on those systems, make such systems vulnerable to service </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">interruptions or to security breaches from inadvertent or intentional actions by our employees, third-party vendors, and/or business partners, or from cyber-attacks by malicious third parties. Cyber-attacks are increasing in their frequency, sophisticat</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ion and intensity, and have become increasingly difficult to detect. Cyber-attacks could include the deployment of harmful malware, ransomware, denial-of-service attacks, social engineering and other means to affect service reliability and threaten the con</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">fidentiality, integrity and availability of information.</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Cyber-attacks could also include phishing attempts or e-mail fraud to cause payments or information to be transmitted to an unintended recipient.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant disruptions of our information technology systems, or those of our third-party vendors, or security breaches could adversely affect our business operations and/or result in the loss, misappropriation and/or unauthorized access, use or disclosure of, or the prevention of access to, confidential information, including, among other things, trade secrets or other intellectual property, proprietary business information and personal information, and could result in financial, legal, business and reputational harm to us. For example, any such event that leads to unauthorized access, use or disclosure of personal information, including personal information regarding our patients or employees, could harm our reputation, require us to comply with federal and/or state breach notification laws and foreign law equivalents, and otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information. Security breaches and other inappropriate access can be difficult to detect, and any delay in identifying them may lead to increased harm of the type described above. While we have implemented security measures to protect our information technology systems and infrastructure, there can be no assurance that such measures will prevent service interruptions or security breaches that could adversely affect our business.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Employee Matters and Managing Growth</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our future success depends on our ability to retain our key executives and to attract, retain and motivate qualified personnel.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are highly dependent on the principal members of our executive and scientific teams. Although we have formal employment agreements with each of our executive officers, these agreements do not prevent our executives from terminating their employment with us at any time. We do not maintain &#8220;key person&#8221; insurance for any of our executives or other employees. The loss of the services of any of these persons could impede the achievement of our research, development and commercialization objectives.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recruiting and retaining qualified scientific, clinical, manufacturing and sales and marketing personnel will also be critical to our success. We may not be able to attract and retain these personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have entered into and may continue to enter into or seek to enter into business combinations, acquisitions or divestitures which may be difficult to consummate, disrupt our business, divert management attention or dilute stockholder value.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of our business strategy, we may enter into business combinations, acquisitions or divestitures. Although we consummated the asset sale to Ipsen in April 2017, we have limited experience in making acquisitions and divestitures. In addition, acquisitions and divestitures are typically accompanied by a number of risks, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the difficulty of integrating or separating the operations and personnel of the acquired companies or divested product;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the potential disruption of our ongoing business and distraction of management;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">potential unknown liabilities and expenses;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the failure to achieve the expected benefits of the combination, acquisition or divestiture;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the maintenance of acceptable standards, controls, procedures and policies; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the impairment of relationships with employees as a result of any integration or separation of management and other personnel.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are not successful in completing acquisitions or divestitures that we may pursue in the future, we would be required to reevaluate our business strategy and we may have incurred substantial expenses and devoted significant management time and resources in seeking to complete the acquisitions or divestitures. In addition, with future acquisitions, we could use substantial portions of our available cash as all or a portion of the purchase price or could issue additional securities as consideration for these acquisitions, which could cause our stockholders to suffer significant dilution.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU46"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Common Stock</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our executive officers, directors and principal stockholders maintain the ability to significantly influence all matters submitted to stockholders for approval.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our executive officers, directors and stockholders who own more than 5% of our outstanding common stock, in the aggregate, beneficially own a large portion of our capital stock. As a result, if these stockholders were to choose to act together, they would be able to significantly influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, would significantly influence the election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. This concentration of voting power could discourage, delay or prevent an acquisition of our company on terms that other stockholders may desire.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Provisions in our corporate charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provisions in our corporate charter and our bylaws may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which our stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Because our board of directors is responsible for appointing the members of our management team, these provisions could in turn affect any attempt by our stockholders to replace current members of our management team. Among others, these provisions:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">allow the authorized number of our directors to be changed only by resolution of our board of directors;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our board of directors;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">limit who may call stockholder meetings;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a &#8220;poison pill&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">require the approval of the holders of at least 75% of the votes that all our stockholders would be entitled to cast to amend or repeal certain provisions of our charter or bylaws.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our stock price has been and may in the future be volatile, which could cause holders of our common stock to incur substantial losses.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our stock price has been and in the future may be subject to substantial price volatility. The stock market in general and the market for biotechnology companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, our stockholders could incur substantial losses. The market price for our common stock may be influenced by many factors, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the success of competitive products or technologies;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">results of clinical trials of our product candidates or those of our competitors;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">regulatory or legal developments in the United States and other countries;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">developments or disputes concerning patents or other proprietary rights;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the recruitment or departure of key personnel;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">variations in our financial results or those of companies that are perceived to be similar to us;</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU47"></a><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">changes in the structure of healthcare payment systems;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">market conditions in the pharmaceutical and biotechnology sectors and issuance of new or changed securities analysts&#8217; reports or recommendations;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">activism by any single large stockholder or combination of stockholders;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">general economic, industry and market conditions; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the other factors described in this &#8220;Risk Factors&#8221; section.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Because we do not anticipate paying regular cash dividends on our common stock in the foreseeable future, capital appreciation, if any, will be the sole source of gain for holders of our common stock.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not historically declared or paid regular cash dividends on our common stock. Although <font style="Background-color:#FFFFFF;color:#000000;">our board of directors declared a special cash dividend of $140.0 million, which was payable on May 26, 2017 to stockholders of record as of the close of business on May 17, 2017</font>, we do not currently intend to pay any regular cash dividends in the foreseeable future. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be the sole source of gain for holders of our common stock for the foreseeable future.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Future sales of shares of our common stock, including by us or our directors and executive officers, or shares issued upon the exercise of currently outstanding options could cause the market price of our common stock to drop significantly, even if our business is doing well.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A substantial portion of our outstanding common stock can be traded without restriction at any time. In addition, a portion of our outstanding common stock is currently restricted as a result of federal securities laws, but can be sold at any time subject to applicable volume limitations. As such, sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares intend to sell shares, by us or others, could reduce the market price of our common stock. In addition, we have a significant number of shares that are subject to outstanding options. The exercise of these options and the subsequent sale of the underlying common stock could cause a further decline in our stock price. For instance, in April 2016, we issued an aggregate of 1,236,766 shares of our common stock to certain holders of our convertible notes who had agreed to convert an aggregate of $64.2 million of convertible notes. Any such sales also might make it difficult for us to sell equity securities in the future at a time and at a price that we deem appropriate. We cannot predict the size of future issuances or the effect, if any, that any future issuances may have on the market price for our common stock.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, on December 15, 2017, we filed a registration statement on Form S-3 with the SEC to allow the issuance of our securities from time to time in one or more offerings of up to $150,000,000 in aggregate dollar amount. This registration statement was declared effective by the SEC on January 5, 2018. Any sale of additional shares of our common stock or other securities could reduce the market price of our common stock.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU48"></a><a name="ITEM_6_EXHIBITS"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item 6.</font><font style="margin-left:36pt;"><a name="ITEM_6_EXHIBITS"></a>E</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">xhibits.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom"  style="width:91.36%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description of Exhibit </p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10.9pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1274792/000156459018005246/mack-ex1023_791.htm"><font style="text-decoration:underline;">Seventh Amendment of Lease, dated as of February 6, 2018, by and between the Registrant and ARE-MA Region No. 59, LLC (incorporated by reference to Exhibit 10.23 to the Registrant&#8217;s Annual Report on Form 10-K filed on March 12, 2018)</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10.9pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2*</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="mack-ex102_263.htm"><font style="text-decoration:underline;">Eighth Amendment of Lease, dated as of February 15, 2018, by and between the Registrant and ARE-MA Region No. 59, LLC</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10.9pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1274792/000156459018005246/mack-ex1011_790.htm"><font style="text-decoration:underline;">Scientific Advisory Board Consulting and Confidentiality Agreement, dated as of February 6, 2018, by and between the Registrant and George D. Demetri (incorporated by reference to Exhibit 10.11 to the Registrant&#8217;s Annual Report on Form 10-K filed on March 12, 2018)</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10.9pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.1*</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="mack-ex311_7.htm"><font style="text-decoration:underline;">Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.2*</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="mack-ex312_11.htm"><font style="text-decoration:underline;">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.1+</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="mack-ex321_6.htm"><font style="text-decoration:underline;">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.2+</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="mack-ex322_8.htm"><font style="text-decoration:underline;">Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.INS*</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Instance Document</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.SCH*</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Schema Document</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.CAL*</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Calculation Linkbase Document</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.DEF*</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Definition Linkbase Document</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.LAB*</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Label Linkbase Database</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.PRE*</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Presentation Linkbase Document</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:83.33%;text-indent:0%;font-size:6pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Filed herewith.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Furnished herewith.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU49"></a><a name="SIGNATURES"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="SIGNATURES"></a>SIGNAT</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">URES</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:46.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:53.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">MERRIMACK PHARMACEUTICALS, INC.</p></td>
</tr>
<tr>
<td valign="top"  style="width:46.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:53.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:46.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: May 8, 2018</p></td>
<td valign="top"  style="width:2.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:50.56%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> /s/ Jean M. Franchi</p></td>
</tr>
<tr>
<td valign="top"  style="width:46.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:2.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:50.56%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jean M. Franchi</p></td>
</tr>
<tr>
<td valign="top"  style="width:46.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:2.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:50.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
<tr>
<td valign="top"  style="width:46.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:2.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:50.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Financial Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>2
<FILENAME>mack-ex102_263.htm
<DESCRIPTION>EX-10.2 - LEASE AMENDMENT
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
mack-ex102_263.htm
</title>
</head>
<!-- NG Converter v4.0.8.21 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.2</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">EIGHTH AMENDMENT OF LEASE</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Eighth Amendment of Lease (this &#8220;<font style="font-weight:bold;">Eighth Amendment</font>&#8221;) is made and entered into as of February 15, 2018 (the &#8220;<font style="font-weight:bold;">Effective Date</font>&#8221;), by and between <font style="font-weight:bold;">ARE-MA REGION NO. 59, LLC</font>, a Delaware limited liability company (&#8220;<font style="font-weight:bold;">Landlord</font>&#8221;), as successor-in-interest to DWF IV One Kendall, LLC, as successor-in-interest to RB Kendall Fee, LLC (&#8220;<font style="font-weight:bold;">Original Landlord</font>&#8221;), and <font style="font-weight:bold;">MERRIMACK PHARMACEUTICALS, INC.</font>, a Delaware corporation (&#8220;<font style="font-weight:bold;">Tenant</font>&#8221;), with reference to the following:</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">RECITALS</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A.<font style="margin-left:36pt;"></font>Pursuant to that certain Indenture of Lease dated as of August 24, 2012, as amended by (i) that certain First Amendment of Lease dated March 18, 2013, (ii) that certain Second Amendment of Lease dated September 12, 2013, (iii) that certain Third Amendment of Lease dated February 23, 2015, (iv) that certain Fourth Amendment of Lease dated July 22, 2015, (v) that certain Fifth Amendment of Lease dated as of April 3, 2017 (the &#8220;<font style="font-weight:bold;">Fifth Amendment</font>&#8221;), (vi) that certain Sixth Amendment of Lease dated as of June 9, 2017, and (vii)&nbsp;&nbsp;that certain Seventh Amendment of Lease dated as of February 6, 2018<font style="font-weight:bold;"> </font>(the &#8220;<font style="font-weight:bold;">Seventh Amendment</font>&#8221;) (as amended, the &#8220;<font style="font-weight:bold;">Lease</font>&#8221;), Tenant leases certain premises (the &#8220;<font style="font-weight:bold;">Existing Premises</font>&#8221;) as more particularly described in the Lease, at the improved real property being Building 600/650/700 located at One Kendall Square, Cambridge, Massachusetts.&nbsp;&nbsp;The Existing Premises consists of approximately (a) 31,747 rentable square feet of space on a portion of the second (2nd) floor of Building 600/650/700 (the &#8220;<font style="font-weight:bold;">2nd Floor Space</font>&#8221;), (b) 4,773 rentable square feet of space on the fourth (4th) floor of Building 650/700 (the &#8220;<font style="font-weight:bold;">Additional Space</font>&#8221;), (c) 30,626 rentable square feet of space on the fourth (4th) floor of Building 600/700 (the &#8220;<font style="font-weight:bold;">4th Floor Space</font>&#8221;), (d) 7,245 rentable square feet of space on the mezzanine level of Building 700 (the &#8220;<font style="font-weight:bold;">Mezzanine Space</font>&#8221;), (e) 8,686 rentable square feet of space on the first (1st) floor of Building 600 (the &#8220;<font style="font-weight:bold;">1<sup style="font-size:85%; vertical-align:top">st</sup> Floor Space</font>&#8221;), (f) 132 rentable square feet in the basement of Building 700 (the &#8220;<font style="font-weight:bold;">Basement Premises</font>&#8221;), (g) 2,922 rentable square feet of space in the basement of Building 700 (the &#8220;<font style="font-weight:bold;">Storage Space</font>&#8221;), (h) 8,763 rentable square feet of space located on the fourth (4th) floor of Building 700 (the &#8220;<font style="font-weight:bold;">Expansion Space I</font>&#8221;), (i) 1,353 rentable square feet of space located on the fourth (4th) floor and the fourth (4th) floor mezzanine of Building 650 (the &#8220;<font style="font-weight:bold;">Expansion Space II</font>&#8221;), (j)&#160;intentionally omitted, (k) 491 rentable square feet of space on the first (1st) floor of Building 700 (the &#8220;<font style="font-weight:bold;">Chemical Storage Space</font>&#8221;), (l) 8,155 rentable square feet of space located on the second (2nd) floor of Building 600 (the &#8220;<font style="font-weight:bold;">600 Expansion Space</font>&#8221;), (m) 784 rentable square feet of space located on the second floor (2nd) of Building 600 (the &#8220;<font style="font-weight:bold;">Hallway Space</font>&#8221;), (n) intentionally omitted, (o) 16,539 rentable square feet of space on the fifth (5th) floor of Building 600/650/700 (the &#8220;<font style="font-weight:bold;">Third Amendment Premises</font>&#8221;), (p)&#160;7,145 rentable square feet of space on the first (1st) floor of Building 700 (the &#8220;<font style="font-weight:bold;">Former Addgene Space</font>&#8221;), (q) 5,687 rentable square feet of space on the first (1st) floor of Building 700 (the &#8220;<font style="font-weight:bold;">Former OmniGuide Space</font>&#8221;), (r)&#160;311 rentable square feet of space on the basement level of Building 700 (the &#8220;<font style="font-weight:bold;">Equipment Room</font>&#8221;), and (s)&#160;700 rentable square feet of storage space in the basement of Building 700 (the &#8220;<font style="font-weight:bold;">Fourth Amendment Storage Space</font>&#8221;).&nbsp;&nbsp;Capitalized terms used herein without definition shall have the meanings defined for such terms in the Lease.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">B.<font style="margin-left:36pt;"></font>Tenant desires to reduce the term of the Lease for the portion of the Premises (the Former OmniGuide Space) containing approximately 5,687 rentable square feet (&#8220;<font style="font-weight:bold;">First Reduction Premises</font>&#8221;) and surrender such First Reduction Premises to Landlord on the date that is 1 day after the Lender Consent Date (as defined below) (the &#8220;<font style="font-weight:bold;">First Reduction Surrender Date</font>&#8221;), and Landlord is willing to shorten such term and accept such surrender of the First Reduction Premises on the First Reduction Surrender Date subject to the terms of this Eighth Amendment.&nbsp;&nbsp;The First Reduction Premises are more particularly shown on Exhibit A attached hereto. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">725902539.5</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C</font><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="margin-left:36pt;"></font><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant desires to reduce the term of the Lease for the portion of the Premises (the Former Addgene Space and the Equipment Room) containing approximately 7,456 rentable square feet (&#8220;</font><font style="font-weight:bold;">Second Reduction Premises</font><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;) and surrender such Second Reduction Premises to Landlord on or before June 30, 2018 (the &#8220;</font><font style="font-weight:bold;">Second Reduction Surrender Date</font><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;), and Landlord is willing to shorten such term and accept such surrender of the Second Reduction Premises on the Second Reduction Surrender Date subject to the terms of this Eighth Amendment.&nbsp;&nbsp;The Second Reduction Premises are more particularly shown on Exhibit A attached hereto.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOW, THEREFORE, in consideration of the foregoing and of the mutual promises made herein, and for other good and valuable consideration the receipt of which is hereby acknowledged, Landlord and Tenant agree as follows:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;"><font style="font-weight:bold;">First</font> <font style="font-weight:bold;">Reduction Premises and Second Reduction Premises</font>.</p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>Effective on the First Reduction Surrender Date, Landlord and Tenant hereby terminate the term of the Lease with respect to the First Reduction Premises.&nbsp;&nbsp;From and after the First Reduction Surrender Date, Tenant shall only be deemed to be leasing approximately 130,372 rentable square feet (the &#8220;<font style="font-weight:bold;">Initial Remaining Premises</font>&#8221;) consisting of approximately (i) 31,747 rentable square feet of space on a portion of the second (2nd) floor of Building 600/650/700 (the &#8220;<font style="font-weight:bold;">2nd Floor Space</font>&#8221;), (ii) 4,773 rentable square feet of space on the fourth (4th) floor of Building 650/700 (the &#8220;<font style="font-weight:bold;">Additional Space</font>&#8221;), (iii) 30,626 rentable square feet of space on the fourth (4th) floor of Building 600/700 (the &#8220;<font style="font-weight:bold;">4th Floor Space</font>&#8221;), (iv) 7,245 rentable square feet of space on the mezzanine level of Building 700 (the &#8220;<font style="font-weight:bold;">Mezzanine Space</font>&#8221;), (v) 8,686 rentable square feet of space on the first (1st) floor of Building 600 (the &#8220;<font style="font-weight:bold;">1<sup style="font-size:85%; vertical-align:top">st</sup> Floor Space</font>&#8221;), (vi) 132 rentable square feet in the basement of Building 700 (the &#8220;<font style="font-weight:bold;">Basement Premises</font>&#8221;), (vii) 2,922 rentable square feet of space in the basement of Building 700 (the &#8220;<font style="font-weight:bold;">Storage Space</font>&#8221;), (viii) 8,763 rentable square feet of space located on the fourth (4th) floor of Building 700 (the &#8220;<font style="font-weight:bold;">Expansion Space I</font>&#8221;), (ix) 1,353 rentable square feet of space located on the fourth (4th) floor and the fourth (4th) floor mezzanine of Building 650 (the &#8220;<font style="font-weight:bold;">Expansion Space II</font>&#8221;), (x)&#160;491 rentable square feet of space on the first (1st) floor of Building 700 (the &#8220;<font style="font-weight:bold;">Chemical Storage Space</font>&#8221;), (xi) 8,155 rentable square feet of space located on the second (2nd) floor of Building 600 (the &#8220;<font style="font-weight:bold;">600 Expansion Space</font>&#8221;), (xii) 784 rentable square feet of space located on the second floor (2nd) of Building 600 (the &#8220;<font style="font-weight:bold;">Hallway Space</font>&#8221;), (xiii) 16,539 rentable square feet of space on the fifth (5th) floor of Building 600/650/700 (the &#8220;<font style="font-weight:bold;">Third Amendment Premises</font>&#8221;), (xiv)&#160;7,145 rentable square feet of space on the first (1st) floor of Building 700 (the &#8220;<font style="font-weight:bold;">Former Addgene Space</font>&#8221;), (xv)&#160;311 rentable square feet of space on the basement level of Building 700 (the &#8220;<font style="font-weight:bold;">Equipment Room</font>&#8221;), and (xvi)&#160;700 rentable square feet of storage space in the basement of Building 700 (the &#8220;<font style="font-weight:bold;">Fourth Amendment Storage Space</font>&#8221;).&nbsp;&nbsp;The Initial Remaining Premises are more particularly as shown on Exhibit B as the Initial Remaining Premises.&nbsp;&nbsp;Nothing herein shall affect or diminish Tenant&#8217;s rights or obligations under the Lease with respect to the Initial Remaining Premises remaining following the First Reduction Surrender Date.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:31.98%;"></td>
<td style="width:1.36%;"></td>
<td style="width:23.08%;"></td>
<td style="width:1.28%;"></td>
<td style="width:42.31%;"></td>
</tr>
<tr>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">725902539.5</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;">2</font></p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font><font style="margin-left:36pt;"></font><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective on the Second Reduction Surrender Date, Landlord and Tenant hereby terminate the term of the Lease with respect to the Second Reduction Premises.&nbsp;&nbsp;From and after the Second Reduction Surrender Date (which follows the Reduction Date (as defined in the Fifth Amendment), Tenant shall only be deemed to be leasing approximately 99,132 rentable square feet (the &#8220;</font><font style="font-weight:bold;">Remaining Premises</font><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;) consisting of approximately (i) 31,747 rentable square feet of space on a portion of the second (2nd) floor of Building 600/650/700 (the &#8220;</font><font style="font-weight:bold;">2nd Floor Space</font><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;), (ii) 4,773 rentable square feet of space on the fourth (4th) floor of Building 650/700 (the &#8220;</font><font style="font-weight:bold;">Additional Space</font><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;), (iii) 30,626 rentable square feet of space on the fourth (4th) floor of Building 600/700 (the &#8220;</font><font style="font-weight:bold;">4th Floor Space</font><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;), (iv) 8,686 rentable square feet of space on the first (1st) floor of Building 600 (the &#8220;</font><font style="font-weight:bold;">1</font><font style="font-weight:bold;"><sup style="font-size:85%; vertical-align:top">st</sup></font><font style="font-weight:bold;"> Floor Space</font><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;), (v) 132 rentable square feet in the basement of Building 700 (the &#8220;</font><font style="font-weight:bold;">Basement Premises</font><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;), (vi) 2,922 rentable square feet of space in the basement of Building 700 (the &#8220;</font><font style="font-weight:bold;">Storage Space</font><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;), (vii) 8,763 rentable square feet of space located on the fourth (4th) floor of Building 700 (the &#8220;</font><font style="font-weight:bold;">Expansion Space I</font><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;), (viii) 1,353 rentable square feet of space located on the fourth (4th) floor and the fourth (4th) floor mezzanine of Building 650 (the &#8220;</font><font style="font-weight:bold;">Expansion Space II</font><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;),&nbsp;&nbsp;(ix) 491 rentable square feet of space on the first (1st) floor of Building 700 (the &#8220;</font><font style="font-weight:bold;">Chemical Storage Space</font><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;), (x) 8,155 rentable square feet of space located on the second (2nd) floor of Building 600 (the &#8220;</font><font style="font-weight:bold;">600 Expansion Space</font><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;), (xi) 784 rentable square feet of space located on the second floor (2nd) of Building 600 (the &#8220;</font><font style="font-weight:bold;">Hallway Space</font><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;), and (xii)&#160;700 rentable square feet of storage space in the basement of Building 700 (the &#8220;</font><font style="font-weight:bold;">Fourth Amendment Storage Space</font><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;).&nbsp;&nbsp;The Remaining Premises are more particularly as shown on Exhibit B as the Remaining Premises.&nbsp;&nbsp;Nothing herein shall affect or diminish Tenant&#8217;s rights or obligations under the Lease with respect to the Remaining Premises remaining following the Second Reduction Surrender Date.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;"><font style="font-weight:bold;">Definition of Premises</font>.&nbsp;&nbsp;</p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>As of the First Reduction Surrender Date, the defined term &#8220;Premises&#8221; in Article 2 of Exhibit 1, Sheet 1 of the Lease shall be amended to remove the First Reduction Premises, and the rentable square footage of the Premises shall be accordingly reduced by approximately 5,687 rentable square feet and shall thereafter, through the Reduction Date, consist of approximately 130,372 rentable square feet.&nbsp;&nbsp;Notwithstanding anything to the contrary contained in the Fifth Amendment, Landlord and Tenant hereby agree that on the Reduction Date, the square footage of the Premises shall be reduced by an additional approximately 23,784 rentable square feet (as identified in the Fifth Amendment, as amended by the Seventh Amendment) and shall thereafter until the Second Reduction Surrender Date consist of approximately 106,588 rentable square feet.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>As of the Second Reduction Surrender Date, the defined term &#8220;Premises&#8221; in Article 2 of Exhibit 1, Sheet 1 of the Lease shall be amended to remove the Second Reduction Premises, and the rentable square footage of the Premises shall be accordingly reduced by approximately 7,456 rentable square feet and shall thereafter, consist of approximately 99,132 rentable square feet. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;"><font style="font-weight:bold;">Yearly Rent</font>.&nbsp;&nbsp;</p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>Commencing on the First Reduction Surrender Date, Tenant shall have no further obligation to pay Yearly Rent, Operating Costs (including Building Operating Costs and Common Area Operating Costs), Taxes (including Building Taxes and Common Area Taxes) or other costs with respect to the First Reduction Premises and Article 9 of Exhibit 1, Sheet 1 of the Lease shall be amended to reflect the removal of the First Reduction Premises from the Premises.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a>(b)<font style="margin-left:36pt;"></font>Commencing on the Second Reduction Surrender Date, Tenant shall have no further obligation to pay Yearly Rent, Operating Costs (including Building Operating Costs and Common Area Operating Costs), Taxes (including Building Taxes and Common Area Taxes) or other costs with respect to the Second Reduction Premises and Article 9 of Exhibit 1, Sheet 1 of </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:31.98%;"></td>
<td style="width:1.36%;"></td>
<td style="width:23.08%;"></td>
<td style="width:1.28%;"></td>
<td style="width:42.31%;"></td>
</tr>
<tr>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">725902539.5</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;">3</font></p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:7.69%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Lease shall be amended to reflect the removal of the Second Reduction Premises from the Premises.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;"><font style="font-weight:bold;">Reduction and Surrender</font>.&nbsp;&nbsp;Tenant shall voluntarily surrender the First Reduction Premises on or before the First Reduction Surrender Date in accordance with all surrender requirements contained in the Lease and in the condition required under the Lease (as amended by this Eighth Amendment).&nbsp;&nbsp;Tenant shall voluntarily surrender the Second Reduction Premises on or before the Second Reduction Surrender Date in accordance with all surrender requirements contained in the Lease and in the condition required under the Lease (as amended by this Eighth Amendment).</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;"><font style="font-weight:bold;">Lease Modification Fee</font>.&nbsp;&nbsp;As consideration for Tenant&#8217;s agreement to enter into this Eighth Amendment and terminating the Lease with respect to the Second Reduction Premises as of the Second Reduction Surrender Date, Landlord shall pay to Tenant, within 30 days after the Second Reduction Surrender Date, an amount equal to 50% of the sublease profits that would have been realized by Tenant under the existing sublease with Fulcrum affecting the Second Reduction Premises for the period commencing on the Second Reduction Surrender Date through June 30, 2019.&nbsp;&nbsp;For example, if the Second Reduction Surrender Date occurs on June 30, 2018, Landlord shall pay to Tenant a lease modification fee in the amount of $98,914.49. The modification fee shall be prorated for any partial calendar month in which the Second Reduction Surrender Date occurs.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;"><font style="font-weight:bold;">No Further Obligations</font>.&nbsp;&nbsp;</p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>Landlord and Tenant each agree that the other is excused as of the First Reduction Surrender Date from any further obligations with respect to the First Reduction Premises, excepting only such obligations under the Lease which expressly survive the termination of the Lease. In addition, nothing herein shall be deemed to limit or terminate any common law or statutory rights Landlord may have with respect to Tenant in connection with any Hazardous Materials or for violations of any governmental requirements or requirements of applicable law. Nothing herein shall excuse Tenant from its obligations under the Lease with respect to the First Reduction Premises prior to the First Reduction Surrender Date.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>Landlord and Tenant each agree that the other is excused as of the Second Reduction Surrender Date from any further obligations with respect to the Second Reduction Premises, excepting only such obligations under the Lease which expressly survive the termination of the Lease. In addition, nothing herein shall be deemed to limit or terminate any common law or statutory rights Landlord may have with respect to Tenant in connection with any Hazardous Materials or for violations of any governmental requirements or requirements of applicable law. Nothing herein shall excuse Tenant from its obligations under the Lease with respect to the Second Reduction Premises prior to the Second Reduction Surrender Date.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:31.98%;"></td>
<td style="width:1.36%;"></td>
<td style="width:23.08%;"></td>
<td style="width:1.28%;"></td>
<td style="width:42.31%;"></td>
</tr>
<tr>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">725902539.5</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;">4</font></p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;">Removal of Personal Property</font><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>Landlord shall not dispose of any personal property located within the First Reduction Premises prior to the First Reduction Surrender Date.&nbsp;&nbsp;Tenant agrees that the First Reduction Premises shall be surrendered on the First Reduction Surrender Date free of all personal property of Tenant.&nbsp;&nbsp;Any personal property of Tenant remaining in the First Reduction Premises after the First Reduction Surrender Date is hereby agreed to be abandoned by Tenant and may be disposed of by Landlord, in Landlord&#8217;s sole discretion, without obligation or liability of any kind to Tenant.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>Landlord shall not dispose of any personal property located within the Second Reduction Premises prior to the Second Reduction Surrender Date.&nbsp;&nbsp;Tenant agrees that the Second Reduction Premises shall be surrendered on the Second Reduction Surrender Date free of all personal property of Tenant.&nbsp;&nbsp;Any personal property of Tenant remaining in the Second Reduction Premises after the Second Reduction Surrender Date is hereby agreed to be abandoned by Tenant and may be disposed of by Landlord, in Landlord&#8217;s sole discretion, without obligation or liability of any kind to Tenant.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;"><font style="font-weight:bold;">Parking Spaces</font>.&nbsp;&nbsp;</p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>On the First Reduction Surrender Date, the parking passes allocated to Tenant in the OKS Garage shall be reduced by 5 parking passes.&nbsp;&nbsp;For the sake of clarity and as described in the Seventh Amendment, on the Reduction Date, the parking spaces allocated to Tenant in the OKS Garage shall be reduced by an additional 24 parking passes.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>On the Second Reduction Surrender Date, the parking passes allocated to Tenant in the OKS Garage shall be reduced by 7 parking passes.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;"><font style="font-weight:bold;">Lender Consent Requirement</font>.&nbsp;&nbsp;Landlord and Tenant agree that this Eighth Amendment shall not be effective unless and until Landlord obtains consent to this Eighth Amendment from the lender that currently holds a mortgage secured by the Complex (the &#8220;<font style="font-weight:bold;">Lender</font>&#8221;).&nbsp;&nbsp;The date on which Landlord obtains Lender&#8217;s consent, if at all, to this Eighth Amendment is referred to in this Eighth Amendment as the &#8220;<font style="font-weight:bold;">Lender Consent Date</font>&#8221;.&nbsp;&nbsp;Landlord agrees to (a) use reasonable efforts to obtain Lender&#8217;s consent to this Eighth Amendment as soon as reasonably possible following the full execution and delivery of this Eighth Amendment by Landlord and Tenant, (b) provide written notice to Tenant of Lender&#8217;s approval or disapproval of this Eighth Amendment promptly following Landlord&#8217;s receipt of such written approval or disapproval from Lender, and (c) if Lender disapproves of this Eighth Amendment, to make such changes as are reasonably required by Lender for its approval of this Eighth Amendment and which are reasonably agreed to by each party to this Eighth Amendment in order to effect the intent of this Eighth Amendment to the extent possible.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;"><font style="font-weight:bold;">OFAC</font>.&nbsp;&nbsp;Tenant and all beneficial owners of Tenant are currently (a) in compliance with and shall at all times during the Term of the Lease remain in compliance with the regulations of the Office of Foreign Assets Control (&#8220;<font style="font-weight:bold;">OFAC</font>&#8221;) of the U.S. Department of Treasury and any statute, executive order, or regulation relating thereto (collectively, the &#8220;OFAC Rules&#8221;), (b) not listed on, and shall not during the term of the Lease be listed on, the Specially Designated Nationals and Blocked Persons List, Foreign Sanctions Evaders List or the Sectoral Sanctions Identifications List, which are all maintained by OFAC and/or on any other similar list maintained by OFAC or other governmental authority pursuant to any authorizing statute, executive order, or regulation, and (c) not a person or entity with whom a U.S. person is prohibited from conducting business under the OFAC Rules.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:31.98%;"></td>
<td style="width:1.36%;"></td>
<td style="width:23.08%;"></td>
<td style="width:1.28%;"></td>
<td style="width:42.31%;"></td>
</tr>
<tr>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">725902539.5</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;">5</font></p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU6"></a><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;">Miscellaneous</font><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>This Eighth Amendment is the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior and contemporaneous oral and written agreements and discussions.&nbsp;&nbsp;This Eighth Amendment may be amended only by an agreement in writing, signed by the parties hereto.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>This Eighth Amendment is binding upon and shall inure to the benefit of the parties hereto, and their respective successors and assigns.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font>This Eighth Amendment may be executed in any number of counterparts, each of which shall be deemed an original, but all of which when taken together shall constitute one and the same instrument.&nbsp;&nbsp;The signature page of any counterpart may be detached therefrom without impairing the legal effect of the signature(s) thereon provided such signature page is attached to any other counterpart identical thereto except having additional signature pages executed by other parties to this Eighth Amendment attached thereto.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font>Except as amended and/or modified by this Eighth Amendment, the Lease shall remain in full force and effect.&nbsp;&nbsp;In the event of any conflict between the provisions of this Eighth Amendment and the provisions of the Lease, the provisions of this Eighth Amendment shall prevail.&nbsp;&nbsp;Whether or not specifically amended by this Eighth Amendment, all of the terms and provisions of the Lease are hereby amended to the extent necessary to give effect to the purpose and intent of this Eighth Amendment.&nbsp;&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES ON FOLLOWING PAGE</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:31.98%;"></td>
<td style="width:1.36%;"></td>
<td style="width:23.08%;"></td>
<td style="width:1.28%;"></td>
<td style="width:42.31%;"></td>
</tr>
<tr>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">725902539.5</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;">6</font></p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU7"></a><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, the parties have executed this Eighth Amendment as of the date first written above.</font></p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:50%;">
<tr>
<td colspan="3" valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">TENANT:</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">MERRIMACK PHARMACEUTICALS, INC.,</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a Delaware corporation</p></td>
</tr>
<tr>
<td valign="top"  style="width:18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:80%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Jeffrey A. Munsie</p></td>
</tr>
<tr>
<td valign="top"  style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Its:</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:80%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General Counsel</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:50%;">
<tr>
<td colspan="3" valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">LANDLORD:</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">ARE-MA REGION NO. 59, LLC<font style="font-weight:normal;">,</font></p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a Delaware limited liability company.</p></td>
</tr>
<tr>
<td valign="top"  style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Alexandria Real Estate Equities, L.P.,</p></td>
</tr>
<tr>
<td valign="top"  style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a Delaware limited partnership,</p></td>
</tr>
<tr>
<td valign="top"  style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">managing member</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:50%;">
<tr>
<td valign="top"  style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARE-QRS CORP.,</p></td>
</tr>
<tr>
<td valign="top"  style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a Maryland Corporation,</p></td>
</tr>
<tr>
<td valign="top"  style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">general partner</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:50%;">
<tr>
<td valign="top"  style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Jackie Clem</p></td>
</tr>
<tr>
<td valign="top"  style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Its: Senior Vice President</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RE Legal Affairs</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:31.98%;"></td>
<td style="width:1.36%;"></td>
<td style="width:23.08%;"></td>
<td style="width:1.28%;"></td>
<td style="width:42.31%;"></td>
</tr>
<tr>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">725902539.5</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;">7</font></p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU8"></a><font style="font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT A</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Reduction Premises</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g201805072101259112278.jpg" title="" alt="" style="width:429px;height:736px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:31.98%;"></td>
<td style="width:1.36%;"></td>
<td style="width:20.51%;"></td>
<td style="width:1.28%;"></td>
<td style="width:44.87%;"></td>
</tr>
<tr>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">725902539.5</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A-<font style="font-size:11pt;"></font>1<font style="font-size:11pt;"></font></p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU9"></a><font style="font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT B</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Remaining Premises</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g201805072101259272279.jpg" title="" alt="" style="width:464px;height:753px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:31.98%;"></td>
<td style="width:1.36%;"></td>
<td style="width:20.51%;"></td>
<td style="width:1.28%;"></td>
<td style="width:44.87%;"></td>
</tr>
<tr>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">725902539.5</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">B-<font style="font-size:11pt;"></font>1<font style="font-size:11pt;"></font></p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU10"></a><img src="g201805072101259432280.jpg" title="" alt="" style="width:410px;height:783px;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:31.98%;"></td>
<td style="width:1.36%;"></td>
<td style="width:20.51%;"></td>
<td style="width:1.28%;"></td>
<td style="width:44.87%;"></td>
</tr>
<tr style="height:55.5pt;">
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">725902539.5</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">B-<font style="font-size:11pt;">2</font></p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU11"></a><img src="g201805072101259582281.jpg" title="" alt="" style="width:427px;height:780px;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p>
<p style="margin-top:12pt; clear:both;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:31.98%;"></td>
<td style="width:1.36%;"></td>
<td style="width:20.51%;"></td>
<td style="width:1.28%;"></td>
<td style="width:44.87%;"></td>
</tr>
<tr>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">725902539.5</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">B-3</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU12"></a><img src="g201805072101259762282.jpg" title="" alt="" style="width:447px;height:777px;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p>
<p style="margin-top:12pt; clear:both;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:31.98%;"></td>
<td style="width:1.36%;"></td>
<td style="width:20.51%;"></td>
<td style="width:1.28%;"></td>
<td style="width:44.87%;"></td>
</tr>
<tr>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">725902539.5</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">B-4</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU13"></a><img src="g201805072101259922283.jpg" title="" alt="" style="width:434px;height:781px;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p>
<p style="margin-top:12pt; clear:both;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:31.98%;"></td>
<td style="width:1.36%;"></td>
<td style="width:20.51%;"></td>
<td style="width:1.28%;"></td>
<td style="width:44.87%;"></td>
</tr>
<tr>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">725902539.5</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">B-5</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU14"></a><img src="g201805072101260072284.jpg" title="" alt="" style="width:438px;height:779px;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p>
<p style="margin-top:12pt; clear:both;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:31.98%;"></td>
<td style="width:1.36%;"></td>
<td style="width:20.51%;"></td>
<td style="width:1.28%;"></td>
<td style="width:44.87%;"></td>
</tr>
<tr>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">725902539.5</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">B-6</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU15"></a><img src="g201805072101260282285.jpg" title="" alt="" style="width:416px;height:776px;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p>
<p style="margin-top:12pt; clear:both;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:31.98%;"></td>
<td style="width:1.36%;"></td>
<td style="width:20.51%;"></td>
<td style="width:1.28%;"></td>
<td style="width:44.87%;"></td>
</tr>
<tr>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">725902539.5</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">B-7</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU16"></a><img src="g201805072101260422286.jpg" title="" alt="" style="width:442px;height:780px;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p>
<p style="margin-top:12pt; clear:both;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:31.98%;"></td>
<td style="width:1.36%;"></td>
<td style="width:20.51%;"></td>
<td style="width:1.28%;"></td>
<td style="width:44.87%;"></td>
</tr>
<tr>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">725902539.5</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">B-8</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g201805072101260812287.jpg" title="" alt="" style="width:458px;height:773px;"></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:31.98%;"></td>
<td style="width:1.36%;"></td>
<td style="width:20.51%;"></td>
<td style="width:1.28%;"></td>
<td style="width:44.87%;"></td>
</tr>
<tr>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">725902539.5</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">B-9</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>mack-ex311_7.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
mack-ex311_7.htm
</title>
</head>
<!-- NG Converter v4.0.8.21 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.1</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATIONS</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Richard Peters, M.D., Ph.D., certify that:</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1. I have reviewed this Quarterly Report on Form 10-Q of Merrimack Pharmaceuticals, Inc.;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p>
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:2.27%;text-indent:2.27%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:20%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: May 8, 2018</p></td>
<td valign="top"  style="width:30%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Richard Peters, M.D., Ph.D.</p></td>
</tr>
<tr>
<td valign="top"  style="width:20%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Richard Peters, M.D., Ph.D.</p></td>
</tr>
<tr>
<td valign="top"  style="width:20%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p></td>
</tr>
<tr>
<td valign="top"  style="width:20%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>mack-ex312_11.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
mack-ex312_11.htm
</title>
</head>
<!-- NG Converter v4.0.8.21 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.2</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATIONS</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Jean M. Franchi, certify that:</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1. I have reviewed this Quarterly Report on Form 10-Q of Merrimack Pharmaceuticals, Inc.;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p>
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:2.27%;text-indent:2.27%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:20%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman,;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: May 8, 2018</p></td>
<td valign="top"  style="width:30%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Jean M. Franchi</p></td>
</tr>
<tr>
<td valign="top"  style="width:20%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jean M. Franchi</p></td>
</tr>
<tr>
<td valign="top"  style="width:20%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
<tr>
<td valign="top"  style="width:20%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Financial Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>mack-ex321_6.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
mack-ex321_6.htm
</title>
</head>
<!-- NG Converter v4.0.8.21 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.1</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Quarterly Report on Form 10-Q of Merrimack Pharmaceuticals, Inc. (the &#8220;Company&#8221;) for the period ended March 31, 2018 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned, Richard Peters, M.D., Ph.D., President and Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that to his knowledge:</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:30%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: May 8, 2018</p></td>
<td valign="top"  style="width:30%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Richard Peters, M.D., Ph.D.</p></td>
</tr>
<tr>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Richard Peters, M.D., Ph.D.</p></td>
</tr>
<tr>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p></td>
</tr>
<tr>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>mack-ex322_8.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
mack-ex322_8.htm
</title>
</head>
<!-- NG Converter v4.0.8.21 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.2</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Quarterly Report on Form 10-Q of Merrimack Pharmaceuticals, Inc. (the &#8220;Company&#8221;) for the period ended March 31, 2018 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned, Jean M. Franchi, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that to her knowledge:</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:30%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: May 8, 2018</p></td>
<td valign="top"  style="width:30%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Jean M. Franchi</p></td>
</tr>
<tr>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jean M. Franchi</p></td>
</tr>
<tr>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
<tr>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Financial Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g201805072101259432280.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g201805072101259432280.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,0 9L# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BDR/6EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *1AN7&<4M% 'G,5MXQT+53"_B31I;.VTXD-?"0NRJYS
M+(H?[V",OG'; KK?#&IS:OHZWDU]I][O=@LU@C+'@<8PQ)W YS7+>,9O#L?C
M.SBUV[FL4ELLM*LN(KE4E#"&1=IP,\@@C/S"ND\*_P!DRVE]=Z/?_;HKN\DG
MEE# CS" "HP!@ !10!O4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(78S)&S'&Q3O)+8& V"<5J_#JWL+?0KM+&&_MV^VR?:;:_E$DL$H"@INYW*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MDU:SL[JS^W6\;B\.(XP\@0OGM@,3S7*:9_PK.XUS5+5[?PQ%':2Q+;2B>/\
M?;HU8D<X.&)''I0!ZE1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MHU@+.V,AB$DDH\QLG+NSM^&6-7: "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBHYYX;:!YKB5(HD&6>1@JJ/<F@"J^K6R-*-L["(E79('901UY
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M3ISZQJ\#6-N84:,+'Y8VC*DGBK5SI%K83VUWIFD6YGB<DB%4C8@HPZG'&2*
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M[6U"XCM[>+=Y9R>KM][/T%4OM?C;_H#:%_X,Y?\ XQ1]K\;?] ;0O_!G+_\
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MIK6.UM[)K6RN6EM_,G8,4(8!"-O &[ Z]!274_BV[N&CLX["V\@[90)MVXD
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MXDEDZXW,DB=!@?\  : .DT(+#!-:M 8KJ*0F?+E_,9N0^X\D$?EC':K&C?\
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MH"?E##&U6S@8QR,<]:TR&W8)7S=Q!)&1OQEC[C9P?[QZ8H'.#'P3M*9ZC/\
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M_CT;)91SQO\ O/G('ISUK"\/R3R3WRKY+XU-T>:.0L!)]ISNP1Z?+C/S9YH
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M44 %%%% !1110 5@>);F)5M[.Y,R6=SN\]XK=Y25&/D&U3@DGKZ XYYK?HH
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MD22(I5&"21,'8/\ <*KC+9[8S5&([Q* WAR_! (,1R"*THD2.)41%55& JC
M%8VKW:WWA6\EACE&Y2@C9"'W!L8QZYK6M;A+JV2:/.QAQD$'TY!Z4NI;^!>K
M_0FHHHID#)O]3)_NFJ'A_P#Y%ZP_ZX+_ "J]-_J9/]TU1\/_ /(O6'_7!?Y5
M/4M? _5?J97B^"QG@M_/NA'.' C0.H+ D=B#Z=JU?#\21:%:;%QNC#-SG)/)
M)]ZY+5GU+2YC#<6MC*]Y*\IGC>1I753P"-F  "!C.!BNMT%B='@B>-HY(1Y3
MJV.&7@]"15$&E1110 5B>*+^PLM,5=2LUN[>X?RC"VW:<*7).X@<!"?7( '-
M;=4M6>WBTV:6X@AG6,;UBF95#..5&6X!SC!/>@# \(7-K</<?V7;)96 CCD6
MT,"JV'4%'W*QZK_"W(P!Q63XOM[9]?N+IM6^R/;6J+,C1;G\N0LO[D[AR>_!
MY"]3Q78::+>*[O8;>P@M?G61VB*9E9ADLP7D'MD]<<5R'C3SSXCM3'J\$$J+
M'Y,3%5\HLS#S&8HV 6"]QG! Y&: /0:*** "BBB@ HHHH **** "BBLYM2G>
M:2.TL9)O+<H7=UC3(ZXY)/Y4 :-%<A>_VC-J<D4]T_FML6.VM7P$!#'[Q9<G
M",<E3U %:.EZ5!=:;%+<7M_?12J'07,V"%(& 0F WUY_&@#F_$.JVO\ PGEK
M!%J5HLL-J_FI]]U.1M&P$9);;P>V:K7=N^H:E9WS1_:9+*.5H7:U9$0N5\QP
MSN#D$;5.,G)!XK0N;9=,\8QVUOY(MYX9)C&D04J>AR1RP&2V!@\#TK6RP;(4
MNP.<$C+$# &>F7')/0@8'- &#<Z9JFI_:8]0;3/*N(O*D@DA:0%@"2#\P& #
MD]<8&VBUT*^AN)I6U<S&8Q 1K#Y*_(N(AA&&<CG!. .>#6Z.@ <XP ) 0.!R
M'Y]_D&>G\54-4U./3H8O,>&)[AS%'YTGEQJ3RV3V"8SCKD\8% '+0^'K73O$
MVD:=;+;"Q$DVIR+#'M\L*HC3;DDD>8_ /WN<UW+,Y+-)M#?.7^<X!QB7GT Q
MSV/ R*RK/3YQKUUK%Q)%+)-;I!%%&#A0I8LI.?FW[@YP.0HQGK56ZD37WDL[
M*]F AC;,JNR'S5;;&Q((Y8JX!Z8&#S0!O-(T1W'8K!EV[\ ;P/D!'0?+R1T'
M4<TH4% %#&+:H4@9)3.4/N2_'^T.37/^'_#9T6R>![_S2TC-YQ#$JK8)."?X
M6&,\$$\\59'AG20H_P!%E&!_JS=3''8I@-T'WR!U[4 :Y4D'S!@$-O()P ?]
M=SUP#C!ZYXZ4'>'S@"7=G!X'F <#V&SD_P!T]*YC5_"UFT<+VPU$)&Y\Y;6\
M?S9%P0""Q();@\=0,#)XK2T&"PMM/>WT^_GN8HY2DD\TI=T?@DG=]TJ<(!_#
MGGK0!I@+@",DKA0GJ1UBX]2<\=".3@UF>(B/^$:U(AEQ]G?DR'&TGYSG_>X!
MZMT/'-:A.0<ILSNRN.%S]Y<=<)]['7)R,"LSQ)&9?#>I*79/W+-NX)R!T],N
M!DGH>W(S0!VYW!P<C9CD8Y_SUJ*VO;6]#FVN(Y@C;6,; X-3,,J1ZC%4=+TY
M]/C97G\XD(H.S;@*N!WH OT444 %%%% !1110 A (P>AKG]$MH;3Q-KD-O&(
MX@ML0J]!\K5H:W?OINER7"*2P*J"(VDV98#<57D@9SQZ5A^$;R"_UC6[FWO)
M;R,F!#-)$8R6"'("D# &1V[]30!TE^$.GW(D9E0Q-N(&2!@YKCXFCDMY97MY
M+FX@20W:/;!8P2BH%8@M\H0@[5W'N<5VTD:S1-&XRC JP]0:S+C2!!8SC33)
M'<,IV9N'P3WZD@$CC...M &+J.JRQ6S06\]B594!FM5SL5F"D$,<<@Y'(Z&I
M+>XTB :;\DCOIT/DPL9XLXVA>?GYX%.U#2=8EQ"C&XM5*RH)9AO#;E)0D@AL
M '#$'J0:@2:Q73[FZO2]M]GNOLLB^5 _S97D$1\C# ^P!]*G6YJE'D3?Z?\
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M9;J2*.&/#EY=V 01C[O.<],5Q5NJ1VDLDMMIR*TLDD(:Y?=Y84G:XW?*6/\
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M"GGG-9_P\TN^T_3+M[XLQFF C4J"1UQD=20Y8D'KC=QTKJP+:QL0% 2SMX0
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M,[URHSN 3&0/]8,?[1Y [?>]J %!/!"'/RD1C'T"#/I]\9_X%ZT=%_OJ!^#
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MO'_NS?\ HEZX/5M0M%&M3710V$1N(I[3S!OFE(8*X4<D#.,X_B!_@KO/$/\
MQ[Q_[LW_ *)>N&U6"\>]U:W2_FBOF,]S:SK*NR)$R=I3H3D<9Z@L?X>0#KO
M/V=? VDQVUF]FL4"Q/;R+AHW7A@?4Y!Y[]:Z2N?\$I<_\(AI\]Y)%)<W4?VJ
M4PC";I/G(7D\#=USS704 >7>(I+9?B7=>1&;._DT^.&/4I&"QH^[=SG@[5P3
MGKD+5_0IH)K36S;J%1?M*, ^_P"<16X8[OXLMD[N^<U4\2_:H/'-ZTLQ_LM+
M)+R6&W;$[D?NR!SDX !'J<BKVCQSPP:M#-<O,$@F:/<X?8KI$P4,/O 9'/>@
M#OG!9& )&1C(KRC6-+%IK%Q!++$[".%&97V[>X<AB=ASP'^Z2VT@9%>L5Y=X
M]-\-1U-M,A2?4%@4V\,RC;* OS(I'+-CDQMP0,CD4 8%S8R:KJVGZ-#FT2_\
M]KB:.+#(@QYD29X1LD':W,9S@X(KJE\$^&$52NA0/M (&YSNQP!R<_/U&><]
M<BN.\-W>K/XBT&74[0"=[6Y,L<,@D:3Y%RVS.&&T8!R3U!^[7HHU6W$BK).;
M:5B-IN$* ,1\C;B,'"Y!;/S=* ,S_A!_# &W^Q[; &W>2V,+SOZ]"?E.._W:
MH7W@WP\NIZ7$FDQ1+-+*LBACQF,M@\]8\9],>]=6L\+0>>DB&W5!)E7 "Q@X
M49[;6^;/\ XKE=7\11Q:[H43V,[F69O+RH7S X*N=I.4#'! /^][4 6IO WA
MV2%A%I%O'(<,N QP>@7&X?>'S#/XU0;P5X?@UG3K9K"&5#:SL[98+*4:/:Y&
M[.&W%>,G/3(KJ[2Z%[&63<LPD,;B0?,DN,Y/K\G&>CY&/6J4Y0^)M-*+M!M+
MAES_  J6B"#=V*GJ>WW>: *G_"#>&,D'1[=<Y4L2<C/))Y_@Z'MSQSQ7.ZMX
M=\/6>OR1'0[,Q-IXE\FXE98P^Y_E[C<< C(Z YYQ7=W-Q!:0-+,I,8R-BQ_,
M^#AD5?5F(('\/7-<I>:Q<P^+<&)()?LBI<)*J.S ,S$H-V&)##Y1][DC&.0"
M?3_"'AB> R#0;4&,A#'&S^62O0 '!^?/IG([@5:_X0?PN,C^QK?'W2Y+=!R6
M.#Z_*?\ QWTK8L)Q=VL<\%W'<!]I291@9/"$]<%1D$]_NU/P%SC$87.W&TA
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M$B2]@M[XHB;=K.BJHX&TG!PQ+=.O-367AR[T6PU66XNXIQ+#,V$0K@L%X Z
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MGEX)"KC ]?UKL7.V-F/8$US.FVRMJ=KJ%U>F]NW&Q6:$(8@T9< 8..@]#]:
M.HK,\13-;^'[V5+HVLBQ_),%W%6[<<9YP,9'6M.LGQ/</:^&-1FC6-G6!L+)
M'Y@)]-O?\>/7B@"MX8UB?5H)&N9(3,J(Y2*%HR@<$@$%FYX/0U'J6C7\^O27
MD5MI5Q;R6ZP$7:'S%&XE@"!RIXX/I3?!^G)IEC<1)9W%JK2;ML]O#$2<=?W9
M(/XUAZQ?)<W6HV$GB35(5F=UCDCM5%M %VAE9]F3M9L$AAC<!D8- 'H-%%%
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M05*L#@Y9O;&,#O7IR?ZM?H*X36;=;AH7C9H'AC+H<?=1BHV8[''\\]Z[N/\
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M-P95D2(F-3RJXZ?YZ5B>(%*>(+A;K49T2Z$8%N=1MH=B@D#9N7>-WJ"#VSZ
M'H-%%% !1110 4444 %%%% !1110 4444 <O_P SM:_6Z_\ 0+>NHKCX83'X
M]A8Q1#=]JS(I^9^(3SQV!QU-=A0 UW6-&=V"JHR23P!69KL6EW%M#%JTT20&
M7*K(^W>V"  >N><\<\5F^*HEN;JTMIKB\BMGM[EY1:S-&S;57'0C/4\'BL&;
M0)K2XMS<W&LH97+AS=R3"+^\2$((88'/(YSDXH [+2H;1;B[GLY8FCD*+LB7
M 0*N!]3[^F!VK3KS]]-9GD*ZKJ&%$@AGFOKF+> H8MC)X7'7 !R.];FG:/9W
M]KYHN]54ABK+_:=R,'W#$$?E0!OW$Z6MK+<29\N)"[8] ,FJ-CKEMJ%RT4"2
M-&=WE7&5,<VT@-L())P3CD#VS7/^)='ATVP%VEQ<2QC,+K>WDLJ)YGRB3#,1
ME<YZ=,]#@U!X->S74%M[>]LYML!(6WFFE\S!7+GS.$[<+USUXH W&5M7UR_L
MKEY/LEIY)$*D!92P+?-QDC(Z9P>^:WJY^TN[:V\4:T+BXBB+"#'F.%S\A]:U
M?[5T[_G_ +7_ +_+_C0!1O\ _D:]'_ZXW'\DK9K N+NVN?%>D?9[B*7;#<9\
MMPV.$]*WZ "L7PS_ ,>-S_U]R_SK98%E(!QGO7+Z8+OP_!(MQID<:22QQ+]G
MF4AVX3=@X.6/)'ZT 2:S%?#Q3IKV%W%;R3V\T3&6#S1A2K=-RT\3^*S8")K+
M3_M6W!G2X(4GN0I4X^F35C4/^1GT3_=N/_05K:H YG_BJ_[D'_@0O_QNC_BJ
M_P"Y!_X$+_\ &ZZ:B@#FXG\5QS*S6]K+& =R/< 9],$1BJ&N#7[W[/;WAL[.
MRN+J"'RXP9G/S;B=V5Q]T#H>M=G6+XA^]I/_ &$8OY-0!LEMJECG@9XKRS1_
M$VB:;:26>I:C;6UP]S*Y0R9S')(6 X&-VX@8]>O%>I]J\T\2ZU927K#5EN62
M.]B2%2N;<$3 +D \YQN)(] ,8H TCXDT@D[]1MMQ+;_O8W'_ %O;.,8]\].*
ML6>LV-]=+!97D4UT3N1!U+ ?(3V^[][MZ<U8DN(+<*TERBJ<;'>4+O"\HP)[
MMTSV'!IL=Q:SDQQW<3#:=WEN"54G+-@=-AX _ASF@#D/&>K0Q2V]M;.LJJA2
M1 A9@F4,8)Z#)+$'TQNJ=]29K/$2S(60A0+N0[0<"3 ST!QCOD>E=?R3DJ-Y
M))3&1N(PR8[C;\^/XSR* [#!5V?&TKE_O8X3G_;[M[;>M %?462.TG:>%)]K
M?-'(!M:3C&>V-F"WI_#5.ST[2;JTAGBTNU5752BF%"<9Q%SC!).?;'7FM+"[
M=N\A-NW>.,+G.[VPWRC^YWI3DD[E"D[MRXX4M]]<>BCYL=S\U &3>Z;I=O;I
M*MM;6X$L>)H8U4H/,4,02.F_ &>3SGBJJW-Q:Y736@O7+7$TR, &#;\3;=F,
MGGN>?X36OJ'-C-EYU)&085$C[NB@#!#%QR3@ANE<RM_JMC!*]K;R3JJ#RWEM
MW61PI^7*J,)DDC=DXVX(&: -*ZNK73])LIM5B"2R2*P,(,9$Y0E">1ABN[=S
MC\:CTSQ+I7V5XYM1!AC;9$\OWWAX*YQG+!R0">H&6J2,0^1(QL8+B2ZNF3?Y
M/E*_R[FD*ODC9@@ 9/?I6EIUHUI%(76'[1-*9I$B7"!RH7RP.Z[ &_VR,\4
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M]M@?:B#</[C' Z!>IZ'H.: -KIP7!()!D)P"1RSY[ CY"?X3P*0G'_3/IC(
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M6(<')PW7C!R1FN;UNRN+/6+E)M,T^[>0)) [6%Q++.S.0R+)YA"E1CG@#.<
M"NJ\,65S83ZA%+IUK:6Y9'B:WE:7S20=Q9V 9B, <C@8K(\1LB^*\RWENT8M
M5?R9Y+A1"%+%FS'\O(YPW)V^E '9VUM':6Z00[O+087<Y8X^I))_&IJ** "B
MBB@ HHHH **** "BBB@ HHHH Y26:*W\9VKSRI$F;H;G8*/N0>M=!_:FG_\
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M\MM0,C7EX?-?;YDC1[N 1M!"C*DC/?- ':4444 %%%% !1110 4444 %%%%
M!1110!QU]9+?^+K6%Y[F$;KEMUO,T;?<@[CM6K_PC$/_ $%-9_\ !A)_C67!
M&5\?0L8-I/VK,N_._B$@8[8!%=A0!@R>$[2>)XIM0U:6)P5>-[^0JRGJ",]"
M*NW^C6^H212--=6[Q*4#6T[1$J<<''4<5HT4 8?_  C$/_04UG_P82?XUBZ/
MX4LIM2U6Y:\U/SXKQHED%[)NV[%/KUYZ]Z[:N8L=5M].N=8642/(U\[B.)"S
M%0B9;'8#U- %#7?"ME%/IMS]JU)YFO88R[WLA.TGZ_EZ=JW/^$9M/^?S4_\
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M_P!N5XA%ME"$"0ON8(,MSZ\4 +KO7_MUE_\ 0HJVJQ==Z_\ ;K+_ .A15M4
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M-8!TBSU+Q))'J&F6]TBRS/NN,2J?ECQA&R <%>?:M7_A$?#7_0NZ3_X!1_\
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M1_MZRCB@DM+>\G(NO)G"%YA&Q.W;TS'WR/NC=DUT$,4<,,<5K&B1JJ")0"%
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M0!TM%<9)XUU6(1D^$;PK*H=&6]MR&4]"#OJ/_A.]3QG_ (1"_P"F?^/NW_\
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MG-8&C>'+E/%6IR2VDEO9,&%G,),!=[AH2H!W97!)!Z=>10!U>I_\@B] ;/\
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MCW^<^G:LS1=&#+>W%U<R/!<7TTT]NJC$AC;:^6]#M4]@>E=1\V_&?WN[&X#
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M:G;10_N4&K0#:<'<0C$@N>@/I]30 Z[TB'7?!W]DO//#'=6<47F0G;(!@&/
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MXH TMRY R.>G/6EKCO#MHUEKA26X\Z%X$-BLBN3;H0244L..F>><<<@<=C0
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M)[4 2Z[U_P"W67_T**M>8!HF5EW*005]1Z5S-Q=SZKK^IZ=;Q^8;.)(R<A5
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MX[JWCN(FW1R*&0^H/2I:YG5O#=A!I\TMLL\<FX%0+J4*"6&> W Y/2N>\/\
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MUO)$QC"%R[#"  J,YYZ<_K3O"-_JNO>$=/O]/U6TFC:%5RJX"LO!4C9D$=*
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2 PS8ZFI:* "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g201805072101260072284.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g201805072101260072284.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,, ;<# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>:ZJL?0_#=GH$EW+;37D\UVRM-+=W#3.VT87ECG@5L4 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHJ*YGCM;66XE.(XD+N<9P ,GB@"6BN>M?$TLL
MEDUUI-Q:6M\P2VGDDC;<S*64,JL2N0#Z\\5T- !1110 4444 %%%% !112$9
M&* .0U#PAK%WXO\ [;M_%-S:1BU>W2*.VA8QAF1MH+(<K\N><G..<<5JZ#X>
M_L6>^NIM0N+^]OG5Y[B=44G:NU0%0   >U<AXGN[KPN0+CQ=XEN9##)<M%9V
M5HYCA3&YVS& %!('7))XS6]X)U&>]348KJYUF6>VF6.1-5A@BDC)4,,"+@@@
M@Y/X4 =91110!R7C];N32]/CMX-2GM7OD%]'INX3-!M<D J00"P0'!!Q7GL]
MC(;;6GM_#7B:34S<(=%N[F!WDM8U5"%$C,2JA_,R.X/.:]OHH "<"N5O/%L(
MEFM9O"^OW"(Y4E=.WH^#U'/(XR#7544 <KX4O=0O]6UJ>>RO[+3MT*V,%Y#Y
M14"/#[5[#=75444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5%=&86DQMT628
M1L8T<X#-C@'VS4M4]60R:-?1AF0O;NH94+%<J1G Y/T'- ' >'M.CM=7TN>V
MM+J2[9B+J"?3&ABLP5.XQL0 N&P %+9!Q[UZ77 Z5=:)I7V)-/\ $LRI&BI-
MIRAIQ(0N/E1@7C.>>,#VKO0<@'GGUH 6BBB@ HHHH **** "BBB@#SKQ+XA\
M'/XP?3-8NXXY!IL]O<2&4A=CLF8F7'4\,"#Q@^M7_ $NGS3:R^GW5[J*>=$C
M:K=,&^U8C&%7"J/D'!XY))SDFE\3S3-XNTJQ&I)HT-Q:S$Z@L<?G2E63$".X
M(7/WR,$G;[5;\':M<7ESK&FRZB-5BTZX6*+4 %!DW(&*-L^4LA."1CMD9S0!
MU5%%% !1110 4444 %%%(2 ,DX% "T49I,@T +129&<9YHR* %HHI,@T +11
MFDR* %HHI,@T +129&<49% "T44F0: %HI,@D@'IUHR,XH 6BD) &3T%+0 4
M4F11D9QGF@!:*,XZT4 %%&<]*3(H 6BD) QD]>*6@ HHS2 @D@'D=: %HI,B
M@D 9/04 +129%+0 4444 %07UP;33[FY6,R-#$T@0=6P"<?C4]0W9D%E.8I4
MBD$;;)'^ZAQP3["@#F-/\6W.I7-M-;V<;Z9-<+:^8LC&02&(2%L8QL!)0\YR
M"?:NMK@[>:]AU/1+&+Q&MTTOEW%U'-(2Y!1C\CJH!5B"=C8X7(X&*[R@ HHH
MH **** "BBB@ HHHH \ST>V\1:MHMY;?V7X?U'3O[3O-BZI-(S'%Q)C*^6PX
MZ#GIBNR\.6NHV5F;:^L-)LDC($$6F,QC"]\@HN.?05L@ =!BEH **** "BBB
M@ HHHH *3%+10 E%%% "T4E+0 F*7%%% !24M% !24M0W-S%:6[SS,5C098@
M$X'T'- #+Z5X+"XFC9%=(V96D^Z"!GGVKFO WBV3Q=:WMR5@$,$JQ(T.[#G8
M"Q^8 ]3Z?G6K?ZM8W&C7AMKN"5S;N502@$_*:Y#X31Q6FCZH%!5!<([,RE.3
M"A/!_GTH ](I*BM;J&\MH[FVD66&1=R.O1AZBI: %I,4M)0 M)12T )BC%+2
M4 +1110 4444 %%%% !1110 4444 %%%(2!U('UH 6BBB@ J*Z6%[29+G;Y#
M1L)-YXVXYS[8J6H+ZV%[87%HS%5GB:,L.H# C/ZT <[H^C::SQFR5;C3HS%=
MP7BW1E::4*R89LG(5-@';\JZFN<.B:#H4EG>O,MA*NR RK-Y*W!VX D4$*YX
M[C/I71T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444AH ,T5
MR=YK,\%WXBFGO98++2EC8+!"C-@Q[C]X')J..Y\2OJ>1!?\ ]G&W#!MEMYAE
M+=.N-NW]30!V%&:YLW.J(!OCU,9.!N6U&3Z=:RK;QG;7&-ESJ@4MM+-:Q<=/
M_BA0!W.:,US-IJESJ-E;WMBVH7%O.A97$4*XP2,$''/%3B?4\\PZD/\ MG;_
M .- &_1GWKFY[^]M;:6YN$U*.*)2[MY4!VJ!DG@U5D\2HGAW^WA=7\FFB)IF
ME6WBRJJ2#E3SGB@#KJ*\\B^(EC/N\A]?EV_>\O2PV/K@<4R3XG:58N&OIM;B
M11N83::$&T=2>,X]Z -+6[.TO?&%]%=VT4\?]A,2KQ[L_O#^.?I7)^#=%DU#
MX<:S%#;W\5RWG1PVH9[59,I@+M)P >YSZ\UW%K/'=^/Q<QD[9-%C=<C!PTI(
MKJ* .06WUKPYX8T^./4K>2:)(+8QSVX\L,2J<;2#@9XK8-WK5M#^\TZ"\<=?
MLL^S/T#XQ_WU3/%%I=7NCK'9QL\JW$,F%VYPKAB1NXS@5";C4\G":I_WY@_Q
MH V[:9I[=)'@>!F&3')C<OUP2*EKR?6OB7J6F^*)?#]GIFI7MY&H8H!$'.5W
M<*%;M[TT>/\ Q?NY\):U[Y1/_C= 'K5%>3CXA^*0,OX2UM1W_=J?_:=._P"%
M@^*"?E\):YCU,:?_ !% 'JU%>23^/O&1@D%OX5U99BIV,\2E0>V1L''XU#;_
M !5U-M9CT>_TZ]T^\F4[/-6,[6VEE+*5!VG% 'L5%4])N)+S2+*YEQYDUO'(
MVT8&2H)_G5R@ HHHH **** "BBB@ HHHH *0@'J!2T4 %%%% !5/59_LNDW<
M^]D\N)FWHRJ5XZ@M\H/UXJY2'I0!S-EHD.HZ=%=Q:OK*F9-VZ2\$@.?5#NC(
M^@Q73*,* 23@8R>]<%9MK47B8M]L0Z7<7QC6;[1^[^0S9A6/'#8V*<8&8R<D
MG%=]VH *JWFHVMDI\Z:,2;24B,BJS^PW$<FK5<E8P:5]NNX=7TW3(+B6=VB\
MZ!%>X7DEOF+;L#DD'ZA: .ELKK[9:I/Y$T&[K',FUUYQR/\ #(JQ5:QLK33[
M406,$<$&2RI&,*,\\"K- !1110 4444 %%%% !1110 4444 %%%% !24M)WH
M \Y\1Q3&U\=O'.B1"*+S$9,EOW(SSGCBNSTG7-+U6!/L%]!<848"-R1ZX/./
M>O//&5[<V]KXZ6&>T",D2-!(#YDFZ)1\IW#U]#742:!/)X!L;;R636+&T4VK
MH1YD,RK@;6Z>Q[$&@#0\6:/+K>D);P6EC=2I.DR)>R2)&"IR&RG.1VK@(?AO
MXEC1@\/AV1F.YF+S<GY?]G_9_6NS36O$WEKNT !L#(W=_P ZD&M>(<?-H))]
MGH 3P/H%YX<T$6%[#8I*KD[[,L1(#SEMP'/:G#QSHIFGB1KJ1H)6BD\NUD<!
MEZC(&*;_ &WXA[Z ?^^ZRO"<NI:)JC:7?6.Q-3NKB[67. AP#MQSGZT 6->\
M8:5<>']1@1;P-);2*"]I(J@E3U)& />N;O;RTM?A7<>%KJ5[;4Y;215CD@D(
M :1BIRJD8(KIO&VMO&3X>C15_M&U=&NG8[(-Y$:EL#@$MU]JT-$*'Q!J0BE2
M5$M[9-\;9!(#T >=R^)5U"6WGOUB22V/[HV,D\+$ 8&Z3R=Q^@(%9FK:RS>$
M=2T:Q^R+!>02*\ER96FR>1\XB&[G^]^=>\USGCURO@?5E'_+6 Q9/1=QV[C[
M#.3[4 ,\(6J1#4)6A5;GS4B=L?-A8DPN?0<UTU<+X;\0P6.HZK9ZA>6,KF1+
MCS[(LT7S*!LYSR-H/4]15R2YAUWQ=#!;7EP+=-/D8F"5H]KEU /H3C/4&@#K
MN.]%<M#;:_<W\^E7-[)'8VP5A?1+MGN >BYQM!&#N('.1C'-5M.UFUT?Q+K]
ME>W\HACD@,"2N\FT&(%L$Y/)H X>S&?VG[LYZ0'_ -$+7M5>(:/=0WO[25W<
MV[AX7@;:V,9_<K7H=[XWBMM:N],ATC4KR:U*B0VT2L!D9'>IE)1W-:-"I6;5
M-7L=9FBN1_X36;_H5]=_\!U_^*J&?X@QV8C:\T#6+:.201B26%57)Z?Q5/M8
M6W-UE^);LH_BO\SM*^??'ID?XZPI&5#>5$ 6!(_U3_XU] *<KGVS7@/C8_\
M%^8AW\N/_P!$O6AQGN^FPK;Z7:0IG9' B+D\X"@5:J"S_P"/*#_KFO\ *IZ
M"BBB@ HHHH **** "BBB@ HHHH **** "D/2EILCK'&SNP5%!+,3P .] 'G4
M7GIX\@WZ)'%#)>2/$=\[<_O%:8+_ *H'Y5);'24<DYKT>O,?(GC\5Q/87>DM
M=S737D<SR3^;-#(K%(G8*5 QR%]$&!QFO35SM&[&['..E "UY_XXBTUM6DEN
M=5DTV>&P,I)$9%Q'B5"D>_\ CQ(W3/WDX/%>@5Y_X_:9;Z IKB6C"',-O]I\
MD[OG4R%MIP 6C.3Q\A'>@#N+%8TT^V2)'2-8E"*X^8# P#[U8J*V#K:PK*P>
M0( S#H3CDU+0 4444 %%%% !1110 4444 %%%% !1110 4E+2&@#SK5"A@^(
M+L 2CQ*"1R/W$?\ C7H:D;%Y'05X[K6L_P#%4^*=(M[:6YEN+R%QY3#&!"@(
M(_X":T%\1Z@GE+_PCFHDACN.X'C\J:Y6MS;ZO5LG;?S7^9ZGD>M+FO++CQ-<
MQNMQ-H5ZD"QLS,6&%^O%5+;XTC/V2V\.7-P\.$.R=<MQV&*4Y1CU+A@\1/X8
MW]+/\CUZLK5M&?4KFTN8=0GLI[4OL>%$;(88/# BN"_X6[?_ /0FZC_W\'^%
M+_PN"X2,O+X1U) .2?,7 'KDBL_:P[E_V=B_^?;^X]"T_2+;3Q,R[YIIR#/-
M,=SRD# S].P& *NJB(,*BK]!BO-8_BS=31K)%X,UB2-N59 &!^A P:0_%RX#
M;3X+UG?D#;@9_+%:')*+C)QEHT>FT$ ]1FO,U^+5R[%4\&:RS#DJH!(_2G_\
M+5ONW@?7#_P#_P"M0(]%\B+&/*3'^Z*<L:)]Q%7/H,5YFGQCB36;+3;[PUJ=
MC)=R*BF8J,!FV[L'DC/I7IU !4;0Q,26C1CZE0:DHH \3TQ0/VF=0"@!1 W
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MWT\FB_\ $2/_ (H"\=X8HY<)N"<@'<.AQ5G3_ 7A2;3+6230K-G>%&9BG))
MS7.^,?$6B7/@"73+/5TO+E4C5>NY\$9/2O1=*S_9%ED8/D1_^@BK@TZK:[+]
M3EQ-*=/!0C-->]+=6Z1[F)_PKSPCC']@67_?!_QK(UWP7X)M4@M)?#^);QS'
M$UG&=X8#=USQP#]:[VJ>I:9;:K:B"Y5L*XD1D8JR..C*1T(K<\H\!U_1M/T7
MXK>%[?3[.[MHYYH9)$N5"EF\S&0!P!@=J^BJ\+\<6UQ;_&;P;#=7CW<@,)65
MXU1L>:W!V\'ZXKW2@!#]T_2O%?V?CEO$Y];B/_V>O:9.(V^AKPCX'2WEM:^)
M)[?[&L22QM+)=2,@4?.<Y /&,]: />:\LN=6N]/\,K+I%W]G-WX@GB\T1A@5
M:1@2 >.HKO\ P_J5QJVCQ7MS;B!I68JJDX*!B%;D \@ _C7F,W/P]\/D<YUV
M3'_@1)659M4W8[LMC&6*@I*Z\_0[3_A'O$__ $.4W_@#'1_PCWB?_H<IO_ &
M.MF<ZS_:12!;/[&4RLCJQ8-Z$9'YBK=LMX ?M;PN<\>4A7^9-)4XWMK][!XN
MJHW]W_P&/_R)S?P_U74=5TB[?4;HW,L-V\(<H%X7V%>5^+&$?QQU5YB$4V#
M%C@<VS 5Z3\,3_Q*-4_["$O\Z\W\3G=\<]9SSC3I.#_U[&G1;=--AF48QQ<X
MQ5E<][LO^/"W_P"N2_R%3U!9_P#'E!_US7^53UJ<(4444 %%%% !1110 444
M4 %-<,1\K;?PS3J* $'3DYI:** "JVH3-;:=<S(4#I$S*9,[<XXSCMGK5FJ>
MK306^DW4US%++ D9:1(02Y7O@#G/TH Y30UUF:2PU&WM;6"SED2.2"&.'#*4
M8RS%T)Y,G0*QXY(YX[>N<T+Q-X=N88;'3M469@[Q(KNS.Q4D'D\GH>?2NCH
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M]*MP_"(2P1O_ ,);K@W*&QYW3/XU<^*P?_A K;S(Q&XN(MR+T4[3D"N_M/\
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M2HMX\"OH.V_X]8?]Q?Y4 >:'X2:ASCQUK63_ +1_^+I!\)-2Q_R/>L_^/?\
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M3M?M@8^@%>]4 5[X[=/N3Z1.?T->0_L]#&E:][W$7_H%>NZC_P @RZ_ZXO\
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M[ @/)<NZDGN./0YKN!TKS=(8W\8>.(C(ENCV*AI2#A,IRQQS[UE5;T2?4]#
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M/!^EW-[I=G)/-'\SR(,L<G\ZW8_"'A*5F$6D:>Y7[P50<5C'VS2EI^)Z=>>
M@Y49<_NZ?9Z:=O(YGX=Z_I%EI&H"[U*V@,E](Z"60*2I/!P:\Y6>*^^*OBNX
M@G6:*2TGV2HV0PW1C@UZ%HNFV5A\8=1M+6UBAMTL@5C5>!D(3Q7 Y'_"W/%@
MX&()AZ?Q1U>'OR6?30X\WC'ZS[2.TTI?>CZ,'0?2EI!TI:W/,"BBB@ HHHH
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MVC@8!&T5C7?N-=ST<JC_ +2JC=E#5^E[?J>JJVO-J.H&#R?LZ&,6T<Z$*XV
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M$<C"7>@?<%/ECC.*]TKP;PBKCXT6ZS>;YR+,'$I!(/ECO7O-<M3XC6&QSGQ
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MM; *SJ#\R]^P^OX$ K>"YHWBU"&%HIXX9PHN[>:22*?*@G:79L$9P0&(S[Y
MB\4>*;CP]JEO"MLGV22)F+F)V,K[9"$7;T.Y$!SDGS!CI6CX;L=0LDNEO8Q%
M&[@P1&\DN608&<N_J<G %<SXI6UM=:N9KRYNXOM<"Q/#_;4-JC1J6 PK$'!W
M-^9[T =]:N\MI#)+'Y<CH&9,YVDCD?A4M0VJHEG"D:A8UC4*H.<#' SWJ:@
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M _Q(M/&M[<VD5C<6LUO&)&$A4J03CJ#UH33V83I3A\46C+_X5EXC[_$36?\
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MM;X7J,-);SV8$G!;=CJ2,]<<5ZE5"]UG3["[BM+FXV7$J-(D85F9E4@$X /
MR/SH \2UC7]?N]1O-#_LSSM1U&+;+++"\,FPYPJJS81 /S.2:BT_0_%U^Z:A
M9V$=QY=XL[!;U=A= 5 *;N"!QGKQ70:C<)>?&A9[?<T:V*Y)4KCMW^M;>GW&
MFP::+F/2KHV]DKN;]I1&YC\QL[=IR3D-\IP< >M<]W=W9[')!02C!-VC^-_-
M?@</8&]O?B FC:Z\D%PWR36OF&421\2%-V<!3\N1W!Q7M6@Z;-I%@;%YQ-!'
M(WV;C!2(G*H?]WH/8"O'=2E$/[0@E$<D@ SMC7<Q_<KT%>OC75Q_R#=3_P#
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M);Z6&X-Q#$H4EG*=(\LN #E6 4,GK@=A<:=!=7MK=R@F2V#A!GY2'&#D=^*
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M(ZD=*RI;&#7%M8I=6-P("LWD;8U;Z,,9'N*TK\79MD%B-TS$+NX&%SABN3U
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M74Z+'/%IRI<02P.&/[N6<3,!V^8=O;M0!I4444 %(=W\./QI:*  9QS1110
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M \2T]@?B)I8)P1I$&#Q_<:N\53OAV.-JJQ P.?>N!TPL?B5IH7.T:5;9 /\
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MKB@#KK4.+2$21K'($7<BG(4XY -2U%;O&]M$\+!HF0%"#D%<<?I4M !1110
M4444 %%%% !1110 4444 %%%% !5>^8+87)/01,?T-6*JZE_R#+K'7R7_P#0
M30!X2H/_  O'PH/[MC;#_P @M7O]>!X_XOOX;'86=L,?]L&KWEY8X_OR*OU8
M"@!]%1?:(?\ GM'_ -]B@W, '^NC_P"^Q2NA\K[$M>1?'\X\/Z-Q_P OK?\
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MF/CY..G'ITJ6H[=&CMXD>0R.J ,Y&"QQU_&I* "BBB@ HHHH **** "BBB@
MHHHH **** "JU^=NGW+>D3G]#5FJFJ'&E7A]('_]!- 'AV2?CWX=P./LEO\
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M\&ASHX/_ #\W?_HF.@#WD4M(*6@ HHHH **** "BBB@ HHHH ***0Y[$?B*
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M(WG:WCDC1D7>X 8[CA>3@'H<9(H W-!U,ZOI8O!L,;RRK$T>=LD:R,J./9E
M/XUIU';M$]O&\.WRF0%-G3;CC'MBI* "BBB@ HHHH **** "BBB@ HHHH **
M** "J&LG;H>H'TMI/_035^L[7N/#^I'_ *=9?_0#0!XK;8_X7WH(QTL;?G_M
MW->QZKX7T77)XY]2L$N)8UV(Q9A@9SC@BO%'OK33OCAI-[?7,=O;Q65N7DD;
M"KFWP,GZFO71\0?"'_0Q:=_W^%)I-69=.I.G+F@VGY"?\*]\*_\ 0(C_ ._K
M_P#Q5'_"O?"G_0'C_P"_C_\ Q5+_ ,+!\(_]#%IW_?X5F>(/'>@3:8(M.\46
M<$\DT:&:*12T:%AN(R".F>HJ?9P[(W^O8K_GY+[V=A8V-MIME%9V<0BMXAM1
M 20!^->1_M!?\@71O7[1)_Z!6Y=?$>STN3R;?6],U=9QM@E:=8C%)_TUVC 3
M )W@=>,<@UP?Q<U6UU72=+%MXBAU>X69RZ0! D8*]@.?;DFK6AS.3D[O<]D\
M#KCP+H7_ %Y1?^@BN@Q7"^%?&OA>S\):1;7&O:?%+%:1HZ-. 5(49!]ZV!X]
M\)'_ )F/3/\ P(6@1T6!6%)J]U=ZQ/IVEQP@6C*MW<W!.U&89"HH^\V""<D
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MVZM@8R?>I: "BBB@ HHHH **** "BBB@ HHHH **** "LOQ&<>&=5/I9R_\
MH!K4K*\2?\BQJW_7G+_Z : /#FT^SU?XXZ=8W]NEQ;/9VZO$_1L6V>?QKUO_
M (5KX-_Z%^T_)O\ &O&-1D^S_&NQE\YHV3[&RE026/D+A.".&/'7O7M,#7\?
MB+3K74;L-)MFGCV1E1(#_ >?X01VYH ;_P *V\&_]"_:?^/?XUY3X3\.:/J'
MQH\0Z-=6$4FFVZRF*V.=J8:,#'/N?SKZ KQ/P,/^+_\ B@_],Y__ $..@#T
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MS?B6'[ UOKMLYBNX98H9,=)HG<*48=\9R#U!^IKI* "BDQ2T %%%% !1110
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M0&5L;CC/[PT >M'1=*/_ ##++_P'3_"D_L/2?^@79?\ @.G^%6_M,'_/:/\
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M#27#+,+F0J%^=B,8J)S4=SHP^%G7ORM*RN[NWD=@/@MX6 ($VJ_^!9_PI?\
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M8P, _3M6]2T %%%% !1110 4444 %%%% !1110 4444 %4=1U#[ L9\LN7.
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MX/R]A7;7=W%:0M+(ZJ%&>3C- 'FNF:;\4=(TRVTZT.C"WMHQ''OY.!ZFK?\
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M1U"*:TGE$UJP:VC8+(V1]T$\ ]JVJS/$5DNI>'K^R<OB>%HSL^]R.W!Y_ T
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M?K2P:!)#-YAN0V65CE3V/UK<HH]I+N'*@HHHJ"@HHHH **** "BBB@ HHHH
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M_P )-=?]"UJ__?M?_BJ!XGN<D?\ "-:QQ_TR7_&@#HJ*Y[_A)KG_ *%S5_\
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M_8X_^>D__?\ ?_&C[''_ ,])_P#O^_\ C0!8HJO]CC_YZ3_]_P!_\:/L<?\
MSTG_ ._[_P"- %BBJ_V./_GI/_W_ '_QH^QQ_P#/2?\ [_O_ (T 6**K_8X_
M^>D__?\ ?_&C[''_ ,])_P#O^_\ C0!8HJO]CC_YZ3_]_P!_\:?';I$20TAS
M_?D+?S- $M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
64444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g201805072101260282285.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g201805072101260282285.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,) :$# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBO.1I'B+0=;BAA\9626<-C.R)>V[R2;!(K%W D 8J#CS..N,<\ 'HU%8'A
M+5)-6TN2YDU>UU/]Z5$EO:/;;.!\K([$YYSDXX(^M;] !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5SFM^)GT/7K*VGL+R;3[B"1FGM+26=HI%*[0P0'"D%O?(]*Z.N*\93"+6]-7
M5;Z_LO#YAD\R6R>2/=<978LCQ_,J[=Y'(!/7L* .FTK6+;68'FM8[I%1]A%S
M:R0-G&> Z@D<]:OURW@BYFN+*_ FO+C38[HIIUQ>AO-EAV*226PS*'+A6/)
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0"<CL?:N<N_!_@JZUQH+K1K*34;E7O&#1G+X8!GSTSN8>_-=/;%FM(2Y=F*
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MUS,9+2'39!)!#'M PKA5W98,QXZMBNCH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MCWJ;3]4L=5B:2QNHYU0X<(>4/HPZ@_6@"Y1110 4444 %%%% !1110 4444
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MI494DR=F.X; R3CMG.,<]7ITJSZ;:RK$(5>)6$8Z(".@]JY_^Q?%W_0WP?\
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MB>%C.WBWQ,;H 7'^A^8!TSY1]"?YU"EN?[,@FM9+MIS) ZE;$[EA3HJY&TD
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MS#&JC<-QVEMH )VXSCOF@#3HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*SK%7&IZH3(64RIA< ;?W:_G3M5M9;NWC6)%DVRAVC:0H' SQD?YXK"TV'7;
M*\O(K:"RE4&(,TUU)D$1J, ;3Q_.@#H;^\M[2#$\H1I<I&N"6<XZ #D_A7':
M6=6M+%(@UW91-YAEW6)?RUR"K+Q]X_-G.?H*GO9_$JZVTD%G8-=);* JEI J
MEFZ$[<9(Y_W156YNM3DTR]MIR\4T\%QYVRV<A"54$_*QY4$=,YSQWH T$U'3
M-'U99VF@*20R23O;6TB;0N"68*2I'/4C/OUIEWJ2O->FVU>.&^+LL-M<3,BN
M-@^1D8?NSDY##U!Y!Q3[VZA^U1QW^I7D4;6D_P#K($BWK\FX#<O)QV'-9US>
MV<ESJ5O]JGN(X7E=_P!]",CR45V7Y>3MD("^H/M0!WL(988U8Y8* 3[T^FQ@
M")0O3''TIU !1110 4444 %<SIW_ "4?7O\ L'6/_H=Q735Q,]M+=>.]<6&(
M3%+*Q9HC*8]XS<C&1[D'\* .VJG=WXMIHX$@FGFD4L$B X QR22 .HJ6SCDB
ML;>.4YD2)5<YSD@<\UB26UI'9RW[V\9FCOBQFVC>%$_//7H.E %];C59ES';
M6D6./WDY<CZA5Q^M5=2O-4L848W=@LCNL8#1,%!8XRQ+\#^9P*Q])TVYA\(6
M.H:;;^7J@CW!6&SSD9B<.._!W#/((^M6=3L;31;S0[AHFD5;IQ<W#+O=RT,@
MRYZ\G'L./:@#0TZZU2^LQ,EU8,YW*5$;%<JQ7((;E3CCBF6%SJ4"7&ZUMI0U
MU)CRY]K=>P88/?O4-O;6FM1WUU:@Q3I<$6]RJ%'1EC0<'NN1@CH>E4;2W6#0
MKG5]4@7[?]J\R<@>9Y(\U253K@*/3K@DT =19WXNWDB:">":, M'*N#@YP00
M2".#T/:K=<W;6=NEMI=TMO&EQ)< M(%&]@=YY(Z]:V=1N9;2Q>:"(R2 J H5
MFX) )PO)P"3QZ4 8.A_\CUXLSZV?_HJL]FO8U$$TUP8(_*WP?NI2&SB3Y5)8
MJ!C" =>>>E6?"TDL_B[Q/+/'Y4K?8RZ>A\HU!]A;4-,2TMH;*5;5U?S&MG\R
M16SAMK8SGDD[N2#TSP 5;X-!<*;FPL@LMOYXBDB\IDRX41)*""&VG+'G!'H>
M-W3M5>VT2\<M!,MAD%EN=V[ W8W$=@0 3UQVJI%?3V"0M!-=/%Y7E!M2G1 6
M5P"1ZG 8?E44=Q(\MP;JQAN+B:65K67,4C!>/+"DGG!S]* '72V,U_<PR:A:
M2S3.(45X"TELQ8R')SP<'CIT6NQ'2N<C:9M02_NM-\TPR-$EQ;,=Z@$K^\3C
M<.3R,XST%:.N:G+I6F_:HXA)APIR"<9X' YY.!^- &G16&FKZB44MII5B.1M
MEX_\<IW]K7__ $#_ /QV7_XB@"AH?_(_>+/]VS_]%M74UQWA>:2?QIXJEFB\
MIR+,;<-_SS;U /Z5JG7+Z6]O(+/1GN$M9O):3[0B MM5N >>C"@#<K,U #^T
M;0_],IOY"H/[3UK_ *%Y_P#P,CJ%;J_N]9MH[S339((9BK&99-Q^48XZ<9//
MI0!JZ7_R";/_ *X)_P"@BK=9^ARF71K8ED;:IC#)]U@I*AA[$#/XU9O)FMK*
MXG5=S11LX7U(&<4 0:-_R!K3_KD*O54TI!'I5JJRI*!$N)$^ZW'4>U6Z ..^
M(-W-;6-BMO<31R/.6"1[P&"*6)9D!(5<9/!!QS6AX0U<:II1629Y;F,EW=E(
M5E=F*%">63&5!."=O057\<1S7.G6]M!IUE?,[LWEW47FX"HQ.U P))''![^]
M6O"&FQ6.AQ2#3X[*XGYE1(FCR 2%.UB2OR@':3QD]\T ;]%%% !1110 4444
M %%%% !1110 4444 %%%% !6=8AQJ6I$L"/-3 QT_=K3]5AGFMXQ KOME#.B
M2F,LO.1GCVKD)_%-WX5N)H[[P_K=XCM HN;=(WC+LJH%#%P22Q"\CKWH Z[4
M+!+@K<I))!<PJVR:(X8 ]0<Y!7@<$=JYRWM+N[T9M2E8.7BD:3%P\>[LWRJI
M R%'2F2>.;]XG4>!O%&2I'^HA_\ CM9%GJ[QZ7';7O@#Q+.Y0K)B./:P)/&/
M-':@#2M;^YGUQ+5+<G4(K64K%->^<BY*@,#MV_4'#8/2MEM2TVXEN;*3R8-3
M@ #K''YSP[AE6.%Q[@&N936+6.-8T^&OB)44':HMX<+GT_>\'W%7;7Q;)8JR
MVOP]\20AN6V6T +?4^9S^- ';0*Z0(LDAD<* SE0-Q]<#I4F:XS_ (3N^_Z$
M7Q1_WXA_^.UB0>-[O3M4M3J7ASQ#:BXDF0-<LFR0_>0!=^%(4'TZ=\T >G45
MRD7C5ITWP>'-9E3.-T<2,/S#5 ?'5\"1_P (-XH..X@A_P#CM '945QG_"=W
MW_0B^*/^_$/_ ,=JIJWB[4M3T:^L(O!'B5)+JWDA1Y(80JEE(!)$G3F@#OJY
MG3O^2CZ]_P!@ZQ_]#N*IRZI=>&YD%GX>UJ^LYDY@MHT/D.,<C<XPK ]!QD>]
M9=G_ &SK'BK4-;&EZMIEE]F@A>SN D<ER5\XY#*QQM+KP",YYZ4 >C5BD!M+
M<$ YU#H?^O@5AV_B;Q/':Q(_AB)V5 "[7[@L<=3^YZTL6MW;Z$4737;4QJ2Q
M-;O((T,I(GP'(SMQP"1D^E '1Z?KFGZD56UF^9U+(KH4+J#@E00,C(ZBD&MZ
M;->16B2^:\LC1(5C+(752Q&[&W( /?M6;;^'KIO!UIITLJ6^H1*'66,[O)<D
MD[3CT)7/?-3:W8WT"Z3/HUC#<-I\Q(MGF\D%#$R<-@XQN':@#0.JV,-[]D9_
M+DW^6"R%59L [0V,$X(XSFJ5EJMG!-=6SR%I1=,&5$+;-S8&X@87.1UIVGVM
MW?Z9>KK%C%:R7<C%H$G\T*-JJ#NP.>,].*HZ?87=IX8N;> +>7\=RTC%W\OS
MY!(&8EL'&2#V..* +5N -,TD 8_TGI_WW6]7$-K5U'I&DPQ:<6U-KUX4MS,O
ME^9'N+J9/3 ;# =<<5>?7_$EMMDOO#=I;VV]5DE&JAM@) SCRQW/K0 :%_R/
M7BS_ 'K/_P!%5GK>HD,4UI+Y:'R('>2_.Q"Q)"#CDJ#DCCKBL[2=3EN/&/B2
M]AU"WM3)!:2Q0LZNDA D4AC@')V#H> 0><XK>@\=>"_)1CK>E0.?G:,SH"CG
MKD>O)S0!#;W4$MK%:1:@4:16DD'S7(4K(.@!R,GGGL:#):W4&H+/>Z<K7#DR
M&[MVBD&  " S9P,9!'X5<_X3WP9YGF?\)'I._&-WVE,X].M#>/?!C,K-XCTH
ME>A-RG'ZT 7(=234;62"*TU+9_JC,$\HG@?,I)#8/7-2ZU8RWNB/:02*LF8R
MK2Y(.U@W..><50_X6!X/_P"AETO_ ,"5_P :R?$7C'PUJND-8V>MZ7<RRNIV
M&Z0#"'><_P#?./J10!U&E:C)J#W&5B,<+A!+"Y9'..0"0.G ^N1VK2KEX?'_
M (-6% OB+2HUP,)]H0;?;%2?\+ \'_\ 0RZ7_P"!*_XT 8-KIKW_ ,6?$3.T
MZ6Z6< $L4I0I*0-I&.^ W7(]>M;'A+4-U_K%A>$QZF+D3O%(FQGC,:()5'=2
M4/3ITKG-&U8ZS\3/$$FAZM&UF]I!()HE66)Y%"J Q]/F/ (-;3^(=+GU[1[R
M>YMHI889X[C+#]TQV#:3]5/UQ0!V=9M__P A&T_ZYS?R%9=[X\T&SF6(7/G[
MEW;H63:/;)8<_P"-1VWBBPU:_@GMR8XH8Y<R2N@4G"\ ACSR.* -W2)$DT>S
M='5E,*<J<CH*N,RHC.[!549))P *I:.A72;<L^]I%\UFP!DO\QX'N35FY@6Y
MM)K=B0LJ%"1U (Q0!5T4@Z+9D'(,2D'UJ_6=HE^+_3(Y-X>1 $D91@;@!G'Y
MUHT <KXWC62'35D_=1BY+-=@2,;?"-@[8V4G/W<YP,UJ>&)9)O#EG)+$T3E3
MPS.21N.&^<EAD8.&.1G!Z5A^*C#<:[8V_P!GOGOXTW68@NI($D9R4;<4[(OS
M,>H!&,YK;\,&'_A'K7R+8VR N#&79_F#L&;<W+9.6R>3G- &O1110 4444 %
M%%% !1110 4444 %%%% !1110 5RUU%:12&'7Q=&(WB-!.TKF%F,@,0(!PK!
MMHP1C(![UM:JD[V\7DK,X$JF187V,5YS@Y'MWK \1!XO".GK?+(\HO[%6R^6
M#?:(\9/?!QGUQ0!UU%%5-0U2RTN));ZXC@C=Q&K.>,G^GOT'>@"W15'4M5M=
M*A5[@LSR-LBAC7=)*W]U5[G]!U.!64C^,96$GEZ-;HSY$,AE=T3' +#@MGKC
MCTH Z.J&KK,U@XM].@OY,C$$SA5/OD@UGX\7><?GT3R]O'RS9S^?3I7/ZW)X
MKFU_1]*ENK"&.[>:0?97FC+A(^5<@YQE@1M(^Z,T =/X;BA336>(*))96:=5
MB\L))T*[>V  .^<9R<YK8KDK)[[2]$DBB:!]5N+QHD$LLLJNX8+DEB6P$7)Y
MXQ45YJWBRRU[3--9=%8:@T@1PLOR[$W'//>@#LJ*YVX;QA'"7A319G4@^7^]
M4N.X!SP2.A/%:NE:E#JMA'=0I)'GAXIEVR1,.J.O9AZ4 7:**S=9BEGMHTCC
MFD0O^]2&38S+M8=<CN1WH T-Z?WE_.LQO#VFR:V-8,;&ZX(^<[-X&T/MZ;@O
MRY]*=9:19)86Z36%MYJQ*'S$I.[ SSBI-(18[.2-%"HMQ,%51@ >8W2@"_11
M10 50TO[EU_U]2_^A5?K*TV\MTN;JS>94N3<2,(G.UB"<@@'J/<4 0GPII)U
M634O)<7#,7!65E$;GAF4 _*S#J1U_$YN-I-N^ \ETZ@AMK7+D$@Y&1GUI^H7
M$T"P"W\OS)91'F0$@9!.<#Z55O+G4K&%9Y3;2Q^8BLD<95B&8+P2V,\]Z -;
M SG'6F[$_N+^516=W'?6D=S$&".. V,]<=JGH ;Y:?W%_*CRT_N+^5+D5R__
M  F$U[=3QZ#H=UK%O;MY<MU#-%'%Y@)W(I=AOQW*Y'.,YS0!T_EI_<7\J#&A
MZHOY5S7_  D'B+_H2K[_ ,#K;_XNH;GQ7K=F@>X\'7J*20";ZV[ G^_Z T =
M7Y:?W%_*N0M/&GAVS>;3Y[Q!=PW$B/&$)(8R, ./4@_E3KGQ?K5I8M>S>#;Y
M;=0&+"]MCP<8XW^]9D=SXAA=R?AK%.YD9Q,^H6P<Y8L,]>1GUH W+GQUX<T^
M]^Q75ZL%T>/)=,-^5:IU"$\_8;O/_7L:Y-]2\22,S/\ #&%F9MQ+:E;$D^O3
MK5K_ (27QG_T3]__  ;P4 7;;58+?3+F^;3KME>Y<B/[,0Z]!\P/W1[GMS5[
M3K8-83W<WV>22[S,?)PR ;0%"GN  .>YS7*Q^.;C359;K1VBGFD:5XB\K^5G
M'RDQQ,">H_ TS3O&UO#'>(EDRK(SS")4F58E(4$Y>)<Y8DX [GUH [K2_P#D
M$V?_ %P3_P!!%6ZS;:\@L="M);F01J(8UZ$DDJ, #J3["K5G>P7]N)[=BT99
MDY4J0RL58$'G(((_"@"#3@!-?@ #_23T_P!Q:OU1T[_77_\ U\G_ - 2KU '
M+>*M7OM#\N>.[ BF;8D"6/FOD DG<94&,"MC0KY]2T6WNI"3(^X/NC$9#*Q4
M@J&8#!&.IK,\4W_V06O[N&XB#GS[66,GS49&7AMI YSD<9&1GL;OA@2#PW9"
M00*P0X6!-J(,G"@87H,#.!G&<4 :]%%% !1110 4444 %%%% !1110 4444
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M8R1@@@<UK^'WN9-#MY+N0R3ON=B58;<L2%^8!OE! R0"<9H TZ*** "BBB@
MHHHH **** "BBB@ HHHH **** ,/Q5_R"4^__K1]SK]UNE-T;50^DP-'9W#(
M-RAMT:@X8@XRX.,BD\8$#15),Z_O1S ,N.&Z#!KEK;P@=3L=+N+F*_\ ,M8W
M1=LB 2 LY!;#J<X?T'- '<_VF?\ GRG_ ._D7_Q=)_:ASC[%/G_KI%_\77!#
MX96:BYVQZF&N @=O-7^ Y&/WM%Q\,K:XT^ZLV&J!;@L2PD3*Y39QF7'3GD'\
MN* /0K2^6ZDFC\F2)XB-RN5/49'W2161>^'K^ZUHWJZQ(+<[@+=D!$8954@>
MH.W//K3_  QI#:+;/:!)EA18TC,Q0NVU<$G;Q6_0)7:U.)M_ ^HVUNT*:\KJ
MR!&,UFLI('098DX Z#H*VO#F@2Z'%<K-?O>-/('WNI!4 8 Y)XXX]*W*RYKR
MZ5[YQ-;PV]IRQ>%G.-@8GAAZ_I0,U*P?& #>'Y$.W#R(AW $<MCD'@CGIWZ5
M@?\ "SM!^U?9O^$@M/.QG;]AEZ8SUWXIFJ^([77[&>QM-4M)Y8GC=U6T;Y<,
MI!Y<@X)4T =#X4BE@T^2*:99G5D&]8A&,>6N!M!.,#BM74O^05>?]<'_ /03
M4&CZ;+IEJ\<]V;J1F!,AC"<   8'':I]2_Y!5Y_UP?\ ]!- '+VKW!^)5BEP
MJ KH<Q5HPVT@S0]SWX_45V5</I\TC_$RTBFDD,J:'*VR0("JM-%@_*>AVGKZ
M5T^L-<"VC$#7"[GQ(;= SA=IZ9![[: -&L+3=$TXZA+JQLXOMPGF438Y^^PS
MZ9QQGKCCI6M9^:;&W\_/G&)?,SUW8Y_6H7TBPDD9VMEW.2S$$C)/4T 7:*H?
MV+IW_/LO_?1_QH_L73O^?9?^^C_C0!?HJA_8NG?\^R_]]'_&C^Q=._Y]E_[Z
M/^- %"[T73K;6+?4X;2)+R:Y4/*!R?E.3[$X&2.N!FMF>WBNH3%,@>,D$@^Q
MR/U%5X])L(IDE2V42(<J<DX/^35F>>*VB,L\BQQKU9C@"@ @@BMH$A@C6.-!
MA54< 5SFD?\ )0O$_P#U[6/\I:Z.&>*XB66%UDC895E.0:YS2 ?^%@^)C@X-
MM98/X2T =*\:2(R.BLK<%6&0:Y7Q!X-FU%M..C:K/I"VUXEQ-% S".=%/*%0
MP S^7J*ZRB@#,UJV6Y@B#:G/8+&QD9H) A=0IR,GMW_"H_#HMVTI9[:^FO(I
MSY@DFE$C*< %21Z$5/JVDQ:Q:>1)-/"><20/M<9&",X/!'M4NGV":?;M$)IY
MV=R[RSON=V/<]!V'0#I0!SVMPVDVF7<.FVMW)=*WE@QK(1N##<,]/6NLK UQ
M)M(M;O5K"<Q.=K20NH:.0Y"YQU!QW!'09K?H QH/^1TOO^P=;_\ HR:MFL:#
M_D=;[_L'6W_HR>MF@ KF]<M8+OQ-I23QB11:7; 'U_=5TE<YK=Q#;>)M)>>5
M(U-I=J"YP"?W7% &QIG.E69/_/!/_015NJFF?\@FS_ZX)_Z"*MT %%%% '(:
MZ-,/B6)=7NY[*%;<307!OY8$,F2K*I#!00IY[G=[&MGPU<F[\/6DY60!PVTR
M.SEEW$*V7^8AA@C/8BJ%]<Q:?XB:XNWN_LK0[=BVLTD9;/!RN5SP>J@^YK9T
M_48M11WAAN4C4X5IX6CW^X# ''OB@"Y1110 4444 %%%% !1110 4444 %%%
M% !1110!A^*L?V4FYF4>:.5Z_=:GZ7J,*:;"ABNB5!!*VTA'4]"!S4'C%Q'H
M@<R2Q@2CYHDW,/E;H,'/Y5RSZ5>ZEY%Y;:W>6\36GE>2UE)]XX^?[N >#],G
MI0!WG]IP_P#/&[_\!9/_ (FC^TX/^>-W_P" DG_Q->>'PMJFV0)XFO09)A*2
M;.4X_P!D?+P/8<>U7=*T/4+&^M)KC7KJ>.&9I'3[%(-X+9"YV]NG^<4 =W;7
MD-TTBQ^8&CQN62-D(STX(%6*SK"3SM1O9D201L(PI>-DS@'/4"IYM3L;:0QS
MWEO&ZXRKR $9Z4 6JSI=/N'ENBEQ"(KG&^.2 M_"%(R&'! JW!=6]TC-;SQR
MJIP2C X-5K:6[:[VRJWE_-G*8 Y^7![\?Y% KF8?"ELQ4M%8DJ, FWDX'_?S
MW/YU1UG15L+&2Y3[-ODE3S&2)PS<@=2Y_NKVZ 5V!X%<S?6<FNZS#(/,_LVT
MD,<JM*ZK,X/554@':1@ELCJ .,T#.FJKJ7_(*O/^N#_^@FK55[]&DTZZ1%+,
MT3 *.Y(- ''Z?<7DOQ,M(KV*WCDCT.5E$#NX*M-%C)95&?EZ#/\ +/<5Y]I,
M^HCQQ;W=[%J,L$>ES0JSZ?Y6UC+$<  G/"]?;WKJKS4'GL8I[1KB-#,R2,D!
M9UVA@?E*G^( =* ->BH+-I7L;=IP1,T:EP1@[L<\=N:GH **** "BBB@ J&Z
MMDNX/*D+A=P8%&P0000<_45-2,RHI9F"@=230!R?AG0-)N=$66YL()YC<7 :
M69 SMB9QDD]3Q6J?"GAYFW-HM@Q]3 N?Y4SPD0?#ZD$$&YN<$?\ 7>2MNBP^
M9[7,;_A$O#O_ $ ]/_\  =?\*S]7\-Z):0VLUMI-G#*+N'#I"H(^<=ZZFLK7
M_P#CTMO^ON'_ -#%*6Q5/XT:@[UE:ZTGDVB1S2Q>9=QQLT3;3M.<C-:HZFLG
M7F54T\LP4"^AY)QW-#%3UDKC#X1\.$8;0]/;UW6ZG/Z4O_")>'?^@'I__@.O
M^%;-9=UKMK:WYLF!,VU6 \R-<YSC&Y@3TIDD/_"(^',Y_L+3L],_9US_ "I?
M^$2\._\ 0#T__P !U_PIW_"0VW_//_R8@_\ CE'_  D-M_SS/_@1!_\ '* &
M_P#")>'?^@'I_P#X#K_A7,Z]H]AIVOP+I]K'9K)I=VT@MU";]KPX!P.1R>*[
M&PU2'4))8XU(:(*6^=&X.<<JQ_NFN7\6.%\56:LX .C7V 3C)WV] T['6Z=_
MR#+7_KBG_H(JS5;3O^09:_\ 7%/_ $$59H$%%%% ')^(=2UC1M4MY8M0T]+&
MY8J(KJ)]P948[5*]<D @'G/ S6[HM^VIZ1;WC[?,<$.%0KM8,5(P>0001^%1
MZQIUU?FT>SO(K:2WF\S][!YJ/P1@KN7D$@@YX(JY9120VD<<KPO(H^9H8_+0
MG/9<G'YF@">BBB@ HHHH **** "BBB@ HHHH **** "BBB@#$\4DC2TPQ7]Z
M.0,D?*U2:5J5@FF0H][;*R@@@S+D')XZU6\82"'1!(TY@"R@F01[RO![8.:Y
M/1[W4YM,TQ]-O(8[-3,LZNT:,Y\R3# -R,G:>W% 'H/]JZ=_S_VO_?Y?\:/[
M5T[_ )_[7_O\O^->;%O'G]JRN-9T[[ 8@(X_,AWK)D9.>XQN[^E6[B7Q>=+N
MUM]3LUO6+?9V::':HV?+G_@>3T/'Y4 >APW5O<Y,$\<H!P3&X;'Y5Q6MZY=V
M<_BB%(HRULUI+:AN#,Y"[@.><;5_.MCPK)=RI.=1:%[T+$)GA=61CM/(V]/I
MUK%UOQ(UC<^*+<VL;/9&TN(-[$&<L%R!QT&SMGK0).ZN=7ITT4]_J,D,B2)Y
MB#<C C[@[BIYM3L8)6BFNHDD7JI;D57TV:&>^U"2"1)(S(@#(<@_(*IW=TL?
M]L01WL%M=N1Y)ED"X/EK@_3- S1_MG3?^?V'_OJN.\76OAXZ?]IL4MH]0EO8
M/W]O\DN6E7<0PYR0365#:^,T=VD\6Z8X9% 3[1PK#.3U[Y'Y4NJ_VI_9]XNJ
MZQ9W5M/<VJP0P3DLO[Z//<GLQZ]_R .U\.0/;[T:[N[@/#%)FYF,A!)<'&>G
M05NNZQHSNP55&22> *YWPQ86]@72W$@#V\3,))7DYS(/XB<5LZE_R"KS_K@_
M_H)H Y7Q!KEFVI0+::[;6DQMY.=N\L-R?+P"5!X^;MQ72:));RZ+:/:Q&*$Q
MJ5C;.5XZ'/)/OWKDM'FEF^)B&5V;&E38S T7\5MZGG_/K76:M/-!!$T,C1[I
M-KNL)D*C:3T'N /QH T:*ALWDDLH))AB5HU+C&,$CGBIJ "BBB@ HHHH *K7
MUFM]:F!V*J65L@ \@@C@@@\BK-% &#X0!3PY"A;=MGN%SM SB9QT''Y5NY]C
M7*^'-(2YTCSFO+Z,M<W/RQW!51^_?H*UO["3_H(:E_X%-2U+M'O^!J;A7&^+
MO$HM-,%U'9236D-Y&AEWA=[JV2%'.1E2"?7IFK-SH?VK5VL#JNK11"W6;=#>
M,C[MQ'4=O:M*Z\,Z;>Z1;Z7<I)):P;-JLYR=HP"3W)R<GO2W122A-,LV6H?:
M)9K>:%X+J+!>)B",'HRD=5.#^7(%4?$L(NK6TAW;0]XB$[5;A@0>"".AJ?5=
M!AU4QLUY?VLD9/SV=RT3,#V)'4>U8=C8[K^&.^U:[%U!<;OLDSC:^"=K+G[P
M(].?7O39,.6]Y'7Q1B*)8QG"@ 9]J\W\>> 9/%NKSNSW$4,MM% 98 "V%=F(
MP6 .<CK7I=4IM22*Y> 03RNBAF\N/(&<XY_"F0<+!X.NH(3&)M4(+3-Q*P_U
MG_;3M^M)9^#KNT1U$VIMNF$O$C+T<OC_ %G^UU_&NR_X2&T_NR?FO_Q5'_"0
M6G]V3\U_^*H S?">B3Z3>:A+*UPRSK&%,[$G(:0GJQX^<5F^/(W_ +6TEXI=
MC2PW4+YC5\KL#\;@<'*#D5UMCJ=OJ#RI#NW1A2P..ASCH3Z&N5\>B0ZAH?EE
M1AKG=N7.5\DY'U]Z .NT[_D&6O?]RG_H(JS5;3O^09:_]<4_]!%6: "BBB@#
MC_%%U!!K$.^?6WVPJ)+?3Y?+5?,D"1NQ++R6RN,G\,5L>%XK>'P];I:7$UQ#
MND823 B3)D8L&SSN!)!SW%8GC/3-9EN(]1TVWM9Q;0,8Q]E66X249*LNY@"N
M<<=0>1GI73:1;RVNDV\,Y1I@NZ0I$(P6)R3M'3DF@"[1110 4444 %%%% !1
M110 4444 %%%% !111T&: ,3Q2P32T8OL E'S>GRM5G2K>%M+@9H8RQ!R2H]
M36%XIU[2I]+6*VURP28R@ K,DA4X/\.>:KZ)XAUN31K9K?1EN(<E1.'*[U#D
M%PNWC/7&?;- '9?9K?\ YX1?]\"C[-;_ //"+_O@5S.E^+QK.FMJ.GHL]FK,
MIE$,H&5^]P5!XIW_  EC?;IK+R@+F& 7,B&&7B,Y ;.W!'!Z4 =.D:1C"(JC
M_9&*=7*ZCXN_LB>SAOXUADO)/*MP893O?CCA3CJ.N*Z&RFFGM]\\?EODC;@C
M^= $LLT,$9DED2-!U9V  _$T]&5T5D8,K#((.017/#P_?/-NO-26^50_EB>'
M'E,Q;)&#@X!4#/(P>>:7&IZ+IME8V427I@MUCP(]I(50H.2P S@T =#7*?$4
MNOA!RB([?:[7Y9/ND>>F<Y[8S3_[7\48_P"0 ,YZ>8G_ ,75#61XDUS3!9RZ
M+Y2F6.4G=&WW'#8QO[XQ0!?\/WNCVY86]W8HI@BSY<J8+;I/0]<8K4U'4[!M
M,NU%];$F%P )5Y^4^]<JVCZK+;V^VQEM/LEP)XX8TA8.0" ,[N/O8R<]*EDC
M\2RSP2G3K@&$D@>9#SD8]: #3))7^)D?FVYA(TJ; +AL_-;>G^>:[FO-K*XU
MRV^(44MSHMU*[Z;.5_>1C.9(0?FW8.-HXZ_-79ZAJ%Q#IT$HVVDDK /YJ^9Y
M65)YVG!.0!UQS0!K45!9RO-8V\L@Q(\:LPQC!(YJ>@ HHHH **** "JNH6C7
MMFT"R!"64Y()!PP.#@@X.,=>]6J* ,#P:GE>&H(_E^2:X7Y00.)G'<D_J:VK
MBXBM;>2XF<)%&I9V/8"N8\.6-[-H^^+59H$-S<XC6)"%_?R=R,U+KVDZJ^B7
M/E:O<22* X7R$/1@<@  DC&< \XQ2N^Q?*G]I?C_ )$]@E_=>*IM3DB>WL&L
M4ACAE8>9OWLVXJ.F01U.>.E=!7-^%K/4(DEGO/$ U>*508F6,*J_^/'FNDIH
MF6^]PKS_ ,7:XYO]+TMFLV>\U5;9(71MZ(5<>:"&&2".W3(KT"O$-9N;J;XI
MVL,MQ<-;P^(K=88L9B0&(L>>S$\]L^] CVR)/+B1"Q;:H&3WK*G<Q7U\KP7!
M2>%%5XXBXZ,#T^M;%)F@#SM?"\JQA/MNI\!Q]V;^( ?T_&H[+PC+9QN@OM2;
M=,)?E29?XR_]>OXUZ1FC- '+>$M&ETN]U&1Y+B19DB :<,#D-(2!NY_C%9/C
MVS9O$&CW&Y'5HIXQ'(I(0JI?>N"/F(&WZ5W^:X?QZT1U/0ED900UR0"V#GR3
MC]: .PT[_D&6O_7%/_015FJVG?\ (-M?^N*?^@BK- !1110!R7B?4;RTU&&-
M=;@TVUD1."%,C_/B0@$$@A,;3C&2<YXK;T"6YGT2VENYHYI6#$2QNK!TW'8<
MKP25VYQQG-8NORQ6^OQ/:W>I6VHR6NUOLEC]H#Q!CC/RD AF/0_Q<]JT?"30
M-X:MC;)<)&'E&+G_ %A82,&+# P2<G&!C..U &W1110 4444 %%%% !1110
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M;>+:X,;W"R*QWY3:HX4!>.W4=<9K'GCE%D9Y[)HD0I!*(;=$D=FR'(88*@9
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M#X-W_P#"+V_FMNE\V?S&V;,OYS[OER<#.>,G'K6U-/#;Q&2>5(HP0"SL%'/
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M5K#;E'(00R;U9>QZ#!]L?G7)^,K>6._M;F>*RDL97$327;SE(/E8[B%;:,D
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MBNY"&A34+AE,H9L@ L2KY' QGMFMBQ/V5P+JSMK-I)"D;(R_/DDJO SG'\J
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M89Y'8&M?_A+-%_Y_&_[\2?\ Q-<[::A+=38L[6[S,LH@F4* >6&1DY'7/(H
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M%L,LP+R*P8MN(X50,*/Y5U-[=M:)&4A:9Y'V*BL!V)ZGV!H L*JHBHBA548
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M$P20#G)YXK;TDR'2K<R>=O*Y/G*@?KW$?R_E0!=HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH R_$5K%=Z#=QS0^:!&6"[BISCU!&*B\)?\BCI(R3BU3J?
M:G^)+DVVB3[89)GD!C5(V"DD@GJ2!VK(\.^(M+L/#MA:75T([B"%8Y4V,=K#
M@C(&#@^E '6T5B_\)9H?_/\ #_OV_P#A3&\9>'D.'U2)2.S*P_I0!NUS:@Z_
M=WD"VL-O;6MYY,\C#,LVT*W''R@YQG). >G;I <C(KG?"MPT]UXC# #RM6DC
M&.X\N,_UH Z*O/+JZAT"?^TK>T1KN65XP5B+EBQ8G(&"?N\\BO0Z\]U>[U"Q
M@2YTPQB9)CN\Q<C82X/8]\=J -+Q+K6G7/ANWNC+#*NY9G@#C<5"DD$=1Z5R
M$7BC3)9P/LEM%,T8MPPC("\D K\QVG]X3DY[\\UVFK2ZU8>'X;C[1#->R($,
M36XV^85)P._45RRZGXIR,QZ>HSP3:<8SU^[TQD\[>E '1-\2O#LBN!<OL+"(
M-L_B;../3 S^-9VBS7NH2Q6^G:A;PSV\<J!6B?.P2 -D]#\V.F/QK-;5/%J#
M:8+#?G  MLG<<<?=YYR,<=#S6EI$5]8WOV^RLK.:YNQ-)GS7!*M+EB5"8^]C
MN<4 =+IVH7UE8VT.L03M=-,83, A5B7(7[IZ8QV^M:]S:6]Y'Y=S$LJ Y"L,
M\^M9.B6-W<00ZAK/F'4 7VQL1LA!) VJ.,[<<GGGMDBM2\O%LT0F*25G;:JQ
MXR3@GN0.@- $Z(L:*B*%51A0!P!7)^(F@5-4:Y&8 DGF<9X\E:ZJ"9;BWCF0
M$+(@<9'.",U@WT-O<WUU;SV3W?F3 *BR;./*7.3D<8[4 >=:])I@;PX-<$MP
M?[4ADLU!\QDM=K8#8'8E=W0\IZ5[/VKE$\-:;$6,?AHKN4J=MR!D'M]ZM/0+
MAYDOX7$H^S7;1 2OO9055\;LG(&_CVH V.W->-^&9+%(-3.GF6*Q%_</J,;M
MM,MOO;:%R <9R0!_!N'4BO3=;G$<^GP2/,L4TK!E@#;WPA(7Y><=S]*QTT;P
MO<#>-'N'V$IGR)N"O&/PQ0 >%CG2-)(((,RX(Z?\>U=3<W4-G T]P^R-<9;!
M/4X'2LBTBL8#90V$+PQI=E6C=6!!\ENS<]-M;%Q;QW47E2@E,@\$@Y!R.1R.
M10!P-N4>,[63:\KL).>A=JDX(S\J[1TY^;FF6X"0LOS>4LS@J9,DG<W///XU
M+SA=Q).!L(;[O- "97[V%.[/R\_+1A<[-R\D?O.>/\_2ERVYL,?,^;>V\8;_
M #^M&1C^+RMPRN\9SC_/:@!O!&<*NT#CGYN:4E>6PIW9^7GY:7G"[B2V!L(;
M[O-&6W-ACYGS;VWC#?Y_6@!,+G9N7D@^9SQQ_GM2<$9^4;0..?FYIV1C^+RM
MPRN\9SC_ #VHYPNXDM@;"&^[S0 A(^]A3NS\O/RTN%SLW+USYG/''^>U&6W-
MACYGS;VWC#?Y_6C(QGYO*W#*[QG./\\XH 3@C.%&T#CGYJI7=[;02K')=I#)
M(\9$04L6'[P >PR1S5[G"[B2V!L(;[O-9.JV<MQJ5G.);I?)D D^SS%=Y)8_
M/@8*_*<Y/\Z /4Z**ANB19SD/L/EM\_]WCK0!-17.Z=;3QW-E<3SCS'.P(L[
MN-@B&%YZDXWDD=ZZ*@#EO%^TR:7+M9S!<L?^/1KJ-"8V ,D:?-CG@C&#BM3P
MW:16/AZTMX9'D15)W/"8N2Q)PA *C)( [#%8OB*W\.6^M07E_=7\%\<,5L9)
M@6!_=JSK%_O;03C/3FNDTQK9],MVLYVGMV7*2O*9"P]V;D_C0!;HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH S/$%O#<Z)<K-&7"H67:Q4A@."""#47A1
MF?PGI;.Q9C;(2Q.2>*=XDN%M]"N=R2/YBE%6,@'.">I(P./6LGPSK^GV_AG3
MH)96$D<"HX$;$ C@C(&#^% '65R^N6-MIUQ=ZY<:;9W\ 022B6)/-C*@#*,1
MR, <$C!&1UK1_P"$ETO_ )[2?]^7_P *S?$.N6-[X>O[:V>1YI865%$3<D_A
M0!U(Y%<+/>>(_#^IZD;71+2XL+F]$OVEKQ4(+A%P4QDG@>YJ>X\4"UO+2%K^
M4VTJN9+HVRJD) &T-GDELG&/2JUGXFT1)KN]UG5A,;>=FMBW*JFT8947O][G
M!- '1>;XF_Y]=*_[_P G_P 1619W4MI-%/)")'7<95C; 7[V<9ZXI+S7H]<M
M[U].NK^.""!O*$=K-$\LVTX&2H.!QP.I//3%8VD:]%>6MHT,7G;T:.8WJF%&
M8 AQE\9.3T^OI0!TVO?:]9ADLM+B!:VG7=<&4*JN!D@=3D9'XU3O-!UQFU<V
M]^7WPQQV0EE^^,-O$G'7Y@ W7Y1[Y7_A(9M-L\16FEQPIP$BNUP/P'O[>]0:
MA\0XM/U&]LW@LW:TM?M3NM[\I3IG[G3K[\'B@"V^C:TM_))'?,8TM,0L\N6,
MN<['&/F3KR>?F]A6C8:,?[(LHKG=#=VV2LD,GS(222 <8((Z@C!K$L?B#'?:
MI;V M[6*2:T%V#)>8"J<=?EXZX_I56+XH0R(C?V='AT#C9>+(0" >0@8J>>A
MP: -S0M<FN=073+F=)[@0M,S+"R$#<-N3]T\-V]*W;JS@O8Q'<(64'<,,5(.
M".H]B:\U\!W5Q>>-9KB6>WDBELI3&D4J.8PLD8 8 D@X/<#/US7I%[>"S1&,
M4DI=MBK&!DG!/<@= : )XXTAB2*-0J(H50.P'2L8?\C$?^NS?^B5K7@F6XMX
MYTSLD0.N1S@C-9 _Y&(_]=F_]$K0!MUB:!_Q^Z]_V$C_ .B8JVZQ- _X_=>_
M["1_]$Q4 0>)[K['>Z-<;2VVX?@'UB<5REEJWV>SNY)5OFO);=9_M*W)17/E
MKD[%X!W9/  .:W_',T4']CF614#794;CC),;8%<@<?8FZ<6&#\W?:* .[L+L
M7UTLX0IG4"-I.>EM6_+-%!&9)I$CC7JSL !^)KEM Z1_]A%N_P#T[UTE[9I?
M6K0.[("58,N,@@@CJ".H[B@#AK?+9*#<YF?: H(8;VY]^U/ ^0[<E<#>=O3G
M_P#545JBI$8@PP)7&\YR/G;T_H*DX(S\J[1TY^;F@!Q V\Y$?S;&V]?\\?2E
MP_F#Y3YV1A-@P1CT_+M3<CEL*=V?EY^6C"YV;EP2/GYX_P _2@  ^4[<E<#>
M=O3G_P#52D#;SD1_-L;;U_SQ]*3@C.%7:!QS\W-&1RV%.[/R\_+0 [#^8/E/
MG9&$V#'3T_\ K4T#Y#MR5P-YV].:7"YV;EY(_><\<?Y[4G!&<*-H''/S<T *
M0-O.1'\VQMO7_/Z4N'\P?*?.R,)Y8QC'I_\ 6IN0,MA3NS\O/RT87.S<N"1^
M\YXX_P ]J  #Y#MR5P-YV_=YJC?S7$)7R;BSCB9T79<C:TO^LP%.>OX&KO!&
M<*-H''/S<UC:K;EM9L;E)/*&=C!85DW9+$(2W*]&((Z8H ]&_M"\BS]HTN8C
M/WK>19!^7!_2H[G6]/\ LLR32-$QC;]W<(T1;CIE@*UJ;(-T;#&<B@#E-&=)
M-1MY(G\V$MMW_:3(#((1N*C&" ,+ZYKK:X_28[<^(?(N-/,-Y$&8/'<F5<#U
M*J #ST;!] :["@#AO&R7UO=KJ-OI<<\$,&]IS+*?WD;%T5XH^64,,@\X)YP.
M:ZG1+=[;1[=)(HHI6!DD2(L5#.Q9L;N>I/6J6J:4USJ7VN34Y[55@V0"*8IY
M<@))?&=K\8R&!&%^M6?#EO-:Z#;1SWT5]*=\C7,7W)-S%LKR>.>.30!J4444
M %%%% !1110 4444 %%%% !1110 4444 97B2!9]!NMPEW1H70Q/M8$#J#46
MEZ-8?V5:%H2S&)26:1B22,DDYJ3Q+<+;Z!=;EF9I$*(L*Y=F(/ _*K&C2>;H
MMD^UDS F588*G R#[T )_8VG_P#/N/\ OMO\:JZEI-C'I=VZ0[66%R"';(.T
M^];-5-5_Y!%[_P!<)/\ T$T 9NE:/87.B6,D]N)6>WC9B[%LDJ#GDU3\3:+I
MMKX=O)H+...15!5ER"/F%:6C7MHGA_3BUU"H%M$,F0?W16/J.L:7?SW5OJ6K
MQV^GQL(Q"K;3*>#N9O[N> !CIR><  Z^N<;P]X7OM8F\ZTLKR["EI()E655R
MW+;#D!B>IK>@N8+A289HY=O78X;'Y5R\6I+:>)-.C01&"\%]OEW?=V2;LYZ8
MZT ::^#_  PIROAS2 ?46,?_ ,32CPAX9&,>'=(&#D?Z%'_\34=O>:W?H;FT
M2Q%J[$P&7?N9,X#'ZCGZ$5+_ ,5%Z:;_ ./T -_X1#PR1@^'=(QG/_'E'_\
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MZYQG..U=3#(L]O'*ARDBA@?4$5R"P^(M;,[QWMB+6*\81QR0G</+DXY'TZT
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M@D?O,'CC_/:DX(SA05 XY^;FER,9Y\K<,IOYSCK_ /7Q1DX7<26P-AW?=YH
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M:S*JIVY!&%!Z\;<G(/XU)H0BN-4^T*=UTJR_:V$++MD+*!&6/90N .> #QW
M+/BO7;G0+"&Y@MEE5I )7<-MC7WVC.3T';-:6D7[:IID5Z86B$I8JK C*AB%
M;D X8 -SZUB>,[Y=-BT^[2>XCNHYV,*PPB4/\A#;E+*",$G.X$''6K_A1D;P
MU:%);B3[X9KA0'WAV# A20,-D8!.  * -FBBB@ HHHH **** "BBB@ HHHH
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MP6T4*9VQH$7)[ 8K)\,_\>-W_P!?]S_Z,:M>*1)84DC;<CJ&4CN#TK(\,_\
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MK/3H[)V,<T[!B25DE+#).2>:Y>S:[,LEM%:BQN8X7DMX)B[R-(05)\QCM;
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MQ&ZR1*Z,&5E!4@\$&N1L]#>ZOM7-KJ=]9R0ZANC\N=C&,A'8&,G:023G([T
M=CWHKGKC0-4NF1I]>=M@( %LJCG'7!YZ?SJ+_A%[W_H,G_P''_Q5 '345S/_
M  B][_T&3_X#C_XJI;?0-5M"_DZ^ZASD@VJL!],GB@"34_\ D;=!_P!RY_\
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M)++-I;236S6TAB.Z)V#%3CID$@T[3?\ D%6?_7!/_010!G_\)1IW_/.^_P#
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MWPKJ0RJAX&0NV<(&X+''8 Y_"@#E;9UFM8FR-LBJWF%G<\C/5@"<]>0#4G!
M)"J0.!@_-S5?39?-TNTE8'88HP4W$9PN <$9Y ST[U9YPH8Y) VG=]WF@ XY
M;:I)SE<'Y:,+]S*[21^\P>/:EYW, WS_ #;FW_>_S^M&1C.#Y>1E-_)..O\
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M=M;LK_3XFMY)?*OI3:V\ZIP6*L=P]N#SZBG:5=2Q2II=R(C)' #'+"^5D5<
M\'E2,C@YZCGKBOX@T>Q;PK<6ZQ&..TB>: 1L5V,%;&,?4C'H35+2/!&BVUK#
M<VL<]M-+"N]X)FC)R <?+CC/:@#K*XC2YXO[0U. B]N)SJ$JI#'/Y2+DLW8C
MLI))SZ#OC0U/PT@ME:#4-51ED4L1=2R';GGY0>:Y<>"=(UF_N(S]OOT@D#&6
M34)[=4E))*@?WNYQZ^M '?:-\^G13)<S303 21>?RZ*0"%)[XYY//N>M5_$3
MRQ6<,L#JDD<C."R[AQ$YZ9%9\/@>R$* ZEKT9"@;$UFXPOL/F'%9M[I5KHFK
M.IU"_EA?3+F0"^OY)E$@**I =B <.P_&@#MK6$6]I# &+".-4W$=<#%96A_\
M?^N?]?W_ +32MA&#(K*05(R"#P:Q]#(_M#7!W^W?^TTH VJ*** "BDS2YQ0!
MB?\ ,[_]P[_VK4OBC_D5-7_Z\Y?_ $$U%D?\)OC_ *AW_M6G^*FV^%M27C]Y
M T0+,% +?+DD]!S0!RUGN^RVFT'S?(AVC:,']VM/'W#LR5P-_ XY_P#U57L'
M673K4Y&PQ(-Y7D84#L3Z=LU8X(!("D 8&#\W- "G&T9W>7\VPX&3]?TIV'\T
M<'SLC VC&,?_ *J9QDL%4DYRN#\M&%^YE=I(_>;3Q[4  ^X=F2N!OX''/_ZJ
M4_=&=WE_-L.T9/U_2DX(!("D 8&#\W-!QDMM4DYRN#\M #_WGFC@^=D8&T8Q
MC_\ 531]P[,E<#><#CGM1A?N97:2/WFT\<=*3@@$A00!@8/S4 *?NC.[R_FV
M':,GZ_I3OWGFC@^=D8&T8QBF<#+!5).<K@_+1A?N97;G_6;3QQTH 4?<.S)3
M WG XY[55N;0S2QW"2O%Y+ #Y0=Z-ORI]/NCFK/! ) 4@# P?FJA>W4D=XD$
M;*AEVLP90%XWC&2>O/09- 'IM%5K&X>ZM1+(JJ^]T(1MPRK%>#QZ59H ****
M .0UR^T*+7E@U!-3M;MP%2>V,Z+*NTGK&><<CGG/M6]HUK80V?G6 E*3G>TD
MS.SN>F27^;\ZS?%AC4Z:9I=0AB,[*[V<;2?*48$.J@G!&1N'0D&M+0H(+?1;
M>*UDFD@ 8QF965@"Q(&& ( Z 'L!0!HT444 %%%% !1110 4444 %%%% !11
M10 4444 9FM+*8+5H3&)%NH\>8I9>3MZ CUJOX/S_P (=I&3G_14_E5K6)$B
MMH'D=447,668X'WQ6!X7U^*#PMI<1L-3?9;(-R6;LIX[$=10!LZQI OKBWNE
MM[6Y>$,I@NHPR.IQG!(.UN!ST['L1SFJ7%KJ>G:;+%I\%ONC8QN]V(C  <$!
M 1O''T]:Z'_A)(?^@;JW_@$_^%4-!TV_ATNSN(62"<PF*6*YA.0-[,#P00?F
M/'0^U $4QN+?052ZN)WL!$JR21B!?,0CG&#W]%Y.>.<4QAJ!UR&.:!EE20/#
M(/(\IP9#N)S\^?+V@8&<@]>M:EIH=Y96<=I%J2/$A+*9;569"3GY3D 8).,@
MX'%1V_ADVZ,KW@G)DB=9)H074(Y? .>I)Z]!S@4 =!619:&MIJ NO.5@IE*@
M1!6.]MQW-_%C\/?-:]% &?KW_(NZG_UZ2_\ H!J?3O\ D%VG_7%/_014&O?\
MB[J?_7I+_P"@&I]-_P"07:?]<4_]!% %;7@AT>827#VZ$KN=)1&<9'&X@]>G
M R<X%<M:_93J4EL18SAHT@B@NL@6YRW VQA5W=<'!..,UU.M@FQC">9YWG)Y
M)CVY#YXSNXQZU4T_3+:^BN-0NB9VOX4CE1TV (N<*5!/S LW.<^G04 3:!J5
MM=:59HDZNXMT;)/4'(!YYYVGWK,\01R-XEM9HF19+?3KF9?,7<K8:,8/(]>M
M0:=8SPK;".W:(6DD</S11YD.\[BS=<!<8.02?6K.OR)'KA:1U11HUWRQP/O1
M4 0Z)JNI0Z580S6D\ZVQ>*\F\AE(56*(57'S' !.,X%1Z;I]CK%V)-1LX+HO
M/=G,\ R0)%"\$=EZ5O:O+<0VD-S;R2"%&W3^2%+&/!Y&X$<'!]P#BHM&BLKD
M+J5G?S7D4F\JS;=N6(W=%']T4 '_  B?AW_H!Z=_X#+_ (4?\(GX=_Z >G?^
M R_X5LT4 <MK7A73(].$NF:):B\CG@D0P0HK@+*A;!X_A![U8$>L)J$VIM;E
MDGC$)LEE&Z)5R5<'[I;+-D9Z;<'CGH:* .,\-Z3%IBZ?$;.."Z0PB;"C=O\
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M<:3-Y<5M(^5 6Y)"=1R< DX]._J*Y?3+>2"[NO[/:9Y=T<UPT2*X) ("\L@
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M\M&%^YE=A(S)M/''2EYRP# .-VYM_P![_/ZT97&['[O(RF_D\=: $X(!("D
M8&#\W-!P"6"J6.<IM/RT= H8Y) VG=]WFEYRP#?.-VYM_P![_/ZT )A?NY7;
MD9DVGCCI1P0"0%( P,'YN:7*XW8_=Y&4W]>.M)G 4,<D@;3N^[S0 <9+!5+'
M.5VGY:7"_<RNS/\ K-IXXZ4<Y8!L.-VYM_WO\_K1E<;L?N]PRF_D\=?_ *]
M"<$ D!2 ,#!^;FL_4+$W-Y!<"*)Q$X#HP(V9WD,.>VWISU]JT.@4,V6(&T[_
M +O-5+JYMTN%@DED,[.C*(RS;O\ 6#+8XV\]^* /2:*** "BBB@#EO$NC6M]
M?6\YU6WLK@!7:.X1)$E6(LPRK$<*78D@]_85>\+)#;Z)%:01SK%!D(\H3$@)
MW;D*$KL.> .@X[56\0>&M/U2_@N;J]^SRMY<4:,$*R.C&2,889.#DE0?F YX
M%:6@6MO9:+!!;72W4:ESYR;=K,6);&W@#<2,#IC':@#2HHHH **** "BBB@
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M^K6NGWL2ZM%&^F.D$B2V8 (. &!W?=ZX)P>* .SN[RWL8?-N)-B$A1P26)Z
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MW#@$DY]/>K/]B:S_ -!.3_P)?_XFNFHH YG^Q-9_Z"<G_@2__P 31_8FL_\
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M#H8N!HMJ+K[5Y^WY_M4D;RYR?O-'\A/TKF_B-:K=V&G1M;Z@Y^TG$UC;"X:
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M$VDPW$,VV$R*S@S^09$YRH<]#T[C.,9&:=HR2++<GYT@?:T43W'G%00<MGG
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-%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g201805072101259272279.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g201805072101259272279.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +R =$# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH ***QM?TS4KXV-QI6H):W-I,9 DZ,\,P*E2'564G&[(YZ@4 ;-
M%>:Z7K'B32](T6#4_%/A@R72B*-Y8Y97F8$ XD$@#') S@#)%>E=J "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)%I-G'-,L\J0(KRKTD8*,L/J>: +=%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HI,TM !1110 4444 %%%% !6;K&O
M:9H,$<VJ7:VT<C;$9E8Y.,XX!K2JKJ/V[[!+_9@MS>8'E_:2PCZ\YV\],]*
M/+]'\56^HVL-QJ?C_4+2_D<^;:06D:Q(V[&U,PDE>F&W<CGBO6ATKS^PTSXA
MW'AFTTR^OM,M93&B37BS2O<I@@DY^Z6X]<5Z!0 4444 %%%% !69X@\D:)<F
MXDOXXL#<VGAS..1]W8"WY=LUIUP?C#69K7Q-9V,^LW^DZ=]C><3V5J93)-O
M56.Q^ ,G'&<]: *FAK(_B_36TJ?Q9/9".;[8-6\](5&WY"/, W-NXP,\$GC
MSZ-VKRCP;K4UQJWAQEU/5;G4;Y)O[9BN8YA$I\LNI"LH2/:P"C;C@XYZUZ=J
M&H6VF6$EY>.R01 %V5&<C)QT4$GKV% 'G$4M_;6>O^)=-N]&TJ.QNKGS;+["
MF9?+=L^?+D,'?&01T#+UKTFPNOMVG6MWY;1>?$DOEMU7< <'W&:\\U_6_ 5Z
MMUJBV4-SK"0L8)9=)F9FD53LSF/G!QC-=]H\T]SHEC/=#%Q+;QO*-N,.5!/'
M;G/% %VBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,2QEEA+>8@#KF1=O)*CY@!R<54\&V]M;:?=QV=O=I;K<;8YKO?YDZB-%#8<
M@#&P< 83B@#I**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<D6[.D:2,FU<[Q'P#NW8X!QC- '1T444 %%%% !1110 4444 %%%% !1110
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ML;QKTXNZB[J_5=5;L9+A45<.RN4(R2  /RJ=U!7=AN ISG[I Z@8K0'@O0P
M/LTA !49G<X!_&C_ (0K0_\ GWFZY_X^'_QK7VJ.#D9S;VTMO?SW27R+)/D?
M,@. HX .?K^=8_P.);_A)BP()NXNO7[AKI]5\#VD4-[<VDPBC-LP,<L?G;2
M?F0D_*3GWZ"N0_9_E>?3M>E<DL;B'D]\)BHG-2148M,]DKQC]H3_ )!^@C_I
MO*?_ !T5[/7B_P"T$-UGX?7_ *;R_P EK(L]D@_X]XO]P?RK"U=%?QEX<+(&
MV+=.I(Z'8HR/S/YUO1?ZF/\ W1_*N5\51;_%/A4"66,2W,\+&*0H=IA9NHYZ
MH* ,[PJ;I=:\8M9)$\_V_P"596(4]>I'-:D&K^))=6L[673;:%9 YFW>80H7
M'1\;><\?TK@[?PW?Z[K&M2Z8JHL-Z\4C2W\JL[ ]3@'/XU<_X5]XC_OP_P#@
MSF_^)KBA.:C9+^K^A]-6H8:4VZDTFTM'NO=2_F^9T/C+_D;O!^,_\?<G\EKF
M/V@Y-O@^P& <WAZ_]<VID'ANYTKQCH=IJH)>X=FBDAOY&*;1[@8[=*J_'JQ2
MS\,::5N+J3?=$$3SM(!\AZ FMJ+<G)O^M#S<QIQIPHPC+F2B]>_O/S9Z'X$0
M)87X#,W^E*"6;)_U,==77*^!S_H>I?\ 7[C_ ,A1UU5;GEA1110 4444 %%%
M% !1110 444A;'8_@* %HH'(HH *HZO9OJ&ESVL:P,T@QMG#%#SWVD$>Q!X.
M#5ZLKQ('/AR_V7RV+"(G[0SE F.>6'(!Z9'(SQS0!EZ7HFHV5W;.;3381$TC
M--]IFN)7\P@O]X#D[1R2<8I/&<?F_P!E".!;N[%PQ@LI(A)'.=C9W D ;1D@
MD]?K5'PP(O[:MY[5+.RMIH)5\BWO7N/M#J4RQR %V9^IWT>-)=0>^BM8=/DG
M@58Y(Y5LYI2CLS*[!XF!78G. <MN(R* -WP@D<?A>S2*1I%7>#NC,>QM[;D"
MDG:%.5 R<!16W67X=MTM?#]G!&&"QI@;K<P'J?X#ROX\]R3UK4H YKQ5=P/$
MNFRI=,SE)@]G)$)HF61=C*KGGY\#@'GM3/#-G<07]Y<,-9\NY/F2-J1@&Z3"
MKD*@W#"J!S@8'2IO&.FVE]I44L]G87$T-Q$8OMJ?*29%^7=@[=W3.,9QFI_#
M6DW&CV=Q;S+:JK3>9&+:%8Q@JN<@ #[VX#OMVYYH VZ*** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH 0U\\?$2*-=9T%415!UBY)P.O\ I*=:
M^A^]?/OQ$'_%0>&QV_M6X_\ 2I: /H*BBLS7=6.BZ=]L^SF91+&C_-M"*S!2
MY.#P,Y/'2@#G?'O.K>#1_P!1N/\ ] :NU/ KEM;T;4=>O]!N0;2&'3[Y;MR)
M6<R*%(PORCUZUT[J7C90Q4L" 1U'O0!@R>.?#$4C1OK-LKH2&!)X(_"F_P#"
M>^%O^@W;?F?\*Y#P8]U8>%Y%M(8;JY?6#;M)<(6^4GEFQSVKMX;ES-Y=SHC1
M#.!+'LDC/OGJ/Q%80G.2OI]QZN(PV'HS<+-V_O)?ARA8>+= U2\2TL=4@GN'
MSMC7.3CD]JVJX/5(XX_BUX?"(J@VDI.!CLU=Y5PDW=/H<N+HTZ:A*G>TE?7U
M:\NQ3U4XT>^/I;R?^@FO)?V>O^0/KG_7Q%_Z!7H'BG2KZZ26\M]4DMX(;602
M0*&P_?<,,!G QR",'I7 _L^'?HVN/M"[KF,X'0?)6AR'LE>+_'WE?#JYZSR?
M^RU[17BOQZ.;[PROK*Y/YI0![2GW%^@KG=6B6?QKX>#@D0I<S(,\;MH7/Y,?
MSKHAT'TKDO%,,\GBOPRL%[-:&9[B!GA"[L>7O_B!'\'I0!D^%KV6PC\47$-N
MUPRZP044'.TL 6X] 2?PK;'B*\?==0P1-9_:_LJ1%7$S\XW#MC'.,=!UKB+G
M1=5M_B!/H6C:_>6HN8OMDLKG[SG.20N!6T/!7C''_([3?]\M_C7'"<XKE2>G
MH?1XFAAIR56=2*YDGKS7M9=DUT+_ (C?9\1O"IVALB=>?H.:Y/\ :$<#PMIB
M;06-TS!O3"'C]:;XHT#Q)X:M8?$-SXD-[<6D@2'?&25W<'&2167\:;2ZB\+Z
M-/=:K<WGFN6"2I&%0E,G&U0:UHR;E)-6ZG%F%&,*%&4)*22<;J^Z;?5+HT>G
M^!8VCL=1WR-(3?$Y8 ?\LX_2NKKFO!G-C?'UO&_] 2NEK<\D**** "BBB@ H
MHHH **** "BBB@ HHHH *RO$NW_A'KPM9M> (#Y"$Y;!!R,<\=>.>.*U:S=?
MU&72=$N;V"%)IHPNR-V*JQ+ #) ) Y]* ,#2U:\\9+J\FDB'[1!,D$X#JYC5
MD :4'Y<OU7(#!1CU N>)[[4K&]TU[*^MX8G=U>W:TEN))CM)&U8SG P2>GU[
M5/HUXZZE>6MSIE[9W4\AN'+GS86PJI\D@XZ*/E.#U.*H>/1*-/LI8K*6?RKC
M>9(C+NBX(X$3!N02,\@9Z4 ;NAFX;1X&NIY)YVW,\DEN8"<L3C8>5 Z#/. *
MT*R_#SO)H<#O!-!DOM29G+[-YVEMY+9*X.#R,XK4H P?%.I:=96<-OJFF37U
MK=R>6RB-&B4]1YA<A5!.,9/6E\(SV=UH:W%CI!TN&21OW)5!N(."WR$CM^E+
MXB.LM%%%I/V<!ED\PSH&5F"_(A!(^5CP3UZ4[PU:7.G6EQI\YC:&VE"6[)&D
M>4V*3\B<+\Q8 8' 'U(!M4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 E?/_P 1B#XD\,@?]!&?/_@4*^@.]?/?Q .[Q/X7_P!K49R/_ O%
M 'T)39(TEC:.10Z,-K*PR"#U!%.HH X+Q)"-!\0^$H-+FN+2WNM1\F6WAF81
M,FQCMV=,9]*[WM7!^/&_XJ[P(GKJCG\HS7<3"1H'6)@DA4A6(R%/8XH \ET/
M5],MM#U#3;V_:TN/[2>8HT$C+(N[[K;1RI[\UK76N^&R84T_6C;6PFCDEMS:
MRLGRD'Y./E)Q]/:NUT>TU&VM635;J*ZF+95T3;@8&?UR?QQ6CL7^Z/RK"-*4
M59/^OO/5J9A2G-S<)7>OQ*W_ *2><?VS8Z[\4]#N-.F:>**VE1V\MEVG#?W@
M*])INP9S@4ZM(0<;WZG)B:\:O(HJRBK;WZM]EW.)U9;V[&LS:I9Z@UO''+':
MPQ./)V!?]8V&!8DY.#T%<I^SX,>'M8)YS=)_Z+%='XST[799M4N8#=/:?8<6
M[07_ )"P.%;>SI_'GCUX&*YW]GS!\-:LR\J;M<?]^Q5G*>P5XE\=F)UWPJG;
M?(3_ -]1U[;7A_QVS_PDGA0#^\__ *&E 'N':N=U-!/XVT)')VPPW%P@ _CP
MJ<^V'-=%7(^(XM0_X3'06L+N*W::&X@+R0^:!PK_ '<C^[ZT 9,N[_A=0*8W
M?V8<9/?FM5;[Q'N"3).CB'.8;565I>?ER3]T<8/?G.*X+5++6->\27[I;27U
MU9/]FDGMX!$.,XX\X5"?"OB3_H%7WX__ +^N12:;MW\_\CZ.5*$XP]IHU&*U
MY?OUFM[]CL/B2UP_PX1KQ$2Y,D)E5#D!NX'XUR7QT_Y$[P[U^\>G_7,52D\/
M:F=4L--U*WDM?MTOEQ-<1LZY'L)C3?C9:ZU9:'H\6I:C9W40D=8EM[1HBN$[
MDNV>/I5TKRFY>AQX_EI8>G15]Y2OI;6RTLY=CU?P.)1IE[YTBR,;Q^53;CY5
M]S745S7@O_D'W^.GVZ0#\EKI:Z#R HHHH **** "BBB@ HHHH **** "BBB@
M JO>WEO86K7-U((X4QEB">O X')-6*H:S;7=WIKQ64_DSY4J^\KC!SU'^!^A
MH S'\40OJ%G%!&RPS/L9KN": DD@#863:WT)';%4O'<WEQZ2K2(D+W1$GG3O
M%$1Y;8W%/FZ].V>O:M'1_%&GZK-;VUO+)*\MOYJR[/D8@*67/]X;U)&!][UR
M!2\:3@+8KYW[J.;?/;F>:$2J58 ;HD8\,,XZ<<]J -CP^8SH5J8C"4VG!@D:
M1.IZ,W)_&M.L#P>^H-H$ OS%)M!\N9)WD+KDXSO16X&%YR3C)K?H R]4T&SU
MBZM);U%FCMBY$,BAD;<N,D'N.Q[<^M4_#MDFEWFIV:O?S;YQ,)KH!AMV*H0.
M.6P%'WOF^O6K.NV5M<BSDNM1N;.-)PN(;AHO.+_*J$J0?O$$>XIN@V-C8S:F
MEE>27!>Y#3"68RM&_E(-I9B2?E"GD]Z -FBBB@ HHHH **** "BBB@ HHHH
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MVL%XHCDT^60I(GG1+.LLQ&QF8B3@Y#JQ(Z[LCBNK^PRPZZ^HF["V[Q>6826
MW9&#][:?^^<^]<[X+TC[-,E\VG6R[X2%NK?43/$?N@^6F,("$7ITV@=!5GQY
M:17ME8P&687!G)@BCMC.'8*225R.@&0<C% '6@YZ45E^'87M]"MTE:9I"7=S
M-%Y;;F=F/RY.T9/ R<#%:E '+>+6T=;FP?669H8EGE$)7*/M3)/4?,.-N,G)
M./4.\&(4AU3S)+TW!NP98[PJTD7[J/:A920V%V\GGG!Y&:MZ_JEA926D%Y:3
M3O*7DB>*V\[R2@!\S Y&,CD FK&@7-G=Z3%+:7L%]P!-<PX'F2!0&9@.C''(
M/(H U**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2O#[K,O
MBOPH[/SBX.XX^;]]-P<U[A7AJN#XD\(\\F.?:.>?WLU73^(F>QWZ']Y&-R+N
MC)Q\IVCTI<?OF!"KL0$GJ3SZ?UJ,.A'F'^X>QZU)<*<X,XW,HP.<G\1749'.
M>* L=SHW[O(^WKR!].AS5B>ZNEOA:@RA&G<MY,L>\ CY5&X\'/)]>U1>(HII
MGTR2W26;R+OS&6)">!R:BCU+89/,TG4IX9Y9)#F+&T^OK6#=I,].$7*E!I)V
M3_,T(9IO[)D\^4&1%F1@S*2@P<!R.,_2ET'']@::@Y3[-D#IC-9-EJ4J:8R1
M:7J=RL[2EII(?F!(QSZUM:3$T&B6*3 H\=MAU*L"O6JA*\OD8UZ;A3:?5_HR
MX%(PWRD[5^4D8/O]:F0$R2KYB-M8<@+\QJ-'Q%R<E8U+<G@4Z/;Y@ ;:S2#!
M%:G$<AJEO:6MKJ4+6:S^=YS*\8WM"2,X?G@>GM6G\$ !X5U# Q_I[=L?PK63
MKHN-.M=0M$OS*D@EFD_T<'[^>"<Y./7L,5L_!+_D4[\YSG4'Y_X"M8UMBX'I
M=>+_ !3_ .2I^$1_TR;_ -&"O:*\7^*JAOBKX14XQY3=3C_EH*QCN6]CL$.X
MN^\_,%P1_2E??^\VR>8JNHQ]TMQ3M[+ <K\P51@-D?G6(/%ME)=SPRV]U')&
MZA@J&0D8_P!G.*ZY-+<SITYS=H*YMH74C9S'AF1B<X&/3-*"Y2(;%.48Y!&:
MQ_\ A)M+B96!N\;&7)MGX/Y57F\5Z? (75;QR(\%3 4_F *7/'N:_5JW\K.@
M=8UBE&XC"#"@CGW^E>7_ !202W]B@E!S$ ??+BO3HKA;JV,H4*KPAB""" >W
ML>:\Y^)"F36+ ,N,1IR<_P#/04Y;,Q6YZWX+(;078=[NX_\ 1K5T5<YX(!_X
M1L'!YN[D\C_IL]='7&;!1110 4444 %%%% !1110 4C%NP!_&EHH !THHHH
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MU2\^RG:5MDE01[_]H@9!_'#>] &UH<%C;:4D.FNKVJR2!2IX!WMN QP &W#
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M=8'4H6=IDB^3<-PWOPI*Y&3ZU%X0NHKO2)'AN&G19BNYKR.YQP.-T? Z]/\
M&M;4-/M]3MA;W2%HQ(D@ ./F5@P_4"JVB:);Z%:26]O+/*KN&+3,"0 JHH&
M!@*JC\,G)YH TZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M .]?.JG?\2_A_P#]>L?_ *.FKZ)-?-DE[;V/C_P)>7<JPVT5A#)+*Q^5!YLW
M)H ^DZ*YC_A8O@[_ *&*Q_[^4G_"QO!O_0Q6/_?R@#J*\^M@S:GXV"VHNF%U
M 1&03_ .<#DXZX'/%;0^(O@X]/$5A_W\KFKB^\ W6IW5^GC"2VFN7#RBVOS&
MK$# X K.I&3M8[<'6ITU-3=KI?A)/]#5NK2[TW2XXOLKWR27"SI+&'VERPXD
MC))QU/7&1S3/%^?^$S\(<?\ +TW\A6;]I\$#_F?+[GK_ ,39J()/ 46I6M^W
MBY[F>U??%]IU'>%/T-9RA.2M;M^!UT\1AX3]HY-NTNF]U;N>F45SX\<^%<?\
MC#IO_@0M'_"=>$R/^1CTO'3_ (^5_P :Z#QSG/$$_P#;'AWQ%/-IFFI>V=O<
M1N)03,JH&VL#MZ$?,#TYJM\".?ANISUO)OYBG>-O%G@J]T74H$U/3[C5'L)4
MMWC;+<J<*''')[9I/@2"/AN@(((O)NOU% 'I=>'_ !:\K_A:_A(W">9!L7S(
M]F_<OF\C;W^E>X5XE\4UD?XP>#D@<),PC".R;PI\X\D<9^F: /2[+0O"&HPF
M:TT;2)5!PV+- 5/HP*Y!]C7-^'K9+#XA^*H--MX81';1^3$BA$#8&.!P!FNF
ML="U"W\0-JUUJ-O*SP>3(D%H8O,YRI8[SDCD#V-<PLL^C_$'7[RZT;4[FSNX
MXXT:VM&D5L 9_"L:NCB_/]#TLO7-&M%;N/W^]$W#<:U_9_RM?'4-F=K0PB+?
MZ$Y^[GWK%\40+>^.?",-_!#*)$D$L3+N0GC(P>HS4UO>Z%;Q>6/"6N.,DCS-
M-9B,]OI5>ZGN-<\=>'+FUT;5+>VL]ZR/<VC1JN1Q^'%93DFK>:.W#4G"JY.-
MERSULEO%VZG7GPEX</70=,_\!$_PKR#XMZ=INC^+_"8L+&VLXW=FD%O$$!Q)
M'R<#GO7N]>*?&@_\5OX.!R/G/_HV.NL\ ]'\ L&\%V+ Y!:8Y'_75ZZ6N8^'
MASX'T\_[4W7_ *ZO73T %%%% !15:>_M+:YM[:>XCCGN21#&[8,A R0OJ<53
M/B/1U56.HP!6S\V[@8)4DG^$9!&3@<4 :M%9KZ[IL=ZEF]SMGD<QHA1AN8#)
M .,'BFKXCT9[:2Y74K8PQA2[B084,<*3[$T :E%9D?B#2I;O[*EXGG_,0C K
MG;][!(P<>U7+.]MM0M(KNSGCGMYE#1RQL&5QZ@]Z )Z*** "BBB@ K(\3?\
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M6F-=75JT!!55W1M&7/EH7.UN0 Y=??;0!MT444 %%%% !1110 4444 %%%%
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M0(K^*W09_P!F-QG\2:ZGP]JPUW0K74_(,'G@DQEMVTAB.O?I6G5F!P7V"?\
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MRN]E*D?FAV7:#"RJXSQD%N,CKSZ4 <UX:\9'7=1:P>S6.=?,9U1R3 H$942
M@88F1EQZHV,U%\1(XSIEG*^IQV125@JR/(%D8HP'$?)VG#8((XYJMX.>U;4X
M;=;Z\NY+2U,49GU&VF 7Y03LB;.3M'+ X]>>='QN\<5K8R3003Q&5HWC>8QR
M$,C#]V5!)8=< =!GC&: (_ 5G=PZ9)=SWT=U'=!65XWD8.PR'?YP-I)P-H
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MJYF,83/4Y!%<%)X=LM0U](M!6XN+0Q@^9)<3^3G#;LN#G/W<8KF<)<S:6_\
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M/&\>XR1JRD':3W)XXKHJ\7\2^)?$"_&<Z/H<=B+A418C<*2"3$6)8@^A/Z4
M>T5R7C/XA:5X'>S34H+N5KLG9Y" @ 8R221Z].M9.[XL9_U?AW'_  /_ !J"
MZM?B??0M#=V?AF>,@@I(K$<_C0!Z-#*L\$<R9VR*&7(P<$9KC_B#X3T/5-#U
M36+RP66_MK"7RIM[ KM4D< X.#SS7-K>_$[1&L-,F.B,LN8X)IRYRPY"%L_>
MQTSUQU)JYJ-I\4M4TRZL)X] $-S$T,FTL"%88.#Z\T +\"ACX=8]+V;^E<9\
M3"][\:-,M7D"QQP)MW+N"_*[$XX]/6MWPUX7^)GA/2?[,TQ]%%MYC2_O6+-E
MNO.*XO6/[9G^+<0\0&U&IV]N6?[-GR]@A=EQ[T ?1&C$'0]/(Z&VCQ_WR*O5
MGZ%_R+^F?]>D7_H K0H **** "BBB@!#GM0,XI:* $Y[TM%% !1110 4444
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M0<*B5HI.]]U?R?<Q?B%;I:?"XVZ>;LC:%1YHPWWN_I7=Z?\ \@ZU_P"N*?\
MH(KC==\+>*/$.EOIU]K.G>0[*Q,=HRG(.1SNKMK:(P6T4).2B!21WP,5I!/G
M;M961S8J</JT*:DF^:3=K]5'NEV/ _B]G_A:ND 8.8[?@_\ 76NTAU:UT?QK
MXH&HV]]Y-VR*C00.V<+S@KTKC/BWS\6M&'JEN/\ R+7O^.:N<.:S70PPN(C1
M4XRC=25M[=4^S['GMMXC\,P01QO'KDS)_P M)(9]QQZXJAXFU^U\0ZEX>CT^
MWOB8-0220RVKH O'<BO4J.*ATFURW_ Z:>.I0J>T4&VK[R[_ ".,^*IQ\,]:
M([QJ/_'UJ'X/_P#),-)^LW_HUZI_%#6;2\\ :Y:VADG:((LDD<9,:'>."W0G
MV&:N_"#_ ))AI/UF_P#1KUL>8=Q7AUU_R<ZA_P"N?_I/7N->'W/_ "<['CN$
MS_X#T >X44M)0!7OK&VU&SDM+N)98)!AE;\P?8@\@]B*Q]-O;K3+]=&U20R;
MQ_H5XW_+=1_ _P#TT _[ZZCO7053U/3;?5K)[6Y3*L0RL.&1@<JRGLP."#0!
M<KY_\8 ?\+VOCZ6!_P#29Z]CTG4[F*\.CZNR_;D7=#.!A;N,?Q =F'&Y>QY'
M%>.>+SGXXZD?33V(_P# 5J /<="X\/Z:/2UB_P#0!6A5#0_^0!IO_7K%_P"@
M"K] !1110 4444 %%%% !1110 4A8#KG\J6B@ HHHH *K7UC;ZC:-;740EA+
M*Q0DC)5@R]/< U9HH \K\ Z/K.F^-)WOX@L;VK,P1&"QEBA";C*VX@[U(QQM
M!S\V*[/QA*D&F0RR/)'&)0&=+J*#&0>K2<'Z#FN/^&%FEI<HLEE;VUT+=_,!
MT.:"8?/G#73\2_EENO:MWQ'=:C-XAM(+33II9;24RP7%LT4H0-&0PDC=U(ZD
M Y'8@]10!O>&4N(_#EDMU*LLQ0L7617R"25^90 3@C) QGI6M65X<LO[.T"V
MMO+F1EW,RS*BMN9BS<(2H&2< ' &!6K0!C>(=#L=:M(Q=RF%H'WQR@CY3TP<
M\$'^>",$ BOX=\-II$SW;7GVJ1T*1E5VHJEB[$99BS,QR6+'H.F*SO'=C_:0
ML;**+[1=R^<L5N\2O&P*89SN90&4'Y22>3TYR-#PC%%;VU];Q1S6YBN0KVDN
MW_1V\I. 5)4AOO\ &.7/% '14444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!E^)#CPQJI]+27_T$UY#HO/[12$=K)1_Y++7K?BEMOA/5SZ6<
MO_H)KPZ;29]>^.$VGV^I7&G2-;)_I-N3O7;;J<#D=: /H>BO-!\+-6'_ #/^
MN?\ ?3?_ !=+_P *MU8<_P#"?:W_ -]-_P#%T =MJ^J7.GRV4-I8_;)KJ4H$
M\T1A0%+$Y(/8=*J-XLLXMT$T%PFI"40BQV9D9R,C&/E*D#.[.T=R#Q7C/@31
MM9\<7VK13>*]5MFTN4)'(LK.6W%U)Y;CA>WK7:'X2:F;I;K_ (3S5_M"H8Q*
M0=X0D$KG?G!(!Q[4 <5\1YKFX^+.AF[M1;2'[-B/S Y \WN1QGZ9KZ&KR6Y^
M"DU[=I=W7B^_GNDQLFDAW.N.1@EL\&KG_"K-=W9_X6+K?Z__ != 'IU0W4!N
M;26 2/'YB,F]#RN1C(]Q7FY^%WB 9V?$361]0W_Q=-_X5AXGZCXD:J/HC?\
MQR@"KX\^R6'P]U#1+778I_LL<<0M%CC4_*R\9'<=2!S71?"'_DF&D<?\]?\
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M R4?2Y?_ !I/^%*^!_\ H'3_ /@5)_C0!V/]O:/_ -!:P_\  E/\:/[=T?\
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M+QM=R6R-OF <A%;=O51N9<E<$*HR, D [#Q/<W5KH<C6,ZPW+R1QHQ*ACN<
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MP)_PG'B03ZGHVH0-/;W >26\E)8LR\KTP5(['IVQ7H*Q_%L#YIM")]<?_6H
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MZ9ZY%9T1C;:'+[MY.=P[5?T!%%XC)G&Q\[L9'S"HG\+''<Z:BBBN4V"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .>\=?\B-K7_7J]0VO_
M "4.8>FC0_\ HUZG\< GP1K '>V:L'5M9&@^.6NW@26.73H;=0;E(SN#NW1B
M,\'M0!WM%</_ ,+%C_Z!G_D]#_\ %4QOB5"K1JVFX,CA%_TV$Y)( X!SU(H
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MBXQ@D\)_]>K6GZ0+"57$N\*K#[N.ISZTI5(N-D-1:9IT445SF@4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!@>-VV^"=8)[6S5SUUI=GK'
MQ->"]B\Q8M.66(Y(:-\D;E(Z$ G!KK?$.G+JWA^^L'N!;K<1%#*PR$SWK@_$
MUYJMCXP6_P##D)U&5[;[/="&/?Y"CH0>A;.>#^- &U=Z]<^'Y_[*NA%?W$I
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[3_XN@"L+_Q-WT6U_P# L?X4?;_$_P#T!+7_ ,"Q_A5@:\W_ $!]3_[]I_\
M%U:;4P+ 77V2X+'_ )=P%\WKZ9Q^M &*UOKFH>(=(N;S3H(+:T:9I&6<,?FC
M*@8_&B2QU;2-<DDT6SBETVXAS) TNQ8Y@?O*.VY>H'&1GO5_^WV/_,(U0?\
M;)/_ (JE_MX_] C4_P#OTO\ \50!YA)X>\;V'Q,O?%-EH%O-YJE4C:Z7805
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MI:O-$S0PI&2IX)  XJUYT7_/5/\ OH4 /HIGG1?\]4_[Z%'G1?\ /5/^^A0
M^BF>=%_SU3_OH4>=%_SU3_OH4 /HIGG1?\]4_P"^A1YT7_/5/^^A0 ^BF>=%
M_P ]4_[Z%*LB,<*RM]#F@!U%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110!!<65K=X%S;PS8Z>9&&Q^=0?
MV+I9ZZ;9G_M@O^%7J* ,\Z%I#==+LC_VP7_"D_L#1_\ H%67_?A?\*T:* ,W
M_A']&_Z!5E_WX7_"D_X1W13_ ,PFR_[\+_A6G10!F?\ ".:)_P! BQ_[\+_A
M2?\ "-Z)_P! BR_[\+_A6I10!E_\(WHG_0)LO^_"_P"%'_"-Z)_T"++_ +\+
M_A6I10!E?\(UH9&/[(LO^_"_X4G_  B^@GKI%E_WY6M:B@#';PKH##G1[/\
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,H **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g201805072101259112278.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g201805072101259112278.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +A :X# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^$=02 ZX)X/1QP* .UHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MID4RJKKD %A\^>M=!X>T6ZT2"2WFU!+F$X\J..SCMUCZYP$ !S_2@#:HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-^(/^1I\)_\ 7[/_ .DLM &OI4TT]H7F+L?,8*SQ&-BH/!*G&*NT44 %%%%
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MY9I=YDCSA,\CGH"22>,U=35-36X@2ZT<012R",R"Z5]I/3C'-._YF[_MQ_\
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M6+XBDUMO%/A]6MK2.(37!MY(9R\AD^RR\%60 #WR:[BN;\0?\C3X3_Z_9_\
MTEEH UM*6X6S(N#,6\QMIG(+[<\9QQ5ZBJ]W>Q6:H9 [,[;42-"[,<9X ]A0
M!8HK/^W7DF##I<H![S2*GZ D_I4%]J&IVD<;"TM"TCB-$^T'ECZDJ !@'UH
MUZHZ/_R";?Z'^9J"RO\ 4;NS2Y6UM2KCA?/((YP1]T@].N>:KZ5?W$6EP>;I
MMQMP?FB99!U/8'/Z4 ;M96K:A<6LL4,5J9EE5MQ ;(Z#L".Y/..E7[6ZBO(?
M-A)*@E2&4J5(Z@@\@TZ?_CWE_P!P_P J .0T.5X?AMX8:.:*-_LMMM\V0HC'
MR^,D=L\X[XQWJ%+73X[Z^62[MU9($:*\%RPDD;&6RP/*[ADKSUSCGF?0?,'P
MW\,M$64K9VYWK%YA3]UUV_I^-+%>ZA>SK#,[I=2(C +'-%'$,$N<9&X# '7)
M)[# H ;937B6,-@Z2+<7443&!WAW*229=J]@1TRN,^E:UKI,TCSVVH1)]G0*
M8I8#Y7FDA@Q8+@@[2 >QZCT'/Z+=K!<P7MO;&-IT1I(DNE</YIR!\_S[]V">
M< ?E70ZS=2RB2TAN(K61-N6GE\M9%<,!AAR#D'WXH UX($MH]B-(5_Z:.6/Y
MGFN+T"_UK2+>[MF\+:C<AKJ25989(54AL'&)'5LCITQQUKI=#\HVTSVTR26K
MRDP!93(%7 &,GISDX[9K3P* .0_M;6?[9^W_ /"(:KM^S^3L\^VSG=G/^MQB
MK"^+;O\ M.#3Y_#&J07$\3RQ*\D!W*A4-RLAQC>O7UKJ*YO4?^2AZ#_UX7O_
M *%;T )J=QJ.IVJVRZ)=Q9E1B[R18 !SV:NEHHH R[E1+JS"24K'%:LP '3<
M2"3^"U1TS1(;CP7'I4SRF&9&R^W8V&<L" >G7(JYJB)]MADVC>;>=2V.<8!Q
M5^Q_Y!]M_P!<E_D* ,W7H<VEN YAA5V$CK$7"(8W!X'0<]>U;-4]5_Y!%Y_U
MP?\ ]!-7.U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M5+4X9YK95@!+"12RB4QEE'4;ATJ[10!R^G#7;.XO(H[6WN!OCRTMZV0?*3(^
MX?Y\U1GO/$<>M74]OI=I-<*B(1N9S&N,X4_+P>OU[\5U%D'%_J.6!'G+@8Z?
MNTJOK=MLMYM2MY9(+N&$[9(R/F YVL""&&?4<<XQF@#FVO+^XAM8#-)$(YH'
M=EMY6_C8XQCG<?EZX^7Z59\^W;4;D7&J-!*DJD(T"1D'RFYPPSC;N&?6EN+2
M>UTN.]WPG?Y1Q)=R1*26R.>0OS,3TQ4>BW\UU<WLD4<6Y9$\T7-RQ)4)_ Q4
MAESR&''7O0!'X:ELI[RPFC+%VC 1@L:\B$?*P7D?*QYZ$@=,+7<5@:7<Z;JI
MM]0TK,:S?,\T5GA9P.,%V0$C/<8K?H **** "BBB@ KE?%B2RZWX:C@;;,US
M<A#NQAOLLV.>U=.LD;NZJZLR'# ')4^_I7/>(/\ D:?"?_7[/_Z2RT :^E1W
M$5H1<*Z,9&*H\OF%5SP-W>LV_M8YCJEPR,T\!'E,'(*?NU/'/'>M^L6\&;76
MP1GD?^BUH R[&"X?19]7TQ)&OC=7$D2NQ47$9F?:K ]MN,'J.,<<%=3L;;3+
M_1I[O?<J\TBW4\BE][&(XW#H!D<#H,"MNUUNRN;DVZF2-_,DB3S$*K(R,58*
M>A(*GCKCFFKKEA<7T%JGF2>>S)'*(R8V*C)PW0\#J.* ,RW@$^GW&IZ2C"ZB
MFD,*C*"8*<>60>-IQ@<<=15,01Z?X?L;J9I&O9MZ/-DD[VCDPH_NKNQ@< <=
MZZ)-6LQ=_93OB8R&)&="J.PZ@-TS[=^U9,6IVLOAZ2V599,PRQ^8(SY>X!R5
MW="1M/2@#2M+2"SU<+;IY:R6[.X#$@MN7GD]:75KZYMGCBAM6F613N8!OEY
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M7'_@1%_\567I=R=/\8W5C?O*&N8(X[&:8?\ 'PL9D9AN[LHD'7D@$\X)KK*
M.?:YN[W4H8KK3Y+%?(FP\DB."<*,?*3CKGGTK3TB8SZ1:R';_JP,J<@XXR/8
MXS4&J FZ@ !),,X '?Y15K39$ETRU>-@RF)<$?2@"+6G*:1.,HOF 1%G.%4,
M0N3[#.?PJ_5'6'6/1[LN< Q,H]R1@#\20*O=J "BBB@ HHHH **** "BBB@
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M1@A W.HZE/TK<UOQ(^A:_P"4-)O[T3V\?SVT194P9/O$#C-,N_&=Q:06\O\
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M2F2O*E2"/8\U44W%M?7;"SEE25U961DQ]T#NP/44 :-%4_MEQ_T#;G_ON/\
M^+H^V7'_ $#;G_ON/_XN@"Y45QY_V:7[,(S/L/EB3.W=CC..<9J#[9<?] VY
M_P"^X_\ XNC[9<?] VY_[[C_ /BZ .;\+2ZU)K,HU5;G"VWWKF-$;S=PWJFW
M@QCC!^O)K?U"YOX+JW2UM_-C<_.=I./F4=<C'!8YYZ4L/GS:H)WM9(8UA*9=
ME.26!_A)]*T* *>JA/[)NV:..39"SA9%#+D D9!KF/!?AY;/PQ87]C>317NH
M6\5U=RR@2B>1D!RP/( S@!2   *Z?5O^0-??]>\G_H)JEX0_Y$K0?^P=;_\
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MW6NALO\ CPM\<_NE_D*Q]9_Y&"P_Z\;S_P!I5L6/_(/MO^N2_P A0!/1110
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M9>YTB]/_ )$MZZVT_P"/*#_KFO\ *@;L34444""BBB@ HHHH **** "BBB@
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M?7%K+86\IM9_*>6*0J&Y7G8023\XXS70;>O&?[QV_=YKB]/%R=3U;RS$(#=
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M]O#:Q>5!&L:9)PH[GK4M5;"[>\@9Y(EC=)&C95?<,@XZX%6J "BBB@ HHHH
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M?0X(P>F/Q/ ZUL_LY1(N8VN(%0$#G,Z#FO0)HX-,LKJYMK6%'6,L0J!=V 2
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MTU86$@E*JZQS7*KF*&1ON(Q[$_ID9ZT ;=<7XLTBXB2:^BO;S[-)/%)<0"5
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M:-% !TKF?&<=RVE[T<BV5X_-0, 2?-3'8Y'7C(KIJQ/%O_(M7/\ OQ?^C5H
M?JZN]W:Q0S/'/*DJ*R(&VK@9/)'(P,8SUK)CTP7XN=1DNKB"Z\QEFAVQ#+%
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MKLVL%\LD[05) 90?+;(XY .]'2EI!TI: "BBB@ HHHH **** "BBB@ HHHH
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MW)7'XF-NNY#FK/AOPYJ&M:5'K&KZ]JR/?(DT-K9WTD<<$14%1P<LQ'+'IDX
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M</L VM;2J\5[&O*%XSN"EA\WR_=.#[9H ?HWABUO[;S8]8\2PJ@"F%M7=\9
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M;"WFM(8E5E="L:JT+#D$<<>6!CTP?6@!UO=V-TBLT=_/&KGBW3=%* Y(R1U
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M.2O0^O6NWKEM+%C;>(+J&/P_%;W"RL!=0"+!1AD$@-N7//&WDC-=30 4444
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MKC=,E2'Q;>60?4(I&N7F,*RPM P*CYRO^L7/\^>AKLJ "BBB@ HHHH ****
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MXMD<E1C<0>3G@8H Z/AARW!SEL[N">3[_-\G^T.!TH/.2Y\O.2Q!^[GA^?\
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MV\VSC46RN9[>#RYF21FB&P!-K!3C8P)R#U.#ZU%).1;6ROYJRM&6LEEG#1H
MK?Q%1AT.<[L[ W<= #3CUFZFW>3H]RQ1F7(N+<;2O?B3@ ?+[9R.31/K%Y @
M9]'FMD+J@DFN(@D62-I;#' 3//'&<]:;I9W7;3AHQ'+&[F!'3Y%$F% "]#D%
MB<X7WJ_JH']D7RRKYG^CRAP!G=\I+C'^UP0/;=[4 .LKH7MJ)E0)ER@56#@8
M8@8/?!&_GJ#DX-5%&?%3-G<#8#]V#G.93QSUR?GYZ]^*LZ:N-*LUP#^X0$!>
M&^0%L#ON7@#^(C/%9UTEW+XI LYX8YOL8+22QF4,"YQC!&?E^7/\1X]Z -L\
M#+#S!@DX/W^<'_OL\CUQCI4,.?\ A*M-S*&_=3@_[1 3+_CT]MN!Q5%;?7?E
M*:E8H3M*DVK?*3D*<[^PRI/?.WWIVEQWB>*]-^US0R V\WEB*$IM7Y<*<L<D
M<\=LXH [>JU_+Y&G74V =D3-@G&< ]ZLTC ,C*0"",$$=: ,OPX'CT6*!S&6
M@9HBT;;E;!/(-5UMX;SQ)JUO<Q++#):6ZO&XR&&9."*KVMK!%X@AMQIT6FQ0
M;G@$:@?:3@@D;>  "3M/)X/:KMI_R-FI_P#7K;_SDH =_P (OH0_YA-I_P!^
MQ1_PC.A_] JU_P"_8K6HH R?^$9T/_H%6O\ W[%)_P (OH7_ $";3G_ID*UZ
M* ,;0E6.\UE$&%6\ 4#L/*CJGXLTPW7V.]2\-O<6S_Z/MM_.8R-C&U<CGCOQ
MC.>,U=T7_D(:W_U^_P#M*.J'B\SO)HUI XC>YO?+$FYU*?NW.0493V(Z]Z (
M]&M_%-Q'=B_UJ%'BN"D>VS3)3:I&[#8SDGH?2M$Z=KF#C7DS_P!>2_XUF:<M
MSX8748+W4OMK2D7%NK;B^]LJ(QN8LP)08],GM4>KZEXETJTN9S<:;*MM"DDG
M[AU/S$C &XYZ>M &YK>E3ZOIAL5O3;I(NV5A$&+#VYXYK(T_P4MA T?]H-*6
M<L6>(9S@>_M74P,7@C=NK*"<?2GT 5=.LET[3XK1&+K&#\Q&,Y)/]:ATK3FT
MV%XVG,VY@V2",< =R>N,_C6A29H KZA&9M.N(P6!:-@-J[CT[#O7+?;]/U*7
M&M7$:P(Q?RKJ PLC' 'WFRN,9!QQSS782)YD;)N9=PQN4X(^E83>$--D1EED
MNY6=2CR23EI&4@@@O][!!/&: *K6MS>:0MMHE_#:PVTB;+@2,S2*%^8.,#!Y
M!ZG(YJ+0K+6);>XECUQ"CSDB46^\2X51N!8YQQCTXSWJYJ5A#;_V=!*&NUN-
M07S#<$-G]VP'  !^Z.U="JA5"J  !@ #I0!YWXCMM1@\1Z:;J_BN5;:,O;E0
M/F/ VG&[@X)XX->BUS'B(.=0AVHK >7N)ZJ/WG(]ZZ>@ HHHH 0]*YG2[;Q%
M'!!]N6QNHI92\\,D8BDA._(*E<J^.#R ??-=,>E<<^N73.ES/8:G;PWEU!%;
M^7+N4$2[2' 7,>1R<Y! QN!H [$=*CNCBTF/F+'B-OG89"\=2/2I!TID[1I;
MR--CRE0E\C(VXYH X#0YM4A\06-G<ZW'.-JDQK<%TV^66(Y0!F8D..<JO&,#
MGT.N%A@T:UUBU326FFD:9'CCNI9OLZDP_*$."!)Y6, _PUW5 !1110 4444
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M3Y\$?Q#"C<O."0,CI6N1J-K=W>D6FAP7+--)<QEYA'L0@!=FW[I"]<'@_=H
M[)L?-YN3]_S,=QTDQ]3C'MP,&JDER]KXETUY$>4E9U*1+N9I=J9Q[8QR2 ,$
M'FJEKJ.J);P(^C74EPJH-_F1 ,X7Y#C=T(W9'T/!K%N];O+B^L;G3]'U#S(2
MT2+YB+O4L H+%@!DJW.><#(/- 'I$.I))=BVD@G@E9=R"51AP.N""1D>G6I-
M0G:VTZZG7&Z*)G&>F0":X30?$NMVUNS7?A;479TC^2*^@F4$$J6W-(#ECV[8
MK0O/%]U)!]FN/#>HVJW3?9EFEF@**S-Y8SM<G&X@<"@#5T*T^T6D,]S>R7DU
MO*X6996V.1E=P&<="14]I_R-FI_]>MO_ #DJWI/_ "#U_P"NDG_H;54M/^1L
MU/\ Z];?^<E &Q1110 4444 8^B_\A#6_P#K]_\ :4=8GCM)!<:++#(L<OVH
MJKM&',9",^Y<]#\F/H36WHO_ "$-;_Z_?_:4=8WCZ1(1HTLC!8TNW9F/11Y,
MG)]J +UMIVJ7,LD[:T1+%(T2O]CBW8!]<4R^\*W6I)(MWK<SK(@1P(54, <C
M('!P2:73O%.@(MQNUBR&;AV'[X=">#4.I^+=):>WAAUA%MV#--);,&;C&$S_
M  YR3G_9[9H UO#EQ-=:!:S7#[Y2I5FP!G#$=!["M6L[0GL9-%MGTS/V)ES$
M6SDC)YYYZYK1H YNU&M:G->R1:PEM%%=20I&+17P%.!R3S3[?0=4LT*6NN>6
MAP6!M%;)  )Y/?&?K5CP]]S4O^PA/_Z%6S0!BRR:AI2P3WEZ+FV5BL[+;A2H
M(.&.#T!QGCH<]JY[1_&-Q-XDU*&]NH'L(WG6W2*/YFV.JJ%()WDACP!7=UAZ
M5%&OB'6BL: B2+&%'&8QF@"*;2=6U*WLI9]36VFA<3[%ME;:^",')YP&(J;^
MS==_Z&%?_ %/\:VZ* /.?$5I?V_B+3&O-02YW%5#/:[0/F)VC:>&.#@G@8->
MC5RWB2>*+4(ED;:66/!P<=7ZGH/QKIT=9$#HP93R"IR#0 ZBBB@!#TKSJ,6U
MIJ<&-7TM[HWR![U-0>2YE!D \ORAQSPA&=H&3CCCT4]*Y2PU70]1OH+> P6\
M$A>5;6YMS$\TOF*RR1E@ PR&/RYY(- '5CI2.BR1LC@,K A@>XIU17._[+-Y
M3JDFQMK-T!QP30!EV6GZ#IRI:V:6<6RY^6-6&1-LZ=<[MG;KCVK9K@M#U&[U
M'4;.XGOHUDDF \@(?)F00X9T<Q@-(7!(*G[OM7>T %%%% !1110 4444 %%%
M% !1110 4444 %9FNR&.QC;S#&/M$67$9<CY@1QWYP/QK3JGJ7_'O%_U\0_^
MC%H X+0-/FE\/:?*NM7ZHT"D!9$  '3G;D8?Y?\ 9''>H-5L-1%T+3_A(YK2
MUFA9"]S"K!CD[UR-H4J<87T)()Y%;'AUC_PCFG$G!\A3C>."!C&>GRCYQ_=[
M\FK&J!3I%XI52/(?Y2."0IVC!]1\_/0C)H P[Y/[.U",*RM(;=866&X/G( !
MOVQ#@*  W!&<[N:DO(T2*0QQ3",QR&Y:2V3" H<A> 2<;2!T;))QBHA _P!D
M4Q6\LMT;:$6FRU5DE(0%0Y()^9LY#$8 !'%6[A _ERVVE3>?$,^68D5)=V1E
MG!^8$EEV@_-@$<"@"+0+5;2_:.,!QMD:%_(51-ND^;D,<CT! W8QVK9O9I[>
MT$EHGG.&CVY4OD;MJL0.3D%L_3;TK-T:T-K.Q^R+;)/&SR 0*OEL7Z;E^]_=
M]^V.:V^O+'R\Y)Q_!GAN?]C@9]\=: *]C+)):(\N0P.%)4Q[@K$(V#RN3P?[
MHXZ'-5!QXG<$;8Q8<M]T@"4D_3#<?[(]:T\GJ1L/< XV<8/TV#YAZ9P>:S%X
M\5L1]X6*XCZ#B0X'/3CY^?NGK0!IMCYA(=G#!\#[HZO@?[)Q@=L[N:Y;5)F>
M=TNE>*V6ZV&&1U>)F)!9F Y"+PP Y8X)(Y%=2.,;5\S'W01]_'W1_P #Y;'J
M,GBN;DMY[J5DMVEDN%NL2OYH$;0[L]4Y!<#&,;BPSTS0!J:7,LLUS&B6C,CK
M\UJ,K(64\>_RC/7YCZ8Q4'B%YX["UDM(Q-,MY;-&"-V?FPA_X$,G/<C;Q52X
M2\MM1D NY)2Y@2 X4F7F3AB2 <G*L1]X 8YS5F_G2YT[2;@R%1)?6LA;'()D
M&>G'RGY,],' YH W-#UJT%C<1R7!Q;7?D&26/R]Q=@5P#ZE\?4&HI9KT^([U
M]-:W$C-%:N+E&(!$;R9&T^C8H&GZ9#IL^IW=JTY=V\Q6<[?O%-VTG:,+U/89
MJ:QT^X@U,R+:2QPM,LK/+<"1N(F3U)[K0!-M\4?\]='_ ._<O_Q5&WQ1_P ]
M='_[]R__ !5;=% '.S7VO:?=6/VW^S9(+BY6!O)616&0>1DD=J;=>*0ECJTU
MLD;26O-OO;Y9UX&\8ZJ'W*<?W?<5NW5E:WT:QW=O'.BL&"R*& (Z&F7&G65U
M"D5Q:0RQQ_<1T!"_3TH RM %U'>WPNFA:2=S,WE*0%8$QD#)/'[L'\35#QK9
MBYFTLF0IB8\A1GY1OX/;.W!]C5]'NM,FN;J:T+0(CDR"9!QYCOGD^AJIXID:
M>'2I$7RWD9V59/X28FP#CT[XH T]$_Y:?]<H/_18J35-/>YGM[F*."5X0RF*
M<?*ZMC.#@[2"!@X/<=^,;2$U_P#>>5/IO^KASNBDZ;!C^+TK4V>)/^>^D_\
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MVPODTB28&)B^YE(!*D#?C/;E<$CMFMG2?^/^3_<?_P!'252\7["VFH^W#2R
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MM#)-'&9!<+#RPRHWLJ_Q84# ]SU:@#$FT][[59+A[+[9!'"G-Y']G<E6?A&
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M5TG_ (_Y/]Q__1TE4_%KJLNE@LH)F? )Z_NVH ATB[UI?,\O2;=_W</6\Q_
M,?PU+?\ B/6K">*$^&Y+B256<"VN0^ I .<J,?>%:&A_\M/^N4'_ *+%7;RQ
MBO1&79TDB;='+&VUD/3@_P P>#0!F: +B#PS%;F-4OTB9C;NP)1B20&P>.HK
M"TU_%JZZKZA;Z<]R]LP"AO+^4,O4J6)P3QGU:JNGP:M_PCU_JHM5DU%KB6Y@
MNA*B$H %PW'<)R,$=*[#0[6--/ANR7DN+F&-Y9I&+,QQGOT')P!P* ,K5IM>
M\N+S+/3QS)C;<N?^63Y_@],U+X)A:+0CYFT2><Z,% P-GR#H!GA1SWK0UO\
MU4/UD_\ 13U5\(NKZ-)M96Q=3=#G^,T 3ZWI":CY,R2I!>1';%.Z!PJM@.-I
MX.5R.0:R]%\.:9<P3W)N6O%EE.&B?R0N %(VQ$+U&>F>:Z'4+%-1M&@:62(Y
MRLD1 9#ZC((_,5#I&DQZ1;-"D\LY8@L\H4$X 4<* .@':@"O_P (OI/_ #QG
M_P# J7_XJC_A%])_YXS_ /@5+_\ %5L44 >>>(M&AL/$6FR6F](SM5PQ$I)+
M$@9D)*\*W*\UZ'7*^)9 FI6ZF:*,L8QM<\OS)PO/7IZUU5 !1110 5YUJ]S
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M&9]MX -Q4-P-O3)J]J.#IEZ'^3_1Y0P ^[\I+<?[)Q@=L[JU?"/_ ")>A?\
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M ZM8@B)00;A/0>]3GQ#HH!)U:QP/^GA?\: )M-MI+:S F?=-(QDD.T ;CR0
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MV<G\%!H I?\ "):;_M_]\I_\31_PB6F_[?\ WRG_ ,34O_"3Z9ZW?_@%-_\
M$T?\)/IGK=_^ 4W_ ,30!%_PB6F_[?\ WRG_ ,31_P (EIO^W_WRG_Q-/?Q3
MI:(SLUT%49)-G-P/^^:IZYX@LY%M=-L[]UU"\GB$20@AR@D7S".. $W<^F:
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MK52+:$$6<V#L']PU9&M::R[EO(BOJ&XK/\0:OIY\.ZG&+N+>]G-M7/)^0]*
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M'C/.1WXK"'A2?[$(OMTJ2;OF03.8F4D$@("-O3C'3WH Z*REFFL8)9X_+F9
M73!&#]#R*GIJ*$14&<*,#)R?SIU %:XL+.[#?:+6&7<NTET!)'I62OA.T:_-
MU<W%U<,L*P1AI2I1%8L!N7!8Y/4\_K6_10!P7B70M/TFS3['%*,QM''&;V7J
M70\+NR>,_3BM73_#&D7UC'/-'-)N,GED7TK (Q(QD-Z<5;\0QL3"\4QBEP5#
M<8QN5C_"?[H]*H173VDD<UK.)1(0[I@N9&9I>!M&.I)/ QLYH AETG2(I[Z9
MK34YK="(9I!>/MC '( WAB!G)^IQFM?_ (1/1]P8P3E@NP$W4I(&<X^]ZUFS
MQ7-YY^HPZ;;W62K(OE8,BE1M=23AB#V8 ^F,#/6#I0!D?\(OI?S?)=?-][_3
M)N>W]Z@>%]*#%A'< D*IVW<HX P.C=AQ6Q10!C)X5TB.+RA#.8S'Y15KJ5@4
MX^7ENG _*LV+2;NTO=4L;"U,5E>>7LE,OR1C:1(0,[MW3 X['-=710!C#PKH
MPC:,6>V-]N]!*X5MIRN1GG!-'_"*:'_SX)_WVW^-;-% &9#H&G6T7E0QRQPE
MMYB6=]A.<],XK3HHH **** "O.[R^\1:=XRAT]]>GDBFNH6AC>.T6-H21YBN
M>) ?O!< YP.N3CT2O.=2^SP?$.2X5YPOVFV2X806K*LC!511O_?8(VY*\#)Q
MT. #T8=*#TI!TH(RI'J* /-;&_CE^)CRK_8LQNI3%#=Q26[/L1&WQC:?-+_<
MSD8&T\XQ7I=>:^&$\+6GB.)=*\47=Y>J?L1M=D)^6,, K;8@P5>><C)QDFO2
MJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *QO$*3O;VYMK:ZFG67Y&MI41HLJ<L2_&,<=#U%;-9^J0:A<+"EA=);$,3([
MQ"0$8.%(.."<="#[T 1>'TG332+B"6&4R,Q\V59&?/\ $67Y>?:M6JFFI=1V
M,<=Y';I*@VXMR=F!TQGD<=N<>IJW0 4444 %%%% !1110 4444 9>I7%PMW%
M;6KLLC12284KSMQ@?,#R21].]<T)_+GMI8(U,C*\;//(Y^<F7?)O3Y3@@@84
M'Y\?+6[XD\GR(1,B298[(OE+NW8*I1B3],>_%2VNI0V-C!%>H\$ZQ;VA5?,,
M:\XR8UV@<>@'% $EK?6UMIVU3E;:,C"KC<$ R0,].1U-:=<E?1I=ZMBUB0*Q
M5Y+F6RWQE3@X0@?.2,<YP/?&*ZP=* %HHHH **** "BBB@ HHHH **** "N%
MU*;?XZ$2_P!D--"T,@NIHS]HM(RRJT:G80=Y8 ?."/,Z=,]U7FTVGZKJ7C:+
M4I=!$4=C,JS.V_%VS2A49 'VXCC".78') &!C@ ]('2E/2D'2FRH)(G0YPRD
M'!Q^M ' V-Y)+X_E@;Q%(GDW3I'IOV=T#@JS,6.-K_P[6SP%/<FO0:X+P\+V
M37H)+W0_$%HWE(-\EZS6ZR!"'RGG$;>!M^4\G)]:[V@ HHHH **** "BBB@
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M?(/IT''-6+0-]KC"CC)!R!G:&^;CID/Q[#IWH WJ*** "BBB@ HHHH ****
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(H **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g201805072101260422286.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g201805072101260422286.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,- ;L# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@"&[NH+&SGN[F01V\$;2RN1PJJ,D_D*@LM6L=1D>*UG$DB11S.F""J2
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M.+RDG1'94D5/X0R@-CWK?H **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[IMU:)*T+3Q-&)4 RA8$;AGN,YK@;#PUXRM;^X62+PQ-;"&&.$S6SD$J&#,
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MWKR=9/#0\5:G;2R>+1-91QQBZBFOY)'#%LJ=HR%!4$'H<DB@#T;PW:BST.&
M:6^F!2W^BR3B8IEC_$"<YZ]>]:U87A!Y)/#L3O;WT*F67RQ?3223-'O;:S&3
MYAN7!P>F<5NT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!'/+Y-O)+Y;R;$+;(URS8'0#N:YD>
M-(PQ8>&/$88]3_9QR?UKJJ\X\7>'+O6]>O;@*]\MHMG)!:17AC.T2,9H]H8
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M_'%;5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 (0""#T-5]/L+;2].M["SC\JUMXQ%$F2=J@8
M R>:LT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-'L+K@<X]B2,C@XS5N2>&$@2RHA;IN8#-9/AS!M;AA$D&Z8_Z.@8"+Y5&/F
M//WN@^]6!\0X5FET6&6'S(+B\6&09'W=P8C\0I_'% '8'4;$'!O+<$=O-7_&
MC^TK'_G]M_\ OZO^-<JOPM\*#.[2K5R23NDMHG8Y/<E,FE_X5=X2_P"@/8_^
M <'_ ,10!U8O;1AD74)'M(*/MEK_ ,_,/_?8KA(O /A^'Q&FGI8PBW%FTP'D
M1\,9!_L]*U9/AOX<DC9#91@,,96&,'_T&@#IOMEK_P _,/\ W\%(U]:+]ZZ@
M'UD%<RGPX\.J7/V.,[FW',,9[ <?+[5R/C?PY9Z'=Z/;:3:VJ2:E.;5_.MT,
M1!*X#@ $C)Z<T >H_P!J:?\ \_UK_P!_E_QI?[3L ,F^ML?]=5_QKRS_ (1F
M$W8LA!H?]L;?^/(^'X-P7^]NW8V?[7Z9XK0\->'+;4[F2PU:"PE&GHZQQQ6,
M/DHS2OO**R' )44 >A?VKIPZW]K_ -_E_P :DCO;2;_574+]_ED!KA9-%T.U
MU/4+6VT>WAFLK9)Q<C3K;:V[/RC$6<@=?J*9IMA87FCQ7>+N60W$T-O;Q0)#
MN8MDX!08'RYR>  : /0?.B_YZ)_WT*B-_9J2&NX 1U!D%<U8^#%S.U],WS/F
M)(G#!%P."2HR<Y[4V713ICQZ;81&YAFW32>>Z#ROWBDL/ER>IXH ZR.6.9-\
M4B2+TRK9%/JE87<5S&I@M9H8F4.K-&%# ^E7: "BBB@ HHHH **** "BBB@
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M]+GM)I(IAJ42J\2*[C(8':K @G!/4=,GM7+PZ9K*ZK+=2>*[^2YF"6YEC@A
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MI7_('LO^O>/_ -!%6ZK:<CQ:7:1R*5=(45E/4$*,BK- !1110 4444 %%%%
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M'AN]1G,B@$7=[+.!CT#DX_"@#5JIJG_((O?^N#_^@FK=5-5_Y!%[_P!<'_\
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MX$2G "A5_>?],^ :T-*N/MFE6=PZK^]ACR%&Y2%.Z/Y>I$K9!3JV-_2F9EI
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M\.6-Q:R7<MO+$&C>\;=,P/0L?6@#)\=6,EY9:>7M)K[3X;L27UC V'N(]C
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M26995W2)Y:RKM(3! X_.@#;HHHH **** "BBB@ HHHH ***.U 'G/BB2"_\
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M6<-5N+;16M6TR[M]1@@4F,08"2K&0B,<_=V R _\LB.<UTAPI;?&TFTOOCV
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MUUSS9;Z*VF\E8S$\(>6X1F^["=P(.1SP><&NSH **** "BBB@ HHHH ****
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M0.V.U:XT?3!@_P!G6@/_ %P7_"J?A;_D7X/]Y_\ T(T +_PB7AO_ *%[2?\
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M#NT&%CCEG/  _B/IQ4_]A:=_SP;_ +^O_C5RWMHK2$0PIM0$G&2>2<GD^YH
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M )**** "BBB@ HHHH **** "JFJ?\@B]_P"N#_\ H)JW535/^01>_P#7!_\
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MI]QP!U_Y9]JR[JQFN[B?SIC';W#;YXE;#;L!9%W] J*/O8XR5J^Q=U9=FXD
M"/& Q PB;>P<9;;_  GYC0!+_P +(\+?\_MSUQSI]QZ9_P">?IS6/X<^(?AF
MUT"VBDO9RP9@=EC.P^:1L<A,=ZE>P9[-K0ZI>?9FA,'F H6\H_QYV\DM\F?^
M6G:H-,T--*@C@BN+K9',TY1Y4'[PC$F6"C[@^;=T7[M #]0\?Z!-J^EW44EZ
M\=L9VE_T"92!MV_Q*.YIMSXPLM9UIK73I+I#*L,?[ZW:-2P9FQ\RY/!S@$<
M\UJ!W!&T;F&W:F,!BO\ JUV^CCYMO\)^8UD7<2RZW!N#2HJHJ,7)$B$R%F..
M&^;Y<G[W4=* .S^T2WGAZXF,<<LK0R#8JEE<C<,8ZD''2N<>&&=ED33YKFQN
M'9"L22+(4" --DL".3M ZD=,UVJ1I$@2-%1 ,!5& *=B@#D8?MVG[;;04DN5
MF?<1>6[1)" A'+A1S\JC&">N:ZFV26.!5GF\V0#E]@7/X5+10 4444 %%%%
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MB@ KG_$,_EWVEGRW813>=(5Q\J A23D^K#I705@^((HI+_1C)&CD78P64'%
M&]VKA?#>LVNE-K4%VLRM)K5T5/EY!#.0#GT)!'UXKNNU>:Z?'&^J:S]MC1T%
MS<8PH)%OYTGF8S_%NQG_ &>G- &9)?M<:GIT*Z)$(Y0[FUDU&?8PPRX *[%"
MX)8#H%K2T+7;74XEC6(P7'SY@"$A]GWV7Y0K>:N,+T(&[K4=YIPAU%7N4BFC
MDN%0I$?+,,[ C.,X93&Y Z8S\P/-:MQ:QW$$(@?R3"$:V?;D(O2#([KG(8=<
M].* *K^(-,2>6$:@OFQ/Y;.BNX1_X6W <A/N9ZL?E/%*NO:;)N*&3RT1I'0Q
M.HCC! *L<?*%8AR1]SM5/2+>2TUW55O9Q*9(S+(8U*D1M(YF7J1D,1SG!7IS
M6U/;)=NHN88IKA7P-RA@)L \9XQY8&W/&1\W- $!U6P#$-?PNP)!(P2Q'WSC
MIF0<!>C ;NM56U=7G=8+^PC0% LLDC'DC*ONXX3[F[J3\IP*NBSL-H,=K;^7
MM4INB&-A/[G/&<;L[N^>GRU5DTN(3SR+Y"Q2 ET>V5F4* )\$$#=D#VQ]WF@
M"+^UAMS]JTT+MSY1W#"YP8^O&#\Y_N=LTIU1@2#J.FNP)!8*3N8#DXS@^8.
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MUXS2!I-Y1S%EDW=]K97/^S6IPGH=97B3_D7KSG'R?U%:M97B3_D7;W_<_J*
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MB@ HHHH **** "BBB@ HHHH *J:I_P @B]XS^X?_ -!-6ZJ:I_R";W_K@_\
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M#PK;74OA^V:.[1%,:84PAOX%[YYK9^QWW_/]'_X##_&@&[NYPK:AX?DD:/\
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MW+IPI7K(&^6/W!&6_P!DC=7H_:O*M*757OM>%C-8PQ_VW<(&G#EE<MQ(<'
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M.T&>\@T66Y6]E"9M(</EL':6+*=HZY).,4 =3#"EO!'#&"$C4*H)S@ 8%8#
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M=WINI6NJVIN;.3S(0Y0-M(R1P>M>;Z7JMA9WVNP3WL5K,=:N0-Y.0Q;*R^P
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M_LG3Y/*'G^1#)Y.[ \T1A1%GL!'^\'_/(\G.:K:Q-#!:00QR12KYT"CS ,M
ML@:.39U(D?Y67^/[_ H U%W?((-F[]R(>#LS_P N?'78!G(^]NY;Y:S6\O\
MMYB?,_L[^SI?,#D%C#YP\WIW\W[_ *C[E:&Z.9=YFQ'('+2K(&VK)_KW#C@F
M(X42=&!V#GFLYY/)\5+/(D<5R+,%+<IY2O('"HG/^Q\X_P">1ZYH UC]I^T'
MS"?M?G-O*E<_: G[\CMGR<;"?E X;YJSO!M]8Z;=3W4]]:V]G_:$J1(V5*Q^
M7F,\G(!!QR,Y'6KH2(((UDWPA5C60QD[XP=T;E>_FO\ *4ZR8W# J[\.P3=Z
MZ[ILD>\9Y%\S?M8G+#=WP<C/M0!T/_"8>'?^@S9_]_15+P$ZRZ#=RQG=')JE
M\Z-CAE-Q(01[$<UU%% !1110 4'D8HKD#<:S<:?JFH1ZP85MKFXCCA%M&P 1
MRHY(SVH TH_!^BQ1K'%%=1QH-JHE].%4=@ 'X%87B7P]I.GM97JR-%)"[%#-
MJC1N21_ TI*_4<'ISQ@[GAJ[O;D7L=[=?:&A>,*_EJG#1J^,#W:G^(-2TK3A
M =0\GSB':V\S;DN!C"[B.3NQ^= $GANZ-YHZS&XCG)=EWI(LG0XP74 ,1W(K
MCM$V^;KOG@^7_:UZ3MQGR-P\S'OG;GVZ<UV^B7$5UIHDCA$3[BLR?+Q(.&^Z
M2.OH:X?0I%CN==VE'?\ MRY<(V.9 WRQ^X(RW^R1NH VU\SSU#8^T>8,XQCS
MMO./;RONYX'\7-8'@?\ Y%#2L_>\L??Y&/-;R,X[;L[L<YQVJS?ZA%;SV]LE
M];PPO&Q:ZE(;$2D$,%S\S.YVG^^!FIM%M;6PTBSM[!LVL:,8W$@;[W^L.\<'
MR\\..!G;0!F>$HHSX9A:[B0YFO#(0HW&/SW\[_@6<>VW[O-7M9LH)=+O#+;6
M[7"Q. ?+&!-LSQ[>6!M]"/FYJGI<MGH_D:?8745W$9V*PLZEXWW,40CKL8EC
MM/,9P3Q5S6;JTBT>[B:[B"O:R(CF099,$[_<E\(?[_&* )K&&U.F6FR&'RS;
M1;,Q\;"!Y.>^-^=P^]GVK)\:Q6P\)7Q>%-H9"Q9!G;YR>?T_BW8Y'&WIS6U9
MS*;&V+NB.8@6'G#*LR 2?-ZQCHW;.VL;4+BUU<SV-S>P6]JDL:"%7"23O&P\
MM>?N([8.T<@@MG!Q0!H^)-W]BZAN_P!;QG;_ ,]>-N/;R_N^ASNJT(+/RU\N
M"'R=B[-T?'ED_NL]\;_O=R>G%1:K#9W.E74-_*RV+Q,LLP8Y$1.XR9'.2_RG
M'^LQQ532=8BO9I(UNFFVKYOF2*8F!;*NI8J!F,#(8?=!VD9Y(!I&&VY,D";?
MG+_(N['_ "W]MV<<]-O YKG]4L+=_$NGSFWC$\4\"R.GR@$K*4 '==JJ0.O'
M/-=$)4&-K1,1LVID ,5_U:[>P<?-M_A/S5@:G/'_ &_I\:,) DD<BL)%8R)^
M]W-URQ#,!D#YNHH ]2HJ*WN(KJ%9H6W1MT."/T/-2T %%%% !1110 4444 %
M%%':@#E-<\V37HX3>ZK;0JBR*MM:RO')(<A<NG "\DJ>#\I/ Q75UR<NJZC9
M:DW_ !.-)GCDN2GV&YE6*6-<D (RDY..<,,^XKK* "BBB@ HHHH **** "BB
MB@ JIJG_ ""+W_K@_P#Z":MU4U3_ )!%[_UP?_T$T >&V%T-$O=8MC(TK&X=
MS+;R?(S [48$@D;&7.X<\XZ5IGQ#%YAW0W3)O;='A1N3;^\3&W WM\VWHO4<
MU7\)0[O[59FE6-;]VBV;,[1&/.QQP^SH3QCCAJZ%;,_*D,I\W]TD6 -OF?>M
M>HSM"9P#R&Y<8YK-QDWHSLIU<.HI2A=^O_ ,W3M5;4+V*V$MPDSA<3':<R@$
M[P"/F+(/+ /^L/WJT[5BUMG+*O5?,.-B,Y6,%@ =L+<E^JD[>G---O:F,MYL
MHM#&[<]?L[-@YP,Y\[E\<G^#(XJ=(VB)60N9A)(96R-QEV_Z4<_=W%,;3]W'
M!PU.*:W,ZTZ<OX:L9E_=P:?KL,]].L=O]EE5H)55"Y5U\Q-O0-*2'V=% W#F
MM*WF6[C5K:\2;+B,7,>'!DQD2C^]E08ES_K"/FZ54N=5AL;I+=0S731)-$L,
M+NOR_P#'L<8SL"DX!^;=][(I!J5D\&X079LVC;[T#9-L6R<X[F;[^.O1*KF5
M[$>QJ<O-;0RM7U*TU".)=.N;1?)Q<$FZ*B%-P$<>0"?W9R2W5"=HXKHIAOBE
M#0NV5DW1-& S;1^]C*]-TN0Y3HH&X9-9_P#PD%N;I4F%VETTN&+0%3Y[?)/@
MD;0VS 7L!UYYK20-\@@\L/\ N1%P=F[_ )<^#SL SP?F#<M\M"DGL*I2J4[<
MZM<PX)O$%G96UG#I"7$\4$<(NA>QA6FVC9* 1R"@V*>DG1NE4=;\/S:AI-F+
M:&)90K2S&1_NK(-NTL1RL3\L>-F0H&VNEE:$V<C(-UMY,APQR3!N_> X_B\_
M[^.H^YWIMJ]^UW=17A!O(KAMS1!5S*8P9R.2-WE<(3A<#D!J+ZB4&XN78I7$
M5UIESYNGZ9]M67*W-N'2#+1X\T[#\NZ8?,8P,84..:K0VFHZAK5M<WEG! 1&
M8'D-VMQAVRT<G3##;A!G_6'[U7[6[D:]BABDA/G!6M%\ME"[& M,Y))49)Z!
M@W+?+3;RXV%PDJK8[55TFC+.8'EQ-RIZF7[WJ/N''%+F12HMR4;[_P##%<W>
MJVKNL.BI<6>3)$3?+%Y<#<)$<C(\F3)+=4X XK=^'\MU!>7R77E>;/>R1R*6
M D#JH9FVCC!)/2H;A-0>XC"2,EW]I;SF3;GSO+/GXSQGRMNP] .&^:I/A;]G
MD34I;?#1^=B*0IM8H.%]QP!Q3OK8AQ]WF.K\7#/AR926"O- C;6*DJ9D!&1S
MR"17':AX8N[+1=7E;3(1LCFDBE-Y(&0!21CYSP.V<'V%=CXM_P"1>D_Z^+?_
M -'I6TRJZ,CJ&5A@@C((IDE?3W$FFVKA]^Z%#NSG/ YJS6 /!ND0LS6"7&FL
MQS_H%P\*_P#?"G;^E/\ ^$<DVE1K^L '_INI(_';0!N5PUE_:]YIFK6]A;VT
MMK+J%TOF>9EL&4[B!D D<XY%;3^$--N%*W\U]J"D_=N[N1D^FP$*?RK9M;2V
ML;9+:TMXK>!!A8XD"*OT XH P_"Z2QSZI'.JK,DL*N%.0"((P<5I:GHMCJ^P
M7L7FHHP8S]UAD'!'?E1571O^0QKW_7TG_HI*VJ (H+>&UA6&")(HE&%1%"J!
M[ =*\QTK2K"_O=>DGM+=ICK-S%YLJY()8;9#Z 8*CU)P>*]3KS?1-OFZ[Y^[
MR_[6O<[?^>&X>9CWSMS[=.: *6J^'M+>:"X.F.MF$9I(;0F-D&0 "%Y(4@EL
M9*9&T$$UL:/]B_LFU_LV?[19A2L4BG?YFW[Y&>IDZ!>A W=:OIYOGKG_ (^/
M,&2.GG;><>WE?=[#^+FN>\%\^#=,S][ROX^1CS6\C..V[.['.<=J +_]@Z4_
M L;,%B )-@(!?E7SW"_=W=6/!P*8VAZ5L=DL4@C="9(HAY>Z/(!B;'HP#M_<
M[5I-Y>&\P/Y>'W]-VS_EO[;MV/;;]WFG#S?,Q_R\[Q]WIYVWMGMY7W<]#]Z@
M#..@:4&*G3K5V!*DB!2691ECCIF0=%Z$#=UH70]+RNRRLT)V[9 @PI?E'SZ)
M]W=U)X.!5X>5L'E@>5M79D''EY_<9[XWYW=\].*5MF&\P/L^??TW;?\ EO[;
MMV/;;]WF@"IJ;67]EW+:@?*L3&S3!G,>V/."A(Y4AOG./N?PUD:7X9TZ.:9O
ML4DD)(1#=YD>1E^9V"-]WS!A54_> +'G%7_$8+>'[Y90#)M 8 <>;QMQGMY?
MW<]#]ZM$>5Y8V8\G8NS<#CR\_N<]\;\[N^>G% %$:#I+ 8T^S7<!A_+&%W_=
M;/7"?=W=2?E.!65<V<6G^(+1K"WBM5N'CC*H-AC_ -9D%1P3E,E3P,\9&:W[
MFYM;2/S+V=(8BS(S2.%))XF /3>3C&.".!S6-?3>9X@@C1E+PW=NEWC( ?RY
M6C"Y'W=A'N._- 'I-I;"TMD@5V?;DEFQDDG)Z<=34]%% !1110 4444 %%%%
M !2'I2T'I0!PKV=M%XF;4IO#TT<373 W%F%F29AE \T>W<I!_B7/;)Q7=5SE
M_J.K3+>VT6@7)A1C&)TNUC9Q@'>F/FQSVYR"*WX(C# D9D>4JH&]SEF]S[T
M24444 %%%% !1110 4444 %5-4_Y!%[_ -<'_P#035NJFJ?\@B]_ZX/_ .@F
M@#P_2II=%O=7@G@;S)+\EE@B$BY3A%;/)5F4DIP3PWM6E_;Z,N&&I!&4[G\M
M2^QS^]?/=PWR[OXEXXJIX20G^VQ%+%%MO=K-G(RV DA/\*QGDL.0>.AKI6CE
M&YF^91YC-";=0S!>)(MO0,Y_>%>BCYEYK-QDWHSKIU*"BE*-WZ_\ PW\4+$5
MED2[CD+[P/*55\T87:#V"H=R?W#US6U9OYMHI&74@*H90255MT(*#_GJW#1]
M6(WYQ3C:SR.(GN4D?S$7S?(5MTF-PE&3SO7Y%_YZ8^;FEMT$=N,;50CS!_ J
M*[8C&1R!"W)?[RD[>!3BI)ZL5:=&4$J<;/UO^B*%[<I#JZ)<,(K::SF4W9?+
M NX\TB3N4/R[NCCY1ZUH6MTUS!%<Q(I=L2"-6VJ)0NWR@>P5,R _\LCUSFLZ
M_N([+5OM%U<JEN+.9'M9,*SE742+LZ R'#;>BCYAS6A;R>=;H4O%E8;8S=)A
M@9<9\WWRH,2Y_P!80=W2E'XF.M']U!VZ;].IE7,SAA#;6DEP@N[9"\L(9?+5
M@8V"@YS(1RO\6=W%;3;6W>9*R(V_?(),E5?_ %S[^YC.$#_Q@[!SS6!<W@NG
MA6VGLK:-KN"4A+IL^42 B'CCRB 2V<K]T<5T#?*6WQ,X4ONB\L!GV?ZV/;T#
M2_?V=% WC)HCNPQ"M""M;?\ 0Y^!;I!);Q:7,S?;&PR3"!2^YMR;3]U50[@#
M_JSSS4,?VJ.:^']CNZM%"8Y#*N]ANQ&"<_/YC#E!][J,5IVJ&:X\HR1D?:I4
M$_F>8K3-EDE /4[08USQ)_%TI)407-P8XE2UE@AD\@$;8E:1E56[XC;YF<#*
M'Y1Q4<NSO_5O0ZE52<H\JU7G_,O,HSFX%[:QW%@Q1OM0:1K]-V2JF256Z94@
MKO[YV]>:;?2W@LC-/IC0)Y]M* MT$4E<;8\'.0%Y_P"F9/-:UU$L%[:,MHTA
M667S8T@3<_EQD2J1T!EX;8. !N&356>"W_L(MY<,LA6)=Z@,1(<,DA^BCRU_
MYZ'[V*3@[/7\NWH.&(BY4WRKIW_F?]X@/FRQN@TF9HHHA&-MV 3ALH0 >3+G
M! _UGWABM[X97$A2YG,2"&\NW52)MY5@N\@Y'/!QG/454A-G<-=,;**-5<EH
MG?.V-L*JENJB-L.QZI]T<5J?#^SB@OM04QH98;B:/?Y2H3C8,X' SUP/6M8Q
ML[G%6JJ4>6UOO_5LZ7Q;_P B])_U\6__ */2MNL3Q;_R+TG_ %\6_P#Z/2MK
M(JSF%HI,BC(]: %HIK2(OWF XSR::;B%2 94!)"@%AR3T'UH R=&_P"0QKW_
M %])_P"BDJ?4]'74KB"5IR@B!! 0$GD'@G[I^7J*I:-=VW]JZZWVB':;E&!W
MC&#&@!^F>/K6VMS [A%FC+DD!0PSD=1^'>@"7M7F%GHL$MYJT\=S>-)+JMPY
MCBG9%\U9#MCP.N0-W^SC<>*]/K@=-^>341'^X;^T[E-Q./G,K;9?8#E0?XB=
MIXH @_L&UQ@7^I&/!42?:G.4)R'QWW/\N/X^HK/L-$M;?4+JPAN+RW@M5C=(
M(KME$1<-YOS?['4-T&=O>MJ\U"ULHP\P8*8WE6W526\M?O)@<C8?G8_P9 7K
M6;'J%O;Z[>NZS2&98$5HX2S2ML=V^0=Y%!^7H0,GGB@"P-!B& MQJ+,-H6/[
M4XRR_P"K3';</FV_P=34<WANVN%$?VZ],1#*9'F,AV,P/F+GHQ<;,CEQTK7B
M99D5H;A"'VA)E?*@M]Q\]2$'R;NK'Y3@4Y2O#;,)C?Y1XPN<&,^FUOG/]SM0
M!SVCZ<;S3H[JYN]1$S2REB+QDP0[(_/;RU ^;M]WJ:KZ0LL>J0M%<75R4EDC
M\F21BO[LN(E*'^\ &Q_"?F-6]'U""STFWBFE>24R3DK%&9#Q*^YB/^FF0 #P
MW7DBLO1H]0;Q/(WVBWBL#-(L0&=RN6DPY;'S*O0'J>AH W/$2!O#EXJNS(L7
M#YSN3>#O/][+?*?^>@''2M;<Y;<R[')9F ?&UB,2#=V\L<AOX?NUE^(<'P[?
M,!L7R2VP_+M4, 8SZ$-\Y_N9XK4VN&VER[ABI8*"68#+''0F0<!>C 9/- &/
M)X?@O=0EN]347YV^7:V[IMC@3!"*J9^](I))ZKP>!7.6&DWUAXC6:^FAD+7<
M<5NQ'F?:(0C8FSU$F8\%OXN3TKN@"0-KA<[=K[N%W?<;/7"?=W=2?E.!6%J>
M/[>TUO*'-Q'LSP8 !,&7'J3R1T7MF@#TZBBB@ HHHH **** "BBB@ H[44=J
M .:O-"L6NYKJ:^Q>*QD5I)FVQ%FPC;=V 0 5!XS^==+7%WU]=OJ=[;_VQ81Y
ME$:+_9KN HP0LDV=@8$GZ9'':NTH **** "BBB@ HHHH **** "JFJ?\@B]_
MZX/_ .@FK=5-4_Y!%[_UP?\ ]!- 'B.AW9TRYUBWNY7A*WLGEJ45BJ[0LY!!
MQNV@@9^7'^U6R-;A# Q7$8E!4Q@6[;0ZC%OU.=H7)&>0WWLBLWPL)9Y-89BD
MKC4!N$T)<@K\R1\GY@[$_)ZDO6Z;7=&4=K58RCHTNS=M1VS+)G/.QL)N_P"6
MGW14-2N=,)4N5<RU_KR*L6J64[+ EPI@9"N'@;F#.XYPV>9>7QR1]SCBM*)I
MR7-R<W FF$A08)D Q<D9XW>7C:?NXXX:F>7<";SA#;)<"1I1&$V[9=NWR\Y^
M7:GSY_Y9=#3H(A#"(P_G#  ;8<.H;=%\G7$K9!CSEL;^!35^I%1P?P_U^"*M
MWJ,-K=1VRP/-=-'')"D-NTBY'%KQU"!>@/S;N6XJTCVLEH)-CI9M$Q*2J0XM
MB_S!@.=WG<OCDC[E59"6U^-')6!K.;?<>9EE#NOG-N[F,X7?_&#M'K6COE#^
M9Y($X<2>2&V@2A=HB_V0L?[P?\\3USFJ,3/&KEIV6:TU!+@%Y)2;<J?,"XN2
M"?ESY> O8 X/S5>CRPC-OY>X^3Y/#;-W6SX/.P+G@_,&Y;Y:R];A3^SE:*(7
M!1H8HV*GYHO,&P[01D3'(9/XL;^!6C=[3!<;Y6C4I+OE$O**X_?2;_6,X0/T
M8?(.>: *AL;8GS9+J=K%3),T3E3^X+_O <#.?.^]@\@_)4MSI[S7TDTLTL=W
M(QCG$93]Y*J'SQ\P(SY3?(?NXX;YJRK'P]I%WIMC<7.AV<UVUO&[1N@.92@!
MBR>@V?O,_P#+(]<YK.\3Z;=7&FV5G;P&:.W'V>-XEPDD9R(&"GD-(V%*?Q'Y
MAQ2Y4:>UG>]SII+/SHK989_+EA\DV\HX ."+3@C[FTMD$;@QR?EI9(8)+&:*
M2YNFMFCE+O(4,BV^\>;C:.HFQNZY'W,U2ET^'6U(UFPB^RKNVBX99)%+X-Q*
M7'&8B H?^(?+UK/GL$TSQ5H[:;I$4,B&29K2WA\H%]C* ?P(?)SY1//2BR$J
MDUUV.@@M;BWOII);F62^DEVRDLG%PL>)BO &3"?D)^4=&^:E\%:K9Z>U\T<3
MM;O=R16RPC)?(1D0*3NR5'?T.3Q65%X;TFX/VF^L+6XN)65C,\/F'8O^I('!
M;>PV%>LF"XP*H66C6SZAOQ?V"?:;EG,-\52,\),Z@<?NPVWS,8;[N,D&FE8F
M4G)W9UWCS6)M0^'NJ- )+2X@OK:W)24$Y,T)R&7V?KZBL@Z!.)RG]M^(_M D
M"'.J'=YZ+NEY'RY,.-I^[V;!JA=^%;1]H=M1FDGN(3+:M=NB22H0$0KG&3&!
M)CK'@9S6Q8*ATVW0D>7Y2QAO))S$&W1OMZGS'^0IUDQN& *!%#_A'ED0>5K6
MN'>D8B9M1DVX=LV9/?:#G(^\&Y/RU5M]+M;FYU%9-8\0&UMI9!(IU!MP@VK]
MH!QP6\XY..J_<YKHC\VYI&,>[>TC!^8]_%PV_IF'@"3H0=G6J.G33-J.I,+:
M(3+=(\,*K@2.D2B./;_"&3,F/^61^8YH K_\(U)YP5]7UTWBRJK$:DW_ !\J
MF9"">.8.$)X'1N:Q&T:\NVGATK4K](H988HY9=2EXC9P;;Y-N<#+#KD,<_=K
ML D6P1K)O@VK&)3&6W19W)(5_B\R3Y"O67&X8 JCI[,]UJK2DH3>2%SYP8QE
MT03D/_"81@!^F#LZT 4!H%K9/<NK:K-;3&6:9I-28.8E 6X4XX+>:!N/0K]S
MFI[*&\M_$.CM!<W0:>Y:VNS)>NP6Z"')VG(9=@ 7H<?>YK9!E5PR6RM,KJRP
M>5M!D08BBV]@R?O-O_+(_,:R;/:OB?P]$&WK#>LL$N=XGA82L)<]F)W!C_'M
M##@4 >M]J\TAL=1:;5)#J<D-LU[>D((%?;!YI$F"><Y X].G->E]J\R?3;2Z
MUZ\N+"VE>6/4VDEE:1U4RHV?)4 X;<02>,+RQSTH N6VEWB37[7M^;J\NL0J
MXA2/RF"'*KCJ/+8E2>_WNU5+/P^89K.9]0:>.W6$Q(80JE55DMLXYP"QW <Y
MQVK;PFS:'W1;=@DVYS'G(?'?<_RD?\M.HIQ+$EG&QB69L-C:6&)/F_Z9CH_;
M.V@#*GT^[^U7$L6K2PVL@D9H3;HY0''V@[N[%QGTP?EYI)=/UII3MU<&X+8!
M$039/M&",?>'E@[0W&3\U:P+A@5B#."I6/9@%E'[M-O8,OS[?X3\QIN%V;-^
M8MNSS"-Q,9.=_N6?Y#_ST[4 9-AHL=EI,UM#=NS3A6%R\8R%+9@^7^Z')R.N
M3QQ3+?19H+Z.XN=2::"-IW>+[.JL0Y/VCY@>NYL^FW@<UMEG+%F78Q9F8!\;
M6(Q)\W;RQT;^'.V@%P1MC#,"FU-N 67_ %:;>P8?-M_A/S&@#,\0[O[!OM_^
MMVC.SIYW&W&>WE_=ST/WJT!Y/EKY8'D[%V;@<>7G]SGOC?\ >[YZ<5G>(4E;
MPW?):Q/=/Y!5%7#-(A8'</4EOE_Z:8XJ];WL=YYDD3?,DC>8N[8T;D8D4YY4
MQK@AB/E!VT 2G9\WF;MOS[^1NQ_RW]MV<>VWIS7-ZO#<MXHT^0!&C66!;A1,
M\>)/WAC90!\RB,,-I(Z\UT@W#&U S#9M3;@$K_JUV]@X^;;_  GYJQ-1V_VS
MIX^9@MS#Y4F[.\%9RS'U.>-W\6,B@#TRBBB@ HHHH **** "BBB@ I#T-+0>
ME '"ZJ+FWOI;A["^DTYYV0Q6UV[+OS]Z2' .QFY.PD<Y(P37=5SCS:['J(N)
M-.MKRT69TB\IS%/ F=N2&.V0$#/!4XZ UT= !1110 4444 %%%% !1110 54
MU3_D$7O_ %P?_P!!-6ZJ:I_R"+W_ *X/_P"@F@#Q'0;B;3I]6BE\JV=K[+F9
MGW,/NA_ESM\MAG<.<Y7IS6L=8<(2TEFY"DM%Y;C=@X>/&,#S/O[>B8RN365X
M>CNKFXUF=HUG#7DAC>>8A^$!FQ@$!MI)#'C!(^\:WELKDRJ(K33_ #"Z+&=\
MFW<5S;<$9V[<X!Y#<MQ6<N:YVT_9<BYEKZHKG6'#8&H698N56;8Y+-C*RX(Y
M++^[Q_&.6K3M9O/M$EVI&I0-\K'8JLVU,-UVPMR7^\I.W@5ES:7#<6J"6QLO
MLB(LB_O9,K#NP3D#.1+]['+<;>*OQQ7%G8R(^Q;F-IMVPYQ(%_T@@G@MY>-I
M^[C(/S41YKZA65%P7)O?R_09(&7Q%&[AGC6TFW6QC 9MCKYJ;>@,O#E1PH&Y
M<FM )(7""?,I98Q. &S(1N649Z[D_=KG_6?Q5@22S6_B^SBA1)[J6TC6#'R(
M"&S;G!YV!><'YMQ^;Y:U8)8);+S9HO*M#"S%6;<?LN_YLD=S-R^.2/N=ZNZ.
M5P:5ROK/SZ5NB=;9#) Z[G("(TJJB;NH$+<ENJD[1\M7KOY8;@O"\@59=T7E
MC<^P?O8]O3=+P^SHH&X9-9>M7=K-9,LUPDLWVE'D$$BEO.W+Y[#MS'C8?NXR
M#\U:LJ.\;I;^5YK+&L.0=F\@_8^.NP#/'W@W+?+3)::W*VDI)_9&GQ^=^^\B
M",3X'^L,899O?*_NE_YZ'ANE1:MA[*!XV6VC^T02;&<@+&9 JQ[NH$3_ #,W
M5#\HXJG9W-Q:Z1;V\FAW1MH;1HW FB.;=2 X^_G)F'S=ROW*EOGU*^9(I]'N
MQ<I>+*["> ?OU4-<$?/C/E<)_"._- C7;Y6;?&TFTOOCV#<^S_6IMZ;IN&V=
M !O&36>X/_"2P1"57G:U*)=JY<([,K+)D_[/[M?^>G\5-34-0*H8-#N Q6#R
M1YL6T,3_ *&,;\[0,DCKNY;Y:K2W%S]N%R-'O3IPLYTF22:'>T/F R8(;O+]
M[N0?DXH V@\93S!$(XBOF"(N0$C)VK&6Z@0O\[-U0G:.*RM.22.9O.=KC;=W
MF]0@R^PKYL>.FZ;[VSH -XY%6?[0U;[3B31KS[5YY#LL\'_'QY?[\CY\?ZG
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MK*E0OXBM<R.MO BR0SY+"7+.6=B!@D$L-Y(#@9[5J!68#9.J;@FV3<2J;_\
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MQ/I5@F_?#\R"4C>3#DNL_P#M,\GRG'^MQN' IDF\!%Y:B$#R]D0BR#MV;O\
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MQ$QV;$,@4Q$@9!1OWC?\\\X7CFK-Y;2_:(MRO=+'NADCC.UV9,,[!=P4F9>
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M!)T;I4V5R_:N46E;3R7YV$ETV&2[MYXY24A*[5,>Y9E /E,4ZDRL<%>K;0_
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M_P#H)H \;\'$'^W &52M]AW\PX)8 )(3_"L;<[QR#\O KIC\NXO$[*N\M"4
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MYIQNIRYB-K?/)O\ ++>0I+N%W2-MW8S*,#9T(&[EJS_[#OA/M,EL;H3!?E4
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M!B9CY!V@9V^8<,.I(W#Y:B5]D4XRY'*+U_KR:-'3YKBZCE$DL43K((TD1SA
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M3F'Y._FMG,?5L;^!5'3[7Q3>"6*PTZR/DJ")KB]=6:0L?WFTQ'G;E2.C#KG
MJ_/IGB6TC:>?2-/2TC)9Q%J3LR1 ?*%_<@DQG+*<Y'W>E %.XL8I3-+]IFB:
M0-NE6X/ 88DD+#KY;83?_P M!\H&>:CABO[NX-S>@VSAD>.RMY=H250 49NV
M$RX[0CKDFIM=\VVUFVT8(-MW92W;2P2JSO&N!(D:[ ,R;@QZA<%E&14*V&H1
M2.L5YYK3,(W9Y&8*Y4E)HV//S)B,9XD(YP>ND%'D=VKO^OZ_X)7/)M:E>SBC
M9H;66[WR6[@K"\0;>JDM"P4C<PE8G*CEOO9&,5L':P/F2,B-OWR"3)57_P!>
M^_N8SA _\8.P>M<]K2W<#V]U90A;>&(-%PS&%&8*L><Y/EG^+AD)VYVUHM?7
M$&G)-/:BZN3(R-;0)_K-C8F0+C[T@S(4Z*%W#)YK/1.R*DI.*DWN1V5OJ$;7
M"K*\4D4Y,<7EJ 90.%Y^Z!&Q<#I%U/6I9HWMHAMU"66+B*(+;JS2IG=#A>YD
M?(*_QXWG %5XIKY?.G@NH+B.:Z"QSC<2"R@QRC/7C,8S_K.C'BM-_*>W+/ !
M"4W^5N*A48[53<.0(6^9F'S(3M'%1#EO:156JU+2VODO\AEK&Z6@2[D5&/F&
M62-_NB0_OW#>L9PN_HV=@]:S;FQO(M0NIK2>"*[NI$F^R?9<-YL:A8XQ\XVK
ML!E)Q^Z/4DXJ:VBU"U@> +'-Y)D&V=&WR%"#(FT9'[U3G;T 7>.:L6%C-;SW
M9DO();FYNLI<QDMY>]5,;Y/4!5,:]I"?F]*<9)K0F:O[U[W+1%ND>&N(UME5
M4\^5<+Y0.Z.1@>TK_*R_\M,;^!7-1K<S:WJK6DL;Q7*M+),]P<1B1-DK+( 0
M?+Z"3T^0"MZ]MK74=.FMYH=EI/%EHMY&R)FVK'NQP(G^=FQE"=HXK \,:']F
MO9=$TY;CS(;FXM46Z9XT:%4YR5##!8EMN.?E]:HS.CLHYK6UMD\H-<PJG[G;
M@&9$VI%[ Q_O,?\ +(\GK4@CC""($>2%6,-]G(S$#NC?R^O[R3Y"G63&[@"K
MB^'/$X"_)HY<;3YAN9]Q9> ^=OWL?*3W'!S5>/3-42^NK*\72H$MK19RZ2S,
MHC+/@9."-A0LO=<\$=* *=[91WX3[3/<0*KO)(8+@I@OQ.6<?>\G@!^ASLZT
MU--2)UDACD6[1@0J#RR\B?ZN$CI@IF7:1^Z/S'K5^#0/%-S#%<"'1464!VC>
M2;HP^8$;2/GXW#D9&1@\T\^&O%VUBK:,).J/Y\Y((^ZQ.WEE&5SW7AMU &?#
MI]G;B40,Q64!3=,AD=X\[HY><DEW_=E/^6@&X8%2PPK!;I$=R*JMN9I,LF_B
MX;S/6'@"3ISY?6K9\,>*3(H5=#6$<&,33?=[(#MX56^9>ZGH0.*JII/B":SM
M9([G2Y+B68031R(X42#=YV<9^_MPPQ@\-@'F@"9#*LJLENIF5U98/*V@R(,1
M1;>P9/WFW_ED?F/6N4UT)_PC5LJ.9(BIB\TMN)@W;EFS_$7?Y"/^6N-PZ5U_
M_",>+1RLVDJXR5?SI2P;^!L[>60?+G^)>&S7,>*=!US2M-MUO4M)K4EHUCLW
M(VC&[:VY>(U(+< E><8% &E%?7,NI-;S+!\J2/<21.<P2/M\X;SQF)#D2=LA
M,<UH!IE<,EJK3*RLD/E;09$&(HMO8.G[S9_RS/S&L;2K&6WG61X)5G<2/>%@
MN9YL*T@"@D$RJ-JH?E*C=RU; 5F(5+I$9BJK.)"55GYBEW'DK&/W08\N?E;
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M9,]O(&"[])<YPI49!.!G=D>FV@#?\/I<KJ\.^3,8)!7<&R=K8_A'O^=7]?\
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J>#4E% %<65L ,0KQMQ_P'I^5.2U@B<.D:JPR 0/4Y/ZU-10 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g201805072101259762282.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g201805072101259762282.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,* < # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MXP$"EMR?+N8@D[<CW)KK* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:ZO;'P-X7,(NI8R]ZP6=F1RK,ZB%L$D$X)S@B@#T9,E!GKCFG4BC"@<?A2T
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MKD9_'E]:7;6MU9^'H+A&VO%)XBC5U/H08\YH [I1A0#VI:13E0?6EH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@!'8*A9B !R23P*\@OM#TMO#4VJVFK6(LP+R*ZEGMR91$UP9
M#(@!R9492 >C<'BO7+BWANK>2WN(DFAE4H\<BAE8'J"#U%>106-IINA7?B6V
MT?PS!8Z==S :?)8!IR$E8$&<ME921E5VX&5'2@#U]/N#!SQUIU-3E0?7UIU
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 <YXZFN[?PI-)8,RW0N+81X<KG,\8()'(!!(/L36/+
MX>U>XU<:K/X4\)R7P8-]H:ZD+9' /^IY(]>M=W10 @X'-+110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZJ7<BR6Q6.."ZD=HPD0?*,Y&V$\\[/*SC/.[[_&*3]32+3DDX_G_ )E%M/\
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MQC0@=V3>KG:1G;N3=@'@G&<9XJ!?,W)Y&SS=T7D_>V[\'[-UYV^7NZ\[OO\
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M&1P%*^4H/<G?Q@4M311A:[91/AO3"VZ*]U"4GB-_MC[G!_U1VYZR<KM]!O\
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M20R'S/M,ODL%)^['C)7C/WOX:Z(LA0L5+P%68Q[O,+1%MKI_M%Y?W@/_ "V
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MF5R5X_U'WL<9QLYS4?9-_P#EZE_6Q9?S%9S-*)'4N9) V-[(,3.&[;UP@?\
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MA^S:7=PQ-%&Z1R@NA"+YJQDRR# PH:,^6&Q^[/R\YS5:TT*P>UMQ]CM!,R(
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MM;*LS-O^1EC\P>;GR^&(EZ]BN-G.:EM]C:$8J2?.E]_^0_3KM9+1F9G#12!
M73RR@+;8.1T\HGE_X<[,&K<4T,L32)&6A0N&01[,HC8=!_=_>?O!_P \A\P/
M.*K6MK':RRV4DSS30.TDJN5++(5/GL#C!)3[I/R]<X>GC3("X$4869G'EA'=
M5\UES%@$\#RLXSR&^_Q0N:Q514N9[_=^FA<*2[F24B5LR))A,^80-TV%[^<N
M-J?QX\SBJ?\ :L$ARL[F5F^6;:S@2,,))G'S!8P8B?\ EJ?EXQFFKIU@54P(
MWEE4,.Z1\;"<6V><XWYW@<YP5^6K2QPPVQC/F_9$CD#AB"WDA@)\D=6\[&<=
M5^YSFGJ9_NTNK_#_ #*;ZMIZ*K()84)7RE*/E!G;"N['6-LDMSM!V?-2>&I#
M)\2( N](4CE187@,11@#O.#T#-\P4?=S[U<O+4W>Z*_7?()F:78V")@O[\J>
MF?+QL_AQG=\]8%A)?V7C*ZCT^PB$\<D=U'=M!+.'C: J(PH(< (5/)SGJ*%>
MX-T^72]SVNBO/['Q!XQU/4$M;0::1AO-FFTRYB6+'0?-)R2<CCTK:\KQS_S^
M^'?_  $G_P#CE,S.FHKF?*\<_P#/[X=_\!)__CE'E>.?^?WP[_X"3_\ QR@#
MIJ*YGRO'/_/[X=_\!)__ (Y6+=^(O%&GZI/8WNH>'X&BB24.;*X(<-NSC#]M
MOZT 6?B&RJ-(W8YN<)VV/E=K[OX IPQ;!P!6:WEH&WPED4/OC$>TLJ']ZF,_
M*6?$@7_EF/G!YQ6)XE\0ZI=W^BI/<Z7?1O<;'-C!+$\2-C<P,C%2=H;&>,UN
M*)-R>1L\W,7D\';OP?LW7G;Y>[KSN^_\N*  H^YD<B1\LCD1[A(VW=*0O\0E
M3"A?^6A&_C%4M0=YD^S0N7N7>)U('FA68CRI"QP"%C!C+$YD/RXXS4$T]VLC
M"UM@UF$C,.]<DQ;_ -V#\X/,V2V!GCY?EK.EM-1$]Q.TEW$LAF>X6/R]K 8%
MP2N\]6"C .,#*8/%0Y=+'1"DU:7,OO.DWQ;0Z1E(MJLBF3:4CSMC4G^$Q29<
MM_RS!V<YK+UHP1MI_GVKRH+P!D6/!^0GS1C/R[G(D"\[ -W?BU&-:D=GFEAC
MN3,Y9!$I(E\K]YSG;_J<;>W9OFK(UV?5M/@L;JV-O,([BW8$1,/+PC?9SC.2
M-F[@\@\MQBAO05."4[77]+T-FZGDBD%NL?VN[D)4JB ASMW2.0>JR)A /^6I
M^; -9]U UCX3,1,6^*&-0R<J'8?NGSW"+F,M_&3LQQ5FU2&\L89)T.T)A"VY
M,P^81$2%.<&7EAUY&SC-4-5TU[?1[K_B8W[I&DI>.5U.8\J+D$XY._!ZX*_=
M^;-7>YE*+BW%]"%K]9+18H]>TR*+RXS$HCVF-=^(5SN.TQN-Y/\ RSSMYS5$
M_9OF>3Q/:RHHD++Y6"R(WS*!NR"9#O S\HR^><5UM\DGD2"51Y_FKYGEJ/\
M7A1YFW_MAC9G@'._YJPI=%$#-,DWRPB%HL0J%>1LFWP#RJXZ@\[L[ODH)%BD
MEN=;M_)U^QDO#*ZYABP&D$3%Y#SR&7"CIO\ O<'FO9+/'V*WQT\M?Y5Y!K.G
MHU];WT$,<\83RDA;$;&$E\$R=?\ 6Y+ =>"AQ7K]I_QY09_YYK_*@":BBB@
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M,AEC"HL1*Y,B [H25[F1\@K_ !@;SMK-MM<(U?5--2RU"Y5FBDBFL[-KC]X
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MX(8_-M4TKRN:R5/E3U5_G^J+5O)%.NQ([D0A(UC>:#_61D[XCC/SL\GRLO\
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M )J*** "BBB@ HHHH **** "BBB@ HHHH Q?%%S!#HDJ2R0(9, >:>@!&64
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MY4W&=RY4N491+)GJ!(/E#?PX\OCK6D8R)-@*I(&VAS&$".%W*Q'\(2/Y"/\
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M-,_\"%JEX<U;3]9\=:]=Z9>0W=N+&R0RPON7<&GR,COR/SKL-J_W1^5  '0
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MQ2HTY.RGKZ,N:PRC26D0B&+? X5CMQ&TJ[8]WKN!?_IH#N)XQ7J=I_QYP?\
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M"/>!*Z?O8P/X@(L2!?\ EH?FZC%5-0,AL6,:+)\T+)G]YOQA83G^+S$R2_\
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M:77RVMU)Y,SE@JJI!/)(//&!TY(YK9K(\0M*FG;H[JYMU5P7:"W,Q*]P0 2
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M #8IB"3]V+?8'_<B#(.T-@FUX/.T+NR#\P;EOEH RO$=U#8Z2\EY*.+B)&F
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M%OD /*DY;"TE=JXYJ$9-:Z?UV*WV_3 NQ;Q&A50BMMW,T:G<C$?Q,\F5*_\
M+11N.,4&_P!.?<);U%5MPD992=H?F<AL<[6PJM_&/DQ@9I923J5N3 %#13,\
M!'RINVAXR!\Q$?\ K3MY).4PN:M98-D0&9@<[3M)E95QM/8F9?G.."!A06YH
M5P:@DM]?Z[&-J^I6SVT9,T9F-PDAC5Q_K"I5EP2!A4P1S^[)VC=G%>MVG_'G
M!_US7^5>6ZLJ_9(E+B1/.B7S&Y#  E9>#GYO]6O7 7#Y/%>I6G_'E!_US7^5
M49NW0FHHHH$%%%% !1110 4444 %%%% !1110!6NXXMJRO;-.RG:%4 G#8!Z
MD<8Z^PHM!&#<&.!XB9B7WD9<\?-U/!&/3Z5A>,5M6@L_M4<!43$J]S<M#"IV
MD?.R@YSG@'N.O%6O"BVRZ2YM((XHVF8_N9#)&YP 61B 2IQ^>: -RBBB@ HH
MHH **** "BBB@ HHHH *0@$$'H>#2TC-M1FZX&: /$]*:34K34!<.TL\>HFT
M@DG/"YE(BV_WO+.YRG<$$GBK3:-NF-R%A:(Q-B$2.Y9"^-@/\1=_W@/60#'
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MBVAT[4/[.^T3H+TN9%.UQ*Q'F./EX,.-V2"N&(ZX-$5W?&^,7D7B!(E=83N
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MO.C:)GND5\!H2ZG9\N-@+#@Q+^\!/"@X;#<UE>(8]<70Y&TB^@CNU$95I;<
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MW;YX==NSSF!/F*#N\PXY/FM^Z;'+$93Y<BE(W$[IWBW%MS[AF/</G;/3,/\
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MG_EJ?E.,5EQ0WJ6D$-HMN(U:!HFD+'*&3= " ,XW[BP'.3D?+5IY;WR9#)!
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M(='=P@U*W#'H&?;_ #J2TT33+&,);V%O&!Z("?S/-2RZ;8SH4EL[=U/9H@:
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M#X'.YMPPHJ6TGDN+59F(G=F<E0!B1ONE,#KO7]ZV/OX^09R:I-7,I0:C>_\
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M$1C0U$4HDC#D B[%QT !^?N2<D^Y- &[7+Z_8^&H[R2]UB,R33HD84[VW<X
M15_B.[MR<>U=17.>(XK1[BU:>?45F4NT2V5L)F48"D_ZMBHYQGC[U &[:+&E
MG"L)W1*BA#ZKCC]*FJ.W4+;QJH(4*  1@_EVJ2@!",BD1%C&U%"CT P*=10
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M(L,, >@,"\@_= ;:?FYJCJ<1FCMX4*PF6<)C.Q4_=NJH=W(5@?."_>7DMU%
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MWMC(2KVK;N2N#R21DD]1\O3.>EU?_D%S?5?_ $(5PY2)KV^*!/)%T_\ :8R
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MBL3HQN;VVT^;R'4I]O4>6&+  %B#MR<#-+X4B6#1%B6>PG57/[RQ1%C8X&[
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M*I5/.1,(C*K# \D[V4'"'E<DXJV,J04E,Q4J48L,RE!^[;=TS-RF[H -IRU
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M6ZNL>(C#DC<J9Q;<] RMNR3P%.UMS5;TB(_\)A82PQ*MNELT;$ IASN)PIY
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M205(RY&10!?D\XNXN$5)2T@E10#MD90;A0O0X3#*O1N7.6XI SEU9-C3%U9
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MBN;U/>VL7'E'$WG*JL_S?O@"8CD#&U4W8&/D8[FW#F@!&\:>)06 \-6#L"X
M752=Y RH'[KG>.4]<'I2V_Q"NXM3%MJVAF&W:-7CNK*=KE#GIGY%P"<KG^\,
M<507R2B^4N(F5/+5D)PC-^X!&<G$F68#EN&!V\4K-#L=I!(T.V1I1N!9HLXN
M!D=6:7!R.'7Y5P: (/%OB?3=9_LB..*Z4O-C;<VS1K&Q*@,S'[NPC)*Y(Q[U
M(SVZ;G>)75=[.FU5+A/ED7 Z%SA\#A -RY)JAX@\S-D+R8EQJ"^:4< /.J_O
M"/0&/:JMT3!5N>:TQ$V]5B6-9-R"+,9 5RN8.#R J9R#RK?,V1S4R3>Q$DWM
M8:R,[&,S&1U+1NR $R-MRS =S*N%4='QN;GBGJ';:%N%1F*A9BY(5F'[N3)Y
M(C&8MQY<G:V!5:2:U0V\:N$CEVB&)E)W(S?NLJ.6(E&YL?>'(.W@23LOV>9M
MCR?NY69"P)=>DXR."7EVG=P&4;5VD&ICNVR8NS;ENBK!,\-Y)$UN\=D55H/,
M+ IDD"(L/NK"QWY^\GW5RO-32WMO!M\Q'F#;LQI%DN%_UBD+POF']YCHH&X?
M,:CM(M7M[AHKNZ6>19"S7(*HQD$8\X9Z?ZL!4; "\*WS<U/)9)<^7&8H68;$
MA#1D*I93Y QU"K'N!4\JQW,"M-\SO8;YVW843H1DW D..9 H;S"!EG /7S%_
M=@'A\;FY&*<)5+ )=)$Q("R[R1&Q&4DSU(B7,>X\L3M;"TBK;^4JQQ@6_EJ(
MT,9.(F;]VI .3^]RS <OP5.T8I6,&UVG61H\2--@@LR9VW/(X+,^,$<,HVKM
M-%I]_P"OO':?=?=_P2.6:-X28I%MP0K*A<C8A.%B/IY;9D)_@SM7@DU,V%+;
MX&EV[P\>P R;/]8FWH#*<2;1PH&]<FDEBD<.DI!G#G<P8*//1,NP/9?*PJGH
MG*M\QS526_DMY!#'&IN2D)LX$'S2-M)MP%/18USD'[I.]LK2C?F=_P"MR8\W
M.[^7ZC-7?R;6-I9&;$Z*957.YBI/F<9.'7" _P >TLV"*]2M/^/.#_KFO\J\
MJN4DN=.B!M(0A1',;-OV1$M\H;')\P,Q/\?!7 KU6T_X\X/^N:_RJT[FB=R:
MBBBF,**** "BBB@ HHHH **** "BBB@"EJ4Z6-N;YK:2<PCI&I9@IQNP!R>!
MT]JAT*5YM/,DNF)ITK.6D@0@C<0#DD 9/.#[@\GK5;Q8V=#DB^SM.)'56"F/
M"C/WF$C*K*.,C/.:/"OF_P!D,TS;G:4_-NC.0  .(V91TZ;B>YZT 9&E1D>-
MI[A'D991('E:W$:.02-BGRP6Q@'.\]#P>M/\9I=^=;265MJ,TC12QO\ 8I?+
MVH=N2V5;(XZ#Y_[H/."S\,R#Q0VH7%A:Q01S,\9CD<LS,2QD^]A<G:-N.?F)
M[5-XDL]0N[Z![6QE)MR?+GC$,G###?+(R[3VR,\=1VH W]+M_LFF6\'FRR[$
M WRG+'Z\#^56ZJZ<)%T^!983"ZH%\LR!RH' RPZG%6J "BBB@ HHHH Y/Q:
M]S!&#8@M'A@TBK<,FX;@H8@,N,]<\]JHZF6F-U:1L\KG_CU@*2'S3^[W9 PO
MRJ,8!Q\QY&:TO%48NKB&U>YBCC\MI#'^[5SCJP=G#* .ZX/O6@]I96MN=3S/
ME4#G9.^&X&>-V#G ^M $6BV]S;7\Z36JJ/*4BY7)\WDX'S$E2!U7ISD'GC:E
M_P!4_P#NFJ]OJ%O<W+00.)-JEBRG(X8J1^8-6)?]4_\ NF@#QKPPR-'K19E\
MG[?<EF!QB(A1.V1TVILPP^;<VWH370GS%E)VXN1)D(PV 3*F%4X^Z/(^9L?Z
ML\KDG%8V@74ES)JDA2(217Q01Q+L!:, )USAI>4+'Y<+MZD5KX4+L#[(P-OG
M*"FU =WF#/W=C_NES_J\_/D&@!$$8V+;%G4"-8-PY8#FVRO3+'=E>A4;SM:D
M/E-&1NS;LA!97+DQ,^21G[Q,WRKG_6#AA@9IS$L&$D8AW!@Z <1;CF1=O7$7
M#A>I)WC"TI9RQ8H7<L6\IF#;F(V^6<?>WI^];'^LQ\O(S0 2,Y\QK@*N?.:<
MJQPN<"[(;KA!M"MU#'8,K3Q]H24E$ NA)]Q_D'FJF%4X(P/(RS <(<%<DXI@
M^7!24S;=I1RPS+LXB;=TS-RF[H -ARU&U NPS^3&!M$R IM4-NWC/W=C_NE!
MYCSE\@XH Z7PG]G%M,D$A95""(,QW&#'[MBO121NZ=1@GDX%'2M*\.2^+9KW
M3I8I9XS*\L1<%HY2R@L ?F /S=/EZXK2\+.YM;@/#Y692QC!&V%SRT07JNWC
MKUW$C@BM,Z;8%X':UB9[<DPNR9:,GK@]10!C>+/(_P!'9W(E$<N1DA1!@"9R
M?X2JD88<Y('0FN>Q,LO$>+E9!M1E"CSE3]VI X4>3\S <(<%>3BND\4O((K7
M;#E0Y<39P1(OW(P>B^825W'C!(ZD5S&U NSS D>-GG*I78F=QD /*^6_[I0>
M8\Y;@XH :JPA46W9WCQ&L.1\S)G-MD="S/NRIX91N;:U22_8S;QXE)5XW\[#
MEL1M)\Q4D9;][A5)&7'##'-(Q9MWF0+"6W;XMIQ&7_UB;>I$0Q)M'+$[UPM/
MD$VZ&8PEB0Q5"0WG-RNTD?>\Q/G;'$F %Y% #':3,C3A%;]\TQ#D!3@+<G=U
M 1<88<JQV+E:Z;Q#/!9^"I9&BLI(%AC4+J(*PX)4#>%4X^@'7'2N8'RXV3-)
MMVE)-X!DV?ZM]W0&7F/<>% V-EJ[B6ZAM-'ADNHXXH"B)(I4*D8; .0>BC/?
MM0!A>!'9K.]!N&EVR@;=[%(^/NH&16"^Q+?7M6?K 0:E=+/E(B&!XVGR6(W-
M@=_,VA3U?D,".:WO"U_:7=E-'9Q)''&YD4)(C@JY+*?E)P<=CR/RK"U/*:K<
M^6@D;S681!=H+D;?+P?[ZY9CT?: O(S0!4=I,NTP17S*TV)" K;0MSR.0$3&
M&'*L=JY%.'V@2KLB'VA9%V(R!1YRQ_NE(' !AR[ <(?F7YCBJOV^S25HUU*%
MGB95R;A%=B@S&Q)/#29V9/"J-K9-.CGM)AY<5]!LV[3)$W^K0G<9 ,Y7RG_=
MJ#RF2S?+0!GZLL.W3!;^<Z_:8%MCL4[D))MRV3U9]W'\:@,V#5YY8S&Y=&\D
MI(7*R9/EE\2D$]3YN I/+C*L".:H>(!YATWS8D@+7ZEE\MCY;,#YD7'9!B0K
MU<MN7 K8WONW+&97SN"%@WF-MVJI(X/FK\[$</C:OS#-2TWLR6F]G8H74,AO
M'O GE7H$B2R*^0<#]^IYSM"D88'<C':I*\5;N PC8.NTAT !4+^]5/W*D#@9
MBRS+T3AA@FJFK23PZ5.UD6N9@(UA)P3)@@1R?5\E-QX15VMDU:G 6)U4@J!L
MX4J%3=N9@#R!$WR*O5,[CP:AII.[OH934E&5W?3_ #'*L.Q%B:1H=D:Q':"S
M19)MS@\%GDR,'AU^9L&JE_>V]K$/-(994E+ 38RG6X*LW7$@ 4GE^5(VC-72
M68L7MU1F+%X=A(0N,21X')"#$N!RY.Y<"D)8D-Y7G.#N568-YC!=J@GH?.7Y
MF(X<#:/FYK1^1L[] +R99Y0B2Y=I09" K[<3\CH%CQ\PY1OE4D'%/3[0)%$,
M0,X=!$C*!F54_<*1T&8LLR]$X88;BF#Y=NR=V5=NR7>%+!?]6^3T+G,0)X0#
M:V2:-B%=CS"%"I1G"D>4A.YG ZCR6^15ZIG<?EXIC$583&BQES 4C6)MH9FB
M+$P'!ZL\N1@\.OS-@BD;[.58S/B,J_FLKDX1F_T@@XR<2853U;[I&T9J0[F)
M+P*K,6+0E"P5G&)(L#J$7$Q Y<G<N *0,X(98_-<$,JE@?-8#:@)Z$S+\S-T
M8#:/FYH S]9F2*V#W03S?M&2GFA1]H"X<<\$*NT]?E8[5)!X]2M/^/.#_KFO
M\J\SO25ME6-C,F53>>Z*&VRXZY))C'= -K9->F6O_'G!_P!<U_E0!-1110 4
M444 %%%% !1110 4444 %%%% &1XB$$FDW$4HC)*%L//Y(VK@L=^#M  R3BJ
M?A*WAE\-LN])[:X=V51)Y@"-_"6*J3WZCH>_6M+6-*L-4LV34+?SXHP6V%RH
M;CD'!Y4]P<@]Q5BR$9MA.B;#<8E;DGD@?T 'X4 <=HEM:VGC1X+9M-&U7S%;
MQQAHQTVY!WD]">,<GIC%6M8UB6/Q#<:?%K\MM((4>.U@TQIW!.<L2%.1TZ=.
M<TFBOY7BFX@1I@K23,;;[5*_D_,3N9&&U0Q.1CID8S69XRN#>:\VGSWL#6\$
M:2?8TLYS*"QQN,L:D@9P/D*GU- '?6H<6D(D8NX0;F(QDXY-35';_P#'O'_N
MCU_KS^=24 %%%% !1110!ROB3RSJD*M#),3Y1"*8SEOWNPX<=!\V3GC@\XK-
MU66#S]1C1KD7[#>[)&I1X_E5D8LP5AN. W&TG.,9SL:[>QVNK0QRI:R>=& B
M3#DXW9V_*><E/RJK]AD6[9Y8M,N+IBN(Y%1)N% # _Q<C.& ^HH O^&5DQ<R
M2LNYR/W:"';&/3='RQ]2<>PK<E_U3_[IK&TG UBZ$P870A3<-L8 7+8^Z3SU
MZ_AWK9E_U3_[IH \?\-PRQOJZ.C0R/J+%6."<N 8VQGDQ<R%#P V[J!6UE2N
M\)OC(W"%27W(3M\L9^]O?]ZN?]9CY\ 5B>'I9)DU?[3(\\:7EQ%\_P Y\A0I
MF3U(*; J_>R-W0&MT^8TI&[-RTF [$.#,R95CC[P\GY6Q_K#PN",T -8%0Q>
M03;0V]PW$NTXD;=UQ-PF[J"-@RM*5<,5,A1P2IE8!=C ;C(<?=V)^Z;'$>?E
MY.*:AC(1K9612(V@W=5!XMLMTRIW9;H%.P[FI/W:QD[,6ZH255"A\I7P5&?N
MD3?,N?\ 5CEC@XH <,,0$C:$MM"(5&8B_,:[>F8>7V]"#O.&ILD\,4+3/$98
M<;_)3=(2F<;!QEM[#SE)YDQA\  U)(L@\Q;C:^/.68*APV,&Z 7KAQM*KU)&
M\86FR0/=L8V"R7!E#!I/G'G%/E<D#G]QE&(XD/"X(S0 H=E1F^T><NTEY%<A
M9@N-[[ASB7A-W4,NU<K3V>?<RM<2(^YE,K';M;&XN<'"[%_=L!PF05Y.*B5H
MB$:V5D0B-H=Q^95)Q;9;H"C;LMT"G8=S4A\I8R2F(%0EE5"I\I7^8#/W3YWS
M*"<QCEC@XH D\QI. LL>XKM1ADQEQ^[7:>"T.-^T\%3N.&INZ,KO$8>/&_R5
M<MO3.WRP3RWFO^]4GF3&&X&:<ZR#S%GV,?WRS (<,0 ;H!>I#KMPHY9AO&%I
MR/>O=;+?3#J-TK>?(QOTB"_* K9VG>3$ZHS#Y6P<=": &,"N[?.LQ7=OEW'$
MA7_62;NH$O$>X<@C8N5J*^OTM3%!-=,KK&6#%57R"2Q#$ \%%!0@?<SE>>*F
MM(=7N+2&>V\(8B*1F)O[84$!#F,CY/X0<#V/.:S]0M[LZ@+/4=.DTJT%NTQA
M@NQ,S*K[AM8*-F&.>>!U/ H 0:WH[@&._LXU8*43SHSL#G$2XS@^4P+[3PP.
MYL-7<P^*?#@LXXI]?TJ0B,*Y-VA#=CU///K7!OH9Q(D]]>,?WR38<D,>&N<#
M&2&7&%ZL?F&%IYT:1IN-0O?M#2?*YN P\YX_W;$@8(\D;6(X<_*O(H [VUU_
MPQ$C16>JZ2BKEBD,\8 YP3@'UQ7">*-<@@U&XBL[D?:'=OW\)\T1G&1+G^\@
MRFWHF[<.<BLBPBB3Q7*D33/;1VL!M_/8-(B_,(/FQA2KGDG(5<J<DUT!CME1
MMT">2J-O58BO[M6_>  \K^]PR@\Q\LQP<4 >>(^B0LJ/HLTK"5F):Q,K,75@
MN6(^9ESOYX8<G#<5L^&[W0X[R3RK!8&\A3M>U,/GHORL@8CGS"0X!Y;;M;BN
MM>$Y=9HX6?,JS8AR&; :Y^4#)#IC"CEF&]0!S3A'*9!LV?:&D78[%6'G,G[I
MB1PP\G*,1PY^5?F&: ,+6+VWEN[&V%S%>2QW@\QQ*0K,@S)+N''SAECSU0_*
MF16Z0V[:)?*<L%5R OEL5W*Q X'E+\A X3.Y?F.*YSQ#9Z68+:X6#RXF="H.
M2S1%=D* #D2!UX8?<7"MN-5=$ALXM1)GM)4(24L3;31CR5P)%&_HV_:1R-O4
M\9%)WZ$RYNAT_G;IX%MP4W@.(U569$;B-,'@[&S)C^(99L&EDPT#;!G*[@%)
M;>H.TH">3YS_ #JW5\8/ JGIDTDXG26.*0QEHS<QQ$QW(*;IBHQDAH\ H/O-
M\RX&36HIN3*OE2 3M(GENS@XF9/W+$]#B'*,PX?A1\W-0H-IWZD*#:?-U*@N
M)\E9$?>J@R2,Y4,5)$LF>V]<1Y'(^ZO!JM?7]Q9(C&+RSE@69E7RR!N7V#1I
M\N.BDY'S&GZ?=K<('ABE2P5(S;D@1DKO80[<YVE).=S<*.&R35IQ;[&\Z(-$
MJOYBB,CY%;]\ #R,R891U3EB=O%1&%1Q]Z3O\O\ (SA3JRC[\FG\O\AHDD?!
MBLG57QY<1 )56'[I-I[JV9-IZCYFYH$W1GM#+%PS*),^8GW74'J?-?Y@>KXP
M<K4S+)N99=C2;G64^66#/MS/P.2&CP,#EV&Y0 ,TY/M#2+Y+@3ET\MV8'$K)
M^X8GH<195FZ/PHRW-7R2_F?X?Y&GLY?SO\/\BOYLZCYQEU'SR^=@,R_ZV3(Z
M!EQ%D?=/RKQ1NNB=J1>7)RJDLH\M^J$CH/*3((Z)G(PQJ16B$:-&KK!LC:-=
MP5EB#;8!D]&27)R?N*=K9)I&\A5;S8R8U5_-54(RBM_I  SD;I,,J]5Y8G;Q
M1R2_F?X?Y![.7\[_  _R,.;68=0LYI+.3[)#;W7E2-*% 5,';&-W7G<W'+9W
M'G%>PVI M( >#Y:_RKR74],LWNK>*YL;:62[O%AN)=H61IC@L5<] R[1V+'+
M(!UKTW3-!TW1ABPM_)4C!&]F_F:J*:W=RXQ:6KO]WZ6-.BBBJ*"BBB@ HHHH
M **** "BBB@ HHHH S/$&I/I&AW.H)#'-Y #O')*L8*9&[YF(&<9QDCFJOAZ
M_O-1T!IM2@LTD#,NVSE$D3)VP<^AQ^&> :;XR,#>&[F&:-Y2VUA%#,L<ORNI
M+(6X++P0#P2 .]9W@:T:U\&R6\MEOD\R0.CW2W'G\8&7P!C&%Z8X]* (] M+
MI/$1DN;2W20&0O<0V(C$I)X^?S6.._W>:U->GT\RVYFM&N9[2X$@$<(=XP &
M)'(P.G/X8-<WX9BMHO%<832[>R(:X$:1"W\Q#GY@Y0[BOIP.V>U;?BEM*@N[
M*74M*LKA6)7S[A,LI X5<*223VXXSUZ4 =/'(LL2R(04<!E([@TZHK=S);1N
M4V%E!*'^$XZ5+0 4444 %%%% &9J^C#6$6&:[F2VP0\"!=DO^]D9(]LXJA<^
M$+2\D=I9I%!8/'Y05&C<;?F5P,_P+QT_3'144 4(M-9;E)Y[RXG:/[JG:BYZ
M9(4#<<>O2KDO^J?_ '33Z9+_ *I_]TT >1Z#:264NJ*9(WF>]6X&TD*&8@VX
M)[*9"ZLWWN ,!3FM9@BQLK[EMPCAV(VL(0^92<?=99L*<?ZM>4ZDU@^%@JKK
M*@")!J4^'7Y=H8!7D'H8EPP<\?.5ZFM_E6W+$/,5@RP!=@WJ,)$ ?N@I^^ /
M^K/+9S0 LGFL\@N5"R%I!,J]0[ &X 7H<)M95Z$98Y;BD!<R IM:<NI0!RP,
MI7$8R?O PY()^^W#D8 IH"JH6-_/0*%0D9$J@[HR5ZD3-G*]6*[_ +O%*=K!
M@TS;&#!IBP8[6.7D)'WCN_=$C_6#A<8H H7FK6&EM;H7E(E53:D*S!PA_P!&
MRPY&Y\ACU!P@&TYJ.36]*C9;>\-U;PON3?-;-&1'NW2$X!VD387CB,<IR<TW
M5H-1EU"&XMK: *T4J7(=U#0[L;]I/RYA  #$;5#;<;JSXM-U>V,<5EIJK$9K
M>26%[G,A:/[J!FY V_O0C9\O[QP.* .GD\XNXN$"REY!,J@<2,H-PH7H<1X9
M5Z-RQRW%("Y=6CV-,74Q@.6!D*XB&3U#19()^^W#D  4F$"[8Y/.0 *I()$J
M@[D)7J1,V05ZL5WCY>*#M8,'F;:P8-*6#$*QR\F1]XAL1$C_ %@^5<8H :OD
MA%,#YC"H82S'!16Q;$GJ TF5=NJG"@;>:?#827VHQ6D*MAH9S$9"(U+*Z&19
M  <CS&8&/[H &.N:"S%BSIY+$LS , 8F(VR8;H# N"K=%!V'YN:N^'P!XLM3
M@(WV2=3$$*B, PA0 ?NAEP^P\C><]10!W*+L0*   ,  <"N"\971A\2VA@LI
M[B^CC7R?+DVCYBX((R V<CY3P<>F:[^N#\7.5\66,>\QQRV4B2R!L&-,\M[\
MX&!R=V!R: 9SQU588?,&G7JV\:*R.[+@1J^("Q#9 +Y#,!E<;0,<U/=7L<$T
MML+6[N(DBD\]HE13'%G=-D9X82@# X12&7)-7)!YJN)HO+W[BZ!@/+)7:X!Z
M#R5^96Z)G:?FYJ.UMDLEQ!;[I"XDV.&S+(HQ'&=W(#K^] /^K(W-QB@#G9HG
MOO$6H2Z@;S3;IXT$B1@*2Q7,Z<9!(C.54GYOO')XJVHU)=-^S*D[S/Y<T4PG
M+ LR'RD+Y# %<X/5SA6( Q4T[10W5R=.FFGN4$:2#R6:.Y7[T9;C_EL<J0#E
MB WW>*75 );W%QMDM4@EEW32@Y9C^\?@$,T>!'G^)6*KR#0!>M#";"V:*3='
MY$1C9G890?Z@D]1F7*L>J\*!MYJ9DAV.LK2+#MD64[0&6+.;@X' 99<# X1?
MF7)I1(S@2-&87;YV0,%,3%=KJ#T'DK\RGHF=I^8YI1E2"ENK,I4I#L(#,@Q'
M%@] ZYEVGE"-S9!H HZPD\A@%S I<W69PJ [)2H\T+](]K(.CY+-S5H+<$@Q
M3YD)0Q'S,@N1BW.3U#1YY/+-\K8%4]22,+:".03A9%5"R$^>F=RL?7SFRK+U
MDV[EXJVYF8/OE5-PDW2^;DKN/SOD#DI_JBP^\#L7FHE:^J,YJ/5$,]L)8E$-
M_<11* 8W$F"8P<0[B02/WN0QZJ>!\IS3$MX[562ZU"[>.421L947*(.;@X48
M#+)C@<*/F4DYJV2QN4<Q;)"&+*.#"V K -T7REPRD\)G:?FYJE;2RSZDT\%F
M)X(BJ19+*KO&"%C6,DY#_P"LYP4.68LN*5DTXH7*G%Q6EO\ @%E+*YCOY;@R
M2?:)GQ- %5H_.\L^<%4\$F(AAV?&6^854U&34+>RCFLIM\BM!M*D$L3\MNP)
M'(9#R3RQ!5L#%:.R/;L$OF1[0@D*%O,3.Y7('+>:_P"[8#F3&Y>!BJNIVL>H
M6$MO//)$LI^>5&W-'N8>8X(ZM&0(]XX8':N"*'%)7U^]A*$4FW?[V9<U[/9.
MMK+>,Y"JJ2Q1 1[=_P"Z+G.8L295MWW>BY!S5O3Y;AI[ZTU>108@QD,,>W9"
MQ+3XY(+*X7IC:"64$TEMHQLXQ'%>WL(#*SQ!XQ\P7:ZDE?X4^?<?N9VGDYKG
M9?M.@:M]CLO/E#& QAW4>=M)*J01\JLIW*G&TG<<C%/9H>S1W.+@RG<@^T&0
M[T50P\YD_>J >"/)PR@\.<EN1BFHTN8V@V,V8FARYPQP1:\]2&7.6/+,-K86
MD*1X*"0/'@()"A;S$SN5R!RWFO\ NV YDQN7@4'#;M\S1AMY>3>"8]_^M?=T
M)B.(]PX8'8N#5FA1U/>=,>&S&^.1!'R^&^S@DAAD8W"0$'^Y@!1@YKT32=+M
M[*)9HVF9Y8UW;Y"P]:\_U'+P+YBF-O-#&(,% <*1Y6.X1<.!_!N*GDUZ;:?\
M><'_ %S7^5 $U%%% !1110 4444 %%%% !1110 4444 <G\1FBM_!=]=F. R
MQ[$1Y8D?:'D16^^"%R.^#C&<'&*3P4\,/@UGMI80B/*0\<L4Z@CWA1%/T S5
MKQW*8/!FH2"66+A 7C5B0"Z@YV$-MYY*\@9(YJOX)^TR^#LKJL%]<EG"3(K^
M6A  "@/\Q P"?4DT 9GA[40OB$/J6I6][=3H$26RN$\O=W#0@!U[8W;\<_,*
MN^+;2X%RM[;V=U<9A9)/(GF4!!@X*I(N2>?7-6=&UF]FUIK"\GTV24*QD^R1
M2@J<G:"S<9PI.#R0,TSQ!IFH:OJ4,"Z?926T3&3[5/&DFU-O,:H3]YG Y/ 7
MWH Z2R*-8V[1@",QJ5 ' &.*GJ.#?]GC\Q51]HW*O13CH*DH **** "BBB@
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M X_A"IE<$?(QW-D&@"TD;QHL1D:9D&PN%4F5@N68#H3,OR*.C ;C\PQ2C<Q
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MES=';^O4:YE\\O(H#@3&X.<*K8 N/F^\H5,<CE6^5<CBF.DKWRI$K?;,+M3
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MF,DE58-S@ X&>:TQ''%:>7$ L:1[5 Z  <4 >1^'[F>\DU4S/F5+]K=95'<
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M^SPA(XO,3)$<8S$&YYP^6([GDGM4\?AGQH6"7$FGR0,I215&"58[I 23SO<
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MRK^[^4DNI('7.3U Z#5M]0BTZ5;*2U,"9RNP,X^;+$EL<Y/ZF@"/_A!_"?\
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M0J2V"I5MW+8X0[O]L=6]MO6@#HZ*!THH **** "BBB@ HHHH **** "BBB@
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@4 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g201805072101260812287.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g201805072101260812287.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,& <L# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MN< =R,XY];H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ K@]<N1I&MZYJ^EZO%:S0PV_\ :4-S
M9/<1L3D1;-K*V\@XP"<Y7I7>5RGB3P4-;ENI[/4Y=.GNTC2XVQK(DGEMNC8J
M<8=3T((]\X% %+P?-)J/B"]O]6GF&MI;)%]DDL3:B& L2"JEFWAF'+;CC;C
M[]C?74=EI]S=R@F.")I' &20H)/\JQ]'\/3V>JS:MJ>JR:CJ$D(MP_DK%''&
M&W85!ZGDDDG@=*LZW>ZG:BWCTS3[.\:8LK+<WGD=L@#Y&W<9].E ' :78)IT
MVD>(;SP[IT.FW<\7V:*&^FE>R:<@1N(V_=9RP!V 8W<9KU6O-])\.7,>J6LW
M_"-6GV>VN,I'_P )!+/%:-GEHX3'M##)P.,=L5Z10 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !116/K]]J>G+9W%AI\E]")L7<4(!E\O:V"@9E!.[;G)Z9H V
M**XO1/'&H7^DV<]WX1UQ)Y4!D,4">6#[;I V/J*[,4 +1110 4444 %%%% !
M1110 4444 %%%% !1110 5RGCQ-2.GZ;+I\^I0QQ7Z-=OIJ;YA#L<'"8.X9*
MY&#CKCBNKKEO'8O6TJR%I#J4\7VV/[7!IK%9I8<-N 8$%1G:3@C.,<9H X2Q
MU?Q-=:A;M?)K\6HPS6T%BLMJ\,-POG-YS2J!L),)0DG@$?+R#7HOB31]1U*?
M2;S2KBTANM.N6G7[5&SHP:)XR,*0>CYZ]JH>$H[)+VX-KI7B*R8Q@,VJS2NC
M#/1=\C<_@*U]?\0Z=X?LR][?6EO-(CFW2YF$8E8#H"?<C\Z ,/0=#\6Z//.'
MOM$DM[J]>[N MM*'^=LL%._ ]L@UV=>9>'/%']J?V9//\1+%KBX,9DTY+6%#
MO)&8AGYAS\H/7O7IM !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(>E+3))$C
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)BMS+&)% P RJP!XXY%=#10!BZ1X3T70KR2[T^UD2X>/RFDDN))3LSG:-['
MSZ5/K.@:9K\4$>I6[2K!)YD125XV1L%<@H0>A(_&M.B@#FK/P#X;T^Z2YM;.
MXCE27S@1?3D%\YR07P3GKG.:Z6BB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>>M>G@Y%<;9_#KP=I=O:P"U.5(2)I;R3<[#_ ($ 3[ 5V0Z4 +1110 4444
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M<&O5A0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*Q+[5[RW6ZD@M8I1%(8HH]SEY7";L !3C/-8_P#PE?B3_H3;S_OZM '9T5Q+
M^--3CMYC+H,D=W&^!9LS;W7 )8,%VX )."<\5!!X\UFYE,</A2[=P2"!(.W6
M@#O:*X2Y^(%S:M#;OI:G4G)WZ?YA$L8Y.3E=IXQT/<5&?B!J@4D^&)P ,DF8
M4 =_17E\WQ@A1D%OIPNU/#/!(2JG8K8R1S][!]"#FHA\9&(&/#]QSM_B/\7X
M?I2NBU3FU=)GJM%>9S_%ATDD%KH<]Y%&F]I82<?>VXZ>N,'OG YJ2'XGWDMV
MD$GANZ@4R,CRR9VIM7<Q/';OZ9YQ3)::=F>D45YL?BC=>843PY>O\RJI"/EM
MWW>-O4CG'ISTJ6U^)TEQ(?-T:>WA$32>:ZL00&"\<=SP#W(P*!'HE%9^D7\F
MHVIF>,1\C &>055AD$ @X;I6A0 4444 %%%% !117(^(_&4N@WTEK'I[7<BQ
MJ\<:,=\I8XVJ,<M[#MS0!UU%>:/\4KY8G=?#<S!8WD4[VPVUMO7;T)X![GBI
MK?XCZI/(J-X;>)C*\3AY6RFU0V3\O09PW]V@#T6BO-7^)&LAX$3PX'DF6.18
M?-8/AN-H^7ELD$>JG/%5$^)OB"=2]OX<BF$:%YMDY 7:2&&2!D'C:P'7C!H
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M =JFK:/I/Q-UDZS)&$FLHQ"C,%+L-A^5LC!'7.1CK6G%K5HUM%<ZEKECJ.F
M_P#'O%>(6CQS\^<>=C&>WKANM<U<AM=\37>IZKHL"6TT4/EK.B2LCIR@5SE0
M)?N[CQVZU)>6VEQV#6D%E9R+*KQ")+4; K-NDDVXR$A;* 'D,<G@@5*DCHG3
ME)K3>WY$7AZ>QO9_$%S;RI-;S:FS-+"=V83L,17/&XRX"CHPR&X K==3\YG2
M(']\9>3L!_Y>^>NQ1C#=0WRKE:YK25U.T62%-*,)DN))&B>U18P2 KQ$*^2I
M0"0@+\V/E'&:U@NL*0%GM9&!4+(&^9V3[CY/&Z4?(&/! VM\W%%_(GV>OQ(?
M#->6VMM;QJ)99YEDA01J'BN%3]R) .,-$"6'1>HPU6QY7D@*6-H8D"LIRQMR
M^8R,]6,W"Y^^/O\ K5&-)+2RO9YO*7>"^+8, $P"7P>?W3#:!U1CDX6IFN;W
M>SG3"6W2N8&E4Y.W!B('7(_>,!][JH[T)V'.+D[JW;<MNTF7,_EALS&;YR%#
M'B[YZ[%&,-U#?*N5JGJ_F'2KM65O,^3:" &\X+_HX(' )CY=1\JCYAAJ59[P
M2*!;R/AX@)1<)N?:N5DSTW2?<#=-HVG+51U&:Y.C7"M9%8VM]K%)!A%:3)('
M7$)X4=5)R<"G<S]G+R^]'6_"V62;P9')+(\DC3R;F=BQ/0=3]*[2N4^'L=E#
MX85-.F>6U\S*NQR22JEN<#^(FNKID!1110 4444 %>8>+&9/B7:$, K6$PDW
M2$#RMO[TMC[H"X.Y?FS@5Z?7DWBU[T?%JR,=LS6Z6@(EC8*XD^; #,0HW8V\
M\<G@T#2N[&DK3B1?*4FX$D?EJP )F"_Z.".F3'DNOW0/F&&J/]R80H)-H8@
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M,#9Q3;GSEO;9GCA16:X-RP;"J2O^E88<[5'1NH;Y1D5=4W(F7RT)N1*FQ64
M^>J?N%*] 3%EG7[JCYAAJ%YA4=E[NB?3YF1%+JTMSY:O&L@FDC-R\7EJ)5&=
M_7(Q'\G3$7UYJ6ROHII#;/L2;<J11>5C*''D@)GG8V6,>?FSOR<4[3?(-@PC
M.;0LRAD8N3 928R-W5C-PH/WQ]_I4CV:F:ZGN0ADF+O/F0[$9>+HJ1R%48^8
M<A_E&032BG9,TG*%W%JUNQ3+7=YILCEX5BDAE9N&+[ VV7YB>3(W(?\ CQM&
M*U=L@?89!]I#E#+]T><J[C)_L@1?)_TQ/8YS66=4AT:ZAT]%N'O%DB\L&+=M
MG(/V57/W0SQY++T'WAAJLK>0-$J)!=&T,<:JP0$_9V;,;#)Y)FX7/WQ]\=ZI
M*QE4GS.RV+(,3!?*C*HP3RT,>=JO_P >Z%,\^6V6*?Q_?SVJ"],9L9692T84
MNX#;R\:N%G7=W,K<A_XQ\GRU!>:TEI;/=7MO<*NY_-VH2 [L([H J2<#*X8<
MJQVJ2O%$UT=0TF:6W20R"98D1U\M_M,9VP(1_"2@)8#Y5&&&&IF9TWPOV_\
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M !1110 5YUXE=AX\A11+S KAU8*$90Q503T:3E,GY<=>HKT6O-/$Z2GXAQL
MWV<VJHXV!E=VR(OEZOM;+%,\C![<@!M!CVF58XR@4N 0L:,V2V.H6%OE ^\K
M')VK3BSY9S$2^7<V[8.6(VM"<=<K^]<#[_5 >M-+1!2\BEXPKO( ^2R*=LXW
M]S(V"'_B V?+3MKB39O N ^SS-NT"8+N#_[($7R8_P"6)YP<YH KW<<Y-O\
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MPIR <G./;-:-9?AQ)(O#MC'+.;B1(@KS$ &0CJW''/7CUK4H **** "BBB@
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M1/=0R:U8K:SVZW:NXEE>$Q_.%R9 Q V?N\(./W9]<YJV]TR2PA+5H[9W 0&
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MAF$6_AG3H0S,(X50,QR3CC)]ZUJ "BBB@ HHHH **** "BBB@ HHHH ****
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M7,C1R; Z*5),N3C" ?>.>PYY'K60]CJ\NJ?:H[R6)0V55KCY"I9< QXP"%W
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M86^4?Q!CSM6C6['[O(N9?UH9MWK>G6L:Q^89;=PT.Z-MQ$.=Y;+=3YF0"?\
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M7S)8HOLY;S"?,+LVY"!M(P =QQSFNT!!&0<@T +1110 4444 %%%% !1110
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M_P *U<'V=D!C3$!5"BM&3B)C^Y4KG)Q)EF7.9/O D<54U9@FEW#EG#@,Q97
M?Y6 N"'R!N9L8DZ8&SY30!Z'X<+-X=L2PVL8@2,8P?I6I6;H'_(!L_\ KG6E
M0 4444 %%%% !1110 4444 %%%% !2'I2TAZ4 <+MWW\D\DNLO9M?86X:_&P
M-Y@ 3R@V2H;CD9QVKNZX==!U*+QK'<3S6KQO*]PD\5I KA!CY'RN_.6 W!N1
MZ5W% !1110 4444 %%%% !1110 444F1C.>* ,+QA;7=]X9N[2R@$T\H4*I
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M 63+,G1?O_*:9^Y,6W?FV,>WS Y8F!FSO']XF7Y0<?O1P0<9IP&8P!*L:%%
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M8*RV2]"*<>5;)>G](M:AOCCCSONF%S"NX;2792")?3=*/E7G! ^8EN*L;25
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MVK=HH S(O#VE0XQ:*W&/WC%OT)Q5Z&V@MQB&&.,>B(!_*I:* "BBB@ HHHH
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M;^$(N"'Z@_7%=UI/^KN?^OA_Z5Q_B%U'C-X\X<VR2(PVY4ISM7/\4@RH!^7
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MU !_$?VR.S@N(&,>V["1E(61ERSRELJ0-XV@8Z=2379(ZR('1@RL,@@Y!%
M>AR,BN=T_5)Y=<FL9+)(VCD;E+=U"1XXRY&UB3CI_>]C71'I7&Z;-=#Q:MK*
M+E+5#+);1O(G .[+$!-Q7.<9;C(SDXH [.BBB@ HHHH **** "BBB@ HHHH
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MG!:9?D4$X8#+$MQ1:-QVC<8NY67RX@TBM'L0IC<Z#]PI3MO7+&/^'[_RTS9
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M8P<77(XWE\<C@KPN&I[/(69Y5$;EI'DQ)C8S#;<8?MY2XQ)_!G9S0IF5U\N
M-*K(4B,> TB#]S'L[!TRY3^ _/Q0!+8L@U*WWE/-%P@=F!*?:0N2<9SM\G(0
M?P'[XS7<?VA8MM;[3 >%(.\=&X'Y]O6O.8;J&[62-')MTC$7G##[H2Q*R<$[
MF:1=A'68=A5AF<LSR((W+.[@28V,PVS_ #]O*7&)/X,[.: .^.HV(#$W4(&&
M))D'1>">O0'@UPLOVDWC^8ZM?^=AG4C:;D+D,.VWR>$_NG[^>M1CS59?+@5I
M59-D1CP&D0?N8]G8.F7*?P'Y^*;MC,7EB0FW,>SS?ODPEMPD_P!HM)^[_P"F
MP^F: $7[.8U\H 0%$\L,I($1;_1@1UP),EQ]XGD';Q4]L%>[C4ACN9]^Y@6*
MY NN1QO+X^8<%>%PU,9Y"S/(HC<L[N!)C8S#;.-_;REQB3^#.SFGV[>7<1LZ
M[0CQG:(\?-&/W*;.V],N8_X"-_% $:I+'((U(^UB0+N!X-R%RI&>WD\)G[A^
M_GK6GX9VG5H39@"$09 (.1;'/E 9S@AMVX'DL00=O%<RNJPB..&YBN8HGC$1
M<1/,51FW;FPOWFD^0D_ZX#'&*T=)\2:=#J*WE\;N!4$ER_\ H<Q D/RRJ?DY
M$>!\W\ )7I0!U/B;59;&,0")@LVT)-Y$LBJ<DMN\L$C  ],Y]JT?.N;G0O.\
MJ2&YD@W; 0K*Q'8L.#]1]:S?^$XT/?Y>^^W[_+V?V=<9WXW!<;.I7YL>G/2H
M)?&7AW5-,F$%^7CDC(W&TD9<-\J_*5Y!/ '\1R!0!S,T]E;V4EPS)%8Q0K)N
MD!VI!G,&X=<"3)<?>8\@E>*R%\9>&Y(P\M]+L=2\BM#)YFQ_^/CG;C>S8YZ;
M>!M-4M:U"ZU)I-^FS^2CR3A"VT>:!ME8D]H^-K'_ %?0YXQ474]768!?#MT7
M#1*J$QC+IN:--N> RG<4_A'S"@#J].U*WU0>;87"2SB4('5&11<A3M(W#A1$
M"$S]T\OG(-4)S;GQ3IHC&+<V3&%6!*B$M^Y!4'=@28+CJQY7CBFZ)J2SV+0W
M<%S:*WR[I!YFZ*0[A(I7(;,@V?\ 348':H%UN&[\36UPSI;AH79P[[#YC[E<
M*_;RU#8)_P!61LYHO8&[;G0L8\,9MY4"4R\C>5'%USTWDXPWW2ORKAJKWL&H
MS26J63A;I;V$S.AV#<JEEQG^'RL!0?NDG?GK3H[ZW+8@E@EDCVD1KC!,?$*E
M!T5QEBG\)&_CI2!HIIVC6=S:QQ>6TFXME';<7/\ ?)?"9Q^]SCWK.4ULGJ92
MJ1T47=O^OR)<*T:?8]@CQ&8_,4D" M^Y!'7B3)<=6/*G;Q3F,8WF;>5'FF7D
M;R!Q=<]-Y.,-]TK\HPU-N1+,CEOW4VYI2!+M"2XQ*-W81+@A_P#EGG9DU'#)
M=EE*V\9P8#&F.)"J_NT"@X^?[^SHN-_%)SY9V:W)E44*EFGJ6 )?- 4I]J\Q
M0I4$+]HVYC(ST40\+G[K??!ZU&/LQC'E@?9S&FP,K$>26_< CJ0)<EQ]YCRI
MV\5G7\]U;01E&22(Q,A==S^8A?.[CD[W.S=_RTQW%:#27A=G98HY"\KL/,(V
M.5VN-V>/*7G?_!G8/2CVFOPL:K7=N5_</8QC<9MY \TRX(WD#BZYZ;R<8;[I
M7Y1AJ<!+YH"%/M7F*%*J0OG[<QD9Z*(N%!^ZWWP>M1*;E639'$Q5H=L>PC<4
M'[I-G;S!\^S^'[YQ4>)3!L,L1C,10S;BV49]S2?[6YOW>?\ EKTYQ3]IY,?M
M?[K^XF'V8QCRP/LQ1=@921Y);]R".I'FY+@<L>5.WBF76\PMMYFW,3NY.X,!
M<\CC>3MPWW=O PU.9[LR,["*.0O(Y'F$;'*[7&[/'E+SO_@SM'I7/WNNP[M1
MT^YE%BMMY(\QB8C(J8V;%'.&R6* <$;N*.?R8>U_NL];\/\ _( LO^N8K2K"
M\+:C8W&@6,<%[#*XA&5$@+_B.N:W:T-0HHHH **** "BBB@ HHHH **** "B
MBB@#FK_5-13Q$MA;36*6\06:0.P,C*S*@3&?EY+'=_N@ Y-3>,)8$T"07'D>
M3O0R>;'&Y"[ADJLGRENF,_D3Q6)J#RS>+$#R6T2M/'L1;F;$BY7ET$>"WRC^
M,#@9R!SJ^+KY+2"W U>/3YO,WHK7,4/G8P"N9$88YSTZXH =X;DCE\),UFH$
M>)!";9(D=ADX.U?D#G\L]0.17/>"5#ZRY6/4VE2+-P^HM;M.C$G"R;1Y@/!P
M,X_"NG\/76[PZUW]H-XVZ1V=+A)]Q!/ 9%5>V, #%5M+\1V=_P"(;B&U>&99
M!M$D=RCL-@R<H.57GJ3U],T =-1110 4444 %%%% &'XBNI['[/<0M(H^9&9
M87D"Y*G)V]!\I&3QS68UTBA;F;6[:#STW11S%7B?+NQ!4\XZ $$?=]L5T6I:
M:FIPI%)/<Q(K;B()3'N]B1U'M5/_ (1NSV)$&D6!8UC:!2H20*21N '8L>F,
M]\T 00BX35K+[66E+;V39<%D3Y3EL; ,<X&3_%705D0^';.&V@M/,N7M( H2
MWDG+( O0'NP'H2:UZ /)M:(7XJ7A/S1KIQ>2(L<2C>%.?0#*L6'S )D5H[75
M]ID:617*E@H+2,@RQ Z%IUX"_=8#<?FXJMK-L1\2S=17"&X:%HH(P1E)!AMW
M7@E#( Q&T'&:F7R#&OD@"$I'Y08':(BW^B@CKM#Y+C[Q/(^7B@!P4L JW")N
MV*LP<E4W\QR[NNV+_5ANI8[6P*0LNPR&+$>UI#;MQA,[6A..FUOWKX^Y_!GK
M0QAVN9A*8<2F4;AO,8.+KD<;R^.1P5X7#4\>=YP&1]L\P#<IP/M(3((ST'D<
M)G[I^_DT )M=7VF1I75RI8*"TCH,LP'0M.O"K]U@-Q^;BFA2P54N$3<$59@Y
M*IOYCDW==L7^K#=2QVMA:AGGMK:Q>X1,VT<*.BX)'D[O]&!&<X#Y+C.XGD?+
MQ6<OB"TFMFN'L=2-I\_G,R*'"'BZ!Y&'+X] 5X4 T :V$16?RU*$-*T.-N%S
MM:$XZ%6_>/C_ %?\ I^UU?:9&ED#E2P4%I'099@.A:=>%7[K ;B=W%5=/O1?
MQ+-;++'<^<$99$*%;L+GHW0>3PF>%/WZF7R#&OD@" I'Y88' B+?Z,".N!)D
MN/O$\CY>* '!2P 6=$W!%64,=J;^8Y-W7;%_JPW4L=K86ERI&]HB(\,YMR,$
M)G:T)QTVM^];'W/X,]::QAPQF$ABQ*9?F&\H#B[Y'&\OCD<%>%PU2()3<JN5
M^U^:J[EX'VC;D$9Z#R>$S]T_?S0 Z%?$4\MF(;'PU*]VK7"?OIV.PI@NW'1A
MM!_O$C.>M7/[%\5;<?V?X9P @_U]QGY/NGIU XSUQQTJ]X(LBFF1:A&L<<-U
M"A*;F=RRY&XL?48R!QQQ73SN8X)' R54D#\* /(K/3;:YTZ&YO(7FDV,[?.Z
MB1$;;Y8P>0IQ(3C*@ J"<U8/A^Q#&,K+(X)C++(Q,C ;F8#=@F8<*O1@-Q.[
MBJ]C<W:*IT_1?+62:,PE)E7-QY8!8[N,^6&V_P (8DM4]K?K(XBEL3:P?9Q+
M&7?>ODA\0 @'.T.=SC[Q/(^48H!"'1+#:77Y> RR?:)-J[Q\DF[.=L6-F[J6
M.TX%4_"!QX8AD9&9,/(8F&,IPK1<>C?O&_N8^3-61J5U+"93I,_E.LS,QN8P
MYCQ_I)STWEL<]-O"X:L;3-&BGL;%8UN$U-G5"1O6,2\L''8#R?N<_*?O"@#L
M-LH?:97ED5]I<*"7=5R6 Z$S+\JCHP&2=W%, +* LZQA@@63<=J;SF-]W7;%
M]P-U+':<+6&V9KK3I9X(HD3REC5F+J8RSB$J =VWS,%P?F)P1\M;;&+#&;S"
MG[TR_,-Y4<7?/3>6QS]TKPN&H <7PID,3!,.Y@(P=H.UX2!T(;]ZP'W!RF>M
M<YK4$2ZS!;K"UU=R*JJD-O&YED1MQG*L0,N@*ISAPQ+9/%=&!+YH"E?M?F*
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MH3*OR*.C@98YXJI>J7T^0*H=66/"@DKAV'EG/#;8N4W_ 'LG;P*91Z#X?_Y
M%E_US%:59?AM2OARP4G)$(!//]>:U* "BBB@ HHHH **** "BBB@ HHHH **
M** ..U7Q'JEOXQATBV72A%F*5C-.!*\3,J, N00P))R>#@  D\:OB*ZOM/BC
MN[?4+*SMD/[]KN%G7&"<Y5ACH<YKD-=M%O/']G=6]C/-&L\#RR1Z@J03+N4
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M&\QYQ=\CC>7QR."G"X:G%Y"S/(OEN6=W ?&QF&V?#]O)7&)/X,[.: 9%93'
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M7K-Y&LLP&I"+:D(E&9(MPW?NR><<_-U'KVH T/)V>$UB@AF@6.V&V#RQ(^T
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M //M/A\467BJYNM0LUN[&2=P\DU]%LA4R#RGC39E<)P1NY/-=-X@\.6_B".
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MJ3;G(\U<L4ZKC>>*V6O=09#;2WLTPP(&^4-YAC&XG:>"95.U5Z,.2<\55 +
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MFU?4;O[0K(DMO=O"IC/RD?*W.[;DGH?I6Q=?#"RGD<Q:_KT*2* \9NQ,K,.
M_P"\5B&   (Q@=* ,:\-O]HM_M(E*^;/OP1NV[&^UY/3>3W'R[>%PU6AYWG
M*5^U^8H!7[OVC9\F,_P^3]S/0_?JW<> GBN;)1XFU<AIE !2W(4)&Y4 >5C
M(SCIDD]>:J-X.NVAD*:MXFEA4-&23:JTBELN0&CR=QZDX+#KQB@",?9_*7RM
MOV?RT\L-NQY);_1\]\>;G>/O$\K\M*_E_/YY?9^]\WD;]O\ R]\]-Y;'(^79
MPN&K5C\"23*LZ^*]>5G)DR5@5@S+C./*R"!P/[O;%.'P^==N/%.L@+LPNVVQ
MA/NC'E8P#SCIGGK0!E@3>< I7[7YBA2OW?M&SY,9_A\G[F>A^_6;'*BZO)"J
MJ+&2TB:WRK8\H.?)#=\>81O ^8GE?EKIH_AMIY1A>:SKMV[!P7:^:/AL;AB/
M:.<<G&3W-84^AV>B>*KL6\MU++]GC97N;LN^&#*[!FR4V( 0_1<8_BH R_%1
MA&G*;CS=XEF(V@,V[8WVK/;<6Q@CY=N-N&S47AA;Z2QN7MKFV%PVH$1.L>4-
MQY2[/3@1Y"D]Q\]7M:L9M0LHK:"$/^]CW(!L+! ?*0+V$H.XQ]5Y?H:BT'34
MT^SNK=[C]W),_P RL&$<+!3O&.N741G_ )ZCI4O=$O=%B&.X" S75H]AY285
M+9U)@R?)ZN3CS>7'WL],K39-3LK*%C?%X8%BE=G+ LZY"W07UD+%0.Q4@+\U
M:1>4LTABQ,6:0Q[P-LA7;(N[MY2\A^B9V')-0"%)1:RR6<4L\!1X$>(':Z#]
MRH7J/,!+%.JD;SQ2?QKT)?\ $7H5;C5VL+:&[NX6MIFDCSN( BN/+)3.3@!8
MAA>N&/SYK0D2SAMT<W>GI9-B*)Y+Q AC'SP@G=R ^3)@Y)^[\O%8FNVUO<ZC
MH,4D[LHN)Q&WFC,BF"5C+NQ][>-F[_EICCI727&G6S63Z)]G'VVUB\Z2?)P(
M0#MD4$XW,05QV(<] ,TBTK&;9WL&I:4VJ1)=S6)+>9,D#%F#G%SC P78@8(^
M4K]W#52N?$#6CPM]DU.&Z8B4@Z9./G4[%(#+]T1\+[YW9KK_  II,LNB6QEG
M467GO.MO&FW<0YP&.?N@C. !T&?2J/CG4ELM<LE:VNY?W.[=#"7'WCQD=Z&K
MJP2CS*QS1\1Z<JLB66I^2@:(*VGSX$:'=$IXSC><OW)Z$#BI;G4I9;<^7IFM
M^9(Z[9'TZ5"3*1YS;BH4.S8 /W0O8'FLV#4C;_;7D@UJ5615B6>UY7K(X&%!
M^\YZDUZEK)$W@R1F0@/;QDJXY'W>"*+>8K/N6_#G_(NV(^;B(#YNOX^]:E0V
MB+'9PHBA5"   8 XJ:F4%%%% !1110 4444 %%%% !1110 444'I0!YKJUM=
MR_%,2RVMTUJAM?(D>VNI8\Y);8T;!$QQG>&&>3QQ78>(-2N-(6&\AL;:=,^7
M)+/=>0(@Q').TC'KTZ"O/[V5M:^)=O=6*:BN)EBD!MT^>**4!V60R#9'OC (
M*[FRVT'/'?>+7DCT&1HYQ%^\3<#YGSKGYE'EC?R,]/Y9H FT"_74=+:Y6V@@
MS,X(@E$B.0Q^97  ;/7.*R=/UV\N/%3V4U[;"-2\:6RQL&D"Y+2;B!T.U=H)
MXR>XJYHMRR^%I)5.QX1)_K?/?81D\B7$F/;\NU4/#UKJ=SJ3:A?3O^[=@UM+
MYH,3D9RJEV7&&[9X./6@#KZ*** "BBB@ HHHH 1T61&1U#*PP589!%1QVUO"
M28H(XR>I5 ,U+10!&T$3HR/$C*QRRE00?K3U544*JA5'0 8Q2T4 <M/J<.FZ
M_?ZA<NT@2(PE$*;D5<,/E)!).YO6N1UK5K"\U>ZN8M/O)%D"$-]C8$GY<]?H
M:]5**QR5!/THV)_=7\J /-H;W1_[9_M+^SW%DA'FQR0KN5VR<",_,P!8<@'I
M[5HW6J^%KS7[76YH-1-]:ILB<6TH 7G@C&#U/6NX\M/[H_*C8G]U?RH \>O]
M?A_X2K4=26SO);>^>)(2D(9T6)")0R$_Q@;=IX(Y/04Q?$H>)6CL-35F12CB
M$G:S']VV<Y/E+\H;JV=IP*]D\M/[H_*C8O\ ='Y4 >//XD@78RZ5?20R1M*L
M4<7 BZ"(X/R_/^\_Z9_PYH/B((&:33]4?8RB23[*,L0/WK[2<'S 0NWH<;CS
M7L.Q?[H_*C8O]T?E0!Y%)K;QR/"MC?\ FJ /,B7>$<\QMNSD^4O&[JV=IXIG
M_"0IYJK_ &)J2Q-)M6-HE5=A'RQDAOE4O^\S_P LS]VO8/+3^Z/RHV)_='Y4
M >0G72)&4V.H3%'VO,MNI#L/]:^,X/F?<V]#C<>:CFU5[VSNK5=/NXY9+60(
M)OD!8\( ^<YC4[=WWF!(Z"O8MB?W1^5'EI_='Y4 8_AA4BTK[/"T9AA;9&(P
M-JC:K$#'& 6(K:I  .@Q2T 8&NZN-/U'3HY+69_,F(@9,8D<QN-F3]T]#D\8
MSSQ69/IME=:R]R^IVD5ZL@^[\TL3'8=A;/0 <#'\73UL>(X@+X7-U;"2UC3,
M<@2([&VN#DOWR4(SQU[T^*XU2)U5MZRB2(>7%;+Y+)@ MO[=^XQ@#![@'0V]
MS#<QAX7# @''?!Z9%35RVDI/'J$$L=H\,+L(I%(FY(0DG#-@*IVJ,CGG':NI
MH *\U\5W7V/QA-*S'RA:HSXB5MJ*'+X)^\6'R[#P<D]A7I502V-I.Y>:UAD8
MC!9XP3C\: /)SKUJ(R1+''@* XN$(0M\T3;MV2(EXW]23L.!5<>*-(\O[0(U
M$,K$B(LBETX7R\ _+E_WA_YY_P ->PBTM@.+>(8_V!1]DM@<BWBS_N"DTF)I
M,\?;Q7IX5@;O=( <R@*2S)_K)-N>3(,(%Z/C<>:5?$MG'# CW"I+)&NQC*IV
MEAF-B0<XB7(W'DD[#Q7L'V:#_GA'_P!\"D%I;#I;Q#_@ HMK<+*]SQ2YURQU
M#4=,FM8U9+<SW1!:-3##Y#H4P3P6=@Y7HG\.:ZN;4[8V;2I=69UAU9I6-Y$(
MW5AM,>=WW  ,>Z@]S7=SZ9I]T%%Q8VTP4Y DA5L'\14OV2VQC[/%C_<%,9RG
MAW7HK/1[>SDMIC(D8E^4J04D)93U[@U1U^^_M6\MI;:-","(*9XPQ9FP.-WO
M7:#2M.'2PM1_VQ7_  H.EZ>1@V-L1Z>2O^% 'F4]Z9%FC%O(&$A4]^0 IY''
M5375#68-?LQHUO!<I(\:>8[!5"(&4,>3S[<&NLCC2*-8XT5$48"J, ?A4<]G
M;7)4W%O%*5Z>8@;'YT 0:1*\VDVSR.'8I@L!C..,U=IL<:11K'&BHBC"JHP
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
***** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g201805072101259922283.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g201805072101259922283.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,. ;,# 2(  A$! Q$!_\0
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M]G<F0>7"-H3[.WS.P7!SGCY01_P*@#J[?QCJUT<0>&)GQ]XBX'R]>OR^QZ5
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MVT1X_B)D^?'_ "V'.>,5)\+FN%O->M9I8I%MG@0L@Y:1D+R-G/()88],$=J
M/1J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH #7E?@J
M&YO+G5O--K+:SY@V7 9-S"67(7CDY4],XQ[5ZI7EFF('TD;KCRU-Q=HV3Q&#
M>S_OB.OR$ C'0L"2!F@#9E7Q7=:0+.:]\.,AC3,HGDW,-P"MTQR1C/K5!?#?
MB9^FHZ$%C<<#S&Y08()XZ=_2J]P9VN(U3,;,LLK0LBN2PVJT)'?(/FO@8;^
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M-PJD\R X8$<T .OF3^S97MXR$*(T<>WGRG<"-,$\GS,L5S^^Z@XXJ.>YG%Y
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M5!=WD%C 9KAPD8(&<$DD\  #DD^@J"+5;66Z6V)DBF=2R)-&T9?'7;D<X]J
M+U>/:%#,([AI;EH8I))4"O+N$?\ I,H:<C/ 1QD$8.Y@20,U[#7DVG/;+:+Y
MJ.S*]\[D-C, O)_-4'/RLP*C/< J"": +,I8WT+-&Q.R>1K=L<GY5>$@=R/W
MK@ @]4!ZTMLA%Y<*+AY"LT:K(&7+%8U*2 Y(W2@[%)XP,,2>*BN(7DU*TC$[
M17*EE5XUV SA59&P<X41?*!C]T>3GK5>VM(&FN-ES=B$^5M4@,1"^/)4CN1)
MDLO60?,"1Q0 ]%4Z)!F58T:.(%\_+&CR*<]<[8&XZ[@Q_A7JMC:/;W<L[6CB
M38XDC8+F9P3N3C.=ZXD?CD ; >M5/LZ#18Y);N\* %Y<2#+ ,HN<-ZL?NOG&
M/DX/70%O<0WT"1W+M(TGE9=,*)A&6B8#'RA8P1@_ZMN2&SF@"2^W+9R#S&FP
MT2B3(RY4@I*#G[T@_=H2<8&')/%5$CF6\070A$4GF>41DB"-CD]@0D+8X^\&
M/55J>^$<FFR^1F.-XT,?R\K"[@1KUYQ)EF7K+U!(^6HY[:1;N(M>76,W#38F
M4$E5 GPV.2W&V3H!\GRDT 6(2?[3NR;4EPX=HR!N=@F&B;C&YQ^\; P1C8"W
M-5!@: VQ0X6/:KICY]N2DHR>K_ZM"3C'#DGBI8+*X_M"6-;V8.)($CX  E";
MHCLV_*H3C81^[;YB"#FJ@MF.A-(MW<;#;ED#,'_<LYV*2/O'S.6Y_>CD$XQ0
M!KD@H3L$:%"2,?*BLW(]=D+<_P!X,>-JUCVJ:J3=R6UPKC[9=-Y$\*R/YBL0
MT1*MC]XO[Q@!@C&T;N:V7WAF,C9<&0R,#@ED&+A@_3++@+)T ^3Y36=;QM87
M)M[>>U+3W60"GEF*5\M =A)RJ [=F 8V.XAJ %6WUG>J+JEN1N1%G%MR0!F.
M8$MU)_=*3VX<D\5I_"M9 FJ&:%XYF\EG)?<!D,0@Y.-@XQV.>V*B C,>[R\V
MICW>64+$P,V-A_O$R_,PS^]'*DXQ5[X<K,+C6FF(+%K=9'#9\R41 .WT)QCT
M  P,4 =Y1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 ':O-VNM-;Q_.;71,O-+<6;WGVQD/GK;AW*Q_=4
ME0JF3ACCTZ^D'I7E6OKI&M>([ZW71K<Z[!<,O[^ZFAC-NL(+7$PCQE2"8QUS
MG!.,@ '>>$YK*X\):1-IUN;>R>TB:"$G)C3:,+GOCU[ULUF>'+V'4?#6F7MO
M:?9(9[6.1+?&/*4J,+] .*TZ "BBB@ HHHH **** "FNXC1G.<*,G R?RIU0
MW3F*SFD"LQ1"P5>IP.@]Z ,R\U*+4;0PZ5<)+=O$)H]G.%R.<D$*Q&0-W?Z&
MDTBWU".:3^T)'>-\O$DSJSH=S<?*.RE<]?YYPM^FVUO,8V%RM] 9KQ(KM@HD
M.Q=Q/&T'^\<'C.#S3KJXMHKN2"$+:2I:N[R6DBS IQGK@ALA0!WW4 =K7COA
MRVN[47$D=K %FNY&@V')DN(YYE0%3C.XJY(Z +NR"*]2TF[DNK60S;A-%*T<
M@*@8([<$@]17F^E;9++Y;U$'G72.N_B/=>SXF;G("$#! SEAD@9H FF4_NVA
MVR6H@:,DS')@=PP<'!W$RC:"1F4=01S2)+J"7,\LUK;AWE>5A]L("OL"7 W8
MX5% ^8?ZLG:"V<56UB^GMIK149H?M#S;HV@$I! PT)4>O^M? P!RF>IE%KJ_
MF +K7F$. LJVR$N57*2 EL%I1\BDG# ?,2>* $1=16SA@CM83/'Y 0&8_,\9
M!MU*XZLH)9,X ^?Y33RIFFA:5$2T1)%,BW!D/D.>6'R_,3+\JGK*."".:SKE
M]4M[BW@.KVL$,T8"S2P;8U!;H#G($+=,X8$D<+4VH-JMC8SWDE^C>4KR-#):
M(N3D*\1P< L/WC#IT*Y.30!=U2?%I)]H(6>60_(K,<SXQ*@(R0%C&=X_U1X!
M(XJ,-<SR6MQ!;QML"&%?-Y<X_P!&&W;C++DF/ICY_E-&FAIKII?[56_DB<0)
M/"J J0 P?[Q!:0#RU)X('S$GY:JZ/)=22W44TX2U@!BC4I@*A?[V[[VR ^P(
M8XRJT 6TWK+/*8HC;RIAF%T3B'/SL&VY8^9\JL1F3[I! S3/)O&LGM9(84F<
MOO87.T+*RD3#@<!(SG(/[L_*I/2B::^EUN2WB<(D4/GM;/"KO(=Q62(]@74;
MV XP04!/-5M=O]0TYTDLYFE2,0[BL89G)<!)@QZ;@=BGD$*0YSQ0!L@(,"(E
ML>6L8*\G;S;#9TR_.8^F/G.TUS,NC:/>ZDSQ1SR1F=Y+J[:=FC6,MF<*QY<B
M7Y%('S<@CC-=,2"A^01H4)Q_ BLV,>NR!N3_ !!CQM6J>EF18KIG26=A?73&
M)PI8E7(:$@9&9!\[#IMY5=W- $?]AZ;ORUC$+C<24,K!1,!ATSGA1'\Q.?W9
MX!;I6A\)[."T&K"*,(2(,,)"WF1[28G(Z E&!/KD'O2J&W*BRL3E$%PN,D_>
M289[D?ND)//1R3Q5CX:2I+/K)2.)<_9F^1LE,Q_ZL^FPY7&>N< #% 'H%%%1
MQ3Q3H7AE2102I*,",C@CB@"2BC.** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** *]]!+<V,\$%R]M+)&RI.@!:,D<
M, >"1UYK@]4OR-6NK:#Q#XLGD@*QSKINFQS11/M!VEO)/.""1DXW5Z(>E>4R
M:Q:V?BSQ%%+XR3P^WVM<6L4$;K(/+7]Z6D5OG)R"!C&T9'<@'I.DL6TFU9GN
M9&,2Y:ZC"2GCJZ@##>HP*NU3TJ5)])M)4O?MRO$K"ZP!YV1][   SUX%7* "
MBBB@ HHHH **** "F2Y\IB"00,@@9_2GU'.VR"1]VW:I.3CCWYH XO3IK^^>
M]$-Y)?3-& LV'@V8(W*8V4*C,.AYI]_8:Q#,(TA6>W@0S6TBVZ.6F!^42+CC
M R"RXS@8(-.TR>VM[X7\UV;RY90GGSRPE@I=5.-OW5!.>@%;1\26!G:.)C/B
M+>/)^8L=X3;CUW$=?6@"WI2.EE^\,AD9V9R\(CR2<G"CH/S/J37EFBP6]NDT
MDRY9VN6<1C;^XCN)4E .>&8 <D<C*@@G->L6=['?1,\:NA1S&Z.,,C#J#_GO
M7F]C,OE1IIXCFC6:61,'<6N/M,SHA&?F#98D'&  V1M% #;BQEGU*PE2=8[B
MUF/W8L!IS&?+(S]U1$< 8)C/+9SFLTZC:Z;JLEK,P^P7*)+:1F%F*QR,=B,,
M\@2_,RYR^<J2!BM=YK5/*MWN$$4R,D9,FYGA)W%Q_>/F?*#C]\.HXS7.:O:W
M&H^)V:!HO/B,<UVGG[/*<9$H#YX")_%G,9;:#VH IZWXFAF>2*WF)2:"2*9+
M@!?GZ3D$\-(V5 P.5)4!6%:WB2^LQ'/H]P4^U3)'A0NT>83^Y.TG(18U( Q^
M[/+9R#7._P#"'7W^NN'2-K?]XBA>7/+11X!^5F W$8X4[SS73:[\*M4O+IY[
M+RS^[5$$MVY?YRS2%G/4JVT=/G!.<8H J>&6AFN;^X\E5BD@M]R- <^5ND2)
M6 Z_,%=D!R^[(XX-S24:+4=2:Y*M(TLS,4 #$(S"Y);@;WSP^ ,#;\I.:N6_
M@3Q3;2W-W_:4C7\ZJ7D\V,JS\ID93*XC)VXY7H,U5T:UFT^^U&S>=+JYBN-D
MK*H ,J,?(41CCYQDE.G&_((H L*SQ^(I4,T4<AMX4B+?*BR[F,)"'D!4P #]
MQN6#9S6?XF#/IK&WVBV\N!U21"^(FN5"C:,G/F_,Q_Y:<%6P"*EN+""]UVX#
M3ND!L!')*OS_ +AY&,C!SU/F#:K8S)C&#UJ'Q:4:VDDN7\J8M$[*)-H$OFJL
MB[N>$CPW_3(_*&.> #HGWAV,AS(&D,C X)=1_I)#=,LN K] /D^5JP]0TCRH
MY9]):.#4DECE7+RK$)"?,A)CR<*$##:1E&^9LCFMK"@A8R6QL6,%>6VG-N-G
MJYSF/IC]Y\IK+U&"PMTO-1FN&C66U:WDE24G]T[?.^X#)*R'8K_\M,E<8^:@
M"GH\^OWMJTUVVCQ0* NR&&6;,)?#@_.,YEPQ .9.Q(&*VOAQ9ZE#IDT=A?Z5
M'+&[172/:N[M,LC[GR)%RIR,'VQU!K#\/:YIJ69!U"/SUN6E F)B)D;Y2#Z
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M3^]FA\LN,  CLW ^\,9.>!7 07NGW39#22-&D[2%<C_1S-(9 N>C,I7GH1D
M@D4 9^ORF*\TNX=84$<L\QBNB%5<(4>)L=#D^:P P/X.N:NPWMA;.T:ZK"\Q
MF.^82H6DD4;C(,G&95^103M*CYB3Q3KZ[CM'"RP--<CY@8K?<JRJ 4;!Z*(C
MA0?N')<'K547^FM&#'I-S]F*#8#8$CR2?W((SDCS.6&<N>0<<4 0:AK5D[QV
MBZE:P6LL(,DP/F*JR'Y OHL1!&X_,"0N IX]9O-0@TRQ%S<&5T#*F8HFD8DD
M ?*H)Y)%>7+J=D9S&^FWGFKN:0?9!O Z7)W=-Q. '^[@;1M;FN]\52QP^&))
M"LYA#)E(8G?<N1PP0A@OJ0>._&10!I:=JL.IM,L4-S'Y)4'[1 \1.1G@, ?Q
MKS=&7_A)->A\W:T=P^\N0,AY/EE.#D)$?XA\P) R%)-=GX,=I-+DDV-'"SCR
MHQN* 8ZJ69B<_@/;N>3U75;!=>U!8+*Z8132*[0VQ!_Z>#N/\17 #_=Q\HP>
M: ,N]_L]O$<IU!%!2W$BP22>6[LKD-$5!"Y8XD8 $ '* DDUF>+9+=-0C6<K
M<7B>1%!N)WR$MN\]!]UMP_=KDG('S'/%;+:Q"+N*'[!<"^?'D*;$_P"L7!AV
M@\A5C/"_P$[FW=:5M5LF #:==&V\MG42VI.;<'(')R29>6 .9/X3@8H U"04
M)""-"F<$_*BLV ,]=L+<D_>#' VK61:Z>ET\]Q=_;+EDO;@_9FD !\MSF$H"
M5W/@2$= O*@FM<,[#S'8ESO=V!&XN%_TDANFXI@*WW0/E^5JR(9X;&\^SV%Y
M9,\UV-T3';Y4S9:%E!YV*"?W9Y1CDY% &PL?SJH(9MT:"=54Y;[R3#/7</W2
M9/S?QDGBL?P3J,FBO$D^HA+'[3%;E&A *B57D6(MR24=MG&.<\ 5I>=:&/)>
M+[*8R2K<G[.6Y4X/)\WYGQS(/NG'%<O!*UU;D7+S.C:O:[S(I4>:L3+)M(Y*
M[ER#G@8% 'M\MY:P.5FN88V !(=P#SG'YX/Y5QO@M;2'7=6@BD6:Y7:9)HB&
MB())"@]2PS\V>YK T6^L+OQ+=3ZW?[6>PA"RLY4MS(",^F&/YUU&@W/A'0(9
M_L6IPLTTC22S.^YF)/0G'0= .U '1:I_J(/^OF'_ -#%7JYZZ\0Z1?&UM[74
M(997N8MJ*>3\X-=#0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJ17M_-#^[5N+6,Q,SD !B^XMP < 8Z]ZZ"B@""T@DMH/*DN))R#P\@&['H<
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MJY^QU:VL99[2%,W;7CLBI&=AFWDVV QSM$9R!V;ELC% '1#SMX03,TNY4$X
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M!NU,N]W,8K:&XF12DNXE0Y\R9G_B*, F<#?]WM5;^V]0*;D\,7Z(4++_ *3
M JDXB^;?D",_Q]5)V' J"RU#5+19TN/#.H3*US/*4#6ZGR\EI(MN_JQ.XJ/N
M_?7/6@#HP\GF"3R\3AQ)Y(;:!*!M\O\ V0L?S@_\LCP<YIWPRM[>+4-:>$Q$
ME+5 R1X:1!'\LC'U8'/OG=_%6&NKZN2J_P#".:@9B47S1-;MF4\^8/GP<I\@
M[2_Q<\5L_"J=IY-2DDM_)>2*%E4=(D&]%BSDY*[<'."N<= * /2:*** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M.*\?W-C9RZ///>:C8WJ32-:W5C:BX,8\L^9O3!RNWV., U2\.^&M,OHK!]'\
M3M?Z%;78O?LXVR,UP,DLT@Y +DN5(^]Z#BNOOM'6^UK2=2,S(VG-*RQA<A]Z
M;.3VQG-8OB#3/#>E7UOXBNM.FCO$G4-=Z?#)O]<RB/EDXYW B@#K.U>2ZC-X
M>D\7ZEYWBF3P]=65Z[/!OC996DA5#*C,OREE)! )P5SUKTR?5[&VT<:I).#9
M>6LGFQJ9 5;&" H).<CH*Q?^%A>%O^?V7_P!G_\ B* -G0X-/MM!L(-*=7T^
M.W1;=E;<#&  ISWX[UH5!:74-[:175NQ:&5 Z$J5R#TX/(_&IZ "BBB@ HHH
MH **** "BBB@ HHHH .HYIC11L<LBMD8Y&>/2GT4 ,\J/.=BYSG.._3/Y4>3
M'C C7C Z>G3\J?10 SR8L8\M<$$=/7K^='EIG.Q<YSG'?&,_E3Z* &>3&!@1
MKP .GIT_*CRHR,&-><CIZ]?SI]% #?+3.=@SG.<=\8S^5)Y,8&!&N  .GIT_
M*GT4 ,\F,]8UYSGCUZ_G1Y:9SL&<YSCOC&?RI]% #/)BQCRUQ@#&.PZ4X*%&
M%  ]J6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH YOQ1/JHO-&LM.NY+&*\N6CN+N*!96C C9E&&! W$8W
M$>W>N:M(O%=O<Z/K%]J6H/>WFI&UN-,6("V6W!9=X7!*G:@DW$]\=ZZ+Q=+K
M+7&D:?I5\^G)>7+)<7R0+*T0$;,J@-D#<1C)_K6)?ZGXHT>YT?2=1=[II]2M
MU35+2#:DT6[YTF3D1MCN/E8=,$$4 >@  * !C'0"O,/$-IXBEUBZO;B]\0PV
M*7SP>7I18[;<P QR(B@ESYN=QY/;&*](O[>*[TZXMYGE2*2)D9X7*NH(Y*D<
M@^A'->80:UX1U:;499V\0I+;W!@3R9M1Q(%1<,50 (3GE< ]^] 'H?AH7J^&
M=,&I*ZWPM8_M =]S>9M&[)[G-:M9GAYI'\.Z<\MI+:2-;(6MYI#(\1VCY69N
M21ZGFM.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH J:G>#3M+N[XQ>;]GA>4H&"EMJDXR>!G'>LS2O&
MGAO6(K5K36].>6Z53' +I/,)(^[MSG/MBM#6II[?0[^>U@%Q<1VTCQ0D9$CA
M20N.^3Q7G6FZA%;7/AZZM?$EMK-UJ-PD<UDMO ,!AEG0(H>/R^^XGI@\T >E
MWMNUW8SVZ7$MLTL;()H2 \>1C<N01D=L@UP.IRV"ZO=P0:QXQGFA94N!I<+2
M11R;1P2L9&[&"1GO7?7EU]BL)[GR)I_*C9_)@7=(^!G:H[D]A7GEXFLV6N:C
M<:6/%5O%>2K.\=MI]F\6[8!D>8V<X !SU(H [_2>=)M"&NF!B7#7:XF/'\8P
M,-Z\5<JEI+SOI-JUR9S.8E,AN$5)-V.=RK\H/J!Q5V@ HHHH **** "BD9@B
M%F("@9))P!7,#XA^&&R5U"1H03FX6TF,/'4^9LV8]\XH ZBBF12I-$DL3J\;
MJ&5U.0P/0@]Q3Z "BBB@ HJM?W]OIEC+>7;E((AEV"ECUQT&2>3VK-/BK2U$
M98W2^9NV!K.4$[2 W&W/!(_.@#;HK#_X2[1\J/-N,L,K_HDO/_CM/;Q3IB+
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M/^>JJI)7\0,?C7F[Z5<W5W'IOA\ZA):)IT-Y+:MKLL4/ER;@L41"EB/D;DD
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MSL%W]2$P@_X$.<]^Y[5G>'_('AS3%;*J;6W#,'Q\H&2_3^]\OJ/85J3"X(E
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MZ9X%='_PCS?]!O5__ @?_$UBW=TUG\0#*EC<W1,!4^0 2HVKU!(K:_M^;_H
MZM_W[3_XN@#%U#0;71YK"Y@U&^:9KZ%?+EN?E;<XS\HQ[UJ>*+N&QET.XN&9
M8DU$;BJ,Y_U,HZ*":R[#59K2^1[_ ,-7L<MS<A&OIFC.-S80#YB0 "  *W-;
M5VOM"*JQ"ZAEB!T'DRC)]N?UH B_X3#1-VW[1<;L9Q]CFSC_ +XIOABYBO%U
M:X@+&.2_<J60J?N)V(!%6]7A>*&;4(+B6*:.+&%VE6 .>00?TJ'0/^/C6O\
ML(/_ .@)0!9M-/GM]2FN7NFDCDW8C^;C)!'5B.,8& .M:-%% !1110 4444
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M0WTPBCEW(R8#$'#C.5X//'?-0> M'O+(W%]<+8)#-:VMM#]AF\R.80JP\[.
M/FW  <X"CFI_%:QW%WI=_97.G37NDW+2BSNKE8UDRA0C/.UQG()!Y^N: (?!
M4S:SJ>J>) ^GI'=I%;BWLKCSL&,OEI&  WG>!C'  KLZY/PO%=W6NZKK=Y_9
M\$EU%#"+2SN!-M"%_GD<  L=V.G11S764 8WBJW%UX:O("X3>%&X]!\PZ^U<
M+X4T.&X\-13/>R&1S*S"&0A"3,VP* ,8+9X[UZ#K[!-%G=F554H26. /G'7V
MKD/"3P/X6A(8.I\_#QM\K9E.['7A1SCWXI]!=2VWARSW-NO[K9NEW'SF^Z!^
M\/3^]QGMT]J2/PS;IY<:7=PC*T:JBR$*KXZ 8X 3G';KQ6L6B$I8*[$2%@N\
M<D+A!_P,<^_?TIJ_9]JKN;9B)=^_^$'._I_>^7U'L*0SFM;T2WMM NIX+NX<
MI &17D+ J9 (\C'.3D^_ZUT5[:6EU')#?-#);F1S('S@@ >8?^^L >G3GI65
MKL-[?V<UE;6L0BFB??))/AD8OEU"A?X0 ?QR,U-XB918I)#;S3M'J%O+L3YV
M*HZ8P,<E@"<]\<GM0 +X7T@LH^PVGG$QC!5O]81TQ_N<D?CQ67<:!I UJSM8
MH(!;2VTDWEA<[@C 1?,1GDN<XX; SG%:(U_3P@!M=4V!$!?[+)]T-DMT['Y?
M;V%4+C6[9M=M9?L.H#;;7*LAMFW;G9,J%QR% R>W(ZYH TSX7T(2-OLK3:'?
M<0'QM"_O3U]>GIZ]JL6.DV6GR_Z'%;P7#^2&"J<E^2N1Z!<DCUYXJL/$-CYH
M9;+56_>!A_HS\_+A.W\?KWZ'TJOI\\-[X@EG6"[BMA800F69#'TE=F(R,_*2
M![9[4 1M8QZAK>I))=S+;0PQ&$1R$91L[1TY)8=>XZYZU</ART\P[]0N<!WW
M-Y[=E_>GI^ ]/7M61J.KKI&LS7L<<%Q%J$T=L8TGS)%(Q*$%0#D*#N/;OS76
M[H1-E5D;$H*_O!\V%PG/^WZ]^A/:@#'7PY;_ "XOKD2'RP!YIX<_=&,=EY(_
M'BJ]]X;L6TRZ O[KRC;2X_?G_5\A>W4MW[CCFMP>1Y2J=X3RT4OOQA=V6;IQ
MM/R_[/L*CO73[%=$Q.'\J<E-PX8CE/P7YL=^HS0!S7P=+/9:Z\BH'^WE&\L8
M7*#9D#WVY_&O3*\O^"QC.DZUY3[X_P"T)-K;MV1EL'/?([UZA3EN);!1112&
M%%%% !1110!Q<*7@^*]P[L39FT C4.,!L+G*XSGWSCKQ7:5QEW:&]\?M&M]=
MVQ$))^SD+GY5ZD@UL_\ "/R?]!W5_P#O\G_Q% $5X9]=DCBM(E%K;7D;M<2M
M@.4?+! !SC&,G SZUKW-W!:R6T<S$-<2^5$ "<MM9L?DIKD9]*CTO4;2.PUG
M6+BZ6ZB,EJ;EG149QN+*!A1@D\X%;FN_\?\ H'_81_\ :$U #O$5U)%8_9(+
M.:ZN+H,B1Q,BXP,DDNP&*@\+RO/_ &M+)!);NVH.3%(5++\B<':2/R)J[KL,
M4ND7#21HY1"R%E!VGU'H:KZ!_P ?&M?]A%__ $!* -JBBB@ HHHH **** ."
M^&,$L$.N"6.5-]\6'F'.1CJ/:N]KF/!WW=0_ZZC^5=/0 4444 %%%% &5KMV
M\5A-9V=Q''JUU!,+!7/WY50D8^G!K@-)-LFI:)_82:__ &UYZ#5?MHN"OE8_
M>^<9/DSG[NWOC'%=9XHT"\UO6M!DM[FXM8;629IKBVD5)$#1D#&X'.3P>*GM
M/"TUK=Q7#>)M=N!&P8Q33QE']F C!Q^- &Q>WL&G:?<7UW(([>WB:65S_"JC
M)/Y"O.=1F_LK6I[C3M7\20R:O$-3DL['389A$NU4W$,A*G@ ]R17H6K:;#J^
MC7NF3EA#=P/ Y7J RD''OS7*/:>,% @33-';4!;_ &4:V;AAB/U\K9G/?;NQ
MGO0!U.B727NAV-U'=M>1S0)(MPZA6E! (8@  $^@ KDM4^'L>L:EJUS>);/)
M=7MO-%=-N,GV=5026YQC"$*XP#@[^177:-ID.BZ)8Z7 S-%:0) K-U8* ,GW
M-8=SX1N;WQ!?7D^O:NEG.L9A@MKZ2(0L 0P 7@J<*?7.Z@"30M&M]*\6ZZ]H
M+*WAN(K8BSML J0'!D90 %+?='J(ZZ:N;T#PL^A:]J5Z+^YNX;N""-?M<[32
MJ4,A.6;^'YQ@?7UKI* "BBB@"*YN8;.UEN;B5(H(4,DDCG"HH&22>P KRR]U
M>PTSQ1K%PMUX-N8[Z2*=?[1O66=?W2@9/E-\I ! SQDGOQZ?J$5S/8316<D$
M=PZX1IXC(@_WE!&1CW%<#;ZMXKEOM;LO[<\,VSZ6RH%N+)T+YC#[B/-^6/D
M-SG#>E '<:)<+=:)9SI]DVR1!A]C?=#_ , .!D?@*\W\2Z[X8T^;Q,+[2_#A
MU:TND%LES:H9+A62)F=L\L<N_(]*] \*ZE+K/A72]2GV^;=6R2OM0HN2,G )
M.!^-.UK7;'0HX#=)/++<R>7!!;0M++*V"2%5>> "2>@Q0!3\,W/A*X:Y'A@Z
M264+Y_V!$4XYV[MH^N,^]=#65HVMQZPTP33=2L_* R;VT:'=G/W<]>G\JU:
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M\]:]&[5YKX&T?3]5N_$$MW:L66_8*I=D*#DX(4XXKL/^$2T3_GS;_O\ R?\
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MVYSTP?QJK>^)FT^&:>XT74EAB)W2!4(QG&?O9Q4?ANW-KJNOPM*TK+=1DNP
M+$PH2<#COVJ;QC_R*.H_]<Q_,4 ._MVY_P"@!JG_ 'S'_P#%U+8:U]MO9;1[
M&ZM9HXQ*5G"\J20,8)[@UJUA++&OCF:-G4/)IZ;%)Y;$C9Q],B@!T?B2U&K3
MV%T\%LT08YEEVG@@#@@#G.1@GI5:Y:PGN9)E\6R0JYR(X[J':O'09!-7T71[
M_5[R+[-!-=P+&L[/$&QD$J,GVS^=6?[)TW_H'VG_ 'Y7_"@#$CL].N+NVW^)
MIKMHIEDCA:YB(9P>. ,FK6M:IJ-IJ-K:V%ND[2HS,I'S<>F64?G46NV-G;'2
MY(+2")_[1@&Y(PIZGN*GO/\ D;=-_P"N,G\J *FF7&JZ=:&W&@7+KO9E"RPJ
M$!.=H&\X SQ5S^U]5_Z%RZ_\"(O_ (JMJB@#BOAW?RW]OJKRVK6[1W6S8QR>
MG^>G%=K7,>#ONW__ %U'\C73T %%%% !1110!S?BLA38/]LM;5XYO,C>\<I#
MN7!Y(8?-C.!R,;JU-#</H=DXD:4-"IWL,;N.N/2LSQ<OF6D,8EN]Y)9(;59"
M9",?>,?(4<@_[PZD"M71P1H]H&G,[>4N96SEN.OS<_GSZT 7J*** "BBB@ H
MHHH **** ,_7;^32O#VI:C#&));2UEG1&Z,54L!^E>71>+1>:I:V-_\ $:!;
M-[)KF2YM$BA9+C*@1EN1MP6(4C)QR37L-)M7^Z/RH Q?!^IW.L^#]*U&\*FY
MN+97D*K@,V.3CMGKCWKCO$/C'2-*;Q/%=1:,-2M;N(6\,\0WW"F*([V'5B-S
M $=EQVKTRDVCT'Y4 8N@:IX;U%K@:!<Z=,R!?.^Q[>,YQNV_0UMT@ '0 4M
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M13/%'B'3[SPU?6\+N9'CPH9"HZ@]3Q78USWC&W^UZ7:VV[;YM] F[&<9;TH
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MJ3.K?W;+_OI_\*,ZM_=LO^^G_P * '6-Q<237,%SY1>%E :,$ @J#T.:)O\
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MIG#F.*_B=RJ%B ,Y.!S61'9>7\6KB[,JL9+!0$(Y4<]#GIQZ=ZV?%-VUKI2
M).XFG2)D@8+(RD\JI)&"0,=<\\<T 16OC7P_>Z@]A;WS2748R\:V\GR_4[<#
MK4'B35K26-=.C:5KI;N#*"%\<2*Q^;&.GO1I>OVXNOLB>'=2L2$P'^QY0@=M
MR9'?^=:%SX@@M+HP2VUV,2"/S/*PA)QT)//7]#0!>NKV.T\L.DCM(VU%C0L2
M<$_R!J'^U!_SY7O_ 'X-&HLT=Q8S>5(Z1RL6\M"Q *,.@YZFE_M.+_GA>?\
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M[TJ+8,%+!?DP?E^4#G=SCH1[UOL&WMNG4+ODW,)#PNWYSGV/ /;H:S=>$O\
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M]+KS;X-K&- U$Q1")3?3879M('F/@$=L# _"O2:;W$M@HHHI#"BBB@ HHHH
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M3O*KNH[L1R?SKKJX#X7O</#KOVA[AB-08+YP/ QVR.GTXKOZ "BBB@ HHHH
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M_L6R\F-HXO(38C.SE1@8&YOF/U//K6%XCL](GU,3O!J?]J)&J"?3X'=E3)8
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M$DO]G:*".<-.N4..0?DX(Z&I]%N]-U&]M;K38K=1Y4RR&V *<,H'S@8/3(H
MZ6J]]_R#[G_KDW\C4S_ZMOI7'V]]HT8MK$V>FM<K:H\@N2(W]#P5)//4^] '
M0>'O^1:TO_KTB_\ 016E7*@Z9<9M4TW2RK HWD2*S1Y1V!P%& =AQ_\ 6KH=
M/8MIEJS$EC"A))R3P* .>Q_Q<DG<V?L2_+GCJW/UJWXJ>2.WTUX83-(NH0E8
MPP7<>>,G@55RW_"QR.-OV)<^N<M^E7_$7_,*_P"PC#_6@""XUG7XD4P^%9IB
M>H%]"N/S-7M!URVU_2TO;=7C;<T<T,HP\$JG#1N.S _GP1P16EVKG[[0'M[Z
MZUC2+B>WO)E4SV\83R[HITW!E.&(^7<"#C&>@H Z&H+JTCNT19"XV-O5D<J0
M<$=1[$US=[K4ESJ5@]A?LD!EACFM]BY.]V!#@C<I&.G'>NK'2@#BH[;6O#4+
M3I:0WBB5D3_27+!991_"$]2"3D]":V(M.O[D7UU?QVJWLD)@MQ'(S+&FWU*@
M@EB<X'0#TJO>^,;18"=.BGNY1*$PMO(5(#A7(8+@X&?Q%:=KKEG=VEW<Q><$
MM2?-5X61AA0W"D9/!H QM)\-7EKX;DM+HVPOUG:Y@>)B5C?@KR1GKP>.A-:/
MG^)?^?'3/_ I_P#XBI;+Q#I^H:1-J=O([6L.[<QC93\HR?E/-1#Q3I^/]5?_
M /@#+_\ $T 4M+\.W,>AW-E?BW$K',#1,6V,!\KY(&&#>GI6AH^HWUS>7EEJ
M$%O%/:K&28)"RMN!/<#TJ33]>L=3LI[NV=S#!G>SQE.@SD9ZBL33[2T\0ZYJ
M5^RZA'"T< C(EFMMW#9X!7/;K0!@_!R0R6/B#<Y8IJDJ#/\ " S8 ]L5Z97F
M?P86--'UU$.2FKSJ<L6/#'&2>>E>F4 %%%% !1110!S?B2XTY+ZRCNM1U"RN
M%5WB>SB+$J< @_(P]/RK1T"VCM-%MXX9[N:'8#&UV ) I' (P,?B,UG>*A<N
M^GQ6UQL\R4JT7F3IOS@ [H>5 )')^7GZ5L:4V[2K4[@W[I>0S-V]7^8_CSZT
M 7**** "BBB@ HHHH **** "BBB@ HHHH **** ,OQ%(D.@W,LD@C1-K,YZ*
M-PYKA_ ,D4WA:603E]US.?-"@"3,ORMV^Z>?:NS\56XN_#5Y 7\L.%&_&=OS
M#FN,\!.?^$6D,C1SYN+HB5%P&!D^<@ X'R]/7IFGT%U.K80AVRTC*'DRNP<@
M+\RX_P!L\X[]1ZT*J[E'GOOW1#S./O$9WYS_ '?ESWZ<T;QYORPIO\P[00<;
MMO[O\ .OH?SIJO!M7]R#%MB_A.?+SZ9ZE^W<<\TAB?NO))#.H\HD+M V@OA!
MUXV'G_9]NE2%8A(V6D8!Y,KL'S +\XQ_MGG'?J/6F,XV-NB3?MDW$9^]G]X<
MY_N\ ]^G%/WKYWR0)N\SY000,[/W0^@'7T/;O0 Q3#YB1?:CYQ\H!LC.X\[^
MO]WY<]^G-!\GRBP+JOELP7:!@;L*O7C:>?\ 9]NE5/L=J]]'>E6*JD0V[!S'
M\P/ODLQXS@CGFK;/\K;HD\S;+N(S]_/SG.?[O /X<=* .7^) @_X0V^C\X>:
M+B(J'P#\LB;B!GJQY]#C..]>D^6F<[%_*O,/B396\WA:^O"C1M%);@!>!M$B
MF($'T#,2.,'MCFO2?M]G_P _<'_?P4^@NI8HJO\ ;[/_ )^X/^_@_P :/M]G
M_P _<'_?P?XTAE?7?^1>U+_KTE_] -2Z>RQZ/:N[!56W0DD\ ;17)V&KW6MZ
M1?Z:]WYUY/>7%JOEHN8X-^-[8X "YP3U..M=<;-3IAL@Y"F'R=W?&,9H Y+X
M<RQRV^K&-PP^W2'(]"[$?F"#73ZG]^R_Z[G_ -%O7,?#SS&BU1YG5W2X$ *H
M%^6+,:\#OA:Z;5/O67_7<_\ HMZ .,T]BUFAM6;^SEXU98S]\[OX,=PN-_JN
M!UKIO")T]O#T3:88S;F20DQYVE]YW8]L^G'I63I^HV3Z8TCZ+;9ME59#+MWR
M=E8#:2=QX'<GCK6CX*+/H#2M9/9"2ZF=;=E \L%S@<<8^G% '15QFNM8_P#"
M5E;5@->:T7R""0P^?Y2>VP#=N]N.I%=G7&W\\<'CJ:.XTE;E;BUB6*XF"B-6
MW,-FX@\MD=/0=R* &:>T9OV5R3?KC[9N(+&39/S_ +I&-O;;CWKJ]-_Y!=G_
M -<$_P#017/0WEO/?/!!IT=J89,-)%MVRGRI@0" ,[2"#[DCUKH=-_Y!=G_U
MP3_T$4 <]L'_  LMI,KG["HQM&<9;OUQ6CXB_P"85_V$8?ZU1P?^%C$\8^QK
M_P"S5>\1?\PK_L(P_P!: -KM11VHH Y?6Y;N[U>.RL-.662TD@NY9#*J;@"V
M%Y'L>:LWNJRS>&GF73Y))IMUN]JDH#!LE6 ;&,C![<U+:_\ (X:E_P!>D'_H
M4E27NB6\KS7$,LEM*X+LR-A"X& [+ZCU&,XY- '$?#FTM#K$M]%Y$<K1S(;>
MSEW)'F0<R+M&U_E &."!TKN=0TJ2XF>>TN1!++$89@R;DD7G&1D$$9."#WYS
MVP/!&QFN,7JR7<<LPO$61MK$R$H50L=@ S]<]ZV]=FU&V6.?3$>6= ?W&S<D
M@]SD88=CG'4'KD &-X8T:6?1D$MV#9/=22M"L>&<AR &;/W<J#@ 9Z$XKL:Y
MKP7<)_PCMO$\KF8M*[>:H4\RN,X' YXQFNEH Y#P_I4U[H,(:ZV6<^?.B5/G
M<!B-N[/"GOQGMFNO' Q6+X2_Y%BS_P"!_P#H;5M4 >:?!Q3]@\0R'&&U>8 #
M_9./Z5Z77F_P=_Y ^N_]ABY_]#->D4 %%%% !1110!RGC0/,EC9QV\LK32,P
M,,9=UV@'C#IQZ\^G'<;^E1^5I-I'Y?E[85&SR]FWCIMR<?3)^M<WXSL)9WM[
MB659+)&(,+6EM*48CAE,V,9YSS^'4UOZ$LB:%8I-Y0D6! WE*H3..P7Y0/IQ
MZ4 :-%%% !1110 4444 %%%% !1110 4444 %%%% &9X@<1Z)<.S*BJ4)9N@
M^8<GVKB/ +.WA:5XYT=6N;ABR, IQ)Q@9Z,>#STZ&NW\0;O[$N-FS=E,;_NY
MWCK[5YSX-TJ.[T&XGEO[^"4W4^Y;2Y9(L^;A2!D< \Y_$T^@NIW9\\R,#+C,
MC@L)!D97+'ZKT'Z^M(K7&5;*[LQ-L\SC/0+],?-]?45DMH%J';.J:TRAI,K]
ML?)4#YQC/5CSCOU'K0N@0EU']LZSO+1C?]M;[Y&2V<_W?E![].32&:A\X0D"
M7<HC8!C(,D*W!Z]6/!_3'2I#YYE(,NW,C@D2CC*Y8_\  >@_4=ZY2^TV."]T
MN&+5=86*Y\S<INWX503&.O&UN3Z=\=*TVT"U#L&U36F4/("/M;\@#+C&>K'G
M'?J!WH UD:Y^1@5W?NF">9QGH%^F/F^OJ*:?.$3#SLJ(W&XR#)4-D-UZL>#[
M=,=*RUT"$LH_MG6?,)C&_P"VM]]A][.?[OR@]^G-,_L*U\HLNJ:R%\LL%^V.
M,#=A!U_A/)]/:@"M\04G?P3JH,F"'4_+)WW(6_[YZ#Z].]:__" Z9_S^:C_W
M_'^%<QXTT6&V\)ZE)'J>JNT9P%FN693ADW @G!W'G'?J/6O4: .5_P"$!TS_
M )_-1_[_ (_PH_X0'3/^?S4?^_X_PKJJ* .)\*7]Q8Z=*)$B>PBU"6U,N2)$
MP^U68]&&2 3QBNU+ *6) 4#))K$U?2[*#POJ\$=M&L4MO/(ZXX9F4DD_4U=@
MA^T^'XH,A?-M0F<9QE,4 <S\.W1[?5BC*P^W2\J<_P ;UTNI_?LO^NY_]%O6
M-X.U&75#J,\T,,31S?9PL6<$1EESSZXK9U/[]E_UW/\ Z+>@#D+*ROIH;.\:
MPN%FL,FS4*K+,"227YZ," O]W[W7BMWPIJ<USID4%]9RV=UNEVQ.A^ZKD=>0
M3R,X-4V\,6TOAR.2U6Y^U-;HZ[;J09. 2!EL#/(]!FK?A^UTR&X06NH7<DJ1
ML!:W4GSQ D;OD(!!S0!T9.!D]JXK4KN\UG6GM(=/G;2YK)0URJ8?:S9( 8@Y
M(4;6 XY/85VC#*$>U>>6UQI3:38RWTZ&5;7=+-/?R1! &P%POUH U+&WNK>:
M.&6UEBM[<"&WED !D41S$9 )^89P3W//?CIM-_Y!=G_UP3_T$5R=DFFB_C^S
ME1<([ ;;R2965H7.</T_*NLTW_D%V?\ UP3_ -!% '/;&_X689.=OV%1]\^K
M?P]/QZUN:MIQU&VC5)3#-%*LT3@9PR],CN.M8O\ S4<]?^/)?IU:NIH QO[/
MUK_H-+_X#+1]@UH==9!^ELM;-% '/)H>JQW\MZNLCSI46-C]F7&%SC^9J6;2
MM7GADADUE3'(I5A]F7D'@UN44 <CIGA#4=*D#Q:\TA7?M+VL8(WMN;)'+<@=
M:CUJ'5K"[M;O^WK/[0JNL<<UKN+ X+%57+$C S@=#795SWBD#R(2W]FM'DAD
MN\AVS_SS(((;^?M0!Q\&EZQ:V=M:V^KI#),HD@C-L$)=YBRX7)^13EO7'45T
MVDVOB6YTNUD;Q%;LZEED86082E25)SN'!(R,"H(SJ!LK*:W74(V6,"/S;4,R
M@OA@P))X3!'S<X'TKJ;!=EC"NZ9L+C=,H5S]0 ,?E0!C6.AZSIUG':P:W#Y4
M>=NZR!/))_O^]6/L&O\ _0;M_P#P!_\ LZVJ* /-_@['(FBZN9% WZG.=P/W
MR'8%L=LD'BO2*\^^$O\ R M0Z_\ (0N>O_7>3I7H- !1110 4444 <GXU$'_
M !+I+BX6WB6?:\LOE>6H; .1(C GG(''0\]CNZ*XDT6S< @&%<94+QCT  'X
M ?2L/QE>RVK:>BW!ABE=_,;[1)!G"Y'SHC$?3&#]<5OZ6P?2[5@^_,2G=YA?
M/'7<0"WU(% %RBBB@ HHHH **** "BBB@ HHHH **** "BBB@#,\0$#1+@L5
M RF2_3[PZ^U<-X#91X5?*0E?M%UL,6=H'F?/M]!MZ>O3BNR\66[W7AB]@C(#
MR!57<2!G<.N.U<!X*TV]D\-S.FJ75E_I%SNM[9X_+C(DZ+N0L<GCK_A3Z"ZG
M<;U\[Y84W^8=HYQNV_NOPQU]#V[U'YELL89HP( D9)(/^JSD\9ZE^WISS5,Z
M3J'FD'Q#J8_>,"?,@XRN6/\ J_X>G^'6HQI.HL@!UW43N6+*&2#!)XV_ZOIC
MG_&D,85N=2N+._:!+>WA\^0!MQ>4L-K-V"C:>,DYZ':>*V-Z>=\D*;O,^4'(
M&=G[H?3')]#V[USVF^$8-(NUN[6^O"4BD7:TR!70'C( '4^_;((Z5TA^T&4@
MR;<R."1(.,KEC_P#H/U'>@"%6@V+F$&+;'G@Y\O//&>I?MW'/-#.-K%HD\S;
M*6()^_GYSG/9>A[].*D1KGY&&W/[E@GF<9Z!?H1\WU]:0^<(F'FY41N-QD&2
M%;.[KU8\'],=* .:^(3H/ 6MLL04*BD;5/&-OE<>W4^A[8YIL_C];<Q[-<MK
MIO-1'BBT]\X)&>0Q[9J?QC8W4]C<7+7 $:$!X]Y.<G+]\':"!R.<?C70H9T5
M2FT<1,$$@ )SA5^A'S>Q]13T%J9[_$KP\LGE1G4)I I;:EC*.!P3\RCCWJK+
M\2K8EEM]&U1V& /-B\O)/;OVYJ^;2X&J27OVD&/[(\'WQN(63=O//<G;C\>.
ME7\W)FP9=I,I!Q*."R?-_P!\#IZ]QWHNNP6?<\ZE\>:]=VYM;\6=O%=0R!@(
MR65=C'DYP.!U/KGD"O5M,(.DV9!R# F#_P !%>:>)HM0\R\ L7E6\@*QR+("
M$_T25/?J#D_3'->@:?"UQX3M8$8!I+%$!/0$Q@4W82OJ8'P\(,&KX.?]/E_]
M&/72:G]^R_Z[G_T6]<O\.4Q#JA\F*';.L)2+."8P4+<]V*Y_&NHU/[]E_P!=
MS_Z+>I*)=+_Y!%E_UP3_ -!%47'_ !6$/_7D?_0JO:7_ ,@BR_ZX)_Z"*HR?
M\CA%_P!>1_\ 0J -A_N-]*\0U/</#4A )/V,XX'/[Q>]>WO]QOI7BFH02-X2
MFNA$3;I:X:4(=JGS >3T'% &KHFIY\21Q26-['N8#>T/R F!N_\ ]:O3=-_Y
M!=G_ -<$_P#017 :-C^WAC'7L#_SP>N_TW_D%V?_ %P3_P!!% '/9?\ X6:R
MX?9]A7GC;G+?CG]*ZNN6R/\ A9!'.[[$IZ<=6_6NIH **** "@]*XU/B!"8U
MG;2;L6QG,+.K(60 XWE,YV=#GT(KLNU &99G4SJ<WVG/V7Y]F=F/O#;C'/3.
M<U1\2/&LMNS6IF\I6=F6-'95RJG:&4Y.2.!CI]*Z&N=\3;]\)6UAGVQL5$ML
MTH9MR_*2 2HQD].WM0!8LM1MM.B@M+TBSFD!9$D"J "QP"5 0,?3/YUM5SUL
M\, B@-E+=23PL"8;<1Q;0W*[7(QRW?J.:V;**.&SCCBMS;QJ,+$<?+[<$B@"
MQ1110!YS\(#<?V1K'G8\H:G<>3C'W?-?/_CV[K7HU<!\*8VBT;4HW#!UU&XW
M ]LS2$8_ BN_H **** "BBB@#*UO2IM4@58;J2%DRRA)9(P[<8W%"&QP1C/?
M/85;TZVDL].M[>64RR1QJK.23N('7)))_$DUSOBM)8;RUGBU6Z@,FY/LR7R6
MZR8'4%E(R.I&03^!%;^CK,FCV:W$XGF$*AY0P;><=<@#/UP,T 7:*** "BBB
M@ HHHH **** "BBB@ HHHH **** ,W7AG1IQM#9*#![_ ##BN&\!HB>&)E(\
MEDN9P53D ^;A.>/NGG/;OC-=OXC4-H-RIB$H.T>62/F^8<<^M<;X+CAM_"D:
MBV$0+7+;"V=F92)!QQPN,>O/-/H+J=*RQ!VW.Y0-+E=G50/G7'^T><?B/6A4
M&]1]H;S-T0WX'WR,[\Y_N_+GOTY-&]/.^2%-_F':,G&X)^Z'TQR?0]N],5[?
M:H\H>3MB'0Y\O/IGJ7[>G/-(88B\G*NRKY1*KMQ@;\1CK_">?]GOCI4C+$)&
MW.[*'DW#R^H"_O!C_:/.._4#O4;.NQMT2^9MD+8)^_G]YW[+T/?IQ3]Z>=\D
M*;O,^4$G&0G[H?3')]#V[T "H"RC[0WF$Q#?M'WR,[\Y_N_+GOTYIA$/DEE9
M@OE,RKMQA=^$7KQM//\ L^U"M;[%!B!BV1@G!SY>?FXSU+]NXY&:5G&UBT2B
M3;*6P3]_/S\Y[+T/?IQ0!G^(X1)HE['&SNY<J%V ;L%=X_X&<<=^H]:L"XE+
M*!:WGF$Q /\ NOOGD/G?_=^4'OT.:ENHUN8VBB58V,R-&V"<%0&AX].,GT_6
MJXCN#&,W4/E%$S_HQSY9;YN-W4OV[CD9H ='=0R.T1M[F#]P\JJZ+C9O 5<A
MCC:QSS@CV%72D0F(9W8"1@W[L?, N9./]OT[]0.]9-U8W\\HF_M$0SJLREHH
M%Y8D>9RQ/10,'\.*:-.U'S1LUJ7_ %B[1]F3'W?W0Z=/7T].] &9XFUBUM'M
MX//F::/'G*L+,#O@DP<C/(4@?3UQ7=Z'_P @#3?^O6+_ -!%>5>(K#7;#]_:
MZI;RF[=%A5XMLLIVLIR "."6R1U'->J):$>'ELX6R1:")&)QGY,"J>R$MV<W
M\/?]1J__ %_R_P#HQZZ/5O,$=O*D,DHBFW.L8RP!5ER!WQN'X9K'\&W%I='4
M9+*P6RC681O&H49==P9OEXY(KJ:D9S5KXB^QVUG9S:1JHG\H(%$ ^8JHSCYJ
MELYYK_Q*MU_9]Y;1):E"UQ&%R=V>Q-6M8TV\O);:YL+J.WN+8L5\Q-RMG .?
M3_Z]4TU77[;*WNC+.00!):2@@CUP>: .A/ )QGVKA[V_O&N$NV\(7T*QD_:'
M#0LLL/\ $K+N^;U&>A'UK<;7;[;\NA7I/'!(%5Y1XEU9'A,5IIMLXPQ9O-D*
MGJ...GTH @?4WO%MI[7P[J$<2AI-YCC!;*,J@!6)YW9YP !72V4;PV%O%( '
M2)58 YY %%E;_9+*&VW[_*0)NQC.!UJ>@#D][_\ "S63^#["K?</7+?Q=/PZ
MUUE<MEO^%D$97;]B7COG+?I74T %%%% 'F)\+>(_L30#3X/M);R/M'VL>6;;
MSM^W;MSG^+/7=QTKTZBB@ K \0WS:=<6TPNH8#*K1*9=^,[E/\*D= 1SCKQ6
M_6=JMA=:A&D4&H/:1\^:$B5C(/3)Z?A0!@WDVH0P"Y60BVDDWS".X$112_8R
M!3R,#/'0@=<UO:;-)#H]J][,'D? #A@^=QPHW 8)P0"1P3S56S\,6%H]I(88
MWDM%*P';C8<L<C))_B/?WJW;Z6L&FPVADSY<HEW*H49W[\ =AGC'I0!H4444
M <'\,9Y9K36?-A:/9J$H&01GYV)Z]>3U%=Y7$_#ALVNK_.&QJ$PP/X?G;@^_
M^-=M0 4444 %%%% '&>,]1L4N+>QENHUN&._;*Z*J#!Y):*3&>W';KZ]-I&W
M^R+/8RLODK@J00>.Q"J,?\!'T%8^OV5_<:C%-#;:A+$B%1]AU$0')Q]Y3@'I
MU!_"M?2(YX=-BBGM_(9!M5#.9FP.[.0,GUZ_6@"]1110 4444 %%%% !1110
M 4444 %%%% !1110!FZ\,Z+.,$Y*# .,_,*Y/PAYZ>%(  8P!-\C2@E=LQXS
MGG<>"?;K72>+8Y9?"]\D!(E95"XZYW#I7+>#44>$X-QDB?\ >DJXR03.VS)_
MV3DY[9YI]!=3IC]H,K*9"N9'4MO&1E<D_5>@]?UIJO<Y5L#/[IMGF#&>@3Z8
M^;Z^M-98@[;G8H&EW+Y?50/W@Q_M-SC\1ZT*GSJ/M#>;NB&_:/OD9W=?[ORY
MZ'IR:0P/GB(CS-P$;C<7'(5NO7^(\'],=*E/VDS$%]N9'!(<<;ER3_P#H/7T
M[U7Q%Y.5D95\K*C;C"[\1CK_  GGV[XJ1DB$C;I&90\FX>7U4+^\&/\ :/./
MQ [T .1[GY& &?W+!/,&,] OT/WOKZTUO/$3#S<J(W&XN.0K9W=?XCP?TQTI
M%3+*/M#>:6B&_:/OD?>SG^[\N>AZ<FL^:.Y^W1R0RD6/DY*<#"[F"+C&?E8J
M<Y&W!S@4 6=7OKK3K"YO -[1.?E\T#EE&>?]C/''/IWJHMWXEPC?V;9=(6V?
M;^/0+]WH?O?XU:U.Q@OK.XM9;J2-'9P[K&,@* TG!X^8@''X@=ZK:?--<WC;
M+X7$"B)!<+$ ///=2#A@$^7/()..2#0 UKGQ((F'V&S($<@W?;NH#9+?=[G@
M_IBI#<^)C,?] M%)E;_E_P"A9.?X?X1T_EWJZ1#Y)968)Y;,%V8PN["+U_A;
MG_9]A4A2(2D.[,!(X;]WU 7,G'^V>WX@=Z .!UVV\2+<_P!KSVFGB,+$H2*8
M[@O(4%CG/?H!][O7J>FS?:-+LYL;?,@1\>F5!KC_ !-Y:^'Y6:3<1Y.XD=6.
M2#GV7Y<]_4FNET]96\*6JP$B8V*!,'!W;!C]:I[(E;LP?A[_ *C5_P#K_E_]
M&/79UPWPX \C5-D<L:>>%997W'S0")#GT+AC7<U)04444 %%%% !1110!Q]R
M\R_$5C;Q022_8U #S!6Q\V>,$XZ<^M;WGZO_ ,^%M_X%'_XFLG'_ !<8G _X
M\E&>_5JZBLW!MWYFON_R#U,WS]7_ .?"V_\  H__ !-'GZO_ ,^%M_X%'_XF
MM*BE[.7\S_#_ "#0S?/U?_GPMO\ P*/_ ,32>?J__/A;?^!1_P#B:TZ*/9R_
MF?X?Y!H8,&LWUQ=O:QV=L9DW[E^U<KM(!S\O&<\5<\_5_P#GPMO_  */_P 3
M6C@ Y &:6CV<OYG^'^0:&;Y^K_\ /A;?^!1_^)I//U?_ )\+;_P*/_Q-:=%'
MLY?S/\/\@T,QKC5@I)L+;CG_ (^C_P#$U1AUV_>S%RVFP;6\LQJET69P_3 V
M=?:MV;_42?[I_E6'X7LH'\/Z/=LFZ5;.(*220/EZ@=,\GFJC3:=W)O[B)2UY
M48?POEN)=/U,W*1([71E"QDG:'RVTY[C)&>*[RN0\!V\5O'JHBM4MP]T7(7'
MSD_Q''K77U984444 %%%% '*^)K"3[9#<V<6HS74O[I8[:]DAC!)4!G"GA0.
M2WH .216_IGF?V9;>:DB2",!ED<LP..Y/)^IYK$\2RV$MY;076EWEZ\;KM>V
MF$1C+Y4<[U)S@\#-;FFO!)IUNUMO$!C7RPY)8#'?/.?K0!:HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH S=>_Y T_7JGW>OWQT]ZX_P (M&/"L ,;<"XY
MD8[_ /6GS,\]0N/KZUUWB+']A7.1(1\F?+SN^^.F.<URO@]I3X4A9/,"$3D"
M1L, )F/(//S=#GD8I]!=3=WIYWR0KO\ -.T;CC<$_=#Z8Y]OUIBM;;%'ECR=
ML8SSGR\]<9ZE^WISS4Y^TF5EWE<R.N[<.-RY)^J]!Z_K2(]S\C!1G]TVS>,>
M@3Z?Q9]>.:0R%G38VZ)1)MD+88\.3^\[]EZ'O[4_?'YWR0KN\SY1DXR$_=#Z
M8Y/IZ=Z4_:!"1OW 1N-Q8<A6SG_@1X/IVQ4A^TF8@L5)D8$[Q\I9,D_\ Z#U
M_6@"NK6VQ08QY.R,$\Y\O=\QQZE^,>G(S65>7U_)JTEC9)8I)';-/*9UD;YW
M=E< JPZ*G![].*VT>YPC!1TA8)O&/0)]#][/KQS60AF'BB]3J5TQ 9=W+ 32
M\]?XCP1V[8H AGB\03QM%%<:3"[.H21(9<J0O[O&6(Y&>HX[CO57;JNDZ/(8
M_P"R6MH8#)M,<V3'N+-_'Q\_&/3IGI75'[29B"Q4F5AG>/E+)R?^ #@>OIWK
M-UII_P#A';]CP/L@;;O&.A 7Z'[WL>.: *>F:X;T(EU8FWNI8'E7=E1++_RV
M"9/1%Q@GKGM1!)KTR0RQ_P!C+O,;(IBFX^7,0^]_^H]N]7EM!=Z/;PW"K/$M
MN<%R/X<'?CL6/R\=.V*O1QSQLL2'RU63:%5Q\F4YQ_N#IZ^G>@#BO%,>MR>%
MKK+Z5Y:Q*WRQ2AMN_P"8\L1G?^?4&O0]%_Y >G_]>L?_ *"*Y/Q>\J^#-2DD
MD*1K;1NV&!P V OT(^;U'3)KIK'S1X5MO(SYWV%?+QUW;!C]:I[$K<P?A[_J
M-7_Z_P"7_P!&/79URO@P:</[1_LPSF#SAYAGW;O-RWF?>_VL^V<UU524%%%%
M !1110 4444 <M_S4C/EO@V0 DV_+QG(SZ\@XKJ:Y#:O_"T]VWYO[-'S8[;C
MQ77TDQ)A1113&%%%% !115>6\@AN$@ED5'="XW' (! /\Q0!8HJNM[;M-Y8D
M4G:&!!X.3M'/KGBK% 'DDWB'Q/\ VP$6]F^PF\:%P85R!OP!T^[C^+KGC&.3
MZ1X<01^&M,C5PZK;1@,O0_*.:T)O]1)_NG^59?A7_D4M(_Z](_\ T$469#?O
MKT,3P!<6]Q'JIMQ( +KYMZL,G'49['L1Q795R'@2&"&/5!!;" -=%G 0+O;N
MW'7/K77T%A1110 4444 <MXCA5=1CO[C5;73H;<(@F,<9E&XMN"LRDJ3@ 8X
MP6X]-S2=QTJU+>7DQJ?W6-IXZC'&/IQ5'45TJSU)=5N[F99H0J^6C,RY(8 ^
M6N<M@OSCIGTJUH1;^R85\E(T48C\N;S%=.S!L#J.V!0!HT444 %%%% !1110
M 4444 %%%% !1110 4444 9NO<:-.>>J=!S]\5R/A((WAB%O,D5CYA.],-DS
M-Y>>F"K9/MGFNL\1%1H5R7=D4;,LG51N'(X/-<AX/>#_ (1.WV;I$Q<;9')W
M,#*?,)Z<A<?6GT%U.B9(@[;I"4#2[E\OJH'[P8_VFYQ^(H5#O4?:#YN^(;]O
M_+0C.[K_ '/E]#[FC>GG96)=_F_*-Q^\$_=#\1SGMT/K3%:VV*-@\G;$,Y/^
MKSG./]_C'X\TAAMB\G*R$+Y65&WHN_$8Z_PGGV[XJ1DB$C;Y"5#R;AY?50O[
MP8_VCSC\1ZU&SIL8M$!)MD+?,>')_>?DO3U]J?OC\[Y(5+>;\HW'J$_=#\1S
M[=_6@ 6/YE'V@^;NB&_;_P M"/O=?[GRYZ'W-9,8'_"1W9$I%O\ V;$43'0>
M=*$&,Y&TX.>W0XK35K;RU!C'E;(P3D_ZO=ECCUW\8_$9KF-2M+R\\7NUEJ$M
MC(MFINDC"G?F23> 65N0N<=,^HZ4 =6R1"1@\A*B20,/+Z@+^]&/]H]OQ'K6
M?K2@:!?YF)D^S#G;_&4.&SGLGRY[].367K$%WI>G37UKK%_)+!+&R1R^5M?!
M7RP<1@\J3]/UI^H:C-=:5=6L6@7Z>;;>4KL4X4D[B?F_O]O3D9Z4 :]H(/[*
MMF5BL?V0,J[.B9 1?^ MSZCO@5;*1"4AY"P$CAOW?4!?WO'^T>WXCUK+TS5K
M2\ME@4+]LAMB\\6_+1NPPP..,A5/U]JCAUR>3RY8_#UQM9HV0&7MM_=#^OMW
M]: .<\<MK7_",:R'2P:Q\I KDGS&)^X>N-P'R^_N:]1TZ$V^F6D!;<8X43([
MX4"O)_$T]])I>I7<FBRK;QV+A-\Y?;@_-(JD84YW#'?J#7J!N99/#OVJU4^:
MUIYD2XR=VS(_7%5T%U.<^'O^HU?_ *_Y?_1CUK>(=9O]-N]+M-.M(;FYOYGB
M432E%7;&SDY /9:\]^'=UXF>UD6"^TJ)[M8[K;>PLSLSKO8+L=>A)XQFNVCT
M;Q'=Z]I5_JU]I306$DD@CM+:1&<M&R=6<C'S9Z4TDGJ,D^V^,O\ H#Z5_P"!
MK?\ Q%'VWQE_T!]*_P# UO\ XBNFHI<R[?G_ )B.9^V^,O\ H#Z5_P"!K?\
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M20R]#[BI/$1QH5P=ZI@I\S=!\XY-1>&#NT6,^:DOSM\Z#@\]N3_.@#9HHHH
M**** "BBJ5]=7-O-:)!:F9990LC#/[M?7@?S]* +M4[G2K*\F2:>'=*HP'5B
MI(SG!P>1GL>*N44 %%%% &))I.HQ/=O9:FL(GD:4(]N&PQ '7/3@55L5FL-'
M2-/WU_>2%662;Y-XR&((7A?E)Z?SKI#R*JV^G6MM,\\47[UL_,Q)(R<D#/09
M["IY=;FRJNUI$>BV<FGZ+9V4K*TD$2QLR]"0.U7ZR='O]3O)9UO],-FJ$>6V
M_.__ #_2M:J,0HHHH **** "BBB@#+U+P_9ZI<QW$[W<<L:%%:WN7B.TG)!V
MD9Y'>JG_  B%A_S^ZO\ ^#.?_P"*K02!YM2%[%J#/;;-GD+@IGUS5^FFUL6J
MDTK)F!_PB%A_S^ZO_P"#.?\ ^*H_X1"P_P"?W5__  9S_P#Q5;]%',^X_:S[
MF!_PB%A_S^ZO_P"#.?\ ^*I/^$0L,?\ 'YJ__@SG_P#BJZ"D/2CF?</:S[F'
MX8B,$.H6_FSRI#?21H9Y6D8* O&YB31XAMXYWM6E9]L9+!-[!2>,%E",&QVS
MTJOX>M7&L:Q=[P$-Y+'L&>3\AR><<8[#O6IJNEMJ@B0W<D4*DEX0H*2^@;N0
M/3.#WS6=/X13^)G.W=U)>6MO+#JC>2R?++'>A &\T LW"EQCC@>HZD&NAT^Y
M,6D6TES,)M[!5D5@^X,V$R1P>",D>]+'HUO]IM[JX"375NFR*4Q@>6.?N@=.
M#BG0:8D5A#:F5F\N43%P NYM^\\#@#/:K(+<W,+CU4UG>&8VB\+Z7&XPRVL8
M(]]HK1FXB<^BFJ'AV7S_  WILN,;[:-L>F5%3>5[="=.;S,?P2Q9-2S*DF+C
M V_PC^Z>>HKJZXGX=V<EI%JHD5%WW((VXYXZ\?UYKMJHH**** "BBB@#.U*/
M24BN'U0VH@D3=*+HKL*H"<D-Q@9R35FQ2UCL8$LMGV58U$.PY79CC!],5Q_Q
M(CD^R:9<KI1OX[>Z$DFV!YF11@D;%89!QU.5!49'<=+X<B>'PWIL<EJ+1EMH
MP;<$D1?*/EY)Z?4T :=%%% !1110 4444 %%%% !1110 4444 %%%% &9X@
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M?110 F!Z4M%% "8'I2T44 %(1D8I:* *MEIUII\0BM8$C09P!SU]SS5JBB@
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MC*IN&3U_P/Y5-F!9HHJ.2>*%D665$:1MJ!F W'T'J: )**** "BBB@ HHHH
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M!BI7HQSUKCQ(_D2#9<9-N%QY+]</QT]Q^===H^J6L6GK'+(X?>QP8GSU/M0
MGAJ**)9O*B2/='$S;% W$@Y)QU/O6]7,>#]2@U**Y>!90L2Q1GS$*[L*>1Z@
MYX-=/0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@"A>V,EU+N27:-A3_=/J/KT/MTQ4/\ 9<N_=YBCYMV!VXQ@
M?[O\/Z^M:M% %"RL9+63<S(W[L+Q_#@]O8]3[^M7Z** "BBB@ HHHH ****
#/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g201805072101259582281.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g201805072101259582281.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,- :P# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*O.X]USC.#7IU<QK7@S2M3OC>&\O=.N'E29VM)P@DD3[KD,"-P&!D#..#D4
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M1>*ZN@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K \0>*
M['PW=6L=_P#NX9XII#,S !?+4':,_>9L\*.3@^E;]<9XG$5EY8U+Q-?0&XNF
MDM(;>QBG?A1\JKY3D[<%MV,C=R>E &IX;\13ZU-?6M[I_P!@O;)H_-A$PE $
MB!U^8 ?-CJ.WJ016_7->$98IHKMX]1U*^)D!>2_L!;,#CM^[3=P.N#T'-=+0
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %>::^[6WC"QCN_'=O97J">2WW6D $$9VYCD+-G# KC(YV9
M[5Z77&ZAXA\ 2:L9M0O-*>_MR\):5 63D!@<C_9'Y4 6O".K-J$^I6[:ZNL_
M99(U-Q%!&D8++NPK(Q#'U]*ZBLG0=6T/4[:0:%<6LL,38<6X 52?8"M:@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *Y'QM%XANC;6NAW-U;*\%R[2VRKDS*@,*,S [4)W9..< 9YKK
MJ\^\:+J5GXHTS4(->D@W1S0VUA;Z=]IF<D(6V@'D?+DEL!>/6@"]X!FU&>/4
M7NI]5GM?,C^SR:G'Y<H/ECS$V[5X5\\XYZ<XS79UR7@C;/\ VG?2ZE=7E_-,
MJ74=S;?9FMV1 %7ROX<@@YYW9ZUUM !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5YMJWBC3+O69I)-<
ML=%UC1;R:VA^T#S4FA94+;TR#AL#H005^HKTGM5'3M*M]+:]:W+DWERUU+O.
M?G8 ''H/E% &!X):RNI-3U*+7+?5[Z[D3[5+;1^7''M7"(JY. !GJ23FNMHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBLPZY:$R&);B:*,X>6&%G0'
MOR!SCOC- &G14=O<174"3P2))$XRKH<@BI* "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJAK=Y/IVA:A>V
MMN;FXM[>26* 9_>,JDA>.>2*XN._N#HHU=OB1;9,/G8:&V%N#C.TKC?CMC=N
M_&@#T.BJ&B7L^I:#I]]<VYMI[BWCEDA/6-F4$KSZ$U?H **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** #K7,WD&NF]E2W6=84):W:*
M2-4!^7:&!Y*@9R,>OJ,=-7.SO9Q7-Y=/9W\L*2YFG\T[4( !VKNSM&,G ]:
M+=GJR"X:UEC9&#/R(F SYA '3N,'/O6O7%[XYKV6%[U%G2YVVZ*\A8EI2S.!
M@9P!MXRHVG)P37:4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M +5%5?[3L/\ G^MO^_J_XT?VG8?\_P!;?]_5_P : +5%4)-<TB)]DFJ62/\
MW6N$!_G0FN:1*2(]5L7(&3MN$.!^= %^BLW_ (2'1/\ H,:?_P"!*?XT^/6]
M)E.(]3LG.,X6X0_UH OT5#]JM_\ GXB_[[%->_LX\;[N!<]-T@% %BBH(;VU
MN'V07,,K8SA) Q_2IZ "BBB@ HHHH **** "BBB@ HK"U;4-2M;V"""73X%G
M;9$;@22-(W^ZN HYZD^GK6EID]Q<V$4URL D<;LP.60@]""0#R.V* +=%%%
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MQ(?.[[WO4?AYY&BU!))9)!%?2QH9'+$*",#)YK9H QO^$:M/^?W5O_!G/_\
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MCZU+0 4444 %%%% !1110 4444 <[XJ33FCM_P"U+BY@LPV9FC0F)E!#;92
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M20BC(Z=ZZ.N3\&V\RW^OW<Z6EK+<72%].MI1)]F81KRY  WL"&.!C&.3764
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M3HMQ)]V//)_PJ+4?OV/_ %]+_P"@M0!>Z"BBB@ HHHH **** "BBB@ HHHH
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M(7-M-HD%U]ADE9)8RI$1&2"Z[C\I#>G49XZ&IM4U26R\2Z=;FYCBLY58S>8
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M.%\L3'R3E>=OF\,?O#@#Y>: +ZZ-OD5H[Z\65G1DD-ZY"R2+B%RV>0J90O\
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M)/\ XFMJB@#S[Q-KFM+!J&EW%M8-'':B6YECE8&.-FP"H8#<>"<#TQU-=^C
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M/B.V>TMQ"FW! 51DA7Y^4^XZ^M '4T444 %<O\0',?A7>$9RM_9$(O5L7,7
M]S745B>*8TFTNWCE17C;4+0,K#((\].HH MZ9J@U(2_Z-+;M$VUDEVY!Y]">
MX-:%9UA%'!J5]'#&L<:B/"H, <'M6C0 4444 %%%% !1110 4444 <GXXMXY
M+:UFE-DODEBK7.-Q)P"J9D09(R>O\('>NCT]733+59559%A0,$Z X&<<GC\3
M7-^-'EA>RF@CU"24+*H6QCC=]I R2'1AM&!SP1G@-TK=T.W>UT2SB>Y>XQ$N
M'?&<8X&0JYQZX!]: -"BBB@ HHHH **** "BBB@#*\2&$:%,;@2&'?'O$>=V
M/,7.,=Z\C\._;/[$B\NZM$M\C:EQ&[$1[SL!PV=OG9+#[W0CY>*]9\4_\B[<
M_P"]'_Z&M>6^$%@'ABV/[MAYMPV]R$.22LWS?["8(D_A/R<YQ0-6ZEU_[1V/
MY]]8E=LOG?NCN(S_ *5T;&XG'3@KPN&HGBUF82Q_;]/%P[LNZ-&7$_E\%3NX
MQ#PA/"G[W/-:"A$=3%! TJM&8XR@ 9T'[A"O8.F7*?P??XZ4P1V7EB,>4UOY
M8C63:'+0[]R/C^(M+\F/^6HYXQFD59#[4#[';BWP%\F 0Y!V[2?]$R#\VT-N
M+#[V[G[M83);ZC?:H6OM4BM[:Z,,J+-_RR8)YX&."3,P)QPP^[Z5T3L7WO/B
M,MYC2L&^YNXN2'_Z9<!9.V?+YKG,QG5]6:_MK:*X2]A\J)W\C>!%&$4KGY04
MRY_YYD9R>E*1=%*4G_PYOS6MQ)']FFGG%PLA$DD4NUS.J#SR']X0 I/ &0WS
M&L/3H6L-<TZSCO+R2ZFM!)&L\[20[\@VIVGG"@MQU!Y/R\UN&.$Q>5#,YBV+
M'')Y>YFC!W0MM_B,DF04_P"6@&\XK$MXY$UNQ#SM+826$WF71 !C#%?.(<<G
M:V%!YW_=QQFGU%'X&[AXND>+PVSVK,D9>/&3AC;F3D$],F89;LPQLXJG/87>
MER1M-XAN"UQ<F*;RXHMV\C$YR>,[,;3T(..&XJS+<QH_F:[ILC2S7(1EEVBW
MCEQM$:C)VJL>&W8)C;/4' T)-.TVQQ<I;QX@*L@\L$.5_P!02GK)DDH,= _'
M2E*_0NBZ=[25_P!2E!IVIS,QM?$D\DJR(L+)%'L:4)F+G;]WR\@>A^_3K"*+
M6?"<4-U+-Y<T*JSK@/Y?FGR<8'02@[N,G@CY:F;4[;[$Z"SOTMF@(++'DK%*
MV68'H6\SY<_\M1P>E'AV<CP[9RL(UW"1QD[02<K)_P!\)@AOX2VSG.*%),BI
M2E%[&:?"^FZ?(1]IU-+*;SS=89))"HVK."P0Y;=SG[I7@8:FWRZD;"Z\[5;U
M[@QREA]G*K]H2/'>/[K09 Z;3][%=))?QVD'VH^5^[9-B>7@-(@Q#'Y8Z;UR
MQC'W#\_!XK+U+5=/?2+NV2X<QO;M LAC<$QD&17W8ZM)E#_ST R<8I\R[B5&
MI)747;T/1_"WD_V=-]G\_P GSOD\_P"_C8G6MRL/PK_R"G_ZZ#_T!:W*9F%%
M%% !1110 4'@44=: ,+PO/'-;WWEMG_2W?H1\IQ@\]CZU3\:NL;^&W=@J+K4
M)9F. !LDZU<\,PK'!?$%V(NGC!=RQ"+@*HSV'I69XFDCUH^'TM[>:> :K%)(
M7@8(8PCY))&".10!TO\ :NG?\_\ :_\ ?Y?\:JWLVD7Z(LM_;AHVWQR)<*KH
MWJ#GC^O0U-_8FD_] RR_\!T_PJO<V>@VDB)-I]H'<$JJV@8D#&3PI]1^= "^
M';J:\TLR33^>5GFC60X^95<A>G!X YK3D=8XV=SA5&2?05D>%XO)TAD\IHE^
MTSE%9"F%,C;>#T&,8K6G3S('0@$$8(/<=Q0!':WL%Y$TD#,RJ<'<A4@X!Z$
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MW_ZZ#_T!:W*HQ"BBB@ HHHH ***0]* ,?P[Q!??]?LO]*H>,O]?X9_[#</\
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M<]/(/SXXSC9S6B31QU*BE_7_  62,)5=A)<*\BL^^828#.@_?2;NP=,1A_\
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ML3_A,?$7_";BW-SX>\]+5HWF"RF) ,.P/S9)],=>WK0!ZEK?_(!U'_KUD_\
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M3R*\5T/49++2XXH[=I,.'$L4C("0Q*MD'&224W]@-O4U[1XH_P"1=N?]Z/\
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MSE#G(HCD0WERXT^>$K=1OL-NN=K1#8G'>+&_!ZCDX8"INK)&SC+GDUT]._\
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M>(KMTAVKY8&0ZQCBW ;& Z/D[NBK\K;C5"RN+!M7@:WOA-8QP/;3VQ+LS1*
MTS*IY +_ '03D'YB<<5T[1RM*WF6L8N&D??&L0.)G3]\@7OMBPZKTD^^<GBL
M9EA3QOI\L+#[8+ F",-\D@#*MN2_4AQG+<;R-A('%%EN)3DDXIZ,LZS$9K,P
MRR;+A[A$,JJ3B<E2[<8R#%@''WVP5  .:8M'_>W%O=:HTH8&$*1GH5M5W=,C
MG+?=Q\O+5>U'"V "2[( 8U\TRF,K"LH._/\ "1+\AX_=#@#!S2V5PMR+A"ZO
MM>0.4PV?, :?"C@E>JIT/+C)XJ)).1U4JLZ=*\>_^1EVMD#:6<LESJ!MOLD<
MNV-P2L:-@K[9D/']SJQY J&TTR]B;4#=7EVD\U[-"VT'+<*TQ88&<QA1_M$9
M& #6AI-S$39>5=1RW;P*$AWCF95PJ\=08R3DG]X1M)&,5&US9VT]P8[S]VMQ
M%A/.Y>)0OE/R 02V0Q!^0#9P#D1RQLF=3K5>><>_EY^A&\$QURT476I+<R++
M+;R/*HV3,@$66Z'$606 P>%7)JMJ,"Q>'YY;:74FLS DA1VPOV=<A-W_ &U)
M;'\(^]R:U[YHXKJTCFF$%DXGBGF:%0R*V#* #D*ROP(QG ^8;J+RY%SH-W<1
M.DDQBE.%.%,YC*NF<]/*&\<_O#R2,8JE!7:,9XBI[.,O+]6=]X83R]/FC%Q#
M<!)L>9#]UOD3IR:VZPO"@ TIP.GF#_T!:W:U//"BBB@ HHHH ***0]* ,?PY
M_P >]]_U^R_TK(^(AB&D:?YJEA]N&S'4/Y4FT^V&QR>!5_PI)*\-Z'!P9RY)
MB*8<_>3DG.T]^]4OB TJZ=I?E1>8K:BJ2CRC)B-HY%<[1R< GB@#.UF:*WLG
M-S8B^5F=7@^4*P&6N/O< '&0.N>>E.TV&YMXY(9<AQ.1!OE\PJ2H*Y/<!,J?
M[W '(S5-=,-U;JT%^LT;JIBDRS!A@K"V2_\ 'D@MV/R]*UR%"%6RL(0J6QM(
MC#9=O8J_RX_Y9CD4 8WB*VLI=(EN5MD,D:QF"1U!>-2V(<-V();GH%.#DUL-
MY(#;US& VX!2/D!_> #J,O@J.J]2<<5G^)#)_85Z955'YWC& ')7S%Q[)A@O
M\7WNM0C7KIV)MM-\Z8;7C1;M6W,%Q%R.2&'5OXC\IQTH U\-N(;:9=Q#$J2"
M^,R' Z@IP0/O'E<=::4650H16W%"@< \G_4DD\9 SENF/EY-5["X>>W8RJ$C
M0A WS1YC7!W?, 1B0E"<?(!QUS53Q%<W5II@>W21IVG6-HXA\Q#L// 4 \J.
M0OI\W)H O?9+'9G['!Y.W.!" ?+#8P,]#YG(S]T?>XXIS6-N"PEM;4L"XD_<
MC!(&9N,9P1C ZD\C KG["_N;RQMKN:_EM;J9%E:UEC<M'*5QL/K\G(/\9X-3
M"7 &S725 78Q1P"%/[HD]@3D%NJ_=Z4 ;8LHBX"6UN)BRA240_O"N8R3C!PF
M0QZ-T'-4=0M[:.R62"WBCC#1L-JJK"+=A #V8/D_[(X;FJ32#:RMKCB/#*Q^
MSN"$ZR''8JV!M_A'S"GZGY\6DI=^9<RWA='%NV&!F<#<FT#) C^8#/SXR>10
M!VNAAPT@D(+^1!N('&=G-;-<YX0G:ZL3/M?RS'$D;LC*'"J0"-W/3%='0 44
M44 %%%% !1110 4444 8&NZ?J]Y,JV4L+6S$,\;W4L# @$##1@G&2IQQTK:M
M8Y8K2&.:3S9415=\8W,!R:YCQ7>7VF30W2ZU-:VL@*&)$MLA\<$&7&1USR>U
M='ISRR:9://(DDS0H7=""K-@9(QQC/I0!9HHHH **** "BBB@ HHHH R?$L3
M3Z!<0H4#.T:C>2%Y=>N.U>7^"HWA\+VD97]X)&/[L\Y<G:/FXW1*?,'\(!^8
M!N:],\6 -X9NU(!!V=>GWUKS'P2 _A&S5%^7?/'M(\WD$M,-OI(F (_XS\XQ
MC- &^&"J&%LLJ@*PB .V0*<+'Z[9C\X!^8L,MN6@A<%&D###(;AB?F .YICC
M^\?W+8Z_P<9%.7SV=?*F5)69/+D+Y"R.O[ERW<(F4+_QYV<]::&41AU4K;A%
M=8]VPK"'VHF?X2DOSY_Y8@X/6@!<EGZ- [,?3=$SCGVW6Z_\!"GL]9>FS23:
MUK+&R*B)[?RXPO$P5"$B&1G#Y,JALD'E^.:U'!7>LX$FWS5E"K]_;S<@)_TU
MX*IWQYG%<9JMCKH\1WLT%DUZ;AXPEQ'<8VL8QL.1C>0@V;CQ)RN!UH [$HH4
MH;E9%"LAE.2)%4[C(<<XF;]VV.21\N5K+F8GQG9QF-D9K*<F].-\!9EW9/W<
MPCY200,'"D-Q5>WU>[CMH1_PCFH[%1,'SXP1&!MA^;/!27)W?P [3FFVTNH7
M7B.&XNM+N;738+*5)X9 O[Q@RF=513P6;#!<_+@OG'% &S<W$EO!YL4.92T?
MEV^Y4 8G8D7S=-N?.4$<#.\9P:6%LP?,T<NQ=K[,E'VM]-Q69O\ @189^9:K
M:M(L%LK3X>07,:&00F4>:2&,F!C<K1?+_P!-2,X&.<^+6K-'>1;FY6,@2KBV
M8,&W;8\O@X\L<%O0[/FZUG*:B]6==/#SJTKQC?7L_(T;*YGN@IGV1K+"9//5
M\D%CEY"<#E1MB8@]#A,'BGB[N6O&S8)'$LP4HS@.&9!M51@#,(RPY "YR _-
M8.G:JEM86L=W=7;>6ACE@%H?EC3G9G'WM^&4_P#+,<]\5)'J(#7KB^#3&;S8
MGDLV7?(8@9"< 9#X"@<;B-W&*A559:G3+ S4Y>[ITT?>W8Z-74(K+:I(H"LL
M(!VN%.%C /.V8_O #\VX9;<M4]7^71+]1(3BUF7[1GD@ LTV>GSG]TQ[X&SC
M(J&RU3[3J-K!!?2S75P-RSN<*DN (G+%?F*KE"V?G^Y@]:FU8QG0+X^61:_8
MV80XY$(RJ1X[%)<O_P!,@<'K6RDGL>?4I2INTCO/#,4D%A/#-Y>])MI,;;E^
MXG? K:K!\)HL>DLJ*JCS.BC ^XM;U,S,36]<GTZXCM+2S6>>1-P:698XT'3)
M)J&.V\0WBK(^J6EO&P! MHM_'L3_ )YINJ6@O?%5G&7*%;<R*P4'D,>Q!'>M
MRRM5LK.*V1BRQC ) !/Y<4 9,FF:VHW0:YEL?=EME*G]:I2Z]JVD3^7J-O9W
M,0(!>UF"R+GU1NOX5U5<KXJTR./3KF^:=PHF28IL7 ;A.N,XQ[T =2.E+2#I
M2T 8WAS_ (][[_K]E_I6;X\OFL-.TQA/%;I)J,:2RR@[43:Y.<$'!QCKWJUX
M4N3/#? JG-P9/D8L%+#.T\###N/>J'Q *"#P^9%W+_;,'&[;SM?!SVP<'/;%
M &)9:KI4 DW:Q:AII?,.TJGE-(.<#)&8\$^F&/1J67Q!:F>RATTV]]-<2@?9
MXI<;556(4<'@E=RY[G+5KLD8R)(D?&X. @^;;S, O^WP0OMOI0OS87:)B0HD
M!R-[#*MGN-GRD_\ +0\<8H YZ3Q,EL["^MFA@>U,L!E?]Y/A\-E>@W\9&XGT
MXJ:'5M.EO?M%QJ5G P+)$%E5G0N/F<L.-R@!3C@#@'/%;/[EE#+'A,!D#'E5
M)Q&-W8HV26_A!V\TDA@AC>1[<,D:LSHL6"RI_K%"]BS?,%_A^]GM0 6\\=S#
M'<6S!XWVL@C((ST"#/\ =Y=<]/X@#S0\<4D6V2-)XP =K+E7"MQQUQ(>?4D=
MUK.\._\ (*6#]VTD4K1,\9$J,Y^=F!'W@R-MV_QD'IC-7+II=D'V:40-)-&H
M<X)4,2(SD\$KT+?\ YZT *;"SP5,$('S*9#$O ZESCT^X<?\!QTI?L5JS?\
M'C$C%ONB)<H6'W>F,QCYAV /.&YK*6ZNGA\Q;J!8=I.PRQH0BOMVXV?*0_S
M9_=]ZD:74065[ZU9@9%?]Y&0Q S+\NSD.,?+W(W<4 : L[, ,-/MWP%8((AA
ML<*G3.)/OCOD?-D51U6SM8+$F.*W4AMGVGRP-H!R93C'!/R'!Y_AXR*03ZF7
M&W4K82%EVN;F,X=E^1L[.<+\I;^+[M1:@\HT-;PW.ZV*1R&&0I&/*)PJ;@."
MK$G/\ X.<T =?X+_ .1/TS_KB*WJP?!@ \):>H>-PL>W?&V5;!(R#Z5O4 %%
M%% !1110 4444 %%%% ',>+X[@"VNK47"R0*Y:6*X:(*A*@YVHY;L<8Z*36_
M8-(^FVK2JZR&%"ZN<L#@9R<#G\!6-K<MU!?VZ#5+FWCG.U5MH(CLZ L[29XR
M1T&>?8FM32&EDTNWEFNOM+2H'$IC"$J>1D D9QZ4 7:*** "BBB@ HHHH **
M** ,GQ+"]SH%Q!$ 7D:-5!..2ZUY%X6U.RM/#EK;WERJRKU!5@NS>6AY4?=\
MPX=OO \+QS7K/BP!O#-V"H8?)P1D'YUKS'P1A/"=IY;'_62MN4^6=Q8A^3QF
M)?F#]$^Z>3F@"Z=<T9@PFNY!&P<2XB;<$8_Z3QC&X/CCH%Y7+4[_ (2"P#^8
MUV!<A]YVQ,1Y^W:V,CD>3RF?O'.^M%79=OEPB0KMV1;2 Y3_ %4>WJ!*,R;>
MJD;VR*H:W((O#FIL)=T:64H\]CU3!?S2>^]_W3?\] /EP!0!=B9&ABDM&#1&
M.%K=FSM*;O\ 0R3][:S9W'[V[Y?NU@W6LWSW>HVUC9VTME:%K>62YF,4F"4:
M<$*I (D<9(^Z/N#O6U;.9;*"20F)GB#NP<$QEU E._IF 8P_W0#L^]63;OJ!
MU34VALK>'9?P[(3"5\YEB01K@G@%29 IY0KEJF3-:*3>IMW']HXE,<<9U N^
M4<?+]H*?OQQG_EC@H.C=6^:LVUU&_%\D+PV0_>0I \4[,&?9FT^]AMI&[)/)
M; ;Y:O3+;K:R*]PCVZQ;#*ZDJ\8.Y9".I$K_ ",HY<C<.*Y?3ULQXU06C1")
MM+VRW,:8>#<29&\SH2F=N1U'RC!IMZV"-/F@Y=CHKN:WBMXT8 VTH\I=[E#Y
M.\Y)(!P1-PV!E1C9QS4L,4T4/E7LK2S*95F< ;RQ'^D\="P3;@?=(RW+<5'>
M/(LMHXC*R?:HV\I7";7"E1&,] J?O%'_ "S_ (NM6  JA4_>JJJJ KQ(%.8Q
MMZXF.25ZDC?RM);BD_<2%7S/,4Q[#<;T*!6)4S;<0X)ZJ8L[2?O-P^!Q3 +8
M1#RV/V<1IL.3_J@W[@GOS+D.>H. N%YIQ"L"K3,$(96F+!B%8Y>4D?>(;]T2
M/]8.%QBG%W+%S#MD+%C'N'R.1M=<_P#3%?F4]$!VGYCFJ,S*U.29=3TNTM[*
MXO)+R6YMQ&'CB8L4+7 8D[5;<I  ^4#!7)Y$NH6GBV33KMG\+[)'C:1G.H1;
M5D*%&;@YVK'P!_$>6SQ5J,V::]H[7%B\D@D=(#;HZ/"1"^T( <J)$R^PG(Y)
M."*[S2K:X6S?[:&W3.6\EY#)Y:D !"3G/ R>V2<<4%-W2\BOX9AEM[":&8*'
M24 [6W#[B8YP*VJP$\*P0/,;/4M2M(Y9&E,,$RJBLW)P"IP/:G_\(X__ $'M
M9_[_ *__ !-!(LY'_"96HR,_8VX_X%6W6/9^'HK74H[^2_OKN>.-XD^TRA@H
M8J6P !_=%;% !4-U:P7MM);7,2RPR+M=&'#"IJS]<OI=,T6ZO(%1I(DRH?."
M<@<XH I_\(=X?_Z!</YG_&C_ (0[P_\ ] N'\S_C3MGB;_GXTG_OS)_\51L\
M3?\ /QI/_?F3_P"*H T;'3[33;?[/9P)#%G.Q>F:YOQYYFSP]Y0R_P#;,.!@
M$XV29QGC.,]:U/#VJ7.I6TOVQ(EG0@CRAA61AE3]XXSSP>:P?B;,+?2M&F9@
MHCU> Y92P^Z_! Y(/3 ]: )ESA3#@C$9CR>",_Z/D]<$YR>N>/NTC;?+8/N\
MC8X8D 'RMW[PG'0B3@X^Z/NUQ6J^+M3MC&+6W@FDDW[S@J8F; +$Y ^3D;AG
M P*TD\3+'<0L\MHT9D!9(T88P"%4>@Z,!_"3DT =,WG&1O,'[XN^\*!_K"O[
MT =/N8*CH>IYI$+[T,>S=NC*?,<;L8AYZX*YYZEN&XK*_M[1@-@U&-U *!BC
M'<JG<"1CD2'@CJQ&1Q2GQ%HXRSZD%&26?DE=PR[9QR5QMST(^48- #?#VT>'
MK8-@1!7QDD?NA*VTG'^W]['(_A]:T+BWCN5*708[6=GVMA@W68C'\0&,#ICG
MEJS_  \7328XVC>.:.0EHFP"KGD*#T&U&#@]$[\U:OKC[)!$8WB :1(@TJ_)
MC/R97(.)#SMSG/S=* &_V3:M)D19F+#&)G(,A'R=3R-G*YZG[V*:-(TW:#'&
M?+VJ4+2OC9G]UGG."^=QZ@\#CFJCZO:+(8I-?T\<E&9ERV#RS??Y.?D)'WAP
M*/[<MV^8ZUIR,?F("XVLW# '?QY:\J>BYP>: +AT?3L-YD4OEX?S#YC;@@_U
MW?&X-CCH%Y&34&IV8AM@Z>;]K$RA%,S,OGE>1@G&/+^[Z_Q<\5%_;=LO*ZOI
MC%>5C\DX.SA$QOZ-]_'8\GBJNH:G;RVOD1:E:7VYA'LBC^=U^\7'S\EF^4_W
ML<4 =OX+_P"1/TS_ *XBMZL/P?')#X4T^*6,QR)'M9"1\I!((XK<H **** "
MBBB@ HHHH **** .7\8R(D=JK6<-]N8@6LULTRDG #X4'!!( _WJW=+;?I-F
MWF>9N@0[]FW=\HYQV^E8/C.25+6,%&-F8Y#<E&MP0!MQGSN-N3SCG.*V]&FG
MGTBUDN;7[-*8U#1AD(''4%"1CTP>E %ZBBB@ HHHH **** "BBB@#(\3123Z
M!<0P@&1VC506VC.]>_;ZUY+X5OX;'P];6LT5PLJLV1% \XR?G8CC!,JD*$Z-
M]X\BO6/%?_(M7?+#[G*G!'SKT->8>#,KX2M!*>Q^^=P\LRGR!\O.T2_>'WCP
M5^7B@"^-;MCC8]U&QQMD^SR$(6_U;[L9(B&4W=7)V'BL6^\26*ZBS3Z9<SVT
M:_);L1&(XR,%&5L%65SO)_Y9CA>":ZIVBPYN#(8\2F;!&XITNN1QN+8Y'!7A
M<-5+4);S3S<:BLJO)"A>6+& ;A(BVY#SC]QPN00#]_F@"ZN?+&\&0[6#)M&Y
MRH#2KLZ9G!&$Z$#?]ZL2VM+J;5=4(U=RS:C"(WBD#K$6A0HY)&2 N8PW5R0#
MBM5)'FT^*33Q&IDA@:W$P;8%8YLPP^]M#;MP^]NP?N5RMGI=^VIWQOUTU7E0
MWERZH\K!5D"2$@,HW%QGCJ!\E*2N:4IJ+NSKP\10.L/E1%0ZQER/+0G:B%NH
M\E_G9NL>=HXK*?CQ6NY2ZQVTGFP8^:8+CS$V=%,A^?:.%'SCDU:>#Q$)GWZA
M9?:?-EWE;4_Z_9^](/F8_P!3@*3\O9L-5&""Z3Q/:F6Z@EG-N@LUCMVCCC)'
M^C9RQ)7 ;@\AN6RO-,S-*[CE>:T1'+R_:44RI&)-S%2WFC/4,G[L'_EICYL8
MJR$<A2D;1!@C)G.(PYQ$=W7$1SE^N3L^[S6;J,TD,VDM93M!ONU$;[<N(#O)
M'IN,JDL3D'C;Q72(-2>-6/B]LD _\>(I6U*;O%(S&PB[G@;RP&8PE-I**</'
M@="7_>D#_5CE<YH(D!*M,&D#%&EP/F<#<[8_Z:K\JKT?&\\C%:,XU..!Y$\5
MO*Z*65/L(R3CH#[]*YL:WXF:,;I+MUP"P:P\L+C! ^93G!SR/2F23/,(_%7A
M9VGC9/MYS^_)$@>"3RR"?OA!\F\\L?E.,"O4;B86UM+,02(T+D#O@9KSC28M
M9O?$6C76J^>8H9WDC#6H107B8$[QPV<G@?6O2I$26-HW4,C JP/0@T <_:R>
M([UKEA/86JI,42)H6D(7 *Y8,!G!&>*CNF\51W,-M;7>ER2R*SDR6[JJ*N!V
M8Y.6''UJUX518]-F"YQYQZL2?NKW-2:K+)!>H\+!9/LS@,1G&9(QG'XT 062
M>+$GS?2Z/+#M/RPK(C9[')SQU[5HVUU<M?/:W,,*D1B0-'(6[D8Y ]*\X3Q[
MK4VAW&L6]Q:SPVTLOG6\<)\X11GYGYXQMY'J3CK7<>&7N=1TZUUF[D?SKJW4
MB)HPFQ22PX]<$=Z -BZF^S6DT^W=Y4;/MSC.!FL?4[75=6T>:U"6<7GH!N\U
MSCH>FVMBXA%S;2P,2%D0H2.HR,5Y[JOB[5=+\7?\(Z+J.(!$=;JXMOW81L $
ME>GSY7/ ''O0!VEQ>:E9V[W$MI;O%&-SB.9MVT=2 5Y('..]:0((!'(-<5IF
ML:IJ-AJ*W\D9"QSHH2+:& 12KC//(?.#VQ79Q\1)_NB@#'\,QQQV]^(XT0&]
MESM4#TK+\?E5@\/EUW*-9@R-VW'ROSGMCKGMBM+PS,DD%Z!N!-T\@#(5RC<J
MPR.0<=:S/B#+Y%MH,WF+$$UB$L[,%"C9)GD\#CUXS0 A)4D.#(06# #ERO,@
MV],RCD+TP-W6CYB0!(-Y(42AMPW-RLF>X"_NP?XSP:HKK6E840ZG9# 3RP9E
MP!G]QD9S@'.X=<\_=H.LZ24;=J5L8=K;@9U),9/[P'!^\9.3CJ/NT 7=ZE=R
MIL0KN"EB-BDX4$]1Y;<ENJYVCBH)[OR)TA-K).7#L8P%4LJ8\Q=I(Y<D-M'W
M1\PJ,ZQ8[BSZG:&3<V]EG3_68_>D'./N8"GH.A^:JUQJ&C3JADU*Q5HBK12"
M<+Y; 'RB#G( 7((ZY/S9% $NAV<MEI%O:R1+%,I(;9M8;B2V[C@[DPH'1^_2
MLOQ7;ZKJ%M;VFGZ:EQ;NZ32-]K$+1X;,0!8'(0@ MCC[O2M#0[AKG1XVN79V
M (?S$(;RB^4R,#DL5+8Y((V]ZAU2> ZS'9:C>^3;202O*GG",RN& G&[C.5/
M ! QQUH Q=$\+0W&C:5<7(:-K-"8HMD<A0*P!4.5)SN7>2"-J],UU\-LMO#'
M!A9#&/+W>6"7*K\QQT)D7@+T;&[K3XF#K&UN\18E?*:+[A?;\A7_ &?+^[Z'
M[V::SQ) 70?NE12@.?N9_<@]\;\[AU)Y'RT/03=E=CA&IP%,2D[0LF<A2W*/
MGN$'R;OXC\IXJAJ\<+:=GR42/<KF+.T[-V/+R.A5OG/]SH.#4PU/3W!$MP47
M:YD60A'V'_7=<#<6'4<%1\O-0:[.8M,:=G4RK.F'#?+Y^.3D \>60%X./XN:
M!IW.E\%C'@_3>2<Q9))SDUO5SG@V7R]"M+!T820P@[_X7&XC(SR.G0@5T= !
M1110 4444 %%%% !1110!@>(Y-/BGL'U&QN;B-)/,CDAC9Q'(I!7<%Z\X(SD
M94>@K9M%C2S@2%&2)8U"*X(*C' (/.?K7/>+(6N)+-(+5+JX D*Q2V\<R;/E
MW-AW49'&,'N>,5N:9Y?]DV?DR-)%Y";'?JPVC!/O0!;HHHH **** "BBB@ H
MHHH R/$\<DWA^YCB3?(S1A5&/F.]>.:\D\*WDFG^&[:+^SKZ7:9Y3)$JHN3_
M *W#;OX$(*R?P'*<UZSXJ)7PW=,KE&!0A@Q!'SKSD<BO,O!3/)X6M'5F#&1Q
MA3N.Y2<'YN-TJ_(H^Z0/F); H OIJEPLB+%HFH-*KQK&AMU 9T7,*%=W 9,L
MR?P'Y^*H:IJ"S:!>0G3=3%K)9&/SC&N?)<DJY.[EFD^0_P#/5>>U;H7<%47"
MQ!@JB4,=L88Y63/7;"?D!/S;CAMJU0UUF7PYJDH1E(LIY/LX^\/E*M#CU4_O
MF],C9QDT -OY'B\.22^8T,@MV8R1ON*%MJW!#]_+X42?[7E\U>M[9+(D6ULB
M3>:)/*V;=TZKA$.3P#%^\()_=$9YZ5E:N94\(S8Q+-]F11YP^\ZJH)8+QNG!
MZ#Y2JYY:K/EZSO\ +6\TU02$6<12G:&&8Y02_P# ?W2D]>CX% %T) $5(Y6D
MA"HB.8]Q>,'="VWN9),J4_Y: ;^*SY9@^M1;PRVACECGNM^?+:3F;#]3L("J
M^,/DI[TN=8*[V&F1H0':+R90$4G:\?W\@1-^\)ZJ3A?EYJE'!<P^*;-[Y;>:
M:2&=VAAC*M,\0"L"I8@M,D@8@ @!<KECF@"YK#?Z3I)DQ&[:DC.@?&)!$X\O
M;W 3#;?^69.,G/'J<,\0A0&5 PC#$%AP,=?I7E6L@$Z8CN7C^VQH\HP0P,4A
M$W/.,?(IY)"_,<CC%MM>T^\NWFDN)Y&N+6.RN!Y;*AMQEHF)*@J#N&>QPWS=
M* /<Y9HX('FD;$:*68XZ <FJMQJ-H-.6Y:X1(IDS$SG;NW#(QGG/MUK(U'Q5
MH4FF7$(U.'S)+=]J\YQMZXQP/F')XY%9UDVOB.PN[;0X9O+LHXHFFNE&WCEE
M';<-N>_% &O8SRWUCI'EV5RD:;'+RA5& A'3.>X[5N32K!!),^=D:EFP.< 9
MK-L=7:6*S6]M)K6ZGPI1HSM#X)(#?0'\JTI(UFB:-QN1P58'N#UH R/#*R)8
M3K+$T3B;E6QD?(OH2*36O^/I,_\ / _^C8J3PLNW3IAEF_?=78L?N+W/-+K/
M_'U'CKY!_P#1L5 'F<5M+9Z7<:?I<EI;ZM.7LDN#?(R1Q,Y"X!8G<IPPQ_%D
M5Z=X3DN)/"NFFZD$EPL(21P,;F7Y2<>^*\GV>5\.]1&K/)_9BQ3E9$96;[8"
M3\I '?)4'_EIGFO6O"WV+_A%=,_LYBUH;=#&Q))(Q[\]<T :]>5^*(&N_&MZ
M^HO%-I'EI:O:^>(68 !VY+ '<2H/L.QKU2O)/$J.WQ4F.BR2'64MH62*1AY+
M/R"""#_!G=C!P!@YH W=&EFGL]1GFD20RBY*NLBN2HCC4;BIQNP!FN[C_P!4
MG^Z*X#0Q;_9]7^SERIEO"_F??\SRH=^[WW9S^G%=_'_JD_W10!B^%X(H;>^\
MM O^F2+^ Q@?0>E9GQ!2.2WT!)?N-K,&1LWY.U\#;WR<#%:?A>>&>VOC%*CC
M[;)]TY]*S?B 0MOH!9 Z_P!LPY!SC[DG)QSQUX]* *[6UJ=QD@A0-O+D(OR[
MO]<=V/X. &]]M4]0TO[3);/;I!#/#-YI3R=NZ0(55./NC8=Y'\'XUI9VMR/-
M8'GIERHY]LRCMTP,\M2#! 57 SM42J<XSRL@SV'^K7/7HU '*+X2E&O_ -IK
MJ2/&(EBCB\IS\@'R'&[!+O\ PXR?O9%:UOH5L$E%U,6\]F,AC;Y0C "0@D$G
M:P #?Q9VX[UJ%U()\I8P06V$D! 3C;ZXC/S'N">,"G;MKY9"VTDE3C+;1\RG
MMEQ\Y'3 R,GF@#G_  W!?)96\YOU>(N[/"\9#[QE-ID+<;$&<X^3I46K6<-S
MK\:W%O;W:):QFWBFA!VD3*$X/>3))7CCFK_AF19-"MQ%(&*N4+H0?FWL0_U8
M?*N>#_%V%0:ASK2?.(E-FOT0-<)@YSG$9X[')QP* -'34C72+2,*L<0@5,(.
M%0X)('?Y_D_Z:#C'&:N%F)+.H1LLSX?&TD8E^;ML&,-_#G;S573SC3+8D;@(
MLE#_ !< ,GX_ZQ@.G50>M6AD-CS?,8-C<,9<@9SZ9D'RCL0.<GB@ PYPODJ[
M KMB:/@NH_=H5[!ERQ7^#[U8FM:382::R16\:QN44RI'R8RV5?"XW%FRO^V.
M>,5M  @ 3H@(4"0$X7/*OZX3[@)YR<-@5G:VZ+IC2.T<*!@Q1S@ $X\L_P"Z
M<.?0D;>.: %T6QN8O#^D:C;ZI,EW*FP1S9D1LAS@#!8=222?4DUTWARZ>^BD
MNI)D>1XX@RJK#'RYS\P'7/4<5B:*8[GP/H4<6Z6>3"PRQR^7L(#;F+<\8# C
M!STQ6IIMU;Z1]KAN5F^T1F,%@QF\T$;8PF%'/!^4#CD]\T =!,"89 K;25.#
MGI67HU[<3_N;AH&Q%&Z&.8.2I7&3QW()!J^)X;G3_/1BT$D>X$#!*D5C>&9%
M GA*W1N $:229%P0478 5^7A<<#OD]Z .AHHHH **** "BBB@#C?$NA:EJ^H
M[/LQN;':&53>K&JL !]TQ-SUYS766B-%9P1N,,D:J1NS@@>N!G\A6-=03_\
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M =_8D5T\UQJT$$][*[M(Q;[I4#> W3[F%#=%.5XI6\-:5(#&NGVRLY"K^[8
M,RYCX[!5SE?X3\QR*T0(L 1%V3"A.,DKG,/'3+-GCH1\QP:#Y14[V_=D-N(8
MGY"?WA!ZG#X"GJW0C'- &.EBVG7;36%L]PMQ H=YG!PNX! W<X89PH)D[&I1
MX=TA(\7%E%.P#&61LEI"I_?-NSU8]&Z?P\&M4[@V6P)=Q9@6( ?&'Y'0!.21
M]T\+GI2+D;1$"6&P1@CDD<P@CIDC)*],?-P: ,W_ (1W2-VP:=;"3=M!"%0'
MQD''8!. /X#R<]:H:;H^C7,U^/[/C*1W6R)74G:A5?*7&>@;)*]6SNR170?N
MRF,DPE<9!R?++9R,]29.!G[X^]ZUFL9]*N+JYN987M[BXDEG^8J8"P5)<$9R
MJX'S<%2<#(S0 ?V!H07<^F1&, LPW$DHIQ(,]RS<Y_B'RC%4M8T#2HK%@+5(
MI_,">="Q4K(/F9@><#9P./D/!Y.:Z/$ZR +'^^#KM4J!^\"_NU(Z#]WDL.B]
M1@UG:L!_9F(LF']V Q7<?*W9C;'<E\@?WAR>: +NF3&;P9I321O=33@N.(\D
MX9B?G! []OZU#;2 :E%/;V_E!VCV"ZE6'[ROB3RT7&0,@9YY[8%.TQ99O NC
MK%&CDIDL;;SPIVMCY>>IP,^F?6F"PU:2 ^39P^4$B,@2S2"8L?OJNX8*CG'0
M\]: .LTCRWT6SV)M0PK\I;=V]>_UJ6VT^SLV9K6VBA+#!**!G%);O$VEQM;L
M4B,0V%NJC'&:R/#"%TDNQ.DJ/&B;DNWG#, =S?-]TG(XQGCF@#H:*** "BBB
M@ HHHH Y;7M*%[>22/H<UV75#%=VURD<T#+T*EBI7D]B0>XY-;>D)/#I5M#<
M1&.2*,)@R!R0!@$D #)[X&*PO$FGR_;XI[%-1DNK@>4$@O7BB4Y4;W"]%"@D
MD>@'4BNDL2QL+<NCHYB7<LC%F!QT)/4^] $]%%% !1110 4444 %%%% &/XI
M1I/#ETB(SLQ0!5&2?G7M7E7@^[@MO#%HLDR6\@9FV!MC#:24?+<;I =@;[H'
MRMD\5ZKXHD>+P[<R1N4=#&P93@@AUKQ'0M$BO_#UM/'#)]M:9=]PD4=PKJ6V
MQIY;$#<NW)4 %@2Y- '9_;;%E$9U"&)"!'O!($:L=Q8#J!"WRJ/O*3DX6JFK
MWMK<:+J"B>,22VTQ\@$$AG4HT7O@?O6 ^^>4[FJME:>5/)(^@6D5NL&642J1
M,J,0X5@"?WC$88_>QL''-.N-"EN)D$J6PF25M\J7#Q*9%4L9,!<*H0B,]HR,
M<YH V+=!]B@0_P"D%8X^'*L9610$)/W2TXXW?=VC;]ZD-S9H3 ;VWC Q%YH?
M:44G<L@!.1L;]T@/*9^?CBI+=,6\,48$3!(HT79C86&8!L_Z8X+&/T/F>U9E
MLEO=76JMBY6W64EH4F)\R,JJNH/\1DD_> _\M0,<8H U-ZRCS3;1KN#,8]I*
MIOX>/ Y*Q<2D#DL=RX6JY>+^U5EV32749V[">)F"G:K'&UFF4EB>C#@ MS4K
M6FRV%JUP3Y64,J3E,O$!YL@<<@.F(]_\!&SO6/;6JVGB.#3X'E"N@>,2'=Y4
MNW,3,IY4Q(<%<_)]_F@"SK#K"^DGS=T2WT2^86 5T$<A64Y[9)C'=0N&).,=
M]%JLHAC']H:0"% QYIZX^M<5>6-EJ4$8N;3S;=66>.$J6*@DJBCGYFWDR#_G
MJ.3TJJ?#VEH"9(/," ER)GP_EG$IW9Z2G #^HV<=: .\N]=EMK*>X%[I,IBC
M+A%E.6P,@#GJ<5SA^(%Z\$H>SL.$RQAN3*H!]648!]0<8K'_ .$;T[=Y8BVR
MY,8D+.FV3&\.1GY=B?(1_P LNO.:3^PM(8!Q8R",[66/>X*K)Q$F,]4(+[?X
M@=_;% '5Z-?+</:7D\=H5&VW0K=B3RRD9)9<?*1@\^G-:&C^(IKBRL[C44@1
M+NW$\4D#$@'9O*$'G=MR1C.0">*X*3P_H4L8:XTX7-NO[XQ-.T@94.UP&)^8
MR.=ROCY\;>.M4-<T#2['0;ORK1$N(4,231,R[95P6D !X&PB/_IF?EYS0!ZG
MX8W#3Y@\<D;";E9%VD?(O:EU;_D*6/X?^C8Z3PNTDFG2R2RO+(\N69\9/R)Z
M "C672/4K-G9548)+'  \V.@#;K&M_\ D<;_ /Z\H/\ T*2K_P#:=A_S_6W_
M ']7_&LRQGAG\7:@\,J2+]C@&48$?>D]* -/4_\ D$WG_7!__037D<TB2:+(
MT3(^-.497D9YXKUO4SC2;P^D#_\ H)KE]$T7PY'X1MM/:: 131+)+F90^Y@"
MWS#!'.?UH YCPS$\.GQAX;B)F69R)Q\Q)@;/X9S@>U>KQ_ZI/]T5R]_:Z3!!
M']ADC:14E&%G+X7R9.V3741_ZI/]T4 87A6V$$-\=P.+@Q#"!>$& 3CJ?4]Z
MS?B+&)K+0XF4E7U>%3M)R!L?)XYXZ\<\5L^'/^/>^_Z_9?Z5E>/=WE>']KA"
M-9A.XMMP-DF>>W&1GM0!D/H411U2\U&1R"%S>-\Y PO/3,H[],#'6L?PSH6E
M:;>++;W=S'=M&8Y(IF*E>A:0 _W6PJGHN<MP:ZP DJ(_D)VA 1]S=S$-O_3/
MDE???6'?,#XQT-L@P_8[QO)\W<64F(%0/XMS9;/\><4 6-:CBFB1I[^73@"[
M;(6QRQ 9-O5A'PVT<DMD8%0V^B>;:CSKG5&E?<<-=$,<YVJ0.-SKAB>AQ@<T
MW4ED'C/0F:924CO?,?.-[*L>]PW8,/EW?PXVUNJK;U56VMN55.S&UB,H=O;8
MO!7^'.[F@#F]#TI;G3([B2ZO(V=\ VTYA4!3M1P,]6V[03TR=WI4M]HWEQ1M
M'J&I00C_ %Y6=W*)W(4\XB;&1UYW<"K/A[']@VW&Y3N(3;N.QI&"ICN0WS8_
MC')Z8K3)"@LY#@!BQ#?>"G$AW?[9P WMLXH HZ1&D5FYAOY=15I7?,LJR$,0
M 8<KUX_>$?Q9^7UK&O\ 1(!J<DD.H2W%W<3JRQ(0&P-N&+ \;AD!CP,8.6J[
MX;1UGUU=P60ZQ.-^S8 VQ#O_  3Y2?X#ZU-HD5NMQK!@M_)\W4-S#;DDLB",
M$=RA&[;W'S4 /_L*V/']H:@B' W_ &J3"KUW8ZX0_*!U!.3@5GZUH<!TQRUW
M>H=P8QRSM(N<_-&5/!V@;SZ]5X&:Z+='M+,N^/:690^=R X=<]][<AOX\;>*
MHZR&%D5+*\WFA0Y?:/, RSY[#;\F?X#P,YH OZ9"][X L?\ 0FNW=0X2WF%M
M@DDY!!& ,]L_0U!HQO9&N[>WO(V>##R?Z2 %!SA<J&W$8.7..PQ3])@MKSP3
MH5G<1S/YQ0(L4NS:0"V3S@@ '@@@^E,-NT=VVF/;&Z6"41QL4MUQYFY^05/'
M!XP.W!ZT 1:?J-VYMX[:6<:>R@;8\7?RD<[FP/+].K"NCT(_: ;HZ8;0B-8@
M\I'FR  =<#!7T.3WZ5A6DBWAL]4-_%>P;O,%K<RB-X>HVA5^0E3R/E!XZUTN
ME:NNJ&<):RPB%@K&1E^\5#8X)_A93^- &E1110 4444 %%%% '+>(;C2I-12
M/5=,O9(+5=PO8 Q6(OU!\L[P, 9.-OO726IA-I";=@T!C7RV#;LKC@Y[\=ZY
M#Q)-=GQ EI8>(EM998D#66Z.)^6QYB.R-N.,Y3T'&._91J4B1"[.54 LV,M[
MG'&: '4444 %%%% !1110 4444 8WBK<?#ET$#%B8\!1DD[U[5Y/X2ND@\,6
ML3O#& T^1<2%#\Q/V@D 9V%<8_BW8V\<5ZUXGD>+P]<R1/LD5HRK;<X.]><'
MK7CWA73OMGAVVGND+N7/S-((R44D1MDKQO(";^BXVGGFE*]M#6DH.7O['1KJ
M;"16BFM!.'C9-\XR)0N(<\8R(\[_ .'&,8:HQJ=LL:K'+ 8/+41HDV7,*OF(
M#*_>\W)7/\/^L]:K'0K4H1)$$4KB1MV-BYS*VW;QY1PNWJN=W(IC^'HGG6;[
M(PN59B(Q-D>8?^69 7YAL^?'_+3)VUFW/H=,886_O-_A_F;9<20%[C;L:.9I
MMN=NTD?;,?Q;<[=O\6[I\E5[/[=_:FI^:%^U?;!Y6<?Z[R%V;L<8\C._'&<;
M.:L192.,HWFLJQE&+Y,A3B [_6;E3)TP/+ZU0T^.W6[U9%N283/L>3:5\I-J
MLS@?PF.3]V!_RR!R<@UJ<3W+Z>1M3R/-\G$/D\#?Y>?]%Z\;_,SUXV??^:LE
M]O\ PD:^9C[']CE^TXSCRM_[_9_%CS?NY^;/7Y:V6,C,QDMU21F<O#Y>0KN/
MWL>WN$7$FS^,G>.*QR2/%UO*OS3+;[XE+?Z]@ L8+]&\U>2_1_N=10(L:Q)=
M)'$BS"&\FO!#))Z2L/WW3_ICC=C^+[G&:8FFW&]#!JU_G=$803'G.W_10?EQ
MG&2?X0O^U1JNQ8K%1,1"+RW03"3RSY:OE9,GH?,_=?\ 3(<'K6@?F#+(!%N#
MJZA>(]_,PV>D7!"=<GS.E &&+287PMSJMW_9_P!C63>NTN8Q+AL97O+C;GD\
M[^*NG3+[>P?5[OSLS"3&S;OX-S_#]T+CWW<+\M )_P"$G,H^>X-H&,!?<"^X
MJJD_Q;TRY/\ RUQ@8-7P(PH G+1@(%E+\LJ?ZI\^KG*;OX -AY.: ,NQAO[Y
MY)8=4O1=)>M$JL(A^_52( <+C_59+X^4?P_-5+7+"2+PS>21ZG>26:VL1VR;
M,-;!CY>?ESDR[L?[/W^<5I:2JM9W"38MXOM%Q&66,KMB,A:1PG4>4_RJG6/.
MXY%-\2*9?#^H&3;%*R%S'V$K8#19]-@$G_30G<,8H [[PHV[2Y.&!$N"&4J0
M=B]CS5/Q_!#+X>A>2)&8:A9J"RY(#7,08?0C@^M2:=I%S>64=X==U.*2X =U
MB\H+G &<&,]@*EN?"HODCCO-:U6XA2:.;RG>(*S(X=<[8P<94=Z -#^PM(_Z
M!5C_ . Z?X5/;:?96;,UK9V\#,,$Q1A<C\*LT4 (RJZE64,K#!!'!%4/["TC
M_H%6/_@.G^%:%4M4U.+2K1;B6*67=*D2I$NYF9C@ #([F@#'U3PVIU"QO-+T
MS2SY D66&9?*5PP&#E4;.,=QWJX9O$N/^0?I/_@=)_\ &JK3^+H+:3RY],U.
M([0Q+PK@*3MR?FZ9-=">E 'F?A*"\M;U([_4;K=)=LP6&\1XY&!/!0_O.@YX
M'3D5M_$1!)::"ADDC+:S %>+&]6VO@C/&<XZ\5;AT:XCUY+F752]P7:4[;2%
M=T8; 0N%W]"._.*@\>[O*\/[4$A.LPC:5W C9)GCOQSCOB@#(;2KG8PFUS4-
MNR02$%,8W?Z01\N<9P!WS_LU1>WFMO&VDB6[N;JZ>&[*FX*823;%Q\H'_+/&
M[&>GRUT0)!4I^\(*E"3]\KQ$=W_33D%O;9UK#V?VAXATZ^M@K:=:VUS"]V4V
M$AF0[DSSA64KTPG!R<T 5-<@^T>+O#:6EY-:R!)VA=$5F:,*GE*0P*Y)SSZ8
MSS6@VG7GDL#KTX3RV#,L"?<W?O".,XWXV]\]>*34X;O_ (2'2K[[(6@A6Z6Y
M"+N,32*NY0G5@H7=M')SN%:T<ID5)H<2[BKI\X(<XP@W=_,7DM_%C;UH YRQ
ML=2AU"[TY=3%LMNH8)%%N E=2922V3C:,G!ZGY:TET_4=P\K6[D-N3R\P19S
MM_<=L9QDGMC_ &J2UVCQ!J"B0E!!;@/OV_*N\J_^R=WR9_@'!J[<W$-M#NN6
M$2L3'A4).7.754')*'HG7^/I0!@^#XA!;:S%+<M<A-3F$D^W:TB?)SC@!O,Q
MMQQC[U3P65Y<7>JNU^]M_I4RNL8RI.U#,WKC;@<<YZ<9J?0+>[@_M*>XMS')
M=:A+<Q0NX<D,JJ%./[R@N1_'[4M@)-/O;U9U8PW%T);>X60$. %$6X]59VRN
MXC 'R]30!*-,U+S?DUBZ\[S!M!5/]84_=@]O]7DMV].:R]:TR\.BR+!JLTD3
M+" LPP##N^3.#G)?./;[W-=(53:59]B;2K,$QM0G+MCML;Y0O\&=W2J>K<VH
M>1563SE;RB,@R-PT9]1M^?\ VSR.E &SX5M(+[P581W5K#L=-_E(253DD;2>
M>/7K6JFAZ5&.-/MB<Y+-&&8GU)/)/UJCX+Q_PA^FXY'DBMZ@"M!I]G:P)#!;
M1)&GW5"# HM]/L[21I+:UAA9@ QC0+D#UQ5FB@ HHHH **** "BBB@#!UF[\
M-12S6>L7.G[IU5WM[MU.1R%;:?H>?:KVB2/)I%LSK JF-?+\AF9"F/E(W 'D
M8X-4]1@U>35"]BUI;1[%1IW@\R1E^8G'S#H0!@C^(G/:M6RW?8+??$(7\I=T
M8'"''3\* )Z*** "BBB@ HHHH **** ,7Q8<>&KO@G[G SS\Z^E>4^#[I8/#
M5K$^TN'/1U)^=B(QM?O&?G"_=8?,<'!KUKQ-++!H%Q+ VV5&C9&P#@[UQUKQ
M70=.^WZ'#=_99I&<2Y99%QOC/[WY>O*?P]6/(XJ9-I:&]"-.4K5'9?UYHZK^
MT[=5WO%%(BJ79!<*0ZH=LB9SDB5L,&ZL1M.5J5;HMO4;7DCW*\_GJ!N7YFE)
M!^4,G[IB/N=$ZXK%'A\O)LBLKD.SA(R;F/[SKN@)/3A<@MT/W1DU9L+7["DD
MD%A<_9IXXG93/&#Y1;"$$_=99AD=D'WJA2G?5?U]QT3HT%'W)7?R_P#DC90^
M:%**T#/MVJ0-T1<9C&WIN@')7[NT[N&JAI\D1N]4=;3;&)U8Q D^<NQ5\L$\
MMYC?O5SR^,/QS5T(8K?RK@*52.5)E13M(7!O %Z[6."J_>W?,/EJO-IES/?2
M2QZA?0W<LO6.1"OV@Q (Q^4Y @&UB.'/"\UJ<+W+;*5W![E)"NX-,7(5RG,D
MN1R%E_U98<JPVKE:Q3+&?&44(E5)VA**^1NMG9=REE^ZK1)\I4'"CYA\W%:G
MEPO:)'"]TD02$Q.'42B('%M\Q& XDR2Q&%4[6R:JPZ=;VR?Z1<75Q"F]YED'
M#JIQ<<  \O@HN<J1N/'% AFL21QV]E.R%(5O+9S%M4[4+;4C^;T;]ZN?OCE\
M4VXUVP"B&UU&QO;MW:%(UNE(E93B0D@[MLI/)'S9&WE:U'C,CE)EC><R,&WQ
M[U,VW+D@=08L!@/OMR@'6JI6SM3'-;6BK*3&8#' #*&8'[-R!RP ;<W0K\IW
M-0-)MV1SS3ZG_P )T]@MZ$D"M&UT;9 4_=^9N8 C:$_U9P?D!^4YK8CU[3XE
M\N_GM+.Z0J)+229$*;CMC4*2#A#^\4' 96W-AJNL]JEJ;HQ VRPEL1QX;R W
M*KSD'SN5&<I_&<<4Q88KR2226UA-SN=96EMMO[P*&N/O ':4*\=2WS+@ TKH
M;A))MK8PM*U-XVUF=F2ZL+*5I6A4[EEBR2ZK(>3YA^=2<ER-K<<U:UG6-+ET
MF]MXM3L[RXVM%NBG1V:0 .TVT'NI$9_N8PG!-:EG<F>=;>V1X[AMLD?FQ[1Y
MK K"Q.-I/EY#D<." ,GFL;6U@32KR*RTN-;<6\9$H1%V6Y)"#'WMRR X[J&
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M\I(Z!V!V_+L< 8'W <BNHY9NIC8M[90L.?;,0_#![-67X@'_ !(IF "C,1"
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MO!4 Y'F;?DQGJ/+Z9^\?O8K)T5K9Y=6-LX:-+[:22<# 3R@3U^^?F/4< <4
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MMF4K_KALQC,_!"=,#S.M!U*V\V.(71\^6011S*KN/-8927..0$_=!C_K#PV
M* '?\)9HNQ$#:FV]$5-VDW!WY)9>-O._!W#^+&1Z4DOC'1TADED;540)([2'
M3I\JI.'?.S&5/R[N 1QQ39I8OM%FRP^6C$O&ID*^4A!5%)["%LEFZQ[MHX-6
M7V[666!I$ <21&( NJ?ZV/;T!D/S[.B@;QDT 0IXPTPN=T=\)%;)6"SDE0$(
M.%=%*X53N7^Z<@^M1GQGI$<D,)CU$M)M2)&TR<"3 W*,;<D.,L1UR-W(JM8A
MVU-X9H8K:[C&R(1*'\W(W&;. KAUQ&J_QG);DBIM319M/.-.2\4A62%V4J@;
MB)MS<XA/REP"V3LQB@!EUX]\/6<*/>3:A!%+E5EEL)AN#'EL[>3D;"?XATQ6
M3<^.=(?4%NK#2]725IO,:\M[7$;# 60-R"=B_=)7*\#WK2TZSL&TJ)VMX;F$
MB29D\D(,$[98@O\ !\_[PKUB R,G-6SI-FK[6M+>216VEA;J3(Z+EB%Z$RI\
MJKT8#?UH @_X6'X>6\%JOVMKH;62W_L^7+[>$7;C.U\[@.S<G(I+WQ7ILMJJ
M1VVHNF8P99["6-?++;O,+%<#<V4/][ Q5B+2[,-'Y$-I#)E%CF &(V?YHI V
M,E8^4W=78[3@4FH$-8[U15A!20VSL1F+=M$!]"C_ +QO^>><+D&@#M_!Z-%X
M4L(FV;HT*'8VY>"1P>];E8/@L8\(::, ?N1T&*WJ "BBB@ HHHH **** "BB
MB@#/NM/TW^T(=3N+:,W:8BCF*Y9=WR\?]]$9]":NQ1I#"D42A8T4*JCH .@K
M%\2Z_INB16XU!;AVE??!' FYY70J0BCN3D<>@)Z FM:SNHKZQM[N DPSQK+&
M2,$JPR./H: )Z*** "BBB@ HHHH **** ,;Q7_R+5WGI\F<?[ZUYCX-#-X2M
M/.^;(;[WS+Y9E/DCY>=OF\N/O'JOR\5ZCXE=8M N)'@6=5:,F)^C_.O!KR/P
MMIUE=^';:Y>!D+%R=L[PJ"/EEP00 (U&X28^4G9SF@#J'\H!_M'F>7B4S<C>
M4_Y>N>FXMCD?*5X7#4\-*+H1Y/VW>&RG \\+R1G@#R.$SP#G?S6%#:ZC'%>Z
M?81S12&\7[/*Z$;-J*T2JK'YMXW,4_@)WG'2JMWILLESIS?VA+8S7%YS+;L9
MUGM_+8J=K !M\@*8(_>XSVH&K=3?DVA;=K8*(@8C%O5BH3YOL? YP&SN'WMW
M/W:Q;"6U:^\0,Y?RFN5:?S3EFM\KYOW>"QDP3CJOW>:N>(X_-T>>:8O#*A:0
MM$YRC,RK<'<#SY7 #]L[,&HK_P -Z4(KB9K(?:45R Q8'S53Y8^3P#'^\(S^
MZ(SDYQ4M,TA-+1FKJ"71AE\Z1TNA(S,\;[3]H"9F((XYBP$_AQD-\U8]M$T?
MBFWCAD+L8E^Q,[,RAB%-OG/S;0.QY#<M\M,32=%CT6&XO7;R%@C9Y96?&W@Q
M.4SUDDRI3^,#?\N*H):VDEV]KH,]I (D\][Q9"XA1BHFC+ <@'(#]7!V <9H
MMK<%-*FX]_\ @?Y'6'R3%T_T4QGA@2?(+]#CJ?.Y?'+#[G&:<^X,YN,EPTIF
M*XW;@/\ 2L'IN*XVG[NWCAZY_4-4O)6M51Y+"X!DDO43@P2H@79DY"H$)<'I
M&>,DFM :9.N%AU>^?&U8U.SYMO, V;?XSDE/;S#CI5&?*[7+Y9H_GW1)*C(0
MV"$64(3$>>BB'.W/1N7R*IV=[;78(BMYHK80121>:N"T#NWV?C)/^M4EP?F)
MP1\N15&\M3$;5)M9NY+6><0N9&20-$^2S?=^;,H"9_Y:C@#BK]S837&H/>K-
M/;73J5E2&0$;AD2CD'_5JQPW\&[9R:!%MO)PYG$IBQ*9LD;_ "^EUR.-Y?'(
M^4KPN&I7A:<F&90]PTBA@ -IN F21GC'D?<SPI^_SBJ TV^5@L>H7WFJRA(2
MB+F1!F"/9M^7<F7*?P??/I4;Z1)- T(UG4&MY(_+$F%8M"QRC_=RQ>7Y,=90
M,\8H T8(8H8E2RC6.,B(PJ5(7!;-ID=<!LEQ][=S]RJ6I%$N;*:83-8J;@2*
M,%S$W$H('5C-G<5X*XV=Z9H[&6UN)IH1:122RD!92=B'"7#AB./+V\/S][9S
M5BZ=H]3L2D2FZ\UB(##M =$PJ?\ 3,>7B3'_ "R)SSG%)[%P2<M0DU5D9I+E
M+I9A(3*_DX_?;<3D$\ ^5@+G@#AOFYIUO=F6:**WADCD)C$)D@94#C_CU!SR
M%"YX/.[ELK4>HB)-+F$,I>)8T1';C=$&#0L1W,CY!3_EH!OXJP)[6<NINUVD
M/YCI/N*H_P#KGW=]C80/CYP=F.]+6]BVH\G,D.Q"8LX_T4QYPP)/D%^AQU/G
M<OCEAC9QQ2LV9)1.Q+HT@N-N-P;:/M7/3<5*[3]W;QP](\ZQ2!Y6CBF+[_+:
M7RP)0-I0'^$+'A\_\LB<<YQ5&SN;:&2Z$<T+*)5,6Y0GF! ##\N?F#G.5]M_
M'2FW8F--N+=C17S/-41E!<;T"%5(7SMO[K&>BB'.W/1OOY%<_=:K':F.<Z5=
M2H (K0!./+9CY ZYP9%)?G).-ORYK>/EM&09"8&0@R^9O)B=LM)G^(F3]WG_
M );#C'&:J:I'+<FV#R-;2FY:5FBF"F-]C"8!CQB)0"&YV9V<T6N2I.-TBE:^
M(;>^A,K:9J_D,C/(3$FYH7&;A@0V-Q?'(XV\+AJN#5KKS03IVI_;/,!.R)1_
MI&WYL9./]1]S/ YWY-1:! ]I;R1V]FA:.ZQ"ICQYSQC]RK#C[Z[G*?\ +,C?
M6D%C,:HK%[<HJ++LWEHBVY'Q_$9)?D(_Y; 9XQ3),XZSY,&^*PODB1(S$SQ
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MQ,KP19#'@,-Q'3.1TZ&NCKF_!-K$GAJRN@I\^:++L3G/)/T')/2NDH ****
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ML$ [<YW@$<<Y/).#Q;F2?6M<T8)J=M#>::)=LBNDR7#%0,A0P8?*&)R./4T
M9&K*PTV4M:M;"2+S5B(P%C=@-G/\,1^=CU!.%PM3[$BD9A:;V#-N01J&D*##
MH0!C=,,.0/EVC*@MS5GQ5I^M3R0P7&JVKJT<A3%N$"X&7/+?*=F0'/ SCC=F
MN4.HZNLF(=0TY2%5HD:VVD,K;;92N<@*,DJ>4;YF!!S2MK<OF]Q+U_0Z+R@[
M*I/F,&15G"JV6^\LHSU+#]TF3AL?.2<"J-I#;R/?;88(5,F, ';$K;<9SR%A
M;DXY#-CY5I/L^I>6,WULT!13M-D6)B9\%2 WS%I?F(!_>#E20,5&+/5XFN9)
MM5BD>1I9)2;;/S+A9RK;@/F4 !NF,I\IH:U",K1:-5LC<6B8@;V,#  G'#Q$
M#H3_ *U@!@#E 3S4,XD%Q:KY[R,+C&\;29&6-CN&3@F9?D7J& ^;+<56^S:Q
MYVU-1M%F\S:A%D5"R!,QG!;Y0L>0 1^[/+ YS4<44WVBU$TT4ENP0PQK:E=J
MD-Y((W$D"3+,G5_O D#%,@30WCG@N/)OD57G^5P6 A5SF.0$@';%@HK=26PV
M%K3+#:7,85<%S Q(VJ3M:$XZ;#^];'*Y^3CFL?23$DU]YXF> -*9E+EF9$8)
M.%; 'S';@CAP"J[36U^\67!?_2A)@R!@H\]4R[@G[H\GY%)_U9X;).: ,[5[
M(7D4<4K74P6;#+ !NF91R6'3,PPV!\I5<\MQ3(]$LV14\^8L<)]I2YDQE^1,
M,MT7!B3/4\/Z5-/-*+RQM;,B)9B@3=$6"IUM5*]0$)RR]<_.<CBJ4NH+'#>P
MI!J$Z%Y(Y9$C#X1@!(,@\EI=K$C_ %@P!BBS;+5G&W4K:6D,FMW4BPPPBU#C
M[.9I7:-&(4!B>@B(WMMY!; P*W;QBMI<%H9'*I(2FU=SE5^=,=-TH_>$?=VC
M*Y;FLG2;K58;N&PN+6&!564F108B98U'FL"21N:,[=_ 3[O4YK4O4E.GW"1&
M-6\H)'F$A58H6M_EZ@(F<IU1CO.1S005M.O[3[)$@O8U=7\O>' )8982@.<D
MNO[M=W# _.2<"K27EK*@\N[@C4J,$2C;$K'Y3G.=L)[_ '@QQ\J5Q.E7>CFU
M5DEM%N1N-RUZRRH\>X?*X)W.V[#$+RZXYQ\M7[>'2+GQ!&BO#=3(L\EZ4=3O
M15'F['7"@-D;2,# *X!YH ZMIX_F9BIQO9H&902!P\1 Z$G]ZP'0<H">:/,5
M7V_;%E<-MW!T+2,JYW#G!:=?E /RE1EB6XJC+H&FS_N9+&W:4OL!*,JB7;N5
ML$_*!%E0#_JSRP.<TJ:1H^Q1!I\:1%4\I"C$*C\6X*YR=K9++G+_ 'P2.* +
MBO$RJ%OX(PP15F$ORIOY24$\[8C^[4GDL<-A:HZO<V_]F22O-%#&/WC0;^BE
MMC0<9/R-B5L#Y21LXR::VA:!YAN9M,1P 9)#NR[1I\LPW=V9SD-T=?D&#46I
MZ58Q6Q#6P-T)0@>)RO\ I"C<[@]E\O"K_P \S\IY.: /0_!?_(GZ:#NR(@#N
M!!R/4&MZL+P8QD\(Z=(S,S/%N+.<DDG/)K=H **** "BBB@ HHHH **** .
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M5-S6ICC5&"[F,!?,+<_>9ILJ ?\ 6+RW3-10&"6!(TNXDC\M5\R/.(T8[O,
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MQ@Y"@"5ACYB<IQDT =SX(D67P9I;HZNIA'S*<@UT%87@YVD\)Z?([!G>/>S
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M4CS*5LS%N9,$D0L=HCX.22^9.N91SGC%9.G:AIEHWV.*\\VW5'DRY;JI_?\
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MDDGE1E61V"$>6A.Z5@O4>4^%5.J9W\BG9=GW-&OG,Q8PE=X\QAM>+'\0\O\
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M[U0?OCEP,"K3?*K%SYJJK%B&^60*<.=W7;,> W4L-O*TNH/^&O5_H9NM7++
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ME1G*%1@EBV,MYARC$8+,,)E*MVJ?:+EKS^T$=I%\L31@*8BP)=S\Q :$80]
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MIO\ OQ)_\30 S3-$L=)C1;9'+)&(E>60NP0=%!/0>PK1JC_:]G_>F_[\2?\
MQ-']KV?]Z;_OQ)_\30!>J&ZM8+VW>WN(UDB<<JW^>OO5?^U[/^]-_P!^)/\
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M8/#NIDH1((DTZY"DQC8L8S%PI'[Q,_=;.Z@#:;[29F\Y,7)D?S%50?WQ3]^
M.AQ%@H/NM]YLM6=K!4Z+<%BFS;"4(=MI;(%KSUVLN<M]XMPV!@57_M&Z2%5_
ML?4Y$_U +6%P=P7Y]S+Y>=LA.UQU+#/2JM_JM_<V,Z1Z%K9DD4D;[&?=F3DG
M/E8\Q,;=W0H0!TH [MWDLK>SNM+C\[59 ZBUW;1<1AC]\]%"YX8],X_BJG?K
M T&C7*2F:YFU,&YD9=K[PC_(5ZKMZ!>WOG)H6>NS:;-<;++5Q)(Y)=M,FE.T
M\A0RQXVKD@#V)[Y-:\U&74-2AO5LM6,\!\XK_9L\4<K*,+NS&-QP2!@@^O%
M'I$TEEI=E)/,T-K:Q L['"(H[D]JX/Q#-.UYJ#6]]''DYB83*,?*,=5/?WK:
MN-:EO+:2WN=.N989!M>-](G*L/0C-8%\76[6XAT=W!;>4;2)4'&/E'!R30 V
MT>^F0M%=QR_,P21'4H1U'1.>"*[35/\ D593_P!,%_I7#:5I[:=-<O'I]S;^
M8RG$6CS!6.Q03@$<Y'I6S?ZO<W-I#I\NGWSVS >:PT^:/Y5QQ[D^E '2^'/^
M19TS_KVC_P#016I65X<B$&A6\01T5-RJK@@@!C@<\XQ6K0 4444 %%%% !11
M10 52U+/D)M_UN_Y!GDG!S@="=N[ /%7:I:IS9[2<*6 8]AWP1U()P,#DYH
MQU)POEX(PFS).#S^YYZX/.3USQTJ:SW_ &N'9DC)QD<[-WS''3(?@^@Z5">2
M2S%,Y).[E=WWSGIE.F>F#CK4MJ ;N+)"?.#MP< C@)CTQ\X'\/>@#H**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "F2Q),FR10RY!P?4=*?10!6-A;'.84.=V1C^]U_.G"SMU<.(QN#;@
0>^<8S^7%3T4 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>17
<FILENAME>mack-20180331.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFS ActiveDisclosure(SM) XBRL Instance Document - http://www.dfsco.com/financial-services/ -->
<!-- Creation Date      : 2018-05-07T16:39:29.0819186+00:00 -->
<!-- Version            : 2.9.6605.1333 -->
<!-- Package ID         : 61e77818d95b40c390d461315935aff4 -->
<!-- Copyright (c) 2018 Donnelley Financial, LLC. All Rights Reserved. -->
<xbrl xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.xbrl.org/2003/instance" xmlns:mack="http://www.merrimackpharma.com/20180331" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2017-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">
  <xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="mack-20180331.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" />
  <unit id="U_shares">
    <measure>shares</measure>
  </unit>
  <unit id="U_iso4217USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="U_iso4217USD_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="U_mackProgram">
    <measure>mack:Program</measure>
  </unit>
  <unit id="U_pure">
    <measure>pure</measure>
  </unit>
  <context id="C_0001274792_20180101_20180331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="C_0001274792_20180503">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
    </entity>
    <period>
      <instant>2018-05-03</instant>
    </period>
  </context>
  <context id="C_0001274792_20180331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="C_0001274792_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001274792_20170101_20170331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="C_0001274792_deiLegalEntityAxis_mackSilverCreekPharmaceuticalsIncMember_20170101_20170331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mack:SilverCreekPharmaceuticalsIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="C_0001274792_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001274792_20170331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
    </entity>
    <period>
      <instant>2017-03-31</instant>
    </period>
  </context>
  <context id="C_0001274792_deiLegalEntityAxis_mackSilverCreekPharmaceuticalsIncMember_us-gaapRangeAxis_us-gaapMaximumMember_20170930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mack:SilverCreekPharmaceuticalsIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-09-30</instant>
    </period>
  </context>
  <context id="C_0001274792_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_20180331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="C_0001274792_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20180331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="C_0001274792_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20180331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="C_0001274792_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20180331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="C_0001274792_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20180331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="C_0001274792_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20180331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="C_0001274792_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperNotIncludedWithCashAndCashEquivalentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20180331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="C_0001274792_us-gaapFairValueByAssetClassAxis_us-gaapUSTreasuryAndGovernmentMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20180331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="C_0001274792_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001274792_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001274792_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20180331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="C_0001274792_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20180331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="C_0001274792_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20180331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="C_0001274792_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_20180331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="C_0001274792_us-gaapInformationByCategoryOfDebtSecurityAxis_mackMarketableSecuritiesMember_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20180331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">mack:MarketableSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="C_0001274792_us-gaapInformationByCategoryOfDebtSecurityAxis_mackMarketableSecuritiesMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20180331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">mack:MarketableSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="C_0001274792_us-gaapInformationByCategoryOfDebtSecurityAxis_mackMarketableSecuritiesMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20180331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">mack:MarketableSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="C_0001274792_us-gaapInformationByCategoryOfDebtSecurityAxis_mackMarketableSecuritiesMember_20180331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">mack:MarketableSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="C_0001274792_us-gaapPlanNameAxis_mackStockIncentivePlan2011Member_20180331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mack:StockIncentivePlan2011Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="C_0001274792_us-gaapPlanNameAxis_mackStockIncentivePlan2011Member_20180101_20180331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mack:StockIncentivePlan2011Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapPlanNameAxis_mackStockIncentivePlan2011Member_20170101_20170331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mack:StockIncentivePlan2011Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapPlanNameAxis_mackStockIncentivePlan2011Member_us-gaapTitleOfIndividualAxis_mackEmployeeMember_20180101_20180331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mack:StockIncentivePlan2011Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mack:EmployeeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMinimumMember_20180101_20180331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMaximumMember_20180101_20180331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20170101_20170331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMinimumMember_20170101_20170331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMaximumMember_20170101_20170331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20180331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20180101_20180331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20170101_20170331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20180101_20180331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20170101_20170331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_20180331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="C_0001274792_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapStockCompensationPlanMember_20180101_20180331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapStockCompensationPlanMember_20170101_20170331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapConvertibleDebtSecuritiesMember_20170101_20170331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20170101_20170331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mack:CommercialBusinessMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapRestructuringPlanAxis_mackJanuaryTwoThousandSeventeenCorporateRestructuringMember_20180101_20180331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">mack:JanuaryTwoThousandSeventeenCorporateRestructuringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapRestructuringPlanAxis_mackJanuaryTwoThousandSeventeenCorporateRestructuringMember_20170107_20170108">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">mack:JanuaryTwoThousandSeventeenCorporateRestructuringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-07</startDate>
      <endDate>2017-01-08</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapRestructuringCostAndReserveAxis_us-gaapContractTerminationMember_us-gaapRestructuringPlanAxis_mackJanuaryTwoThousandSeventeenCorporateRestructuringMember_20180101_20180331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">mack:JanuaryTwoThousandSeventeenCorporateRestructuringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapRestructuringCostAndReserveAxis_us-gaapOneTimeTerminationBenefitsMember_us-gaapRestructuringPlanAxis_mackJanuaryTwoThousandSeventeenCorporateRestructuringMember_20180101_20180331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">mack:JanuaryTwoThousandSeventeenCorporateRestructuringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapDisposalGroupClassificationAxis_us-gaapDiscontinuedOperationsDisposedOfBySaleMember_us-gaapRestructuringPlanAxis_mackJanuaryTwoThousandSeventeenCorporateRestructuringMember_20180101_20180331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">mack:JanuaryTwoThousandSeventeenCorporateRestructuringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <dei:DocumentType id="F_000000" contextRef="C_0001274792_20180101_20180331">10-Q</dei:DocumentType>
  <dei:AmendmentFlag id="F_000001" contextRef="C_0001274792_20180101_20180331">false</dei:AmendmentFlag>
  <dei:DocumentPeriodEndDate id="F_000002" contextRef="C_0001274792_20180101_20180331">2018-03-31</dei:DocumentPeriodEndDate>
  <dei:DocumentFiscalYearFocus id="F_000003" contextRef="C_0001274792_20180101_20180331">2018</dei:DocumentFiscalYearFocus>
  <dei:DocumentFiscalPeriodFocus id="F_000004" contextRef="C_0001274792_20180101_20180331">Q1</dei:DocumentFiscalPeriodFocus>
  <dei:TradingSymbol id="F_000005" contextRef="C_0001274792_20180101_20180331">MACK</dei:TradingSymbol>
  <dei:EntityRegistrantName id="F_000006" contextRef="C_0001274792_20180101_20180331">MERRIMACK PHARMACEUTICALS INC</dei:EntityRegistrantName>
  <dei:EntityCentralIndexKey id="F_000007" contextRef="C_0001274792_20180101_20180331">0001274792</dei:EntityCentralIndexKey>
  <dei:CurrentFiscalYearEndDate id="F_000008" contextRef="C_0001274792_20180101_20180331">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:EntityFilerCategory id="F_000009" contextRef="C_0001274792_20180101_20180331">Accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityCommonStockSharesOutstanding id="F_000010" contextRef="C_0001274792_20180503" decimals="INF" unitRef="U_shares">13342784</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000011" contextRef="C_0001274792_20180331" decimals="-3" unitRef="U_iso4217USD">34268000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000012" contextRef="C_0001274792_20171231" decimals="-3" unitRef="U_iso4217USD">93441000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:MarketableSecuritiesCurrent id="F_000013" contextRef="C_0001274792_20180331" decimals="-3" unitRef="U_iso4217USD">41998000</us-gaap:MarketableSecuritiesCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="F_000014" contextRef="C_0001274792_20180331" decimals="-3" unitRef="U_iso4217USD">844000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="F_000015" contextRef="C_0001274792_20171231" decimals="-3" unitRef="U_iso4217USD">1605000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:AssetsCurrent id="F_000016" contextRef="C_0001274792_20180331" decimals="-3" unitRef="U_iso4217USD">77110000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent id="F_000017" contextRef="C_0001274792_20171231" decimals="-3" unitRef="U_iso4217USD">95046000</us-gaap:AssetsCurrent>
  <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent id="F_000018" contextRef="C_0001274792_20180331" decimals="-3" unitRef="U_iso4217USD">674000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
  <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent id="F_000019" contextRef="C_0001274792_20171231" decimals="-3" unitRef="U_iso4217USD">674000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
  <us-gaap:PropertyPlantAndEquipmentNet id="F_000020" contextRef="C_0001274792_20180331" decimals="-3" unitRef="U_iso4217USD">5358000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet id="F_000021" contextRef="C_0001274792_20171231" decimals="-3" unitRef="U_iso4217USD">6467000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:EquityMethodInvestments id="F_000022" contextRef="C_0001274792_20180331" decimals="-3" unitRef="U_iso4217USD">9805000</us-gaap:EquityMethodInvestments>
  <us-gaap:EquityMethodInvestments id="F_000023" contextRef="C_0001274792_20171231" decimals="-3" unitRef="U_iso4217USD">10551000</us-gaap:EquityMethodInvestments>
  <us-gaap:OtherAssetsNoncurrent id="F_000024" contextRef="C_0001274792_20180331" decimals="-3" unitRef="U_iso4217USD">4548000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherAssetsNoncurrent id="F_000025" contextRef="C_0001274792_20171231" decimals="-3" unitRef="U_iso4217USD">4588000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:Assets id="F_000026" contextRef="C_0001274792_20180331" decimals="-3" unitRef="U_iso4217USD">97495000</us-gaap:Assets>
  <us-gaap:Assets id="F_000027" contextRef="C_0001274792_20171231" decimals="-3" unitRef="U_iso4217USD">117326000</us-gaap:Assets>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent id="F_000028" contextRef="C_0001274792_20180331" decimals="-3" unitRef="U_iso4217USD">15323000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent id="F_000029" contextRef="C_0001274792_20171231" decimals="-3" unitRef="U_iso4217USD">17606000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:DeferredRentCreditCurrent id="F_000030" contextRef="C_0001274792_20180331" decimals="-3" unitRef="U_iso4217USD">2211000</us-gaap:DeferredRentCreditCurrent>
  <us-gaap:DeferredRentCreditCurrent id="F_000031" contextRef="C_0001274792_20171231" decimals="-3" unitRef="U_iso4217USD">2171000</us-gaap:DeferredRentCreditCurrent>
  <us-gaap:LiabilitiesCurrent id="F_000032" contextRef="C_0001274792_20180331" decimals="-3" unitRef="U_iso4217USD">17534000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent id="F_000033" contextRef="C_0001274792_20171231" decimals="-3" unitRef="U_iso4217USD">19777000</us-gaap:LiabilitiesCurrent>
  <us-gaap:DeferredRentCreditNoncurrent id="F_000034" contextRef="C_0001274792_20180331" decimals="-3" unitRef="U_iso4217USD">651000</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:DeferredRentCreditNoncurrent id="F_000035" contextRef="C_0001274792_20171231" decimals="-3" unitRef="U_iso4217USD">1209000</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:OtherLiabilitiesNoncurrent id="F_000036" contextRef="C_0001274792_20180331" decimals="-3" unitRef="U_iso4217USD">56000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:OtherLiabilitiesNoncurrent id="F_000037" contextRef="C_0001274792_20171231" decimals="-3" unitRef="U_iso4217USD">56000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:Liabilities id="F_000038" contextRef="C_0001274792_20180331" decimals="-3" unitRef="U_iso4217USD">18241000</us-gaap:Liabilities>
  <us-gaap:Liabilities id="F_000039" contextRef="C_0001274792_20171231" decimals="-3" unitRef="U_iso4217USD">21042000</us-gaap:Liabilities>
  <us-gaap:CommitmentsAndContingencies id="F_000040" xsi:nil="true" contextRef="C_0001274792_20180331" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CommitmentsAndContingencies id="F_000041" xsi:nil="true" contextRef="C_0001274792_20171231" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:PreferredStockValue id="F_000042" xsi:nil="true" contextRef="C_0001274792_20180331" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:PreferredStockValue id="F_000043" xsi:nil="true" contextRef="C_0001274792_20171231" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CommonStockValue id="F_000044" contextRef="C_0001274792_20180331" decimals="-3" unitRef="U_iso4217USD">1334000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue id="F_000045" contextRef="C_0001274792_20171231" decimals="-3" unitRef="U_iso4217USD">1334000</us-gaap:CommonStockValue>
  <us-gaap:AdditionalPaidInCapitalCommonStock id="F_000046" contextRef="C_0001274792_20180331" decimals="-3" unitRef="U_iso4217USD">578485000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AdditionalPaidInCapitalCommonStock id="F_000047" contextRef="C_0001274792_20171231" decimals="-3" unitRef="U_iso4217USD">577721000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="F_000048" contextRef="C_0001274792_20180331" decimals="-3" unitRef="U_iso4217USD">-500553000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="F_000049" contextRef="C_0001274792_20171231" decimals="-3" unitRef="U_iso4217USD">-482771000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax id="F_000050" contextRef="C_0001274792_20180331" decimals="-3" unitRef="U_iso4217USD">-12000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:StockholdersEquity id="F_000051" contextRef="C_0001274792_20180331" decimals="-3" unitRef="U_iso4217USD">79254000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000052" contextRef="C_0001274792_20171231" decimals="-3" unitRef="U_iso4217USD">96284000</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="F_000053" contextRef="C_0001274792_20180331" decimals="-3" unitRef="U_iso4217USD">97495000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="F_000054" contextRef="C_0001274792_20171231" decimals="-3" unitRef="U_iso4217USD">117326000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="F_000055" contextRef="C_0001274792_20180331" decimals="INF" unitRef="U_iso4217USD_shares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="F_000056" contextRef="C_0001274792_20171231" decimals="INF" unitRef="U_iso4217USD_shares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized id="F_000057" contextRef="C_0001274792_20180331" decimals="INF" unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized id="F_000058" contextRef="C_0001274792_20171231" decimals="INF" unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued id="F_000059" contextRef="C_0001274792_20180331" decimals="INF" unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued id="F_000060" contextRef="C_0001274792_20171231" decimals="INF" unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding id="F_000061" contextRef="C_0001274792_20180331" decimals="INF" unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding id="F_000062" contextRef="C_0001274792_20171231" decimals="INF" unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:CommonStockParOrStatedValuePerShare id="F_000063" contextRef="C_0001274792_20180331" decimals="INF" unitRef="U_iso4217USD_shares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare id="F_000064" contextRef="C_0001274792_20171231" decimals="INF" unitRef="U_iso4217USD_shares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized id="F_000065" contextRef="C_0001274792_20180331" decimals="INF" unitRef="U_shares">20000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized id="F_000066" contextRef="C_0001274792_20171231" decimals="INF" unitRef="U_shares">20000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued id="F_000067" contextRef="C_0001274792_20180331" decimals="-3" unitRef="U_shares">13343000</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued id="F_000068" contextRef="C_0001274792_20171231" decimals="-3" unitRef="U_shares">13343000</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding id="F_000069" contextRef="C_0001274792_20180331" decimals="-3" unitRef="U_shares">13343000</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding id="F_000070" contextRef="C_0001274792_20171231" decimals="-3" unitRef="U_shares">13343000</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000071" contextRef="C_0001274792_20180101_20180331" decimals="-3" unitRef="U_iso4217USD">13106000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000072" contextRef="C_0001274792_20170101_20170331" decimals="-3" unitRef="U_iso4217USD">21605000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000073" contextRef="C_0001274792_20180101_20180331" decimals="-3" unitRef="U_iso4217USD">4270000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000074" contextRef="C_0001274792_20170101_20170331" decimals="-3" unitRef="U_iso4217USD">5634000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:OperatingExpenses id="F_000075" contextRef="C_0001274792_20180101_20180331" decimals="-3" unitRef="U_iso4217USD">17376000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses id="F_000076" contextRef="C_0001274792_20170101_20170331" decimals="-3" unitRef="U_iso4217USD">27239000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss id="F_000077" contextRef="C_0001274792_20180101_20180331" decimals="-3" unitRef="U_iso4217USD">-17376000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="F_000078" contextRef="C_0001274792_20170101_20170331" decimals="-3" unitRef="U_iso4217USD">-27239000</us-gaap:OperatingIncomeLoss>
  <us-gaap:InvestmentIncomeInterest id="F_000079" contextRef="C_0001274792_20180101_20180331" decimals="-3" unitRef="U_iso4217USD">275000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InvestmentIncomeInterest id="F_000080" contextRef="C_0001274792_20170101_20170331" decimals="-3" unitRef="U_iso4217USD">14000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InterestExpense id="F_000081" contextRef="C_0001274792_20170101_20170331" decimals="-3" unitRef="U_iso4217USD">1979000</us-gaap:InterestExpense>
  <us-gaap:OtherNonoperatingIncomeExpense id="F_000082" contextRef="C_0001274792_20180101_20180331" decimals="-3" unitRef="U_iso4217USD">-681000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense id="F_000083" contextRef="C_0001274792_20170101_20170331" decimals="-3" unitRef="U_iso4217USD">-2000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense id="F_000084" contextRef="C_0001274792_20180101_20180331" decimals="-3" unitRef="U_iso4217USD">-406000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense id="F_000085" contextRef="C_0001274792_20170101_20170331" decimals="-3" unitRef="U_iso4217USD">-1967000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest id="F_000086" contextRef="C_0001274792_20180101_20180331" decimals="-3" unitRef="U_iso4217USD">-17782000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest id="F_000087" contextRef="C_0001274792_20170101_20170331" decimals="-3" unitRef="U_iso4217USD">-29206000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax id="F_000088" contextRef="C_0001274792_20170101_20170331" decimals="-3" unitRef="U_iso4217USD">-947000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
  <us-gaap:ProfitLoss id="F_000089" contextRef="C_0001274792_20180101_20180331" decimals="-3" unitRef="U_iso4217USD">-17782000</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss id="F_000090" contextRef="C_0001274792_20170101_20170331" decimals="-3" unitRef="U_iso4217USD">-30153000</us-gaap:ProfitLoss>
  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest id="F_000091" contextRef="C_0001274792_20170101_20170331" decimals="-3" unitRef="U_iso4217USD">-467000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
  <us-gaap:NetIncomeLoss id="F_000092" contextRef="C_0001274792_20180101_20180331" decimals="-3" unitRef="U_iso4217USD">-17782000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000093" contextRef="C_0001274792_20170101_20170331" decimals="-3" unitRef="U_iso4217USD">-29686000</us-gaap:NetIncomeLoss>
  <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent id="F_000094" contextRef="C_0001274792_20180101_20180331" decimals="-3" unitRef="U_iso4217USD">-12000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent id="F_000095" contextRef="C_0001274792_20180101_20180331" decimals="-3" unitRef="U_iso4217USD">-12000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
  <us-gaap:ComprehensiveIncomeNetOfTax id="F_000096" contextRef="C_0001274792_20180101_20180331" decimals="-3" unitRef="U_iso4217USD">-17794000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax id="F_000097" contextRef="C_0001274792_20170101_20170331" decimals="-3" unitRef="U_iso4217USD">-29686000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:IncomeLossFromContinuingOperations id="F_000098" contextRef="C_0001274792_20180101_20180331" decimals="-3" unitRef="U_iso4217USD">-17782000</us-gaap:IncomeLossFromContinuingOperations>
  <us-gaap:IncomeLossFromContinuingOperations id="F_000099" contextRef="C_0001274792_20170101_20170331" decimals="-3" unitRef="U_iso4217USD">-28739000</us-gaap:IncomeLossFromContinuingOperations>
  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity id="F_000100" contextRef="C_0001274792_20170101_20170331" decimals="-3" unitRef="U_iso4217USD">-947000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
  <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare id="F_000101" contextRef="C_0001274792_20180101_20180331" decimals="2" unitRef="U_iso4217USD_shares">-1.33</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
  <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare id="F_000102" contextRef="C_0001274792_20170101_20170331" decimals="2" unitRef="U_iso4217USD_shares">-2.20</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare id="F_000103" contextRef="C_0001274792_20170101_20170331" decimals="2" unitRef="U_iso4217USD_shares">-0.07</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000104" contextRef="C_0001274792_20180101_20180331" decimals="2" unitRef="U_iso4217USD_shares">-1.33</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000105" contextRef="C_0001274792_20170101_20170331" decimals="2" unitRef="U_iso4217USD_shares">-2.27</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000106" contextRef="C_0001274792_20180101_20180331" decimals="-3" unitRef="U_shares">13343000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000107" contextRef="C_0001274792_20170101_20170331" decimals="-3" unitRef="U_shares">13059000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:PaidInKindInterest id="F_000108" contextRef="C_0001274792_20170101_20170331" decimals="-3" unitRef="U_iso4217USD">1508000</us-gaap:PaidInKindInterest>
  <us-gaap:DepreciationDepletionAndAmortization id="F_000109" contextRef="C_0001274792_20180101_20180331" decimals="-3" unitRef="U_iso4217USD">1239000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization id="F_000110" contextRef="C_0001274792_20170101_20170331" decimals="-3" unitRef="U_iso4217USD">1182000</us-gaap:DepreciationDepletionAndAmortization>
  <mack:PremiumsPaidOnMarketableSecurities id="F_000111" contextRef="C_0001274792_20180101_20180331" decimals="-3" unitRef="U_iso4217USD">51000</mack:PremiumsPaidOnMarketableSecurities>
  <mack:AmortizationAndAccretionOnMarketableSecurities id="F_000112" contextRef="C_0001274792_20180101_20180331" decimals="-3" unitRef="U_iso4217USD">141000</mack:AmortizationAndAccretionOnMarketableSecurities>
  <mack:AllocatedShareBasedCompensationExpenseIncludingNonEmployees id="F_000113" contextRef="C_0001274792_20180101_20180331" decimals="-3" unitRef="U_iso4217USD">764000</mack:AllocatedShareBasedCompensationExpenseIncludingNonEmployees>
  <mack:AllocatedShareBasedCompensationExpenseIncludingNonEmployees id="F_000114" contextRef="C_0001274792_20170101_20170331" decimals="-3" unitRef="U_iso4217USD">796000</mack:AllocatedShareBasedCompensationExpenseIncludingNonEmployees>
  <us-gaap:GainLossOnSaleOfEquityInvestments id="F_000115" contextRef="C_0001274792_20180101_20180331" decimals="-3" unitRef="U_iso4217USD">-746000</us-gaap:GainLossOnSaleOfEquityInvestments>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="F_000116" contextRef="C_0001274792_20180101_20180331" decimals="-3" unitRef="U_iso4217USD">-801000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="F_000117" contextRef="C_0001274792_20170101_20170331" decimals="-3" unitRef="U_iso4217USD">372000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities id="F_000118" contextRef="C_0001274792_20180101_20180331" decimals="-3" unitRef="U_iso4217USD">-2397000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities id="F_000119" contextRef="C_0001274792_20170101_20170331" decimals="-3" unitRef="U_iso4217USD">8054000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <mack:IncreaseDecreaseInDeferredRent id="F_000120" contextRef="C_0001274792_20180101_20180331" decimals="-3" unitRef="U_iso4217USD">-518000</mack:IncreaseDecreaseInDeferredRent>
  <mack:IncreaseDecreaseInDeferredRent id="F_000121" contextRef="C_0001274792_20170101_20170331" decimals="-3" unitRef="U_iso4217USD">-86000</mack:IncreaseDecreaseInDeferredRent>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations id="F_000122" contextRef="C_0001274792_20180101_20180331" decimals="-3" unitRef="U_iso4217USD">-17339000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations id="F_000123" contextRef="C_0001274792_20170101_20170331" decimals="-3" unitRef="U_iso4217USD">-18124000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations id="F_000124" contextRef="C_0001274792_20170101_20170331" decimals="-3" unitRef="U_iso4217USD">7968000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="F_000125" contextRef="C_0001274792_20180101_20180331" decimals="-3" unitRef="U_iso4217USD">-17339000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="F_000126" contextRef="C_0001274792_20170101_20170331" decimals="-3" unitRef="U_iso4217USD">-10156000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="F_000127" contextRef="C_0001274792_20180101_20180331" decimals="-3" unitRef="U_iso4217USD">16000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="F_000128" contextRef="C_0001274792_20170101_20170331" decimals="-3" unitRef="U_iso4217USD">290000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquireMarketableSecurities id="F_000129" contextRef="C_0001274792_20180101_20180331" decimals="-3" unitRef="U_iso4217USD">41818000</us-gaap:PaymentsToAcquireMarketableSecurities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="F_000130" contextRef="C_0001274792_20180101_20180331" decimals="-3" unitRef="U_iso4217USD">-41834000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="F_000131" contextRef="C_0001274792_20170101_20170331" decimals="-3" unitRef="U_iso4217USD">-290000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:ProceedsFromStockOptionsExercised id="F_000132" contextRef="C_0001274792_20170101_20170331" decimals="-3" unitRef="U_iso4217USD">4053000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock id="F_000133" contextRef="C_0001274792_deiLegalEntityAxis_mackSilverCreekPharmaceuticalsIncMember_20170101_20170331" decimals="-3" unitRef="U_iso4217USD">2024000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations id="F_000134" contextRef="C_0001274792_20170101_20170331" decimals="-3" unitRef="U_iso4217USD">6077000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect id="F_000135" contextRef="C_0001274792_20180101_20180331" decimals="-3" unitRef="U_iso4217USD">-59173000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect id="F_000136" contextRef="C_0001274792_20170101_20170331" decimals="-3" unitRef="U_iso4217USD">-4369000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents id="F_000137" contextRef="C_0001274792_20171231" decimals="-3" unitRef="U_iso4217USD">94217000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents id="F_000138" contextRef="C_0001274792_20161231" decimals="-3" unitRef="U_iso4217USD">22300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents id="F_000139" contextRef="C_0001274792_20180331" decimals="-3" unitRef="U_iso4217USD">35044000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents id="F_000140" contextRef="C_0001274792_20170331" decimals="-3" unitRef="U_iso4217USD">17931000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CapitalExpendituresIncurredButNotYetPaid id="F_000141" contextRef="C_0001274792_20180101_20180331" decimals="-3" unitRef="U_iso4217USD">114000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
  <us-gaap:CapitalExpendituresIncurredButNotYetPaid id="F_000142" contextRef="C_0001274792_20170101_20170331" decimals="-3" unitRef="U_iso4217USD">34000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
  <us-gaap:NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1 id="F_000143" contextRef="C_0001274792_20170101_20170331" decimals="-3" unitRef="U_iso4217USD">76000</us-gaap:NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1>
  <us-gaap:InterestPaid id="F_000144" contextRef="C_0001274792_20170101_20170331" decimals="-3" unitRef="U_iso4217USD">1368000</us-gaap:InterestPaid>
  <us-gaap:NatureOfOperations id="F_000145" contextRef="C_0001274792_20180101_20180331">&lt;div&gt;

&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1. Nature of the Business&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Merrimack Pharmaceuticals, Inc. (the &amp;#8220;Company&amp;#8221;) is a clinical stage biopharmaceutical company based in Cambridge, Massachusetts that is outthinking cancer by targeting biomarker-defined cancers. The Company&amp;#8217;s vision is to ensure that cancer patients and their families live fulfilling lives. The Company&amp;#8217;s mission is to transform cancer care through the smart design and development of targeted solutions based on a deep understanding of cancer pathways and biological markers. All of the Company&amp;#8217;s development programs, including four clinical trials and six candidates in preclinical development, fit into the Company&amp;#8217;s strategy of (1) understanding the biological problems it is trying to solve, (2) designing specific solutions against the problems it is trying to solve and (3) developing those solutions for biomarker-selected patients. This three-pronged strategy seeks to ensure optimal patient outcomes.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company owns worldwide development and commercial rights to all of its clinical and preclinical programs. The Company&amp;#8217;s most advanced assets and a description of the status of each asset are as follows:&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;MM-121 (seribantumab)&lt;font style="font-weight:normal;"&gt;: MM-121 is a fully human monoclonal antibody that binds to the ErbB3 (HER3) receptor and targets heregulin positive cancers. There are two active development programs for MM-121, each in a Phase 2 clinical trial. The Company is conducting the global, open-label, biomarker-selected, Phase 2 randomized SHERLOC clinical trial evaluating MM-121 in combination with docetaxel in patients with heregulin positive non-small cell lung cancer. The Company is also conducting the global, double-blinded, placebo-controlled, biomarker-selected, Phase 2 randomized SHERBOC clinical trial evaluating MM-121 in combination with fulvestrant in patients with heregulin positive, hormone receptor positive, ErbB2 (HER2) negative, metastatic breast cancer;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.63%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;MM-141 (istiratumab)&lt;font style="font-weight:normal;"&gt;: MM-141 is a fully human tetravalent bispecific antibody designed to block tumor survival signals by targeting receptor complexes containing the insulin-like growth factor 1 (&amp;#8220;IGF-1&amp;#8221;), receptor and ErbB3 (HER3) cell surface receptor. The Company is conducting and has completed enrollment of the global, double-blinded, placebo-controlled, Phase 2 randomized CARRIE clinical trial evaluating MM-141 in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer with high serum levels of free IGF-1; and&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.63%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;MM-310&lt;font style="font-weight:normal;"&gt;: MM-310 is an antibody-directed nanotherapeutic that targets the ephrin receptor A2 (&amp;#8220;EphA2&amp;#8221;) receptor and contains a novel prodrug of the highly potent chemotherapy docetaxel. The EphA2 receptor is highly expressed in most solid tumor types, such as prostate, ovarian, bladder, gastric, pancreatic and lung cancers. The Company is conducting a Phase 1 clinical trial to evaluate safety and preliminary activity of MM-310 in patients with solid tumors and to identify the maximum tolerated dose.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is subject to risks and uncertainties common to companies in the biopharmaceutical industry, including, among other things, its ability to secure additional capital to fund operations, success of clinical trials, development by competitors of new technological innovations, dependence on collaborative arrangements, protection of proprietary technology, compliance with government regulations and dependence on key personnel. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of capital, adequate personnel, infrastructure and extensive compliance reporting capabilities.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s product candidates are in development, and none are approved for any indication by the U.S. Food and Drug Administration (&amp;#8220;FDA&amp;#8221;) or any other regulatory agency. There can be no assurance that the Company&amp;#8217;s research and development will be successfully completed, that adequate protection for the Company&amp;#8217;s intellectual property will be obtained or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&amp;#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies, among others. In addition, the Company is dependent upon the services of its employees and consultants.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In accordance with Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;) 205-40, &lt;font style="font-style:italic;"&gt;Going Concern&lt;/font&gt;, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company&amp;#8217;s ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued. As of March 31, 2018, the Company had an accumulated deficit of $500.6 million.&amp;#160;During the three months ended March 31, 2018, the Company incurred a net loss from continuing operations of $17.8 million and used $17.3 million of cash in continuing operations for operating activities.&amp;#160;The Company expects to continue to generate operating losses in the foreseeable future. The Company expects that its cash and cash equivalents and marketable securities of $76.3 million at March 31, 2018 will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next 12 months from the date that the condensed consolidated financial statements are issued.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company will ultimately need to seek additional funding through equity offerings, debt financings, collaborations, licensing arrangements and other marketing and distribution arrangements, partnerships, joint ventures, combinations or divestitures of one or more of its businesses. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborative arrangements or divest its assets. The terms of any financing may adversely affect the holdings or the rights of the Company&amp;#8217;s stockholders. Arrangements with collaborators or others may require the Company to relinquish rights to certain of its technologies or product candidates. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate its research and development programs or commercialization efforts, which could adversely affect its business prospects.&lt;/p&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
  <us-gaap:SignificantAccountingPoliciesTextBlock id="F_000146" contextRef="C_0001274792_20180101_20180331">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2. Summary of Significant Accounting Policies &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basis of Presentation &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying condensed consolidated financial statements reflect the operations of Merrimack Pharmaceuticals, Inc. and its wholly owned subsidiary. All intercompany accounts and transactions have been eliminated.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The condensed consolidated financial statements are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America (&amp;#8220;GAAP&amp;#8221;).&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accounting policies followed in the preparation of the interim condensed consolidated financial statements are consistent in all material respects with those presented in Note 1 to the financial statements included in the Company&amp;#8217;s Annual Report on Form 10-K for the year ended December&amp;#160;31, 2017.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Certain reclassifications have been made to the prior year&amp;#8217;s condensed consolidated balance sheet and condensed consolidated statement of cash flows to enhance comparability with the current year&amp;#8217;s condensed consolidated financial statements presentation. These reclassifications had no effect on previously reported net income within the condensed consolidated statement of operations and comprehensive loss.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Consolidation&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:12pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying condensed consolidated financial statements reflect Merrimack Pharmaceuticals, Inc. and its wholly owned subsidiary. For the three months ended March 31, 2017, the condensed consolidated financial statements also include the accounts of Silver Creek Pharmaceuticals, Inc. (&amp;#8220;Silver Creek&amp;#8221;). For the three months ended March 31, 2017, Silver Creek represented a variable interest entity that the Company consolidated as the primary beneficiary. In the third quarter of 2017, the Company deconsolidated Silver Creek from its financial statements since the Company was no longer the primary beneficiary of Silver Creek. The Company&amp;#8217;s ownership percentage decreased to less than 50% and the Company no longer controlled Silver Creek&amp;#8217;s board of directors or directed the activities that had the most significant impact on Silver Creek&amp;#8217;s economic performance. The Company accounts for its investment in Silver Creek under the equity method of accounting.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On April&amp;#160;3, 2017, the Company completed the sale of its right, title and interest in the non-cash assets, equipment, inventory, contracts and intellectual property primarily related to developing, manufacturing and commercializing ONIVYDE and MM-436 (the &amp;#8220;Commercial Business&amp;#8221;). As of March 31, 2017, the Commercial Business met all the conditions to be classified as a discontinued operation since the disposal of the Commercial Business represented a strategic shift that had a major effect on the Company&amp;#8217;s operations and financial results. Therefore, the operating results of the Commercial Business are reported as a loss from discontinued operations, net of tax in the condensed consolidated statements of operations and comprehensive loss for the three months ended March 31, 2017. During the three months ended March 31, 2018, there were no discontinued operations. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unaudited Interim Financial Information&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The condensed consolidated balance sheet as of December&amp;#160;31, 2017 was derived from audited financial statements, but does not include all disclosures required by GAAP. The condensed consolidated balance sheet as of March 31, 2018, the condensed consolidated statements of operations and comprehensive loss for the three months ended March 31, 2018 and 2017 and the condensed consolidated statements of cash flows for the three months ended March 31, 2018 and 2017 are unaudited. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the Company&amp;#8217;s financial position as of March 31, 2018, the results of its operations for the three months ended March 31, 2018 and 2017, and its statements of cash flows for the three months ended March 31, 2018 and 2017. The financial data and other information disclosed in the notes related to the three months ended March 31, 2018 and 2017 are unaudited. The results for the three months ended March 31, 2018 and 2017 are not necessarily indicative of results to be expected for the year ending December&amp;#160;31, 2018, any other interim periods, or any future year or period.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The unaudited interim financial statements of the Company included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the &amp;#8220;SEC&amp;#8221;). Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this report, as is permitted by such rules and regulations. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and the notes thereto contained in the Company&amp;#8217;s Annual Report on Form 10-K for the year ended December&amp;#160;31, 2017 filed with the SEC on March 12, 2018.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Condensed Consolidated Statements of Cash Flows&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the statement of financial position that sum to the total of the same such amounts shown in the statement of cash flows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.13%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt; (in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&amp;#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&amp;#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34,268&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,155&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash in prepaid expenses and other current assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;102&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash (short term)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;102&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash (long term)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;674&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;674&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash, cash equivalents and restricted cash shown in the condensed consolidated&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; statement of cash flows&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35,044&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,931&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash included in prepaid expenses and other current assets and restricted cash long term on the statement of financial position represent amounts pledged as collateral for operating lease obligations as contractually required. This restriction will lapse when the arrangements expire.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Use of Estimates&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates, assumptions and judgments reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuation of stock-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from the Company&amp;#8217;s estimates.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable Securities&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities consist of investments with original maturities greater than ninety days. The Company has classified its investments with maturities beyond one year as short term based on their highly liquid nature and because such marketable securities represent the investment of cash that is available for current operations. The Company considers its investment portfolio of marketable debt securities as available-for-sale. Accordingly, these marketable debt securities are recorded at fair value and unrealized gains and losses are reported as a component of accumulated other comprehensive loss in stockholders&amp;#8217; equity. Realized gains and losses and declines in value judged to be other than temporary are included as a component of other income (expense), net based on the specific identification method. When determining whether a decline in value is other than temporary, the Company considers various factors, including whether the Company has the intent to sell the security, and whether it is more likely than not that the Company will be required to sell the security prior to recovery of its amortized cost basis.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:FairValueDisclosuresTextBlock id="F_000147" contextRef="C_0001274792_20180101_20180331">&lt;div&gt;

&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;3. Fair Value of Financial Instruments&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. Fair value is determined based on observable and unobservable inputs. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect certain market assumptions. As a basis for considering such assumptions, GAAP establishes a three-tier value hierarchy, which prioritizes the inputs used to develop the assumptions and for measuring fair value as follows: Level 1 observable inputs such as quoted prices in active markets for identical assets; Level 2 inputs other than the quoted prices in active markets that are observable either directly or indirectly; and Level 3 unobservable inputs in which there is little or no market data, which requires the Company to develop its own assumptions. This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following tables show assets measured at fair value on a recurring basis as of March&amp;#160;31, 2018 and December&amp;#160;31, 2017:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&amp;#160;31, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,785&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,009&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,781&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Totals&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,785&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,790&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,217&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,841&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Government securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,940&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Totals&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41,998&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31, 2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;89,310&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Totals&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;89,310&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the three months ended March 31, 2018 and the year ended December&amp;#160;31, 2017, there were no transfers between Level 1 and Level 2. The fair value of Level 2 instruments classified as cash equivalents and marketable debt securities were determined through third-party pricing services.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The carrying amounts reflected in the condensed consolidated balance sheets for accounts payable, accrued expenses and other liabilities approximate fair value due to their short-term maturities.&lt;/p&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock id="F_000148" contextRef="C_0001274792_20180101_20180331">&lt;div&gt;

&lt;p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;4. Marketable Securities and Cash Equivalents&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the Company&amp;#8217;s marketable securities and cash equivalents as of March 31, 2018. The Company did not hold any marketable securities as of December 31, 2017.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&amp;#160;31, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,785&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,785&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,010&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,009&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,781&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,781&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,576&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,575&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,227&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(10&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,217&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,841&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,841&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Government securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,941&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,940&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42,009&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41,998&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash equivalents and marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;64,585&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(12&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;64,573&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock id="F_000149" contextRef="C_0001274792_20180101_20180331">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;5. Accounts Payable, Accrued Expenses and Other&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accounts payable, accrued expenses and other as of March&amp;#160;31, 2018 and December&amp;#160;31, 2017 consisted of the following:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.52%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt; (in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.16%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&amp;#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.16%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.52%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accounts payable&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,560&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,887&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.52%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued goods and services&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,027&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,682&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.52%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued clinical trial costs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,925&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,901&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.52%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued drug purchase costs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;918&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;222&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.52%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued payroll and related benefits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,240&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,884&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.52%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued restructuring expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;251&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;628&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.52%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax incentives&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,402&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,402&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.52%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total accounts payable, accrued expenses and other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,323&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,606&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock id="F_000150" contextRef="C_0001274792_20180101_20180331">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;6. Stock-Based Compensation&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s 2011 Stock Incentive Plan (the &amp;#8220;2011 Plan&amp;#8221;) is administered by the Company&amp;#8217;s Board of Directors and permits the Company to grant incentive and non-qualified stock options, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At March&amp;#160;31, 2018, there were 0.5 million shares remaining available for grant under the 2011 Plan.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the three months ended March 31, 2018 and 2017, the Company issued options to purchase 0.6 million and 0.0 million shares of common stock, respectively. These options generally vest over a three-year period for employees. Options granted to directors generally vest immediately.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of stock options granted to employees during the three months ended March&amp;#160;31, 2018 and 2017 was estimated at the date of grant using the following assumptions:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.52%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="4" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.52%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.52%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.16%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.3 &amp;#8211; 2.7%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.52%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.16%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.16%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.52%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.16%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.8 years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.16%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.8 years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.52%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.16%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;62 &amp;#8211; 63%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.16%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;67 &amp;#8211; 68%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company uses the simplified method to calculate the expected term, as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term. The computation of expected volatility is based on the historical volatility of comparable companies from a representative peer group selected based on industry and market capitalization. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected life of the stock options. Management estimates expected forfeitures based on historical experience and recognizes compensation costs only for those equity awards expected to vest.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognized stock-based compensation expense during the three months ended March&amp;#160;31, 2018 and 2017 as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.52%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.52%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.52%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Employee awards:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.52%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expense&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;334&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;468&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.52%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative expense&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;430&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;328&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.52%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;764&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;796&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes stock option activity during the three months ended March&amp;#160;31, 2018:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.94%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands, except per share amounts)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&amp;#160;Price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&amp;#160;Term&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December&amp;#160;31, 2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,616&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22.07&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.65&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;60,031&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;566&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.74&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(145&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.12%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.04&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.48%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.74%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at March&amp;#160;31, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,037&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.12%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.22&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.74%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested and expected to vest at March&amp;#160;31, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,036&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.22&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable at March&amp;#160;31, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,032&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25.17&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.97&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The weighted-average grant date fair value per share of stock options granted during the three months ended March&amp;#160;31, 2018 and 2017 was $6.26 and $24.30, respectively. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The aggregate intrinsic value is calculated as the difference between the exercise price of the stock options and the fair value of the underlying common stock. The aggregate intrinsic value of stock options exercised during the three months ended March&amp;#160;31, 2017 was $1.4 million. There were no options exercised during the three months ended March 31, 2018.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of March&amp;#160;31, 2018, there was $7.2 million of total unrecognized stock-based compensation expense related to unvested employee stock awards. The Company expects to recognize this expense over a weighted-average period of approximately 2.58 years.&lt;/p&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:EarningsPerShareTextBlock id="F_000151" contextRef="C_0001274792_20180101_20180331">&lt;div&gt;

&lt;p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;7. Net Loss Per Common Share&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per share is calculated by dividing the net loss attributable to Merrimack Pharmaceuticals, Inc. by the weighted-average number of common shares outstanding during the period. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Diluted net loss per share is computed by dividing the net loss attributable to Merrimack Pharmaceuticals, Inc. by the weighted-average number of dilutive common shares outstanding during the period. Dilutive shares outstanding is calculated by adding to the weighted shares outstanding any potential (unissued) shares of common stock from outstanding stock options based on the treasury stock method. In a period when a net loss is reported, all common stock equivalents are excluded from the calculation because they would have an anti-dilutive effect, meaning the loss per share would be reduced. Therefore, in periods where a loss is reported, there is no difference in basic and dilutive loss per share.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company follows the two-class method when computing net loss per share when it has issued shares that meet the definition of participating securities. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participating rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based on their respective rights to receive dividends, as if all income for the period has been distributed or losses to be allocated if they are contractually required to fund losses. There were no amounts allocated to participating securities for the three months ended March 31, 2018 and 2017, as the Company was in a loss position and had no shares that met the definition of participating securities outstanding as of March 31, 2018 and 2017. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The stock options and conversion premium on the 4.50% convertible notes due 2020 (the &amp;#8220;Convertible Notes&amp;#8221;) are excluded from the calculation of diluted loss per share because the net loss for the three months ended March&amp;#160;31, 2017 causes such securities to be anti-dilutive. Outstanding securities excluded from the calculation of diluted loss per share for the three months ended March&amp;#160;31, 2018 and 2017 are shown in the chart below:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.32%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding options to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,037&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,652&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Conversion of the Convertible Notes&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,216&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock id="F_000152" contextRef="C_0001274792_20180101_20180331">&lt;div&gt;

&lt;p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;8. Discontinued Operations&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;On April&amp;#160;3, 2017, the Company completed the sale of the Commercial Business. As of March 31, 2017, the Commercial Business met all the conditions to be classified as a discontinued operation since the disposal of the Commercial Business represented a strategic shift that had a major effect on the Company&amp;#8217;s operations and financial results.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The condensed consolidated financial statements for the three months ended March 31, 2017 reflect the operations of the Commercial Business as a discontinued operation.&amp;#160;Discontinued operations for the three months ended March 31, 2017 includes the following:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt; (in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.2%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.2%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenues:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Product revenues, net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,135&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;License and collaboration revenues&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,797&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other revenues&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,973&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total revenues&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,905&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Costs and expenses:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost of revenues&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,890&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,730&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Selling, general and administrative expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,733&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restructuring expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,265&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total costs and expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,618&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other income and expenses:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest expense&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,234&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.14%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Loss from discontinued operations&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(947&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:5pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On January 8, 2017, the Company announced a reduction in headcount by approximately 30% in connection with the sale of the Commercial Business and the completion of its strategic pipeline review. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under this corporate restructuring, for the three months ended March 31, 2017, the Company recognized total restructuring expenses of $5.3 million related to contractual termination benefits for employees with pre-existing severance arrangements. These one-time employee termination benefits are comprised of severance, benefits and related costs, all of which resulted in cash expenditures. The expense of $5.3 million was included in discontinued operations, as the costs are directly associated with the sale of the Commercial Business. For the three months ended March 31, 2018, there were no discontinued operations.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
  <us-gaap:MinorityInterestDisclosureTextBlock id="F_000153" contextRef="C_0001274792_20180101_20180331">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;9. Investment in Silver Creek&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On August 20, 2010, the Company acquired a controlling financial interest in Silver Creek. At such time, the Company had the ability to direct the activities of Silver Creek that most significantly impacted Silver Creek&amp;#8217;s economic performance through its ownership percentage and through the board of director seats controlled by the Company. As such, Silver Creek was consolidated by the Company.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Since the Company acquired its financial interest, Silver Creek has raised funding through the issuance of preferred stock. The Company has not participated in any Silver Creek financings nor has it provided any funding. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the third quarter of 2017, Silver Creek completed its Series C preferred stock financing, reducing the Company&amp;#8217;s ownership percentage in Silver Creek below 50% and resulting in the Company no longer controlling the Silver Creek board of directors. Accordingly, the Company determined that it was no longer the primary beneficiary of Silver Creek and deconsolidated Silver Creek from its financial statements on July 13, 2017. Starting on July 14, 2017, the Company accounted for its investment in Silver Creek under the equity method of accounting since the Company has the ability to exercise significant influence over Silver Creek. Under the equity method of accounting, the Company has recorded its proportionate share of the investee&amp;#8217;s earnings (losses) in its results of operations with a corresponding increase (decrease) in the carrying value of the investment. Silver Creek continues to be a related party to the Company after deconsolidation.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:MinorityInterestDisclosureTextBlock>
  <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock id="F_000154" contextRef="C_0001274792_20180101_20180331">&lt;div&gt;

&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;10. Recent Accounting Pronouncements&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued the following new Accounting Standards Updates (&amp;#8220;ASU&amp;#8221;), which the Company adopted on January 1, 2018:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ASU 2014-09, &amp;#8220;Revenue from Contracts with Customers (Topic 606)&amp;#8221; and related amendments;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ASU 2016-01, &amp;#8220;Financial Instruments &amp;#8211; Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Liabilities&amp;#8221;;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ASU 2016-15, &amp;#8220;Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments&amp;#8221;;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ASU 2016-18, &amp;#8220;Statement of Cash Flows - Restricted Cash (a consensus of the FASB Emerging Issues Task Force)&amp;#8221;; and&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ASU 2017-09, &amp;#8220;Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting.&amp;#8221;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The adoption of these standards did not have a material impact on the Company&amp;#8217;s financial position, results of operations or statement of cash flows; however, the adoption of ASU 2016-18 resulted in the reclassification of certain prior year amounts in the Company&amp;#8217;s condensed consolidated statements of cash flows to conform to the current year presentation. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2016, the FASB issued ASU 2016-02, &amp;#8220;Leases (Topic 842),&amp;#8221; which supersedes all existing lease accounting guidance within ASC 840, &lt;font style="font-style:italic;"&gt;Leases&lt;/font&gt;. The new standard requires that lease assets and lease liabilities be recognized by lessees for those leases previously classified as operating leases under ASC 840, with limited exceptions. This update also creates a new definition of a lease and provides guidance as to whether a contract is or contains a lease. This guidance will be effective for annual reporting periods beginning after December 15, 2018, including interim periods within those annual reporting periods, and early adoption is permitted. The Company is currently evaluating the potential impact that the adoption of this guidance may have on the condensed consolidated financial statements.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2016, the FASB issued ASU 2016-13, &amp;#8220;Financial Instruments &amp;#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,&amp;#8221; which represents a new credit loss standard that will change the impairment model for most financial assets and certain other financial instruments. Specifically, this guidance will require entities to utilize a new &amp;#8220;expected loss&amp;#8221; model as it relates to trade and other receivables. In addition, entities will be required to recognize an allowance for estimated credit losses on available-for-sale debt securities, regardless of the length of time that a security has been in an unrealized loss position. This guidance will be effective for annual reporting periods beginning after December 15, 2019, including interim periods within those annual reporting periods, and early adoption is permitted. The Company is currently evaluating the potential impact that the adoption of this guidance may have on the condensed consolidated financial statements.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2018, the FASB issued ASU 2018-02, &amp;#8220;Income Statement - Reporting Comprehensive Income (Topic 220)&amp;#8221;. ASU 2018-02 addresses the effect of the change in the U.S. federal corporate tax rate due to the enactment of the December 22, 2017 Tax Cuts and Jobs Act (the &amp;#8220;Tax Act&amp;#8221;) on items within accumulated other comprehensive loss. The guidance will be effective for the Company in the first quarter of fiscal 2020 with early adoption permitted. The Company is currently assessing the impact that adopting this new accounting standard will have on the condensed consolidated financial statements.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed above, the Company does not believe that the adoption of recently issued standards has or may have a material impact on the Company&amp;#8217;s condensed consolidated financial statements or disclosures.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock id="F_000155" contextRef="C_0001274792_20180101_20180331">&lt;div&gt;

&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basis of Presentation &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying condensed consolidated financial statements reflect the operations of Merrimack Pharmaceuticals, Inc. and its wholly owned subsidiary. All intercompany accounts and transactions have been eliminated.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The condensed consolidated financial statements are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America (&amp;#8220;GAAP&amp;#8221;).&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accounting policies followed in the preparation of the interim condensed consolidated financial statements are consistent in all material respects with those presented in Note 1 to the financial statements included in the Company&amp;#8217;s Annual Report on Form 10-K for the year ended December&amp;#160;31, 2017.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Certain reclassifications have been made to the prior year&amp;#8217;s condensed consolidated balance sheet and condensed consolidated statement of cash flows to enhance comparability with the current year&amp;#8217;s condensed consolidated financial statements presentation. These reclassifications had no effect on previously reported net income within the condensed consolidated statement of operations and comprehensive loss.&lt;/p&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:ConsolidationPolicyTextBlock id="F_000156" contextRef="C_0001274792_20180101_20180331">&lt;div&gt;

&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Consolidation&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:12pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The accompanying condensed consolidated financial statements reflect Merrimack Pharmaceuticals, Inc. and its wholly owned subsidiary. For the three months ended March 31, 2017, the condensed consolidated financial statements also include the accounts of Silver Creek Pharmaceuticals, Inc. (&amp;#8220;Silver Creek&amp;#8221;). For the three months ended March 31, 2017, Silver Creek represented a variable interest entity that the Company consolidated as the primary beneficiary. In the third quarter of 2017, the Company deconsolidated Silver Creek from its financial statements since the Company was no longer the primary beneficiary of Silver Creek. The Company&amp;#8217;s ownership percentage decreased to less than 50% and the Company no longer controlled Silver Creek&amp;#8217;s board of directors or directed the activities that had the most significant impact on Silver Creek&amp;#8217;s economic performance. The Company accounts for its investment in Silver Creek under the equity method of accounting.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On April&amp;#160;3, 2017, the Company completed the sale of its right, title and interest in the non-cash assets, equipment, inventory, contracts and intellectual property primarily related to developing, manufacturing and commercializing ONIVYDE and MM-436 (the &amp;#8220;Commercial Business&amp;#8221;). As of March 31, 2017, the Commercial Business met all the conditions to be classified as a discontinued operation since the disposal of the Commercial Business represented a strategic shift that had a major effect on the Company&amp;#8217;s operations and financial results. Therefore, the operating results of the Commercial Business are reported as a loss from discontinued operations, net of tax in the condensed consolidated statements of operations and comprehensive loss for the three months ended March 31, 2017. During the three months ended March 31, 2018, there were no discontinued operations. &lt;/p&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
  <mack:UnauditedInterimFinancialInformationPolicyTextBlock id="F_000157" contextRef="C_0001274792_20180101_20180331">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unaudited Interim Financial Information&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The condensed consolidated balance sheet as of December&amp;#160;31, 2017 was derived from audited financial statements, but does not include all disclosures required by GAAP. The condensed consolidated balance sheet as of March 31, 2018, the condensed consolidated statements of operations and comprehensive loss for the three months ended March 31, 2018 and 2017 and the condensed consolidated statements of cash flows for the three months ended March 31, 2018 and 2017 are unaudited. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the Company&amp;#8217;s financial position as of March 31, 2018, the results of its operations for the three months ended March 31, 2018 and 2017, and its statements of cash flows for the three months ended March 31, 2018 and 2017. The financial data and other information disclosed in the notes related to the three months ended March 31, 2018 and 2017 are unaudited. The results for the three months ended March 31, 2018 and 2017 are not necessarily indicative of results to be expected for the year ending December&amp;#160;31, 2018, any other interim periods, or any future year or period.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The unaudited interim financial statements of the Company included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the &amp;#8220;SEC&amp;#8221;). Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this report, as is permitted by such rules and regulations. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and the notes thereto contained in the Company&amp;#8217;s Annual Report on Form 10-K for the year ended December&amp;#160;31, 2017 filed with the SEC on March 12, 2018.&lt;/p&gt;&lt;/div&gt;</mack:UnauditedInterimFinancialInformationPolicyTextBlock>
  <mack:CondensedConsolidatedStatementsOfCashFlowsPolicyTextBlock id="F_000158" contextRef="C_0001274792_20180101_20180331">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Condensed Consolidated Statements of Cash Flows&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the statement of financial position that sum to the total of the same such amounts shown in the statement of cash flows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.13%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt; (in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&amp;#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&amp;#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34,268&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,155&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash in prepaid expenses and other current assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;102&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash (short term)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;102&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash (long term)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;674&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;674&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash, cash equivalents and restricted cash shown in the condensed consolidated&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; statement of cash flows&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35,044&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,931&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash included in prepaid expenses and other current assets and restricted cash long term on the statement of financial position represent amounts pledged as collateral for operating lease obligations as contractually required. This restriction will lapse when the arrangements expire.&lt;/p&gt;&lt;/div&gt;</mack:CondensedConsolidatedStatementsOfCashFlowsPolicyTextBlock>
  <us-gaap:UseOfEstimates id="F_000159" contextRef="C_0001274792_20180101_20180331">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Use of Estimates&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates, assumptions and judgments reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuation of stock-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from the Company&amp;#8217;s estimates.&lt;/p&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:MarketableSecuritiesAvailableForSaleSecuritiesPolicy id="F_000160" contextRef="C_0001274792_20180101_20180331">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable Securities&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities consist of investments with original maturities greater than ninety days. The Company has classified its investments with maturities beyond one year as short term based on their highly liquid nature and because such marketable securities represent the investment of cash that is available for current operations. The Company considers its investment portfolio of marketable debt securities as available-for-sale. Accordingly, these marketable debt securities are recorded at fair value and unrealized gains and losses are reported as a component of accumulated other comprehensive loss in stockholders&amp;#8217; equity. Realized gains and losses and declines in value judged to be other than temporary are included as a component of other income (expense), net based on the specific identification method. When determining whether a decline in value is other than temporary, the Company considers various factors, including whether the Company has the intent to sell the security, and whether it is more likely than not that the Company will be required to sell the security prior to recovery of its amortized cost basis.&lt;/p&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesAvailableForSaleSecuritiesPolicy>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock id="F_000161" contextRef="C_0001274792_20180101_20180331">&lt;div&gt;

&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued the following new Accounting Standards Updates (&amp;#8220;ASU&amp;#8221;), which the Company adopted on January 1, 2018:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ASU 2014-09, &amp;#8220;Revenue from Contracts with Customers (Topic 606)&amp;#8221; and related amendments;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ASU 2016-01, &amp;#8220;Financial Instruments &amp;#8211; Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Liabilities&amp;#8221;;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ASU 2016-15, &amp;#8220;Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments&amp;#8221;;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ASU 2016-18, &amp;#8220;Statement of Cash Flows - Restricted Cash (a consensus of the FASB Emerging Issues Task Force)&amp;#8221;; and&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ASU 2017-09, &amp;#8220;Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting.&amp;#8221;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The adoption of these standards did not have a material impact on the Company&amp;#8217;s financial position, results of operations or statement of cash flows; however, the adoption of ASU 2016-18 resulted in the reclassification of certain prior year amounts in the Company&amp;#8217;s condensed consolidated statements of cash flows to conform to the current year presentation. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2016, the FASB issued ASU 2016-02, &amp;#8220;Leases (Topic 842),&amp;#8221; which supersedes all existing lease accounting guidance within ASC 840, &lt;font style="font-style:italic;"&gt;Leases&lt;/font&gt;. The new standard requires that lease assets and lease liabilities be recognized by lessees for those leases previously classified as operating leases under ASC 840, with limited exceptions. This update also creates a new definition of a lease and provides guidance as to whether a contract is or contains a lease. This guidance will be effective for annual reporting periods beginning after December 15, 2018, including interim periods within those annual reporting periods, and early adoption is permitted. The Company is currently evaluating the potential impact that the adoption of this guidance may have on the condensed consolidated financial statements.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2016, the FASB issued ASU 2016-13, &amp;#8220;Financial Instruments &amp;#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,&amp;#8221; which represents a new credit loss standard that will change the impairment model for most financial assets and certain other financial instruments. Specifically, this guidance will require entities to utilize a new &amp;#8220;expected loss&amp;#8221; model as it relates to trade and other receivables. In addition, entities will be required to recognize an allowance for estimated credit losses on available-for-sale debt securities, regardless of the length of time that a security has been in an unrealized loss position. This guidance will be effective for annual reporting periods beginning after December 15, 2019, including interim periods within those annual reporting periods, and early adoption is permitted. The Company is currently evaluating the potential impact that the adoption of this guidance may have on the condensed consolidated financial statements.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2018, the FASB issued ASU 2018-02, &amp;#8220;Income Statement - Reporting Comprehensive Income (Topic 220)&amp;#8221;. ASU 2018-02 addresses the effect of the change in the U.S. federal corporate tax rate due to the enactment of the December 22, 2017 Tax Cuts and Jobs Act (the &amp;#8220;Tax Act&amp;#8221;) on items within accumulated other comprehensive loss. The guidance will be effective for the Company in the first quarter of fiscal 2020 with early adoption permitted. The Company is currently assessing the impact that adopting this new accounting standard will have on the condensed consolidated financial statements.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed above, the Company does not believe that the adoption of recently issued standards has or may have a material impact on the Company&amp;#8217;s condensed consolidated financial statements or disclosures.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <mack:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock id="F_000162" contextRef="C_0001274792_20180101_20180331">&lt;div&gt;

&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the statement of financial position that sum to the total of the same such amounts shown in the statement of cash flows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.13%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt; (in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&amp;#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&amp;#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34,268&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,155&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash in prepaid expenses and other current assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;102&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash (short term)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;102&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash (long term)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;674&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;674&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash, cash equivalents and restricted cash shown in the condensed consolidated&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; statement of cash flows&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35,044&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,931&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</mack:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock>
  <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock id="F_000163" contextRef="C_0001274792_20180101_20180331">&lt;div&gt;

&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The following tables show assets measured at fair value on a recurring basis as of March&amp;#160;31, 2018 and December&amp;#160;31, 2017:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&amp;#160;31, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,785&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,009&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,781&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Totals&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,785&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,790&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,217&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,841&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Government securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,940&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Totals&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41,998&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31, 2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;89,310&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Totals&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;89,310&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
  <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock id="F_000164" contextRef="C_0001274792_20180101_20180331">&lt;div&gt;

&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The following table summarizes the Company&amp;#8217;s marketable securities and cash equivalents as of March 31, 2018. The Company did not hold any marketable securities as of December 31, 2017.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&amp;#160;31, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,785&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,785&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,010&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,009&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,781&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,781&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,576&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,575&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,227&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(10&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,217&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,841&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,841&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Government securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,941&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,940&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42,009&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41,998&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash equivalents and marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;64,585&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(12&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;64,573&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
  <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock id="F_000165" contextRef="C_0001274792_20180101_20180331">&lt;div&gt;

&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Accounts payable, accrued expenses and other as of March&amp;#160;31, 2018 and December&amp;#160;31, 2017 consisted of the following:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.52%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt; (in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.16%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&amp;#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.16%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.52%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accounts payable&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,560&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,887&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.52%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued goods and services&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,027&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,682&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.52%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued clinical trial costs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,925&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,901&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.52%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued drug purchase costs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;918&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;222&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.52%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued payroll and related benefits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,240&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,884&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.52%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued restructuring expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;251&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;628&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.52%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax incentives&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,402&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,402&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.52%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total accounts payable, accrued expenses and other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,323&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,606&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock id="F_000166" contextRef="C_0001274792_20180101_20180331">&lt;div&gt;

&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The fair value of stock options granted to employees during the three months ended March&amp;#160;31, 2018 and 2017 was estimated at the date of grant using the following assumptions:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.52%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="4" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.52%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.52%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.16%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.3 &amp;#8211; 2.7%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.52%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.16%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.16%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.52%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.16%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.8 years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.16%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.8 years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.52%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.16%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;62 &amp;#8211; 63%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.16%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;67 &amp;#8211; 68%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <mack:ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock id="F_000167" contextRef="C_0001274792_20180101_20180331">&lt;div&gt;

&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The Company recognized stock-based compensation expense during the three months ended March&amp;#160;31, 2018 and 2017 as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.52%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.52%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.52%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Employee awards:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.52%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expense&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;334&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;468&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.52%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative expense&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;430&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;328&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.52%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;764&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;796&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</mack:ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock id="F_000168" contextRef="C_0001274792_20180101_20180331">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The following table summarizes stock option activity during the three months ended March&amp;#160;31, 2018:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.94%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands, except per share amounts)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&amp;#160;Price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&amp;#160;Term&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December&amp;#160;31, 2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,616&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22.07&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.65&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;60,031&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;566&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.74&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(145&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.12%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.04&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.48%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.74%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at March&amp;#160;31, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,037&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.12%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.22&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.74%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested and expected to vest at March&amp;#160;31, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,036&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.22&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable at March&amp;#160;31, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,032&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25.17&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.97&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock id="F_000169" contextRef="C_0001274792_20180101_20180331">&lt;div&gt;

&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Outstanding securities excluded from the calculation of diluted loss per share for the three months ended March&amp;#160;31, 2018 and 2017 are shown in the chart below:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.32%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding options to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,037&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,652&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Conversion of the Convertible Notes&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,216&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock id="F_000170" contextRef="C_0001274792_20180101_20180331">&lt;div&gt;

&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Discontinued operations for the three months ended March 31, 2017 includes the following:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt; (in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.2%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.2%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenues:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Product revenues, net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,135&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;License and collaboration revenues&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,797&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other revenues&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,973&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total revenues&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,905&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Costs and expenses:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost of revenues&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,890&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,730&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Selling, general and administrative expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,733&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restructuring expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,265&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total costs and expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,618&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other income and expenses:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest expense&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,234&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.14%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Loss from discontinued operations&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(947&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
  <mack:NumberOfDevelopmentProgramsActive id="F_000171" contextRef="C_0001274792_20180331" decimals="INF" unitRef="U_mackProgram">2</mack:NumberOfDevelopmentProgramsActive>
  <us-gaap:CashCashEquivalentsAndShortTermInvestments id="F_000172" contextRef="C_0001274792_20180331" decimals="-5" unitRef="U_iso4217USD">76300000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
  <us-gaap:MinorityInterestOwnershipPercentageByParent id="F_000173" contextRef="C_0001274792_deiLegalEntityAxis_mackSilverCreekPharmaceuticalsIncMember_us-gaapRangeAxis_us-gaapMaximumMember_20170930" decimals="2" unitRef="U_pure">0.50</us-gaap:MinorityInterestOwnershipPercentageByParent>
  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax id="F_000174" contextRef="C_0001274792_20180101_20180331" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000175" contextRef="C_0001274792_20170331" decimals="-3" unitRef="U_iso4217USD">17155000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:RestrictedCashCurrent id="F_000176" contextRef="C_0001274792_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_20180331" decimals="-3" unitRef="U_iso4217USD">102000</us-gaap:RestrictedCashCurrent>
  <us-gaap:RestrictedCashCurrent id="F_000177" contextRef="C_0001274792_20170331" decimals="-3" unitRef="U_iso4217USD">102000</us-gaap:RestrictedCashCurrent>
  <us-gaap:RestrictedCashNoncurrent id="F_000178" contextRef="C_0001274792_20180331" decimals="-3" unitRef="U_iso4217USD">674000</us-gaap:RestrictedCashNoncurrent>
  <us-gaap:RestrictedCashNoncurrent id="F_000179" contextRef="C_0001274792_20170331" decimals="-3" unitRef="U_iso4217USD">674000</us-gaap:RestrictedCashNoncurrent>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000180" contextRef="C_0001274792_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20180331" decimals="-3" unitRef="U_iso4217USD">6785000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000181" contextRef="C_0001274792_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20180331" decimals="-3" unitRef="U_iso4217USD">2009000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000182" contextRef="C_0001274792_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20180331" decimals="-3" unitRef="U_iso4217USD">13781000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000183" contextRef="C_0001274792_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20180331" decimals="-3" unitRef="U_iso4217USD">6785000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000184" contextRef="C_0001274792_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20180331" decimals="-3" unitRef="U_iso4217USD">15790000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:AvailableForSaleSecurities id="F_000185" contextRef="C_0001274792_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20180331" decimals="-3" unitRef="U_iso4217USD">6217000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities id="F_000186" contextRef="C_0001274792_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperNotIncludedWithCashAndCashEquivalentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20180331" decimals="-3" unitRef="U_iso4217USD">21841000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities id="F_000187" contextRef="C_0001274792_us-gaapFairValueByAssetClassAxis_us-gaapUSTreasuryAndGovernmentMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20180331" decimals="-3" unitRef="U_iso4217USD">13940000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities id="F_000188" contextRef="C_0001274792_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20180331" decimals="-3" unitRef="U_iso4217USD">41998000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000189" contextRef="C_0001274792_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20171231" decimals="-3" unitRef="U_iso4217USD">89310000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000190" contextRef="C_0001274792_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20171231" decimals="-3" unitRef="U_iso4217USD">89310000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:FairValueAssetsLevel1ToLevel2TransfersDescription id="F_000191" contextRef="C_0001274792_20180101_20180331">no</us-gaap:FairValueAssetsLevel1ToLevel2TransfersDescription>
  <us-gaap:FairValueAssetsLevel1ToLevel2TransfersDescription id="F_000192" contextRef="C_0001274792_20170101_20171231">no</us-gaap:FairValueAssetsLevel1ToLevel2TransfersDescription>
  <us-gaap:MarketableSecurities id="F_000193" contextRef="C_0001274792_20171231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:MarketableSecurities>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000194" contextRef="C_0001274792_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20180331" decimals="-3" unitRef="U_iso4217USD">6785000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000195" contextRef="C_0001274792_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20180331" decimals="-3" unitRef="U_iso4217USD">2010000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000196" contextRef="C_0001274792_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20180331" decimals="-3" unitRef="U_iso4217USD">13781000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000197" contextRef="C_0001274792_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_20180331" decimals="-3" unitRef="U_iso4217USD">22576000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000198" contextRef="C_0001274792_us-gaapInformationByCategoryOfDebtSecurityAxis_mackMarketableSecuritiesMember_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20180331" decimals="-3" unitRef="U_iso4217USD">6227000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000199" contextRef="C_0001274792_us-gaapInformationByCategoryOfDebtSecurityAxis_mackMarketableSecuritiesMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20180331" decimals="-3" unitRef="U_iso4217USD">21841000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000200" contextRef="C_0001274792_us-gaapInformationByCategoryOfDebtSecurityAxis_mackMarketableSecuritiesMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20180331" decimals="-3" unitRef="U_iso4217USD">13941000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000201" contextRef="C_0001274792_us-gaapInformationByCategoryOfDebtSecurityAxis_mackMarketableSecuritiesMember_20180331" decimals="-3" unitRef="U_iso4217USD">42009000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000202" contextRef="C_0001274792_20180331" decimals="-3" unitRef="U_iso4217USD">64585000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax id="F_000203" contextRef="C_0001274792_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20180331" decimals="-3" unitRef="U_iso4217USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax id="F_000204" contextRef="C_0001274792_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_20180331" decimals="-3" unitRef="U_iso4217USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax id="F_000205" contextRef="C_0001274792_us-gaapInformationByCategoryOfDebtSecurityAxis_mackMarketableSecuritiesMember_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20180331" decimals="-3" unitRef="U_iso4217USD">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax id="F_000206" contextRef="C_0001274792_us-gaapInformationByCategoryOfDebtSecurityAxis_mackMarketableSecuritiesMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20180331" decimals="-3" unitRef="U_iso4217USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax id="F_000207" contextRef="C_0001274792_us-gaapInformationByCategoryOfDebtSecurityAxis_mackMarketableSecuritiesMember_20180331" decimals="-3" unitRef="U_iso4217USD">11000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax id="F_000208" contextRef="C_0001274792_20180331" decimals="-3" unitRef="U_iso4217USD">12000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000209" contextRef="C_0001274792_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20180331" decimals="-3" unitRef="U_iso4217USD">6785000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000210" contextRef="C_0001274792_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20180331" decimals="-3" unitRef="U_iso4217USD">2009000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000211" contextRef="C_0001274792_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20180331" decimals="-3" unitRef="U_iso4217USD">13781000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000212" contextRef="C_0001274792_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_20180331" decimals="-3" unitRef="U_iso4217USD">22575000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000213" contextRef="C_0001274792_us-gaapInformationByCategoryOfDebtSecurityAxis_mackMarketableSecuritiesMember_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20180331" decimals="-3" unitRef="U_iso4217USD">6217000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000214" contextRef="C_0001274792_us-gaapInformationByCategoryOfDebtSecurityAxis_mackMarketableSecuritiesMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20180331" decimals="-3" unitRef="U_iso4217USD">21841000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000215" contextRef="C_0001274792_us-gaapInformationByCategoryOfDebtSecurityAxis_mackMarketableSecuritiesMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20180331" decimals="-3" unitRef="U_iso4217USD">13940000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000216" contextRef="C_0001274792_us-gaapInformationByCategoryOfDebtSecurityAxis_mackMarketableSecuritiesMember_20180331" decimals="-3" unitRef="U_iso4217USD">41998000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000217" contextRef="C_0001274792_20180331" decimals="-3" unitRef="U_iso4217USD">64573000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AccountsPayableCurrent id="F_000218" contextRef="C_0001274792_20180331" decimals="-3" unitRef="U_iso4217USD">2560000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent id="F_000219" contextRef="C_0001274792_20171231" decimals="-3" unitRef="U_iso4217USD">2887000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedLiabilitiesCurrent id="F_000220" contextRef="C_0001274792_20180331" decimals="-3" unitRef="U_iso4217USD">4027000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent id="F_000221" contextRef="C_0001274792_20171231" decimals="-3" unitRef="U_iso4217USD">5682000</us-gaap:AccruedLiabilitiesCurrent>
  <mack:AccruedClinicalTrialCosts id="F_000222" contextRef="C_0001274792_20180331" decimals="-3" unitRef="U_iso4217USD">4925000</mack:AccruedClinicalTrialCosts>
  <mack:AccruedClinicalTrialCosts id="F_000223" contextRef="C_0001274792_20171231" decimals="-3" unitRef="U_iso4217USD">3901000</mack:AccruedClinicalTrialCosts>
  <mack:AccruedDrugPurchaseCostsCurrent id="F_000224" contextRef="C_0001274792_20180331" decimals="-3" unitRef="U_iso4217USD">918000</mack:AccruedDrugPurchaseCostsCurrent>
  <mack:AccruedDrugPurchaseCostsCurrent id="F_000225" contextRef="C_0001274792_20171231" decimals="-3" unitRef="U_iso4217USD">222000</mack:AccruedDrugPurchaseCostsCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent id="F_000226" contextRef="C_0001274792_20180331" decimals="-3" unitRef="U_iso4217USD">1240000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent id="F_000227" contextRef="C_0001274792_20171231" decimals="-3" unitRef="U_iso4217USD">2884000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:RestructuringReserveCurrent id="F_000228" contextRef="C_0001274792_20180331" decimals="-3" unitRef="U_iso4217USD">251000</us-gaap:RestructuringReserveCurrent>
  <us-gaap:RestructuringReserveCurrent id="F_000229" contextRef="C_0001274792_20171231" decimals="-3" unitRef="U_iso4217USD">628000</us-gaap:RestructuringReserveCurrent>
  <us-gaap:DeferredCreditsAndOtherLiabilitiesCurrent id="F_000230" contextRef="C_0001274792_20180331" decimals="-3" unitRef="U_iso4217USD">1402000</us-gaap:DeferredCreditsAndOtherLiabilitiesCurrent>
  <us-gaap:DeferredCreditsAndOtherLiabilitiesCurrent id="F_000231" contextRef="C_0001274792_20171231" decimals="-3" unitRef="U_iso4217USD">1402000</us-gaap:DeferredCreditsAndOtherLiabilitiesCurrent>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant id="F_000232" contextRef="C_0001274792_us-gaapPlanNameAxis_mackStockIncentivePlan2011Member_20180331" decimals="-5" unitRef="U_shares">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000233" contextRef="C_0001274792_us-gaapPlanNameAxis_mackStockIncentivePlan2011Member_20180101_20180331" decimals="-5" unitRef="U_shares">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000234" contextRef="C_0001274792_us-gaapPlanNameAxis_mackStockIncentivePlan2011Member_20170101_20170331" decimals="-5" unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="F_000235" contextRef="C_0001274792_us-gaapPlanNameAxis_mackStockIncentivePlan2011Member_us-gaapTitleOfIndividualAxis_mackEmployeeMember_20180101_20180331">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="F_000236" contextRef="C_0001274792_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMinimumMember_20180101_20180331" decimals="3" unitRef="U_pure">0.023</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="F_000237" contextRef="C_0001274792_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMaximumMember_20180101_20180331" decimals="3" unitRef="U_pure">0.027</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="F_000238" contextRef="C_0001274792_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20170101_20170331" decimals="3" unitRef="U_pure">0.021</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="F_000239" contextRef="C_0001274792_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMinimumMember_20180101_20180331" decimals="2" unitRef="U_pure">0.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="F_000240" contextRef="C_0001274792_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMaximumMember_20180101_20180331" decimals="2" unitRef="U_pure">0.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="F_000241" contextRef="C_0001274792_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMinimumMember_20170101_20170331" decimals="2" unitRef="U_pure">0.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="F_000242" contextRef="C_0001274792_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMaximumMember_20170101_20170331" decimals="2" unitRef="U_pure">0.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="F_000243" contextRef="C_0001274792_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20180331" decimals="2" unitRef="U_pure">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="F_000244" contextRef="C_0001274792_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20170101_20170331" decimals="2" unitRef="U_pure">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000245" contextRef="C_0001274792_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20180331">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000246" contextRef="C_0001274792_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20170101_20170331">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000247" contextRef="C_0001274792_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20180101_20180331" decimals="-3" unitRef="U_iso4217USD">334000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000248" contextRef="C_0001274792_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20170101_20170331" decimals="-3" unitRef="U_iso4217USD">468000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000249" contextRef="C_0001274792_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20180101_20180331" decimals="-3" unitRef="U_iso4217USD">430000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000250" contextRef="C_0001274792_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20170101_20170331" decimals="-3" unitRef="U_iso4217USD">328000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000251" contextRef="C_0001274792_20171231" decimals="-3" unitRef="U_shares">1616000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000252" contextRef="C_0001274792_20180101_20180331" decimals="-3" unitRef="U_shares">566000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod id="F_000253" contextRef="C_0001274792_20180101_20180331" decimals="-3" unitRef="U_shares">145000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000254" contextRef="C_0001274792_20180331" decimals="-3" unitRef="U_shares">2037000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber id="F_000255" contextRef="C_0001274792_20180331" decimals="-3" unitRef="U_shares">2036000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="F_000256" contextRef="C_0001274792_20180331" decimals="-3" unitRef="U_shares">1032000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000257" contextRef="C_0001274792_20171231" decimals="2" unitRef="U_iso4217USD_shares">22.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="F_000258" contextRef="C_0001274792_20180101_20180331" decimals="2" unitRef="U_iso4217USD_shares">10.74</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice id="F_000259" contextRef="C_0001274792_20180101_20180331" decimals="2" unitRef="U_iso4217USD_shares">21.04</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000260" contextRef="C_0001274792_20180331" decimals="2" unitRef="U_iso4217USD_shares">19.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice id="F_000261" contextRef="C_0001274792_20180331" decimals="2" unitRef="U_iso4217USD_shares">19.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice id="F_000262" contextRef="C_0001274792_20180331" decimals="2" unitRef="U_iso4217USD_shares">25.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="F_000263" contextRef="C_0001274792_20170101_20171231">P6Y7M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="F_000264" contextRef="C_0001274792_20180101_20180331">P7Y2M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 id="F_000265" contextRef="C_0001274792_20180101_20180331">P7Y2M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 id="F_000266" contextRef="C_0001274792_20180101_20180331">P4Y11M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="F_000267" contextRef="C_0001274792_20171231" decimals="-3" unitRef="U_iso4217USD">60031000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="F_000268" contextRef="C_0001274792_20180101_20180331" decimals="2" unitRef="U_iso4217USD_shares">6.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="F_000269" contextRef="C_0001274792_20170101_20170331" decimals="2" unitRef="U_iso4217USD_shares">24.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue id="F_000270" contextRef="C_0001274792_20170101_20170331" decimals="-5" unitRef="U_iso4217USD">1400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue id="F_000271" contextRef="C_0001274792_20180101_20180331" decimals="-6" unitRef="U_iso4217USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions id="F_000272" contextRef="C_0001274792_20180331" decimals="-5" unitRef="U_iso4217USD">7200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 id="F_000273" contextRef="C_0001274792_20180101_20180331">P2Y6M29D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <mack:UndistributedEarningsLossAllocatedToParticipatingSecurities id="F_000274" contextRef="C_0001274792_20180101_20180331" decimals="INF" unitRef="U_iso4217USD">0</mack:UndistributedEarningsLossAllocatedToParticipatingSecurities>
  <mack:UndistributedEarningsLossAllocatedToParticipatingSecurities id="F_000275" contextRef="C_0001274792_20170101_20170331" decimals="INF" unitRef="U_iso4217USD">0</mack:UndistributedEarningsLossAllocatedToParticipatingSecurities>
  <mack:ParticipatingSecuritiesOutstandingShares id="F_000276" contextRef="C_0001274792_20180331" decimals="INF" unitRef="U_shares">0</mack:ParticipatingSecuritiesOutstandingShares>
  <mack:ParticipatingSecuritiesOutstandingShares id="F_000277" contextRef="C_0001274792_20170331" decimals="INF" unitRef="U_shares">0</mack:ParticipatingSecuritiesOutstandingShares>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage id="F_000278" contextRef="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_20180331" decimals="INF" unitRef="U_pure">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000279" contextRef="C_0001274792_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapStockCompensationPlanMember_20180101_20180331" decimals="-3" unitRef="U_shares">2037000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000280" contextRef="C_0001274792_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapStockCompensationPlanMember_20170101_20170331" decimals="-3" unitRef="U_shares">1652000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000281" contextRef="C_0001274792_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapConvertibleDebtSecuritiesMember_20170101_20170331" decimals="-3" unitRef="U_shares">1216000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <mack:DisposalGroupIncludingDiscontinuedOperationProductRevenuesNet id="F_000282" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20170101_20170331" decimals="-3" unitRef="U_iso4217USD">16135000</mack:DisposalGroupIncludingDiscontinuedOperationProductRevenuesNet>
  <mack:DisposalGroupIncludingDiscontinuedOperationLicenseAndCollaborationRevenues id="F_000283" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20170101_20170331" decimals="-3" unitRef="U_iso4217USD">7797000</mack:DisposalGroupIncludingDiscontinuedOperationLicenseAndCollaborationRevenues>
  <mack:DisposalGroupIncludingDiscontinuedOperationOtherRevenue id="F_000284" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20170101_20170331" decimals="-3" unitRef="U_iso4217USD">1973000</mack:DisposalGroupIncludingDiscontinuedOperationOtherRevenue>
  <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue id="F_000285" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20170101_20170331" decimals="-3" unitRef="U_iso4217USD">25905000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
  <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold id="F_000286" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20170101_20170331" decimals="-3" unitRef="U_iso4217USD">3890000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
  <mack:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses id="F_000287" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20170101_20170331" decimals="-3" unitRef="U_iso4217USD">3730000</mack:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses>
  <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense id="F_000288" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20170101_20170331" decimals="-3" unitRef="U_iso4217USD">8733000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
  <mack:DisposalGroupIncludingDiscontinuedOperationRestructuringExpenses id="F_000289" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20170101_20170331" decimals="-3" unitRef="U_iso4217USD">5265000</mack:DisposalGroupIncludingDiscontinuedOperationRestructuringExpenses>
  <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense id="F_000290" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20170101_20170331" decimals="-3" unitRef="U_iso4217USD">21618000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
  <us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense id="F_000291" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20170101_20170331" decimals="-3" unitRef="U_iso4217USD">5234000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense>
  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax id="F_000292" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20170101_20170331" decimals="-3" unitRef="U_iso4217USD">-947000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
  <us-gaap:RestructuringAndRelatedActivitiesInitiationDate id="F_000293" contextRef="C_0001274792_us-gaapRestructuringPlanAxis_mackJanuaryTwoThousandSeventeenCorporateRestructuringMember_20180101_20180331">2017-01-08</us-gaap:RestructuringAndRelatedActivitiesInitiationDate>
  <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent id="F_000294" contextRef="C_0001274792_us-gaapRestructuringPlanAxis_mackJanuaryTwoThousandSeventeenCorporateRestructuringMember_20170107_20170108" decimals="2" unitRef="U_pure">0.30</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
  <us-gaap:RestructuringCharges id="F_000295" contextRef="C_0001274792_us-gaapRestructuringCostAndReserveAxis_us-gaapContractTerminationMember_us-gaapRestructuringPlanAxis_mackJanuaryTwoThousandSeventeenCorporateRestructuringMember_20180101_20180331" decimals="-5" unitRef="U_iso4217USD">5300000</us-gaap:RestructuringCharges>
  <us-gaap:RestructuringAndRelatedActivitiesDescription id="F_000296" contextRef="C_0001274792_us-gaapRestructuringCostAndReserveAxis_us-gaapOneTimeTerminationBenefitsMember_us-gaapRestructuringPlanAxis_mackJanuaryTwoThousandSeventeenCorporateRestructuringMember_20180101_20180331">One-time employee termination benefits are comprised of severance, benefits and related costs, all of which are expected to result in cash expenditures. The majority of these payments were made during the second quarter of 2017. The remaining payments represent severance payments that will be paid over one year.</us-gaap:RestructuringAndRelatedActivitiesDescription>
  <us-gaap:RestructuringCharges id="F_000297" contextRef="C_0001274792_us-gaapDisposalGroupClassificationAxis_us-gaapDiscontinuedOperationsDisposedOfBySaleMember_us-gaapRestructuringPlanAxis_mackJanuaryTwoThousandSeventeenCorporateRestructuringMember_20180101_20180331" decimals="-5" unitRef="U_iso4217USD">5300000</us-gaap:RestructuringCharges>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>18
<FILENAME>mack-20180331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFS ActiveDisclosure(SM) XBRL Schema Document - http://www.dfsco.com/financial-services/ -->
<!-- Creation Date      : 2018-05-07T16:39:29.0819186+00:00 -->
<!-- Version            : 2.9.6605.1333 -->
<!-- Package ID         : 61e77818d95b40c390d461315935aff4 -->
<!-- Copyright (c) 2018 Donnelley Financial, LLC. All Rights Reserved. -->
<schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:mack="http://www.merrimackpharma.com/20180331" xmlns:exch="http://xbrl.sec.gov/exch/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.merrimackpharma.com/20180331" xmlns="http://www.w3.org/2001/XMLSchema">
  <import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <import schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd" namespace="http://fasb.org/us-gaap/2017-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2014-01-31" />
  <import schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-types-2017-01-31.xsd" namespace="http://fasb.org/us-types/2017-01-31" />
  <import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
  <import schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" namespace="http://xbrl.sec.gov/country/2017-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2017-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/exch/2017/exch-2017-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2017-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" namespace="http://xbrl.sec.gov/invest/2013-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2011-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2011-01-31" />
  <annotation>
    <appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.merrimackpharma.com/20180331/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mack-20180331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mack-20180331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mack-20180331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mack-20180331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" id="Role_StatementCondensedConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" id="Role_StatementCondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>100030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss2" id="Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss2">
        <link:definition>100040 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss2</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" id="Role_StatementCondensedConsolidatedStatementsOfCashFlows">
        <link:definition>100050 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureNatureOfBusiness" id="Role_DisclosureNatureOfBusiness">
        <link:definition>100060 - Disclosure - Nature of the Business</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100070 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureFairValueOfFinancialInstruments" id="Role_DisclosureFairValueOfFinancialInstruments">
        <link:definition>100080 - Disclosure - Fair Value of Financial Instruments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureMarketableSecuritiesAndCashEquivalents" id="Role_DisclosureMarketableSecuritiesAndCashEquivalents">
        <link:definition>100090 - Disclosure - Marketable Securities and Cash Equivalents</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureAccountsPayableAccruedExpensesAndOther" id="Role_DisclosureAccountsPayableAccruedExpensesAndOther">
        <link:definition>100100 - Disclosure - Accounts Payable, Accrued Expenses and Other</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
        <link:definition>100110 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureNetLossPerCommonShare" id="Role_DisclosureNetLossPerCommonShare">
        <link:definition>100120 - Disclosure - Net Loss Per Common Share</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureDiscontinuedOperations" id="Role_DisclosureDiscontinuedOperations">
        <link:definition>100130 - Disclosure - Discontinued Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureInvestmentInSilverCreek" id="Role_DisclosureInvestmentInSilverCreek">
        <link:definition>100140 - Disclosure - Investment in Silver Creek</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureRecentAccountingPronouncements" id="Role_DisclosureRecentAccountingPronouncements">
        <link:definition>100150 - Disclosure - Recent Accounting Pronouncements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100160 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>100170 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsTables" id="Role_DisclosureFairValueOfFinancialInstrumentsTables">
        <link:definition>100180 - Disclosure - Fair Value of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureMarketableSecuritiesAndCashEquivalentsTables" id="Role_DisclosureMarketableSecuritiesAndCashEquivalentsTables">
        <link:definition>100190 - Disclosure - Marketable Securities and Cash Equivalents (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureAccountsPayableAccruedExpensesAndOtherTables" id="Role_DisclosureAccountsPayableAccruedExpensesAndOtherTables">
        <link:definition>100200 - Disclosure - Accounts Payable, Accrued Expenses and Other (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
        <link:definition>100210 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureNetLossPerCommonShareTables" id="Role_DisclosureNetLossPerCommonShareTables">
        <link:definition>100220 - Disclosure - Net Loss Per Common Share (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureDiscontinuedOperationsTables" id="Role_DisclosureDiscontinuedOperationsTables">
        <link:definition>100230 - Disclosure - Discontinued Operations (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail" id="Role_DisclosureNatureOfBusinessAdditionalInformationDetail">
        <link:definition>100240 - Disclosure - Nature of the Business - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>100250 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail">
        <link:definition>100260 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetail" id="Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetail">
        <link:definition>100270 - Disclosure - Fair Value of Financial Instruments - Summary of Assets Measured at Fair Value on a Recurring Basis (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetail" id="Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetail">
        <link:definition>100280 - Disclosure - Fair Value of Financial Instruments - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureMarketableSecuritiesAndCashEquivalentsAdditionalInformationDetail" id="Role_DisclosureMarketableSecuritiesAndCashEquivalentsAdditionalInformationDetail">
        <link:definition>100290 - Disclosure - Marketable Securities and Cash Equivalents - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureMarketableSecuritiesAndCashEquivalentsSummaryOfMarketableSecuritiesAndCashEquivalentsDetail" id="Role_DisclosureMarketableSecuritiesAndCashEquivalentsSummaryOfMarketableSecuritiesAndCashEquivalentsDetail">
        <link:definition>100300 - Disclosure - Marketable Securities and Cash Equivalents - Summary of Marketable Securities and Cash Equivalents (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureAccountsPayableAccruedExpensesAndOtherScheduleOfAccountsPayableAccruedExpensesAndOtherDetail" id="Role_DisclosureAccountsPayableAccruedExpensesAndOtherScheduleOfAccountsPayableAccruedExpensesAndOtherDetail">
        <link:definition>100310 - Disclosure - Accounts Payable, Accrued Expenses and Other - Schedule of Accounts Payable, Accrued Expenses and Other (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" id="Role_DisclosureStockBasedCompensationAdditionalInformationDetail">
        <link:definition>100320 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToCalculateFairValueOfOptionsGrantedToEmployeesDetail" id="Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToCalculateFairValueOfOptionsGrantedToEmployeesDetail">
        <link:definition>100330 - Disclosure - Stock-Based Compensation - Schedule of Assumptions Used to Calculate Fair Value of Options Granted to Employees (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRecognizedStockBasedCompensationExpenseDetail" id="Role_DisclosureStockBasedCompensationScheduleOfRecognizedStockBasedCompensationExpenseDetail">
        <link:definition>100340 - Disclosure - Stock-Based Compensation - Schedule of Recognized Stock-Based Compensation Expense (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" id="Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail">
        <link:definition>100350 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetail" id="Role_DisclosureNetLossPerCommonShareAdditionalInformationDetail">
        <link:definition>100360 - Disclosure - Net Loss Per Common Share - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfOutstandingSecuritiesExcludedFromComputationOfDilutedLossPerShareDetail" id="Role_DisclosureNetLossPerCommonShareScheduleOfOutstandingSecuritiesExcludedFromComputationOfDilutedLossPerShareDetail">
        <link:definition>100370 - Disclosure - Net Loss Per Common Share - Schedule of Outstanding Securities Excluded from Computation of Diluted Loss Per Share (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureDiscontinuedOperationsScheduleOfDiscontinuedOperationsDetail" id="Role_DisclosureDiscontinuedOperationsScheduleOfDiscontinuedOperationsDetail">
        <link:definition>100380 - Disclosure - Discontinued Operations - Schedule of Discontinued Operations (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureDiscontinuedOperationsAdditionalInformationDetail" id="Role_DisclosureDiscontinuedOperationsAdditionalInformationDetail">
        <link:definition>100390 - Disclosure - Discontinued Operations - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureInvestmentInSilverCreekAdditionalInformationDetail" id="Role_DisclosureInvestmentInSilverCreekAdditionalInformationDetail">
        <link:definition>100400 - Disclosure - Investment in Silver Creek - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </appinfo>
  </annotation>
  <element id="mack_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="mack_PremiumsPaidOnMarketableSecurities" name="PremiumsPaidOnMarketableSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="mack_AmortizationAndAccretionOnMarketableSecurities" name="AmortizationAndAccretionOnMarketableSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees" name="AllocatedShareBasedCompensationExpenseIncludingNonEmployees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="mack_IncreaseDecreaseInDeferredRent" name="IncreaseDecreaseInDeferredRent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="mack_SilverCreekPharmaceuticalsIncMember" name="SilverCreekPharmaceuticalsIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="mack_UnauditedInterimFinancialInformationPolicyTextBlock" name="UnauditedInterimFinancialInformationPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="mack_CondensedConsolidatedStatementsOfCashFlowsPolicyTextBlock" name="CondensedConsolidatedStatementsOfCashFlowsPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="mack_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" name="ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="mack_ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock" name="ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="mack_NumberOfDevelopmentProgramsActive" name="NumberOfDevelopmentProgramsActive" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <element id="mack_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="mack_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="mack_CashCashEquivalentsAndRestrictedCashLineItems" name="CashCashEquivalentsAndRestrictedCashLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="mack_CashCashEquivalentsAndRestrictedCashTable" name="CashCashEquivalentsAndRestrictedCashTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="mack_AmortizedCostAndFairValueDebtSecuritiesAbstract" name="AmortizedCostAndFairValueDebtSecuritiesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="mack_MarketableSecuritiesMember" name="MarketableSecuritiesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="mack_AccruedClinicalTrialCosts" name="AccruedClinicalTrialCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="mack_AccruedDrugPurchaseCostsCurrent" name="AccruedDrugPurchaseCostsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="mack_StockIncentivePlan2011Member" name="StockIncentivePlan2011Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="mack_EmployeeMember" name="EmployeeMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="mack_UndistributedEarningsLossAllocatedToParticipatingSecurities" name="UndistributedEarningsLossAllocatedToParticipatingSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="mack_ParticipatingSecuritiesOutstandingShares" name="ParticipatingSecuritiesOutstandingShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <element id="mack_DisposalGroupIncludingDiscontinuedOperationProductRevenuesNet" name="DisposalGroupIncludingDiscontinuedOperationProductRevenuesNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="mack_DisposalGroupIncludingDiscontinuedOperationLicenseAndCollaborationRevenues" name="DisposalGroupIncludingDiscontinuedOperationLicenseAndCollaborationRevenues" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="mack_DisposalGroupIncludingDiscontinuedOperationOtherRevenue" name="DisposalGroupIncludingDiscontinuedOperationOtherRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="mack_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses" name="DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="mack_DisposalGroupIncludingDiscontinuedOperationRestructuringExpenses" name="DisposalGroupIncludingDiscontinuedOperationRestructuringExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="mack_DisposalGroupIncludingDiscontinuedOperationRevenueAbstract" name="DisposalGroupIncludingDiscontinuedOperationRevenueAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="mack_DisposalGroupIncludingDiscontinuedOperationCostAndExpensesAbstract" name="DisposalGroupIncludingDiscontinuedOperationCostAndExpensesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="mack_DisposalGroupIncludingDiscontinuedOperationOtherIncomeAndExpensesAbstract" name="DisposalGroupIncludingDiscontinuedOperationOtherIncomeAndExpensesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="mack_CommercialBusinessMember" name="CommercialBusinessMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="mack_JanuaryTwoThousandSeventeenCorporateRestructuringMember" name="JanuaryTwoThousandSeventeenCorporateRestructuringMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>19
<FILENAME>mack-20180331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFS ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfsco.com/financial-services/ -->
<!-- Creation Date      : 2018-05-07T16:39:29.0819186+00:00 -->
<!-- Version            : 2.9.6605.1333 -->
<!-- Package ID         : 61e77818d95b40c390d461315935aff4 -->
<!-- Copyright (c) 2018 Donnelley Financial, LLC. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="mack-20180331.xsd#TemplateLink" roleURI="http://www.merrimackpharma.com/20180331/role/TemplateLink" />
  <roleRef roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" xlink:href="mack-20180331.xsd#Role_StatementCondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20180331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="10020.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="10030.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="10040.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="10050.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="10060.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10070.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="10080.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="10090.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="10100.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="10110.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="10120.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRentCreditCurrent" order="10130.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="10140.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" order="10150.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10160.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_EquityMethodInvestments" order="10170.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10180.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10190.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="10200.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10210.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="mack-20180331.xsd#Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20180331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" order="10020.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="10030.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" order="10040.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" order="10050.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_ProfitLoss" order="10060.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="10070.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" order="10080.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" order="10090.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="10100.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="10110.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="10120.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" order="10130.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10140.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="10150.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10160.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10170.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss2" xlink:href="mack-20180331.xsd#Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss2" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20180331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss2">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperations" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" order="10020.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:href="mack-20180331.xsd#Role_StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20180331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows">
    <loc xlink:href="mack-20180331.xsd#mack_IncreaseDecreaseInDeferredRent" xlink:type="locator" xlink:label="mack_IncreaseDecreaseInDeferredRent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfEquityInvestments" xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfEquityInvestments" />
    <loc xlink:href="mack-20180331.xsd#mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees" xlink:type="locator" xlink:label="mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees" />
    <loc xlink:href="mack-20180331.xsd#mack_AmortizationAndAccretionOnMarketableSecurities" xlink:type="locator" xlink:label="mack_AmortizationAndAccretionOnMarketableSecurities" />
    <loc xlink:href="mack-20180331.xsd#mack_PremiumsPaidOnMarketableSecurities" xlink:type="locator" xlink:label="mack_PremiumsPaidOnMarketableSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaidInKindInterest" xlink:type="locator" xlink:label="us-gaap_PaidInKindInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="10020.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="10030.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="10040.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="10050.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10060.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="10070.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="10080.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" order="10090.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" order="10100.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_PaidInKindInterest" order="10110.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10120.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="mack_PremiumsPaidOnMarketableSecurities" order="10130.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="mack_AmortizationAndAccretionOnMarketableSecurities" order="10140.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees" order="10150.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_GainLossOnSaleOfEquityInvestments" order="10160.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10170.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="10180.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="mack_IncreaseDecreaseInDeferredRent" order="10190.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail" xlink:href="mack-20180331.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashCurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashNoncurrent" order="10040.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureMarketableSecuritiesAndCashEquivalentsSummaryOfMarketableSecuritiesAndCashEquivalentsDetail" xlink:href="mack-20180331.xsd#Role_DisclosureMarketableSecuritiesAndCashEquivalentsSummaryOfMarketableSecuritiesAndCashEquivalentsDetail" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureMarketableSecuritiesAndCashEquivalentsSummaryOfMarketableSecuritiesAndCashEquivalentsDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10020.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureAccountsPayableAccruedExpensesAndOtherScheduleOfAccountsPayableAccruedExpensesAndOtherDetail" xlink:href="mack-20180331.xsd#Role_DisclosureAccountsPayableAccruedExpensesAndOtherScheduleOfAccountsPayableAccruedExpensesAndOtherDetail" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureAccountsPayableAccruedExpensesAndOtherScheduleOfAccountsPayableAccruedExpensesAndOtherDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserveCurrent" xlink:type="locator" xlink:label="us-gaap_RestructuringReserveCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <loc xlink:href="mack-20180331.xsd#mack_AccruedDrugPurchaseCostsCurrent" xlink:type="locator" xlink:label="mack_AccruedDrugPurchaseCostsCurrent" />
    <loc xlink:href="mack-20180331.xsd#mack_AccruedClinicalTrialCosts" xlink:type="locator" xlink:label="mack_AccruedClinicalTrialCosts" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="mack_AccruedClinicalTrialCosts" order="10030.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="mack_AccruedDrugPurchaseCostsCurrent" order="10040.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10050.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_RestructuringReserveCurrent" order="10060.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" order="10070.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRecognizedStockBasedCompensationExpenseDetail" xlink:href="mack-20180331.xsd#Role_DisclosureStockBasedCompensationScheduleOfRecognizedStockBasedCompensationExpenseDetail" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRecognizedStockBasedCompensationExpenseDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <loc xlink:href="mack-20180331.xsd#mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees" xlink:type="locator" xlink:label="mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10010.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureDiscontinuedOperationsScheduleOfDiscontinuedOperationsDetail" xlink:href="mack-20180331.xsd#Role_DisclosureDiscontinuedOperationsScheduleOfDiscontinuedOperationsDetail" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureDiscontinuedOperationsScheduleOfDiscontinuedOperationsDetail">
    <loc xlink:href="mack-20180331.xsd#mack_DisposalGroupIncludingDiscontinuedOperationOtherRevenue" xlink:type="locator" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationOtherRevenue" />
    <loc xlink:href="mack-20180331.xsd#mack_DisposalGroupIncludingDiscontinuedOperationLicenseAndCollaborationRevenues" xlink:type="locator" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationLicenseAndCollaborationRevenues" />
    <loc xlink:href="mack-20180331.xsd#mack_DisposalGroupIncludingDiscontinuedOperationProductRevenuesNet" xlink:type="locator" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationProductRevenuesNet" />
    <loc xlink:href="mack-20180331.xsd#mack_DisposalGroupIncludingDiscontinuedOperationRestructuringExpenses" xlink:type="locator" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationRestructuringExpenses" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" />
    <loc xlink:href="mack-20180331.xsd#mack_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses" xlink:type="locator" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" order="10030.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" order="10040.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="mack_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses" order="10050.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" order="10060.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="mack_DisposalGroupIncludingDiscontinuedOperationRestructuringExpenses" order="10070.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:to="mack_DisposalGroupIncludingDiscontinuedOperationProductRevenuesNet" order="10080.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:to="mack_DisposalGroupIncludingDiscontinuedOperationLicenseAndCollaborationRevenues" order="10090.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:to="mack_DisposalGroupIncludingDiscontinuedOperationOtherRevenue" order="10100.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>20
<FILENAME>mack-20180331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFS ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfsco.com/financial-services/ -->
<!-- Creation Date      : 2018-05-07T16:39:29.0829186+00:00 -->
<!-- Version            : 2.9.6605.1333 -->
<!-- Package ID         : 61e77818d95b40c390d461315935aff4 -->
<!-- Copyright (c) 2018 Donnelley Financial, LLC. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <roleRef xlink:type="simple" xlink:href="mack-20180331.xsd#TemplateLink" roleURI="http://www.merrimackpharma.com/20180331/role/TemplateLink" />
  <roleRef roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:href="mack-20180331.xsd#Role_StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20180331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaid" xlink:type="locator" xlink:label="us-gaap_InterestPaid" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" xlink:type="locator" xlink:label="us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <loc xlink:href="mack-20180331.xsd#mack_IncreaseDecreaseInDeferredRent" xlink:type="locator" xlink:label="mack_IncreaseDecreaseInDeferredRent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfEquityInvestments" xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfEquityInvestments" />
    <loc xlink:href="mack-20180331.xsd#mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees" xlink:type="locator" xlink:label="mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees" />
    <loc xlink:href="mack-20180331.xsd#mack_AmortizationAndAccretionOnMarketableSecurities" xlink:type="locator" xlink:label="mack_AmortizationAndAccretionOnMarketableSecurities" />
    <loc xlink:href="mack-20180331.xsd#mack_PremiumsPaidOnMarketableSecurities" xlink:type="locator" xlink:label="mack_PremiumsPaidOnMarketableSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaidInKindInterest" xlink:type="locator" xlink:label="us-gaap_PaidInKindInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <loc xlink:href="mack-20180331.xsd#mack_SilverCreekPharmaceuticalsIncMember" xlink:type="locator" xlink:label="mack_SilverCreekPharmaceuticalsIncMember" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain_2" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10200.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10230.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_2" order="10240.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10260.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="mack_SilverCreekPharmaceuticalsIncMember" order="10280.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10310.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="10390.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" order="10430.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" order="10470.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10550.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_PaidInKindInterest" order="10630.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10670.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="mack_PremiumsPaidOnMarketableSecurities" order="10710.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="mack_AmortizationAndAccretionOnMarketableSecurities" order="10750.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees" order="10790.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfEquityInvestments" order="10830.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="10870.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10950.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="10990.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="mack_IncreaseDecreaseInDeferredRent" order="11030.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="11070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" order="11110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="11150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="11190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="11270.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="11310.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="11350.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="11390.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="11470.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="11510.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="11550.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="11590.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="11630.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="11710.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="11790.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" order="11830.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="11870.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaid" order="11950.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="mack-20180331.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" />
    <loc xlink:href="mack-20180331.xsd#mack_SilverCreekPharmaceuticalsIncMember" xlink:type="locator" xlink:label="mack_SilverCreekPharmaceuticalsIncMember" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="mack-20180331.xsd#mack_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="mack_SummaryOfSignificantAccountingPoliciesTable" />
    <loc xlink:href="mack-20180331.xsd#mack_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="mack_SummaryOfSignificantAccountingPoliciesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mack_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="mack_SummaryOfSignificantAccountingPoliciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mack_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_RangeAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember_2" order="10050.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mack_SummaryOfSignificantAccountingPoliciesTable" xlink:to="dei_LegalEntityAxis" order="10120.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="mack_SilverCreekPharmaceuticalsIncMember" order="10170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mack_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" order="10200.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mack_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" order="10250.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail" xlink:href="mack-20180331.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="locator" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <loc xlink:href="mack-20180331.xsd#mack_CashCashEquivalentsAndRestrictedCashTable" xlink:type="locator" xlink:label="mack_CashCashEquivalentsAndRestrictedCashTable" />
    <loc xlink:href="mack-20180331.xsd#mack_CashCashEquivalentsAndRestrictedCashLineItems" xlink:type="locator" xlink:label="mack_CashCashEquivalentsAndRestrictedCashLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mack_CashCashEquivalentsAndRestrictedCashLineItems" xlink:to="mack_CashCashEquivalentsAndRestrictedCashTable" order="10050.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mack_CashCashEquivalentsAndRestrictedCashTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_2" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mack_CashCashEquivalentsAndRestrictedCashLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10160.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mack_CashCashEquivalentsAndRestrictedCashLineItems" xlink:to="us-gaap_RestrictedCashCurrent" order="10200.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mack_CashCashEquivalentsAndRestrictedCashLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" order="10280.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mack_CashCashEquivalentsAndRestrictedCashLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="10320.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetail" xlink:href="mack-20180331.xsd#Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:type="locator" xlink:label="us-gaap_USTreasuryAndGovernmentMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_2" order="10050.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10100.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="10110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10200.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" order="10210.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="10230.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="10250.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10270.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" order="10290.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" order="10330.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasuryAndGovernmentMember" order="10350.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="10600.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecurities" order="10840.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureMarketableSecuritiesAndCashEquivalentsSummaryOfMarketableSecuritiesAndCashEquivalentsDetail" xlink:href="mack-20180331.xsd#Role_DisclosureMarketableSecuritiesAndCashEquivalentsSummaryOfMarketableSecuritiesAndCashEquivalentsDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureMarketableSecuritiesAndCashEquivalentsSummaryOfMarketableSecuritiesAndCashEquivalentsDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_CashEquivalentsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <loc xlink:href="mack-20180331.xsd#mack_MarketableSecuritiesMember" xlink:type="locator" xlink:label="mack_MarketableSecuritiesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:type="locator" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:type="locator" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:type="locator" xlink:label="us-gaap_InformationByCategoryOfDebtSecurityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_InformationByCategoryOfDebtSecurityAxis" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:to="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_2" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:to="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:to="mack_MarketableSecuritiesMember" order="10110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="10180.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" order="10190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="10210.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember" order="10230.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10300.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_2" order="10310.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10330.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10350.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10370.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" order="10390.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="10450.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="10480.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10740.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="11000.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:href="mack-20180331.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <loc xlink:href="mack-20180331.xsd#mack_EmployeeMember" xlink:type="locator" xlink:label="mack_EmployeeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualAxis" />
    <loc xlink:href="mack-20180331.xsd#mack_StockIncentivePlan2011Member" xlink:type="locator" xlink:label="mack_StockIncentivePlan2011Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="10050.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="mack_StockIncentivePlan2011Member" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TitleOfIndividualAxis" order="10180.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_2" order="10190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="10210.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="mack_EmployeeMember" order="10230.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10260.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10310.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="10350.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10420.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="10490.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="10560.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="10580.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToCalculateFairValueOfOptionsGrantedToEmployeesDetail" xlink:href="mack-20180331.xsd#Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToCalculateFairValueOfOptionsGrantedToEmployeesDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToCalculateFairValueOfOptionsGrantedToEmployeesDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="10050.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RangeAxis" order="10100.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="10360.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="10460.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10590.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10660.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRecognizedStockBasedCompensationExpenseDetail" xlink:href="mack-20180331.xsd#Role_DisclosureStockBasedCompensationScheduleOfRecognizedStockBasedCompensationExpenseDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRecognizedStockBasedCompensationExpenseDetail">
    <loc xlink:href="mack-20180331.xsd#mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees" xlink:type="locator" xlink:label="mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10160.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees" order="10240.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetail" xlink:href="mack-20180331.xsd#Role_DisclosureNetLossPerCommonShareAdditionalInformationDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <loc xlink:href="mack-20180331.xsd#mack_ParticipatingSecuritiesOutstandingShares" xlink:type="locator" xlink:label="mack_ParticipatingSecuritiesOutstandingShares" />
    <loc xlink:href="mack-20180331.xsd#mack_UndistributedEarningsLossAllocatedToParticipatingSecurities" xlink:type="locator" xlink:label="mack_UndistributedEarningsLossAllocatedToParticipatingSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_2" order="10050.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="mack_UndistributedEarningsLossAllocatedToParticipatingSecurities" order="10120.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="mack_ParticipatingSecuritiesOutstandingShares" order="10160.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="10230.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfOutstandingSecuritiesExcludedFromComputationOfDilutedLossPerShareDetail" xlink:href="mack-20180331.xsd#Role_DisclosureNetLossPerCommonShareScheduleOfOutstandingSecuritiesExcludedFromComputationOfDilutedLossPerShareDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfOutstandingSecuritiesExcludedFromComputationOfDilutedLossPerShareDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:type="locator" xlink:label="us-gaap_StockCompensationPlanMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="10050.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember" order="10110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10140.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureDiscontinuedOperationsScheduleOfDiscontinuedOperationsDetail" xlink:href="mack-20180331.xsd#Role_DisclosureDiscontinuedOperationsScheduleOfDiscontinuedOperationsDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureDiscontinuedOperationsScheduleOfDiscontinuedOperationsDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" />
    <loc xlink:href="mack-20180331.xsd#mack_DisposalGroupIncludingDiscontinuedOperationOtherIncomeAndExpensesAbstract" xlink:type="locator" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationOtherIncomeAndExpensesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" />
    <loc xlink:href="mack-20180331.xsd#mack_DisposalGroupIncludingDiscontinuedOperationRestructuringExpenses" xlink:type="locator" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationRestructuringExpenses" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" />
    <loc xlink:href="mack-20180331.xsd#mack_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses" xlink:type="locator" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" />
    <loc xlink:href="mack-20180331.xsd#mack_DisposalGroupIncludingDiscontinuedOperationCostAndExpensesAbstract" xlink:type="locator" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationCostAndExpensesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" />
    <loc xlink:href="mack-20180331.xsd#mack_DisposalGroupIncludingDiscontinuedOperationOtherRevenue" xlink:type="locator" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationOtherRevenue" />
    <loc xlink:href="mack-20180331.xsd#mack_DisposalGroupIncludingDiscontinuedOperationLicenseAndCollaborationRevenues" xlink:type="locator" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationLicenseAndCollaborationRevenues" />
    <loc xlink:href="mack-20180331.xsd#mack_DisposalGroupIncludingDiscontinuedOperationProductRevenuesNet" xlink:type="locator" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationProductRevenuesNet" />
    <loc xlink:href="mack-20180331.xsd#mack_DisposalGroupIncludingDiscontinuedOperationRevenueAbstract" xlink:type="locator" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationRevenueAbstract" />
    <loc xlink:href="mack-20180331.xsd#mack_CommercialBusinessMember" xlink:type="locator" xlink:label="mack_CommercialBusinessMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="locator" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="locator" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="locator" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="locator" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" order="10110.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" order="10140.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" order="10170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="mack_CommercialBusinessMember" order="10190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="mack_DisposalGroupIncludingDiscontinuedOperationRevenueAbstract" order="10220.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mack_DisposalGroupIncludingDiscontinuedOperationRevenueAbstract" xlink:to="mack_DisposalGroupIncludingDiscontinuedOperationProductRevenuesNet" order="10260.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mack_DisposalGroupIncludingDiscontinuedOperationRevenueAbstract" xlink:to="mack_DisposalGroupIncludingDiscontinuedOperationLicenseAndCollaborationRevenues" order="10280.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mack_DisposalGroupIncludingDiscontinuedOperationRevenueAbstract" xlink:to="mack_DisposalGroupIncludingDiscontinuedOperationOtherRevenue" order="10300.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mack_DisposalGroupIncludingDiscontinuedOperationRevenueAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" order="10320.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="mack_DisposalGroupIncludingDiscontinuedOperationCostAndExpensesAbstract" order="10340.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mack_DisposalGroupIncludingDiscontinuedOperationCostAndExpensesAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" order="10380.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mack_DisposalGroupIncludingDiscontinuedOperationCostAndExpensesAbstract" xlink:to="mack_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses" order="10400.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mack_DisposalGroupIncludingDiscontinuedOperationCostAndExpensesAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" order="10420.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mack_DisposalGroupIncludingDiscontinuedOperationCostAndExpensesAbstract" xlink:to="mack_DisposalGroupIncludingDiscontinuedOperationRestructuringExpenses" order="10440.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mack_DisposalGroupIncludingDiscontinuedOperationCostAndExpensesAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" order="10460.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="mack_DisposalGroupIncludingDiscontinuedOperationOtherIncomeAndExpensesAbstract" order="10480.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mack_DisposalGroupIncludingDiscontinuedOperationOtherIncomeAndExpensesAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" order="10520.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" order="10540.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureDiscontinuedOperationsAdditionalInformationDetail" xlink:href="mack-20180331.xsd#Role_DisclosureDiscontinuedOperationsAdditionalInformationDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureDiscontinuedOperationsAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDescription" xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDescription" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCharges" xlink:type="locator" xlink:label="us-gaap_RestructuringCharges" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesInitiationDate" xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedActivitiesInitiationDate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:type="locator" xlink:label="us-gaap_DisposalGroupClassificationDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:type="locator" xlink:label="us-gaap_DisposalGroupClassificationDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:type="locator" xlink:label="us-gaap_DisposalGroupClassificationAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OneTimeTerminationBenefitsMember" xlink:type="locator" xlink:label="us-gaap_OneTimeTerminationBenefitsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractTerminationMember" xlink:type="locator" xlink:label="us-gaap_ContractTerminationMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:type="locator" xlink:label="us-gaap_TypeOfRestructuringDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:type="locator" xlink:label="us-gaap_TypeOfRestructuringDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:type="locator" xlink:label="us-gaap_RestructuringCostAndReserveAxis" />
    <loc xlink:href="mack-20180331.xsd#mack_JanuaryTwoThousandSeventeenCorporateRestructuringMember" xlink:type="locator" xlink:label="mack_JanuaryTwoThousandSeventeenCorporateRestructuringMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:type="locator" xlink:label="us-gaap_RestructuringPlanDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:type="locator" xlink:label="us-gaap_RestructuringPlanDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringPlanAxis" xlink:type="locator" xlink:label="us-gaap_RestructuringPlanAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="locator" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="locator" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="us-gaap_RestructuringPlanAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestructuringPlanAxis" xlink:to="us-gaap_RestructuringPlanDomain_2" order="10050.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestructuringPlanAxis" xlink:to="us-gaap_RestructuringPlanDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringPlanDomain" xlink:to="mack_JanuaryTwoThousandSeventeenCorporateRestructuringMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" order="10220.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain_2" order="10230.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" order="10250.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_ContractTerminationMember" order="10270.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_OneTimeTerminationBenefitsMember" order="10290.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="us-gaap_DisposalGroupClassificationAxis" order="10300.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DisposalGroupClassificationAxis" xlink:to="us-gaap_DisposalGroupClassificationDomain_2" order="10310.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DisposalGroupClassificationAxis" xlink:to="us-gaap_DisposalGroupClassificationDomain" order="10330.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisposalGroupClassificationDomain" xlink:to="us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" order="10350.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_RestructuringAndRelatedActivitiesInitiationDate" order="10380.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" order="10400.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_RestructuringCharges" order="10450.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDescription" order="10470.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" order="10510.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureInvestmentInSilverCreekAdditionalInformationDetail" xlink:href="mack-20180331.xsd#Role_DisclosureInvestmentInSilverCreekAdditionalInformationDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureInvestmentInSilverCreekAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="mack-20180331.xsd#mack_SilverCreekPharmaceuticalsIncMember" xlink:type="locator" xlink:label="mack_SilverCreekPharmaceuticalsIncMember" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:type="locator" xlink:label="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:type="locator" xlink:label="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:to="dei_LegalEntityAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="mack_SilverCreekPharmaceuticalsIncMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:to="us-gaap_RangeAxis" order="10100.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" order="10200.00" priority="2" use="optional" />
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>21
<FILENAME>mack-20180331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFS ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfsco.com/financial-services/ -->
<!-- Creation Date      : 2018-05-07T16:39:29.0829186+00:00 -->
<!-- Version            : 2.9.6605.1333 -->
<!-- Package ID         : 61e77818d95b40c390d461315935aff4 -->
<!-- Copyright (c) 2018 Donnelley Financial, LLC. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <loc xlink:href="mack-20180331.xsd#mack_DocumentAndEntityInformationAbstract" xlink:type="locator" xlink:label="mack_DocumentAndEntityInformationAbstract" />
    <label xml:lang="en-US" xlink:label="mack_DocumentAndEntityInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Document And Entity Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_DocumentAndEntityInformationAbstract" xlink:to="mack_DocumentAndEntityInformationAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="mack_DocumentAndEntityInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document And Entity Information [Abstract]</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</label>
    <label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Cash Equivalents Noncurrent</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" />
    <label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity method investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestments" xlink:to="us-gaap_EquityMethodInvestments_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investments</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Noncurrent</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and stockholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable, accrued expenses and other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable And Accrued Liabilities Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditCurrent" xlink:to="us-gaap_DeferredRentCreditCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Rent Credit Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditNoncurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent, net of current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Rent Credit Noncurrent</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities Noncurrent</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.01 par value: 10,000 shares authorized at March 31, 2018 and December 31, 2017; no shares issued or outstanding at March 31, 2018 or December 31, 2017</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.01 par value: 20,000 shares authorized at March 31, 2018 and December 31, 2017; 13,343 shares issued and outstanding at March 31, 2018 and December 31, 2017</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital Common Stock</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income Loss Net Of Tax</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Par Or Stated Value Per Share</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Authorized</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Issued</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Outstanding</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Income And Comprehensive Income [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from continuing operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income and expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income Expense [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income Interest</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <label xml:lang="en-US" xlink:label="us-gaap_InterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_InterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income Expense</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income and expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income Expense</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss from continuing operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Discontinued operations:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Discontinued Operations Net Of Tax [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss from discontinued operations, net of tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Discontinued Operations Net Of Tax</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss attributable to non-controlling interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss Attributable To Noncontrolling Interest</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss attributable to Merrimack Pharmaceuticals, Inc.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive loss:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized loss on marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Net Of Tax</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amounts attributable to Merrimack Pharmaceuticals, Inc.:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" xlink:to="us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Amounts Attributable To Reporting Entity Disclosures [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperations" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss from continuing operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperations" xlink:to="us-gaap_IncomeLossFromContinuingOperations_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss from discontinued operations, net of tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic and dilutive net loss per common share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss from continuing operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations Per Basic And Diluted Share</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss from discontinued operations, net of tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average common shares used per share calculations&#8212;basic and diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</label>
    <loc xlink:href="mack-20180331.xsd#mack_PremiumsPaidOnMarketableSecurities" xlink:type="locator" xlink:label="mack_PremiumsPaidOnMarketableSecurities" />
    <label xml:lang="en-US" xlink:label="mack_PremiumsPaidOnMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Premiums paid on marketable securities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_PremiumsPaidOnMarketableSecurities" xlink:to="mack_PremiumsPaidOnMarketableSecurities_lbl" />
    <loc xlink:href="mack-20180331.xsd#mack_AmortizationAndAccretionOnMarketableSecurities" xlink:type="locator" xlink:label="mack_AmortizationAndAccretionOnMarketableSecurities" />
    <label xml:lang="en-US" xlink:label="mack_AmortizationAndAccretionOnMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amortization and accretion on marketable securities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_AmortizationAndAccretionOnMarketableSecurities" xlink:to="mack_AmortizationAndAccretionOnMarketableSecurities_lbl" />
    <loc xlink:href="mack-20180331.xsd#mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees" xlink:type="locator" xlink:label="mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees" />
    <label xml:lang="en-US" xlink:label="mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and nonemployees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees" xlink:to="mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees_lbl" />
    <loc xlink:href="mack-20180331.xsd#mack_IncreaseDecreaseInDeferredRent" xlink:type="locator" xlink:label="mack_IncreaseDecreaseInDeferredRent" />
    <label xml:lang="en-US" xlink:label="mack_IncreaseDecreaseInDeferredRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in deferred rent.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_IncreaseDecreaseInDeferredRent" xlink:to="mack_IncreaseDecreaseInDeferredRent_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <label xml:lang="en-US" xlink:label="dei_LegalEntityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal Entity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" />
    <label xml:lang="en-US" xlink:label="dei_LegalEntityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity [Axis]</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <label xml:lang="en-US" xlink:label="dei_EntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" />
    <label xml:lang="en-US" xlink:label="dei_EntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity [Domain]</label>
    <loc xlink:href="mack-20180331.xsd#mack_SilverCreekPharmaceuticalsIncMember" xlink:type="locator" xlink:label="mack_SilverCreekPharmaceuticalsIncMember" />
    <label xml:lang="en-US" xlink:label="mack_SilverCreekPharmaceuticalsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Subsidiary of the Company.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_SilverCreekPharmaceuticalsIncMember" xlink:to="mack_SilverCreekPharmaceuticalsIncMember_lbl" />
    <label xml:lang="en-US" xlink:label="mack_SilverCreekPharmaceuticalsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Silver Creek Pharmaceuticals Inc [Member]</label>
    <label xml:lang="en-US" xlink:label="mack_SilverCreekPharmaceuticalsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Silver Creek Pharmaceuticals Inc [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</label>
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Loss from continuing operations</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaidInKindInterest" xlink:type="locator" xlink:label="us-gaap_PaidInKindInterest" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaidInKindInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaidInKindInterest" xlink:to="us-gaap_PaidInKindInterest_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaidInKindInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Paid In Kind Interest</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <label xml:lang="en-US" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation Depletion And Amortization</label>
    <label xml:lang="en-US" xlink:label="mack_PremiumsPaidOnMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Premiums paid on marketable securities</label>
    <label xml:lang="en-US" xlink:label="mack_PremiumsPaidOnMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Premiums Paid On Marketable Securities</label>
    <label xml:lang="en-US" xlink:label="mack_AmortizationAndAccretionOnMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Amortization and accretion on marketable securities</label>
    <label xml:lang="en-US" xlink:label="mack_AmortizationAndAccretionOnMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amortization And Accretion On Marketable Securities</label>
    <label xml:lang="en-US" xlink:label="mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</label>
    <label xml:lang="en-US" xlink:label="mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense Including Non Employees</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfEquityInvestments" xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfEquityInvestments" />
    <label xml:lang="en-US" xlink:label="us-gaap_GainLossOnSaleOfEquityInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss on equity method investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfEquityInvestments" xlink:to="us-gaap_GainLossOnSaleOfEquityInvestments_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_GainLossOnSaleOfEquityInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Gain Loss On Sale Of Equity Investments</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Deferred Expense And Other Assets</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable, accrued expenses and other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable And Accrued Liabilities</label>
    <label xml:lang="en-US" xlink:label="mack_IncreaseDecreaseInDeferredRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent</label>
    <label xml:lang="en-US" xlink:label="mack_IncreaseDecreaseInDeferredRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Deferred Rent</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in continuing operations for operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities Continuing Operations</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net cash provided by discontinuing operations for operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided By Used In Operating Activities Discontinued Operations</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property Plant And Equipment</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Marketable Securities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of options to purchase common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Stock Options Exercised</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of Series C preferred stock by Silver Creek Pharmaceuticals, Inc., net of issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Preferred Stock And Preference Stock</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities Continuing Operations</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net decrease in cash, cash equivalents and restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash, beginning of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents</label>
    <label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash, end of period</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash investing and financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Investing And Financing Items [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <label xml:lang="en-US" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchases of property and equipment in accounts payable, accrued expenses and other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred But Not Yet Paid</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" xlink:type="locator" xlink:label="us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" />
    <label xml:lang="en-US" xlink:label="us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Receivables related to property and equipment sale in other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" xlink:to="us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Or Part Noncash Divestiture Amount Of Consideration Received1</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of cash flows</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaid" xlink:type="locator" xlink:label="us-gaap_InterestPaid" />
    <label xml:lang="en-US" xlink:label="us-gaap_InterestPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_InterestPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NatureOfOperations" xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" />
    <label xml:lang="en-US" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature of the Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nature Of Operations</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investments Debt And Equity Securities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents And Marketable Securities [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payables And Accruals [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Payable, Accrued Expenses and Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable And Accrued Liabilities Disclosure [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Common Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Discontinued Operations And Disposal Groups [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Discontinued Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Groups Including Discontinued Operations Disclosure [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncontrollingInterestAbstract" xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_NoncontrollingInterestAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncontrolling Interest [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestAbstract" xlink:to="us-gaap_NoncontrollingInterestAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterestDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_MinorityInterestDisclosureTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_MinorityInterestDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment in Silver Creek</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestDisclosureTextBlock" xlink:to="us-gaap_MinorityInterestDisclosureTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_MinorityInterestDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minority Interest Disclosure [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Changes And Error Corrections [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements And Changes In Accounting Principles [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Accounting Policy Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consolidation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation Policy [Text Block]</label>
    <loc xlink:href="mack-20180331.xsd#mack_UnauditedInterimFinancialInformationPolicyTextBlock" xlink:type="locator" xlink:label="mack_UnauditedInterimFinancialInformationPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="mack_UnauditedInterimFinancialInformationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Unaudited interim financial information.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_UnauditedInterimFinancialInformationPolicyTextBlock" xlink:to="mack_UnauditedInterimFinancialInformationPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="mack_UnauditedInterimFinancialInformationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unaudited Interim Financial Information</label>
    <label xml:lang="en-US" xlink:label="mack_UnauditedInterimFinancialInformationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unaudited Interim Financial Information Policy [Text Block]</label>
    <loc xlink:href="mack-20180331.xsd#mack_CondensedConsolidatedStatementsOfCashFlowsPolicyTextBlock" xlink:type="locator" xlink:label="mack_CondensedConsolidatedStatementsOfCashFlowsPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="mack_CondensedConsolidatedStatementsOfCashFlowsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Condensed consolidated statements of cash flows.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_CondensedConsolidatedStatementsOfCashFlowsPolicyTextBlock" xlink:to="mack_CondensedConsolidatedStatementsOfCashFlowsPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="mack_CondensedConsolidatedStatementsOfCashFlowsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Condensed Consolidated Statements of Cash Flows</label>
    <label xml:lang="en-US" xlink:label="mack_CondensedConsolidatedStatementsOfCashFlowsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Condensed Consolidated Statements Of Cash Flows Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MarketableSecuritiesAvailableForSaleSecuritiesPolicy" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesAvailableForSaleSecuritiesPolicy" />
    <label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesAvailableForSaleSecuritiesPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesAvailableForSaleSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesAvailableForSaleSecuritiesPolicy_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesAvailableForSaleSecuritiesPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Available For Sale Securities Policy</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy Policy [Text Block]</label>
    <loc xlink:href="mack-20180331.xsd#mack_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:type="locator" xlink:label="mack_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" />
    <label xml:lang="en-US" xlink:label="mack_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of cash, cash equivalents and restricted cash.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:to="mack_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="mack_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</label>
    <label xml:lang="en-US" xlink:label="mack_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Cash Cash Equivalents And Restricted Cash Table [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Assets Measured at Fair Value on a Recurring Basis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Measured On Recurring Basis [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Marketable Securities and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Available For Sale Securities Reconciliation Table [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accounts Payable, Accrued Expenses and Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accounts Payable And Accrued Liabilities Table [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Assumptions Used to Calculate Fair Value of Options Granted to Employees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</label>
    <loc xlink:href="mack-20180331.xsd#mack_ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock" xlink:type="locator" xlink:label="mack_ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock" />
    <label xml:lang="en-US" xlink:label="mack_ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tabular disclosure of employee and nonemployee service share based compensation allocation of recognized period costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock" xlink:to="mack_ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</label>
    <label xml:lang="en-US" xlink:label="mack_ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Recognized Stock-Based Compensation Expense</label>
    <label xml:lang="en-US" xlink:label="mack_ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee And Nonemployee Service Share Based Compensation Allocation Of Recognized Period Costs Table [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Outstanding Securities Excluded from Computation of Diluted Loss Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Discontinued Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Disposal Groups Including Discontinued Operations Income Statement Balance Sheet And Additional Disclosures [Text Block]</label>
    <loc xlink:href="mack-20180331.xsd#mack_NumberOfDevelopmentProgramsActive" xlink:type="locator" xlink:label="mack_NumberOfDevelopmentProgramsActive" />
    <label xml:lang="en-US" xlink:label="mack_NumberOfDevelopmentProgramsActive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of development programs active.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_NumberOfDevelopmentProgramsActive" xlink:to="mack_NumberOfDevelopmentProgramsActive_lbl" />
    <label xml:lang="en-US" xlink:label="mack_NumberOfDevelopmentProgramsActive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of development programs active</label>
    <label xml:lang="en-US" xlink:label="mack_NumberOfDevelopmentProgramsActive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Development Programs Active</label>
    <label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</label>
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net loss from continuing operations</label>
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cash in continuing operations for operating activities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents and marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents And Short Term Investments</label>
    <loc xlink:href="mack-20180331.xsd#mack_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="mack_SummaryOfSignificantAccountingPoliciesLineItems" />
    <label xml:lang="en-US" xlink:label="mack_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="mack_SummaryOfSignificantAccountingPoliciesLineItems_lbl" />
    <loc xlink:href="mack-20180331.xsd#mack_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="mack_SummaryOfSignificantAccountingPoliciesTable" />
    <label xml:lang="en-US" xlink:label="mack_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_SummaryOfSignificantAccountingPoliciesTable" xlink:to="mack_SummaryOfSignificantAccountingPoliciesTable_lbl" />
    <label xml:lang="en-US" xlink:label="mack_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Table]</label>
    <label xml:lang="en-US" xlink:label="mack_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_RangeMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="us-gaap_MinimumMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</label>
    <label xml:lang="en-US" xlink:label="mack_SilverCreekPharmaceuticalsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Silver Creek Pharmaceuticals Inc [Member]</label>
    <label xml:lang="en-US" xlink:label="mack_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Line Items]</label>
    <label xml:lang="en-US" xlink:label="mack_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" />
    <label xml:lang="en-US" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ownership interest (as a percent)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minority Interest Ownership Percentage By Parent</label>
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Discontinued operations</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" />
    <loc xlink:href="mack-20180331.xsd#mack_CashCashEquivalentsAndRestrictedCashLineItems" xlink:type="locator" xlink:label="mack_CashCashEquivalentsAndRestrictedCashLineItems" />
    <label xml:lang="en-US" xlink:label="mack_CashCashEquivalentsAndRestrictedCashLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash, cash equivalents and restricted cash.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_CashCashEquivalentsAndRestrictedCashLineItems" xlink:to="mack_CashCashEquivalentsAndRestrictedCashLineItems_lbl" />
    <loc xlink:href="mack-20180331.xsd#mack_CashCashEquivalentsAndRestrictedCashTable" xlink:type="locator" xlink:label="mack_CashCashEquivalentsAndRestrictedCashTable" />
    <label xml:lang="en-US" xlink:label="mack_CashCashEquivalentsAndRestrictedCashTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash, cash equivalents and restricted cash.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_CashCashEquivalentsAndRestrictedCashTable" xlink:to="mack_CashCashEquivalentsAndRestrictedCashTable_lbl" />
    <label xml:lang="en-US" xlink:label="mack_CashCashEquivalentsAndRestrictedCashTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Cash Equivalents And Restricted Cash [Table]</label>
    <label xml:lang="en-US" xlink:label="mack_CashCashEquivalentsAndRestrictedCashTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents And Restricted Cash [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="locator" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid Expenses and Other Current Assets [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expenses And Other Current Assets [Member]</label>
    <label xml:lang="en-US" xlink:label="mack_CashCashEquivalentsAndRestrictedCashLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Cash Equivalents And Restricted Cash [Line Items]</label>
    <label xml:lang="en-US" xlink:label="mack_CashCashEquivalentsAndRestrictedCashLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents And Restricted Cash [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash (short term)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted cash (long term)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash Noncurrent</label>
    <label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total cash, cash equivalents and restricted cash shown in the condensed consolidated statement of cash flows</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Measurement Frequency [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Measurement Frequency</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Frequency [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recurring Basis [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Recurring [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Fair Value Hierarchy Level [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Fair Value Hierarchy [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level1 [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level2 [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level3 [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Asset Class [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Debt Securities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Debt Securities [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Paper [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Paper [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper Not Included With Cash And Cash Equivalents [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:type="locator" xlink:label="us-gaap_USTreasuryAndGovernmentMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_USTreasuryAndGovernmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Government Securites [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasuryAndGovernmentMember" xlink:to="us-gaap_USTreasuryAndGovernmentMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_USTreasuryAndGovernmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">U S Treasury And Government [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Fair Value Disclosure</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecurities" />
    <label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecurities" xlink:to="us-gaap_AvailableForSaleSecurities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersDescription" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersDescription" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value transfers between Level 1 and Level 2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsLevel1ToLevel2TransfersDescription" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersDescription_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Level1 To Level2 Transfers Description</label>
    <loc xlink:href="mack-20180331.xsd#mack_AmortizedCostAndFairValueDebtSecuritiesAbstract" xlink:type="locator" xlink:label="mack_AmortizedCostAndFairValueDebtSecuritiesAbstract" />
    <label xml:lang="en-US" xlink:label="mack_AmortizedCostAndFairValueDebtSecuritiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amortized Cost and Fair Value Debt Securities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_AmortizedCostAndFairValueDebtSecuritiesAbstract" xlink:to="mack_AmortizedCostAndFairValueDebtSecuritiesAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="mack_AmortizedCostAndFairValueDebtSecuritiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amortized Cost And Fair Value Debt Securities [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MarketableSecurities" xlink:type="locator" xlink:label="us-gaap_MarketableSecurities" />
    <label xml:lang="en-US" xlink:label="us-gaap_MarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecurities" xlink:to="us-gaap_MarketableSecurities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_MarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Available For Sale Securities [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Available For Sale Securities [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:type="locator" xlink:label="us-gaap_InformationByCategoryOfDebtSecurityAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_InformationByCategoryOfDebtSecurityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Security Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:to="us-gaap_InformationByCategoryOfDebtSecurityAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_InformationByCategoryOfDebtSecurityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Information By Category Of Debt Security [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:type="locator" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:to="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Than Temporary Impairment Credit Losses Recognized In Earnings Categories Of Investments [Domain]</label>
    <loc xlink:href="mack-20180331.xsd#mack_MarketableSecuritiesMember" xlink:type="locator" xlink:label="mack_MarketableSecuritiesMember" />
    <label xml:lang="en-US" xlink:label="mack_MarketableSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Marketable Securities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_MarketableSecuritiesMember" xlink:to="mack_MarketableSecuritiesMember_lbl" />
    <label xml:lang="en-US" xlink:label="mack_MarketableSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities [Member]</label>
    <label xml:lang="en-US" xlink:label="mack_MarketableSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_CashEquivalentsMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Equivalents [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type Categorization [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Government Securities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">U S Government Agencies Debt Securities [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Available For Sale Securities [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Available For Sale Securities [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Amortized Cost Basis</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized Losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities</label>
    <loc xlink:href="mack-20180331.xsd#mack_AccruedClinicalTrialCosts" xlink:type="locator" xlink:label="mack_AccruedClinicalTrialCosts" />
    <label xml:lang="en-US" xlink:label="mack_AccruedClinicalTrialCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Carrying value as of the balance sheet date of obligations incurred through that date arising from ongoing clinical trial activity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_AccruedClinicalTrialCosts" xlink:to="mack_AccruedClinicalTrialCosts_lbl" />
    <loc xlink:href="mack-20180331.xsd#mack_AccruedDrugPurchaseCostsCurrent" xlink:type="locator" xlink:label="mack_AccruedDrugPurchaseCostsCurrent" />
    <label xml:lang="en-US" xlink:label="mack_AccruedDrugPurchaseCostsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued drug purchase costs current.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_AccruedDrugPurchaseCostsCurrent" xlink:to="mack_AccruedDrugPurchaseCostsCurrent_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued goods and services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Current</label>
    <label xml:lang="en-US" xlink:label="mack_AccruedClinicalTrialCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accrued clinical trial costs</label>
    <label xml:lang="en-US" xlink:label="mack_AccruedClinicalTrialCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Clinical Trial Costs</label>
    <label xml:lang="en-US" xlink:label="mack_AccruedDrugPurchaseCostsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued drug purchase costs</label>
    <label xml:lang="en-US" xlink:label="mack_AccruedDrugPurchaseCostsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Drug Purchase Costs Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued payroll and related benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Related Liabilities Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserveCurrent" xlink:type="locator" xlink:label="us-gaap_RestructuringReserveCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestructuringReserveCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued restructuring expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringReserveCurrent" xlink:to="us-gaap_RestructuringReserveCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestructuringReserveCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Reserve Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax incentives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" xlink:to="us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Credits And Other Liabilities Current</label>
    <label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accounts payable, accrued expenses and other</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</label>
    <loc xlink:href="mack-20180331.xsd#mack_StockIncentivePlan2011Member" xlink:type="locator" xlink:label="mack_StockIncentivePlan2011Member" />
    <label xml:lang="en-US" xlink:label="mack_StockIncentivePlan2011Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Detail of the plan under which options are granted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_StockIncentivePlan2011Member" xlink:to="mack_StockIncentivePlan2011Member_lbl" />
    <label xml:lang="en-US" xlink:label="mack_StockIncentivePlan2011Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Incentive Plan 2011 [Member]</label>
    <label xml:lang="en-US" xlink:label="mack_StockIncentivePlan2011Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Incentive Plan2011 [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_TitleOfIndividualAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_TitleOfIndividualAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Relationship to Entity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual With Relationship To Entity [Domain]</label>
    <loc xlink:href="mack-20180331.xsd#mack_EmployeeMember" xlink:type="locator" xlink:label="mack_EmployeeMember" />
    <label xml:lang="en-US" xlink:label="mack_EmployeeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_EmployeeMember" xlink:to="mack_EmployeeMember_lbl" />
    <label xml:lang="en-US" xlink:label="mack_EmployeeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee [Member]</label>
    <label xml:lang="en-US" xlink:label="mack_EmployeeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares of common stock available for grant (in shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options vesting period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Award</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options to Purchase Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense for employee awards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</label>
    <label xml:lang="en-US" xlink:label="mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stock-based compensation expense</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Options, Outstanding, Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period</label>
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Options, Outstanding, Ending balance</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options, Vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted-Average Exercise Price, Outstanding, Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price</label>
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted-Average Exercise Price, Outstanding, Ending balance</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price, Vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Term, Vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Term, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average grant date fair value per share of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value of options exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation expense related to nonvested stock awards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average period over which unrecognized stock-based compensation expense is expected to be recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</label>
    <loc xlink:href="mack-20180331.xsd#mack_UndistributedEarningsLossAllocatedToParticipatingSecurities" xlink:type="locator" xlink:label="mack_UndistributedEarningsLossAllocatedToParticipatingSecurities" />
    <label xml:lang="en-US" xlink:label="mack_UndistributedEarningsLossAllocatedToParticipatingSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Undistributed earnings (loss) allocated to participating securities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_UndistributedEarningsLossAllocatedToParticipatingSecurities" xlink:to="mack_UndistributedEarningsLossAllocatedToParticipatingSecurities_lbl" />
    <loc xlink:href="mack-20180331.xsd#mack_ParticipatingSecuritiesOutstandingShares" xlink:type="locator" xlink:label="mack_ParticipatingSecuritiesOutstandingShares" />
    <label xml:lang="en-US" xlink:label="mack_ParticipatingSecuritiesOutstandingShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Participating securities outstanding shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_ParticipatingSecuritiesOutstandingShares" xlink:to="mack_ParticipatingSecuritiesOutstandingShares_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Debt, Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Longterm Debt Type [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Debt, Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Longterm Debt Type [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_ConvertibleDebtMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Notes [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtMember" xlink:to="us-gaap_ConvertibleDebtMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ConvertibleDebtMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Debt [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</label>
    <label xml:lang="en-US" xlink:label="mack_UndistributedEarningsLossAllocatedToParticipatingSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amounts allocated to participating securities</label>
    <label xml:lang="en-US" xlink:label="mack_UndistributedEarningsLossAllocatedToParticipatingSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Undistributed Earnings Loss Allocated To Participating Securities</label>
    <label xml:lang="en-US" xlink:label="mack_ParticipatingSecuritiesOutstandingShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Participating securities outstanding, shares</label>
    <label xml:lang="en-US" xlink:label="mack_ParticipatingSecuritiesOutstandingShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Participating Securities Outstanding Shares</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest rate (as a percent)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Interest Rate Stated Percentage</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Name [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:type="locator" xlink:label="us-gaap_StockCompensationPlanMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockCompensationPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding Options to Purchase Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockCompensationPlanMember" xlink:to="us-gaap_StockCompensationPlanMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockCompensationPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Compensation Plan [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of the Convertible Notes [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Debt Securities [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding securities excluded from calculation of diluted loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</label>
    <loc xlink:href="mack-20180331.xsd#mack_DisposalGroupIncludingDiscontinuedOperationProductRevenuesNet" xlink:type="locator" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationProductRevenuesNet" />
    <label xml:lang="en-US" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationProductRevenuesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disposal group including discontinued operation product revenues net.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_DisposalGroupIncludingDiscontinuedOperationProductRevenuesNet" xlink:to="mack_DisposalGroupIncludingDiscontinuedOperationProductRevenuesNet_lbl" />
    <loc xlink:href="mack-20180331.xsd#mack_DisposalGroupIncludingDiscontinuedOperationLicenseAndCollaborationRevenues" xlink:type="locator" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationLicenseAndCollaborationRevenues" />
    <label xml:lang="en-US" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationLicenseAndCollaborationRevenues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disposal group including discontinued operation license and collaboration revenues.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_DisposalGroupIncludingDiscontinuedOperationLicenseAndCollaborationRevenues" xlink:to="mack_DisposalGroupIncludingDiscontinuedOperationLicenseAndCollaborationRevenues_lbl" />
    <loc xlink:href="mack-20180331.xsd#mack_DisposalGroupIncludingDiscontinuedOperationOtherRevenue" xlink:type="locator" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationOtherRevenue" />
    <label xml:lang="en-US" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationOtherRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disposal group including discontinued operation other revenue.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_DisposalGroupIncludingDiscontinuedOperationOtherRevenue" xlink:to="mack_DisposalGroupIncludingDiscontinuedOperationOtherRevenue_lbl" />
    <loc xlink:href="mack-20180331.xsd#mack_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses" xlink:type="locator" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses" />
    <label xml:lang="en-US" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disposal group including discontinued operation research and development expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses" xlink:to="mack_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses_lbl" />
    <loc xlink:href="mack-20180331.xsd#mack_DisposalGroupIncludingDiscontinuedOperationRestructuringExpenses" xlink:type="locator" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationRestructuringExpenses" />
    <label xml:lang="en-US" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationRestructuringExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disposal group including discontinued operation restructuring expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_DisposalGroupIncludingDiscontinuedOperationRestructuringExpenses" xlink:to="mack_DisposalGroupIncludingDiscontinuedOperationRestructuringExpenses_lbl" />
    <loc xlink:href="mack-20180331.xsd#mack_DisposalGroupIncludingDiscontinuedOperationRevenueAbstract" xlink:type="locator" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationRevenueAbstract" />
    <label xml:lang="en-US" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationRevenueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disposal group including discontinued operation revenue.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_DisposalGroupIncludingDiscontinuedOperationRevenueAbstract" xlink:to="mack_DisposalGroupIncludingDiscontinuedOperationRevenueAbstract_lbl" />
    <loc xlink:href="mack-20180331.xsd#mack_DisposalGroupIncludingDiscontinuedOperationCostAndExpensesAbstract" xlink:type="locator" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationCostAndExpensesAbstract" />
    <label xml:lang="en-US" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationCostAndExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disposal group including discontinued operation cost and expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_DisposalGroupIncludingDiscontinuedOperationCostAndExpensesAbstract" xlink:to="mack_DisposalGroupIncludingDiscontinuedOperationCostAndExpensesAbstract_lbl" />
    <loc xlink:href="mack-20180331.xsd#mack_DisposalGroupIncludingDiscontinuedOperationOtherIncomeAndExpensesAbstract" xlink:type="locator" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationOtherIncomeAndExpensesAbstract" />
    <label xml:lang="en-US" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationOtherIncomeAndExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disposal group including discontinued operation other income and expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_DisposalGroupIncludingDiscontinuedOperationOtherIncomeAndExpensesAbstract" xlink:to="mack_DisposalGroupIncludingDiscontinuedOperationOtherIncomeAndExpensesAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="locator" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disposal Group Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="locator" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disposal Group Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Groups Including Discontinued Operations Name [Domain]</label>
    <loc xlink:href="mack-20180331.xsd#mack_CommercialBusinessMember" xlink:type="locator" xlink:label="mack_CommercialBusinessMember" />
    <label xml:lang="en-US" xlink:label="mack_CommercialBusinessMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercial business.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_CommercialBusinessMember" xlink:to="mack_CommercialBusinessMember_lbl" />
    <label xml:lang="en-US" xlink:label="mack_CommercialBusinessMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Business [Member]</label>
    <label xml:lang="en-US" xlink:label="mack_CommercialBusinessMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Business [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="locator" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</label>
    <label xml:lang="en-US" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationRevenueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenues:</label>
    <label xml:lang="en-US" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationRevenueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group Including Discontinued Operation Revenue [Abstract]</label>
    <label xml:lang="en-US" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationProductRevenuesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product revenues, net</label>
    <label xml:lang="en-US" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationProductRevenuesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group Including Discontinued Operation Product Revenues Net</label>
    <label xml:lang="en-US" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationLicenseAndCollaborationRevenues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License and collaboration revenues</label>
    <label xml:lang="en-US" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationLicenseAndCollaborationRevenues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group Including Discontinued Operation License And Collaboration Revenues</label>
    <label xml:lang="en-US" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationOtherRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other revenues</label>
    <label xml:lang="en-US" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationOtherRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group Including Discontinued Operation Other Revenue</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group Including Discontinued Operation Revenue</label>
    <label xml:lang="en-US" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationCostAndExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Costs and expenses:</label>
    <label xml:lang="en-US" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationCostAndExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group Including Discontinued Operation Cost And Expenses [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group Including Discontinued Operation Costs Of Goods Sold</label>
    <label xml:lang="en-US" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expenses</label>
    <label xml:lang="en-US" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group Including Discontinued Operation Research And Development Expenses</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling, general and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group Including Discontinued Operation General And Administrative Expense</label>
    <label xml:lang="en-US" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationRestructuringExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring expenses</label>
    <label xml:lang="en-US" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationRestructuringExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group Including Discontinued Operation Restructuring Expenses</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total costs and expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group Including Discontinued Operation Operating Expense</label>
    <label xml:lang="en-US" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationOtherIncomeAndExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income and expenses:</label>
    <label xml:lang="en-US" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationOtherIncomeAndExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group Including Discontinued Operation Other Income And Expenses [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group Including Discontinued Operation Interest Expense</label>
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from discontinued operations</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringPlanAxis" xlink:type="locator" xlink:label="us-gaap_RestructuringPlanAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestructuringPlanAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringPlanAxis" xlink:to="us-gaap_RestructuringPlanAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestructuringPlanAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Plan [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:type="locator" xlink:label="us-gaap_RestructuringPlanDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestructuringPlanDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringPlanDomain" xlink:to="us-gaap_RestructuringPlanDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestructuringPlanDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Plan [Domain]</label>
    <loc xlink:href="mack-20180331.xsd#mack_JanuaryTwoThousandSeventeenCorporateRestructuringMember" xlink:type="locator" xlink:label="mack_JanuaryTwoThousandSeventeenCorporateRestructuringMember" />
    <label xml:lang="en-US" xlink:label="mack_JanuaryTwoThousandSeventeenCorporateRestructuringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">January two thousand seventeen corporate restructuring.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_JanuaryTwoThousandSeventeenCorporateRestructuringMember" xlink:to="mack_JanuaryTwoThousandSeventeenCorporateRestructuringMember_lbl" />
    <label xml:lang="en-US" xlink:label="mack_JanuaryTwoThousandSeventeenCorporateRestructuringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">January 2017 Corporate Restructuring [Member]</label>
    <label xml:lang="en-US" xlink:label="mack_JanuaryTwoThousandSeventeenCorporateRestructuringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">January Two Thousand Seventeen Corporate Restructuring [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:type="locator" xlink:label="us-gaap_RestructuringCostAndReserveAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestructuringCostAndReserveAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_RestructuringCostAndReserveAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestructuringCostAndReserveAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Cost And Reserve [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:type="locator" xlink:label="us-gaap_TypeOfRestructuringDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_TypeOfRestructuringDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Type of Restructuring</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_TypeOfRestructuringDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_TypeOfRestructuringDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Restructuring [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractTerminationMember" xlink:type="locator" xlink:label="us-gaap_ContractTerminationMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_ContractTerminationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contractual Termination Benefits [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractTerminationMember" xlink:to="us-gaap_ContractTerminationMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ContractTerminationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract Termination [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OneTimeTerminationBenefitsMember" xlink:type="locator" xlink:label="us-gaap_OneTimeTerminationBenefitsMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_OneTimeTerminationBenefitsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">One-time Employee Termination Benefits [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OneTimeTerminationBenefitsMember" xlink:to="us-gaap_OneTimeTerminationBenefitsMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OneTimeTerminationBenefitsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">One Time Termination Benefits [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:type="locator" xlink:label="us-gaap_DisposalGroupClassificationAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupClassificationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disposal Group Classification</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupClassificationAxis" xlink:to="us-gaap_DisposalGroupClassificationAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupClassificationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group Classification [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:type="locator" xlink:label="us-gaap_DisposalGroupClassificationDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupClassificationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disposal Group Classification</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupClassificationDomain" xlink:to="us-gaap_DisposalGroupClassificationDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupClassificationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group Classification [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Discontinued Operations [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:to="us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Discontinued Operations Disposed Of By Sale [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesInitiationDate" xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedActivitiesInitiationDate" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestructuringAndRelatedActivitiesInitiationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring activity, announcement date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesInitiationDate" xlink:to="us-gaap_RestructuringAndRelatedActivitiesInitiationDate_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestructuringAndRelatedActivitiesInitiationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring And Related Activities Initiation Date</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reduction in headcount, percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring And Related Cost Number Of Positions Eliminated Period Percent</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCharges" xlink:type="locator" xlink:label="us-gaap_RestructuringCharges" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCharges" xlink:to="us-gaap_RestructuringCharges_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Charges</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDescription" xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDescription" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring activities, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesDescription" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDescription_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring And Related Activities Description</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:type="locator" xlink:label="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Effects Of Changes Net [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:to="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Effects Of Changes Net [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:type="locator" xlink:label="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Effects Of Changes Net [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Effects Of Changes Net [Line Items]</label>
    <label xml:lang="en-US" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Ownership interest percentage held by parent</label>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>22
<FILENAME>mack-20180331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFS ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfsco.com/financial-services/ -->
<!-- Creation Date      : 2018-05-07T16:39:29.0829186+00:00 -->
<!-- Version            : 2.9.6605.1333 -->
<!-- Package ID         : 61e77818d95b40c390d461315935aff4 -->
<!-- Copyright (c) 2018 Donnelley Financial, LLC. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef roleURI="http://www.merrimackpharma.com/20180331/role/TemplateLink" xlink:href="mack-20180331.xsd#TemplateLink" xlink:type="simple" />
  <roleRef roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="mack-20180331.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20180331/taxonomy/role/DocumentDocumentAndEntityInformation">
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <loc xlink:href="mack-20180331.xsd#mack_DocumentAndEntityInformationAbstract" xlink:type="locator" xlink:label="mack_DocumentAndEntityInformationAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_DocumentAndEntityInformationAbstract" xlink:to="dei_TradingSymbol" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_DocumentAndEntityInformationAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFilerCategory" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" xlink:href="mack-20180331.xsd#Role_StatementCondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20180331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_EquityMethodInvestments" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRentCreditCurrent" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:href="mack-20180331.xsd#Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20180331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="mack-20180331.xsd#Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20180331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ProfitLoss" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperations" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" xlink:to="us-gaap_NetIncomeLoss" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="11500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="11540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:href="mack-20180331.xsd#Role_StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20180331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaid" xlink:type="locator" xlink:label="us-gaap_InterestPaid" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" xlink:type="locator" xlink:label="us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_li0l2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <loc xlink:href="mack-20180331.xsd#mack_IncreaseDecreaseInDeferredRent" xlink:type="locator" xlink:label="mack_IncreaseDecreaseInDeferredRent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfEquityInvestments" xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfEquityInvestments" />
    <loc xlink:href="mack-20180331.xsd#mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees" xlink:type="locator" xlink:label="mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees" />
    <loc xlink:href="mack-20180331.xsd#mack_AmortizationAndAccretionOnMarketableSecurities" xlink:type="locator" xlink:label="mack_AmortizationAndAccretionOnMarketableSecurities" />
    <loc xlink:href="mack-20180331.xsd#mack_PremiumsPaidOnMarketableSecurities" xlink:type="locator" xlink:label="mack_PremiumsPaidOnMarketableSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaidInKindInterest" xlink:type="locator" xlink:label="us-gaap_PaidInKindInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <loc xlink:href="mack-20180331.xsd#mack_SilverCreekPharmaceuticalsIncMember" xlink:type="locator" xlink:label="mack_SilverCreekPharmaceuticalsIncMember" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="mack_SilverCreekPharmaceuticalsIncMember" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_PaidInKindInterest" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="mack_PremiumsPaidOnMarketableSecurities" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="mack_AmortizationAndAccretionOnMarketableSecurities" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfEquityInvestments" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="mack_IncreaseDecreaseInDeferredRent" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="11380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="11500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="11540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="11580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="11620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_li0l2" order="11660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="11700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="11780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" order="11820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="11860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaid" order="11940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureNatureOfBusiness" xlink:href="mack-20180331.xsd#Role_DisclosureNatureOfBusiness" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureNatureOfBusiness">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NatureOfOperations" xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="mack-20180331.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureFairValueOfFinancialInstruments" xlink:href="mack-20180331.xsd#Role_DisclosureFairValueOfFinancialInstruments" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureFairValueOfFinancialInstruments">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureMarketableSecuritiesAndCashEquivalents" xlink:href="mack-20180331.xsd#Role_DisclosureMarketableSecuritiesAndCashEquivalents" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureMarketableSecuritiesAndCashEquivalents">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureAccountsPayableAccruedExpensesAndOther" xlink:href="mack-20180331.xsd#Role_DisclosureAccountsPayableAccruedExpensesAndOther" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureAccountsPayableAccruedExpensesAndOther">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureStockBasedCompensation" xlink:href="mack-20180331.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureStockBasedCompensation">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureNetLossPerCommonShare" xlink:href="mack-20180331.xsd#Role_DisclosureNetLossPerCommonShare" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureNetLossPerCommonShare">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureDiscontinuedOperations" xlink:href="mack-20180331.xsd#Role_DisclosureDiscontinuedOperations" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureDiscontinuedOperations">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureInvestmentInSilverCreek" xlink:href="mack-20180331.xsd#Role_DisclosureInvestmentInSilverCreek" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureInvestmentInSilverCreek">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterestDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_MinorityInterestDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncontrollingInterestAbstract" xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncontrollingInterestAbstract" xlink:to="us-gaap_MinorityInterestDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureRecentAccountingPronouncements" xlink:href="mack-20180331.xsd#Role_DisclosureRecentAccountingPronouncements" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureRecentAccountingPronouncements">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="mack-20180331.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MarketableSecuritiesAvailableForSaleSecuritiesPolicy" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesAvailableForSaleSecuritiesPolicy" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <loc xlink:href="mack-20180331.xsd#mack_CondensedConsolidatedStatementsOfCashFlowsPolicyTextBlock" xlink:type="locator" xlink:label="mack_CondensedConsolidatedStatementsOfCashFlowsPolicyTextBlock" />
    <loc xlink:href="mack-20180331.xsd#mack_UnauditedInterimFinancialInformationPolicyTextBlock" xlink:type="locator" xlink:label="mack_UnauditedInterimFinancialInformationPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="mack_UnauditedInterimFinancialInformationPolicyTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="mack_CondensedConsolidatedStatementsOfCashFlowsPolicyTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesAvailableForSaleSecuritiesPolicy" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="mack-20180331.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables">
    <loc xlink:href="mack-20180331.xsd#mack_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:type="locator" xlink:label="mack_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="mack_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsTables" xlink:href="mack-20180331.xsd#Role_DisclosureFairValueOfFinancialInstrumentsTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureMarketableSecuritiesAndCashEquivalentsTables" xlink:href="mack-20180331.xsd#Role_DisclosureMarketableSecuritiesAndCashEquivalentsTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureMarketableSecuritiesAndCashEquivalentsTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureAccountsPayableAccruedExpensesAndOtherTables" xlink:href="mack-20180331.xsd#Role_DisclosureAccountsPayableAccruedExpensesAndOtherTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureAccountsPayableAccruedExpensesAndOtherTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureStockBasedCompensationTables" xlink:href="mack-20180331.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureStockBasedCompensationTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <loc xlink:href="mack-20180331.xsd#mack_ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock" xlink:type="locator" xlink:label="mack_ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="mack_ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureNetLossPerCommonShareTables" xlink:href="mack-20180331.xsd#Role_DisclosureNetLossPerCommonShareTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureNetLossPerCommonShareTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureDiscontinuedOperationsTables" xlink:href="mack-20180331.xsd#Role_DisclosureDiscontinuedOperationsTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureDiscontinuedOperationsTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail" xlink:href="mack-20180331.xsd#Role_DisclosureNatureOfBusinessAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <loc xlink:href="mack-20180331.xsd#mack_NumberOfDevelopmentProgramsActive" xlink:type="locator" xlink:label="mack_NumberOfDevelopmentProgramsActive" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="mack_NumberOfDevelopmentProgramsActive" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="mack-20180331.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" />
    <loc xlink:href="mack-20180331.xsd#mack_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="mack_SummaryOfSignificantAccountingPoliciesLineItems" />
    <loc xlink:href="mack-20180331.xsd#mack_SilverCreekPharmaceuticalsIncMember" xlink:type="locator" xlink:label="mack_SilverCreekPharmaceuticalsIncMember" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="mack-20180331.xsd#mack_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="mack_SummaryOfSignificantAccountingPoliciesTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="mack_SummaryOfSignificantAccountingPoliciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_RangeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_SummaryOfSignificantAccountingPoliciesTable" xlink:to="dei_LegalEntityAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="mack_SilverCreekPharmaceuticalsIncMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_SummaryOfSignificantAccountingPoliciesTable" xlink:to="mack_SummaryOfSignificantAccountingPoliciesLineItems" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail" xlink:href="mack-20180331.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="mack-20180331.xsd#mack_CashCashEquivalentsAndRestrictedCashLineItems" xlink:type="locator" xlink:label="mack_CashCashEquivalentsAndRestrictedCashLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="locator" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <loc xlink:href="mack-20180331.xsd#mack_CashCashEquivalentsAndRestrictedCashTable" xlink:type="locator" xlink:label="mack_CashCashEquivalentsAndRestrictedCashTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="mack_CashCashEquivalentsAndRestrictedCashTable" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_CashCashEquivalentsAndRestrictedCashTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_CashCashEquivalentsAndRestrictedCashTable" xlink:to="mack_CashCashEquivalentsAndRestrictedCashLineItems" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_CashCashEquivalentsAndRestrictedCashLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_CashCashEquivalentsAndRestrictedCashLineItems" xlink:to="us-gaap_RestrictedCashCurrent" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_CashCashEquivalentsAndRestrictedCashLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_CashCashEquivalentsAndRestrictedCashLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetail" xlink:href="mack-20180331.xsd#Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:type="locator" xlink:label="us-gaap_USTreasuryAndGovernmentMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasuryAndGovernmentMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecurities" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetail" xlink:href="mack-20180331.xsd#Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersDescription" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersDescription" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersDescription" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureMarketableSecuritiesAndCashEquivalentsAdditionalInformationDetail" xlink:href="mack-20180331.xsd#Role_DisclosureMarketableSecuritiesAndCashEquivalentsAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureMarketableSecuritiesAndCashEquivalentsAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MarketableSecurities" xlink:type="locator" xlink:label="us-gaap_MarketableSecurities" />
    <loc xlink:href="mack-20180331.xsd#mack_AmortizedCostAndFairValueDebtSecuritiesAbstract" xlink:type="locator" xlink:label="mack_AmortizedCostAndFairValueDebtSecuritiesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_AmortizedCostAndFairValueDebtSecuritiesAbstract" xlink:to="us-gaap_MarketableSecurities" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureMarketableSecuritiesAndCashEquivalentsSummaryOfMarketableSecuritiesAndCashEquivalentsDetail" xlink:href="mack-20180331.xsd#Role_DisclosureMarketableSecuritiesAndCashEquivalentsSummaryOfMarketableSecuritiesAndCashEquivalentsDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureMarketableSecuritiesAndCashEquivalentsSummaryOfMarketableSecuritiesAndCashEquivalentsDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_CashEquivalentsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <loc xlink:href="mack-20180331.xsd#mack_MarketableSecuritiesMember" xlink:type="locator" xlink:label="mack_MarketableSecuritiesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:type="locator" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:type="locator" xlink:label="us-gaap_InformationByCategoryOfDebtSecurityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_InformationByCategoryOfDebtSecurityAxis" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:to="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:to="mack_MarketableSecuritiesMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="10050.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10050.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureAccountsPayableAccruedExpensesAndOtherScheduleOfAccountsPayableAccruedExpensesAndOtherDetail" xlink:href="mack-20180331.xsd#Role_DisclosureAccountsPayableAccruedExpensesAndOtherScheduleOfAccountsPayableAccruedExpensesAndOtherDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureAccountsPayableAccruedExpensesAndOtherScheduleOfAccountsPayableAccruedExpensesAndOtherDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserveCurrent" xlink:type="locator" xlink:label="us-gaap_RestructuringReserveCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <loc xlink:href="mack-20180331.xsd#mack_AccruedDrugPurchaseCostsCurrent" xlink:type="locator" xlink:label="mack_AccruedDrugPurchaseCostsCurrent" />
    <loc xlink:href="mack-20180331.xsd#mack_AccruedClinicalTrialCosts" xlink:type="locator" xlink:label="mack_AccruedClinicalTrialCosts" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="mack_AccruedClinicalTrialCosts" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="mack_AccruedDrugPurchaseCostsCurrent" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_RestructuringReserveCurrent" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:href="mack-20180331.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <loc xlink:href="mack-20180331.xsd#mack_EmployeeMember" xlink:type="locator" xlink:label="mack_EmployeeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualAxis" />
    <loc xlink:href="mack-20180331.xsd#mack_StockIncentivePlan2011Member" xlink:type="locator" xlink:label="mack_StockIncentivePlan2011Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="mack_StockIncentivePlan2011Member" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TitleOfIndividualAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="mack_EmployeeMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToCalculateFairValueOfOptionsGrantedToEmployeesDetail" xlink:href="mack-20180331.xsd#Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToCalculateFairValueOfOptionsGrantedToEmployeesDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToCalculateFairValueOfOptionsGrantedToEmployeesDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRecognizedStockBasedCompensationExpenseDetail" xlink:href="mack-20180331.xsd#Role_DisclosureStockBasedCompensationScheduleOfRecognizedStockBasedCompensationExpenseDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRecognizedStockBasedCompensationExpenseDetail">
    <loc xlink:href="mack-20180331.xsd#mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees" xlink:type="locator" xlink:label="mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" xlink:href="mack-20180331.xsd#Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="11710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="12010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="12110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetail" xlink:href="mack-20180331.xsd#Role_DisclosureNetLossPerCommonShareAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <loc xlink:href="mack-20180331.xsd#mack_ParticipatingSecuritiesOutstandingShares" xlink:type="locator" xlink:label="mack_ParticipatingSecuritiesOutstandingShares" />
    <loc xlink:href="mack-20180331.xsd#mack_UndistributedEarningsLossAllocatedToParticipatingSecurities" xlink:type="locator" xlink:label="mack_UndistributedEarningsLossAllocatedToParticipatingSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="mack_UndistributedEarningsLossAllocatedToParticipatingSecurities" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="mack_ParticipatingSecuritiesOutstandingShares" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfOutstandingSecuritiesExcludedFromComputationOfDilutedLossPerShareDetail" xlink:href="mack-20180331.xsd#Role_DisclosureNetLossPerCommonShareScheduleOfOutstandingSecuritiesExcludedFromComputationOfDilutedLossPerShareDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfOutstandingSecuritiesExcludedFromComputationOfDilutedLossPerShareDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:type="locator" xlink:label="us-gaap_StockCompensationPlanMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureDiscontinuedOperationsScheduleOfDiscontinuedOperationsDetail" xlink:href="mack-20180331.xsd#Role_DisclosureDiscontinuedOperationsScheduleOfDiscontinuedOperationsDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureDiscontinuedOperationsScheduleOfDiscontinuedOperationsDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" />
    <loc xlink:href="mack-20180331.xsd#mack_DisposalGroupIncludingDiscontinuedOperationOtherIncomeAndExpensesAbstract" xlink:type="locator" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationOtherIncomeAndExpensesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" />
    <loc xlink:href="mack-20180331.xsd#mack_DisposalGroupIncludingDiscontinuedOperationRestructuringExpenses" xlink:type="locator" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationRestructuringExpenses" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" />
    <loc xlink:href="mack-20180331.xsd#mack_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses" xlink:type="locator" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" />
    <loc xlink:href="mack-20180331.xsd#mack_DisposalGroupIncludingDiscontinuedOperationCostAndExpensesAbstract" xlink:type="locator" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationCostAndExpensesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" />
    <loc xlink:href="mack-20180331.xsd#mack_DisposalGroupIncludingDiscontinuedOperationOtherRevenue" xlink:type="locator" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationOtherRevenue" />
    <loc xlink:href="mack-20180331.xsd#mack_DisposalGroupIncludingDiscontinuedOperationLicenseAndCollaborationRevenues" xlink:type="locator" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationLicenseAndCollaborationRevenues" />
    <loc xlink:href="mack-20180331.xsd#mack_DisposalGroupIncludingDiscontinuedOperationProductRevenuesNet" xlink:type="locator" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationProductRevenuesNet" />
    <loc xlink:href="mack-20180331.xsd#mack_DisposalGroupIncludingDiscontinuedOperationRevenueAbstract" xlink:type="locator" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationRevenueAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="locator" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" />
    <loc xlink:href="mack-20180331.xsd#mack_CommercialBusinessMember" xlink:type="locator" xlink:label="mack_CommercialBusinessMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="locator" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="locator" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="mack_CommercialBusinessMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="mack_DisposalGroupIncludingDiscontinuedOperationRevenueAbstract" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_DisposalGroupIncludingDiscontinuedOperationRevenueAbstract" xlink:to="mack_DisposalGroupIncludingDiscontinuedOperationProductRevenuesNet" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_DisposalGroupIncludingDiscontinuedOperationRevenueAbstract" xlink:to="mack_DisposalGroupIncludingDiscontinuedOperationLicenseAndCollaborationRevenues" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_DisposalGroupIncludingDiscontinuedOperationRevenueAbstract" xlink:to="mack_DisposalGroupIncludingDiscontinuedOperationOtherRevenue" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_DisposalGroupIncludingDiscontinuedOperationRevenueAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="mack_DisposalGroupIncludingDiscontinuedOperationCostAndExpensesAbstract" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_DisposalGroupIncludingDiscontinuedOperationCostAndExpensesAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_DisposalGroupIncludingDiscontinuedOperationCostAndExpensesAbstract" xlink:to="mack_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_DisposalGroupIncludingDiscontinuedOperationCostAndExpensesAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_DisposalGroupIncludingDiscontinuedOperationCostAndExpensesAbstract" xlink:to="mack_DisposalGroupIncludingDiscontinuedOperationRestructuringExpenses" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_DisposalGroupIncludingDiscontinuedOperationCostAndExpensesAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="mack_DisposalGroupIncludingDiscontinuedOperationOtherIncomeAndExpensesAbstract" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_DisposalGroupIncludingDiscontinuedOperationOtherIncomeAndExpensesAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureDiscontinuedOperationsAdditionalInformationDetail" xlink:href="mack-20180331.xsd#Role_DisclosureDiscontinuedOperationsAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureDiscontinuedOperationsAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDescription" xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDescription" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCharges" xlink:type="locator" xlink:label="us-gaap_RestructuringCharges" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesInitiationDate" xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedActivitiesInitiationDate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="locator" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:type="locator" xlink:label="us-gaap_DisposalGroupClassificationDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:type="locator" xlink:label="us-gaap_DisposalGroupClassificationAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OneTimeTerminationBenefitsMember" xlink:type="locator" xlink:label="us-gaap_OneTimeTerminationBenefitsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractTerminationMember" xlink:type="locator" xlink:label="us-gaap_ContractTerminationMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:type="locator" xlink:label="us-gaap_TypeOfRestructuringDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:type="locator" xlink:label="us-gaap_RestructuringCostAndReserveAxis" />
    <loc xlink:href="mack-20180331.xsd#mack_JanuaryTwoThousandSeventeenCorporateRestructuringMember" xlink:type="locator" xlink:label="mack_JanuaryTwoThousandSeventeenCorporateRestructuringMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:type="locator" xlink:label="us-gaap_RestructuringPlanDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringPlanAxis" xlink:type="locator" xlink:label="us-gaap_RestructuringPlanAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="locator" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="us-gaap_RestructuringPlanAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringPlanAxis" xlink:to="us-gaap_RestructuringPlanDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringPlanDomain" xlink:to="mack_JanuaryTwoThousandSeventeenCorporateRestructuringMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_ContractTerminationMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_OneTimeTerminationBenefitsMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="us-gaap_DisposalGroupClassificationAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupClassificationAxis" xlink:to="us-gaap_DisposalGroupClassificationDomain" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupClassificationDomain" xlink:to="us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_RestructuringAndRelatedActivitiesInitiationDate" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_RestructuringCharges" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDescription" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureInvestmentInSilverCreekAdditionalInformationDetail" xlink:href="mack-20180331.xsd#Role_DisclosureInvestmentInSilverCreekAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureInvestmentInSilverCreekAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:type="locator" xlink:label="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="mack-20180331.xsd#mack_SilverCreekPharmaceuticalsIncMember" xlink:type="locator" xlink:label="mack_SilverCreekPharmaceuticalsIncMember" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:type="locator" xlink:label="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncontrollingInterestAbstract" xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncontrollingInterestAbstract" xlink:to="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:to="dei_LegalEntityAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="mack_SilverCreekPharmaceuticalsIncMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:to="us-gaap_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:to="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6757325952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>May 03, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MACK<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MERRIMACK PHARMACEUTICALS INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001274792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,342,784<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document And Entity Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6757747680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 34,268<span></span>
</td>
<td class="nump">$ 93,441<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">41,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">844<span></span>
</td>
<td class="nump">1,605<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">77,110<span></span>
</td>
<td class="nump">95,046<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">674<span></span>
</td>
<td class="nump">674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">5,358<span></span>
</td>
<td class="nump">6,467<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investment</a></td>
<td class="nump">9,805<span></span>
</td>
<td class="nump">10,551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">4,548<span></span>
</td>
<td class="nump">4,588<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">97,495<span></span>
</td>
<td class="nump">117,326<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable, accrued expenses and other</a></td>
<td class="nump">15,323<span></span>
</td>
<td class="nump">17,606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Deferred rent</a></td>
<td class="nump">2,211<span></span>
</td>
<td class="nump">2,171<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">17,534<span></span>
</td>
<td class="nump">19,777<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent, net of current portion</a></td>
<td class="nump">651<span></span>
</td>
<td class="nump">1,209<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">18,241<span></span>
</td>
<td class="nump">21,042<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.01 par value: 10,000 shares authorized at March 31, 2018 and December 31, 2017; no shares issued or outstanding at March 31, 2018 or December 31, 2017</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value: 20,000 shares authorized at March 31, 2018 and December 31, 2017; 13,343 shares issued and outstanding at March 31, 2018 and December 31, 2017</a></td>
<td class="nump">1,334<span></span>
</td>
<td class="nump">1,334<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">578,485<span></span>
</td>
<td class="nump">577,721<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(500,553)<span></span>
</td>
<td class="num">(482,771)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">79,254<span></span>
</td>
<td class="nump">96,284<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 97,495<span></span>
</td>
<td class="nump">$ 117,326<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.26(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66022249&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26626-111562<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6812-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6916742080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">13,343,000<span></span>
</td>
<td class="nump">13,343,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">13,343,000<span></span>
</td>
<td class="nump">13,343,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6757810544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">$ 13,106,000<span></span>
</td>
<td class="nump">$ 21,605,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">4,270,000<span></span>
</td>
<td class="nump">5,634,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">17,376,000<span></span>
</td>
<td class="nump">27,239,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from continuing operations</a></td>
<td class="num">(17,376,000)<span></span>
</td>
<td class="num">(27,239,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">275,000<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,979,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(681,000)<span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income and expenses</a></td>
<td class="num">(406,000)<span></span>
</td>
<td class="num">(1,967,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net loss from continuing operations</a></td>
<td class="num">(17,782,000)<span></span>
</td>
<td class="num">(29,206,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract', window );"><strong>Discontinued operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Loss from discontinued operations, net of tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(947,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(17,782,000)<span></span>
</td>
<td class="num">(30,153,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to non-controlling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(467,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Merrimack Pharmaceuticals, Inc.</a></td>
<td class="num">(17,782,000)<span></span>
</td>
<td class="num">(29,686,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized loss on marketable securities</a></td>
<td class="num">(12,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="num">(12,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">(17,794,000)<span></span>
</td>
<td class="num">(29,686,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract', window );"><strong>Amounts attributable to Merrimack Pharmaceuticals, Inc.:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Net loss from continuing operations</a></td>
<td class="num">(17,782,000)<span></span>
</td>
<td class="num">(28,739,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Loss from discontinued operations, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(947,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Merrimack Pharmaceuticals, Inc.</a></td>
<td class="num">$ (17,782,000)<span></span>
</td>
<td class="num">$ (29,686,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Basic and dilutive net loss per common share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare', window );">Net loss from continuing operations</a></td>
<td class="num">$ (1.33)<span></span>
</td>
<td class="num">$ (2.20)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare', window );">Net loss from discontinued operations, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.07)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share</a></td>
<td class="num">$ (1.33)<span></span>
</td>
<td class="num">$ (2.27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average common shares used per share calculations&#8212;basic and diluted</a></td>
<td class="nump">13,343<span></span>
</td>
<td class="nump">13,059<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e557-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4613673-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721675-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1012-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721525-107759<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721523-107759<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e957-107759<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721675-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721525-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721523-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e957-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1012-107759<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per basic and diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation, when the per share amount is the same.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569643-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763857168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (17,782,000)<span></span>
</td>
<td class="num">$ (30,153,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Loss from discontinued operations, net of tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(947,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Loss from continuing operations</a></td>
<td class="num">(17,782,000)<span></span>
</td>
<td class="num">(29,206,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Non-cash interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,508,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">1,239,000<span></span>
</td>
<td class="nump">1,182,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_PremiumsPaidOnMarketableSecurities', window );">Premiums paid on marketable securities</a></td>
<td class="num">(51,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_AmortizationAndAccretionOnMarketableSecurities', window );">Amortization and accretion on marketable securities</a></td>
<td class="num">(141,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees', window );">Stock-based compensation expense</a></td>
<td class="nump">764,000<span></span>
</td>
<td class="nump">796,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfEquityInvestments', window );">Loss on equity method investment</a></td>
<td class="nump">746,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">801,000<span></span>
</td>
<td class="num">(372,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable, accrued expenses and other</a></td>
<td class="num">(2,397,000)<span></span>
</td>
<td class="nump">8,054,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_IncreaseDecreaseInDeferredRent', window );">Deferred rent</a></td>
<td class="num">(518,000)<span></span>
</td>
<td class="num">(86,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in continuing operations for operating activities</a></td>
<td class="num">(17,339,000)<span></span>
</td>
<td class="num">(18,124,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Net cash provided by discontinuing operations for operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,968,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(17,339,000)<span></span>
</td>
<td class="num">(10,156,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(16,000)<span></span>
</td>
<td class="num">(290,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(41,818,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(41,834,000)<span></span>
</td>
<td class="num">(290,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,053,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,077,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents and restricted cash</a></td>
<td class="num">(59,173,000)<span></span>
</td>
<td class="num">(4,369,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">94,217,000<span></span>
</td>
<td class="nump">22,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">35,044,000<span></span>
</td>
<td class="nump">17,931,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment in accounts payable, accrued expenses and other</a></td>
<td class="nump">$ 114,000<span></span>
</td>
<td class="nump">34,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1', window );">Receivables related to property and equipment sale in other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flows</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid for interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,368,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=mack_SilverCreekPharmaceuticalsIncMember', window );">Silver Creek Pharmaceuticals Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from issuance of Series C preferred stock by Silver Creek Pharmaceuticals, Inc., net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,024,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and nonemployees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_AmortizationAndAccretionOnMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization and accretion on marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_AmortizationAndAccretionOnMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_IncreaseDecreaseInDeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in deferred rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_IncreaseDecreaseInDeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_PremiumsPaidOnMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Premiums paid on marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_PremiumsPaidOnMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfEquityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the carrying value and the sale price of equity securities, not separately or otherwise categorized as trading or available-for-sale. This element includes investments in which the entity holds a small ownership stake (generally, less than 20% of the shares outstanding) and cannot exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.13(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfEquityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721675-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1012-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721525-107759<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721523-107759<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e957-107759<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest. Includes, but is not limited to, payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash consideration received for selling an asset or business through a noncash (or part noncash) transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow for purchase of trading, available-for-sale securities and held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mack_SilverCreekPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mack_SilverCreekPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6753948864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of the Business</a></td>
<td class="text"><div>

<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1. Nature of the Business</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Merrimack Pharmaceuticals, Inc. (the &#8220;Company&#8221;) is a clinical stage biopharmaceutical company based in Cambridge, Massachusetts that is outthinking cancer by targeting biomarker-defined cancers. The Company&#8217;s vision is to ensure that cancer patients and their families live fulfilling lives. The Company&#8217;s mission is to transform cancer care through the smart design and development of targeted solutions based on a deep understanding of cancer pathways and biological markers. All of the Company&#8217;s development programs, including four clinical trials and six candidates in preclinical development, fit into the Company&#8217;s strategy of (1) understanding the biological problems it is trying to solve, (2) designing specific solutions against the problems it is trying to solve and (3) developing those solutions for biomarker-selected patients. This three-pronged strategy seeks to ensure optimal patient outcomes.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company owns worldwide development and commercial rights to all of its clinical and preclinical programs. The Company&#8217;s most advanced assets and a description of the status of each asset are as follows:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">MM-121 (seribantumab)<font style="font-weight:normal;">: MM-121 is a fully human monoclonal antibody that binds to the ErbB3 (HER3) receptor and targets heregulin positive cancers. There are two active development programs for MM-121, each in a Phase 2 clinical trial. The Company is conducting the global, open-label, biomarker-selected, Phase 2 randomized SHERLOC clinical trial evaluating MM-121 in combination with docetaxel in patients with heregulin positive non-small cell lung cancer. The Company is also conducting the global, double-blinded, placebo-controlled, biomarker-selected, Phase 2 randomized SHERBOC clinical trial evaluating MM-121 in combination with fulvestrant in patients with heregulin positive, hormone receptor positive, ErbB2 (HER2) negative, metastatic breast cancer;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.63%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">MM-141 (istiratumab)<font style="font-weight:normal;">: MM-141 is a fully human tetravalent bispecific antibody designed to block tumor survival signals by targeting receptor complexes containing the insulin-like growth factor 1 (&#8220;IGF-1&#8221;), receptor and ErbB3 (HER3) cell surface receptor. The Company is conducting and has completed enrollment of the global, double-blinded, placebo-controlled, Phase 2 randomized CARRIE clinical trial evaluating MM-141 in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer with high serum levels of free IGF-1; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.63%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">MM-310<font style="font-weight:normal;">: MM-310 is an antibody-directed nanotherapeutic that targets the ephrin receptor A2 (&#8220;EphA2&#8221;) receptor and contains a novel prodrug of the highly potent chemotherapy docetaxel. The EphA2 receptor is highly expressed in most solid tumor types, such as prostate, ovarian, bladder, gastric, pancreatic and lung cancers. The Company is conducting a Phase 1 clinical trial to evaluate safety and preliminary activity of MM-310 in patients with solid tumors and to identify the maximum tolerated dose.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks and uncertainties common to companies in the biopharmaceutical industry, including, among other things, its ability to secure additional capital to fund operations, success of clinical trials, development by competitors of new technological innovations, dependence on collaborative arrangements, protection of proprietary technology, compliance with government regulations and dependence on key personnel. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of capital, adequate personnel, infrastructure and extensive compliance reporting capabilities.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s product candidates are in development, and none are approved for any indication by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) or any other regulatory agency. There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s intellectual property will be obtained or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies, among others. In addition, the Company is dependent upon the services of its employees and consultants.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 205-40, <font style="font-style:italic;">Going Concern</font>, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued. As of March 31, 2018, the Company had an accumulated deficit of $500.6 million.&#160;During the three months ended March 31, 2018, the Company incurred a net loss from continuing operations of $17.8 million and used $17.3 million of cash in continuing operations for operating activities.&#160;The Company expects to continue to generate operating losses in the foreseeable future. The Company expects that its cash and cash equivalents and marketable securities of $76.3 million at March 31, 2018 will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next 12 months from the date that the condensed consolidated financial statements are issued.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will ultimately need to seek additional funding through equity offerings, debt financings, collaborations, licensing arrangements and other marketing and distribution arrangements, partnerships, joint ventures, combinations or divestitures of one or more of its businesses. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborative arrangements or divest its assets. The terms of any financing may adversely affect the holdings or the rights of the Company&#8217;s stockholders. Arrangements with collaborators or others may require the Company to relinquish rights to certain of its technologies or product candidates. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate its research and development programs or commercialization efforts, which could adversely affect its business prospects.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6631752752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2. Summary of Significant Accounting Policies </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Basis of Presentation </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying condensed consolidated financial statements reflect the operations of Merrimack Pharmaceuticals, Inc. and its wholly owned subsidiary. All intercompany accounts and transactions have been eliminated.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The condensed consolidated financial statements are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;).</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accounting policies followed in the preparation of the interim condensed consolidated financial statements are consistent in all material respects with those presented in Note 1 to the financial statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2017.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain reclassifications have been made to the prior year&#8217;s condensed consolidated balance sheet and condensed consolidated statement of cash flows to enhance comparability with the current year&#8217;s condensed consolidated financial statements presentation. These reclassifications had no effect on previously reported net income within the condensed consolidated statement of operations and comprehensive loss.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Consolidation</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying condensed consolidated financial statements reflect Merrimack Pharmaceuticals, Inc. and its wholly owned subsidiary. For the three months ended March 31, 2017, the condensed consolidated financial statements also include the accounts of Silver Creek Pharmaceuticals, Inc. (&#8220;Silver Creek&#8221;). For the three months ended March 31, 2017, Silver Creek represented a variable interest entity that the Company consolidated as the primary beneficiary. In the third quarter of 2017, the Company deconsolidated Silver Creek from its financial statements since the Company was no longer the primary beneficiary of Silver Creek. The Company&#8217;s ownership percentage decreased to less than 50% and the Company no longer controlled Silver Creek&#8217;s board of directors or directed the activities that had the most significant impact on Silver Creek&#8217;s economic performance. The Company accounts for its investment in Silver Creek under the equity method of accounting.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April&#160;3, 2017, the Company completed the sale of its right, title and interest in the non-cash assets, equipment, inventory, contracts and intellectual property primarily related to developing, manufacturing and commercializing ONIVYDE and MM-436 (the &#8220;Commercial Business&#8221;). As of March 31, 2017, the Commercial Business met all the conditions to be classified as a discontinued operation since the disposal of the Commercial Business represented a strategic shift that had a major effect on the Company&#8217;s operations and financial results. Therefore, the operating results of the Commercial Business are reported as a loss from discontinued operations, net of tax in the condensed consolidated statements of operations and comprehensive loss for the three months ended March 31, 2017. During the three months ended March 31, 2018, there were no discontinued operations. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unaudited Interim Financial Information</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The condensed consolidated balance sheet as of December&#160;31, 2017 was derived from audited financial statements, but does not include all disclosures required by GAAP. The condensed consolidated balance sheet as of March 31, 2018, the condensed consolidated statements of operations and comprehensive loss for the three months ended March 31, 2018 and 2017 and the condensed consolidated statements of cash flows for the three months ended March 31, 2018 and 2017 are unaudited. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the Company&#8217;s financial position as of March 31, 2018, the results of its operations for the three months ended March 31, 2018 and 2017, and its statements of cash flows for the three months ended March 31, 2018 and 2017. The financial data and other information disclosed in the notes related to the three months ended March 31, 2018 and 2017 are unaudited. The results for the three months ended March 31, 2018 and 2017 are not necessarily indicative of results to be expected for the year ending December&#160;31, 2018, any other interim periods, or any future year or period.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The unaudited interim financial statements of the Company included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;). Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this report, as is permitted by such rules and regulations. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and the notes thereto contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2017 filed with the SEC on March 12, 2018.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Condensed Consolidated Statements of Cash Flows</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the statement of financial position that sum to the total of the same such amounts shown in the statement of cash flows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.13%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,268</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,155</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash in prepaid expenses and other current assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash (short term)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash (long term)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">674</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">674</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash, cash equivalents and restricted cash shown in the condensed consolidated</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; statement of cash flows</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,044</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,931</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash included in prepaid expenses and other current assets and restricted cash long term on the statement of financial position represent amounts pledged as collateral for operating lease obligations as contractually required. This restriction will lapse when the arrangements expire.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates, assumptions and judgments reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuation of stock-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from the Company&#8217;s estimates.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Marketable Securities</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities consist of investments with original maturities greater than ninety days. The Company has classified its investments with maturities beyond one year as short term based on their highly liquid nature and because such marketable securities represent the investment of cash that is available for current operations. The Company considers its investment portfolio of marketable debt securities as available-for-sale. Accordingly, these marketable debt securities are recorded at fair value and unrealized gains and losses are reported as a component of accumulated other comprehensive loss in stockholders&#8217; equity. Realized gains and losses and declines in value judged to be other than temporary are included as a component of other income (expense), net based on the specific identification method. When determining whether a decline in value is other than temporary, the Company considers various factors, including whether the Company has the intent to sell the security, and whether it is more likely than not that the Company will be required to sell the security prior to recovery of its amortized cost basis.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6754021856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div>

<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3. Fair Value of Financial Instruments</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. Fair value is determined based on observable and unobservable inputs. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect certain market assumptions. As a basis for considering such assumptions, GAAP establishes a three-tier value hierarchy, which prioritizes the inputs used to develop the assumptions and for measuring fair value as follows: Level 1 observable inputs such as quoted prices in active markets for identical assets; Level 2 inputs other than the quoted prices in active markets that are observable either directly or indirectly; and Level 3 unobservable inputs in which there is little or no market data, which requires the Company to develop its own assumptions. This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables show assets measured at fair value on a recurring basis as of March&#160;31, 2018 and December&#160;31, 2017:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,785</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,009</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,781</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Totals</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,785</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,790</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,217</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,841</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,940</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Totals</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,998</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89,310</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Totals</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89,310</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the three months ended March 31, 2018 and the year ended December&#160;31, 2017, there were no transfers between Level 1 and Level 2. The fair value of Level 2 instruments classified as cash equivalents and marketable debt securities were determined through third-party pricing services.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amounts reflected in the condensed consolidated balance sheets for accounts payable, accrued expenses and other liabilities approximate fair value due to their short-term maturities.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6637302256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities and Cash Equivalents<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments Debt And Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Marketable Securities and Cash Equivalents</a></td>
<td class="text"><div>

<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4. Marketable Securities and Cash Equivalents</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company&#8217;s marketable securities and cash equivalents as of March 31, 2018. The Company did not hold any marketable securities as of December 31, 2017.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,785</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,785</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,010</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,009</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,781</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,781</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash equivalents</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,576</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,575</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,227</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,217</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,841</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,841</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,941</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,940</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total marketable securities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,009</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,998</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash equivalents and marketable securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,585</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,573</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -URI http://asc.fasb.org/topic&amp;trid=2122426<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6753962272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable, Accrued Expenses and Other<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable, Accrued Expenses and Other</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5. Accounts Payable, Accrued Expenses and Other</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable, accrued expenses and other as of March&#160;31, 2018 and December&#160;31, 2017 consisted of the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,560</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,887</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued goods and services</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,027</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,682</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued clinical trial costs</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,925</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,901</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued drug purchase costs</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">918</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">222</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued payroll and related benefits</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,240</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,884</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued restructuring expenses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">251</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">628</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax incentives</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,402</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,402</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accounts payable, accrued expenses and other</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,323</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,606</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6637965440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6. Stock-Based Compensation</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s 2011 Stock Incentive Plan (the &#8220;2011 Plan&#8221;) is administered by the Company&#8217;s Board of Directors and permits the Company to grant incentive and non-qualified stock options, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At March&#160;31, 2018, there were 0.5 million shares remaining available for grant under the 2011 Plan.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the three months ended March 31, 2018 and 2017, the Company issued options to purchase 0.6 million and 0.0 million shares of common stock, respectively. These options generally vest over a three-year period for employees. Options granted to directors generally vest immediately.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of stock options granted to employees during the three months ended March&#160;31, 2018 and 2017 was estimated at the date of grant using the following assumptions:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="4" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.16%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.3 &#8211; 2.7%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.8 years</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.8 years</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62 &#8211; 63%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67 &#8211; 68%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company uses the simplified method to calculate the expected term, as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term. The computation of expected volatility is based on the historical volatility of comparable companies from a representative peer group selected based on industry and market capitalization. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected life of the stock options. Management estimates expected forfeitures based on historical experience and recognizes compensation costs only for those equity awards expected to vest.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognized stock-based compensation expense during the three months ended March&#160;31, 2018 and 2017 as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee awards:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expense</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">334</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">468</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expense</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">430</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">328</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">764</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">796</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes stock option activity during the three months ended March&#160;31, 2018:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except per share amounts)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise&#160;Price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual&#160;Term</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December&#160;31, 2017</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,616</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22.07</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.65</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,031</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">566</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.74</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(145</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.12%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.04</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.48%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.74%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at March&#160;31, 2018</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,037</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.12%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.00</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.22</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.74%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and expected to vest at March&#160;31, 2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,036</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.00</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.22</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at March&#160;31, 2018</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,032</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25.17</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.97</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average grant date fair value per share of stock options granted during the three months ended March&#160;31, 2018 and 2017 was $6.26 and $24.30, respectively. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate intrinsic value is calculated as the difference between the exercise price of the stock options and the fair value of the underlying common stock. The aggregate intrinsic value of stock options exercised during the three months ended March&#160;31, 2017 was $1.4 million. There were no options exercised during the three months ended March 31, 2018.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March&#160;31, 2018, there was $7.2 million of total unrecognized stock-based compensation expense related to unvested employee stock awards. The Company expects to recognize this expense over a weighted-average period of approximately 2.58 years.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6754006432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text"><div>

<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7. Net Loss Per Common Share</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is calculated by dividing the net loss attributable to Merrimack Pharmaceuticals, Inc. by the weighted-average number of common shares outstanding during the period. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Diluted net loss per share is computed by dividing the net loss attributable to Merrimack Pharmaceuticals, Inc. by the weighted-average number of dilutive common shares outstanding during the period. Dilutive shares outstanding is calculated by adding to the weighted shares outstanding any potential (unissued) shares of common stock from outstanding stock options based on the treasury stock method. In a period when a net loss is reported, all common stock equivalents are excluded from the calculation because they would have an anti-dilutive effect, meaning the loss per share would be reduced. Therefore, in periods where a loss is reported, there is no difference in basic and dilutive loss per share.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company follows the two-class method when computing net loss per share when it has issued shares that meet the definition of participating securities. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participating rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based on their respective rights to receive dividends, as if all income for the period has been distributed or losses to be allocated if they are contractually required to fund losses. There were no amounts allocated to participating securities for the three months ended March 31, 2018 and 2017, as the Company was in a loss position and had no shares that met the definition of participating securities outstanding as of March 31, 2018 and 2017. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The stock options and conversion premium on the 4.50% convertible notes due 2020 (the &#8220;Convertible Notes&#8221;) are excluded from the calculation of diluted loss per share because the net loss for the three months ended March&#160;31, 2017 causes such securities to be anti-dilutive. Outstanding securities excluded from the calculation of diluted loss per share for the three months ended March&#160;31, 2018 and 2017 are shown in the chart below:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding options to purchase common stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,037</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,652</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of the Convertible Notes</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,216</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6618797664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations And Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Discontinued Operations</a></td>
<td class="text"><div>

<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8. Discontinued Operations</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">On April&#160;3, 2017, the Company completed the sale of the Commercial Business. As of March 31, 2017, the Commercial Business met all the conditions to be classified as a discontinued operation since the disposal of the Commercial Business represented a strategic shift that had a major effect on the Company&#8217;s operations and financial results.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The condensed consolidated financial statements for the three months ended March 31, 2017 reflect the operations of the Commercial Business as a discontinued operation.&#160;Discontinued operations for the three months ended March 31, 2017 includes the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.2%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues:</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenues, net</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,135</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License and collaboration revenues</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,797</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other revenues</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,973</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenues</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,905</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs and expenses:</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of revenues</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,890</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,730</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expenses</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,733</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restructuring expenses</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,265</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total costs and expenses</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,618</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income and expenses:</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,234</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from discontinued operations</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(947</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:5pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 8, 2017, the Company announced a reduction in headcount by approximately 30% in connection with the sale of the Commercial Business and the completion of its strategic pipeline review. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under this corporate restructuring, for the three months ended March 31, 2017, the Company recognized total restructuring expenses of $5.3 million related to contractual termination benefits for employees with pre-existing severance arrangements. These one-time employee termination benefits are comprised of severance, benefits and related costs, all of which resulted in cash expenditures. The expense of $5.3 million was included in discontinued operations, as the costs are directly associated with the sale of the Commercial Business. For the three months ended March 31, 2018, there were no discontinued operations.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6621214960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Silver Creek<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDisclosureTextBlock', window );">Investment in Silver Creek</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9. Investment in Silver Creek</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 20, 2010, the Company acquired a controlling financial interest in Silver Creek. At such time, the Company had the ability to direct the activities of Silver Creek that most significantly impacted Silver Creek&#8217;s economic performance through its ownership percentage and through the board of director seats controlled by the Company. As such, Silver Creek was consolidated by the Company.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since the Company acquired its financial interest, Silver Creek has raised funding through the issuance of preferred stock. The Company has not participated in any Silver Creek financings nor has it provided any funding. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the third quarter of 2017, Silver Creek completed its Series C preferred stock financing, reducing the Company&#8217;s ownership percentage in Silver Creek below 50% and resulting in the Company no longer controlling the Silver Creek board of directors. Accordingly, the Company determined that it was no longer the primary beneficiary of Silver Creek and deconsolidated Silver Creek from its financial statements on July 13, 2017. Starting on July 14, 2017, the Company accounted for its investment in Silver Creek under the equity method of accounting since the Company has the ability to exercise significant influence over Silver Creek. Under the equity method of accounting, the Company has recorded its proportionate share of the investee&#8217;s earnings (losses) in its results of operations with a corresponding increase (decrease) in the carrying value of the investment. Silver Creek continues to be a related party to the Company after deconsolidation.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6632701440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recent Accounting Pronouncements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Accounting Changes And Error Corrections [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div>

<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10. Recent Accounting Pronouncements</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Financial Accounting Standards Board (&#8220;FASB&#8221;) issued the following new Accounting Standards Updates (&#8220;ASU&#8221;), which the Company adopted on January 1, 2018:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASU 2014-09, &#8220;Revenue from Contracts with Customers (Topic 606)&#8221; and related amendments;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASU 2016-01, &#8220;Financial Instruments &#8211; Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Liabilities&#8221;;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASU 2016-15, &#8220;Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments&#8221;;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASU 2016-18, &#8220;Statement of Cash Flows - Restricted Cash (a consensus of the FASB Emerging Issues Task Force)&#8221;; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASU 2017-09, &#8220;Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting.&#8221;</p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The adoption of these standards did not have a material impact on the Company&#8217;s financial position, results of operations or statement of cash flows; however, the adoption of ASU 2016-18 resulted in the reclassification of certain prior year amounts in the Company&#8217;s condensed consolidated statements of cash flows to conform to the current year presentation. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued ASU 2016-02, &#8220;Leases (Topic 842),&#8221; which supersedes all existing lease accounting guidance within ASC 840, <font style="font-style:italic;">Leases</font>. The new standard requires that lease assets and lease liabilities be recognized by lessees for those leases previously classified as operating leases under ASC 840, with limited exceptions. This update also creates a new definition of a lease and provides guidance as to whether a contract is or contains a lease. This guidance will be effective for annual reporting periods beginning after December 15, 2018, including interim periods within those annual reporting periods, and early adoption is permitted. The Company is currently evaluating the potential impact that the adoption of this guidance may have on the condensed consolidated financial statements.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU 2016-13, &#8220;Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,&#8221; which represents a new credit loss standard that will change the impairment model for most financial assets and certain other financial instruments. Specifically, this guidance will require entities to utilize a new &#8220;expected loss&#8221; model as it relates to trade and other receivables. In addition, entities will be required to recognize an allowance for estimated credit losses on available-for-sale debt securities, regardless of the length of time that a security has been in an unrealized loss position. This guidance will be effective for annual reporting periods beginning after December 15, 2019, including interim periods within those annual reporting periods, and early adoption is permitted. The Company is currently evaluating the potential impact that the adoption of this guidance may have on the condensed consolidated financial statements.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2018, the FASB issued ASU 2018-02, &#8220;Income Statement - Reporting Comprehensive Income (Topic 220)&#8221;. ASU 2018-02 addresses the effect of the change in the U.S. federal corporate tax rate due to the enactment of the December 22, 2017 Tax Cuts and Jobs Act (the &#8220;Tax Act&#8221;) on items within accumulated other comprehensive loss. The guidance will be effective for the Company in the first quarter of fiscal 2020 with early adoption permitted. The Company is currently assessing the impact that adopting this new accounting standard will have on the condensed consolidated financial statements.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed above, the Company does not believe that the adoption of recently issued standards has or may have a material impact on the Company&#8217;s condensed consolidated financial statements or disclosures.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6757353104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div>

<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Basis of Presentation </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying condensed consolidated financial statements reflect the operations of Merrimack Pharmaceuticals, Inc. and its wholly owned subsidiary. All intercompany accounts and transactions have been eliminated.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The condensed consolidated financial statements are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;).</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accounting policies followed in the preparation of the interim condensed consolidated financial statements are consistent in all material respects with those presented in Note 1 to the financial statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2017.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain reclassifications have been made to the prior year&#8217;s condensed consolidated balance sheet and condensed consolidated statement of cash flows to enhance comparability with the current year&#8217;s condensed consolidated financial statements presentation. These reclassifications had no effect on previously reported net income within the condensed consolidated statement of operations and comprehensive loss.</p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text"><div>

<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Consolidation</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The accompanying condensed consolidated financial statements reflect Merrimack Pharmaceuticals, Inc. and its wholly owned subsidiary. For the three months ended March 31, 2017, the condensed consolidated financial statements also include the accounts of Silver Creek Pharmaceuticals, Inc. (&#8220;Silver Creek&#8221;). For the three months ended March 31, 2017, Silver Creek represented a variable interest entity that the Company consolidated as the primary beneficiary. In the third quarter of 2017, the Company deconsolidated Silver Creek from its financial statements since the Company was no longer the primary beneficiary of Silver Creek. The Company&#8217;s ownership percentage decreased to less than 50% and the Company no longer controlled Silver Creek&#8217;s board of directors or directed the activities that had the most significant impact on Silver Creek&#8217;s economic performance. The Company accounts for its investment in Silver Creek under the equity method of accounting.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April&#160;3, 2017, the Company completed the sale of its right, title and interest in the non-cash assets, equipment, inventory, contracts and intellectual property primarily related to developing, manufacturing and commercializing ONIVYDE and MM-436 (the &#8220;Commercial Business&#8221;). As of March 31, 2017, the Commercial Business met all the conditions to be classified as a discontinued operation since the disposal of the Commercial Business represented a strategic shift that had a major effect on the Company&#8217;s operations and financial results. Therefore, the operating results of the Commercial Business are reported as a loss from discontinued operations, net of tax in the condensed consolidated statements of operations and comprehensive loss for the three months ended March 31, 2017. During the three months ended March 31, 2018, there were no discontinued operations. </p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_UnauditedInterimFinancialInformationPolicyTextBlock', window );">Unaudited Interim Financial Information</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unaudited Interim Financial Information</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The condensed consolidated balance sheet as of December&#160;31, 2017 was derived from audited financial statements, but does not include all disclosures required by GAAP. The condensed consolidated balance sheet as of March 31, 2018, the condensed consolidated statements of operations and comprehensive loss for the three months ended March 31, 2018 and 2017 and the condensed consolidated statements of cash flows for the three months ended March 31, 2018 and 2017 are unaudited. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the Company&#8217;s financial position as of March 31, 2018, the results of its operations for the three months ended March 31, 2018 and 2017, and its statements of cash flows for the three months ended March 31, 2018 and 2017. The financial data and other information disclosed in the notes related to the three months ended March 31, 2018 and 2017 are unaudited. The results for the three months ended March 31, 2018 and 2017 are not necessarily indicative of results to be expected for the year ending December&#160;31, 2018, any other interim periods, or any future year or period.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The unaudited interim financial statements of the Company included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;). Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this report, as is permitted by such rules and regulations. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and the notes thereto contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2017 filed with the SEC on March 12, 2018.</p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_CondensedConsolidatedStatementsOfCashFlowsPolicyTextBlock', window );">Condensed Consolidated Statements of Cash Flows</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Condensed Consolidated Statements of Cash Flows</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the statement of financial position that sum to the total of the same such amounts shown in the statement of cash flows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.13%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,268</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,155</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash in prepaid expenses and other current assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash (short term)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash (long term)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">674</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">674</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash, cash equivalents and restricted cash shown in the condensed consolidated</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; statement of cash flows</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,044</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,931</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash included in prepaid expenses and other current assets and restricted cash long term on the statement of financial position represent amounts pledged as collateral for operating lease obligations as contractually required. This restriction will lapse when the arrangements expire.</p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates, assumptions and judgments reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuation of stock-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from the Company&#8217;s estimates.</p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAvailableForSaleSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Marketable Securities</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities consist of investments with original maturities greater than ninety days. The Company has classified its investments with maturities beyond one year as short term based on their highly liquid nature and because such marketable securities represent the investment of cash that is available for current operations. The Company considers its investment portfolio of marketable debt securities as available-for-sale. Accordingly, these marketable debt securities are recorded at fair value and unrealized gains and losses are reported as a component of accumulated other comprehensive loss in stockholders&#8217; equity. Realized gains and losses and declines in value judged to be other than temporary are included as a component of other income (expense), net based on the specific identification method. When determining whether a decline in value is other than temporary, the Company considers various factors, including whether the Company has the intent to sell the security, and whether it is more likely than not that the Company will be required to sell the security prior to recovery of its amortized cost basis.</p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div>

<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The Financial Accounting Standards Board (&#8220;FASB&#8221;) issued the following new Accounting Standards Updates (&#8220;ASU&#8221;), which the Company adopted on January 1, 2018:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASU 2014-09, &#8220;Revenue from Contracts with Customers (Topic 606)&#8221; and related amendments;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASU 2016-01, &#8220;Financial Instruments &#8211; Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Liabilities&#8221;;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASU 2016-15, &#8220;Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments&#8221;;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASU 2016-18, &#8220;Statement of Cash Flows - Restricted Cash (a consensus of the FASB Emerging Issues Task Force)&#8221;; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASU 2017-09, &#8220;Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting.&#8221;</p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The adoption of these standards did not have a material impact on the Company&#8217;s financial position, results of operations or statement of cash flows; however, the adoption of ASU 2016-18 resulted in the reclassification of certain prior year amounts in the Company&#8217;s condensed consolidated statements of cash flows to conform to the current year presentation. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued ASU 2016-02, &#8220;Leases (Topic 842),&#8221; which supersedes all existing lease accounting guidance within ASC 840, <font style="font-style:italic;">Leases</font>. The new standard requires that lease assets and lease liabilities be recognized by lessees for those leases previously classified as operating leases under ASC 840, with limited exceptions. This update also creates a new definition of a lease and provides guidance as to whether a contract is or contains a lease. This guidance will be effective for annual reporting periods beginning after December 15, 2018, including interim periods within those annual reporting periods, and early adoption is permitted. The Company is currently evaluating the potential impact that the adoption of this guidance may have on the condensed consolidated financial statements.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU 2016-13, &#8220;Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,&#8221; which represents a new credit loss standard that will change the impairment model for most financial assets and certain other financial instruments. Specifically, this guidance will require entities to utilize a new &#8220;expected loss&#8221; model as it relates to trade and other receivables. In addition, entities will be required to recognize an allowance for estimated credit losses on available-for-sale debt securities, regardless of the length of time that a security has been in an unrealized loss position. This guidance will be effective for annual reporting periods beginning after December 15, 2019, including interim periods within those annual reporting periods, and early adoption is permitted. The Company is currently evaluating the potential impact that the adoption of this guidance may have on the condensed consolidated financial statements.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2018, the FASB issued ASU 2018-02, &#8220;Income Statement - Reporting Comprehensive Income (Topic 220)&#8221;. ASU 2018-02 addresses the effect of the change in the U.S. federal corporate tax rate due to the enactment of the December 22, 2017 Tax Cuts and Jobs Act (the &#8220;Tax Act&#8221;) on items within accumulated other comprehensive loss. The guidance will be effective for the Company in the first quarter of fiscal 2020 with early adoption permitted. The Company is currently assessing the impact that adopting this new accounting standard will have on the condensed consolidated financial statements.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed above, the Company does not believe that the adoption of recently issued standards has or may have a material impact on the Company&#8217;s condensed consolidated financial statements or disclosures.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_CondensedConsolidatedStatementsOfCashFlowsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Condensed consolidated statements of cash flows.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_CondensedConsolidatedStatementsOfCashFlowsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_UnauditedInterimFinancialInformationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unaudited interim financial information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_UnauditedInterimFinancialInformationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=d3e5614-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355100-122828<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesAvailableForSaleSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investments in debt and equity securities that are classified as available-for-sale. This policy also may describe the entity's accounting treatment for transfers between investment categories, how the entity determines whether impairments of available-for-sale securities are other than temporary, and how the fair values of such securities are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.M)<br> -URI http://asc.fasb.org/extlink&amp;oid=65877573&amp;loc=d3e87990-122713<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesAvailableForSaleSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6636431824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock', window );">Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text"><div>

<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the statement of financial position that sum to the total of the same such amounts shown in the statement of cash flows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.13%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,268</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,155</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash in prepaid expenses and other current assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash (short term)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash (long term)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">674</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">674</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash, cash equivalents and restricted cash shown in the condensed consolidated</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; statement of cash flows</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,044</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,931</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of cash, cash equivalents and restricted cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6633457088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Summary of Assets Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div>

<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The following tables show assets measured at fair value on a recurring basis as of March&#160;31, 2018 and December&#160;31, 2017:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,785</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,009</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,781</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Totals</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,785</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,790</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,217</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,841</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,940</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Totals</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,998</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89,310</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Totals</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89,310</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19190-110258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6633469760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities and Cash Equivalents (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments Debt And Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Summary of Marketable Securities and Cash Equivalents</a></td>
<td class="text"><div>

<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The following table summarizes the Company&#8217;s marketable securities and cash equivalents as of March 31, 2018. The Company did not hold any marketable securities as of December 31, 2017.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,785</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,785</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,010</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,009</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,781</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,781</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash equivalents</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,576</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,575</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,227</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,217</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,841</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,841</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,941</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,940</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total marketable securities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,009</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,998</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash equivalents and marketable securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,585</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,573</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6753972208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable, Accrued Expenses and Other (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable, Accrued Expenses and Other</a></td>
<td class="text"><div>

<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Accounts payable, accrued expenses and other as of March&#160;31, 2018 and December&#160;31, 2017 consisted of the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,560</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,887</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued goods and services</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,027</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,682</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued clinical trial costs</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,925</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,901</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued drug purchase costs</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">918</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">222</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued payroll and related benefits</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,240</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,884</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued restructuring expenses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">251</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">628</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax incentives</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,402</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,402</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accounts payable, accrued expenses and other</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,323</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,606</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6903267792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions Used to Calculate Fair Value of Options Granted to Employees</a></td>
<td class="text"><div>

<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The fair value of stock options granted to employees during the three months ended March&#160;31, 2018 and 2017 was estimated at the date of grant using the following assumptions:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="4" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.16%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.3 &#8211; 2.7%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.8 years</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.8 years</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62 &#8211; 63%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67 &#8211; 68%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock', window );">Schedule of Recognized Stock-Based Compensation Expense</a></td>
<td class="text"><div>

<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The Company recognized stock-based compensation expense during the three months ended March&#160;31, 2018 and 2017 as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee awards:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expense</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">334</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">468</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expense</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">430</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">328</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">764</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">796</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The following table summarizes stock option activity during the three months ended March&#160;31, 2018:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except per share amounts)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise&#160;Price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual&#160;Term</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December&#160;31, 2017</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,616</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22.07</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.65</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,031</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">566</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.74</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(145</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.12%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.04</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.48%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.74%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at March&#160;31, 2018</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,037</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.12%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.00</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.22</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.74%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and expected to vest at March&#160;31, 2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,036</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.00</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.22</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at March&#160;31, 2018</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,032</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25.17</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.97</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of employee and nonemployee service share based compensation allocation of recognized period costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6753927568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Outstanding Securities Excluded from Computation of Diluted Loss Per Share</a></td>
<td class="text"><div>

<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Outstanding securities excluded from the calculation of diluted loss per share for the three months ended March&#160;31, 2018 and 2017 are shown in the chart below:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding options to purchase common stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,037</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,652</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of the Convertible Notes</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,216</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6754027360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations And Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Schedule of Discontinued Operations</a></td>
<td class="text"><div>

<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Discontinued operations for the three months ended March 31, 2017 includes the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.2%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues:</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenues, net</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,135</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License and collaboration revenues</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,797</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other revenues</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,973</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenues</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,905</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs and expenses:</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of revenues</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,890</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,730</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expenses</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,733</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restructuring expenses</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,265</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total costs and expenses</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,618</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income and expenses:</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,234</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from discontinued operations</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(947</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721665-107760<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1474-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721683-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=SL51724579-110230<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721675-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721663-107760<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2941-110230<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721659-107760<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721671-107760<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5D<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721677-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763541088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business - Additional Information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($) </div>
<div>Program</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_NumberOfDevelopmentProgramsActive', window );">Number of development programs active | Program</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 500,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 482,771<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net loss from continuing operations</a></td>
<td class="nump">17,782<span></span>
</td>
<td class="nump">$ 29,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Cash in continuing operations for operating activities</a></td>
<td class="nump">17,339<span></span>
</td>
<td class="nump">$ 18,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash and cash equivalents and marketable securities</a></td>
<td class="nump">$ 76,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_NumberOfDevelopmentProgramsActive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of development programs active.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_NumberOfDevelopmentProgramsActive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6752895952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Discontinued operations</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (947,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member] | Silver Creek Pharmaceuticals Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership interest (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721675-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1012-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721525-107759<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721523-107759<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e957-107759<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mack_SilverCreekPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mack_SilverCreekPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6758072992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_CashCashEquivalentsAndRestrictedCashLineItems', window );"><strong>Cash Cash Equivalents And Restricted Cash [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 34,268<span></span>
</td>
<td class="nump">$ 93,441<span></span>
</td>
<td class="nump">$ 17,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash (short term)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash (long term)</a></td>
<td class="nump">674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash shown in the condensed consolidated statement of cash flows</a></td>
<td class="nump">35,044<span></span>
</td>
<td class="nump">$ 94,217<span></span>
</td>
<td class="nump">$ 17,931<span></span>
</td>
<td class="nump">$ 22,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember', window );">Prepaid Expenses and Other Current Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_CashCashEquivalentsAndRestrictedCashLineItems', window );"><strong>Cash Cash Equivalents And Restricted Cash [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash (short term)</a></td>
<td class="nump">$ 102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_CashCashEquivalentsAndRestrictedCashLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, cash equivalents and restricted cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_CashCashEquivalentsAndRestrictedCashLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6812-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760795184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Instruments - Summary of Assets Measured at Fair Value on a Recurring Basis (Detail) - Recurring Basis [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 6,785<span></span>
</td>
<td class="nump">$ 89,310<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">6,785<span></span>
</td>
<td class="nump">$ 89,310<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">15,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable securities</a></td>
<td class="nump">41,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 [Member] | Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">2,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable securities</a></td>
<td class="nump">6,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 [Member] | Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">13,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 [Member] | Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable securities</a></td>
<td class="nump">21,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 [Member] | Government Securites [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable securities</a></td>
<td class="nump">$ 13,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75030427&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26610-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6631746224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersDescription', window );">Fair value transfers between Level 1 and Level 2</a></td>
<td class="text">no<span></span>
</td>
<td class="text">no<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the transfers of assets measured on a recurring basis out of Level 1 and into Level 2 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel1ToLevel2TransfersDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6752841008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities and Cash Equivalents - Additional Information (Detail)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_AmortizedCostAndFairValueDebtSecuritiesAbstract', window );"><strong>Amortized Cost And Fair Value Debt Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_AmortizedCostAndFairValueDebtSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized Cost and Fair Value Debt Securities [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_AmortizedCostAndFairValueDebtSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total debt and equity financial instruments including: (1) securities held-to-maturity, (2) trading securities, and (3) securities available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763710464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities and Cash Equivalents - Summary of Marketable Securities and Cash Equivalents (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 64,585<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">64,573<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember', window );">Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">22,576<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">22,575<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember', window );">Cash Equivalents [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">6,785<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">6,785<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember', window );">Cash Equivalents [Member] | Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">2,010<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">2,009<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember', window );">Cash Equivalents [Member] | Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">13,781<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">13,781<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=mack_MarketableSecuritiesMember', window );">Marketable Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">42,009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">41,998<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=mack_MarketableSecuritiesMember', window );">Marketable Securities [Member] | Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">6,227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">6,217<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=mack_MarketableSecuritiesMember', window );">Marketable Securities [Member] | Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">21,841<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">21,841<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=mack_MarketableSecuritiesMember', window );">Marketable Securities [Member] | Government Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">13,941<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 13,940<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of debt securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75030427&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26610-111562<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)-(g)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62557-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=mack_MarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InformationByCategoryOfDebtSecurityAxis=mack_MarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6753042032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Payable, Accrued Expenses and Other - Schedule of Accounts Payable, Accrued Expenses and Other (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">$ 2,560<span></span>
</td>
<td class="nump">$ 2,887<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued goods and services</a></td>
<td class="nump">4,027<span></span>
</td>
<td class="nump">5,682<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_AccruedClinicalTrialCosts', window );">Accrued clinical trial costs</a></td>
<td class="nump">4,925<span></span>
</td>
<td class="nump">3,901<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_AccruedDrugPurchaseCostsCurrent', window );">Accrued drug purchase costs</a></td>
<td class="nump">918<span></span>
</td>
<td class="nump">222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll and related benefits</a></td>
<td class="nump">1,240<span></span>
</td>
<td class="nump">2,884<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveCurrent', window );">Accrued restructuring expenses</a></td>
<td class="nump">251<span></span>
</td>
<td class="nump">628<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent', window );">Deferred tax incentives</a></td>
<td class="nump">1,402<span></span>
</td>
<td class="nump">1,402<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Total accounts payable, accrued expenses and other</a></td>
<td class="nump">$ 15,323<span></span>
</td>
<td class="nump">$ 17,606<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_AccruedClinicalTrialCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date arising from ongoing clinical trial activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_AccruedClinicalTrialCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_AccruedDrugPurchaseCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued drug purchase costs current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_AccruedDrugPurchaseCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income during the current period and current obligations not separately disclosed in the balance sheet (other liabilities, current).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6757546944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Detail) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="nump">566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value per share of stock options</a></td>
<td class="nump">$ 6.26<span></span>
</td>
<td class="nump">$ 24.30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of options exercised</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation expense related to nonvested stock awards</a></td>
<td class="nump">$ 7.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period over which unrecognized stock-based compensation expense is expected to be recognized</a></td>
<td class="text">2 years 6 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mack_StockIncentivePlan2011Member', window );">Stock Incentive Plan 2011 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares of common stock available for grant (in shares)</a></td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="nump">600<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mack_StockIncentivePlan2011Member', window );">Stock Incentive Plan 2011 [Member] | Employee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Options vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested options awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mack_StockIncentivePlan2011Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mack_StockIncentivePlan2011Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=mack_EmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=mack_EmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6752886944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Assumptions Used to Calculate Fair Value of Options Granted to Employees (Detail) - Options to Purchase Common Stock [Member]<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">62.00%<span></span>
</td>
<td class="nump">67.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">63.00%<span></span>
</td>
<td class="nump">68.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6757810096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Recognized Stock-Based Compensation Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 764<span></span>
</td>
<td class="nump">$ 796<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense for employee awards</a></td>
<td class="nump">334<span></span>
</td>
<td class="nump">468<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense for employee awards</a></td>
<td class="nump">$ 430<span></span>
</td>
<td class="nump">$ 328<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and nonemployees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763925792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Option Activity (Detail) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding, Beginning balance</a></td>
<td class="nump">1,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="nump">566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, Forfeited</a></td>
<td class="num">(145)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding, Ending balance</a></td>
<td class="nump">2,037<span></span>
</td>
<td class="nump">1,616<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Options, Vested and expected to vest</a></td>
<td class="nump">2,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Exercisable</a></td>
<td class="nump">1,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Outstanding, Beginning balance</a></td>
<td class="nump">$ 22.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Granted</a></td>
<td class="nump">10.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Forfeited</a></td>
<td class="nump">21.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Outstanding, Ending balance</a></td>
<td class="nump">19.00<span></span>
</td>
<td class="nump">$ 22.07<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Vested and expected to vest</a></td>
<td class="nump">19.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Exercisable</a></td>
<td class="nump">$ 25.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Contractual Term</a></td>
<td class="text">7 years 2 months 19 days<span></span>
</td>
<td class="text">6 years 7 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Term, Vested and expected to vest</a></td>
<td class="text">7 years 2 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Term, Exercisable</a></td>
<td class="text">4 years 11 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,031<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6904435776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_UndistributedEarningsLossAllocatedToParticipatingSecurities', window );">Amounts allocated to participating securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_ParticipatingSecuritiesOutstandingShares', window );">Participating securities outstanding, shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_ParticipatingSecuritiesOutstandingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Participating securities outstanding shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_ParticipatingSecuritiesOutstandingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_UndistributedEarningsLossAllocatedToParticipatingSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Undistributed earnings (loss) allocated to participating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_UndistributedEarningsLossAllocatedToParticipatingSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6920574656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share - Schedule of Outstanding Securities Excluded from Computation of Diluted Loss Per Share (Detail) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Outstanding Options to Purchase Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Outstanding securities excluded from calculation of diluted loss per share</a></td>
<td class="nump">2,037<span></span>
</td>
<td class="nump">1,652<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Conversion of the Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Outstanding securities excluded from calculation of diluted loss per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,216<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763929152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations - Schedule of Discontinued Operations (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_DisposalGroupIncludingDiscontinuedOperationOtherIncomeAndExpensesAbstract', window );"><strong>Other income and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Loss from discontinued operations</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (947,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mack_CommercialBusinessMember', window );">Commercial Business [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_DisposalGroupIncludingDiscontinuedOperationRevenueAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_DisposalGroupIncludingDiscontinuedOperationProductRevenuesNet', window );">Product revenues, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,135,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_DisposalGroupIncludingDiscontinuedOperationLicenseAndCollaborationRevenues', window );">License and collaboration revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,797,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_DisposalGroupIncludingDiscontinuedOperationOtherRevenue', window );">Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,973,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,905,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_DisposalGroupIncludingDiscontinuedOperationCostAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold', window );">Cost of revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,890,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,730,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,733,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_DisposalGroupIncludingDiscontinuedOperationRestructuringExpenses', window );">Restructuring expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,265,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense', window );">Total costs and expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,618,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_DisposalGroupIncludingDiscontinuedOperationOtherIncomeAndExpensesAbstract', window );"><strong>Other income and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,234,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Loss from discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (947,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_DisposalGroupIncludingDiscontinuedOperationCostAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation cost and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_DisposalGroupIncludingDiscontinuedOperationCostAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_DisposalGroupIncludingDiscontinuedOperationLicenseAndCollaborationRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation license and collaboration revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_DisposalGroupIncludingDiscontinuedOperationLicenseAndCollaborationRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_DisposalGroupIncludingDiscontinuedOperationOtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation other income and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_DisposalGroupIncludingDiscontinuedOperationOtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_DisposalGroupIncludingDiscontinuedOperationOtherRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation other revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_DisposalGroupIncludingDiscontinuedOperationOtherRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_DisposalGroupIncludingDiscontinuedOperationProductRevenuesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation product revenues net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_DisposalGroupIncludingDiscontinuedOperationProductRevenuesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_DisposalGroupIncludingDiscontinuedOperationRestructuringExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation restructuring expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_DisposalGroupIncludingDiscontinuedOperationRestructuringExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_DisposalGroupIncludingDiscontinuedOperationRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_DisposalGroupIncludingDiscontinuedOperationRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section S99<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=26872618&amp;loc=d3e7436-122677<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1063-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1060-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721675-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1012-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721525-107759<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721523-107759<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e957-107759<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mack_CommercialBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mack_CommercialBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760838256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 08, 2017</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (947,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=mack_JanuaryTwoThousandSeventeenCorporateRestructuringMember', window );">January 2017 Corporate Restructuring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesInitiationDate', window );">Restructuring activity, announcement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  08,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Reduction in headcount, percent</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=mack_JanuaryTwoThousandSeventeenCorporateRestructuringMember', window );">January 2017 Corporate Restructuring [Member] | Discontinued Operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=mack_JanuaryTwoThousandSeventeenCorporateRestructuringMember', window );">January 2017 Corporate Restructuring [Member] | Contractual Termination Benefits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=mack_JanuaryTwoThousandSeventeenCorporateRestructuringMember', window );">January 2017 Corporate Restructuring [Member] | One-time Employee Termination Benefits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDescription', window );">Restructuring activities, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">One-time employee termination benefits are comprised of severance, benefits and related costs, all of which are expected to result in cash expenditures. The majority of these payments were made during the second quarter of 2017. The remaining payments represent severance payments that will be paid over one year.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721675-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1012-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721525-107759<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721523-107759<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e957-107759<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of a specific restructuring plan and related activities including the facts and circumstances leading to the restructuring or decision to exit an activity, and the expected completion date. This concept and related items would be utilized for each plan if multiple exit plans have been implemented in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesInitiationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the restructuring activities were initiated or are expected to be initiated, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesInitiationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=mack_JanuaryTwoThousandSeventeenCorporateRestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=mack_JanuaryTwoThousandSeventeenCorporateRestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6637625488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investment in Silver Creek - Additional Information (Detail)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=mack_SilverCreekPharmaceuticalsIncMember', window );">Silver Creek Pharmaceuticals Inc [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems', window );"><strong>Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Effects Of Changes Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership interest percentage held by parent</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mack_SilverCreekPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mack_SilverCreekPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>63
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M?_A=A%UO[-;^8^.S8-O K[MHOP!02P,$%     @ (E6H3)E<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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M!?G*F"3*H?!)N5*I'CTM*+E*/4W5G ^-:EA(UHU-.)C^"11_ 5!+ P04
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ML_X&Z0>"ML/MB,8KNO@/4$L#!!0    ( ")5J$RF$RI6PP,  '<1   8
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MG@JO',6DHQ@[$I:C01)/$D4@0FP(Z^*$1TX_">DGP7ZDY2=!>9C@@N@0%H(
MGCH="=*1P(Y2RY% B=XY+!'*VYXDZ4FB?2@<\2D9GZ*:!+-J2HGFQ;@@+&/N
M)6<A3880V[&_N:/FNL>I<#>..2C$<"Z$(89S)9+AXBDAN!V1U+IG@!U%MB/
MB2(*"I20I8EPFZ)!QS@V%=NF.+7MA03"%B&%%*XKN/9% Y1%>.<GCAEHX#%,
M/&$3CV&4H8JPY%T:W>@SC3N&>2=LWC',,6>?"2D/6<S=OFCH,4P]D=K)")A%
MM[8:S3(F42H9VBV0;V\!(84TD3>V&LU(EJ*M)EVW(S37 '--6EQ; <4U-T.
MIAI@JDF;:D# ZE8FFE: :25M6@$%(2'2"*\6);V]6D #"_"MF73<F@&-%L W
M9PAYH^8M^Y"2@A0W?NJ!!A:\#JPU_">-@*818!JAK^*H$6]I 2%]97%I&H'
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MBGQO:OT?^D,71MX[,37V==$.G][^O>WJ<LIBK)3YC_'[4@W?MRG_9Y@<@%,
MW@-,[:4 F@+H9T X-'YT-C3UE[S+-ZNFOGG-.%K7O'\IX)E,9^[[AT/?#;^9
MUK;FZ<<F4ZO@H\\S2;:C!&<2N"L"D_Q> :4*6V3A^%A@QQ5Q*%<@L0TTQ-.\
M#0Z'H1@?#O'A+#Y)K3X8)<D@J0;)$R1):J:+U5L[04D*(IHK'SQ%HJ>(>THL
M3Z,DFE6RO7#%4Q8F3B>QZ"1F3N+,<A+S.H[>$928H8J=GA+14\)''.7X5(Q/
M69LRLIRFS"E$*G7ZS,0Z&:\36GV7\3I(&>\Y00>//?S@!Y0\W15W%-GS7?%!
MBL!=R0$6X)5BNQ((+TZX4$HDS L@+V5/EDDS+Y7$(>]F29>Y7T^0B03$'=E(
MF30/E<*%2C*[(.13(7-DD$D#'#5H3W#@)$D5"+TG$(>2A;=41@YPYA ;4 DE
ME"6"*:Y,512Z3<G,@82;8F.:2%,G%3P)PG1A\&6, ><8V*6VP$EFZ$P28T1I
M"KC05S+W@(,/%-C5.-+,5',C%F6D(4<:*&N+L46!:8Y.$*5F!7>/#LH$1&!3
M$Q0Y4LAD0TXV4/8*@AQ93Q +#1-TV'> JUDRVY"S#92]AB"'VU-H7J6%T97Y
MAGQS!LI>1R:178T$ODO2Q4Z0H8F1,+:)(X4,.>20 Y7:=CF[0K6PF4297<C9
M!2JS:W$FQ2IQ;Q=1AA(*4 (;2BB0)LK,C!1&3)"&%&=N7S*34& 2@.V+,RD+
M$81515 B]O9=MDC&%PGX AM?Q)E$D0J%]UM00I*1>T]%,KQ(@!<XX$4RO$B
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M]SAIMQ0HO"2QXW-\[#CY:-V3[P ">=;*^()V(?1'QGS5@1;^QO9@\*:Q3HN
MIFN9[QV(.H&T8CS+7C,MI*%EGGQG5^9V"$H:.#OB!ZV%^W$"9<>"[NB+XU&V
M78@.5N:]:.$SA"_]V:'%%I9::C!>6D,<- 6]WQU/AQB? KY*&/WJ3&(E%VN?
MHO&A+F@6!8&"*D0&@=L5'D"I2(0ROL^<=$D9@>OS"_N[5#O6<A$>'JSZ)NO0
M%?2.DAH:,:CP:,?W,-?SBI*Y^(]P!87A40GFJ*SR:275X(/5,PM*T>)YVJ5)
M^SC=W+Z98=L /@/X KA+>=B4*"E_*X(H<V='XJ;>]R(^\>[(L3=5=*96I#L4
M[]%[+7<\R]DU$LTQIRF&KV.6"(;L2PJ^E>+$_X+S;?A^4^$^P?>_*?Q'_L,F
MP2$1'/Y;XE;,GRK9JJ<:7)NFR9/*#B9-\LJ[#.P]3V_R*WR:]D_"M=)X<K$!
M7S;UO[$V $K);G"$.OQ@BZ&@"?%XBV<WC=ED!-O//X@MW[C\"5!+ P04
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M?L*SG<9L,KSIYQ_$EF]<_ 902P,$%     @ (E6H3$9\"7^U 0  T@,  !D
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M971S+W-H965T,C(N>&UL;5/;CILP$/T5RQ^P3@S;;B- VFQ5M5(K15MU^^S
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M1X&K+580M^L[)*M&$\]/EB;H=EU@LRJP\0*;=QZOSF&_AKDV\CDF%$(6UR=
MU?ZE:U3(H?-=MLC.S71/_?6_P4,G_F*J;CN-3M+81^2ONI+2@"TENK'/N['-
M/P<<*N.F6SM7H05"8&0_=3>9?S'Y?U!+ P04    "  B5:A,A6^J$9P!  !7
M P  &0   'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6QM4]MNVS ,_15!'U Y
M<K=T@6U@Z3"L0 <$+;H]*S8="]7%DY2X^_M1DFMX15[,BP[/(2FYFJQ[]0-
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M<K0!UYN6T%L; -F*&[S' 5_Y$BCH0W2WZ+M\USD(=IR?,5O^I>8?4$L#!!0
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M>Q@?.5=,$^(G+3S7%_HP*=E1F6&LQZ*[U;J)XDU_8Z/ALR'[#U!+ P04
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M;Z?[,AG>#/-38,M[K/X#4$L#!!0    ( ")5J$RH/J]?'S(   L" 0 4
M>&PO<VAA<F5D4W1R:6YG<RYX;6SM?6EOXTB2Z.?1KR#Z52]L@%;KL&6[:J8!
ME>WJ]4Q=6ZZ>P6*P'R@Q);&+(C4\[-)@?_R+(R^228ERU?3#VQ6P.UVVDYF1
MD7%'9.0?\[SPRB3Z1RENTC(I_O3#^/S\!^_K.D[R/_VP*HK-RY]^RN<KL0[R
M?KH1"?QED6;KH( ?L^5/^28309BOA"C6\4^CP6#RTSJ(DA]^_F,>_?S'XN?;
M=%ZN15)X01)Z=TD1%5OO/N$9HC3QSKQ\%60B_^-/Q<]__ F_X>_&WKLT*58Y
M?!.*L/[7=T'6]\9#WQL-AE?-/VZ]P=C]-PW.U W.WZ>SO,B">?%?K5]^WFY$
M_8_#P=E_U'\WA=$A??$F#I;UORZ".&],H]?X*+(H10!#[S8H&N/4]GM_^,/.
M3;Z)\GD0>_\I@LQ[ []L8+D^4J[K'/L?P_IO/F=!&"5+[V&[GJ5Q \CIS5_J
MOY,8_R26$:(9%GX?K)O;N_OTZ1X_]S[^^_03_./NU\_W-].W#][]^YN6*6]@
M%QGLX![(Y:OW%[&MC[LILZR.DS;\GIT-1V?CQG[E4F^B6&3>#7RW3+/&.M/Y
M7,#?X:\ACVP#.%VO@> >BG3^Q?<>B F\#V61%\ I@-4&_"GL+,EA5OA7GL91
M2$N\#N(@F0N8 #@P!W;Z]>'6.WEQZKWPHL3[O$K+'.9K'KR8:P:Z;$-5D.<P
MY\O&GX-\1>P\QW^(?Y318Q##^,8B0*9?1!',8N'E8EYF41$U&?UC)C9!%'KB
MZP:WE]/,:;$"%,\K<#2H+RW@''>/^22 S*(Y(@J!;:X-$BV#P\ U<2,;9 ;?
M2T31.#7X*PQ<BV(%#!(ECS S#JZ/^T"0[X+8_3>%\S@*9E%,F&H@'D@+173N
M;8(M8M7W@OD\*X4+><T#7PA8(?0R!]!55%H@[)R%\.2E"_WA)LU0B+I1$J?)
M\JP0V7K7_ S(C@'(-1$AGO<Z!R4!S"*2>7,P*K&7^2:8BS_] %HJ%]FC^.%G
MKSXE<> JC4.1Y?_V?ZY&P\M71 O%MG$ 0*MR_SFS[8M!?S"$X\@\8(%2O/2&
M W\P&$B=Y@4E4$L6_1,^" H/V&&^TEJ+P <V%.L98$>QXBLO2=7749[CV::9
MEQJQX)@(!C3F<>$-I$T;V*-O!GLX]L?GXQKH1(T[87?.UJ#[,(R0L( T4%2<
M@6";!YL(2,7!(>6ZC$DRAF(1S:,&K=M#I)A)UT >*V"@Z%$ G>8M9)FW$LI>
M,J9]=O^^FZP_^1@@VZU$$8%&.P79_\+[J<6<>BA@!M+T'Q:@EA*8)T)]G^;1
M'KNG0?.:;/:.;)!3UR^8?+J.3G<I39OL6R&O#ML+MG.X&V;GT)T .T]>'U^.
M\O;#!NT+.#:FJYL*_;X%^K7,  7=#EO -J8;O"?7 N95.J8A%4')"N)J!"84
MCR).28_J+^H?_"(2@;8:C@_"=920,5@@]&V?,$>E#6#JXVCWBRQ=2\U0XN!4
MX\NMFJ($1(!@(Z!MD_<)Z"[0^7)PZY_E!#L7.I&#3IV6AMQJ&V3UX>]!!\>'
M[?H63& >AS)0#VOLV2 S='^A+8 B^-H&5RN\00&FV:QD^[!(0?$E9[A(EL8Q
MPA])E':>X!T(AV@=S+]X'X'HX1^B),D(8-XG\[[[2)K"OX&&7Q-P<6-2A[0N
M\/.ZBV7;MH!#1NP9,5VSW7?@CAL[>1WDT9S9-(I+8KA$87/#L)*T0IFQF\Z^
M@2!H)><2?Q/1<@7B[BQXA F7H@)/[I4H%O7'8 +$<]3CN"ZIT]&K675_+G'<
M0;R2?_,F3I\L.>KT@18TAO!A)!/HT.C120_3\+<RE[8K'%XF (-S\!#-&2 7
MP+_)KZ+=@MCN,O-[9!W\*-HCAFX%4!IH?M+Y)'[7:+/_DW_1\A'HW754KG,R
MOCI3_]2>F98"7T703UVG(,O\# X5W3=@$@!N)Z!O)7>*CK[:S2H UR&O89G<
M,X)XER_VOGY.3LGK+=!Z[W*":KI-ECY&(4PYVUI,]JVS'D),==)F_.W^YF,)
M^A_."=EGXW2JV[X@CNM$#8W-= &LOID%F[Z[-Y.E<R%"^87X*K)YQ%M+-XQ_
MX-.-VO'<LO ZG6H7$/##4 "_X KD[N0KOQ%O(0QGNT,<-YV_]+V96$9)0K2V
M0$$;I4T!>L!T KV_MHDLD:5/$<9W.A^;=-S4AC@+OB%:\@E<4M@<?)7#OMA9
MQ$-W+Y8#%HB[.D2M'LK-)B9= T8>,C@(_C(CZIIK6G52,4E?Y/PVP^@ABA\Q
M,)D)T3 (T![P_OZ._&R'BV<3/#HRY&8"2 ]P=H""&]AYQ?=".MZU'-L?VAK0
M4\[3O(F2]T$A,0#X\UZ7>92(I@WT(5L&B=(G1GOC3QC+_X@!'D J_:+BXUK*
MO=W+'?8]-QC[;"SO!$>C_3$:O$)++DBV]-/PU2GLVPN\.5BS^ %@#FV:691N
M*A.1:H.O/%9T0$<WP7J61>$22/8=4%$P7X'(*]!J6 4%3@H.9+&*DB_()W-$
M;(8'4@394A GP1HD4K,S#((DQ)$X*N^#%R@\"\SAY:O<>XQRQ%I$@@TX ]%
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M*M@(P5II@)R7L]_@T"EF%^5?>*X2MX='1>D]&00H4FG,1VS?25NL9N\#@Y6
MN:UE-/H8B$,+E3Q(M.V7:%.BR4 1J"T961@: 25KLJ$R"XI_7)1)-1 +)SA'
M_P6-WJHQZE<4,T@TBJT548%X@N&)> *!.5\EVHB,$B!&-7$H0-L"&M%#1*:.
M0?&F,GT39!F&U,C;\I%X8!YEYZ#S#-YD@<>GIP<DD'"*R#VD8UL"W6<)P4:Z
MQ,IT59?^(K887,C3)$&B!R\6*<LVL:4K3O("2+:R[R=P6& !<.(!IV3_@D9
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MZZ+ZWM0&B4C3@$P&2B89A)97BM!& .560>?"7_*5%=11@D2>B3%Q!,W:U&'
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M).A?3 ;TWZLK&D @+],TE.TVI+#OG?L#H+@+?W(UTL-J-TZI+PT,O!Y=]("
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M11_0<MZ_MF.)2$M/]0;4K#C#6G#&'&RK1G^^$G\QZ8\F]*L7H_/^>."P:+Q
M41Y*5TD,.GVD=9J^S,3%!B3.5+B.Y:BD.<HW. 6I#@Y6K1@*M2>4Y.+K;<8
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M>G?_2.G0;[%FN#[\%VR8^AMAKO[-V/T 4$L#!!0    ( ")5J$QQRL[1J $
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M]!M02P$"% ,4    "  B5:A,'R// \     3 @  "P              @ $
M    7W)E;',O+G)E;'-02P$"% ,4    "  B5:A,9O,+8((   "Q    $
M            @ 'I    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( ")5
MJ$Q&3!0I[P   "L"   1              "  9D!  !D;V-0<F]P<R]C;W)E
M+GAM;%!+ 0(4 Q0    ( ")5J$R97)PC$ 8  )PG   3              "
M ;<"  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ (E6H3%$?[ )D
M @  %0@  !@              ( !^ @  'AL+W=O<FMS:&5E=',O<VAE970Q
M+GAM;%!+ 0(4 Q0    ( ")5J$R.7T=7G0,  #(0   8              "
M 9(+  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    "  B5:A,
MJ"4N9#4"  "N!P  &               @ %E#P  >&PO=V]R:W-H965T<R]S
M:&5E=#,N>&UL4$L! A0#%     @ (E6H3*83*E;# P  =Q$  !@
M     ( !T!$  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    (
M ")5J$Q4I0!4, 0  ,L3   8              "  <D5  !X;"]W;W)K<VAE
M971S+W-H965T-2YX;6Q02P$"% ,4    "  B5:A,); L_[,!  #2 P  &
M            @ $O&@  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#
M%     @ (E6H3(G3D@FT 0  T@,  !@              ( !&!P  'AL+W=O
M<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( ")5J$QT],=RM $  -(#
M   8              "  0(>  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q0
M2P$"% ,4    "  B5:A,%C\%=K,!  #2 P  &               @ 'L'P
M>&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ (E6H3%9D':>T
M 0  T@,  !D              ( !U2$  'AL+W=O<FMS:&5E=',O<VAE970Q
M,"YX;6Q02P$"% ,4    "  B5:A,1GP)?[4!  #2 P  &0
M@ ' (P  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( ")5
MJ$RI.J3DM $  -(#   9              "  :PE  !X;"]W;W)K<VAE971S
M+W-H965T,3(N>&UL4$L! A0#%     @ (E6H3%&)34*T 0  T@,  !D
M         ( !ER<  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4
M    "  B5:A,@ OH?+0!  #2 P  &0              @ &"*0  >&PO=V]R
M:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( ")5J$SXD\S M $  -(#
M   9              "  6TK  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL
M4$L! A0#%     @ (E6H3"XD+R ) @  - 8  !D              ( !6"T
M 'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    "  B5:A,\9)%
MF;8!  #2 P  &0              @ &8+P  >&PO=V]R:W-H965T<R]S:&5E
M=#$W+GAM;%!+ 0(4 Q0    ( ")5J$R54.K8MP$  -(#   9
M  "  84Q  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @
M(E6H3"MR7,JV 0  T@,  !D              ( !<S,  'AL+W=O<FMS:&5E
M=',O<VAE970Q.2YX;6Q02P$"% ,4    "  B5:A,1FY8L+<!  #2 P  &0
M            @ %@-0  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4
M Q0    ( ")5J$S[Z%4>S@$  )P$   9              "  4XW  !X;"]W
M;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ (E6H3)X2(5^S 0
MT@,  !D              ( !4SD  'AL+W=O<FMS:&5E=',O<VAE970R,BYX
M;6Q02P$"% ,4    "  B5:A,DXNW?K<!  #2 P  &0              @ $]
M.P  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( ")5J$QD
MQJ-.1 (  *(&   9              "  2L]  !X;"]W;W)K<VAE971S+W-H
M965T,C0N>&UL4$L! A0#%     @ (E6H3#T$FJ + @  H 4  !D
M     ( !IC\  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ")5J$RD<9E460,  .X0   9              "
M 0E+  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ (E6H
M3&M;S_=4 @  H@<  !D              ( !F4X  'AL+W=O<FMS:&5E=',O
M<VAE970S,2YX;6Q02P$"% ,4    "  B5:A,#2 +,WP"  """   &0
M        @ $D40  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0
M   ( ")5J$R_6AU-4P(  $ (   9              "  ==3  !X;"]W;W)K
M<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ (E6H3.82OH@K @  ?08
M !D              ( !858  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q0
M2P$"% ,4    "  B5:A,WUO%+M$"  #2"@  &0              @ '#6
M>&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( ")5J$R $K/8
M"0(  ,H%   9              "  <M;  !X;"]W;W)K<VAE971S+W-H965T
M,S8N>&UL4$L! A0#%     @ (E6H3(]I%J<% @  C04  !D
M ( !"UX  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    "  B
M5:A,P$$N6L "   ("@  &0              @ %'8   >&PO=V]R:W-H965T
M<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( ")5J$PBX]$+2@(  $((   9
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M<W1Y;&5S+GAM;%!+ 0(4 Q0    ( ")5J$PU,9X?1P,  ,<:   /
M      "  5.<  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  B5:A,_O=.
M0Z0!  #=&   &@              @ ''GP  >&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;'-02P$"% ,4    "  B5:A,<<K.T:@!   N&0  $P
M    @ &CH0  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     ,0 Q $D-  !\
%HP     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.8.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>52</ContextCount>
  <ElementCount>175</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>31</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="mack-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20180331/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mack-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20180331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mack-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20180331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mack-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20180331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mack-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100050 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20180331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mack-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100060 - Disclosure - Nature of the Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureNatureOfBusiness</Role>
      <ShortName>Nature of the Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mack-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mack-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureFairValueOfFinancialInstruments</Role>
      <ShortName>Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mack-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Marketable Securities and Cash Equivalents</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureMarketableSecuritiesAndCashEquivalents</Role>
      <ShortName>Marketable Securities and Cash Equivalents</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mack-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Accounts Payable, Accrued Expenses and Other</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureAccountsPayableAccruedExpensesAndOther</Role>
      <ShortName>Accounts Payable, Accrued Expenses and Other</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mack-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mack-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Net Loss Per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureNetLossPerCommonShare</Role>
      <ShortName>Net Loss Per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mack-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Discontinued Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureDiscontinuedOperations</Role>
      <ShortName>Discontinued Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="mack-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Investment in Silver Creek</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureInvestmentInSilverCreek</Role>
      <ShortName>Investment in Silver Creek</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="mack-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Recent Accounting Pronouncements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureRecentAccountingPronouncements</Role>
      <ShortName>Recent Accounting Pronouncements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="mack-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="mack-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="mack-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Fair Value of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsTables</Role>
      <ShortName>Fair Value of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureFairValueOfFinancialInstruments</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="mack-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Marketable Securities and Cash Equivalents (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureMarketableSecuritiesAndCashEquivalentsTables</Role>
      <ShortName>Marketable Securities and Cash Equivalents (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureMarketableSecuritiesAndCashEquivalents</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="mack-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Accounts Payable, Accrued Expenses and Other (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureAccountsPayableAccruedExpensesAndOtherTables</Role>
      <ShortName>Accounts Payable, Accrued Expenses and Other (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureAccountsPayableAccruedExpensesAndOther</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="mack-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="mack-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Net Loss Per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureNetLossPerCommonShareTables</Role>
      <ShortName>Net Loss Per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureNetLossPerCommonShare</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="mack-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Discontinued Operations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureDiscontinuedOperationsTables</Role>
      <ShortName>Discontinued Operations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureDiscontinuedOperations</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="mack-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Nature of the Business - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail</Role>
      <ShortName>Nature of the Business - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="mack-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="mack-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="mack-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Fair Value of Financial Instruments - Summary of Assets Measured at Fair Value on a Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetail</Role>
      <ShortName>Fair Value of Financial Instruments - Summary of Assets Measured at Fair Value on a Recurring Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="mack-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Fair Value of Financial Instruments - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetail</Role>
      <ShortName>Fair Value of Financial Instruments - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="mack-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Marketable Securities and Cash Equivalents - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureMarketableSecuritiesAndCashEquivalentsAdditionalInformationDetail</Role>
      <ShortName>Marketable Securities and Cash Equivalents - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="mack-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Marketable Securities and Cash Equivalents - Summary of Marketable Securities and Cash Equivalents (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureMarketableSecuritiesAndCashEquivalentsSummaryOfMarketableSecuritiesAndCashEquivalentsDetail</Role>
      <ShortName>Marketable Securities and Cash Equivalents - Summary of Marketable Securities and Cash Equivalents (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="mack-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Accounts Payable, Accrued Expenses and Other - Schedule of Accounts Payable, Accrued Expenses and Other (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureAccountsPayableAccruedExpensesAndOtherScheduleOfAccountsPayableAccruedExpensesAndOtherDetail</Role>
      <ShortName>Accounts Payable, Accrued Expenses and Other - Schedule of Accounts Payable, Accrued Expenses and Other (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="mack-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="mack-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Stock-Based Compensation - Schedule of Assumptions Used to Calculate Fair Value of Options Granted to Employees (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToCalculateFairValueOfOptionsGrantedToEmployeesDetail</Role>
      <ShortName>Stock-Based Compensation - Schedule of Assumptions Used to Calculate Fair Value of Options Granted to Employees (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="mack-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Stock-Based Compensation - Schedule of Recognized Stock-Based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRecognizedStockBasedCompensationExpenseDetail</Role>
      <ShortName>Stock-Based Compensation - Schedule of Recognized Stock-Based Compensation Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="mack-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Option Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="mack-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Net Loss Per Common Share - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetail</Role>
      <ShortName>Net Loss Per Common Share - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="mack-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Net Loss Per Common Share - Schedule of Outstanding Securities Excluded from Computation of Diluted Loss Per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfOutstandingSecuritiesExcludedFromComputationOfDilutedLossPerShareDetail</Role>
      <ShortName>Net Loss Per Common Share - Schedule of Outstanding Securities Excluded from Computation of Diluted Loss Per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="mack-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Discontinued Operations - Schedule of Discontinued Operations (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureDiscontinuedOperationsScheduleOfDiscontinuedOperationsDetail</Role>
      <ShortName>Discontinued Operations - Schedule of Discontinued Operations (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="mack-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Discontinued Operations - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureDiscontinuedOperationsAdditionalInformationDetail</Role>
      <ShortName>Discontinued Operations - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="mack-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Investment in Silver Creek - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20180331/taxonomy/role/DisclosureInvestmentInSilverCreekAdditionalInformationDetail</Role>
      <ShortName>Investment in Silver Creek - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>mack-20180331.xml</File>
    <File>mack-20180331.xsd</File>
    <File>mack-20180331_cal.xml</File>
    <File>mack-20180331_def.xml</File>
    <File>mack-20180331_lab.xml</File>
    <File>mack-20180331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2014-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2017-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>69
<FILENAME>0001564590-18-011543-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-18-011543-xbrl.zip
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MZNJ\W=B)0"7,>\T]S)1\&0H1_18X.E=5%))/H1ASZ;[]/@;F"'7CNQ^C(7!
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M/1=N\7R*)-&=I3!_AZ^2XQY+ ]S'6GVOVRD,<'LZ=S_:?2SN]ZZZ.QQM5B'
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MI&0<!G<A'X%\R#389H,@#G,! -\-\J/?I>1WI,&5+L3A"D''LIGTPL)C:VR
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M)[^!90Z#!S2(X.[@'AAC(27Q_M=WY\UB0J)6=JHE=ZO] I &3\K-Y#+GAT\
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M0ZV"YZ1I5/@T#B7H+LAU]GA@@@[').J1D><[, BAKVG3T^)DG=.LHQ1?_4V
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M_S/+)NJYN)G*OA&.[B:0SQ*3*5;OE"3E-@D(<?D!0MXLTU,T?B/NBA0<L]R
M;"RQ?H&T]+FGM5P-A4B+\^=>F"&=3?<'6!YO@O>A?H8VUV&:?DE$2:3+-6N3
M-%>ZQ@47G2Z;S.,(9NHQWD37%/C%:AJS\(&+X (5 '=DI#F@)=/DTK +?B[9
MQI"?M:!S$=O*Y:7MH=)MQA,8_>:#3 95U+\T:+(Q-?#HH.C1(="[Q!JN2O#U
M:IOG>+"N.C'6)NN:1E<Z[,?>+DPW=UFTX;#@P8N7ESSY)@,HO3,4N=_A3".$
M,UF9]O 6YJ2+Z:6N\KBY2BVAGL[T(4S!1)SF['L_H4N&+OL[YB$F'F#D.3/3
M1[JB]- 2F3K7A@C.93',89WR;/\!2 +#Y.'.L7 1<=, +-[EA *CDS^X NR@
M7;S#+0:FQX:>R'LXB08N^>RB\=-,!B8G):]\9// U&_K!QQX!<29.J(DOY$5
M%1D9RIH_:6C0$.LB%5VA4YA+2B# F.:%KT.V!R,L=10A:BSZEG)2*I-8#!JD
MCCW21KT8?920,B4"NK;)).Q& N(;/9P\_MK";J\WI[?!HGWTV0U(FU<(HVIS
MQ#VOG]5+<-S+<H,Z.047R\@SA069-B:^$W=UF%RZ3LG5-*N3Q7.$QL=5V9J1
M->XD\[CY2\1&+:3VUV9)1&>ETHV;-0AU_!BKC,TB2'DWH?PW?O?Q]_?_^I\W
M;_5O'SY@6YMYFZ33#8C9'O*2^9JS>).S:_I6%"D=3Z>F.%GLPGIK^"*)48Q=
MXIC5S?I*YA%%P6; !>- \>*&WYDWELUDLA,5]\<.Y2#*59 #N_["+%X6$"V*
MS*="F]RLP6MB+TJW->$22ZTXY]>5XOJ*9>3R4.3QE^9"OO8TGQ\@1!BGZ6W5
MW]F:,9I:*TC+IAHK?5.=;;S6!@-]P'^!A5TPL/JJW-E\RZ)CQ%41X9QYRY1I
M66J%MK<Q?V0YA??)[/1=)D'O?6W%'Q4Y-M8)'!\W^B=+S$Q-N;30+I[JZM !
M7)C4-4>H,"FGYX4>-=:/(^8&0ND5EC3,0^.$X@CBK]> D@4)%RN6, MCW.L&
M],Y;97YB[;S4#] L2L.;M2@HS%VW>54Q@6;8EN?3MLG,S,F_I54P'&:H?9VC
M3@+:/&^GTRCSPWO?K:7V$EUFDC@",>=FO:J6S5)0*GAV5F6V/),*3>#C:JB6
M:9QJPRQ>>]SB#7DA5LK* 9=A>=*\R./DU)L]D+B*N%"V"CZFL(2>UA9LAF$M
MFW[M4#",*.1C L1Y86%7YC8P5<0\4P::JG4RBW<>+Y,IO[:4<+0=*;88BZ4U
MCO<Z)DP?;N(;4U61%$06,W@H+0OMVF6M4.68ZLU8]PQ,%H]Q(5<7<9@'XMJG
M_GEGL;K.1MCO16;-RUR]#Z86@=-L+(8D(&=SS,PX#K&?:I1*7!A[22E*L4 [
M>6ZA [/>LI>T;]317M)'9SK(_O+VMAQ4IYG,HC+H8#,((M2!DHLR;/ FI;SR
MHM3@PG4+=&Z%L>>&&1?H1S**4J<:87\7$Z+6T [!)Q"WY KPDGI+R5P.I=G(
M'*=-S+\:IHOP,'=WDQ*JOV+?R7<0%BW_(I-?L",Z"$U*ITR5[1,DY($P3Q?I
M)O0"]O@T8V.:+:/R"S6WPH'O;8;U;2E95%),[)+(WJ%G.:T V"QFZ0F4SN*-
M34MCG/^%F.5QI">SI2UTO[7YE7AAUF_2_)Y-)0OY^U+,,2>VT'-BI?=+&8\8
M1/D46X=:9M=8LMT"]/+!9_.>G8<)TZV!MBO[Z-2;[9^FP5JXP?.'0K7)=OMM
MD_V1CBZYVNWV6S/@,]:_TY+XZNP?[_0_V5L2.LYQR[!F1/K%9RUZC7KOHO#E
M5^26^<H0T>W6KRY_>I&,-N6OV2EG+C35 6-]NOB+.?L_5R*3?,P(+%L>_&)M
MVW.Y9]/#GFGQ#&(%.J)^7FM7[+X1:M:[K4<!5#"$1D)7YULK!-F:6[:!/&"1
MKT^\W3]RZ5>O<PXG8+;KERO4+67AR2&I(YM2'+2&:S]"/F!<9X?EF=?)X-A=
MP(8M(,CZ5P$MLO[6(TG6/[/^/3LL#UG_^1@\+\[4%O=,RG&Y??>N\>YVCW8E
MF<3M!QNK"C<7[2[<4F/VCHQQWT]ES&V"ZM%QU/ZQR3TQLGBN&WXR"V@3=/]A
M+6*M4OST2-0**JC+L8Y- ]N=6JN[[4SR*;3O))6K G:1?):]V)#/(I]UQ#ZK
MV:LU+RZLQ9)\UNYFQ7O/MIW,K/CSU%J^3"J2I%MNAV,JP]*]@V9CP8%3312$
MV+L 06:P>LB88(-B"1U+-%K6XD0:9"LRY'?LQ8:TQE9DR.],P875X&L>JT&:
M9)4FT?*N-1/99VJ(>RBP$^6VM;B4+;?7+5&^[G21H8!AEP$#:=+I:A+Y'WNQ
M(:VQ%1GR/[M(E)(&56FB>H0[1VW";&;VBOT 'S5Y/86M1#8A6(%$ZWJ[A\AF
MVHE>:^W]7Q29X&B[O8X=IG-]NTFJ9P%<Y.FJ AAYNN-$CSP=>;I35;V#K2 O
MFYCC,:^>8*WZZ4W,O^J^9!LT0RMU*IO?>C!'_ZA95Q#W[*]%O=L.G$-<$OIM
M(OL4^MF0]%VY76H9PB<=&U9^(]SND#WVF+%]46MTM@T;=VQVU[>Y)ZF5UAA=
M\I(5 XR\)'E)\I*/VU)^U6[:87:KX24-'"D:3]???-/<RG/=J#N[JMC">_L3
M+/!SD4GVM8&?W>Z=G^:P]K[ON7F/K& A.R]G10?X[,RTK,G[V!/NG3F13/<[
MC_ T:WWP07ZZF8='*K*@#ZBDYQ:I["2[6)]0D9ZFA"=!Z%,D#*'F  ?/8[J1
M.GL8"D,G#T,\.L.<#@!CAUN/\62$/Y0^+.8MR#&>,WUB1Q],G=N]X,1L%"1\
M8G9>LCZO))$G53BT"4\M&/%O@HF4G7A*B8I'X_PLK;]B]\X\6)]UP,V9?^;T
MI/3HO5%VTFM!LSQISFR6^-3D!,+D'!:=- OT&9E3ZEBXB25GL6*N,3U18:,3
M:9/S2^:1&8I[X<?FV,G,3KCYJ7SF'OR4'!Y49U\*QXVNQ:[D/*SLI!2U&?F)
M23-'KZ6G)WER),UI3K7TD-TP-@=.H!'2YZ(@%<G1EAKCDAW$F\#5QYD(J2AP
MOIWW]0&O_(&'.-1,N?1[#0?PK%YME.ZE2 Z2]U"Z-93ZT!XC>3)TXA$,PW>0
M.X/L7$ZD(I1"'[IZ8T[G3 ]\<O19-:X$R0K38W/FGRN3\7V/ENT);=D''GX3
MYJ2-_""D#0S::^Y\NPM!J-WSQ%"9A;"J6[H"7U1^0!2JC%1:X/*#>94Q< &$
M[:!$'EBS*+W^+A3H>LUQQ;[T!5A#ET]4^=#?(?K=_"S5\K&_R=,+#^V+28#A
MA)^<8,3UF2[)!CUFU,@$#C)D0V *Z(PGP?"ZS.?ZV#%4AKYP>*R2LV%&<T>;
MAQ6H#(63B-/U!FV-\1"_>RX]?3=&&&F$4SP8M#A<S40(OM7T <=H[P9@D0)S
MK%]&DBOZ49$N7GCC.;SQ'(_T197&$[+ 8'J36F+LECU$']R*=Z#5B<SQ?FB6
M#'MB'Z#S0/I<=L=E8ECQ%$<Q[\Q7/.P1\#"L 8,8CV)SY%T2\\V>!0EV2IN]
M(>@[L*)@8I+3G.OL\V("M'EU/#R"%I]DR$:S;T[9ZXODQ5KNP)H#K7B4(1*>
MA:FSA*='UL&7@CU+;/;/YKC:HE@Q-18.^B$F47NU1]*VW!Q 76?_C0&A*U >
MI8\>#")$_6R>DIU3#>(SC];I$YQ3D4%E#6*EK7H0JEHRGN)+HBG5,L(;);&&
M$LEQQHDL3,RAB>G-4@OT* !.>?*;\":)[@;1[,GL.@36YYLE9X[.>SR>^XSG
MC05:VNZ%.0P=)1]B ?#O_]:>6$7F/,R]'=>=NID#[Z[#GO)3L\IDOOCR>:S.
M[S@?7Q>BG)OL'/-/8!<<T-NO\-+7'BC.+S_^P-C+])YWH+W_0GEZDQ^TEUT*
M8OKJ[-V?X%2:G=Z9COK@I\]B\.KL5G_;ZG5Z5ZT_\<2/1K/1-'^TV\VS7Y#"
MA, ??YCKYI'9E^-YZ9JUO/P&>#QFB:+.D$-,LPCEKWB&,<SIXE&Y>_>ZLI?Z
M\N6#M^&H^'>Y>4>'Y4,P"*H.NNF(6N[HTMC;A.E&XQ_R8PP=D9]57#Q*GOMF
M_J"/\L1Y/Y[$IBG3-B^=4$ST.8X0\F+J"2T+7L+-=+HOH@<\Q]%X+'@*F 9'
M@IG! \K+Q*>&51]@G%CEH*]$>*\=G?%>A2^D/X[Q*1^GO\J.R\4#&O$PU*"/
MYRH:=XFGO.J!(HACH9%D*HA#'50_#*4GYKTF>Z:3'(F9#*@P1]%GT//D_%\=
M,"36';EOCJK++ZZ9B2.$"/ 2J8;ZB#U]YNLYN/&4*T/X$R<>D_2D7VUT)5K7
MU/YKXF)EK'0R-S%83\V>D**1X,K,Q(IA@4J._5/7[#=\ &NRV?$G V!_QP$&
M %K"E#G 4Y\R:_AA!F[<)\QJDNGGB^2YK?1A1<\(I*YZIID=X]PV)TM(_0P7
M')03(<:A/O/6?'JA1VQ>VIX+)[S$<-2<  ^(@2!'*/8AG@2?H(O2DK(^F^,7
M766!Y_J4XP>_+!$ZO92AN/ 9L2J-;>KMH#Y97&B\.N86( (9@1SH1\4F<S-O
MH _3,4N._!9..4I/X;7?,LXYSM(<$IGF1(PRS$3)>,1MX?3L[#CO])SKV8.1
M-22+3UK=S:&3FP4Z=!KEO 62BUZ]\[@]A7M9F+8A@K6AW#LM'F@??-_GVCEY
M&PX,*AY UFP<] 2R3J.^YL8*.H#,^ X[5([.XMJVU-Y^EW5,F%EY?C*YJZW=
MU8'/RVS6>]W-BZ'(G^%8DTR!'3I(_NOP&)3LX%:Z1(:2#.6Q&LI#GQ5 AK)B
MAI) (0-X'% GRS!V*)^%_0>L <KJY@,+=3/)D!P.FZ<I=;B=ZBQPO:4^/4''
MX/9)G"9P'%OX3G)[7@6@:ZP7<- >O(K@28V&;46&W)4M2)"[JBQTY*Z."T]R
M5[8B0^[*%B3(7546.G)7QX4GN:O=)6SWOIBRUX2M3?!\@)\GZ6:.0>R[V_8P
M?8)CR2FJL 2)$S5EVW9,VS\@)E:@4 !'VZWU+B^L1>I$5:<"1HW<BRU(G*B.
MD'NI DJ//ZF:%.AT31LY&5N0.%$=(2=3!93(R=@-#16@V@K/;1!B$[MHINF@
MM>L"%!+8@@19-%N1H=A@E[$!:=+I:A)Y&UN0(!VQ%1GR-CE<K5JC<64M4J1#
MMB)#?L86)$A';$6&_ S-:JH"C:T5G!9U(+0)L]M@-!*A.:F.CT5XX%4$>]H0
MV@12)59)UVD70V;13O3*6T@>CR %(4]L,"WL!&0=7C:H(/DWJ^$A_W:<Z)%_
MVPS29KO6N[2F'3*YMBIH'[DVJ^$AUW:<Z)%KHZG;J:O@P<IHER65W2#&P^A:
M]5T[O6:[WK,>MJ]!Q+U#U](N"4GVALYQ:-3!%] V[4Y>PO.D8Y9M-^Y8TZAH
M=\@>>RSSF X&.[:QZQO8DU1*:VPNN42KX2&72"Z17.)C,M<7M=Y5PPXC2SZQ
M&D:7?*+5\)!/))](/O$H2J;),5:^CGJAWNZH<T0ELML56!>D?56V(%'V912!
M5 BZV5"$PHPJXTD;LVQ%AMR5+4B0NZHL=.2NC@M/<E>V(D/NRA8DR%U5%CIR
M5\>%)[DK^RJ4]YVNG0]/D<O]P',?B=<CP/F@#RSC:%7R%K_7UJY]45QA"Q)D
MS&Q%AKIA50HN4B1;D2%G8PL2I".V(D/.IE)PD2+9B@PY&UN0(!VQ%1ER-I6"
MBQ3I],I3[8=GUP>;T6*J+1:-5G#VA R==5H%E.SIW$0*5#W31D[&%B1.5$?(
MR50!I6ZMU>Q9B]2)JDX%C!JY%UN0.%$=(?=2!91H#F,W-%3&:2L\.SJHC!8Z
M;8D$:'WF=)&AD&"7(0%ITNEJ$GD;6Y @';$5&?(V.5RM9NVRL^W)7J1$IZM$
MY&AL08)TQ%9DR-'0M*8JT-A:P+GL2*T3/D?RU^!>A/X(:+.GHI-._*SL$BF=
M^%E=]!ITXF=%UUSIQ,]*J2#Y-ZOA(?]VG.B1?]L,TF:[=M79]L@K<FTGJ7WD
MVJR&AUS;<:)'KHVF;J>N@@>KH5V66=[;.8^5.,[J:Q!Q;]ML,IW">6B-.O@J
M&IW"2:=P/AI9BF6>V-+2*9S5L+SD&*V&AQPC.49RC(^ NM.L75U=VF%DR2=6
MP^B23[0:'O*)Y!/))])D\:E5TV"20K(,O</FO9_K$ZFRJUQYOP6'2@SY:1.!
M74BSIJ!(C3DYRR#_ZJQQQASA>8@M2$GV.9$:_3F11P>($F$F?8GH &(>'RMQ
MG?[Q@J4&I%'<7#1_66#?BSN/KSDO6"7#@%V8)1LLD0VKJO:4+!2YO.AT.XW)
MY3J6:/_8 'G $ "G"0IZP.7O3J.^9OW"4^F6-4B^$8X8]45H_'ZSVWC1;M98
MJW'P7H1/OU/*&DQVLYAMO]<Z)LR>29]%PR!6W'?5SW;H#GFL[3U6ZZ .J]G<
M:EY++@W'^INX%Q[;MM4$^:_CCMRWTB4RE&0HC]50MNQ04C*4A\=@/4-)H) !
M/ ZHC0%LVZ%\%E;X6P.4U>7]"W5SKRVRU\%F@]S](\"YY6K(Q-^Q!#X#>>K:
MVM5B:B5G"Q)K>*R3K+2H '1KEEQ0.45%\*1>=+8B0^[*%B3(7546.G)7QX4G
MN2M;D2%W90L2Y*XJ"QVYJ^/"D]S5[A*V1UB_9A-F'^#G"0.:OXF(#6+?I3;?
M-L)DS:+Q.O''LN7&DS2,MI^63"WBUD7R\JK6;E+WTRI 98W))(]F-3SDT<BC
MG;!'HZ:G%<3+!KM);LUJ>,BMD5LCMT9NK4IXV5KL2[V\%\%&O;RMA:82ZV34
MGHW:LST:V6./91Z5=#[)SFQD=,DG6@T/^43RB>03#SJ_)\=XDI:7'*/5\)!C
M),=(CI$<(_7RWKZ7=T'$_XI5) >3U4*^?7OOO<DP]J7-F;+;(7;J%YV?%LM!
MX^D%X4T<@OZP:"C@_Z$0; 27#A430+#+/O#0&;*D2^\EX[ZKKYP('B97+.[I
M6\-+0\$>\%]^8%1N($+%^B)Z$,)G2?-$_=BD/UB=?87G#[@,T5+$@@6#]"<F
M?16%\0C;?C#'XTK)@00*.'R:Z@JBGVB*RW5K=U?T(Z:$ V.-)'!4D^2*2(0C
MZ0L<4QC$=T/XKPS=<S +T82-0XG]W^&V\%XZ0M5W)1/-EO5"@1@X/ PGR  ^
M"F+D:2@&GG B8)=N/PM7!$B_$MB?RM?ND^.O?>YQWQ%,#86 V^!]C#N.><:8
M3Q"0&GX3QG"Q^#[&1QC$ A08YDG>EYX!BH_'8?!=CN#!1:%PX?]1@$3 5VH8
MA# VP!(@CQ*(ZU-F+3%8+Y_'ZOR.\_'U.WC:O_!A;Z1RO$#%H5!?@4FOO<#Y
M]LN//S#V,KT4>\[@_]_F G;CNQ\R\?J2"5;V ";=5V?O_@0DFYW+,^0/ O!9
M#%Z=W>IO6[U.[ZKU)VI5H]EHFC_:[>;9+TAN0NV//\QU02A$5^-Y$<0\:UIL
MV[.I>7V$"'7J+.<0RUFD@=9=? KLW%RUD ?=E3Q8J%F'6[A$ZQ9X7O"@K:YF
MCHI', QXJ])J=1N,QMR?9 %5[X4JVC)59N6LZ5-H,\N&VUC5Y,',A3C7#R(V
M!)%@^,6"I^L'I?8]?59O9W;P<>Z?3O?8SSZSO33ALR&NLZ$X;D>UB\?=*)'.
M^S@6)+43FID8;'L()O4 MJ3:S7XG=DR8'>-A'\=M]JBI\\E ?3,*P@A>Y*XQ
M*3K"X=\&*K+#(I$W/SP&>S_ZY+B5B=S&R4#]AQ\*&-S)^HW? J6$)1U_R',<
M'H.MSX(Y;C4ACW R4.-RY&GZ KT(:X<9LG"OK#4P6;U1=J%-HE-QENC34X-!
M39NM*7^EILV5A6[-RF6J2JX(GM2TF7Q596 @7T70D:\Z63S)5Y&OJ@P,Y*L(
M.O)5)XLG^:K=Y6GWOG:TUSRM3?!8=^[-YE'%<2]'6;,T3I:M8DV2*3+ T79K
MO<L+:Y$Z4=6I@%&C.:PM2)RHCI![J0)*]O37)P6JGFDC)V,+$B>J(^1DJH 2
MS6$L!(4*4*V&YS8(QT&(?;JFFJW1DJGE2D/K-(0,A00KX&K5&@<_"H5TB.IR
MC@ &4A!"AIS,W%9/36MA.E$%6J_?%CF6DS5?)ZH7%4"&'$MI]M*XLA8ITB'[
M*C4MZL1I$V:WP6@D0D=RCXWY6(3;A >6]>(\,H0JL?:Y3@L<LHEVHE?>)_)X
M!(\]]FBV:[W+;2>VQ]_@QR:H'I=/);]F$3;DUP@]\FNG48E*SHV<VTEA0\Z-
MT"/G1I,V\FNVU\4N2R,O/(_[L9@UV_6>];!]#2+NS9S>><CEYB6AR=Z@.@[U
M.OCZV:8]UTMXGG3LLNV&'&OZ$>T.V6./:5JMVD6O>V"\%\4T"RWL26JE-4:7
M?*+5\)!/))](/K'*%<?D#W=7ADQND-P@N4%R@^0&MYH:;MOQ@5RA;4:7^MM:
M#<\!<:"=4]8LR98=&(4=%8)N-OZ@V*+*>-(&+/)5E8&!?!5!1[[J9/$D7T6^
MJC(PD*\BZ,A7G2R>Y*OLJT@^3(JVR.5%QUMM@-<CP/F@CQ[C:%7R'KW7UBYU
M45QA"Q)DS&Q%ACI=50HN4B1;D2%G8PL2I".V(D/.IE)PD2+9B@PY&UN0(!VQ
M%1ER-I6"BQ2)2E+M@^=Q)Y,=8MV 0@-;D#A1BT;'E%8!I6ZMU>I9B]2)JDX%
MC!JY%UN0.%$=(?=2!92>;7W@)2G.GB#9M@\ ^13R*4>.#/F4*J $4Y8F35DL
M X7J-:V&9ZLSQVA%T]X8@!9B3A<9"@9RN%K-VF7GT WH2(FJIT3D:&Q!@G3$
M5F3(T4S!]:BCNDB33E>3R-O8@@3IB*W(D+>A:8W=J%A=I+GLF*P3/A;RU^!>
MA/X(:+.G:I,.\*SLNB@=X%E=]!IT@.=&D#;;M:NM@Q ZP/,DM8]<F]7PD&L[
M3O3(M6U:EVJ'G22W9G6M*GFSBMI#\F951H^\V183M4-OM""/5ODZV64IY+V=
MT=ALUWO6P_8UB+C'1O/ZGAYXD8:.U:SH<B<=J_GT&W7H6,W*0=UIU1J-*SN,
M+!VK60VC2S[1:GC()Y)/))_XJ.SUH4O#R"'N,WU-?I#\(/E!\H/D!U?,#9NU
MJZM+.XPLN<+C+)VFO+?''*Z&3/P=2\ !R%2,^^Y.D^%/L%Y/ 8_-*[YKG%A)
M 4]%NU8](;+''O!T.[6+RPL[C"P%/-4PNN03K8:'?"+Y1/*)CTJ&M^RPL.00
MJUK+37Z0_.!QPDM^\&3\(,X->VT[C&PU7*&!(T5C&7"'S84_UUG6["I7WF_!
MH1)#?MI$5A?2O ,*$L;V \]]47COU;+7%IGP\GFLSN\X'U_?<C7$_[_-T]0W
MOOLA2U)_R7+47X&.UU[@?/OEQQ\8>YD^X,9Q@ACN^L0G>#W<#-^$L7!_D[PO
M/7WK&ZD<+U!Q*+*',.F^.GOW)PA5LW-UQAP8 _ST60Q>G=WJ;UN]3N^J]6>K
MT;QL-!M-\T>[W3S[!0>2C./''W;,S$UMT2/$^:+.4MZQA'DUEO".O?T^%KX2
M9LG@8S0LMIY>:)__BE4D!Y/BF+OC>0:[R(5._:*SD5SO0;,S/HQ3/O"$#Z+(
MAP#YP+ABP8"!A#I#TURPV6V\:#=K#"5$7_=&.&+4!Y9-_]Q#.5-21?!D> 8\
MC@T"SPL>P!Q?[U1!=V$BB@;++!@9Y_#JK $*(SP/S3]0GGU.'(O^G+@L!X@2
M8>:@$N\"1MWC8R6NTS]>L#2\:!3[[<U?3=RW&^R"2+8.O7%TQC(L<H27ZSC"
M1^@&>R9]D-0@5B#:RI;9X,6*C88G!-":4T$@#Q@"X+3.#CJ!N*@WU]PDNGPR
M8"S++F8#UB YZU/6<+I'R =TI';8F2=LF&@-]ZU)+1V!K;\%)O5#23:>;'R"
MY-RYP<F:^4.?!T9FWLZ.!@M-2S(W._X5@.F4A+75\=H]'S\>Q['[A!;3K$*L
M4XJ3'HG:L2^4M6H7W6V;)5%K_=,UB^2@;$&"'!0YJ*-V4)>7VTYHR4$=T"P>
M; ,C37/3>H.[('#-(KL2X;UT#KXED>()6Y8!R*15#QD3-U!8@*/MU!JM0^>Y
M28>JIT/D9VQ!@G3$5F3(SQ3J>6O=RT-OJ2,=HE76*L&33C\=3_K2X1Z+X"*/
M.8&*#MT@G@*#*B2TR:C9B0P%!L4)Z%5KV^8SI$.GJT/D9VQ!@G3$5F3(S^1P
MM6M7C4,W."<=HO7/*L&33D#=,+YCXSATAER)1\T_*3%MB_>AI-KI(D-Q00[7
MU<%W<Y(&54^#R,O8@@3IB*W(D)<I5-^V:/'3,DAH\=-J>-*YYYA/PL#S=/5M
M*#R.W:GZPA<#28N@A\:H BE0,FZV(D/A00Y7L];JT.Y1RT"I@ Z1G[$%"=(1
M6Y$A/U/>!-JQ%BG2(5H$M0^>="(:"A6%L1/%(? C:[UL;5:'0@-;D""S9BLR
M%!H40H.+;:NC2(-.5X/(R]B"!.F(K<B0E\GAZK:HVL8R2*Q>![7HS!.;,'LC
M!B(,85(:\>],^MA^6]YO/1G=+5@VM,2W":L*I$C7ZX9/UM%.]#IKGV= ,8A9
M;.TTMJW&VK&I7-].DO)9 !=Y-COA(<]VG.B19R//=KK*=[ UWV63[H5G;C\6
MLV:[WK,>MJ]!Q#T\?G?M WD/G.U:$KCL#<GCT+Z#)R-7]K5?AN=)1S;;GECP
M5$L!3XCLT4<\%[5VJVV'D5W?PIZD5EIC=,DG6@T/^43RB>03'^,3>[5NHVN'
MD:V&3S1PI&@L ^ZP68#GD3YL-;W*E?=;<*C$D)\*#+@:1RO(2E[X\GFLSN\X
M'U^GY\!^,A/A&]]-JJ5_D[PO/1E)H=Y(Y7B!BD/Q%=[\V@N<;[_\^ -C+].'
MY!=\'-P&(YQ!\T@&_F>SV_<6VTU]&8*4O.9*N/"J$9"NLH<QZ;XZ>_<G@-F\
M:)PQ!\8#/WT6@U=GM_K;5J_3NVK]V6HT+QO-1M/\T6XWSW[!025C^O&'';"Q
M>'+RIC;@,44U=?8E DZ<:P:Q(@]S !?:P+]B%<G!I#B^[GB>42R.N%._Z/QT
MZ&3,4.BQ<G]BSBN_;#5[+Q0#?)N&(>Q]6AK!/GG<9\\BN"6]MM5XH:_$7[+O
MFB]^9E(Q[HZD+U4DL,:B/V'1@E>]#GCHLF# WLA0.%$0FLS/6(0C&:GB;2P*
MV!V,+,K+-?2E,,;SOV- 8B#A54I3'8P1.E5+/O+Q&!XN-9Y,>RSX2>]&D$Z4
MWC3[#8M]I"'+1)EOS_M:1O@#$*[JVXE'LU4)^;B)V <>.L/28?8H'9<U1"84
M[ '_U:A?,*#00^XJ-#,*6#GB@+]_Q_@]EQZ:-@9O3 ",88BAQC:3G^-FY!NS
MY05'' U#(=@(+ATJ)H!$U_"8I:S5\@9_]&HEZ9=*87XTD6Q4AJR=8*/>S?B/
M-S?JC6D\0,&<8#3"+S)9'X.^@1)YDSH#0P#/29]])WP1<L^;L'O0"!;< UC<
M$'X^$3Q$[92!JP$5H[$73(10=?8QO1TQQLJJ@+F94D\]4XY&P@6%Q+<?-?)H
M8@=<AA@PQ@)Q*%FH(K,R5C)WM;C,JF0F-^R!PZ7 L)%N]<$C_2 7/N#K$PU4
MZ0L&@><%#UI30<)&AJSKS3'9S,^OA\?"6.J'0MQA(G)M84R@_.H,@QCA>1@*
MP\"RSTF0K3\GX3LZ$A%FP7H2:4. Z_&Q$M?I'R]8$HTW&L5B_?EK2ON>$CR^
MEK. HF' +B9PE'VQK=)E)J)>-'&[7&?BMG]L@#Q@"(#3.3MD/J7=JE]>KE<T
M\52Z90V27[4[^F#<T5MT1VMXBB/DPZP/ML/J/.$.#&NPV$TER(EZ[4JA2/[[
MQ+%9O ;2W6H-A)PZCA5GCQ8JW58@DE8NC*I;!XVJFQ>DH8_1T$,?,4X!IIW[
M>Q<JW,FTE_HLU;?S <Y+)2H^II=#'@EK]V10QP];D%@S:#S!"IA6O9TM\S:;
M+UBKWOO)6AA)H6Q!8@UE.LG:P0I MV81(14(&O-(!V%:!LD2]T2M7P^&RMOO
M6&6"!V#*>PDDNFPBA>=NJ3S4C<\6?_14"=T3]"V-;0-MTHZGU0Z[$JND*39I
MRHD&890IM1J>+!J+1#BR=@)#7L86)$XV!KNH7S*L=#]T/U!2DEV&8OM'Y61#
M,?L5AB(RRH_9!T\6D=T''H]PO^_$VCD-N1Q;D#C9N*S;*JU*=]OV9@!(6RA7
M9A%.W5Y9<R[MU9S#1FHGW\ED%UMS=[9?V)8MW.DN_!A;D^*V:25'XZ3EQ$A$
MPT#OX':XY\38<D5?(HK9MAKCBLF(N0$\P \B-N3W\)1X,)".A)&RH511$$IX
M!-PH0D<JO6>;ZYW^88"KIXRS4' 5^&:S,U=2L7@<^ STQ1GJ+>3)KN_RN_7^
M?MS_/XXCTP,C&.17Y)$G]NTPS2W@$AQ!@:;"5::7P)B'F@S]IR]A5(,P&&D2
MQZ%0,"2N6W2,A<"V#T$,,B$\\\KL)8 R2$4XT7O700R^B0B8.)81B,R_-:F&
M]G!^B6>)8. 4<B>&ITD?#QK%)C? F@ 8B5S BYW 5]B4!'^0T; ,$\"I=\AK
M>(N;].OL _?YG= /3%FL\AM!B 9"1C$V6LC(*>&)#1.$[YB&):%P@CL?)%9I
MYJ6-9N"#BA3<ZDUT9X5(4R[^CI'GIMM( =9 ]U$X_MX)J>)E3'-+75A*#$QZ
M!S^V?0(HJFF*L+@- O4\>.)]!Y;NGJQ&\$U[)BW=-%*<&'6IYX&E2%+/ ^IY
M8!L6I]+SX)@P>R9Q5A7$"B)-];,=ND,>N^*I3-I/O=7^#6LZ'I#S.CP&U'6"
MK"192>HZ81?WJ9;:Z@75MTFWWB0U?[VEHE"EJ"VY4-H=3] MA(YVQQ\7GE0-
M;"LRY*YL08+<566A(W=U7'B2NZ+-*_;!\UDHH8\NPM(I5]P++QB;&CE3B&5M
MA3'%&+8@<:*&S?:S9"DPP-&VVQUK<3I1Q:F 22/G8@L2)ZHCY%RJ@%*G>^@*
M%%*<*JVX6E11:1-FOYIS9?44-#US.C0[SQXW"]TM;C846MH$6R5R;NL4!9&A
MM!.]<@;\\0@>?3C2;MAA*->WDJ1Z%L!%?LU.>,BO'2=ZY-<VS.&VMIUFDU^S
M3?4.MM2[;.[M!C&V86C5=^WLFNUZSWK8O@813+Y7=>2P8Q/!O%!E;^@=A\8=
M/ ^YZ<:=$IXG'<O8O@KPA,@>>XS3ZQYZG7I1C+/0O)ZD2EIC<<DA6@T/.41R
MB.00'^,0K[IV6-AJ.,23;7F[<9/+$^MZ:]I@2NREJ7M-JG@$5.O.I<4&J8P[
MD;S'-J5;==Y<V&7SL6RDQIO[Z15X6;_JK&JB3CTVG[#BM+FW[29%AEK?#>/@
MP3DU*;$0EI96CXT#XR/LYU,!L$B'K(2%/(P5,)!V6 D+>9@*@44Z9"4LY&&L
M:YW9J7<NGVZ:;PU*_ZUI$.[YS;T(^5VA>.64N/!9C+CT03"LM1ADR*V$A0RY
M=8:\6>\]8;[6&I1N[NY"<<>C0Y<?D@G;?:'OOE=NDS4.ZOD^>W))C8GOC@ &
MC$7(U! 8P/@HB/W(FC--F@??(6T-<A7S5.V5V)UL,_Z/YBQ2.U2,'-?A,2 S
M1V;N^,P<95]PK&^3$\#S8JE/H70./9$AXV^7\2>>VV343;J<C/H<)&_AEY [
M4<R]W*)]%>'H-*T[3J<G@H>V3)@MW)IN#59D^*WEN2V&WZ37R?#/0?(]V'WI
M*^F<IJ'_%_=B:X)VLO'[79+84]_/+;9A'-ENOH]QI"+N(Q<8C]@;X8A17X0S
M&XFV/:OT"<ZTVI_3M@FH"K3/HC.M*@M=JY0T?21\Q[X#NEGK-K?= TW'69VN
MDI&GL@4)\E2[;>-!#LHJ&%NM>L/>@)T<E*W(D(.R!0ER4)6%KEU:JB1/M13/
M;KU[82V2Y*AL188<E2U(D*.JVDRJ45I1)?^TW#\U:HUVTUHLR4/M;DWQ@*W=
MC@R>7^'"2+@'7INGZ,&6ZBJR7]5#9LNV.T<9!%QT#]WQF#2H>AI$7L86)$Y4
M1^SMR4_.I5!,@O-Q:Y$Z4=6I@%$C]V(+$J0CMB)CEN+(SU0$+E(D6Y$A9V,+
M$J0CMB)CUM7(V50$+E*DW2V=T7:\7<&3]J;9=O&,2F]LL6"T^'^ZR%!^<PJN
M?URVFBU[\2)-LA49\C:V('&B.F)O'2<Y&7(R58'&;M-&3L86)$A';$6&EM(J
M!1<IDJW(D+.Q!0G2$5N1H:6T2L%%BK2[I;0C/&G+)LS>!>% R,-O3K/GF!F;
MT*E$V< ZO:C)'MJ)7FOMLX$H^,#1/FMVMFW/<OPMMFT"RI+#+LB?V6D128FJ
ML&%N;2>U.5+'[JA:S7KCT+OH2,FJ:!/)95D-#VE3I>!JKSRGCWR7[1B2RE4*
M+G)@5L-#VE0IN!HKSQLD!V8[AJ1RU=T"N&S=T@WBOB=8JWYZ7FWJF+X//'2&
M,V?T71ZX0F!)0'+"T%6B@&-E.^AE>-*JI]WPKGEVTNX@/O: IU5KM ]]OM*B
M6&>AI27MM  N\HU6PT/:9/5FR&4+I(]$ZMA=5O.JWFC8 1\I6:5L(KDLJ^$A
M;:H47',72,EW+<6P5V^U[$"/E*U2RD:NRVIX2)NJ,-N:NR)*'JLB_6A(U2J_
ME7-A8O]DNJ+^2ZA(N(S[+A/?Q\+!#U' [N'KW:^&4C=U6\*-I]S-B2RF1<T*
M03>[J$D+EDL7+.D,0\M J8"2D:>R!8D3U9%#;\E<Y7_(O3QV<9%4YW2-&KD7
M6Y @';$5&6J\NI.%0%*ATU4A<C.V('&B.F+O+(8ZK>YRT8X4J$KK<W1JX:[@
M24XMY)A^MW9W(L4'MI3_D'FK'C*4[BRD.VN-]J$+4DF'JJ=#Y&=L0>)$=>30
M%:7D7M8JUKBH-P^]NYQ4IWI&C=R++4B0CMB*#*VFY7!UZE?D9BS#I (J1&[&
M%B1.5$?LG<70:IJ-6^!L52##_I3[RX Z[&+:\P@7=K*K7'F_!8>*#.G4+T!-
M-A#/A60O5*F_8A7)P62U4CV*KCV \W4HF'FB<,_YO0CYG6!W<'?$7!X)-N R
M1)V)!1N+D*DA#P4+!L""P/G&@G$D U^9&X3+W#@$R6<1/#0:AD*P$;QXJ)B
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M@7C@>7+8R;P=2(C ?US4VPPXX)GCC#T@ F]"C&$D< ?<'8EP)'USXG%?^&*
ML"%I K ,)@*>I.5@'(IS\5T"(/ 2)>YA/@0"QG@(_[T3V%U(U=G7H5 @*;XX
MCX#EV2/FOP1,M9:84"J<80WRI]8*%X%HI93K2MH:XYZ'5X.-!Q[!X&,/?T31
MY6IHQN]*X(8P!*4<F6'( U=8O^'%KKE]P80/7J@2Z58)U:X$$"+0&:Y4 *J
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M4'0TDN6'#KGQI+PO/1!_--;&V)AOP2_?RT@:ZUY\)OS,([ E\#8%7)<#Z<"
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M@RWUM%'7 *>QSYXMWQ59ON.U?,4XZG*A];N<CJ/>FX:=>>8%<RTIZHAC*(;
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ML*W;<B/9\KF1X\*UHL2U))OTDUAP>M_J?-J+\<:\/?HZ[MAD *5W9GEVW:=
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M;50;>',4$F;/=J^B,N-!F]<V7"6"A* "!ZWY;@^AS82)GI'[_A=Z)F*VH_$
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M4PUEW<7*T% J9B@1%#2 S8 Z,H!]&,H', $:#%"@LY^WZF9\0E(?-@4.[@\
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M2VO-5TOU0@%DD%A6=B^]*5BD4(?@96H"JL0)";,+;SZGOFD31UN0!?7+N ?
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M$^5#MJ*D]X!_-YCYE&IS_HLSIE'^>$N[)+XY6VD9K@EYRD,0T49;^T[X1[G
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M#;6?E$I)/^[DJ @,)+Y+MC-'.H%[-E5RLQYA\ME,_/:<_(*A^OJ^+1W^B[T
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M"JXYX8B@AXK^_G4G05N'!0@GFU/RZZTO,X $,NT#A &%>8E"XRA!G!\<.X'
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M"K38TL/$Z:.:8X=$=XE#Q0!,CF6-5V.M,S!4)X^SK3XG!*3'>'<#4]I;+-C
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M=IP4WH6/,-HCN%KWY\'*7;$4B&KA(4W?PFMU!6OZAMM@2N]#PRIU<+&VDI<
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M/&7YU:ZU87L@N!I5]0!2#X( *UF8.43J0_9Z$A:D4H<5MV ZLS3: YW ]GL
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MZ<BJUKL-E298ZRT-*I.L68HH)$!39[(U&U1G;?@N!V]HJE,D9GKS!KDI]GL
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M8E&$57[YI0K])-\:U(F"M[FN2THGV!T)T.JW1Q2^8A>5,[0J?IKF+61;BUF
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M<$1DW@\@K7RCXFP :M?89IV1%K!($KG5G8-GY]69U/24V0=:;/)ML=DFX$,
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M4FV_%\\-6.>@:7[]U#A):9=.LQ7MF\#U$P\'LSOZ:.T3(ARJW:H-W<9Z(=Y
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MX&AXZXWAC?/:V@2W2\I$BH#BQ12K)0[O1BV93H9J23UTZ2%8I-7O>7>Q+"<
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M'/A'4*^8@CZ\3U6JBY(8NX[/EF:@!XP0+2'\(N1^G)'7 P]A!MTI^X$Q?UI
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M,S,Q+GAM;%!+ 0(4 Q0    ( ")5J$QPFE5Z40T  '.+   1
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M 0!M86-K+3(P,3@P,S,Q7W!R92YX;6Q02P4&      8 !@"* 0  858!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
